# ECCMID 2025 Presenter Information

| Date | Time | Session | Session Title | Chairs | Presenters |
|------|------|---------|---------------|--------|------------|
| 11/04 | 08:30 - 10:30 | EW001 | Surgical site infections: principles and practice in the era of multidrug resistance | Gabriel BIRGAND (France), Efthymia GIANNITSIOTI (Greece) | **Evolving antimicrobial resistance: do we need a change in surgical antimicrobial prophylaxis?**: Camilla RODRIGUES (India)<br>**Role of decolonisation and bowel decontamination in regions of overwhelming multidrug resistance**: Prasannakumar PALANIKUMAR (India)<br>**Screening for MDR GNR coloniSation: is there evidence for prophylaxis**: Elisabeth PRESTERL (Austria)<br>**Perioperative prophylaxis in special populations in the era of MDR**: Divyashree SHANTHAMURTHY (India) |
| 11/04 | 08:30 - 10:30 | EW002 | Demystifying pharmacokinetics and population pharmacokinetics: a toolkit for non-experts | Shampa DAS (United Kingdom), Jo�o Paulo TELLES (Brazil) | **Pharmacokinetics 101: navigating the basics for optimal dosing**: Linda AULIN (Netherlands)<br>**The ABCs of population pharmacokinetic models**: Erwin DREESEN (Belgium)<br>**Looking into the crystal ball: exploring the fabulous world of PK-PD simulations**: Vincent ARANZANA-CLIMENT (France)<br>**Decoding population pharmacokinetic papers: interpreting, comparing and discussing results**: Iris K. MINICHMAYR (Austria) |
| 11/04 | 08:30 - 10:30 | EW003 | Challenges in identification and relevance of slow-growing pathogens | Kerrie DAVIES (United Kingdom), Yann DUMONT (France) | **Sampling and culturing anaerobes**: Hugo CRUZ (Portugal)<br>**I have an anaerobe: what is it and does it matter?**: Kathleen BOITEN (Netherlands)<br>**Actinomyces in clinical samples: when is it worth the trouble?**: Eija Inkeri K�N�NEN (Finland)<br>**Nocardiosis: when to test and how to manage results?**: David LEBEAUX (France) |
| 11/04 | 08:30 - 10:30 | EW004 | A hard nut to crack in HIV | Yoav KEYNAN (Canada), Justyna KOWALSKA (Poland) | **Viral reservoir: what a physician should know**: Ivailo ALEXIEV (Bulgaria)<br>**Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians**: Jose ARRIBAS (Spain)<br>**Chronic vascular and pulmonary disease and HIV: what can we do about it?**: Susanne Dam POULSEN (Denmark)<br>**Opportunistic infections: most common and most deadly**: Milena STEVANOVIKJ (Republic Of) |
| 11/04 | 08:30 - 10:30 | EW005 | Diagnostic parasitology in the XXIst century: is microscopy "+" still useful? | Miriam Jos� �LVAREZ-MART�NEZ (Spain), Caroline R�NNBERG (Sweden) | **Artificial Intelligence for the diagnosis of parasitic infections**: Bobbi PRITT (United States)<br>**Histopathology of parasitic infections**: Richard BRADBURY (Australia)<br>**Molecular diagnosis vs. microscopy in the diagnosis of parasitic infections**: Sitara Sr AJJAMPUR (India)<br>**Paleoparasitology: what diagnostic tools?**: Ayman EL-BADRY (Egypt) |
| 11/04 | 08:30 - 10:30 | EW006 | Vaccine hesitancy: from issues to solutions through developing communication skills | Monia CHEMAIS (Belgium), Petar VELIKOV (Bulgaria) | **Vaccine hesitancy and its consequences**: Noni MACDONALD (Canada)<br>**Why are patients and parents hesitant about vaccination?**: Eve DUBE (Canada)<br>**Using social media to deal with vaccine hesitancy**: Muge CEVIK (United Kingdom)<br>**Strengthening vaccine confidence in patients and parents**:  TBA (TBA) |
| 11/04 | 08:30 - 10:30 | SP1 | Antimicrobial Stewardship in Different Scenarios | Murat AKOVA (T�rkiye), Andre FUCHS (Germany), Maddalena GIANNELLA (Italy), Angela HUTTNER (Switzerland), Benedikt HUTTNER (Switzerland), Jose Ramon PANO-PARDO (Spain), Galadriel PELLEJERO-SAGASTIZ�BAL (Spain), Holger ROHDE (Germany), Oana SANDULESCU (Romania), Jeroen SCHOUTEN (Netherlands), Valentijn SCHWEITZER (Netherlands), Thomas T�NGD�N (Sweden), Suzanne VAN ASTEN (Netherlands), Dafna YAHAV (Israel) |  |
| 11/04 | 08:30 - 16:00 | IW | Improving infectious disease prevention: vaccination strategies focusing on AI technology, public health, and communications | Giovanni CHECCUCCI LISI (Italy), Peter OPENSHAW (United KingdomESCMID-appointed chair), Barbara RATH (FranceESCMID-appointed chair) | **Welcome and Introduction**: Giovanni CHECCUCCI LISI (Italy)<br>**Integration of AI into preventative vaccine strategies**:  TBA (TBA)<br>**Integration of AI a public health perspective: vaccination impact on infectious respiratory diseases preventative vaccine strategies**:  TBA (TBA)<br>**Behavioural science: supporting vaccination conversations**:  TBA (TBA)<br>**Panel Discussion and Q&A**:  TBA (TBA)<br>**Workshop 1: Using behavioural science to support vaccine conversations**:  TBA (TBA)<br>**Wokrshop 2: Navigating the complexity of vaccine schedules and the potential role of generative AI**:  TBA (TBA)<br>**Workshop 3: Real-world application of AI and behavioural science for a vaccine implementation strategy**:  TBA (TBA)<br>**Closing Remarks**: Giovanni CHECCUCCI LISI (Italy) |
| 11/04 | 11:00 - 12:00 | ME007 | How to interpret resistance patterns from antibiograms |  | ****: Tommaso GIANI (Italy), Diaz LORENA (Chile) |
| 11/04 | 11:00 - 12:00 | ME008 | Children are not just small adults: interactive paediatric cases |  | ****: Julie TOUBIANA (France), Sanjay PATEL (United Kingdom) |
| 11/04 | 11:00 - 12:00 | ME009 | How to practise WHO Guidelines for the prevention of bloodstream infections and other intravascular catheter infections |  | ****: Kushlani JAYATILLEKE (Sri Lanka), Walter ZINGG (Switzerland) |
| 11/04 | 11:00 - 12:00 | ME010 | Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional experience |  | ****: Ecaterina NOROC (Republic Of), Fakhriddin NIZAMOV (Kazakhstan) |
| 11/04 | 11:00 - 12:00 | ME011 | Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare |  | ****: Jaime ESTEBAN (Spain), Philippe MORAND (France) |
| 11/04 | 11:00 - 12:00 | ME012 | How to understand infectious disease risks in changing climates |  | ****: Kimberly FORNACE (Singapore), Rachel LOWE (Spain) |
| 11/04 | 11:00 - 12:00 | SP2 | Principles of systematic reviews (with and without meta-analysis) | Chiara IARIA (Italy), Miranda LANGENDAM (Netherlands), Blin NAGAVCI (Kosovo), Mical PAUL (Israel), Luigia SCUDELLER (Italy) |  |
| 11/04 | 13:30 - 14:30 | ME013 | Orthopaedic implant infections: new approaches for improved outcomes |  | ****: Marjan WOUTHUYZEN-BAKKER (Netherlands), Trisha PEEL (Australia) |
| 11/04 | 13:30 - 14:30 | ME014 | Timing of antimicrobials in sepsis and septic shock - the sooner the better? |  | ****: Laura EVANS (United States), Evangelos GIAMARELLOS-BOURBOULIS (Greece) |
| 11/04 | 13:30 - 14:30 | ME015 | PrEP in Europe: Current gaps and solutions |  | ****: Teymur NOORI (Sweden), Milosz PARCZEWSKI (Poland) |
| 11/04 | 13:30 - 14:30 | ME016 | Short regimens for treating drug-susceptible and drug-resistant tuberculosis: Insights from guidelines |  | ****: Daria PODLEKAREVA (Denmark), Raquel DUARTE (Portugal) |
| 11/04 | 13:30 - 14:30 | ME017 | How to navigate Risk Communication in Public Health |  | ****: Christina ROLFHEIM-BYE (Norway), Marius GILBERT (Belgium) |
| 11/04 | 13:30 - 14:30 | ME018 | Do we need antiviral stewardship in immunocompromised hosts? role of cell-mediated immunity |  | ****: Michelle YONG (Australia), Genovefa PAPANICOLAOU (United States) |
| 11/04 | 13:30 - 14:30 | SP3 | Top five mistakes in Infection prevention and control | Maeve DOYLE (Ireland), Barbara Juliane HOLZKNECHT (Denmark), David ONG (Netherlands), Arjana TAMBIC ANDRASEVIC (Croatia) |  |
| 11/04 | 14:45 - 15:45 | ME019 | Healthcare-associated CNS infections |  | ****: Diederik VAN DE BEEK (Netherlands), Alexandra MAILLES (France) |
| 11/04 | 14:45 - 15:45 | ME020 | Translation of gut microbiome data to clinical practice: a guide for clinicians |  | ****: Aycan GUNDOGDU (T�rkiye), Niranjan NAGARAJAN (Singapore) |
| 11/04 | 14:45 - 15:45 | ME021 | How to make sense out of guidelines and scientific evidence |  | ****: Luigia SCUDELLER (Italy), Blin NAGAVCI (Kosovo) |
| 11/04 | 14:45 - 15:45 | ME022 | Multidisciplinary management of bone and joint infections: is there a recipe for success? |  | ****: Natividad BENITO (Spain), Tiziana ASCIONE (Italy) |
| 11/04 | 14:45 - 15:45 | ME023 | How to manage and prevent travellers' diarrhoea |  | ****: Tinja LAAVERI (Finland), David TRIBBLE (United States) |
| 11/04 | 14:45 - 15:45 | ME024 | How to diagnose and treat infectious complications in critically ill patients receiving ECMO support |  | ****: Jordi RIERA (Spain), Giacomo GRASSELLI (Italy) |
| 11/04 | 14:45 - 15:45 | SP4 | Science Slam - How to Communicate Science with Clarity | Mary HORGAN (Ireland), Jaroslav HRABAK (Czech Republic), Nina KHANNA (Switzerland), Preeti MALANI (United States), Emily G. MCDONALD (Canada), Joshua NOSANCHUK (United States), Jes�s RODR�GUEZ-BA�O (Spain) |  |
| 11/04 | 15:00 - 16:45 | SCI1 | UNGA political declaration on AMR: moving from commitments to action - Science to inform policy: Implementing UNGA targets on AMR | Onyebuchi CHUKWU (Nigeria), Holger ROHDE (Germany) | **The overall impact of currently known AMR interventions**: Joseph LEWNARD (United States)<br>**Reducing AMR-related mortality: monitoring and achieving the 10% reduction by 2030**: Yvan HUTIN (Switzerland)<br>**Monitoring and achieving meaningful reductions in antimicrobial use in the animal health sector**: Chantal MOREL (Switzerland)<br>**Global antibiotic policy: achieving the global 70 per cent access target**: Mike SHARLAND (United Kingdom)<br>**Accelerating One Health action in agrifood systems to meet UNGA commitments on AMR**: Junxia SONG (Italy)<br>**Setting and implementation targets at the country level**: Tochi OKWOR (Nigeria) |
| 11/04 | 16:15 - 18:15 | EW025 | AMR surveillance: current challenges and new perspectives | Tomislav MESTROVIC (Croatia) | **The essentials of GRAM project: data sources, methodology and challenges in estimating AMR burden**: Authia GRAY (United States)<br>**Networks for surveillance of AMR in animal pathogens**: Lucie COLLINEAU (France)<br>**Transition to genomic-based methodology for surveillance and outbreak detection to effectively combact AMR**: Camilla WIUFF COIA (Denmark)<br>**Implementing and running hospital-wide genomic surveillance of pathogens**: Alexander MELLMANN (Germany) |
| 11/04 | 16:15 - 18:15 | EW026 | New insights into antifungal agents and resistance | Anuradha CHOWDHARY (India), Jon SALMANTON-GARCIA (Germany) | **Emerging resistance in Candida tropicalis**: Sharon CHEN (Australia)<br>**Mechanisms of resistance in Candida glabrata**: David PERLIN (United States)<br>**Surveillance of resistance in Aspergillus species**: Maiken Cavling ARENDRUP (Denmark)<br>**Environmental surveillance for antifungal resistance**: Eveline SNELDERS (Netherlands) |
| 11/04 | 16:15 - 18:15 | EW027 | Going Viral! Phage Therapy Clinical rounds | Gregory GERMAN (Canada), Ameneh KHATAMI (Australia) | **Clinical cases and lessons from the STAMP protocol**: Holly SINCLAIR (Australia)<br>**Difficult cases treated with phages**: Ghady HAIDAR (United States)<br>**Challenging osteoarticular cases treated with phages**: Tristan FERRY (France)<br>**Treating urinary tract infections with phages: dream or reality?**: Saima ASLAM (United States) |
| 11/04 | 16:15 - 18:15 | EW028 | Addressing infection challenges in immunocompromised patients: a case-based exploration | Maddalena GIANNELLA (Italy), Asma NASIM (Pakistan) | **Challenges in managing gastrointestinal infections in patients with primary immunodeficiency**: Effrossyni GKRANIA-KLOTSAS (United Kingdom)<br>**Respiratory infections in patients receiving CAR-T cells or bispecific monoclonal antibodies**: Gemma REYNOLDS (Australia)<br>**Mycobacterial infections in patients with HIV infection**: Graeme Ayton MEINTJES (South Africa)<br>**Breakthrough fungal infections in haematopoietic cancer and in stem cell transplantation**: Dimitrios P. KONTOYIANNIS (United States) |
| 11/04 | 16:15 - 18:15 | EW029 | Impact of diabetes on infectious diseases: what should we know? | Mark G. J. DE BOER (Netherlands), Suzanne VAN ASTEN (Netherlands) | **The impact of diabetes and host-pathogen interaction and gut microbiome**: Reinout VAN CREVEL (Netherlands)<br>**Diabetes and invasive fungal infections**: Jochem BUIL (Netherlands)<br>**Viral infections and diabetes: is there a connection?**: Malin FLODSTR�M-TULLBERG (Sweden)<br>**Pathogenesis of diabetic wound infection**:  TBA (TBA) |
| 11/04 | 16:15 - 18:15 | EW030 | Primer on infection prevention and control: the crucial support by clinical microbiology | Nico Tom MUTTERS (Germany), Margreet C. VOS (Netherlands) | **Microbial fundamentals: building blocks of infection prevention and control**: Laurence ARMAND-LEFEVRE (France)<br>**Optimising environmental sampling in infection control: rational use of the microbiology laboratory**: John E. COIA (Denmark)<br>**The crucial role of molecular typing in infection control**: Stefanie KAMPMEIER (Germany)<br>**How can we link diagnostic and antibiotic stewardship?**: Constantinos TSIOUTIS (Cyprus) |
| 11/04 | 16:15 - 18:15 | SP5 | Multidisciplinary approach to early sepsis management | Markus BALD (Germany), Aleksandra DAVIDOVIC (Germany), Charalambos DOKOS (Germany) |  |
| 11/04 | 17:00 - 18:30 | SCI2 | UNGA political declaration on AMR: moving from commitments to action - Policy to drive action: establishing the independent panel on evidence for action on AMR and updating the Global Action Plan | Lothar WIELER (Germany), Annelies ZINKERNAGEL (Switzerland) | **Progress update by the Quadripartite Joint Secretariat on setting up the panel and updating the GAP**: Jean-Pierre NYEMAZI (Switzerland)<br>**Lessons from the Intergovernmental Panel on Climate Change**: Abdalah MOKSSIT (Switzerland)<br>**Q&A/Panel discussion**: Sabiha ESSACK (South Africa) |
| 12/04 | 08:30 - 09:30 | EF003 | On the frontiers of vaccine driven prevention | Maria GANCZAK (Poland) | **A Pragmatic Randomized Trial to Evaluate Bivalent RSV Prefusion F Protein–based Vaccine Effectiveness for Preventing RSV Hospitalizations in Older Adults (DAN-RSV): Rationale & Trial Design**: Mats LASSEN (Denmark)<br>**A phase 1 study with an innovative approach for an HIV-1 prophylactic vaccine**: Pedro GARBES (United States)<br>**Changes in dose interval can impact T cell responses but not antibody levels in individuals receiving the modified vaccinia Ankara Mpox vaccine**: Joseph PARSONS (United Kingdom)<br>**Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years**: Mihir DESAI (United Kingdom)<br>**Comparative Immune Responses to Homologous and Heterologous SARS-CoV-2 Vaccination Using DNA and Protein Platforms**: Sonia PRIETO MARTIN GIL (Spain)<br>**Quantitative correlates of protection against SARS-CoV-2 variants using individual-level reconstructed antibody kinetics**: Tim RUSSELL (United Kingdom)<br>**Effectiveness of the 2023-24 seasonal influenza vaccine in UK healthcare workers: results from the SIREN prospective cohort study**: Luke MCGEOCH (United Kingdom)<br>**Immunogenicity and safety of second COVID-19 booster and Influenza vaccination coadministration**: Isabell WAGENH�USER (Germany)<br>**The degree of immunization against the Measles virus of the infant population in Sibiu county, Romania**: Stefan-Vasile CRISTEA (Romania) |
| 12/04 | 08:30 - 09:30 | EF004 | Pharmacology from bench to the bedside | Alina Karoline NUSSBAUMER-PR�LL (Austria) | **Enterococcus faecalis impairs Escherichia coli response to antibiotics in a dual-species intracellular infection model**: Francoise VAN BAMBEKE (Belgium)<br>**In vitro investigations of ceftazidime-avibactam and fosfomycin against carbapenemase-producing Enterobacterales clinical isolates**: Miklas MARTENS (Germany)<br>**In vivo activity and PK of the novel siderophore-cephalosporin AR-2126 in a lethal lung infection model in mice infected with a carbapenem-resistant Pseudomonas aeruginosa following subcutaneous administration**: Wolfgang WICHA (Austria)<br>**Synergistic Potency Unveiled: β-Lactam and β-Lactamase Inhibitor Combination against Mycobacterium abscessus with Dual Action of β-Lactamase Inhibition and Multi-Target Receptor Inactivation**: Eunjeong SHIN (United States)<br>**Pharmacokinetic/pharmacodynamic evaluation of benzoxaborole MRX-5 in mouse pneumonia model with Mycobacterium abscessus infection**: Wen WANG (United States)<br>**Pharmacokinetic/pharmacodynamic modelling of immune response and meropenem activity in immunocompetent and neutropenic mouse lung infection models**: Rapha�l SAPORTA (Sweden)<br>**Implementation of a model-based nomogram for amoxicillin precision dosing in patients suspected of infective endocarditis: preliminary results of the NOMOBA-AMX multicentre study**: Paul LE TURNIER (French Guiana)<br>**No time to waste: hospital-wide assessment of IV- vial and line residuals and impact on target attainment.**: Dorian VANNESTE (Belgium)<br>**Population pharmacokinetic modelling of colistin in critically-ill patients on sustained low-efficiency dialysis: implications for dose selection**: Dominika FUHS (Australia) |
| 12/04 | 08:30 - 10:30 | EW039 | Are urinary tract infections still the same? | Suzanne GEERLINGS (Netherlands), Agnes Maria SONNEVEND (Hungary) | **Update on paediatric UTI**: Michael BUETTCHER (Switzerland)<br>**Diagnosis and treatment of UTI in the era of antimicrobial resistance**: Jennifer KRANZ (Germany)<br>**Can UTI be prevented?**: Chris HARDING (United Kingdom)<br>**Fungal and parasitic infections of the urinary tract**: Gladys MBWANJI (United Republic Of) |
| 12/04 | 08:30 - 10:30 | EW040 | OPAT: from aged wine to new vintage | Birgit KOCH (Netherlands), Sonia LUQUE (Spain) | **OPAT: principles, practice and checklists**: Charlotte QUINTENS (Belgium)<br>**COPAT: complex outpatient parenteral antimicrobial therapy**: Ronald Andrew SEATON (United Kingdom)<br>**Antimicrobial stability and other challenges for OPAT practice?**: Mark GILCHRIST (United Kingdom)<br>**New OPAT safety and efficacy data to guide practice**: Matthew RAWLINS (Australia) |
| 12/04 | 08:30 - 10:30 | EW041 | RSV infections: diagnosis, surveillance and treatment in the advent of vaccines | Monika REDLBERGER-FRITZ (Austria), Makeda SEMRET (Canada) | **Costs of RSV infection, compared to other respiratory viruses**: Barbara RATH (France)<br>**Virology and host interactions of RSV**: Peter OPENSHAW (United Kingdom)<br>**RSV surveillance in the EU/EEA in the vaccine era**: Eeva BROBERG (Sweden)<br>**RSV fusion inhibitors and monoclonals: current status and future developments**: Louis BONT (Netherlands) |
| 12/04 | 08:30 - 10:30 | EW042 | Traumatic wound infections: diagnosis and treatment options | Amparo FERN�NDEZ-RODR�GUEZ (Spain), Veroniek SAEGEMAN (Belgium) | **Multidrug-resistant infections after trauma in warzone**: Shehan HETTIARATCHY (United Kingdom)<br>**Fungal infections during natural disasters**: Anuradha CHOWDHARY (India)<br>**Bacteriophage therapy for multidrug-resistant wound infections in trauma**: Tristan FERRY (France)<br>**Infection of burn wounds**: Nur BENZONANA (T�rkiye) |
| 12/04 | 08:30 - 10:30 | M4 | Malaria differential diagnosis (beginners) | Debbie NOLDER (United Kingdom), Claire ROGERS (United Kingdom) |  |
| 12/04 | 08:30 - 10:30 | OS001 | One Health means resistance everywhere | Alessandra CARATTOLI (Italy), Prasannakumar PALANIKUMAR (India) | **Decoding the role of blaCPE-carrying plasmids on wings: A holistic view using the One Health approach**: Sandra A. MART�NEZ-�LVAREZ (Spain)<br>**A novel isolation room model leveraging culture-independent Hi-C metagenomics for tracking antimicrobial resistance transmission between patients and hospital environmental reservoirs**: Vanessa KOH (Singapore)<br>**Deciphering the pathogenic potentials and epidemiological identities of Staphylococcus pseudintermedius colonizing companion dogs in Sao Paulo**: Ikechukwu Benjamin MOSES (Nigeria)<br>**Recent progress towards integrated surveillance of antimicrobial resistance in France**: Lucie COLLINEAU (France)<br>**Exploring the plasmidome of 3rd generation cephalosporin-resistant Enterobacterales in wild birds: Insights into horizontal gene transfer and AMR dissemination**: B�lint TIMMER (Hungary)<br>**Emergence of mobile colistin resistance in Klebsiella at human-animal-environment interface in Bangladesh**: Saifur RAHMAN (United Kingdom)<br>**Unveiling the invisible: antimicrobial resistance genes and pathogenic microbial diversity in sewage of North India's largest industrial hub, A metagenomic perspective**: Inderjit SINGH (India)<br>**Culturomics as a tool for ONE HEALTH approach: Unveiling the role of unknown microorganisms as antibiotic resistance carriers in wastewater samples**: Eleni OURANOU (Greece)<br>**One Health intervention impacts on antibiotic resistance in Denmark, England and Senegal: A mathematical model comparison**: Gwen KNIGHT (United Kingdom)<br>**Clinically important sequence types and resistance genes in Enterobacteriaceae from coastal environments and gulls**: Vanessa SILVA (Portugal) |
| 12/04 | 08:30 - 10:30 | OS002 | Translating metagenomics into clinical practice | Benjamin Peter HOWDEN (Australia), Paula M�LLING (Sweden) | **Nanopore metagenomic sequencing for rapid bloodstream infection diagnostics evaluated in a prospective observational study**: Hans Linde NIELSEN (Denmark)<br>**Interpretative Criteria for Adjudicating Clinical Significance to Next-Generation Sequencing Results from Bronchial-alveolar Lavage and Bronchial Wash.**: Jose ALEXANDER (United States)<br>**Implementing same-day respiratory metagenomic diagnostics in paediatric intensive care**: Robbie HAMMOND (United Kingdom)<br>**Detection of pathogenic microorganisms using metagenomic next-generation sequencing in ICU patients with ongoing antibiotic therapy**: Torsten SCHROEDER (Germany)<br>**Analysis of metagenomic pathogen detection compared to conventional diagnostics: clinical usage and relevance for patient outcomes**: Ekkehard SIEGEL (Germany)<br>**Same-day pan-microbial metagenomics for personalized therapy and pathogen surveillance on the intensive care unit: a single-centre prospective study**: Luke Blagdon SNELL (United Kingdom)<br>**Evaluation of the diagnostic efficacy of targeted next-generation sequencing in the detection of pathogens in bronchoalveolar lavage fluid from patients with lower respiratory tract infections in ICU**: Bowen RAN (China)<br>**Prognostic and diagnostic value of Next-generation sequencing in female reproductive tract infection and HPV persistence**: Chunyan PENG (China)<br>**A promising approach to rapid, non-culture diagnosis of invasive fungal infections (IFIs) by targeted next-generation sequencing (tNGS)**: M. Hong NGUYEN (United States)<br>**Implementation of Clinical Metagenomics in France: Insights from a Five-Years Study**: Marion DUTKIEWICZ (France) |
| 12/04 | 08:30 - 10:30 | SY031 | To screen or not to screen prior to transplant? | Laura Alicia BARCAN (Argentina), Oscar LEN (Spain) | **HHV-8 Screening**: Alessandra MULARONI (Italy)<br>**TB screening and prevention in endemic regions**: Rubina NAQVI (Pakistan)<br>**Screening for and prevention of chagas in immunocompromised hosts**: Marcelo Victor RADISIC (Argentina)<br>**Screening of lung donors for Molicutes**: Michael G ISON (United States) |
| 12/04 | 08:30 - 10:30 | SY032 | New insights into Candida pathogenesis | Aleksandra BARAC (Serbia), Joshua NOSANCHUK (United States) | **Insights into the evolution of Candida under antifungal pressure**: Attila GACSER (Hungary)<br>**How do Candida extracellular vesicles modify virulence during disease?**: Leonardo NIMRICHTER (Brazil)<br>**The commensal to pathogen transition: kind to killer**: Ilse D. JACOBSEN (Germany)<br>**Fungal-bacterial interactions: who wins?**: Rebecca HALL (United Kingdom) |
| 12/04 | 08:30 - 10:30 | SY033 | Single-cell approaches to dissect cellular phenotypic heterogeneity of bacterial pathogen populations. | Christian Stephan LENTZ (Norway), Annelies ZINKERNAGEL (Switzerland) | **Adaptive evolution and phenotypic heterogeneity of bacterial pathogens during infections**: Christoph ERNST (Germany)<br>**Single-cell imaging and heterogeneity in antimicrobial resistance**: Stefano PAGLIARA (United Kingdom)<br>**Single-cell RNAseq and heterogeneity in bacterial transcription**: Anna KUCHINA (United States)<br>**Dissecting the function of individual bacteria in their spatial context**: Knut DRESCHER (Switzerland) |
| 12/04 | 08:30 - 10:30 | SY034 | Endoscopy: infection risks and mitigation | Elisabeth PRESTERL (Austria), Gordon RAMAGE (United Kingdom) | **Should we be concerned about infection from contaminated endoscopes?**: Claire AUMERAN (France)<br>**Prevention of multidrug-resistant infections from contaminated duodenoscopes**: Margreet C. VOS (Netherlands)<br>**Understanding the causes of medical device contamination: it is all biofilm!**: Roberto RUSCONI (Italy)<br>**Does the European medical Device Regulation bring us safer duodenoscopes?**: Markus HELL (Austria) |
| 12/04 | 08:30 - 10:30 | SY035 | Barriers to TB/HIV elimination in low- and high-incidence settings | Daria PODLEKAREVA (Denmark) | **HIV and TB epidemic: the storm hasn't subsided yet**: Tetiana KOVAL (Ukraine)<br>**Approaches for latent and active TB screening in people living with HIV**: Raimonda MATULIONYTE (Lithuania)<br>**Integration of HIV and TB care to improve patient outcome in resource-limited settings**: Akaki ABUTIDZE (Georgia)<br>**How researchers can influence policy and practice in HIV/TB care**: Jens D. LUNDGREN (Denmark) |
| 12/04 | 08:30 - 10:30 | SY036 | The quality of antibiotics used in the communities of LMICs | Thi Thuy Nga DO (Vietnam), Christina OBIERO (Kenya) | **The quality of antibiotics and their potential impact on patient outcome and AMR**: Paul NEWTON (United Kingdom)<br>**Community antibiotic access and use in Sub-Sahara Africa**: Samuel AFARI-ASIEDU (Ghana)<br>**Encountered challenges and reflections on conducting multi-country medicine quality studies**: Noudy SENGXEU (Lao People's Democratic Republic)<br>**Confusion in appearance of common used antibiotics in LMICs**: Heiman WERTHEIM (Netherlands) |
| 12/04 | 08:30 - 10:30 | SY037 | Unveiling the challenges: nosocomial infections in ECMO-supported patients | Antonios KATSOUNAS (Germany), Jordi RIERA (Spain) | **Source of infection and pathogens**: Christian ECKMANN (Germany)<br>**Prophylaxis and empiric treatment**: Giacomo GRASSELLI (Italy)<br>**Diagnostic criteria and definitions**: Graeme MACLAREN (Singapore)<br>**Microbial films**: Marta HERN�NDEZ-MENESES (Spain) |
| 12/04 | 08:30 - 11:30 | EW038 | EUCAST Educational Workshop | Marlene AMARA (France), Alasdair P. MACGOWAN (United Kingdom) | **EUCAST update**: S�ren G. GATERMANN (Germany)<br>**Setting clinical breakpoints, assessing evidence**: Anouk Edwina MULLER (Netherlands)<br>**Benzylpenicillin susceptibility testing of S. pneumoniae by disk diffusion**: Gunnar KAHLMETER (Sweden)<br>**What to do when there are no breakpoints**: Barbara Juliane HOLZKNECHT (Denmark)<br>**Detection of resistance mechanisms**: Christian GISKE (Sweden) |
| 12/04 | 08:30 - 12:00 | TAE1 | TAE Day: morning round | Murat AKOVA (T�rkiye), Marc J.M. BONTEN (Netherlands), Anu KANTELE (Finland), Xavier LESCURE (France), Preeti MALANI (United States), Evelina TACCONELLI (Italy) |  |
| 12/04 | 09:30 - 10:30 | EF005 | It's all in the blood | Colin R. MACKENZIE (Germany) | **Limited delayed incubation of blood culture bottles has limited effect on yield and time-to-positivity**: Liselotte HARDY (Belgium)<br>**Unnecessary clinical interventions due to blood culture contamination in a large Canadian hospital network**: Clayton Wallace HALL (Canada)<br>**Utility of sigmoidal growth curve when no organisms are seen on Gram stain in positive blood cultures**: Declan CRILLY (United Kingdom)<br>**Clinical microbiology laboratory consultancy to optimize blood culture workflow: Analysis of results**: Carlotta MAGRI (Italy)<br>**Comparison of Syndromic Sepsis Panel and Standard Blood Culture Results: Contribution to Patient Management**: Sevim Gayenur BUYUKBERBER (T�rkiye)<br>**Predicting blood culture positivity using machine learning with complete blood and differential counts in a tertiary care hospital of Turkiye**: �zlem T�RKMEN RECEN (T�rkiye)<br>**Performance of direct pathogen and β-lactamase detection workflow using MALDI-TOF MS from positive blood culture specimens**: Kosuke KOSAI (Japan)<br>**Waiting for follow-up blood cultures is not always necessary for diagnosis of central line-associated bloodstream infections**: Lieke VAN BALEN (Netherlands)<br>**Economic and health gains associated with the adoption of the 2-hour phenotypic antimicrobial susceptibility testing in patients with bloodstream infection in Europe**: Cid�lia PINA-VAZ (Portugal) |
| 12/04 | 09:30 - 10:30 | EF006 | Emerging developments in antifungal pharmacology | Roger BR�GGEMANN (Netherlands) | **NATURE-US: the natural history of antifungal failure in invasive candidiasis**: Luis OSTROSKY-ZEICHNER (United States)<br>**The antidepressant vortioxetine enhances resistance toward multiple azoles**: Silvia RIZZO (Italy)<br>**Enhancing Isavuconazole Pharmacokinetics: A Comprehensive Population (PPK) Model from Three Phase 3 Trials and Covariate Exploration**: Desai AMIT (United States)<br>**Identification of efflux inhibitors for Candida albicans through a drug repurposing strategy**: D�bora MARQUES (Portugal)<br>**Clinical outcomes of micafungin 100 mg vs. 150 mg daily for the treatment of Candida auris fungemia**: Jysheng HOU (United States)<br>**Resolution of clinical signs in adults with invasive candidiasis and/or candidaemia treated with rezafungin or caspofungin: ReSTORE and STRIVE trial pooled analysis**: George R THOMPSON (United States)<br>**Ibrexafungerp is effective in treatment of patients with candidiasis, including candidaemia, caused by Candida auris: a multicentre, open-label study (CARES)**: Marisa H. MICELI (United States)<br>**High-dose isavuconazole therapy is well-tolerated and significantly improves survival in a fruit fly model of invasive mucormycosis**: Sebastian WURSTER (United States)<br>**Pharmacokinetics, pharmacodynamics, safety, and efficacy of innovative dosing schedules of liposomal amphotericin B for treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits**: Ruta PETRAITIENE (United States) |
| 12/04 | 09:30 - 10:30 | MEET60 | Genomic and Molecular Diagnostics Study Group open meeting (ESGMD) | Hege Vangstein AAMOT (NorwayESCMID official), Adrian EGLI (SwitzerlandESCMID official), Mario RAMIREZ (PortugalESCMID official), Belen RODRIGUEZ-SANCHEZ (SpainESCMID official), John W. A. ROSSEN (NetherlandsESCMID official) |  |
| 12/04 | 09:30 - 10:30 | MEET61 | Anaerobic Infections Study Group open meeting (ESGAI) | Michael BUHL (GermanyESCMID official), Yann DUMONT (FranceESCMID official), Samo JEVERICA (SloveniaESCMID official), Trefor MORRIS (United KingdomESCMID official), Jozsef SOKI (HungaryESCMID official) |  |
| 12/04 | 09:30 - 10:30 | SY043 | Year in infection control | Nico Tom MUTTERS (Germany), Ermira TARTARI (Malta) | ****: Andrew James STEWARDSON (Australia), Kalisvar MARIMUTHU (Singapore) |
| 12/04 | 10:30 - 10:50 | IPT01 | Clinical application of the UllCORE BSI Test - deepull's direct-from-blood multiplex PCR |  | **Clinical application of the UllCORE BSI Test - deepull's direct-from-blood multiplex PCR**: Kimberle CHAPIN (Spain) |
| 12/04 | 11:00 - 11:20 | IPT02 | Race against resistance: understanding the impact of AMR on cancer care and advancing solutions |  | **Race against resistance: understanding the impact of AMR on cancer care and advancing solutions**: Matteo BASSETTI (Italy) |
| 12/04 | 11:00 - 12:00 | EF014 | Infection control and prevention around the World | Divyashree SHANTHAMURTHY (India) | **WHO Global Survey on Infection Prevention and Control Minimum Requirements: Laying the Foundation for 2030 Global Targets**: Peter BISCHOFF (Switzerland)<br>**Healthcare-associated infections in african intensive care units: A muliticentre prospective cohort study**: Bamba GAYE (Senegal)<br>**Epidemiology of community-acquired versus hospital-acquired sepsis in acute hospitals in Ireland - 2016-2022.**: Emer LIDDY (Ireland)<br>**Epidemiology of Central Line-Associated Bloodstream Infections (CLABSIs) in a Network of Ten Hospitals across Greece: A 30-Month Surveillance Study – GRIPP-SNF Network**: Ioannis KOPSIDAS (Greece)<br>**Characterisation of plasmids disseminating antibiotic resistance in Klebsiella pneumoniae isolates from Pretoria, South Africa**: Theevasha GOVENDER (South Africa)<br>**Transmission dynamics of carbapenemase-producing bacteria between hospital and household settings in Benin**: Kevin Mael Patrick Zinsou SINTONDJI (Benin)<br>**Evaluating the impact of a rapid screening test for carbapenem-resistant organisms in Brazilian intensive care units.**: Matias SALOM�O (Brazil)<br>**Genomic Insights into the Rapid Rise of Pseudomonas aeruginosa ST463: A High-Risk Clone's Adaptive Strategy in China**: Xu DONG (China)<br>**Nanopore long-read only genome assembly for public health surveillance of Enterobacterales bloodstream infections and plasmid epidemiology in England: A pilot study**: Dorottya NAGY (United Kingdom) |
| 12/04 | 11:00 - 12:00 | EF015 | Advances in the diagnosis and treatment of skin, bone, and joint infections | Norma JUNG (Germany) | **Potential benefits of PET-CT in the management of bone and joint infections in infective endocarditis: a retrospective analysis from the Mayo Clinic**: Francesco PETRI (Italy)<br>**Synovial fluid microRNA biomarkers enable accurate diagnosis of periprosthetic joint infection**: Bernhard J.h. FRANK (Austria)<br>**Diagnostic accuracy of 16S rDNA PCR, multiplex PCR and metagenomic Next-Generation Sequencing in periprosthetic joint infections: a systematic review and meta-analysis**: Flaminia OLEARO (Germany)<br>**Comparison of microbiology, management and outcome between patients with native and with post-surgical vertebral osteomyelitis: a 7-year retrospective study**: Giacomo FRANCESCHI (Italy)<br>**Cefiderocol real-life use in bone and joint infection: a retrospective French multicenter study**: Ava DIARRA (France)<br>**Real-Life Experience with Dalbavancin as Suppressive Antibiotic Treatment in orthopaedic implant-related infections.**: Rosa ESCUDERO-S�NCHEZ (Spain)<br>**Short or Long Antibiotic Regimes in Orthopaedics: the SOLARIO multicentre randomised controlled trial**: Maria DUDAREVA (United Kingdom)<br>**Clinical and Antibacterial Diversity of Staphylococcal Phenotypes in Skin and Soft Tissue Infections: A Resource-Limited Country Perspective.**: Faiza ZEESHAN (Pakistan)<br>**Discrepancy between clinical-radiological diagnosis and surgical confirmation in 62 patients undergoing fasciotomy for suspected necrotizing fasciitis: a 11-year retrospective study.**: Federico ROMANI (Italy) |
| 12/04 | 11:00 - 12:00 | EF016 | Rising threats: antimicrobial resistance in STIs | Marcos RUST (Austria) | **Important rise of antibiotic resistance of Mycoplasma genitalium, a sexually transmitted pathogen, in a French University hospital**: Florence DOUCET POPULAIRE (France)<br>**Molecular characterization of antimicrobial resistance and genotyping of Mycoplasma genitalium positive samples of the Lisbon area, Portugal**: Margarida BARROS (Portugal)<br>**Antimicrobial Resistance in Mycoplasma genitalium: Surveillance and Management in São Paulo, Brazil**: Victor PASSARELLI (Brazil)<br>**Impact of genotypic substitutions on treatment failure for Mycoplasma genitalium infection**: Nicholas Brian BANA (Italy)<br>**Macrolide-resistant Mycoplasma genitalium: an emerging threat to public health?**: Jorge CISCAR SORIANO (Spain)<br>**Comparison of carbapenem MIC in wild-type, MDR and XDR Neisseria gonorrhoeae isolates**: Julie BROUSSEAU (France)<br>**Unsettling surge in antimicrobial resistance patterns of Neisseria gonorrhoeae - A study from national reference centre in India.**: Devanshi SHARMA (India)<br>**Surveillance of Neisseria gonorrhoeae antimicrobial resistance rate and treatment regimes in Singapore from 2014 to 2024**: Marcella GIOVANNI (Singapore)<br>**Molecular surveillance results of N. gonorrhoeae in Korea**: Kyoung Ho ROH (Republic Of) |
| 12/04 | 11:00 - 12:00 | FO050 | HIV: a global ethical Conundrum | Seif AL-ABRI (Oman) | **HIV, from key population to general population: a Pandora's Box**: Syed Faisal MAHMOOD (Pakistan)<br>**Ethical considerations in preventing mother-to-child HIV transmission**: Glory ALEXANDER (India)<br>**HIV drug trials in Africa: ethical concerns**: Shah REENA (Kenya)<br>**HIV-related stigma and discrimination in the healthcare setting**: Teymur NOORI (Sweden) |
| 12/04 | 11:00 - 12:00 | KN044 | Asia: an AMR Hot Zone | Giulia DE ANGELIS (Italy), Robert Leo SKOV (Denmark) | ****: David L. PATERSON (Singapore) |
| 12/04 | 11:00 - 12:00 | LB001 | Advances in vaccine effectiveness for viral respiratory infections | Jean Paul STAHL (France) | **Vaccination in pregnancy with RSVpreF elicits IgG, IgA and total secretory antibody responses in milk of lactating individuals**: Jessica ATWELL (United States)<br>**Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults ≥65 years of age in the United States**: Amanda MILES (United States)<br>**Safety and immunogenicity of the MERS vaccine, ChAdOx1 MERS, in older adults with and without prior ChAdOx1 exposure**: Daniel JENKIN (United Kingdom)<br>**Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants**: Amparo FIGUEROA (United States)<br>**JN.1-adapted vaccine effectiveness against COVID-19 hospitalisation in Europe: a test-negative case-control study using id.DRIVE**: Hannah R VOLKMAN (United States) |
| 12/04 | 11:00 - 12:00 | ME048 | Cut a long story short: choosing NGS platforms |  | ****: Etienne RUPPE (France), Stefan GREEN (United States) |
| 12/04 | 11:00 - 12:00 | ME049 | How to perform clinical trials in mycoses? |  | ****: Monica SLAVIN (Australia), Nkechi AZIE (United States) |
| 12/04 | 11:00 - 12:00 | MEET62 | Clostridioides difficile Study Group open meeting (ESGCD) | John E. COIA (DenmarkESCMID official), Kerrie DAVIES (United KingdomESCMID official), Erik DUBBERKE (United StatesESCMID official), John HERITAGE (United KingdomESCMID official), Andrea MARINO (ItalyESCMID official), Wiep Klaas SMITS (NetherlandsESCMID official) |  |
| 12/04 | 11:00 - 12:00 | MEET63 | Viral Hepatitis Study Group open meeting (ESGVH) | Imran HASANOGLU (T�rkiyeESCMID official), Mojca MATICIC (SloveniaESCMID official), Oana SANDULESCU (RomaniaESCMID official) |  |
| 12/04 | 11:00 - 12:00 | OS007 | New developements in prophylaxis and treatment of COVID-19 | Snjezana ZIDOVEC LEPEJ (Croatia), G�lsen �ZKAYA SAHIN (Sweden) | **Ensitrelvir for the prevention of COVID-19 among household contacts: key subgroup analyses of a randomized, double-blinded, placebo controlled post-exposure prophylaxis study, SCORPIO-PEP**: Frederick HAYDEN (United States)<br>**Efficacy of nirmatrelvir/ritonavir on overall COVID-19 related symptoms in immunocompromised adult participants from the EPIC-IC trial**: Ruth MOKGOKONG (United Kingdom)<br>**COVID-19 patients benefitting from remdesivir for improved survival: a neural network-based approach.**: Tommaso Francesco AIELLO (Spain)<br>**Efficacy and safety of sotrovimab vs oral antivirals in omicron waves: a retrospective analysis**: Chiara CACACE (Italy)<br>**Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial**: Cl�ment MASSONNAUD (France) |
| 12/04 | 11:00 - 12:00 | OS008 | Advancing Malaria Research: From Molecular Insights to Clinical Challenges | Kamruddin AHMED (Malaysia), Giri Shan RAJAHRAM (Malaysia) | **Influence of second blood meals on Plasmodium vivax development and infectivity in mosquitoes**: Sirasate BANTUCHAI (Thailand)<br>**Severe imported Plasmodium falciparum malaria with hyperparasitaemia: evaluation of predictors for critical disease**: Tilman LINGSCHEID (Germany)<br>**The current status of Plasmodium falciparum chloroquine resistance transporter gene (K76T) and Plasmodium falciparum multi-drug resistance gene 1 (N86Y) in Cameroon**: Magdany FRU (Cameroon)<br>**SOFA score vs WHO severity criteria to guide antimalarial treatment - 10 years of imported malaria cases in a UK tertiary centre reviewed.**: Emmie SAVORY (United Kingdom) |
| 12/04 | 11:00 - 12:00 | OS009 | Osteoarticular uninvited guests | Tiziana ASCIONE (Italy), Jaime ESTEBAN (Spain) | **Antibiotic-refractory oligoarthritis in an adolescent caused by Borrelia bavariensis in Croatia**: Nina KRAJCAR (Croatia)<br>**Progression of vertebral echinococcosis despite radiotherapy treatment**: Marta GONZ�LEZ-SANZ (Spain)<br>**Two cases of septic osteoarthritis of Cutibacterium acnes detected by 16S rRNA gene sequencing in immunocompetent adolescents**: Hideo OKUNO (Japan)<br>**A UK case of Melioidosis with osteomyelitis two years after geographical exposure**: Christopher DARLOW (United Kingdom)<br>**When Infection Masquerades as Malignancy: A Case of Disseminated Mycobacterium fortuitum complex infection with Mixed Osteoblastic and Osteolytic Lesions and Lymphadenopathy in Anti-IFN-γ Immunodeficiency Syndrome**: Napon HIRANBURANA (Thailand) |
| 12/04 | 11:00 - 12:00 | OS010 | Antimicrobial drugs in action | Katy JEANNOT (France), Timothy R. WALSH (United Kingdom) | **In vivo cefiderocol resistance due to cirA modification during treatment**: Edoardo CARRETTO (Italy)<br>**Long-term outcomes in dalbavancin-treated patients with vascular graft infection.**: Antoine SPECKLIN (France)<br>**Aztreonam, ceftazidime/avibactam, and tigecycline combination for the management of multi-drug resistant E.coli on peritonitis in a pediatric liver transplant recipient**: Ronaldo MORALES JUNIOR (United States)<br>**Early oral antibiotic treatment in patients with post-neurosurgical brain abscesses caused by Cutibacterium acnes – a case series**: Mario KAROLYI (Austria)<br>**Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant K. pneumoniae shunt-related ventriculitis: two case reports.**: Gabriele GIULIANO (Italy) |
| 12/04 | 11:00 - 12:00 | OS011 | Around the lab in 80 ways: a journey through innovative therapeutics | Zuzanna DRULIS-KAWA (Poland), Helena ZEMLICKOVA (Czech Republic) | **In vivo expression of an mRNA encoded multi-mechanistic mAb combination against Staphylococcus aureus and protection in a disease model**: Christine TKACZYK (United States)<br>**Hijacking intrinsic resistance in Mycobacterium abscessus**: Gregory PHELPS (United States)<br>**Tripartite bacteriophage-based strategy to combat human clinical pathogens**: Panos KALATZIS (Denmark)<br>**Eosin Y and Ceragenin combinations for enhanced antimicrobial photodynamic therapy**: Yamac TEKINTAS (T�rkiye)<br>**Identification of compounds capable of removing established bacterial biofilms**: Thomas INZANA (United States) |
| 12/04 | 11:00 - 12:00 | OS012 | Climate Impact and One Health Approaches Against Infectious Diseases | Chadia WANNOUS (France) | **Airborne Threats: Pollution, Climate, and Respiratory Infections in a Pyrenean setting: The Andorran hospital based respiratory perspective**: Cristina ROYO-CEBRECOS (Andorra)<br>**Effects of climate change on Aedes aegypti abundance and dengue transmission**: Lin GENG (Singapore)<br>**Impact of climate variables on Crimean-Congo hemorrhagic fever in Iran, Iraq, Kazakhstan, and Russia**: Mohammad FEREIDOUNI (Islamic Republic Of)<br>**Successful public health and one health response to a high pathogenicity avian influenza outbreak in poultry farms in Victoria, Australia: implications for future planning**: Eugene ATHAN (Australia)<br>**Turning disease surveillance into reality: Using metagenomic sequencing with piggery wastewater**: Manavi MURALIDHAR (Australia) |
| 12/04 | 11:00 - 12:00 | OS013 | Viral challenges in organ transplantation | Ghady HAIDAR (United States), Cristiana OPREA (Romania) | **Evaluation of an individualized CMV prevention strategy guided by post-transplant CMV-specific cell-mediated immunity in intermediate-risk kidney transplant recipients**: Isabel RODR�GUEZ-GONCER (Spain)<br>**Real-world Use of Letermovir Prophylaxis for Cytomegalovirus (CMV) Prevention in Non-kidney Transplant Recipients**: Abdallah MUGHRABI (United States)<br>**Real-world administration of maribavir beyond the eight weeks established in the clinical trial**: David MART�NEZ-SIM�N (Spain)<br>**Prediction of BK Polyomavirus nephropathy in kidney transplantation by measuring neutralizing responses in a large cohort of donor and recipients**: Morgane SOLIS (France)<br>**Dengue in solid organ transplant recipients**: Santiago Iv�n GALIAN (Argentina) |
| 12/04 | 11:00 - 12:00 | SY045 | What happens following TB infection? | Catherine ONG (Singapore), Sean WASSERMAN (United Kingdom) | **Post-TB disease: burden and treatment strategies**: Deborah CHONG (United Kingdom)<br>**TB sequelae and fungal infection**: Helmut SALZER (Austria) |
| 12/04 | 11:00 - 12:00 | SY046 | New frontiers in bacterial pathogenesis | Silvio Daniel BRUGGER (Switzerland), Abdou HACHANI (Australia) | **Bacterial infections and cellular immunity**: Charlotte ODENDALL (United Kingdom)<br>**Immuno-metabolism in bacterial diseases**: Tania WONG (United States) |
| 12/04 | 11:00 - 12:00 | SY047 | How long should contact isolation precautions be continued? | Cansu CIMEN (Germany), Kyriaki TRYFINOPOULOU (Greece) | **Contact isolation in patients with MDR organisms: Why, when, where?**: Gabriel BIRGAND (France)<br>**Is discontinuation of contact precautions associated with an increase in infections?**: Daniel DIEKEMA (United States) |
| 12/04 | 11:00 - 12:00 | YIA | Young Investigator Award Session |  | **Deciphering the pathogenic traits and epidemiological identities of Staphylococcus pseudintermedius: an emerging and underestimated zoonotic pathogen**: Ikechukwu Benjamin MOSES (Nigeria)<br>**Drugs for Vector-borne Infections: Facts and Fibrillations**: Xin Hui CHAN (United Kingdom)<br>**Duke criteria for the diagnosis of infective endocarditis in clinical practice: are we there yet?**: Matthaios PAPADIMITRIOU OLIVGERIS (Switzerland)<br>**Finding a place for observational studies in infectious diseases research**: Anthony BAI (Canada)<br>**Clearing fungal fog in viral storms: deciphering influenza- and COVID-19-associated pulmonary aspergillosis**: Simon FEYS (Belgium) |
| 12/04 | 11:30 - 11:50 | IPT03 | Developing a potential first-in-class live biotherapeutic product (LBP) to prevent recurrent C. difficile infection (rCDI) |  | **Developing a potential first-in-class live biotherapeutic product (LBP) to prevent recurrent C. difficile infection (rCDI)**: Oliver A. CORNELY (Germany) |
| 12/04 | 12:00 - 12:20 | IPT04 | The DRAIGON project: developing MDR diagnosis with AI-driven whole-genome sequencing for rapid, precise, and comprehensive detection of resistant infections |  | **The DRAIGON Project: developing MDR diagnosis with AI-driven whole-genome sequencing for rapid, precise, and comprehensive detection of resistant infections**: Irina MELN (France) |
| 12/04 | 12:00 - 13:30 | PS001 | 01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance) |  | **Measles seroprevalence in  people living with human immunodeficiency virus in  northern Transylvania, Romania**: Adriana Violeta TOPAN (Romania)<br>**Evaluation of HIV Ag/Ab combo, HBsAg and anti-HCV serological assays on a new-to-market, high throughput analyser for emergency department opt-out testing in a high prevalence population as part of the United Kingdom screening programme**: Ana Sofia GIL VIEIRA DA SILVA (United Kingdom)<br>**Enhanced clearance of broadly neutralising HIV-1 Antibody VRC07-523-LS under Viremia: influences on trial design and analysis**: Brian HO (United States)<br>**Clinical impact of integrase inhibitor resistance: a growing challenge for the future?**: Jorge CISCAR SORIANO (Spain)<br>**Evaluation of the new DxI 9000 anti-HIV antibody and antigen combo assay**: Martin OBERMEIER (Germany)<br>**Cytomegalovirus IgG concentration is associated with reduced lung function in well-treated persons with HIV**: Jeppe Terpager CHRISTIANSEN (Denmark)<br>**Mental health in PLWH: psychopathological variables and personality traits in patients compared with non-clinical subjects in Italy**: Francesco ROMANO (Italy)<br>**Significant mortality reduction of severe Pneumocystis jirovecii pneumonia in people living with HIV treated in the intensive care unit, Croatia, 2002-2023**: Filip GLAVAC (Croatia)<br>**Analysis of resistance profiles in relation to subtypes and immune markers in newly diagnosed HIV patients**: �znur G�NES (T�rkiye)<br>**Analysis of the effect of high-sensitive CRP on bone density in people living with HIV**: Philipp MATH� (Germany)<br>**Understanding the evolution of HIV-1 in Ghana: subtype distribution and drug resistance challenges**: Pious APPIAH (Ghana)<br>**Safety and efficacy of long-acting HIV treatment in real life at a tertiary care hospital**: Francisco ARNAIZ DE LAS REVILLAS ALMAJANO (Spain)<br>**Evaluating HIV-1 protease drug binding affinity: structural prediction with AlphaFold2 and AutoDock Vina**: Francisco MERCA (Belgium)<br>**Toll-like receptors (TLRs) polymorphism in HIV-I infected patients with and without tuberculosis (TB) co-infection**: Gaurav KAUSHIK (India)<br>**Generic HIV-1 Viral Load Ver 2.0: a dual target quantitative assay for HIV-1**: Vera ALLERHEILIGEN (Germany)<br>**Clinical characteristics and treatment outcomes in critically ill people living with HIV: a single-centre study from an infectious disease intensive care unit, 2002-2023**: Filip GLAVAC (Croatia)<br>**Acceptability and feasibility interventions measures (AIM & FIM) of the implementation of long-acting cabotegravir plus rilpivirine (CAB LA + RPV LA) administration out of HIV units: the IMADART study**: Alfonso CABELLO (Spain)<br>**Gender defines factors related to linkage to HIV care and early antiretroviral therapy—The Go Holistic Go Beyond project**: Dominik BURSA (Poland)<br>**Identification of APOBEC mutations and their impact on HIV drug resistance using next-generation sequencing (NGS)**: Paloma MU�OZ (Spain)<br>**Longitudinal study of type I interferon neutralising antibodies in people living with HIV**: Alessandra D'AURIA (Italy)<br>**Influence of immune exhaustion receptors PD-1 and PD-1L on immune reconstitution in ART-treated patients living with HIV**: Milosz PARCZEWSKI (Poland)<br>**NAFLD and hepatitis B status as predictors of liver fibrosis in PLWH who switch to LA-ART**: Jose Ignacio MATEO GONZALEZ (Spain)<br>**Development of engineered nanocarrier for controlled delivery of a protease inhibitor**: Prakash GOSAIN (India)<br>**Three decades of HIV/AIDS in Iran: epidemiological trends, socioeconomic impacts, and risk factors**: Seyed Aria NEJADGHADERI (Islamic Republic Of)<br>**Incidence density and risk factors of hepatitis B and/or hepatitis C co-infection among newly enrolled HIV patients in a tertiary government hospital treatment hub**: Honey Jane BLANCO-LIMOS (Philippines)<br>**CMV disease predictors and CMV viremia impact on immune reconstitution in advanced HIV infection**: Paula SUANZES (Spain)<br>**A nationwide survey on self-perception of HIV acquisition risk among people in prisons in Iran**: Seyed Aria NEJADGHADERI (Islamic Republic Of)<br>**Treatment and follow-up of HIV-infected patients diagnosed during the COVID-19 pandemic**: Masa JOVANOVIC (Serbia)<br>**NGF levels differ by CD4+ T cell count and change after treatment in PLWH**: Luca MADDALONI (Italy)<br>**Whole-genome sequencing: new strategies for managing HIV**: Marta ILLESCAS L�PEZ (Spain)<br>**Resistance to integrase inhibitors in HIV patients with therapeutic failure: striving for "zero resistance"**: Lucia PEREZ RODRIGUEZ (Spain)<br>**Genetic diversity in the capsid protein-coding region of HIV-1 circulating in Angola: implications for primary resistance to the novel capsid inhibitor lenacapavir**: Gon�alo QUEIR�S (Portugal)<br>**Assessing the prevalence of latent tuberculosis infection among people living with HIV with viral suppression and CD4+ T cell counts = 200 cells/μl in Thailand**: Shodok PROMSANJAN (Thailand)<br>**Phenotypic modulation of RBD-specific B cells in people living with HIV upon booster vaccinations with SARS-CoV-2 mRNA vaccines**: Jacopo POLVERE (Italy)<br>**Medication optimisation in older people living with HIV: a multidisciplinary approach**: Fatma Nisa BALLI TURHAN (T�rkiye)<br>**Long-acting CAB + RPV: safety, efficacy, and discontinuation risks in ODOACRE cohort**: Andrea DE VITO (Italy)<br>**Statins under-prescription in people with HIV in Thailand**: Sireethorn NIMITVILAI (Thailand) |
| 12/04 | 12:00 - 13:30 | PS002 | 01b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance) |  | **Development and characterisation of surface modified chitosan nanoparticles for selective targeting of lamivudine to hepatocyte**: Saurabh BHARGAVA (India)<br>**Evaluation of the new DxI 9000 ACCESS anti-HCV assay**: Martin OBERMEIER (Germany)<br>**Hepatitis E virus in northern Italy: focus on wild fauna for a One Health approach**: Sara ARNABOLDI (Italy)<br>**Performance evaluation of chemiluminescence anti-HCV assay**: Laura GRUMIRO (Italy)<br>**Novel S/Co ratios for predicting HCV RNA positivity in cancer patients: a study from a tertiary care cancer centre in India**: Shreya PANI (India)<br>**Missed opportunities for diagnosing HCV infection in patients identified by an emergency department screening strategy**: Anny CAMELO (Spain)<br>**Characterising HBV reactivation in non-liver solid organ transplant recipients: clinical insights from a multicentre study**: Imran HASANOGLU (T�rkiye)<br>**Screening for Y93H resistance associated substitution in chronic HCV patients presenting to a tertiary care hospital of north India**: Mini P SINGH (India)<br>**Refining diagnostics: a novel chemiluminescence assay for improved sensitivity and precision in HEV detection**: Ingrid ALBRECHT-WALZ (Germany)<br>**Evaluation of the new DxI 9000 ACCESS HBsAg assay**: Martin OBERMEIER (Germany)<br>**Enhancing HDV detection: prevalence and diagnostic advances in northern Spain**: Helena GARCIA LOPEZ (Spain)<br>**Acute HCV infection diagnosed by hepatitis C virus core antigen among people with HIV: an exploratory systematic review and meta-analysis**: Tsung-Yu TSAI (China)<br>**Influence of education level on the choice of hepatitis C virus self-testing: findings from Unitaid-funded STAR project in Nasarawa state, Nigeria**: Oluwabukolami LANLOYE (Nigeria)<br>**Bone metabolism and management of bone diseases in patients with chronic hepatitis B**: Gamze SANLIDAG ISBILEN (T�rkiye)<br>**Outcomes of mitigating hepatitis B mother-to-child transmission through early detection and prophylaxis; a prospective study at a tertiary care centre**: Sumit Kumar RAWAT (India)<br>**Prevalence and risk factors of active hepatitis C infection in migrants between 2019-2023 in Madrid, Spain**: Felipe P�REZ-GARC�A (Spain)<br>**Molecular surveillance of hepatitis A virus in Portugal, 2015 to 2024: high-impact value for outbreak case detection**: Mafalda BRITES DE ARA�JO LUCAS (Portugal)<br>**Sex and age differences in the hepatitis C virus continuum of care among people living with HIV and key populations in Nasarawa state, Nigeria**: Harrison NWABUEZE (Nigeria)<br>**Hepatitis C screening and treatment in the largest mariginalised Roma community with risky behavior**: Kristian PAVOL (Slovakia)<br>**Surveillance of ratHEV in extensively raised pigs in Spain**: Javier CABALLERO G�MEZ (Spain)<br>**Genotypic variations of hepatitis delta virus among chronic hepatitis patients in Uzbekistan**: Eldor URINOV (Uzbekistan)<br>**Optimising molecular diagnosis of hepatitis delta**: Marta ILLESCAS L�PEZ (Spain)<br>**Hepatitis delta virus prevalence in the European Union estimated with novel methodology**: Hugh WATSON (France)<br>**Epidemiology and testing of hepatitis delta virus infection in Australia**: Krispin HAJKOWICZ (Australia)<br>**Diagnostic value of consecutive samples for anti-HEV IgG analyses**: Marie Louise SLOTT JENSEN (Denmark)<br>**Whole genome sequencing of hepatitis C virus from dried blood spots by hybrid capture for genotype and antiviral resistance determination**: Emma Ann DAVIES (United Kingdom)<br>**Validation of a new molecular assay for the quantification of hepatitis D RNA in EDTA-plasma and serum samples**: Felipe P�REZ-GARC�A (Spain)<br>**Treat and Follow-Up: Recontamination by Hepatitis C Virus After Effective Treatment**: Samia BENADDA (Algeria)<br>**Comparative analysis of HBsAg and anti-HCV testing: dried blood spots vs whole blood**: Bouchra BELEFQUIH (Morocco)<br>**Relink-C study in Almer�a, Spain: opportunistic rescue of patients with HCV infection lost to follow-up in the healthcare system**: Anny CAMELO (Spain)<br>**Finite NA therapy in chronic hepatits B: a retrospective study on safety and prevalence of HBsAg-HBsAb seroconversion**: Erika ASPERGES (Italy)<br>**HDV full genome sequencing and genotype determination in a Berlin cohort**: Robert EHRET (Germany)<br>**Neurological injury associated with rat hepatitis E virus infection**: Lucia RIOS-MU�OZ (Spain)<br>**Febrile syndrome without a focus linked to rat hepatitis E infection**: Lucia RIOS-MU�OZ (Spain)<br>**Y.E.L.L.O.W. score (yellow fever end-stage liver and organ worsening score)**: Wanessa CLEMENTE (Brazil)<br>**Redetermination Anti-HCV Levels (S/Co) Based on Correlation with HCV-RNA for Diagnosing Hepatitis C Virus (HCV) Infection**: Muhammet KIPLAPINAR (T�rkiye)<br>**Epidemiology of the hepatitis delta virus in Spain through whole genome sequencing**: Ana ALBEROLA ROMANO (Spain)<br>**"ProLink" HCV study: optimising the HCV elimination cascade to re-engage the unreached**: Alberto VAZQUEZ BLANQUI�O (Spain)<br>**Characterisation of a cohort of liver transplant patients for HBV and/or HBV/HDV related complications: results of a Campania multicentre study**: Lorenzo SALMONI (Italy)<br>**Opportunistic diagnosis of hepatitis C virus infection by hypertransaminasemia: a one-year, single-centre, prospective study**: Felipe P�REZ-GARC�A (Spain) |
| 12/04 | 12:00 - 13:30 | PS003 | 01c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance) |  | **Burden of RSV hospitalisations among high-risk vs low-risk children in the second year of life: insights from a multicentre retrospective study**: Diana TASHER (Israel)<br>**The cost-effectiveness of influenza vaccination for adults aged 50 years or older in Spain**: Roberto FLORES (Spain)<br>**The pandemic respiratory virus epidemiological surveillance trial (PREVENT)-metagenomics study: total RNASeq enhances community-based respiratory virus surveillance in the Australian flutracking network**: Krispin HAJKOWICZ (Australia)<br>**Characterisation of respiratory pathogen coinfection in the bivalent RSVpreF pivotal RENOIR efficacy study**: John WOODSIDE (United Kingdom)<br>**A comparative study of methods for estimating the timing of RSV epidemics: an analysis within the GERi (Global epidemiology of RSV in hospitalised and community care) study**: Saverio CAINI (Netherlands)<br>**A deep learning model leveraging environmental information improves the forecasting accuracy of respiratory syncytial virus with seasonal patterns**: Jingyi LIANG (United Kingdom)<br>**Efficacy of syndromic IVD devices in identifying influenza A strains for pandemic preparedness**: Sven REISTER (Germany)<br>**Wastewater-based epidemiology of respiratory viruses: integration to conventional surveillance systems in Belgium**: Veronik HUTSE (Belgium)<br>**Adaptation of commercial syndromic device for quantification of viral influenza A load in clinical samples**: Sven REISTER (Germany)<br>**Monitoring the transmission and health care burden of respiratory viruses in emergency departments, Lombardy (northern Italy), 2023-2024**: Elena PARIANI (Italy)<br>**Development of a predictive severity scale for respiratory syncytial virus associated acute respiratory infection in adults at the emergency department**: Manuel GIL MOSQUERA (Spain)<br>**Comparative analysis of galectin-3-mediated inflammasome activation in human and avian influenza A virus infections**: Zih-Syuan YANG (China)<br>**A low pathogenic avian influenza A/Mallard/South Korea/KNU2019-34/2019 (H1N1) virus has the potential to increase the mammalian pathogenicity**: Haryoug POO (Republic Of)<br>**Severe acute respiratory infection (SARI) due to RSV in Wales: burden, symptoms and clinical risks in sentinel emergency departments**: Jana ZITHA (United Kingdom)<br>**Patients at risk of developing severe influenza-associated illness can be recognised at the emergency department using basic clinical assessment**: Susanna BERGBRANT (Sweden)<br>**Six-month persistence and safety of mRNA-based influenza or multicomponent influenza/COVID-19 vaccines versus licensed comparators in adults aged ≥18 years**: Mieke SOENS (United States)<br>**Effects of high-dose vs standard-dose quadrivalent influenza vaccine among patients with chronic lung disease: a prespecified secondary analysis of the DANFLU-1 trial**: Lisa Steen DUUS (Denmark)<br>**Analysis of myxovirus resistance protein A for diagnosis of respiratory viral infections**: Sunjoo KIM (Republic Of)<br>**Diagnostic efficacy of different tests for influenza and their impact on clinical decision-making**: Yu LUO (China)<br>**Molecular characterisation of RSV infections in elderly patients during the 2023/2024 season**: Amandine CAILLAULT (France)<br>**Demographic, clinical and molecular epidemiology of respiratory syncytial virus infection in infants in central Tunisia**: Boutheina EL KISSI (Tunisia)<br>**Association between seasonal respiratory virus activity and invasive pneumococcal disease in central Ontario, Canada**: David FISMAN (Canada)<br>**Respiratory syncytial virus (RSV) incidence estimates in primary care among adults aged 50 years and older in the Netherlands**: Joost VANHOMMERIG (Netherlands)<br>**Characterization of adenovirus at the species level and association with the severity of acute respiratory infection in a Chilean paediatric population, 2022-2023**: Gustavo SAINT-PIERRE CONTRERAS (Chile)<br>**Hospitalisation due to influenza infection in children: a multicentre nationwide study**: K�bra AYKAC (T�rkiye)<br>**The BEready pilot study: a population-based cohort to assess transmission of respiratory viral infections within households**: Karin GRIMM (Switzerland)<br>**Change in the epidemiology of influenza infection among cancer patients in the post-COVID era: insights from India**: Soumyadip CHATTERJI (India)<br>**Respiratory viruses in patients with haematological malignancy in Boreal autumn/winter 2023-2024**: Jon SALMANTON-GARCIA (Germany)<br>**Epidemiology of respiratory syncytial virus among childrens and adults in a third-level care hospital in Mexico City**: Lucia MARTINEZ-HERNANDEZ (Mexico)<br>**Evidence of oseltamivir-resistant influenza A virus transmission**: Anastasia COUZENS (United Kingdom)<br>**Respiratory syncytial virus burden of disease and molecular epidemiology in adults 50 years of age and older in Queensland, Australia: interim results from the 2024 season**: Krispin HAJKOWICZ (Australia)<br>**Burden and outcomes of RSV in adults aged 60 and older: a tertiary care analysis**: Oguzhan ACET (T�rkiye)<br>**Surveillance for respiratory viruses through DHR-ICMR VRDL network**: Lakshmi Jyothi TADI (India)<br>**Public health impact of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus among patients with chronic obstructive pulmonary disease in Italy**: Andrea BRAMBILLA (Italy)<br>**Facing the future of influenza surveillance: integrated surveillance for respiratory viruses in Serbia**: Dragana DIMITRIJEVIC (Serbia)<br>**Impact of rapid viral screening on influenza management: less haste, more waste**: Michael BURROWS (United Kingdom)<br>**Genomic epidemiology of respiratory syncytial virus circulating in Lombardy in 2023-2024 and variability in binding sites of monoclonal antibodies and small-molecule inhibitors**: Claudia ALTERI (Italy)<br>**Duration of recommended and reported isolation for seasonal influenza: updates from the 2023-24 influenza season**: Jennie KWON (United States)<br>**An unconjugated composite peptide vaccine comprising epitopes from SARS-CoV-2 RNA polymerase and influenza heamagglutinin, neuraminidase, and matrix generates broadly reactive and durable antibodies to coronavirus and influenza virus**: Nimisha RIKHI (United States)<br>**The mitochondrial carrier homolog 2 is involved in down-regulation of influenza A virus replication**: Pinar ULUPINAR (T�rkiye)<br>**Impact of respiratory syncytial virus hospitalisation on quality of life in the Valencia region of Spain ageing population**: Alejandro ORRICO-S�NCHEZ (Spain)<br>**Phyloepidemiology of influenza A/H3N2 and A/H1N1 viruses circulating in Georgia**: Nino SAGIRIDZE (Georgia)<br>**Comprehensive clinical validation of a novel real-time PCR assay for the detection of respiratory viruses in simulated human-like clinical samples**: Henar ALONSO-EZCURRA (Spain)<br>**Burden of disease (BoD), healthcare resource use (HCRU) and costs of respiratory syncytial virus (RSV) among adults in the Netherlands in 2021-2023: a real-world retrospective observational study of five hospitals**: Karin VELTHOVE (Belgium)<br>**How has the disappearance of influenza B/Yamagata altered the proportion of Influenza A and B cases? Exploring post-COVID pandemic surveillance data**: Marco DEL RICCIO (Italy)<br>**A bench-to-data analysis workflow for the sequencing of RSV whole genomes using short- and long-read technologies**: Laura CIUFFREDA (Spain)<br>**Operational framework and feasibility of the GALFLU study: a pragmatic randomised controlled trial evaluating high-dose vs standard-dose influenza vaccination in the elderly population**: Federico MARTIN�N-TORRES (Spain)<br>**Human metapneumovirus in Italian adults over 50 years: epidemiology and molecular evolution, 2022-2024**: Alessandro MANCON (Italy)<br>**Post-COVID-19 trends: enterovirus D68's seasonal reappearance and its public health relevance**: Cristina ANDR�S (Spain)<br>**Post-acute sequelae after non-COVID-19 community-acquired pneumonia as an underappreciated problem: findings from a prospective study in Singapore**: Pei Min THONG (Singapore)<br>**Between-region and serotype variations in seasonality of human parainfluenza viruses, and influence of climate factors: a global systematic analysis**: Xin WANG (China)<br>**The epidemiology of severe acute respiratory tract infections in Glasgow, UK: 2023-24**: Elen VINK (United Kingdom)<br>**Prevention and control of influenza: available tools in seven Latin American countries**: Hebe Noemi VAZQUEZ (United States)<br>**Respiratory syncytial virus vs influenza virus infection: mortality and morbidity comparison over two epidemic seasons before the pandemic in adults aged =50 years**: Benjamin DAVIDO (Benjamin DAVIDO)<br>**Respiratory syncytial virus (RSV)-associated hospitalisations and clinical progression in adolescents and adults in Valencia, Spain, 2014/2015–2019/2020: the VALSARI study**: Alejandro ORRICO-S�NCHEZ (Spain)<br>**Shifting viral landscapes: severe disease and mortality due to respiratory infections among older adults in the VALSARI study from Valencia, Spain, 2014-2023**: Alejandro ORRICO-S�NCHEZ (Spain)<br>**Influenza-related mortality among hospitalised adults in a Portuguese hospital during the 2023-2024 influenza season: are the elderly more vulnerable?**: F�bio REIS (Portugal)<br>**Outcomes of respiratory syncytial virus infections among cancer patients during the two recent respiratory viral seasons, 2022-2024**: Amy SPALLONE (United States)<br>**Investigating Cas13d activity in RNA cleavage against influenza virus**: Diana PEREZ-SANJOSE (Spain)<br>**Sequence independent amplification and sequencing of respiratory viruses direct from clinical sample**: Kate DINGLE (United Kingdom)<br>**Age-related asymptomatic rhinovirus infections contribute to the sustained prevalence of rhinovirus in adults and are not mitigated by non-pharmaceutical interventions**: Dong WEI (China)<br>**Effectiveness of universal prophylaxis with nirsevimab for prevention of infant hospitalisations due to respiratory syncytial virus : full 2023-24 season analysis of the NIRSE-GAL study https://www.nirsegal.es/**: Federico MARTIN�N-TORRES (Spain)<br>**Air and surface sampling to investigate bovine coronavirus shedding around calves**: Susan GOULD (United Kingdom)<br>**Elucidating the novel role of cholesterol consensus motif in coronavirus infections**: Jasper CHAN (China)<br>**Clinical characteristics and outcomes in hospitalised older adults with community onset or nosocomial respiratory syncytial virus infection (RSV) in Auckland**: Teena MATHEW (New Zealand)<br>**Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States**: Clarisse DEMONT (France)<br>**Serological influenza responses over the 2023-24 winter: the SIREN study**: Edward CARR (United Kingdom)<br>**Respiratory syncytial virus vs parainfluenza and human metapneumovirus infections: mortality and morbidity comparison over two epidemic seasons before the pandemic**: Benjamin DAVIDO (Benjamin DAVIDO)<br>**Epidemiological shifts in paediatric respiratory infections: pre- and post-COVID-19 pandemic**: Yi-Ting CHEN (China)<br>**Identifying low-frequency mutations in influenza**: Fredrik DYRKELL (Sweden)<br>**Bacterial co-infections and antibiotic use in adult patients hospitalised with respiratory syncytial virus compared to patients with influenza A or B, and their relation to mortality: a multicentre cohort study**: Kristine Lilhammer KARLSEN (Denmark)<br>**Paediatric patients with respiratory syncytial virus (RSV) are at greater risk of ICU admission when co-infections are present**: Anna SSENTONGO (United States)<br>**Overview of NA inhibitors mutations during the last 15 years in Spain**: Ivan SANZ-MU�OZ (Spain)<br>**Unveiling an optimal case definition and the natural history of RSV infection in adult outpatients aged ≥50 years**: Alexander DOMNICH (Italy)<br>**Burden of medically-attended respiratory syncytial virus (RSV) disease in German infants: a seven-season analysis using claims data**: Oliver DAMM (Germany)<br>**Prolonged fatigue post-hospitalisation: novel insights across a broad range of respiratory viral infections**: Tommaso MORELLI (United Kingdom)<br>**Quality of life in the toddler population (9-36 months of age) experiencing RSV infection in the 2023-2024 winter season in Italy–the EVOLUTE study**: Elisa BARBIERI (Italy)<br>**Thromboembolic complications in viral respiratory tract infections: insights into the role of clinical and biochemical coagulation parameters**: Merve MERT VAHABI (T�rkiye)<br>**Cardiac impairment during influenza flu heart: a prospective cohort study of hospitalised patients with influenza infection**: Kristoffer SKAARUP (Denmark)<br>**Clinical burden of respiratory syncytial virus among adults hospitalised with acute respiratory infections in Austria**: Harald ROUHA (Austria)<br>**Mortality among adults aged 50+ years admitted with COVID-19, influenza A or respiratory syncytial virus (RSV) in Denmark, 2022-2024**: Frederikke LOMHOLT (Denmark)<br>**How did respiratory viruses impact UK healthcare workers over winter 2023/24**: Sarah FOULKES (United Kingdom)<br>**Hospital disease burden of respiratory syncytial virus in adults 2021-2023 compared to influenza and COVID-19 using rapid PCR testing**: Niklas ANDREEN (Sweden)<br>**SARS-CoV-2 phylogenetics in a Spanish cohort of hospital healthcare workers, 2021-2024**: Miriam LATORRE-MILL�N (Spain)<br>**Prospective surveillance of acute lower respiratory tract infection due to RSV and other respiratory viruses in outpatient infants under two years of age in W�rzburg (Germany) since November 2022**: Andrea STRENG (Germany)<br>**Relative effectiveness of high-dose vsstandard-dose quadrivalent influenza vaccine in patients with hypertension: a secondary analysis of the DANFLU-1 trial**: Anne Marie REIMER JENSEN (Denmark)<br>**Epidemiology of respiratory pathogens in children with severe acute respiratory infection: a Tunisian three years survey**: Sarra SAYARI (Tunisia)<br>**Epidemiology and seasonality of human coronaviruses in Portugal since the COVID-19 pandemic**: Tiago P. RODRIGUES (Portugal)<br>**Prevalence and determinants of respiratory virus screening and isolation among hospitalised patients**: Elke LOOTS (Belgium)<br>**Similar proportions and temporal patterns of influenza, RSV and hMPV among ESKD patients tested between 2020 and 2023**: Carla TALARICO (United States)<br>**Real-world effectiveness of live attenuated (LAIV) and inactivated (IIV) influenza vaccines in children: a systematic literature review (SLR) and network meta-analysis (NMA)**: Wilhelmine MEERAUS (United Kingdom)<br>**Detection of various respiratory viruses based on MALDI-TOF MS**: Fei CHEN (China)<br>**From primary care to hospitalisation: understanding the burden of the 2024 enterovirus D68 outbreak in Catalonia**: Anna CREUS-COSTA (Spain)<br>**The age factor in viral codetections: insights from a multicentric study on paediatric respiratory infections**: Anna CREUS-COSTA (Spain)<br>**Changing epidemiology: impact of the COVID-19 pandemic on bacterial and viral infections in children**: Giulia BRIGADOI (Italy)<br>**Symptomology of influenza-like illness reported during home self-collected swab testing: a systematic review**: Nabila SHAIKH (United Kingdom)<br>**Respiratory syncytial virus infection and heart disease: a systematic review and pooled analysis of clinical features**: Matteo RICC� (Italy)<br>**Trends in the circulation of influenza A/B viruses, SARS CoV2 and respiratory syncytial virus in Indian settings, 2023-2024: emerging spectre of a tridemic?**: Ira PRAHARAJ (India)<br>**High-dose vs standard-dose influenza vaccine in patients with chronic inflammatory disease: a secondary analysis of the DANFLU-1 trial**: Julie BORCHSENIUS (Denmark)<br>**Molecular characterisation of human adenovirus genotypes in paediatric patients**: Luna COLAGROSSI (Italy)<br>**Surveillance of influenza A in red foxes and seals in Ireland**: Maeve Louise FARRELL (Ireland)<br>**Influenza vaccination rates among healthcare workers and key factors influencing vaccination in Bangladesh**: Md Golam Dostogir HARUN (Bangladesh)<br>**Isolation, production and validation of the first GMP RSV-B virus for use in controlled human infection studies**: Nicolas NOULIN (United Kingdom)<br>**Pathogen characteristics of respiratory infections in the season after the COVID-19 pandemic: evidence from direct-to-consumer testing-based surveillance, China, 2023-2024**: Yanxia SUN (China)<br>**Association of virology swab positivity in adults aged =40 years with computerised medical record reported acute respiratory infection (ARI) subgroups: observational study of ARI (ObservatARI)**: Jos� M ORD��EZ-MENA (United Kingdom)<br>**Assessing immunomodulators in human challenge studies: insights from wild-type influenza infections in healthy adults and rhinovirus infections in patients with asthma**: Nicolas NOULIN (United Kingdom)<br>**Cold perception as a key endpoint in human challenge trials with respiratory viruses**: Nicolas NOULIN (United Kingdom)<br>**Management of respiratory infections in primary care (RespiCare): a cluster-randomised, controlled crossover study with molecular point-of-care testing**: Tobias TUCHSCHERER (Germany)<br>**Epidemiology of five respiratory viruses circulating in Taiwan, 2015-2023: a multicentre retrospective study**: Tu-Hsuan CHANG (China)<br>**Can unsupervised machine learning predict outbreaks of respiratory tract infections in acute Irish hospitals (2016-2021)?**: Doaa AMIN (Ireland)<br>**Factors influencing hospital stay length and acute respiratory failure in influenza patients**: Victor Daniel MIRON (Romania)<br>**Epidemiology and burden of the human metapneumovirus among Italian inpatient and outpatient adults**: Vincenzo PAOLOZZI (Italy)<br>**Comparing viral loads in nasopharyngeal swabs and bronchoalveolar lavages after normalisation of multiplex real-time PCR data**: Timo FROYEN (Belgium)<br>**RELAB 2023-24: compared community epidemiologies of RSV, influenza and SARS-CoV-2 in France**: Benoit VISSEAUX (France)<br>**Spectrum of respiratory viruses in in-patients with severe acute respiratory infection in north India: insights from a two-year analysis**: Ruchita CHHABRA (India)<br>**Broad-spectrum antiviral activity of spiro-beta-lactams: targeting SARS-CoV-2, influenza, and HIV through ferroptosis induction**: Paloma GON�ALVES (Portugal)<br>**IFN-β administration results in mixed alterations in brain functions in elderly mice during influenza A virus infection**: Douglas DREVETS (United States)<br>**Optimising respiratory syncytial virus (RSV) antibody pair selection for enhanced diagnostic accuracy and speed**: Tarja SORSA-LESLIE (Finland)<br>**Relative effectiveness of high-dose vs standard-dose influenza vaccine in immunocompromised individuals: a posthoc analysis of the DANFLU-1 trial**: Anne Marie REIMER JENSEN (Denmark)<br>**Epidemiological and molecular characteristic of enteroviruses identified in influenza-like illness cases in Lombardy (northern Italy), January 2022-October 2024**: Laura PELLEGRINELLI (Italy)<br>**Vakzimeter FLU: real-time in-season monitoring of adult influenza vaccination rates in Germany**: Christine HAGEMANN (Germany)<br>**Characterisation of hMPV and RSV hospitalisations in the French national hospital claims database during the 2022-2023 season**: Liem Binh LUONG (France)<br>**Molecular epidemiology of paediatric respiratory syncytial virus infection in Hungary**: Gabriella TERHES (Hungary)<br>**Assay development and pipeline considerations for amplicon-based respiratory syncytial virus whole genome sequencing in a clinical setting**: Kuganya NIRMALARAJAH (Canada)<br>**Impact of respiratory syncytial virus (RSV) disease on health-related quality of life (HRQoL) among European older adults: combined results over three RSV seasons**: Frederik VERELST (Belgium)<br>**Unveiling the dynamics of respiratory infections through multiplex PCR testing after the COVID-19 pandemic in Taiwan**: Meng-Shuan LIN (China)<br>**Impact of multiplexed respiratory panel on the diagnosis and management of respiratory infections in the emergency department**: Samuel GOODFELLOW (United States) |
| 12/04 | 12:00 - 13:30 | PS004 | 01d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts) |  | **Estimating genital herpes prevalence and treatment patterns among US healthcare-engaged individuals: insights from claims data**: Jason DEER (United States)<br>**Reactivation of Ebstein-Barr virus among ARDS patients: do acute changes in the immune system play a role?**: Martina GASSNER (Germany)<br>**Characterisation of humoral and T-cell specific response to EBV, CMV and VZV in people with MS under DMT**: Federica DOMINELLI (Italy)<br>**Trends in herpes simplex virus type 1 and type 2 seroprevalence in Croatia**: Filip STEVANOVSKI (Croatia)<br>**Burden of herpes zoster in immunocompromised adults aged 18 years or older: a retrospective analysis of German claims data**: Sara PEDRON (Germany)<br>**Newer is not always better: evaluation of the new version of LIAISON VZV IgG CLIA**: Daniela HUZLY (Denmark)<br>**Adjuvanted recombinant zoster vaccine is associated with lower risk of herpes zoster ophthalmicus, acute myocardial infarction, and stroke in adults aged ≥50 years**: Emily RAYENS (United States)<br>**Real-life drug-drug interactions between immunosuppressive treatments and letermovir in solid organ transplant recipients**: Fanny VUOTTO (France)<br>**Incidence rates of herpes zoster in immunocompromised adults aged 18 years or older in England: a large retrospective cohort study using data from the clinical practice research datalink, 2012-2019**: Abda MAHMOOD (Belgium)<br>**The risk of vascular events following herpes zoster: a matched cohort study**: Mads Frederik EIBERG (Denmark)<br>**Predictors of CMV-colitis in patients with moderate to severe ulcerative colitis needing hospitalisation: interim analysis from a prospective study**: Matteo RINALDI (Italy)<br>**Preclinical profile of ABI-5366, a novel potent HSV helicase-primase inhibitor, with potential for weekly or monthly oral dosing for the treatment of recurrent genital herpes**: Kathryn KITRINOS (United States)<br>**Comparison of rapid multiplexed real-time PCR platform with laboratory real-time PCR platform for detection of HSV-1, HSV-2, and VZV in lesion swab specimens**: Preeti PANCHOLI (United States)<br>**Genital ulcer etiology in northwest Spain: from 2019 to 2024**: Noelia PARAJ�-PAZOS (Spain)<br>**Targeted screening for congenital cytomegalovirus infection in a high seroprevalence country**: Siwar FRIGUI EP OUESLATI (Tunisia)<br>**CMV RNA: a new marker for monitoring CMV in HCT with LTV prophylaxis**: Alice NAVA (France)<br>**Enhancing EBV diagnostics: T-cell-based assay for accurate immune monitoring in patients with multiple sclerosis**: Tatjana SCHWARZ (Germany)<br>**Concordance of a multiplex PCR assay with HSV1-2 and VZV-specific PCR in diagnosing central nervous system infections**: Xiaohui Chen NIELSEN (Denmark)<br>**Distribution of ganciclovir in the porcine central nervous system**: Johan GULDB�K (Denmark)<br>**Leveraging French compassionate programme data in refractory CMV to further describe maribavir effectiveness and resistance profile**: Sophie ALAIN (France)<br>**Modelling the public health impact of herpes zoster vaccination in adults aged ≥ 50 Years via increased recombinant zoster vaccine uptake worldwide**: Charles WILLIAMS (Belgium)<br>**Varicella zoster virus central nervous system infections: a multi-site retrospective review of clinical features, treatments, and outcomes in an Australian setting**: Katrina FERNANDES (Australia)<br>**Comparison of two commercial real-time PCR assays for quantification of Epstein-Barr virus (EBV) DNA in nasopharyngeal carcinoma (NPC) patients**: Rym TOUATI (Algeria)<br>**Role of human herpesvirus 6 in unexplained infertility: among Indian women in a tertiary care hospital of north India**: Vani ANGRA (India) |
| 12/04 | 12:00 - 13:30 | PS005 | 01e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID) |  | **Correlation between building features and prevalence of Aedes aegypti mosquitoes in Singapore**: Kyaw ZWA THANT (Singapore)<br>**Shifting pattern of circulating dengue serotypes and their associated severity in children: a report from south India**: Sara CHANDY (India)<br>**RAB3GAP2 dysregulation in adult T-cell leukemia/lymphoma (ATLL) compared to acute lymphoblastic leukemia (ALL)**: Arash LETAFATI (Islamic Republic Of)<br>**Molecular characterization of Tick-borne encephalitis cases in north-eastern Italy**: Simone MALAG� (Italy)<br>**Secondary infection rates after mpox exposure in multiple settings: a systematic review**: Aiman EL-SEAD (Saudi Arabia)<br>**A critical analysis of dengue epidemic in Venezuela, 2024**: Alfonso J. RODRIGUEZ-MORALES (Colombia)<br>**Modes of transmission of mpox by virus clade and geographic distribution: a systematic review**: Majid ALSHAMRANI (Saudi Arabia)<br>**Neurologic manifestations and outcome of West Nile virus infection**: Manel BEN SELMA (Tunisia)<br>**Assessing the direct and spillover protective efficacies of Wolbachia-mediated introgression to combat dengue**: Jo Yi CHOW (Singapore)<br>**First usutu virus infection in an asymptomatic blood donor in Greece**: Anna PAPA-KONIDARI (Greece)<br>**Epidemiological overview of ICU-diagnosed dengue fever cases at Hargeisa group hospital, Somaliland (January-October 2024)**: Ling-Li HUANG (Somalia)<br>**Seroprevalence of hantavirus exposure among healthy individuals in the Ampara district of Sri Lanka**: Nipun RATHNAYAKE (Sri Lanka)<br>**Investigation of Crimean-Congo haemorrhagic fever virus in patient room air samples**: Mert KUSKUCU (T�rkiye)<br>**Beyond familiar threats: numerous RNA virus families display pandemic potential**: Thomas LEINEWEBER KRISTENSEN (Denmark)<br>**Exploring transmission routes of rat hepatitis E from a One Health perspective**: Hon Kiu Estie SHUN (China)<br>**Comparison of assays for assessing the humoral immune response to monkeypox virus in HIV and non-HIV individuals following two doses of the MVA vaccine**: Ut Man CHAN (China)<br>**Antibody generation and development of a rapid test for the diagnosis of infection caused by the monkeypox virus**: Arnaud CHALIN (France)<br>**Confirmed dengue cases in returning travellers in Milan, Italy: clinical and microbiological features from 2018 to 2024**: Margherita Eleonora PIERUZZI (Italy)<br>**Comparative analysis of clinical features between patients with severe fever with thrombocytopenia syndrome and haemorrhagic fever with renal syndrome in Korea**: Da Young KIM (Republic Of)<br>**West Nile human infections in Europe from 2000–2023**: Nadja HEDRICH (Switzerland)<br>**Dengue incidence in 26 cities affected by a tailing dam rupture at the Córrego do Feijão mine in Brumadinho/ Brazil: a ten-year ecological study.**: Carlos STARLING (Brazil)<br>**whole-genome sequencing of MERS-CoV: comparison of amplicon-based approaches and short read and long read sequencing platforms**: Umair HUSSAINI (United Kingdom)<br>**West Nile virus infection investigation at the clinical virology laboratory, Pasteur Institute of Tunis**: Hannachi HANNACHI (Tunisia)<br>**Target identified: a comparison of Brazilian and Singaporean dengue control ecosystems to aid antiviral target product profile development**: Alice SCHARMELI (United Kingdom)<br>**Wastewater monitoring of dengue virus RNA during a local outbreak in central Italy, August-October 2024**: Carolina VENERI (Italy)<br>**Did Marburg virus disease clinical features change overtime? A systematic review and meta-analysis,1967-2024**: Matteo RICC� (Italy)<br>**Seroprevalence of dengue IgG antibodies among adult community residents in Enugu, south-east Nigeria: a cross-sectional survey**: Chizaram ONYEAGHALA (Nigeria)<br>**Integrating spatial-environmental models to evaluate Wolbachia-mediated intervention efficacy on dengue transmission**: Jue Tao LIM (Singapore)<br>**Association of sonographic findings with severity of dengue fever: a systematic review and meta-analysis**: Juliana MUNIZ (Germany)<br>**Exploring the anti-interferon autoantibodies in mosquito-borne viral infections**: Federica FRASCA (Italy)<br>**Whole-genome sequencing based phylogenetic analysis of CCHFV strains isolated in Georgia (2013–2023)**: Gvantsa CHANTURIA (Georgia)<br>**Detection of West Nile virus, Usutu virus and phleboviruses in Culex spp. mosquitoes in Central Macedonia, Greece, 2024**: Anna PAPA-KONIDARI (Greece)<br>**Clinical characteristics of Marburg virus disease: a systematic review of the literature**: Emanuele NICASTRI (Italy)<br>**Promising results with anakinra in severe cases of Crimean-Congo haemorrhagic fever**: Nurcan BAYKAM (T�rkiye)<br>**Addressing the emerging threat of oropouche virus: implications and public health responses for healthcare systems**: Olalekan John OKESANYA (Nigeria)<br>**Genetic variants of the rabies virus and prevention of diagnostic errors**: Jeferson MANOEL TEIXEIRA (Brazil)<br>**Prevalence, haematological profile, and risk factors of dengue fever in under-five children with acute febrile illness in Nigeria**: Ibuchukwu ORABUEZE (Nigeria)<br>**Febrile illness of vector-borne and zoonotic origin in Ho Chi Minh city, Vietnam: not just dengue is in there**: Olga STUKOLOVA (Russian Federation)<br>**Dengue epidemiology in the elderly population of a municipality in Bol�var, Colombia, 2018-2024**: Alfonso J. RODRIGUEZ-MORALES (Colombia)<br>**Differences in the clinical profile between ratHEV and HEV**: Antonio RIVERO-JUAREZ (Spain)<br>**Epidemiology, clinical presentation, and outcome of human mpox in Rivers state Nigeria during the 2022-23 outbreak: an observational retrospective study**: Chizaram ONYEAGHALA (Nigeria)<br>**CT-detected lymphadenopathy and prognostic markers in severe fever with thrombocytopaenia syndrome: a retrospective study**: Yoshito HOMMA (Japan)<br>**Seroprevalence of toscana virus in blood donors in mainland Portugal**: Rafael ROCHA (Portugal)<br>**Return of WNV infection in Vlora**: Arsilda GJATAJ (Albania)<br>**Impact of dengue fever on maternal and fetal outcomes: a cross-sectional study in Guatemala**: Iris CAZALI (Guatemala)<br>**Role of biomarkers in predicting mortality in patients with flaviviral disease endemic to south India: a prospective observational study**: Rachna BHAT (India)<br>**Monocyte CD169 (mCD169) expression in peripheral blood in patients with symptomatic arbovirosis: a retrospective series in the emergency department**: Massimo CRAPIS (Italy)<br>**Role of genetic determinants in pathogenesis and evolution of chikungunya virus**: Garvita MATHUR (India)<br>**Tick-borne encephalitis virus (TBEV) is one the three leading causes of meningoencephalitis/encephalitis in Saint-Etienne area, France**: Emilie MAYER (France)<br>**Clinical features of measles during the 2023-2024 outbreak in Minsk, Belarus**: Alexandra BYLINA (Belarus)<br>**Attitudes and knowledge of the adult population on arboviral diseases**: Fabiana NUCCETELLI (Italy)<br>**Expression of Galectin-3 ameliorates dengue virus infection**: Yun Tzu HSU (China)<br>**Retrospective molecular epidemiological survey of an unexpected dengue outbreak in Taiwan, 2023**: Sheng-Fan WANG (China)<br>**A stepwise approach to developing practical guidance for healthcare professionals to safely meet the needs of patients and relatives during admission to a high-level isolation unit**: Luca ZWEERS (Netherlands)<br>**???Survivors of an outbreak: exploring the patient experience of a specialised regional infectious diseases centre virtual ward during the mpox outbreak of 2022**: Irvine MANGAWA (United Kingdom)<br>**Detection of anti-oropouche virus-specific IgM in a patient panel from a zika virus epidemic area in 2015 / 2016**: Jens WARNECKE (Germany)<br>**Viral haemorrhagic fever: auditing emergency care for at-risk patients at university college London hospital**: James BEVAN (United Kingdom)<br>**Increasing incidence of neurological infections of unknown etiology in upper Corsica: a matter of arboviruses?**: Agnieszka KOLAKOWSKA (France)<br>**West Nile virus infections in Turkey**: �zlem ALHAN (T�rkiye)<br>**Mediating analysis of IPA in the association between steroid therapy and mortality risk in patients with SFTS**: Guang ZHU (China)<br>**Ethical drug development for global health: an interdisciplinary analysis for the current dengue emergency**: Shanghavie LOGANATHAN (United Kingdom)<br>**Unraveling global mpox cross-border transmission patterns and risks: a comprehensive analysis**: Qiangru HUANG (China)<br>**Dengue seroprevalence in healthy blood donors in Romagna (Emilia-Romagna region, Italy)**: Alessandra Mistral DE PASCALI (Italy)<br>**Phylogenetic analysis of the autochthonous dengue cases emerged in Emilia-Romagna region, in Italy, during arbovirus surveillance in 2024**: Luca RUOTOLO (Italy)<br>**Clinical-laboratory features of the abortive form of tick-borne encephalitis virus infection in Italy: a 25-year retrospective observational study**: Nicole BARP (Italy)<br>**The next frontier in Toscana virus (TOSV) genome analysis: development of a novel amplicon-based whole genome sequencing technology**: Vittorio SAMBRI (Italy)<br>**Developing an evidence-based at-home specimen collection procedure for patients suspected of a high-consequence infectious disease**: Luca ZWEERS (Netherlands)<br>**Clinical spectrum and diagnostic challenges of tick-borne encephalitis in Belarus: a retrospective analysis of 190 cases**: Mikita SALAVEI (Belarus)<br>**West Nile virus in European countries between 2018 and 2024: trends in case fatality rate and incidence over time**: �zge EREN KORKMAZ (T�rkiye)<br>**Risk of cardiovascular complications during acute dengue infection: a population-based cohort study**: Jue Tao LIM (Singapore)<br>**Enhancing mpox diagnostics: insights from an external quality assessment programme**: Katherine LAU (Australia)<br>**Clinical-laboratory features of tick-borne encephalitis virus infection in children and adolescents in Italy: a 25-year retrospective observational study**: Nicole BARP (Italy)<br>**Mpox among Venezuelan migrants in a hospital of Pereira, Colombia, 2022-2024**: Alfonso J. RODRIGUEZ-MORALES (Colombia) |
| 12/04 | 12:00 - 13:30 | PS006 | 01f. Diagnostic virology�(other than respiratory viruses, herpesviruses, hepatitis & HIV; incl traditional, molecular, genomic and other methods) |  | **High percent of co-detections of viral versus bacterial gastrointestinal pathogens in stool samples calls for a different approach in analysis of molecular testing results**: Ulrich EIGNER (Germany)<br>**Genomic characterisation of JC virus in progressive multifocal leukoencephalopathy**: Palani GNANASOUNDARI (India)<br>**Accelerating dengue detection: comparing the performance of rapid tests and ELISA for NS1, IgG, and IgM antibodies**: Nadia WOHLWEND (Switzerland)<br>**Evaluation of INSTAND EQA samples for virus genome detection: target values by dPCR results instead of consensus values?**: Martin KAMMEL (Germany)<br>**On the hotline: the imported fever service response to the mpox Clade I outbreak**: Martine ALTIDOR (United Kingdom)<br>**Emergence of Enterovirus D68 infection in northern of Spain**: Maria Del Carmen NIETO TOBOSO (Spain)<br>**Neither nor or norovirus GI/GII? Good consensus in international EQA pilot study for norovirus antigen detection**: Heidi BERGHALL (Finland)<br>**New raw materials for serology immunoassay quality controls**: Jean-Christophe PETER (France)<br>**Diagnostic accuracy of MxA protein as a biomarker for acute viral infections: a multi-centre validation study**: Run HUANG (China)<br>**Increased detection of human parvovirus B19 on a tertiary care Greek hospital**: Eleni VAGDATLI (Greece)<br>**Evaluating the impact of EDTA K2 vs. EDTA K3 on viral load quantification using real-time PCR assays**: Henar ALONSO-EZCURRA (Spain)<br>**Gene promoter methylation as a progression biomarker of HPV-associated precancerous lesions in young women**: Julia ALCOBA FL�REZ (Spain)<br>**Molecular identification of enterovirus 71 and coxsackie A16 among paediatric patients with aseptic meningitis in Khartoum state, Sudan**: Tarteel HASSAN (Sudan)<br>**In vitro validation of a preservative media for circulating cell-free HPV-DNA stabilisation in artificial human plasma samples**: Chiara SENTI (Italy)<br>**Evaluation of Torque teno virus DNA as an immunological marker through correlation with clinical parameters and survival in paediatric haematopoietic stem cell transplantation patients**: Suyeon JO (Republic Of)<br>**Determination of measles-virus-IgG titre in blood drawn by finger prick**: Volker STRENGER (Austria)<br>**A lyophilised and deployable real time RT-PCR assay for the detection of viral RNA**: Lucie MANGIN (France)<br>**Ongoing MPXV infections in the Berlin MSM cohort: multiplex PCR for differentiation between MPXV Clade I; Ib and Clade II**: Robert EHRET (Germany)<br>**Detection of immune response to rubella antigen using an anti-rubella IgM ELISA and a newly designed anti-rubella IgG ELISA**: Jens WARNECKE (Germany)<br>**Bridging diagnostic gaps and strengthening vaccination strategies in mumps control: a tertiary care experience in western India**: Bhoomika RAJYAGURU (India)<br>**Hybridisation-capture approaches for the diagnosis and surveillance of viruses using  real-time sequencing**: Oscar Enrique TORRES MONTAGUTH (United Kingdom)<br>**Next-generation sequencing method for analysis of multi-infections and antibiotic resistance markers in self-collected swabs from HPV positive women**: Karol�na TOMC�KOV� (Slovakia) |
| 12/04 | 12:00 - 13:30 | PS007 | 01g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV) |  | **An in-depth review of epidemiologic, clinical, and laboratory characteristics in women with cervical abnormalities: insights from a leading referral centre**: Amir ABOOFAZELI (Islamic Republic Of)<br>**Serotype distribution of enterovirus associated with hand, foot, and mouth disease in China based on laboratory surveillance, 2012-2023**: Na LIU (China)<br>**Comprehensive identification of respiratory viruses in wastewater using a broad-spectrum respiratory virus manel and whole genome sequencing**: Pamela MANCINI (Italy)<br>**Vaccine hesitancy and measles resurgence: lessons from Novi Pazar**: Selma HABIBOVIC (Serbia)<br>**Phylogenetic analysis of human parvovirus B19, northern Italy, 2017-2024**: Silvia BIANCHI (Italy)<br>**Coxsackieviruses type B infections: the effect of COVID-19 pandemic**: Ioannis DANIIL (Greece)<br>**Rotavirus A outbreak predominantly affecting adults in Santa Maria, southern Brazil**: Priscila TRINDADE (Brazil)<br>**Declining trend of HTLV-1 among organ/tissue donors in Iranian population**: Arash LETAFATI (Islamic Republic Of)<br>**A large outbreak of acute hemorrhagic conjunctivitis in Yunnan, China in 2023**: Xiaolei LI (China)<br>**Hand, foot, and mouth disease amid COVID-19: an overlapping epidemic within a pandemic**: Alpana MOHTA (India)<br>**Compelling increase in parvovirus B19 infections: analysis of diagnostic trends, 2019–2024**: Flora Marzia LIOTTI (Italy)<br>**Different genotypic distributions of hantaan virus causing human infections on Jeju island, South Korea**: Keun Hwa LEE (Republic Of)<br>**An outbreak caused by imported sub-genotype B5 of EV-A71 reveals multiple recombination pattern in China**: Tianjiao TIANJIAO (China)<br>**Improved surveillance of viral gastroenteritis after implementation of wastewater surveillance in Belgium**: Koenraad VAN HOORDE (Belgium)<br>**Resurgence of measles: new evidence of viral circulation in Liguria, northern Italy, 2024**: Giada GARZILLO (Italy)<br>**Viral myocarditis manifesting as sudden death in infants and children: an ESGFOR approach from symptoms to autopsy**: Amparo FERN�NDEZ-RODR�GUEZ (Spain)<br>**Parvovirus: a growing problem?**: Anna SMIELEWSKA (United Kingdom)<br>**Molecular epidemiology of human rotavirus in post-vaccination era in Chiang Mai, Thailand**: Pattara KHAMRIN (Thailand)<br>**Colonoscopic observations in asymptomatic norovirus infection: insights from a small-scale study at a single Japanese centre**: Kyoko YOKOTA (Japan)<br>**Sequencing of MPXV positive samples in Berlin 2022 to 2024**: �zlem YILDIRIM (Germany)<br>**Etiologic involvement of enterovirus and human boca virus in acute flaccid paralysis cases in India**: Dharam Veer SINGH (India)<br>**Clinical significance of torque teno virus (TTV) in CSF samples/TTV dynamics in paediatric population**: Dee DAVIS (United Kingdom)<br>**Prevalence of anti-parvovirus B19 IgG and IgM antibodies in a local population from 2019 to 2024**: Federico FALLETTA (Italy)<br>**Measles seroprevalence of medicine faculty student**: Dilsah BASKOL ELIK (T�rkiye)<br>**Prevalence and genotype distribution of high-risk HPV genotypes by the RT-PCR method among women in Serbia in a two-year period, 2022-2024**: Edita GREGO (Serbia)<br>**Epidemiology of human sapovirus in Korea: impact of COVID-19**: Hyun Soo KIM (Republic Of)<br>**Hospitalised dengue patients: insights from Argentina's 2023-2024 outbreak**: Gustavo Adolfo M�NDEZ (Argentina)<br>**Spreading and epidemiological characteristics of measles in the area of Zenica-Doboj Canton, Bosnia-Herzegovina**: Muhamed SKOMORAC (Bosnia And Herzegovina)<br>**Increase in parvovirus B19 cases in Barcelona: comparative analysis from 2019 to 2024**: Marta BERNAT (Spain)<br>**Incidence and severity of sporadic, medically attended norovirus infection in the United States, 2023-2024**: Mark A SCHMIDT (United States)<br>**Increased circulation of human parvovirus B19 during spring of 2024 in Madrid, Spain**: Maria ALBERTUZ CRESPO (Spain)<br>**Clinical, laboratory profile and outcome of expanded dengue syndrome and its correlation with virus specific serotype at a tertiary care hospital in north India**: Harpreet SINGH (India)<br>**Sexual behaviour and age related incidence of sexually transmitted infections among MSM and transgender women using daily and event-driven pre-exposure prophylaxis (PrEP): two-year follow-up**: Francesco ROMANO (Italy)<br>**Screening for human papillomavirus in women over 30 years of age at the mother and child laboratory of a west Algiers hospital**: Siham AZROU (Algeria)<br>**The landscape of human papillomavirus types among women screened for cervical cancer in a rural healthcare facility in Eswatini**: Clara FAPPANI (Italy)<br>**Parvovirus B19 on the rise in 2024: a multifaceted pathogen with varied clinical manifestations**: Daniela JAVORSK� (Slovakia)<br>**Adeno-associated virus (AAV2) is a common finding in adenovirus infections in children and adults**: Xuewei ZHOU (Netherlands)<br>**Prevalence and distribution of vaccine-preventable HPV genotypes in unvaccinated PrEP users**: Federica SALARI (Italy)<br>**Molecular epidemiology of classic and novel human astroviruses in paediatric patients with acute gastroenteritis in Thailand**: Kattareeya KUMTHIP (Thailand) |
| 12/04 | 12:00 - 13:30 | PS008 | 01h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV) |  | **Evaluation of the antiviral activity of new dermaseptin analogs against zika virus**: Houda HADDAD (Tunisia)<br>**Discovery of PROTAC compounds as potent viral protease degraders and inhibitors against Corona viruses**: Xicheng SUN (United States)<br>**Salicylamide derivative JMX0312 protects immunosuppressed Syrian hamsters against adenovirus lethal challenge**: Javier MART�N-ESCOLANO (Spain)<br>**Investigation of the HPV 53 E2 protein as a potential treatment for cervical cancer**: Carlo FERRAZZANO (United Kingdom) |
| 12/04 | 12:00 - 13:30 | PS009 | 01i. Fundamental and applied virology (incl in vitro and in vivo models, novel methods) |  | **Exploring the pathogenesis of TBE in an infant rat model**: Simone LEONI (Switzerland)<br>**Impact of the route of EBV transmission on viral infection and reactivation in the rabbit model**: Gulfaraz KHAN (United Arab Emirates)<br>**Gut virome composition modifies the risk of subsequent coeliac disease in two European birth cohorts**: Ondrej CINEK (Czech Republic)<br>**Preliminary analysis of viral infection in human organoids from different GI tracts: SARS-CoV-2 and beyond**: Virginia LOTTI (Italy)<br>**A genetically encoded BRET-based SARS-CoV-2 main protease activity sensor**: Anupriya M G (Qatar)<br>**Advancing vaccine and treatment development, state-of-the-art human challenge trial facility**: Nicolas NOULIN (United Kingdom)<br>**Expression of human endogenous retroviruses in clinical samples of patients with colorectal cancer**: Maria DOLCI (Italy)<br>**Study of the endothelial response to SARS-CoV-2 in vitro infection of human lung microvascular endothelial cells**: Lucia SIGNORINI (Italy) |
| 12/04 | 12:00 - 13:30 | PS010 | 01j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact) |  | **Phenotyping and genotyping analysis using baseline swab samples in ensitrelvir clinical studies**: Keiko BABA (Japan)<br>**SARS-CoV-2 reinfections in a large cohort study: results from the UnCoVER-Brazil project**: Patricia MARTELETO SCANAVEZ (Brazil)<br>**Challenges on the implementation of wastewater as a prediction tool: the paradigm of SARS-CoV-2**: Dimosthenis CHOCHLAKIS (Greece)<br>**Long-term exposure to air pollution and serum levels of inflammatory markers in acute severe COVID-19: an ICU based multicentric study**: Andr� ALMEIDA (Portugal)<br>**Long term impact on lung function of patients with moderate and severe COVID-19: a prospective cohort study**: Sonia QURESHI (Pakistan)<br>**Mucocutaneous adverse events following COVID-19 vaccination- a clinico-histopathological correlation study**: Alpana MOHTA (India)<br>**The consequences of reinfections in long COVID patients**: Lourdes MATEU PROUNONOSA (Spain)<br>**The role of leptin on macrophage function in patients with COVID-19**: Philipp W�HLER (Germany)<br>**Risk and resilience for depression, anxiety, and stress among healthcare workers and health-related staff in Indonesia, Nepal, and Vietnam during COVID-19: a multi-site cross-sectional study**: Ha LE THANH (Vietnam)<br>**Preliminary safety and effectiveness estimate of 2023-2024 COVID-19 vaccines (XBB.1.5) in preventing symptomatic infections in US adults**: Sarang YOON (United States)<br>**Viral co-infection reduces SARS-CoV-2 illness severity in community, but not in healthcare cohorts: a meta-analysis of 11 prospective studies**: Patricia BRUIJNING-VERHAGEN (Netherlands)<br>**Graphene biosensors: bridging basic science and applied diagnostics for viral infections**: Anil BOZDOGAN (Austria)<br>**Post-COVID condition in vulnerable populations: the ORCHESTRA Delphi consensus on prevention, diagnosis and management**: Elisa GENTILOTTI (Italy)<br>**Humoral immunity after PHH-1V COVID-19 booster vaccination in adults with immunosuppressive conditions**: Dalia RA�CH-REGU� (Spain)<br>**Evolution of determinants and severity of post-COVID Condition across 24 months: the ORCHESTRA long-term sequelae extended follow up**: Elisa GENTILOTTI (Italy)<br>**Challenges in the diagnosis of SARS-CoV-2 infection in the nervous system**: Samya DA SILVA (Brazil), Samya DA SILVA (Brazil)<br>**Impact of SARS-CoV-2 infection and long COVID on health-related quality of life among school-aged children in Vietnam**: Thu-Trang VU (Vietnam)<br>**Evaluation of digital PCR technique for the study of SARS-CoV-2 viremia as a predictor of poor clinical evolution**: Nelly Daniela ZURITA CRUZ (Spain)<br>**Assessing the synergistic effect of NMV-r and acquired immunity in reducing severe COVID-19**: Romina QUERCIA (United Kingdom)<br>**Assessment of the levels of some prognostic biomolecules (galectins, ACE2, SCUBE1/2/3) in COVID-19 patients**: Murat KARAMESE (T�rkiye)<br>**Immune disturbances in individuals with post-COVID syndrome (PCS) are not characterised by enhanced SARS-CoV2-specific immunity**: Veronica OBER (Germany)<br>**Functional measurements of muscle strength and assessment of sarcopenia to evaluate post-COVID chronic fatigue**: Elisa GENTILOTTI (Italy)<br>**Evaluating the feasibility of SARS-CoV-2 and influenza genomic sequencing from lateral flow devices: a pilot study within the UK SIREN cohort**: Sarah FOULKES (United Kingdom)<br>**Evaluating quasi-experimental approaches for estimating vaccine effectiveness: an empirical and simulated COVID-19 study**: Jo Yi CHOW (Singapore)<br>**Forecasting the impact of declining COVID-19 vaccination rates: scenario analysis using machine learning-enabled susceptible-infected-recovered models in England**: Peter MORTENSEN (United Kingdom)<br>**From evaluation to action: applying WHO IPC COVID-19 outcomes/impact evaluation findings to current public health emergency responses**: Hannah HAMILTON HURWITZ (Switzerland)<br>**SARS-CoV-2 vaccination influence in development of long-COVID clinical phenotypes**: Michele ANTONACCI (Italy)<br>**The association between COVID-19 vaccination with the prevalence of post-COVID conditions in Thai patients with mild COVID-19**: Saikhuan TOWACHIRAPORN (Thailand)<br>**The impact of non-pharmaceutical interventions implemented during the COVID-19 pandemic on the number of close contacts of SARS-CoV-2 cases in the Netherlands**: S�ndor MAHIEU (Netherlands)<br>**Protracted COVID-19 in immunocompromised hosts: a multicentre retrospective cohort study**: Maria DIOVERTI (United States)<br>**Spatio-temporal modelling of inequalities in the 2020-2021 COVID-19 pandemic waves in the Netherlands using reported SARS-CoV-2 infections and hospitalisations**: Carsten VAN ROSSUM (Netherlands)<br>**Prospective one-year post-acute sequelae of COVID-19 in youth**: Kees C. VAN DEN WIJNGAARD (Netherlands)<br>**Higher SARS-CoV-2 viral load and delayed viral clearance in patients with autoantibodies neutralizing type I interferons**: Thibault KERDILES (France)<br>**Features of long COVID-19 in the Armenian population**: Lyudmila NIAZYAN (Armenia)<br>**Platelet-rich plasma therapy for resistant post-COVID-19 olfactory dysfunction: a systematic review and meta-analysis of placebo-controlled studies**: Mohamed Hamouda Elsayed Ahmed Ali ELKASABY (Egypt)<br>**Brachial neuritis as a side effect of COVID-19 vaccine: a systematic review on reported cases**: Hanieh RADKHAH (Islamic Republic Of)<br>**Ophthalmoplegia following oculomotor, trochlear, or abducens nerves disorder after COVID-19 vaccination: a systematic review of reported cases**: Hanieh RADKHAH (Islamic Republic Of)<br>**Clinical performance evaluation of GeneFinder COVID-19/Flu antigen test and SGTi-flexM COVID-19 & flu A/B Ag for diagnosis of SARS-CoV-2, influenza A and influenza B infection**: Jeonghyun CHANG (Republic Of)<br>**Nasopharyngeal microbiome composition by SARS-CoV-2 presence and severity**: Juana CLAUS (Netherlands)<br>**Evaluation of SARS-CoV-2 spike mutations in immunocompromised and immunocompetent patients before and after SARS-CoV-2  treatment**: Alessandra D'ABRAMO (Italy)<br>**COVID-19 outbreaks caused by different SARS-CoV-2 variants: a descriptive, comparative study from China**: Cao CHEN (China)<br>**Antibody persistence against omicron subvariants induced by monovalent mRNA, bivalent mRNA or nuvaxovid vaccines: final results from Phase D of the PRIBIVAC study, a randomised clinical trial**: Xuan Ying POH (Singapore)<br>**Correlation of immune response with COVID-19 outcomes**: Karolina AKINOSOGLOU (Greece)<br>**Comparative subgenomic RNA expression profiles in SARS-CoV-2 variants: insights from symptomatic and asymptomatic cases in Sri Lanka**: Sibra R.M. SHIHAB (Sri Lanka)<br>**Uncovering mutational drivers of enhanced transmission in the B.1.411 SARS-CoV-2 lineage in Sri Lanka**: Sibra R.M. SHIHAB (Sri Lanka)<br>**Work productivity losses after COVID-19 infection among high-risk US patients with or without treatment with nirmatrelvir/ritonavir**: Maria FERNANDEZ (United States)<br>**Trends and impacts of SARS-CoV-2 genome sharing: a comparative analysis of China and the global community, 2020-2023**: Yenan FENG (China)<br>**Fc-mediated effector functions in mild and severe COVID-19: focus on ADE and ADCP**: Jong Su JONG SU (Republic Of)<br>**Impact of Lactobacillus gasseri on inflammatory responses in intestinal cells exposed to SARS-CoV-2**: Hamidi-Fard MOJTABA (Islamic Republic Of)<br>**Early vs late vs no remdesivir initiation in patients with immunocompromising conditions hospitalised with COVID-19**: Mark BERRY (United States)<br>**Development and internal validation of a simplified scoring model with CURB-65 plus RNAemia for predicting mortality at diagnosis of SARS-CoV-2 pneumonia**: Sonsoles SALTO-ALEJANDRE (Spain)<br>**Efficacy of HMG-CoA  reductase inhibitors in hospitalisation and mortality of COVID-19 patients: a meta-analysis of randomised control trials**: Mohammadreza SHAFIEI (Islamic Republic Of)<br>**Trends in type 1 diabetes incidence between 2007 and 2023 and its association with SARS-CoV-2 infection in a population-based matched cohort study among individuals under 30 years in Sweden**: Dominik DIETLER (Sweden)<br>**MicroRNAs in SARS-CoV-2 infection: analysis of immunocompromised and non-immunocompromised patients**: Chiara SINISCALCHI (Italy)<br>**Development of the long COVID/post-acute sequelae of COVID-19 (PASC) patient-reported outcome (PRO) instrument**: Ruth MOKGOKONG (United Kingdom)<br>**Inflammatory biomarkers in hospitalised COVID-19 patients during different pandemic waves as predictors for outcome**: Violeta BRICIU (Romania)<br>**Increased MP/CP co-infection in COVID-19-positive kidney transplant recipients**: Zhonghao WANG (China)<br>**Viral resistance analyses from the obeldesivir BIRCH study in high-risk nonhospitalised patients with COVID-19**: Charlotte HEDSKOG (United States)<br>**Investigating the prevalence of Streptococcus pneumoniae co-infection in patients with COVID-19 in the world: a meta-analysis study and systematic review**: Saeed SHAMS (Islamic Republic Of)<br>**THE EFFECT of pregnancy on the severity of the course of COVID-19: an analysis of clinical data**: Gulbanu SHAIMERDENOVA (Kazakhstan)<br>**Remdesivir and risk of multi-systemic long-term sequelae following COVID-19 hospitalisation**: An Ting TAY (Singapore)<br>**Correlation between urinary neutrophil gelatinase-associated lipocalin and neutrophil-to-lymphocyte ratio in hospitalised COVID-19 patients**: Luka SVITEK (Croatia)<br>**Deterioration of swallowing function among patients with COVID-19: propensity score-matched cohort study**: Ishikawa KAZUHIRO (Japan)<br>**Health-related quality of life, work productivity and activity levels in younger and older adults with acute COVID-19**: Manuela DI FUSCO (United States)<br>**Cost-effectiveness of oral nirmatrelvir/ritonavir for high-risk severe COVID-19 patients in Germany**: Eveline Katharina OTTE IM KAMPE (Germany)<br>**Acceptance of booster dose of COVID-19 vaccine: a community based study**: Sanskruti SHAH (India)<br>**Utility of population-wide digital contact tracing in estimating vaccine effectiveness in a real-world pandemic setting**: Muhammad Ismail BIN ABDUL MALEK (Singapore)<br>**Impact of adjustment for differential testing by age and sex on apparent epidemiology of SARS-CoV-2 infection in Ontario, Canada**: David FISMAN (Canada)<br>**The evolving challenge of appropriate antibiotics use in hospitalised COVID-19 patients: a systematic literature review**: Guido GRANATA (Italy)<br>**Risk of long-term complications following steroid treatment for COVID-19 in hospitalised Singaporean adults: a retrospective cohort study**: David Chien LYE (Singapore)<br>**Human ACE2 and TMPRSS2 polymorphisms for predicting susceptibility to tuberculosis and COVID-19 co-infection in Cameroonian cohort**: Mary Ngongang KAMENI (Cameroon)<br>**Role of frailty index-laboratory (FI-LAB) to predict COVID-19 mortality: a cross-sectional study**: Elda DE VITA (Italy)<br>**Breast milk secretory IgA against SARS-CoV-2 S antigen: a comparative study between pandemic and post-pandemic periods in Peru**: Antonella SANCHEZ ZERILLO (Peru)<br>**Clinical evaluation of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine**: Spyros CHALKIAS (United States)<br>**The impact of convalescent immune reactions on long-term pulmonary sequelae in mild to moderate COVID-19 patients during active treatment era**: Minkyeong LEE (Republic Of)<br>**JAK inhibitors in adults hospitalised due to COVID-19: individual participant data meta-analysis**: Alain AMSTUTZ (Switzerland)<br>**Viral resistance analyses from the obeldesivir OAKTREE study in low-risk nonhospitalised patients with COVID-19**: Lauren RODRIGUEZ (United States)<br>**New circulating variants of SARS-CoV-2 in Asturias during the post-COVID era**: Santiago MEL�N GARC�A (Spain)<br>**Assessing the impact of public health policies affecting indoor SARS-CoV-2 transmission: a retrospective analysis in Amsterdam**: S�ndor MAHIEU (Netherlands)<br>**Bayesian estimation of counterfactual mortality reduction following COVID-19 vaccine introduction in the United States, 2020–2023**: Guillermo RODRIGUEZ-NAVA (United States)<br>**Non-invasive COVID-19 detection using FTIR spectroscopy and machine learning on nasopharyngeal and salivary samples**: Craig WILLIAMS (United Kingdom)<br>**Exploring the role of LAMP1 (CD107a) and PDCD1 high Tfh cells in COVID-19 immunopathogenesis and vaccine response**: Zhangfan FU (China)<br>**SARS-Cov-2 evolution in patients with prolonged viral shedding**: Julien AUCLAIRE (France)<br>**Estimating population protection against emerging SARS-CoV-2 variants: a risk assessment utilising convalescent sera before the roll-out of XBB-lineage vaccines**: Ana ATTI (United Kingdom)<br>**Understanding COVID-19 mitigation behaviours during the pandemic: comprehensive analysis from 12,626 healthcare workers**: Daniel PAN (United Kingdom)<br>**Structure of VYD2311 & in vitro neutralisation against a panel of contemporary SARS-CoV-2 variants**: Pamela HAWN (United States)<br>**Healthcare worker attitudes to lateral flow device testing and sick leave for influenza-like illness in the UK: a hypothetical scenario-based study**: Sarah FOULKES (United Kingdom)<br>**Molecular pathways affected by anakinra treatment in patients with severe COVID-19: analysis of the SAVE-MORE trial**: Emmanouil STYLIANAKIS (Netherlands)<br>**The nasal microbiome modulates risk for COVID-19 infection**: Cindy M. LIU (United States)<br>**Clinical outcomes of immunocompromised patients using tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: real-world experience in Taiwan**: Yi-Tsung LIN (China)<br>**Screening of COVID-19 antibodies in recovered healthcare workers after thee months and after six months**: Basant Mahmoud ABDELHAMID (Egypt)<br>**The effect of immunomodulatory therapy on the incidence of secondary bacterial and fungal infections of hospitalised COVID-19 patients in England, January 2020 – August 2023: a case-control study**: Chloe DAVISON (United Kingdom)<br>**Mental well-being and resilience during a pandemic: co-creating with students**: Nicole VAN DEN BRAAK (Netherlands)<br>**Risk of multi-systemic long-term sequelae following COVID-19 in older adults, stratified by frailty: a population-based cohort study**: Yong Yi TAN (Singapore)<br>**Different innate immune response in SARS-CoV-2 vaccinated and unvaccinated individuals with COVID-19**: Luca MADDALONI (Italy)<br>**Evaluating blood sampling strategies in large-scale multi-site cohort studies: insights from the SIREN study**: Irina LUT (United Kingdom)<br>**Risk of new-incident mental health diagnoses during COVID-19 and post-SARS-CoV-2 infection amongst children and young adults in Singapore: a retrospective cohort study**: Janice Yu Jin TAN (Singapore)<br>**Impact of remdesivir in Portugal: enhancing healthcare capacity and outcomes in COVID-19**: Malwina MEJER (Belgium)<br>**Relative effectiveness of COVID-19 vaccinations in immunocompromised individuals: a real-world study in South Korea**: Matthew ROUSCULP (United States)<br>**Understanding winter and summer surges of COVID-19 in the post pandemic period: a multinational analysis of surveillance data for 2023-2024**: Irini ZOGRAFAKI (Greece)<br>**Longitudinal analysis of antibody dynamics post-COVID-19 vaccination in the context of healthcare worker-driven COVID-19 transmission**: Tadas ALCAUSKAS (Lithuania)<br>**Variable selection for prediction models of Omicron infection: insights from two population-based cohort studies**: Joanne LACY (Switzerland)<br>**Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged ≥12 years**: Christina GRASSI (United States)<br>**Benefits and risks of systematic screening for SARS-CoV-2 in asymptomatic hospitalised patients**: Marvin WEISS (Switzerland)<br>**Post pandemic burden of COVID-19 in ix European countries: a national surveillance analysis for 2023-2024 fall-winter season**: Irini ZOGRAFAKI (Greece)<br>**Factors associated with the development of SARS-CoV-2 RNAemia at COVID-19 diagnosis**: Javier MART�N-ESCOLANO (Spain)<br>**Development of a definition of post-acute sequelae of SARS-CoV-2 (PASC) in a Korean long COVID cohort by using machine learning**: Choi Young JANG (Republic Of)<br>**SARS-CoV-2 infection and hospitalisations in the omicron era: triangulation of symptom onset, positive test, and vaccination**: Essy MOZAFFARI (United States)<br>**Evaluating the efficiency of population-based infectious disease surveillance: a modelling study**: David SMITH (United Kingdom)<br>**Impact of the COVID-19 pandemic on healthcare seeking and antibiotic prescribing for acute respiratory infection in primary care centres in Nam Dinh province, Vietnam: analysis of routinely collected electronic prescription data**: Sonia LEWYCKA (Vietnam)<br>**Changes in management of immunosuppressed patients with SARS-CoV-2 infection: impact on cure and mortality rates**: Berta PERNAS-SOUTO (Spain)<br>**Persistent SARS-CoV-2 infection among immunosuppressed patients: characterisation of subpopulations of lymphocytes**: Berta PERNAS-SOUTO (Spain)<br>**The impact of baricitinib on systemic inflammation in COVID-19 and its association with prolactin: an exploratory analysis of interleukin levels**: Georgios SCHINAS (Greece)<br>**A nationwide cohort study of delta and omicron SARS-CoV-2 outcomes in older Singaporean adults stratified by frailty**: Muhammad Ismail BIN ABDUL MALEK (Singapore)<br>**SARS-CoV-2 infection and different-term thrombotic outcomes in patients with coronary atherosclerosis disease in China: a prospective cohort study**: Huajie XU (China)<br>**A validated threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19 enabling rapid development for future SARS-CoV-2 variants**: Sam MATTHEWS (United Kingdom)<br>**Characterisation of serological response against SARS-CoV-2 throughout the pandemic within the UK-based SIREN study**: Ana ATTI (United Kingdom)<br>**Long-term multi-systemic sequelae following hospitalisation for respiratory syncytial virus vs omicron SARS-CoV-2/influenza in Singaporean adults and children**: Janice Yu Jin TAN (Singapore)<br>**Analysing adaptive immune responses to BBV152 (Covaxin) and ChAdOx1 nCoV-19 (Covishield)**: Tanu BANSAL (India)<br>**Chronic stress prior to SARS-CoV-2 infection as predictor of ongoing symptomatic COVID-19**: Christian FAZEKAS (Austria)<br>**The effect of SARS-CoV-2 mRNA vaccination on contagiousness of individuals with breakthrough infection following vaccination: a systematic review and meta-analysis of over six million study participants**: Ji Soo CHOI (United Kingdom)<br>**Factors associated with silent hypoxia in patients with COVID-19**: Shinichiro MORIOKA (Japan)<br>**Different transcriptional metabolic response in SARS-CoV-2 infected CFTR-defective vs wild-type bronchial cells**: Anna LAGNI (Italy)<br>**Kinetics of neutralising antibodies against omicron BA.2 and BA.5 beyond the acute phase of infection in residential care homes for the elderly**: Kwok KIN ON (China)<br>**Long COVID in a cohort of patients hospitalised for COVID-19**: Pierantonio GRIMALDI (Italy)<br>**Immunological imprinting by seasonal coronaviruses and previous herpesvirus infections in patients with long COVID**: Ashwin MAK (Netherlands)<br>**Post-COVID in autumn 2023: pre- and post-infection comparison**: Sim�on DE BRUIJN (Netherlands)<br>**Differential long-term serological responses to SARS-CoV-2 vaccination in patients with solid and heamatologic malignancies**: Maria Giulia CAPONCELLO (Spain)<br>**Prevalence of post-COVID syndrome and its societal impact**: Merlin VAN LOENEN (Netherlands)<br>**Cytokine profile-based symptom clustering in patients with post-acute sequelae of COVID-19**: Ji-Soo KWON (Republic Of)<br>**Sequential SARS-CoV-2 antigen exposures drive durable, broad and non-waning neutralising antibodies over four years**: David GREENWOOD (United Kingdom)<br>**Anti-SARS-CoV-2 antibody and cellular immune responses to third, fourth and fifth heterologous vaccine doses in Indonesian healthcare workers**: Raph L. HAMERS (Indonesia)<br>**SARS-CoV-2 infection management in haematological malignancy patients: the ORCHESTRA Delphi consensus**: Anna Maria AZZINI (Italy)<br>**Social support in a pandemic: impact of household situation on severity of COVID outcomes**: Kelvin Bryan TAN (Singapore)<br>**Impact of secondary infections on the outcomes of patients with SARS-CoV-2 infection and heamatological malignancies**: Francesca BOBBIO (Italy)<br>**First antigenic exposures to SARS-CoV-2 Spike inform subsequent Omicron infection risk but do not indelibly shape longitudinal neutralising immunity**: Joshua GAHIR (United Kingdom)<br>**Routinely captured measurements of vital signs within long-term care facilities indicate substantial and sustained physiological impacts associated with COVID-19 infection**: Harriet DICKINSON (United Kingdom)<br>**A dynamic latent transition model for predicting post-COVID condition trajectories and guiding patient management**: Anna GORSKA (Italy)<br>**Neutralising antibody responses against omicron variants in individuals vaccinated or unvaccinated with the bivalent BA.4/5 vaccine: a six-month prospective study**: Hye Hee CHA (Republic Of)<br>**Longitudinal humoral response to SARS-CoV-2 mRNA vaccines and boosters in heart and lung transplant patients**: Arianna LIPPI (Italy)<br>**Regression-based forecasting of SARS-CoV-2-related ICU admissions during the pandemic: impact of widespread vaccination**: David FISMAN (Canada)<br>**Retrospective analysis of SARS-CoV-2 omicron variant prevalence over two years in southern Brazil**: Priscila TRINDADE (Brazil)<br>**Association of AB0 blood type with humoral immune responses to SARS-CoV-2 vaccination and infection**: Manuel KRONE (Germany)<br>**Low dosage of a novel SARS-COV-2 mRNA VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine**: Phillip SWANSON (United States)<br>**Dynamics of cellular and humoral immune responses in healthcare workers following a fourth COVID-19 vaccination**: Juliane MEES (Germany)<br>**Short-term challenges, long-term consequences: a comprehensive study of COVID-19 in solid organ transplant recipients**: Imran HASANOGLU (T�rkiye)<br>**Antibody kinetics and duration of protection against SARS-CoV-2 following vaccination**: Julia DEICHMANN (United States)<br>**Characterisation of young vs older stroke in hospitalised patients with COVID-19 infection: a UK based, multicentred, case-control study**: Orla HILTON (United Kingdom)<br>**Correlation analysis of immune checkpoint molecules in children with post-acute sequelae of SARS-CoV-2 infection in Taiwan**: Yu-Lung HSU (China)<br>**Epidemiology of Pseudomonas aeruginosa superinfection in critical COVID-19 patients in a tertiary-care teaching hospital in Mexico City**: Valente-Acosta VALENTE-ACOSTA (Mexico)<br>**Validation and longitudinal analysis of the consensus immune dysregulation framework in a multi-cohort study of COVID-19**: Anastasiya SUSHKOVA (United States)<br>**Chronic SARS-CoV-2 infection demonstrate immune compromisation type- and intensity-dependent viral load dynamics and adaptive evolution trajectory: results from an aggregated meta-analysis**: Tsz Kin Mark CHENG (United Kingdom)<br>**Both clinical status and practices affect microbiome dynamics of the upper respiratory tract during COVID-19 infection**: Mi-Kyung LEE (Republic Of)<br>**Antibody responses to SARS-CoV2 among cancer patients in New York city during the 2020 wave of the COVID-19 pandemic**: Genovefa PAPANICOLAOU (United States)<br>**Artificial intelligence-enhanced nurse navigation: a new paradigm for long COVID diagnosis and care**: Ana Paula BARBOZA (Brazil)<br>**Nasopharyngeal microbiome evolution after SARS-CoV-2 infection: insights into long COVID progression**: Ana Paula BARBOZA (Brazil)<br>**Combination therapy with ensitrelvir and remdesivir reduces viral shedding duration in COVID-19 patients treated with anti-CD20 monoclonal antibodies**: Tomonori TAKANO (Japan)<br>**Impact of long COVID on health-related quality-of-life among Japanese adults: findings of CARE Japan study**: Shinya TSUZUKI (Japan) |
| 12/04 | 12:00 - 13:30 | PS045 | 06a. Fundamental mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome) |  | **Unveiling the skin mycobiome: fungal diversity in intensive care patients**: Teresa NASCIMENTO (Portugal)<br>**Integrative transcriptome profiling and flow cytometric analysis of Th1/Th17 cell dynamics in chronic dermatophytosis**: Gargi RAI (India)<br>**Impact of loss of heterozygosity in diploid fungi on outbreak detection**: Bram SPRUIJTENBURG (Netherlands)<br>**Planktonic and sessile Candida albicans cells release extracellular vesicles carrying the virulence factor Eno1p**: Silvia ANCONA (Italy)<br>**In vitro evaluation of thermal stress on the biofilm formation by a neurotropic fungus, Cladophialophora bantiana**: Haseen AHMAD (India)<br>**The influence of biofilm forming abilities and fluconazole trailing effect of clinical candida albicans isolates on the outcomes of children with Candida bloodstream infections**: Ming Horng TSAI (China)<br>**Longitudinal analysis of the mycobiome in acute leukaemia using metagenomic long-read sequencing**: Thomas TAYNTON (United Kingdom)<br>**Impact of extracellular vesicles from various species of Candida fungi on the cross-species adhesion to human epithelial cells**: Justyna KARKOWSKA-KULETA (Poland)<br>**Rapid onset cardiac pathology caused by a virulent and antifungal-resistant Candida auris outbreak lineage isolate**: Vanessa MEZA-PEREZ (United States)<br>**Serum cytokine profiles in patients with candidaemia**: Jack MCHUGH (United States)<br>**Candidemia's silent weapon: biofilm's role and the race against time in candidemia outcomes**: Alberto PAGOTTO (Italy)<br>**Nakaseomyces glabratus yapsins are involved in antimicrobial peptides degradation and fungal biofilm detachment**: Dorota SATALA (Poland) |
| 12/04 | 12:00 - 13:30 | PS046 | 06b. Fungal disease epidemiology |  | **Cavitary pneumonia unveiled: tracing causes in the arid landscapes of southern Arizona, United States**: Sandhya NAGARAKANTI (United States)<br>**Surveillance of fungi in Germany: first results 2019-2023**: Ines NOLL (Germany)<br>**Impact of candidemia and septic metastases on survival in critically ill patients colonised with Candida auris: a retrospective cohort study**: Kemel HAMMU (Spain)<br>**Predictors of bloodstream infection caused by Candida auris in comparison to other Candida species in adults in Colombia**: Jorge Alberto CORTES LUNA (Colombia)<br>**Short tandem repeat genotyping of extensive Sporothrix brasiliensis collection reveals spread is largely driven by clonal clades**: Eelco F.J. MEIJER (Netherlands)<br>**Urgent consultation: evaluation of 47 invasive fungal sinusitis cases**: Sukru DIRIK (T�rkiye)<br>**Keratomycosis in a tertiary hospital: an eight-year experience from southwest Nigeria**: Anthony ANUFORO (Nigeria)<br>**Corneal keratitis: a clinical and microbiological analysis of fungal and bacterial species in a tertiary hospital over 14 years**: Paula MU�OZ-BRELL (Spain)<br>**Invasive aspergillosis (IA) and survival of acute myeloid leukemia (AML) patients at 12 weeks and 12 months after AML diagnosis**: Alessandra MICOZZI (Italy)<br>**The epidemiology of chronic pulmonary aspergillosis in Denmark**: Marie Louise JOERGENSEN (Denmark)<br>**Pneumocystis jirovecii pneumonia in South Africa: trends and insights from 2018 to 2022**: Nkosi MBALI (South Africa)<br>**Characteristics, treatment outcomes and Aspergillus susceptibility in chronic pulmonary aspergillosis patients treated with echinocandins**: Laura MICHON (Netherlands)<br>**Pneumocystis jirovecii colonisation in mothers of preterm newborns and risk of vertical transmission**: Elena CHARPENTIER (Spain)<br>**Identifying the impact of fungal exposure on TB patient outcomes in Ivory Coast**: David KOFFI (C�te D'ivoire)<br>**An analysis of risk factors associated with high mortality of candidaemia by Candida albicans compared with Candida parapsilosis (CANDIPAR study)**: Ana SORIANO-MART�N (Spain)<br>**Determining the significance of Candida growth in nephrostomy urine samples**: Yusuf KAMESHKI (United Kingdom)<br>**Trichophyton indotineae or not-indotineae, that is the question: evaluation of Piacenza epidemiology of dermatophytes and presence of emerging species**: Valentina LEPERA (Italy)<br>**Trends in invasive Candida infections in Swiss hospitals: a 15-year surveillance study (2009-2023) on species distribution, resistance, and antifungal use**: Olivier FRIEDLI (Switzerland)<br>**T. indotineae as an agent of dermatophytosis in Barcelona, Spain**: M.Teresa MARTIN-GOMEZ (Spain)<br>**Detection of causative agents of infectious keratitis in patients from western Rajasthan**: Twishi SHRIMALI (India)<br>**Paediatric eumycetoma patients: a threefold neglected patient group**: Joanna BRODERSEN (Austria)<br>**Risk factors for mortality among adult patients with bloodstream infection caused by Candida auris in Colombia**: Jorge Alberto CORTES LUNA (Colombia)<br>**Characterisation and risk factors of occupational aspergillosis: a national multicentre retrospective study using RNV3P data**: Anastasia SAADE-ANTYPAS (France)<br>**High prevalence of behaviours known to increase the risk of recurrent vulvovaginal candidiasis in Nigeria**: Samuel Adetona FAYEMIWO (Nigeria)<br>**Epidemiology of Meyerozyma guilliermondii species complex isolated from invasive fungal diseases: a multicentre study in China**: Yuyan HUANG (China)<br>**Rhinosporidiosis in South Africa (2012 to 2024)**: Charlotte SRIRUTTAN-NEL (South Africa)<br>**Impact of the Candida auris management protocol on epidemiological trends: a study at IRCCS San Martino hospital**: Lucia INGLESE (Italy)<br>**Fungal endocarditis: experience in a tertiary hospital**: Maricela VALERIO MINERO (Spain)<br>**Otomycosis: a retrospective study**: Yousra ZEKRI (Morocco)<br>**Candidemia and the Candida equal score: a clinical evaluation in a tertiary care hospital**: Kruthi MALUR KUMARASWAMY (India)<br>**Global transmission of Candida auris to Austria: epidemiological, phenotypical, and phylogenetic insights**: Kathrin SPETTEL (Austria)<br>**High prevalence of histoplasmosis among persons with advanced HIV disease in Ivory Coast, 2024**: Serge DOU (C�te D'ivoire)<br>**International survey on the diagnosis and treatment of disseminated histoplasmosis in people living with HIV (PLHIV): the PROPULS2A study**: Fr�d�gonde ABOUT (French Guiana)<br>**Incidence of Aspergillus species isolates in samples from the lower respiratory tract in the years 2017 to 2024**: Mar�a Paula VARGAS DUR�N (Spain)<br>**Factors associated with mortality in critically ill patients: a comparison between HIV-infected and non-immunodeficient individuals with histoplasmosis**: Paula FIGUEROA (Guatemala)<br>**Management of Candida spp. prosthetic joint infections (PJI) according to country**: Christel MAMONA (France)<br>**Parinaud syndrome as a clinical manifestation of Sporothrix brasiliensis more often than it should!**: Filipe PROHASKA BATISTA (Brazil)<br>**Culture-positive-CAPA of three German tertiary care hospitals: incidence, management and risk factors**: Alexander Maximilian ALDEJOHANN (Germany)<br>**Candidemia epidemiology and antifungal resistance during and after COVID-19 pandemic: comparison between two tertiary care hospitals in Greece and Turkey**: Esma ERYILMAZ EREN (T�rkiye)<br>**Strengthening fungal infection diagnosis and treatment: an in-depth analysis of capabilities in Honduras**: Jon SALMANTON-GARCIA (Germany)<br>**Disseminated histoplasmosis in non-endemic area: comparative analysis of clinical features, risk factors, and outcome of histoplasmosis in HIV-positive and HIV-negative cohorts in western India**: Akshatha RAVINDRA (India)<br>**The role of a fungal multidisciplinary team in diagnosing and managing respiratory fungal disease: a retrospective study at a tertiary referral centre**: Lydia FINNEY (United Kingdom)<br>**Retrospective analysis of risk factors and outcomes in Candida auris and non-Candida auris candidemia in critically ill patients**: Ezgi G�LTEN (T�rkiye)<br>**Epidemiology of HIV and non-HIV cryptococcosis at a tertiary care hospital of a developing country**: Harsimran KAUR (India)<br>**Pneumocystis primary infection in infants is a community-acquired infection: results of a single-centre prospective observational study**: Sol�ne LE GAL (France)<br>**Evaluation of EQUAL Candida score and other risk factors predicting mortality in patients with candidemia**: Melike INAN HEKIMOGLU (T�rkiye)<br>**Nationwide surveillance of Candida bloodstream infections in Korea: species distribution, antifungal resistance, and molecular characteristics (2022-2024)**: Yong Jun KWON (Republic Of)<br>**Candida infective endocarditis: clinical insights and outcomes**: Muammer �ELIK (T�rkiye)<br>**Trichophyton indotineae, an emerging and recalcitrant dermatophytosis agent in Iran and Middle East: a two-centre study from Iran and literature review**: Mohammad Taghi HEDAYATI (Islamic Republic Of)<br>**Epidemiological analysis of candidaemias in a Spanish tertiary hospital during a five-year period**: Maddalen GURRUTXAGA OLANO (Spain)<br>**Clinical, diagnostic and therapeutic characterstics of CNS fungal infections: insights from a single-centre reptrospective study**: Ilias MASOURIS (Germany)<br>**Changing epidemiology of Candida spp. isolated from patients with candidemia in a tertiary hospital in northern Greece: appearance of Candida auris**: Dimitrios KOUROUPIS (Greece)<br>**Characterisation of cryptococcal isolates and clinical outcomes in HIV-negative Korean patients with cryptococcosis: a four-year multicentre study**: Eun Jeong WON (Republic Of)<br>**Invasive fungal diseases among COVID-19 patients at a tertiary university hospital in Thailand**: Aliyavong THAMMAVONG (Lao People's Democratic Republic)<br>**Prediction of in-hospital mortality and persistence by biofilm phenotype in patients with Candida glabarata bloodstream infections and screening of related biofilm genes**: Jing LIN (China)<br>**Distribution of Candida species colonising skin of inpatients in Southern Africa**: Tshiama Miriam MWAMBA (South Africa)<br>**Comparative clinical profile of non-neutropaenic patients with Candida auris vs non-C.auris candidemia**: Jui ATHAVALE (India)<br>**Burden of fungal keratitis(FK) in Sagarmatha Choudhary eye hospital (SCEH), Nepal: epidemiological and microbiological profile**: Pankaj CHAUDHARY (Nepal)<br>**Risk stratification in candidemia: a case-control study from 2016-2023**: Shashikala SHIVAPRAKASHA (India)<br>**A retrospective study of ocular fungal infections over a two-year period in a tertiary Hellenic hospital**: Kalliopi AVGOULEA (Greece)<br>**Isolation of a novel genus in the family Myriangiales from a patients with onychomycoses using whole-genome sequencing**: Mi-Kyung LEE (Republic Of)<br>**Molecular characterisation of the genotype of Candida albicans in patients with candidemia in Ecuador**: Jeannete ZURITA (Ecuador)<br>**Factors associated with the development of esophageal candidiasis in oncological patients**: Juli�n Andres HOYOS PULGARIN (Colombia)<br>**Candidemia in paediatric population: a nine-year review at a tertiary hospital**: Paula MU�OZ-BRELL (Spain)<br>**Long-term survival of patients undergoing myelosuppressive therapy for acute leukemia**: Denise D'ELIA (Switzerland)<br>**Inter-hospital spread of fluconazole-resistant C. parapsilosis in northern Italy: study of clonality aspects, resistance mechanisms and their correlation with biofilm production**: Giorgia PALLADINI (Italy)<br>**Candida and non- yeasts prevalence in vulvovaginal infection during pregnancy: Serbian national survey viewed through the MALDI-TOF MS analysis**: Valentina ARSIC ARSENIJEVIC (Serbia)<br>**An analysis of Candida albicans and Candida parapsilosis candidaemia in the last 14-years (CANDIPAR Study)**: Ana SORIANO-MART�N (Spain)<br>**Candida auris colonisation in multiple facilities in Kenya**: Loice OMBAJO (Kenya)<br>**Breakthrough invasive mold infections under posaconazole prophylaxis**: Camille MARCHETTI (Switzerland)<br>**Whole-genome sequencing of recently introduced Clade I Candida auris clinical isolates from hospitals in Korea**: Yong Jun KWON (Republic Of)<br>**Candidemia caused by different Candida species: a five-years retrospective study**: Anna MAVROMMATI (Greece)<br>**Candida auris in polymicrobial bloodstream infections: probably a deadlier foe compared to other Candida species?**: Konstantina GKARTZONIKA (Greece)<br>**A six-year evaluation of invasive candidiasis epidemiology including emergence of Candida auris from a large, southern US metro area**: Ricky HUYNH-PHAN (United States)<br>**Chromoblastomycosis in Peru: an underreported infection**: Dina Mercedes SANCHEZ DIAZ (Peru)<br>**Establishing the optimal length of testing to detect Candida auris colonisation after discharge from an endemic area**: Laura MEZZOGORI (Italy)<br>**Changes in the epidemiology of candidemia after the COVID-19 pandemic at a Brazilian**: Simone NOU�R (Brazil) |
| 12/04 | 12:00 - 13:30 | PS047 | 06c. Diagnostic mycology (incl traditional, molecular and other methods) |  | **Value of CRISPR-Cas12-based polymerase chain reaction for diagnosing invasive fungal infection and chronic fungal pneumonia**: Qingqing WANG (China)<br>**Epsilometer test-based limitations in detecting anidulafungin resistance in Candida parapsilosis**: Cornelia LASS-FL�RL (Austria)<br>**Performance of Aspergillus PCR on mini broncho-alveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis using BM-aspICU criteria: a cross-sectional diagnostic test validation study**: Sayan MAHARATNA (India)<br>**Service evaluation of fungal antigen testing in renal transplant patients at a UK regional transplant centre**: Jonathan BYROM (United Kingdom)<br>**Fungal DNA-barcoding on a chip: ITS-DNA biosensors for yeast infection diagnosis**: Maria ZOLOTAREVA (Portugal)<br>**Enhancing the diagnosis of invasive candidiasis using Candida real-time PCR: uncovering hidden challenges**: Elizabeth ISKANDAR (Italy)<br>**Prognostic value of serum and bronchoalveolar lavage fluid galactomannan in invasive aspergillosis: an eight-year experience at a tertiary cancer centre**: Saliba WEHBE (United States)<br>**Results of a universal fungal PCR performed in clinical samples of patients: experience of a Chilean university centre**: Claudia CASTILLO (Chile)<br>**The diagnostic value of metagenomic next-generation sequencing for mucormycosis and the risk factors of poor prognosis in mucormycosis**: Weili ZHANG (China)<br>**Comparison of clinical performances between a commercial real-time PCR kit and in-house real-time PCR assay in plasma and paraffin-embedded tissue samples for diagnosis of Aspergillosis**: Ji Yeun KIM (Republic Of)<br>**A promising combination for fast molecular diagnosis of dermatophytosis**: Truong Giang NGUYEN (France)<br>**Evaluation of a new multiplex-tandem PCR assay for the diagnosis of superficial fungal infections of the skin, hair and nails**: Jean MENOTTI (France)<br>**The Candida auris surveillance: why do we need to implement it? A validation study on new enrichment broth to increase the sensibility of Candida auris detection**: Giulia GATTI (Italy)<br>**Evaluation of real-time PCR assay for detection of Candida auris in surveillance specimens on a fully automated system**: Tin Long LUI (China)<br>**1,3-beta-D-glucan on ascitic fluid: possible early marker of fungal infection in patients with cirrhosis and/or acute liver failure?**: Elisa MATARAZZO (Italy)<br>**Performance evaluation of a novel Candida auris differentiation medium**: Hannah PAY (United Kingdom)<br>**Prospective evaluation of a new multiplex PCR for dermatophyte detection in clinical samples from a tertiary hospital**: Silvia BOLA�O GARC�A (Spain)<br>**Application of the Fourier transform-infrared (FT-IR) biotyper for Candida auris clade level differentiation**: Lara Rubbia FERREIRA (United Kingdom)<br>**Assessing the utility of a pan-fungal (ITS2 gene) PCR assay on whole blood in the paediatric setting: five years' experience**: Surjo DE (United Kingdom)<br>**Evaluation of endotracheal aspirate galactomannan antigen detection for diagnosis of invasive pulmonary aspergillosis: a diagnostic test validation study**: Sandeep RAO KORDCAL (India)<br>**External validation and refinement of a clinical predictive model of candidemia by Candida auris in critically ill patients**: Victor GARCIA-BUSTOS (Spain)<br>**Using MALDI-TOF MS for identification of dermatophyte and non-dermatophyte molds: single centre experience**: Marko ARSENIJEVIC (Serbia)<br>**Microsatellite typing: validating a new tool for molecular epidemiology of Trichosporon asahii infections**: Elaine Cristina FRANCISCO (Brazil)<br>**Pneumocystis jirovecii pneumonia and the possible prognostic role of quantitative polymerase chain reaction: preliminary results from a retrospective multicentre study**: Riccardo PAGGI (Italy)<br>**QCMD Candida auris: a new EQA scheme designed in response to a serious global health threat from an emerging pathogen**: Dorothy MONTGOMERY (United Kingdom)<br>**Beta-d-glucan where are you? Impact of false negative BDG on antifungal treatment initiation in patients with candidemia**: Enrica BONO (Italy)<br>**Candida albicans nucleic acid sample preparation in 15-seconds with Autolab HBH**: Alem ABEBE (United States)<br>**Integration of MALDI-TOF and ITS sanger sequencing into a streamlined pipeline for identification of fungi from clinical specimens**: Corrie BELANGER (Canada)<br>**Mycological testing in Australasian clinical mycology laboratories: survey of the current state and access to testing**: Adam STEWART (United States)<br>**Effect of galactomannan in food on serum levels in suspected IPA patients: insights from a hospital-based and mouse study**: Animesh RAY (India)<br>**Mycological evaluation of sinus lavage fluid in patients with heamatological malignancies and suspected invasive fungal sinusitis**: Mohammadreza SALEHI (Islamic Republic Of)<br>**Detection of clinically relevant Candida species from positive blood culture using an automated point-of-care assay: MoiM Dx Candida 9-plex assay**: Eun Jeong WON (Republic Of)<br>**Assessment of prioritised fungal pathogen detection in aerobic blood culture system**: Christopher CANTRELL (United States)<br>**Fungi under fire: addressing a Peruvian health challenge**: Jon SALMANTON-GARCIA (Germany)<br>**Evaluation of a novel Aspergillus galactomannan chemiluminescence immunoassay for the diagnosis of invasive pulmonary aspergillosis: a multicentre controlled study**: Zeqi ZHOU (China)<br>**Evaluation of SYBR green real-time PCR for rapid and specific detection of Trichophyton indotineae**: Faezeh ROUHI (Islamic Republic Of)<br>**Time- and temperature-dependent pentraxin 3 stability in serum and bronchoalveolar lavage fluid samples**: Andrea LANGER SERME�O (Czech Republic)<br>**Implementation of in-house Histoplasma antigen tesing from serum and urine samples using**: Ruben MERTENS ALBUSAC (United Kingdom)<br>**MP65/ENO1 ratio as a diagnostic marker for pathogenic Candida albicans in vulvovaginal candidiasis**: Robert MARKS (Israel)<br>**Evaluation of a new commercial real-time PCR assay to detect dermatophytes in nails**: Rosalie SACHELI (Belgium)<br>**High volume culture technique: a good alternative to conventional culture on the bronchioalveolar lavage samples in invasive pulmonary aspergillosis patients**: Renu KUMARI (India)<br>**Development and evaluation of simple molecular methods for the distinction of the newly emerging dermatophyte Trichophyton indotineae**: Shima ABOUTALEBIAN (Islamic Republic Of)<br>**Pentraxin-3 as a novel prognostic biomarker in nonneutropaenic invasive pulmonary aspergillosis patients**: Xin SU (China)<br>**Comparative analysis of chemiluminescence immunoassay (CLIA)-based tests in the diagnosis of invasive aspergillosis in patients with heamatologic malignancies**: Ayse KALKANCI (T�rkiye)<br>**Optimisation of C.auris culture: the influence of temperature, enrichment broth and chromogenic agar**: Monique WETZELS-VRANCKEN (Netherlands)<br>**Real-time application of ITS and D1-D3 nanopore amplicon metagenomic sequencing in fungal infections: enhancing fungal infection diagnostics**: Kon CHU (Republic Of)<br>**Comparison of two Aspergillus galactomannan detection tests: platelia galactomannan and virclia galactomannan mono test**: Ioanna MARINOU (Greece)<br>**Development and validation of a TaqMan-based real-time PCR assay for direct detection of Trichosporon asahii in spiked blood culture bottles**: Elaine Cristina FRANCISCO (Brazil)<br>**Clinical evaluation of a novel qPCR assay for the detection of dermatophyte fungi and Candida albicans in skin and nail material**: Miguel FERN�NDEZ-HUERTA (Spain)<br>**Usefulness of sequence-based identification methods for differentiating clade II and non-clade II Candida auris isolates from Korean hospitals**: Jong Hee SHIN (Republic Of)<br>**Sequential serum galactomannan as predictive response marker for invasive aspergillosis**: Jannik STEMLER (Germany)<br>**Verification of a new enrichment broth and two chromogenic agars for the identification of Candida auris**: Dina OULKADI (Belgium)<br>**Aspergillus IgG antibodies in diagnosing pulmonary aspergillosis**: Tingting WANG (China)<br>**Diagnostic value of combined detection of BDG assay and GM assay in invasive aspergillosis**: Zeqi ZHOU (China)<br>**A novel multiplex Aspergillus PCR assay for detection of of invasive aspergillosis**: Zeqi ZHOU (China)<br>**Accuracy and actionability of mold PCR panel on bronchoalveolar lavage for the diagnosis of invasive mold disease**: Koray DEMIR (United States)<br>**A novel multiplex real-time quantitative PCR detecting system approach for detection of Candida auris**: Zeqi ZHOU (China)<br>**Prospective national multicentre study to determine the usefulness of 18-FDG-PET-TC for the management of invasive fungal infection (PETIFI project)**: Ana FERN�NDEZ-CRUZ (Spain)<br>**Efficient lateral flow assay for rapid sporothricosis diagnostic**: Herv� BOUTAL (France)<br>**Use of MT-PCR (multiplex tandem) in dermatomycosis diagnostic**: Enrico FURCHI (Italy)<br>**Enhancing molecular detection of Candida auris through broth media enrichment**: Chiara SENTI (Italy)<br>**Is a good KOH Calcoflour white microscopic examination sufficient for diagnosis of mucormycosis in a resource limited setting instead of an expensive real time PCR assay?**: Priyadarshini PADAKI (India) |
| 12/04 | 12:00 - 13:30 | PS048 | 06d. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms) |  | **Declining azole susceptibility in candida parapsilosis: a ten-year analysis of US blood culture isolates, 2015-2024**: Jack MCHUGH (United States)<br>**P-bromodomiphen bromide potentiates conventional antifungal activity against Candida auris**: Francesca TRIVA (Italy)<br>**In vitro activitiy of rezafungin in comparison with anidulafungin and caspofungin against invasive fungal isolates in China, 2017-2022**: Wenjuan WU (China)<br>**Activity of the new antifungal oteseconazole against Pichia kudriavzevii clinical isolates from invasive fungal infections**: Isaac ALONSO GARCIA (Spain)<br>**First report of fluconazole-resistant Candida parapsilosis harbouring the G438S ERG11p substitution in a Brazilian hospital**: Pilar ESCRIBANO (Spain)<br>**Fungal colonisation, resistance, and invasive infections in spanish ICUs: findings from 22 centres**: Laura ALGUACIL CU�LLAR (Spain)<br>**Study of Tac1a and Tac1b in azole resistance in Candida auris**: Camille MARCHETTI (Switzerland)<br>**Spread of Y132F fluconazole-resistant C. parapsilosis genotypes causing candidemia in patients admitted to a tertiary hospital in Genoa, Italy**: Teresa CARRASCO GIL (Spain)<br>**Antifungal resistance surveillance: insights from a multicentre survey**: Alexandre ALANIO (France)<br>**Understanding multiazole resistance in Aspergillus fumigatus: the impact of non-cyp51A mutation and efflux pump overexpression**: Pooja SEN (India)<br>**Photodynamic inactivation and the paucity of the antifungal arsenal against oral fluconazole-resistant non-Candida albicans Candida species**: Lucia CERN�KOV� (Slovakia)<br>**The new triterpenoid antifungal SCY-247 retained activity against most echinocandin- and fluconazole-resistant Candida spp isolates: reduced susceptibility in C. glabrata isolates showing substitutions at the first amino acid in hotspot 1 FKS2 gene**: Jesus GUINEA (Spain)<br>**In vitro activity of rezafungin against antifungal-resistant Candida spp isolates: loss of activity against C. glabrata isolates harbouring S663 and delF659 substitutions**: Celia SANCHEZ (Spain)<br>**Unlocking the fungicidal activity of triazoles against Candida auris**: Laura DOORLEY (United States)<br>**Fluconazole heteroresistance in Candida auris**: Erganis SIDRE (T�rkiye)<br>**Investigation of expression levels of 14-alpha lanosterol demethylase gene (ERG11) and efflux pump-encoding genes (CDR1, CDR2, and MDR1) in C. albicans isolates with decreased susceptibility to azoles from vaginal cultures**: Ayse BARIS (T�rkiye)<br>**Evaluation of rezafungin on the thermo scientific sensititre YeastOne panel**: Dylan STAATS (United States)<br>**In vitro antagonism between voriconazole and olorofim against 30 clinical strains of Aspergillus fumigatus**: Illan LALOUM (France)<br>**Optimising the screening method for fluconazole-resistant Candida parapsilosis with chromogenic media**: Nazaret BETANZOS GUTIERREZ (Spain)<br>**Antifungal susceptibility profile of Aspergillus species isolated from 2019 to 2024 in a tertiary care hospital**: Maddalena ALBERTINI (Italy)<br>**Cladophialophora bantiana: first insights into susceptibility patterns and whole-genome sequencing analysis of a clinical case**: Kathrin SPETTEL (Austria)<br>**DBRMC: database for resistance mutations in Candida**: Richard KRIZ (Austria)<br>**Effect of rezafungin against biofilm of Candida parapsilosis fluconazole-resistant isolates**: Elizabeth ISKANDAR (Italy)<br>**Prospective single centre surveillance of clinically isolated azole-resistant Aspergillus fumigatus in Japan**: Yasuhiro TSUCHIDO (Japan)<br>**Identification of antifungal resistance mechanisms in the Tardiomyces genus**: Bram SPRUIJTENBURG (Netherlands)<br>**Resistance profiles of Candida auris strains in Cluj-Napoca, Romania: a minireview**: Teodora SHERBAN (Romania)<br>**ECMM-Candida IV: a worldwide study on antifungal tolerance, resistance, and clinical outcomes in candidemia caused by non-albicans Candida species**: Stella WOLFGRUBER (Austria)<br>**Characteristics of Candida auris colonized in different sites of the same patient**: Zitong PAN (China)<br>**Novel rapid antifungal susceptibility testing system for yeasts based on fast cell growth**: Zeqi ZHOU (China)<br>**Echinocandin susceptibility patterns and genetic changes in nonsusceptible Candida glabrata with non-hotspot FKS alterations**: Marisa WINKLER (United States)<br>**Antifungal susceptibility patterns and genomic mutations in Candida glabrata isolates from patients with candidemia**: Eloy ORDAYA (United States)<br>**Activity of manogepix against a worldwide collection of yeast isolates from 2023**: Marisa WINKLER (United States)<br>**Rapid antifungal susceptibility testing direct from positive blood culture**: Ken BABCOCK (United States)<br>**Copy number variants (CNVs) at chromosome 3 as azole resistance mechanisms additional to ERG11p substitutions in azole-resistant Candida parapsilosis isolates**: Pilar ESCRIBANO (Spain)<br>**Biocide, antifungal susceptibilities and virulence characteristics of Clade 1 Candida auris strains**: Ayse KALKANCI (T�rkiye)<br>**Trends of azole-resistant Aspergillus fumigatus susceptibility over more than one decade from a German ECMM excellence centre**: Hedda Luise VERHASSELT (Germany)<br>**whole-genome sequencing of Candida glabrata and Candida albicans for detection of resistance mutations against echinocandins**: Fanny WEGNER (Switzerland)<br>**Revolutionising the fight against fungi with clinically relevant in silico tools for fungal drug resistance**: Aakriti JAIN (India)<br>**Antifungal susceptibility testing of SCY-247 against contemporary clinical yeast isolates**: Luis OSTROSKY-ZEICHNER (United States)<br>**Antifungal susceptibility profiles of Cryptococcus neoformans isolates from Czech Republic: a 20-year surveillance study, 2002-2023**: Radim DOBIAS (Czech Republic)<br>**Phylogenomics reveals patterns of azole activity against Aspergillus section Nigri clinical isolates**: Mariana CASTANHEIRA (United States)<br>**Azole-resistant Aspergillus fumigatus in people with cystic fibrosis with lung transplantation: susceptibility patterns and molecular epidemiology**: Ulrike SCHARMANN (Germany)<br>**Fluconazole-nonsusceptible Candida tropicalis bloodstream isolates in South Korea, 2003–2024: resistance mechanisms and genetic relatedness**: Soo Bin LEE (Republic Of)<br>**Isavuconazole MIC determination: comparative evaluation of a new gradient strip to the EUCAST E.DEF 9.4 BMD on 110 Aspergillus isolates**: Veronique SAUVONNET (France)<br>**Rapid vs standard susceptibility testing to echinocandins: is RAST for antifungal agents possible?**: Luc�a G�MEZ BARRAL (Spain)<br>**In vitro susceptibility testing of rare moulds "RaMo Study": an ECMM-EC/EFISG/ECMM/ISHAM initiative**: Lisa HAHN (Austria)<br>**The susceptibility of Meyerozyma guilliermondii and Kluyveromyces marxianus to manogepix and other antifungal drugs**: Aleksandra G�RZYNSKA (Poland)<br>**National survey on azole-resistant clinical Aspergillus fumigatus collected in 2023: environmentally generated azole-resistant isolates (TR34-L98H and TR46-Y121F-T289A substitutions) are expanding across Spain**: Jesus GUINEA (Spain)<br>**New insights into antifungal susceptibility testing on Sporothrix brasiliensis**: Carolina DO PRADO (Brazil)<br>**A guanidine-functionalised anthranilamide peptidomimetic RK758 targets Candidozyma auris: integrative mechanistic insights from morphology to transcriptomics**: Shyam Kumar MISHRA BAISHNAB (Australia) |
| 12/04 | 12:00 - 13:30 | PS049 | 06e. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials) |  | **Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis**: Yazed ALSOWAIDA (Saudi Arabia)<br>**Potent and broad-spectrum antifungal activity of 6-alpha-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one, a triterpenoid from Paullinia pinnata**: Benjamin Kingsley HARLEY (Ghana)<br>**Manogepix and amphotericin B combination is synergistic against Candida glabrata as evidenced by a new pharmacodynamic-modelling approach**: Vincent ARANZANA-CLIMENT (France)<br>**Fluconazole-resistant Candida urinary tract infections: rare but difficult to manage**: Emma OLIOSI (France)<br>**Isavuconazole comparison with other azoles regarding CYP3A-based drug-drug interactions in combination with ibrutinib, venetoclax, or midostaurin**: Theunis GOOSEN (United States)<br>**Antifungal alternatives to itraconazole for the treatment of histoplasmosis: a multicentre retrospective study**: Fr�d�gonde ABOUT (French Guiana)<br>**In-vitro investigation of the gold nanoparticles efficiency in the treatment of multidrug-resistant Candida auris**: Pelinsu ARMUTCUOGLU (T�rkiye)<br>**Cytotoxicity and antifungal activity of Felimare lajensis**: Natalia IORIO (Brazil)<br>**Posaconazole tablets in preventing invasive fungal diseases in patients with end-stage liver disease**: Tianyan CHEN (China)<br>**Collateral sensitivity counteracts the evolution of antifungal drug resistance in Candida auris**: Patrick VAN DIJCK (Belgium)<br>**SCY-247, a novel second-generation IV/oral triterpenoid antifungal, demonstrates in vitro activity against C. auris including the majority of strains exhibiting high MICs for echinocandins**: Eelco F.J. MEIJER (Netherlands)<br>**Assessment of in vitro activity of the new triterpenoid antifungal, SCY-247, against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024**: Jesus GUINEA (Spain)<br>**Evaluation of posaconazole therapeutic drug monitoring for anti-fungal prophylaxis in patients with a heamatological malignancy: a tertiary referral centre's experience**: Ashok AADITH (Australia)<br>**Mold-active therapy in critically ill patients from 2008 to 2023 in a tertiary care hospital in Germany**: Dominic WICHMANN (Germany)<br>**Clinical outcome of different treatments in patients with vulvovaginal candidiasis**: Vasiliki KROUSTALI (Greece)<br>**Tolerability and pharmacological monitoring of voriconazole and isavuconazole in chronic pulmonary aspergillosis: a real-world comparison**: Federico FAMA (Italy)<br>**Fluconazole pharmacodynamics against Candidozyma auris isolates in an in vitro pharmacokinetic/pharmacodynamic model**: Maria-Ioanna BEREDAKI (Greece)<br>**Inhibition of tumor necrosis factor-alpha production by azole antifungal agents**: Ippei SAKAMAKI (Japan)<br>**Isavuconazole pharmacokinetics in critically ill patients with acute-on-chronic liver failure and continuous haemodialysis: an observational study**: Emily BEHRENS (Germany)<br>**A survey on candidemia management in Germany**: Ilana REINHOLD (Germany)<br>**ASLdC3 elevates mitochondrial dysfunction by impeding the central carbon metabolism to inhibit yeast-to-hyphae transition in Candida albicans**: Yachna KUMARI (India)<br>**Deciphering connections between isavuconazole (ISAV) drug exposures and responses among different infections: Mucorales**: Laura KOVANDA (United States)<br>**Real-world dataset demonstrates favorable safety profile of liposomal amphotericin B for the treatment of invasive aspergillosis in high-risk haemato-oncology patients**: Johan MAERTENS (Johan MAERTENS)<br>**Antifungal treatment regimens as primary therapy for invasive aspergillosis: a systematic review and network meta-analysis**: Dayu CHEN (China)<br>**Healthcare resource utilisation, all-cause treatment costs, and mortality in patients with malignancies that develop invasive aspergillosis**: Craig COLEMAN (United States)<br>**Retrospective, multicentre study of the renal safety of liposomal amphotericin B in critically ill with invasive pulmonary aspergillosis**: Borja SUBERVIOLA (Spain)<br>**Azole-loaded mucosomes: a hopeful approach to fight Candida albicans in mucosal infections**: Giuliana BANCHE (Italy)<br>**Real-world experience with rezafungin: a novel long-acting echinocandin**: Lucinda VAN ANGLEN (United States)<br>**Safety and pharmacokinetics of SF001, a next-generation polyene antifungal, following single and multiple doses in healthy adults**: Kieren MARR (United States)<br>**Deciphering connections between Isavuconazole (ISAV) drug exposures and responses among different infections: dimorphic fungi/mould/other filamentous fungi and mixed infections**: Desai AMIT (United States)<br>**Availability of antifungals in low- and middle-income countries: updating the maps**: Stella WOLFGRUBER (Austria)<br>**Deciphering connections between isavuconazole (ISAV) drug exposures and responses among different infections: invasive candidiasis**: Laura KOVANDA (United States)<br>**Evaluation of the compliance of the antifungal treatment approach with the recommendations in current international guidelines in patients with invasive candida infection or candida colonisation**: Zarifa ORTA (T�rkiye)<br>**A study on intensive care unit invasive fungal stewardship (IFS) cognition and clinical practice among ICU physicians in Sichuan province**: Lingai PAN (China)<br>**Old friends, new foes: explorative assessment of the potential drug-drug interaction between metamizole and mold-active azoles**: Dorian VANNESTE (Belgium)<br>**Study design: Phase 2, multicentre, open-label, randomised, active-controlled trial to evaluate the efficacy and safety of rezafungin adjunctive therapy in HIV-associated Pneumocystis jirovecii pneumonia**: Sean WASSERMAN (United Kingdom)<br>**Clinical outcomes with rezafungin or caspofungin in adults with invasive infections due to  non-albicans Candida: pooled analysis from STRIVE and ReSTORE trials (including extension phase data)**: Oliver A. CORNELY (Germany)<br>**Implementation of antifungal stewardship rounds at a large teaching hospital**: Navjeet NAGI (United Kingdom)<br>**Isavuconazole therapeutic drug monitoring and dosage adjustments**: Sara COBO SACRIST�N (Spain) |
| 12/04 | 12:00 - 13:30 | PS050 | 07a. Fundamental parasitology |  | **Hookworm modulated immune responses to bystander antigens among adults in endemic rural communities in southern India**: Ramya MADHAVAN (India)<br>**Advancing blastocystis research through a One Health approach: insights from a COST action**: Anja GODFREY (United Kingdom)<br>**Bulk and single-cell transcriptome profiling revealed dynamic pathological changes of granulomatous amebic encephalitis caused by Balamuthia mandrillaris: a cohort study**: Jingjia ZHANG (China)<br>**Evaluation of natural killer cell exhaustion markers in the peripheral blood of hydatid cyst patients**: Soodeh GHADIMI (Islamic Republic Of)<br>**Emsb microsatellites analysis of Echinococcus multilocularis specimens isolated from Belgian patients with alveolar echinococcosis and host animals**: Sabrina EGREK (Belgium)<br>**Spatiotemporal transcriptomic profiling reveals the dynamic immunological landscape of alveolar echinococcosis**: Zhihua OU (China)<br>**Single-cell analysis of gene expression in a pathogenic strain of Entamoeba species**: Hiroshi TACHIBANA (Japan)<br>**Evaluation of natural killer cell frequency and exhaustion markers in the peripheral blood of patients with cutaneous leishmaniasis**: Mohammadreza SHAFIEI (Islamic Republic Of)<br>**Stage-specific immune response to AgB T-peptides in patients with cystic echinococcosis**: Settimia SBARRA (Italy)<br>**Prevalence of parasites in three-spot gourami (Trichopodus trichopterus) from natural water sources in Khlong 7, Thanyaburi district, Pathum Thani province**: Surachai TECHAOEI (Thailand) |
| 12/04 | 12:00 - 13:30 | PS051 | 07b. Parasitic disease epidemiology |  | **Presence of Wolbachia bacteria in Mansonella perstans isolates from migrants of different geographical origin: a pilot study from the ESCMID study group on clinical parasitology**: Francesca TAMAROZZI (Italy)<br>**D-dimer as a marker of severe disease in imported P. falciparum malaria: a retrospective observational study**: Andrea POLONI (Italy)<br>**Optimisation of PCR-based detection of Wolbachia bacterial strains in Anopheles malaria vectors in the field**: Isabel HUGHES (United Kingdom)<br>**Visceral leishmaniasis and lymphatic filariasis co-endemicity in Bihar, India**: Sundaram PANDEY (India)<br>**Unveiling Ehrlichia canis: genetic diversity, population structure, and haplotype variations of an emerging zoonotic pathogen**: Anil Kumar NEHRA (India)<br>**Visceral leishmaniasis among children and adults in a Tunisian hospital**: Meriem ABDELJELIL (Tunisia)<br>**Epidemiological investigation of a malaria outbreak in overseas deployment units in 2022**: Suryeong GO (Republic Of)<br>**Prevalence and molecular typing of the parasite Dientamoeba fragilis in patients from two hospitals in the Czech Republic**: Jolana HAVLOV� (Czech Republic)<br>**Unveiling the molecular diversity of Leishmania infantum in human tegumentary leishmaniasis: evidence from Italy and Spain**: Tommaso GRITTI (Italy)<br>**Intestinal parasitic infections in upper Corsica: current epidemiology and diagnostic approach**: Arthur MAKA (France)<br>**Risk factors for Trichuris trichuira infection in children**: Rose Chimezie IHEZIE (Nigeria)<br>**Comprehensive mapping of Blastocystis epidemiology and subtypes: insights from COST action CA21105 'One Health Blastocystis`**: Eylem AKDUR �ZT�RK (T�rkiye)<br>**Recent spread and outcomes of human alveolar echinococcosis in Croatia**: Natalia OSLAJ (Croatia)<br>**Congenital toxoplasmosis screening of pregnant women in Cameroon: proposing a novel algorithm with a cost savings analysis**: Malika MADHAVA (United States)<br>**Investigating hybrid Schistosoma spp. imported infections to Europe: a cohort from the ESCMID study group on clinical parasitology**: Francesca TAMAROZZI (Italy)<br>**Clinical outcomes in chagas disease among military personnel: a retrospective observational study in Bogota, Colombia**: Santiago RODR�GUEZ (Colombia)<br>**Knowledge on female genital schistosomiasis among women attending public healthcare facilities in Namayingo and Mayuge Districts, Uganda**: Eddy KYAGULANYI (Uganda)<br>**Neglected blood parasitic diseases and malaria in the Peruvian Amazon: molecular screening employing a new multiplex qPCR**: Maria Delmans FLORES-CHAVEZ (Spain)<br>**Mitochondrial nad5 gene-based molecular insights into zoonotic Echinococcus granulosus sensu lato genotypes endemic in north India**: Pallavi MOUDGIL (India)<br>**Breakthrough infection with Plasmodium species in deployed military personnel who completed prophylactic antimalarial medication during their deployment period and returned home: a case-control study**: Junwon SEO (Republic Of)<br>**Ultrasonographic prevalence of cystic echinococcosis in school-aged children in Chile: results of a pilot survey in the context of a developing control programme**: Francesca TAMAROZZI (Italy)<br>**Risk factors for trichomoniasis in women: a nationwide study**: Filip JANS�KER (Sweden)<br>**Awareness and knowledge of human leishmaniasis in a mediterranean endemic area: a cross-sectional study from Sardinia**: Chiara FANELLI (Italy) |
| 12/04 | 12:00 - 13:30 | PS052 | 07c. Diagnostic parasitology (incl traditional, molecular and genomic methods) |  | **Detecting Plasmodium falciparum histidine-rich proteins 2 and Plasmodium lactate dehydrogenase in saliva: a non-invasive means of diagnosing malaria in children**: Enoch ANINAGYEI (Ghana)<br>**Evaluation of the BioFire global fever panel compared to laboratory-developed PCR for malaria diagnostics**: Allison HAAS (United States)<br>**Concordance between computed tomography and transfontanellar ultrasound for diagnosing central nervous system lesions in congenital toxoplasmosis**: Carlos Mauricio CULMA RAMIREZ (Colombia)<br>**Molecular assays on cutaneous swabs as an effective and less invasive diagnostic technique for cutaneous leishmaniasis: results from a retrospective study conducted in Italy**: Anna BARBIERO (Italy)<br>**Benefit of pan-nematode PCR in unusual clinical presentations of nematodosis**: Marie Gladys ROBERT (France)<br>**Investigation the transmission dynamics of Cryptosporidium sp. and Giardia duodenalis in humans, animals, and the environment in rural Turkey: a One Health approach**: Eylem AKDUR �ZT�RK (T�rkiye)<br>**Diagnostic practices and therapeutic modalities for the management of visceral leishmaniasis: a joint ESCMID-ESGCP and LeishMan study**: Jean-Pierre GANGNEUX (France)<br>**Comparing molecular methods for the identification of Leishmania infantum in blood samples: a retrospective study of diagnostic accuracy**: Tommaso GRITTI (Italy)<br>**Performance of VIRapid HYDATIDOSIS  test for diagnosis of cystic echinococcosis: can it be used for field screening?**: Gian Luca D'ALESSANDRO (Italy)<br>**Screening and diagnosis access for neglected and tropical parasitic diseases in Italy: a national survey**: Agnese COMELLI (Italy)<br>**Comparative analysis of chronic schistosomiasis cases diagnosed by microscopy or by serology only: a retrospective study in the Belgian national reference centre**: Pierre Martin ENGLERT (Belgium)<br>**LAMP for malaria diagnosis in a non-endemic country Denmark**: Didi BANG (Denmark)<br>**Comparison of the sensitivity and specificity of diagnostic tests to detect Schistosoma spp. infection in the adult population of Ch�kw� district in Mozambique**: Joao SERRA (Portugal)<br>**Establishing a diagnostic algorithm with high performance for Schistosoma serology: an approach using composite reference standard and latent class analysis ??????**: Caroline R�NNBERG (Sweden)<br>**Diagnostic performance of a novel real-time PCR assay for Toxoplasma gondii DNA using amniotic fluid and plasma clinical-like samples**: Henar ALONSO-EZCURRA (Spain)<br>**Advancing Chagas disease diagnosis: a real-time PCR validation for congenital and chronic infections**: Henar ALONSO-EZCURRA (Spain)<br>**Usefulness of molecular diagnostic techniques in imported strongyloidiasis**: Azucena RODRIGUEZ-GUARDADO (Spain)<br>**Polymerase chain reaction for malaria diagnosis**: Anna SMIELEWSKA (United Kingdom)<br>**The 18S rDNA sequencing of Plasmodium species**: Silje HOEGH (Denmark)<br>**Evaluation of the humoral immune response to Plasmodium vivax antigens in patients with Plasmodium vivax malaria recurrences**: Mariana RIBEIRO GON�ALVES (Brazil)<br>**Verification of an ultra-sensitive mitochondrial cytochrome c oxidase III (cox3) gene primer for the detection of Plasmodium spp. using conventional PCR**: Lena BAUKART (Denmark)<br>**Emerging tools in parasitological diagnostics: a comparative study of AI, microscopy, and rapid antigen testing**: Varol TUNALI (T�rkiye)<br>**A simple, extraction-free molecular assay for the diagnosis of malaria**: Jamie LEMON (United States)<br>**Detecting and differentiating plasmodium species using real-time PCR in clinical samples collected over five years in a Spanish tertiary hospital**: Henar ALONSO-EZCURRA (Spain)<br>**Evaluation of bead beating preparation of stool samples for detection of helminths by multiplex PCR**: Patricia VIVAS (France)<br>**Demodex sp.: parasitological diagnosis, molecular identification and clinical expressions**: Lilia KRICHENE (Tunisia) |
| 12/04 | 12:00 - 13:30 | PS053 | 07d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials) |  | **The anti-Leishmanial potential of Toona ciliata leaf extract: harnessing nature's arsenal against leishmaniasis**: Vishal Kumar SINGH (India)<br>**Carrier-mediated delivery of amphotericin-B through mannosylated liposomes for effective management of leishmaniasis**: Varun BHARGAVA (India)<br>**Ligand conjugated carbon nanotubes for effective antileishmanial therapy**: Toshi NEMA (India)<br>**Optimising deworming interventions: a study on Taenia multiceps control in rural northern Tanzanian livestock and dog populations**: Tito KIBONA (United Republic Of)<br>**Design, characterisation, and in vitro assessment of amine-functionalised graphene quantum dots conjugated with amphotericin B for visceral leishmaniasis therapy**: Prasoon MADHUKAR (India)<br>**Long-term follow up of Chagas disease individuals treated with posaconazole and benznidazole: the CHAGASAZOL cohort**: Joan ROIG SANCHIS (Spain)<br>**Concentrations of artemether/lumefantrine in hair: a potential tool to retrospectively determine drug exposure following malaria treatment**: Hanna DE JONG (Netherlands)<br>**Screening of a chalcone-based library for anti-Leishmania activity**: Sara MORSELLI (Italy)<br>**Nucleo-cytoplasmic shuttling inhibitors as novel anti-Leishmania agents**: Sara MORSELLI (Italy)<br>**Investigation of anti-leishmanial activities of Aspergillus metabolites and their effects on the pathogenesis of Leishmania virus at molecular level: in vitro studies from Turkey**: Kurt �ZG�R (T�rkiye)<br>**Unveiling the veil: risk factors for Chagas disease treatment discontinuation in a non-endemic country: a retrospective cohort study**: Martina BELTRAMI (Italy) |
| 12/04 | 12:00 - 13:30 | PS055 | 07f. Travel medicine, migrant and refugee health |  | **The difference in seasonal variation in the number of arrival aircrafts investigated for invasive mosquitoes between airports in Japan**: Soichi TAKEISHI (Japan)<br>**Impact of Chagas disease on quality of life in women diagnosed through neonatal screening**: Paloma MERINO AMADOR (Spain)<br>**Dynamics and persistence of antimicrobial resistance genes and gut microbiome of healthy individuals after travel**: Cong SHEN (China)<br>**Challenges for malaria control among Myanmar migrants in western Thailand: a qualitative study**: Pyae Linn AUNG (Thailand)<br>**Traveller profiles and pre-travel counselling: a retrospective cross-sectional study**: Milan TROJANEK (Czech Republic)<br>**Describing immigrants' experiences of accessing healthcare in an Irish infectious diseases clinic**: Fergal HOWLEY (Ireland)<br>**What probabilistic antibiotic therapy for skin abscess in the Amazon?**: Olivier LESENS (French Guiana)<br>**National genomic surveillance of travellers with co-infections involving typhoidal Salmonella over a 20-year period in England**: Vanessa WONG (United Kingdom)<br>**Carriage of multidrug-resistant bacteria among Ukrainian refugees**: Tuomas ARO (Finland)<br>**Breaking barriers to health: the urgent need for targeted screening in migrant populations**: Agnese COLPANI (Italy)<br>**Prevalence of neglected tropical diseases among migrants living in Europe: a systematic review and meta-analysis**: Giacomo GUIDO (Italy)<br>**Assessing health disparities and access: a data-driven analysis of Afghan refugee health in Pakistan**: Saeed AHMAD (Finland)<br>**Differential characteristics of imported schistosomiasis in female immigrant population**: Azucena RODRIGUEZ-GUARDADO (Spain)<br>**Strongyloidiasis diagnosed by ELISA in Brussels: a bicentric retrospective study**: Juliette BECU (Belgium)<br>**Incidence of Hymenolepis nana infection within people seeking asylum and refugees attending health screening at an integrated refugee health service (respond)**: Kieran KILLINGTON (United Kingdom)<br>**Burden of dengue fever in travellers from non-endemic areas: a systematic literature review**: Martin P. GROBUSCH (Netherlands)<br>**A successful checklist order set for infectious disease screening in immigrant patients in the US**: Eirini ILIAKI (United States)<br>**A cross-sectional study on diphtheria and other wound infections among asylum seekers arriving in Baden-Wuerttemberg, Germany, August-October 2024**: Bernadette WALTER (Germany)<br>**Preliminary evaluation of a multiplex PCR assay for detecting protozoan and helminth infections in travelers returning to Berlin, Germany**: Paul Clemens PITZINGER (Germany)<br>**Empowering migrants health: results from a monocentric prospective study**: Giovanni MORI (Italy)<br>**Appropriateness of malaria treatment according to WHO criteria for severe malaria in a non-endemic country**: Anatolio ALONSO CRESPO (Spain)<br>**Malaria and travel medicine: how to prevent it**: Jeferson MANOEL TEIXEIRA (Brazil) |
| 12/04 | 12:00 - 13:30 | PS065 | 09a. Microbial pathogenesis & virulence |  | **Sub-minimum inhibitory concentrations of rifampicin attenuate methicillin-resistant Staphylococcus aureus virulence by suppressing SaeRS two-component system and arginine biosynthesis**: Yinjuan GUO (China)<br>**Turicella otitidis: from an external auditory canal coloniser to a cause of severe ear infections in children, a three-year retrospective study**: Helen KIRIKOU (Greece)<br>**Knockout of the wza gene significantly affects capsule formation in Acinetobacter baumannii, weakening its virulence and environmental adaptability**: Ping LU (China)<br>**Predicting high-risk clone pathogenesis in Pseudomonas aeruginosa through a random forest model of the pangenome**: Cansel VATANSEVER (T�rkiye)<br>**Bacterial fluid dynamics unmasked: how Klebsiella pneumoniae capsules rewrite virulence mechanics**: Luisa Maria Vieira PEIXE (Portugal)<br>**SalComSNP: an interactive platform for shortlisting key genes putatively associated with bloodstream infections of invasive non-typhoidal Salmonella**: Lijuan LUO (United Kingdom)<br>**Staphylococcus aureus biofilm metabolite interactome act as key modulators for host immune evasion**: Deepak KUMAR (India)<br>**Prophage and central metabolic genome adaptations drive virulent Staphylococcal infections in the community**: Grace LEE (United States)<br>**Molecular conservation of itaconate metabolism and type 6 secretion in the high-risk clone of Pseudomonas aeruginosa ST235**: Cansel VATANSEVER (T�rkiye)<br>**Compensatory mechanisms in capsule production following RmpA deletion in hypervirulent Klebsiella pneumoniae**: Hyun Ah KIM (Republic Of)<br>**Plt-1 acted as a novel virulence factor by enhancing inflammation level and macrophage death in ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae**: Peiyao JIA (China)<br>**Functional genomics of hypervirulent Klebsiella pneumoniae, a step forward for accurate diagnosis**: Francois LEBRETON (United States)<br>**Biofilm formation of lactose-pre-adapted Streptococcus mutans**: Natalia IORIO (Brazil)<br>**Serotype O16:H5 ST131 Escherichia coli are significantly more virulent in the galleria mellonella insect model than O25:H4 ST131**: Jordan Aston Tregurtha MATHIAS (United Kingdom)<br>**"Superbugs vs bugs": Galleria mellonella (greater wax moth) larvae as a model for the pathogenicity of Staphylococcus aureus neonatal bacteraemia**: Jordan Aston Tregurtha MATHIAS (United Kingdom)<br>**Neuraminidase structural diversity across bacteria, metazoa, fungi and viruses: observations for target-based development of new selective drugs**: Giulia Chiara Maria PERRONE (Italy)<br>**Differential cultivability of isogenic Staphylococcus aureus sub-populations in diferent growth environments**: Nadia AFTAB (Norway)<br>**Genetic diversity and regulatory context of vaginolysin in Gardnerella species: implications for virulence and host-pathogen interactions**: M�rcia SOUSA (Portugal)<br>**Capsular cluster expression in hypermucoviscous KPC-producing Klebsiella pneumoniae sequence type 101**: Alice DE FRANCESCO (Italy)<br>**Molecular epidemiology of Pseudomonas aeruginosa in cystic fibrosis patients: insights from the Brazilian Amazon region**: Yan Corr�a RODRIGUES (Brazil)<br>**The role of ompW on infectivity and adherence of Acinetobacter baumannii in relation to colistin resistance**: Jale BORAL (Sweden)<br>**The multidrug efflux pump AcrAB contributes to the aggregative-adherence phenotype of enteroaggregative Escherichia coli**: Martina LAUDAZZI (Italy)<br>**Potential Role of malR-malABC Operon in Enhanced Virulence of Staphylococcus pseudintermedius During Canine Otitis Externa**: Soojin YANG (Republic Of)<br>**Virulence potential and characteristics of multidrug-resistant Corynebacterium amycolatum strains in mountainous region of Rio de Janeiro state**: Helv�cio CARDOSO CORR�A P�VOA (Brazil)<br>**In vivo transcriptome analysis of Aeromonas dhakensis isolated from fatal cases of multidrug-resistant bacteraemia reveals novel virulence genes**: Blake NEIL (United States)<br>**Strain-dependent internalisation of S. aureus in podocytes and renal epithelial cells**: Franziska Dorothee SCHULER (Germany)<br>**Klebsiella oxytoca subgroup KO5: highly resistant and superior immune evasion capability**: Yun WU (China)<br>**Impact of insertion mutation in the accessory gene regulator agrC gene in the Staphylococcus aureus: reduced virulence and enhanced persistence capacity**: Jiawei JIAWEI (China)<br>**Epidemiological analysis and functional characterisation of HlyA hemolysin in Morganella morganii**: Jiawei JIAWEI (China)<br>**Characterisation of Pseudomonas aeruginosa virulence factors and immune response during exacerbations and stable phase in bronchiectasis**: Roberto CABRERA ORTEGA (Spain)<br>**Preliminary investigation of how Acinetobacter baumannii enhances intracellular survival via the specific TonB-dependent transporter BauA in outer membrane vesicles**: Jiayuan QIN (China)<br>**Virulence signature of the dominating vancomycin-resistant Enterococcus faecium clones in Denmark, 2015-2023**: Ingrid Maria Cecilia RUBIN (Denmark)<br>**Monoclonal lung dissemination by Pseudomonas aeruginosa precipitating bilateral lung transplantation in primary ciliary dyskinesia**: Steven TAYLOR (Australia)<br>**The impact of type IV pili-mediated twitching motility in biofilm formation by Streptococcus sanguinis**: Yi-Ywan Margaret CHEN (China)<br>**Molecular epidemiology and comparative virulence patterns of Acinetobacter baumannii isolates from war-related injuries in Ukraine**: Jale BORAL (Sweden)<br>**You are not my type: large-scale bioinformatics analysis uncovers the distribution and diversity of Type VI secretion systems in Escherichia coli**: Kristina NESPOROVA (Belgium)<br>**Investigating Staphylococcus aureus infections in human-derived musculoskeletal tissue slices: a new ex vivo approach**: Kerstin STRENGER (Switzerland)<br>**Unveiling the role of the glc locus in Campylobacter: a key to glucose metabolism, survival, and niche adaptation**: Mohammed ALOSAIMI (Saudi Arabia)<br>**Uncovering the mechanisms behind carbapenem-resistant Escherichia coli causing recurrent and multi-site infections: adaptive genotypic and phenotypic evolution within the host**: Cheng-Yen KAO (China)<br>**High lethality of methicillin-susceptible Staphylococcus aureus ST398 in animal models**: Miquel S�NCHEZ-OSUNA (Spain)<br>**Dynamic evolutionary strategies of clinically isolated hypervirulent carbapenem-resistant Klebsiella pneumoniae in response to drug and survival pressures within the host**: Rui WENG (China)<br>**Resistance and persistence: a reciprocal driving force of survivability in uropathogenic E. coli?**: Jad ATRISSI (Belgium)<br>**Carbapenem-resistant Acinetobacter baumannii causing the dual-strain persistent infection with significant loss-of-function mutations in virulence factors and the ability to form persisters under PMB-MEM combination therapy: an eight-month genetic-based ICU patient monitoring study**: Yang ZHONG (Singapore)<br>**A-to-I RNA editing in Klebsiella pneumoniae influences the oxidative stress tolerance**: Xingyu WU (China)<br>**Novel inhibitors targeting lipid A phosphoethanolamine transferase (EptA) to break beta-lactam resistance in extensively drug-resistant Neisseria gonorrhoeae**: Van Chi THAI (Australia)<br>**Genomic characterisation of a novel capsular operon in extensively drug-resistant Haemophilus parainfluenzae urogenital strains**: Luc�a SAIZ-ESCOBEDO (Spain)<br>**Characterisation of the susceptibility and adaptive mechanisms of Legionella to serum bactericidal activity**: Sophie JARRAUD (France) |
| 12/04 | 12:00 - 13:30 | PS066 | 09b. Host-pathogen interaction (incl basic microbiome studies, animal models) |  | **Naringin is a possible protective agent in a rat model of polymicrobial sepsis**: Murat KARAMESE (T�rkiye)<br>**The influence of time of day of vaccination and infection on immunity in rodent animal models, and translational aspects: a systematic review**: Astrid Christine ERBER (Austria)<br>**Galleria mellonela as an experimental model for the study of bacterial co-infection**: Helv�cio CARDOSO CORR�A P�VOA (Brazil)<br>**Peste des petits ruminats virus (PPRV) non-structural C and V proteins modulate the NF-kB signalling pathway**: Juhi JAIN (India)<br>**Study on the interaction mechanism of Paeniclostridium sordellii haemorrhagic toxin and its host**: Xingxing LI (China)<br>**Prospective case-control study on bacterial gut microbiota and invasive enterococcal disease**: Diaz BENITEZ (Spain)<br>**Staphylococcus capitis NRCS-A target tight junctions to disrupt intestinal epithelial barrier and induce bacteraemia in vivo**: Aur�lien PEYRON (France)<br>**Commensal vs clinical staphylococci, the yin and yang of bacterial interaction with the host**: Alaa ABOUELFETOUH (Egypt)<br>**Female urinary microbiota characterisation by culturomics**: Camille VILLENAVE (France)<br>**Gastrointestinal symptomatology in Sanfilippo syndrome is related to gut microbiota metabolism**: Mario ROMERO RIVERA (Spain)<br>**Gut microbiota in patients with metastasic prostate cancer: analysis of potential effects of androgen receptor pathway inhibitors**: Sonia P�REZ CASTRO (Spain)<br>**Gut microbiota alterations in relapsing-remitting multiple sclerosis**: Matteo Domenico MARSIGLIA (Italy)<br>**Limiting the spread of nosocomial bacterial pathogens through endotracheal illumination in a long-term ventilation pig model**: Barbara SPELLERBERG (Germany)<br>**Microbiome bacterial DNA quantity is unchanged during antimicrobial therapy in patients with Clostridioides difficile infection**: Khurshida BEGUM (United States)<br>**The secondary messenger ppGpp controls virulence and pathogenicity of adherent-invasive Escherichia coli strains through changes in gene expression**: Lloren� FERN�NDEZ-COLL (Spain)<br>**Peripheral CD34+ cells as a niche for Mycobacterium tuberculosis**: Tonino ALONZI (Italy)<br>**Exploring residual antigen distribution and neuroinflammation in calcified neurocysticercosis**: Luz M. TORIBIO (United Kingdom)<br>**Dynamics of gut microbiome enterotypes in a healthy Hungarian cohort using whole-length 16S metabarcoding**: Csongor FREYTAG (Hungary)<br>**Airway epithelial air-liquid-interface culture systems for high-resolution investigations of bacterial infection dynamics during treatment with elexacaftor/tezacaftor/ivacaftor**: Maria PALS BENDIXEN (Denmark)<br>**Phage-antibiotics synergy and antagonism in Pseudomonas aeruginosa clinical isolate ZS-PA-35**: Bijie HU (China)<br>**Lung pathogens persist in the gut microbiome during critical illness**: Brendan KELLY (United States)<br>**Exploring microbial diversity in calcific aortic valve disease**: Angela KUKA (Italy)<br>**Development of a chronic wound infection model in rats for testing novel wound therapies**: Mariliis HINNU (Estonia)<br>**The role of periodontal disease in modulating salivary microbiome in atherosclerotic cardiovascular patients**: Monika BRZYCHCZY-WLOCH (Poland)<br>**Evaluation of mobilome impact in isolates of Staphylococcus aureus sequence type 8 during in vitro cellular internalisation**: Dafne BONGIORNO (Italy)<br>**Fecal microbiota features and pathways potentially associated with spontaneous clearance of carbapenem-resistant Enterobacterales colonization**: Lima Rodriguez OLALLA (Spain)<br>**Membrane vesicles as potential surrogate for impaired intestine barrier**: Vera RAUSCHENBERGER (Germany)<br>**The protective effects of a single dose myricetin application on CLP-induced rat sepsis model by analysing some immune mechanisms**: Ali G�RASLAN (T�rkiye)<br>**Pulmonary microbiota analysis and host gene expression: a diagnostic model for distinguishing respiratory colonisation and pneumonia**: Zhangfan FU (China)<br>**Two flavonoids, baicalein and naringin, are effective as anti-inflammatory and anti-oxidant agents in a rat model of polymicrobial sepsis**: Selina AKSAK KARAMESE (T�rkiye)<br>**Investigation of the anti-inflammatory, anti-oxidant and anti-apoptotic activity of 18-beta-glycyrrhetinic-acid on the model of LPS-induced lung injury in rats**: Gulfem Nur YILDIZ (T�rkiye)<br>**Giardia infection is associated with alterations in the community structure of the murine gut microbiome**: Sucheta GULERIA (India)<br>**The effect of selective estrogen receptor modulators on the clearance of Staphylococcus aureus and Pseudomonas aeruginosa by monocyte-derived macrophages**: Jessica MCLOUGHLIN (United Kingdom)<br>**Relative abundance of bacterial phyla and diversity of pathogenic bacteria in patients with irritable bowel syndrome compared with healthy controls relative abundance of bacterial phyla and diversity of pathogenic bacteria in patients with irritable bowel syndrome compared with healthy controls**: Ganji LEILA (Islamic Republic Of)<br>**The beneficial effects of dose-dependent umbelliferone application on CLP-induced experimental sepsis model**: Ali G�RASLAN (T�rkiye)<br>**An assessment of breastmilk microbiome focusing on probiotics**: Nazila KASSAIAN (Islamic Republic Of)<br>**Escherichia coli division and nonresponse factors to antibiotic therapy in a murine model of acute prostatitis**: Guillaume COSSON (France)<br>**Evolution of phage resistance through CRISPR-Cas adaptation in the  mucosal environment**: Sophia GOLADZE (Finland)<br>**Autologous host-pathogen pairing enhances early immune responses and bacterial control in tuberculosis in vitro granuloma model**: Oana DUMITRESCU (France)<br>**Identification of anti-CRISPR (Acr genes) proteins harbored in Pseudomonas aeruginosa clinical strains**: Lucia ARMAN FERNANDEZ (Spain)<br>**Breaking new ground: human intestinal organoids reveal Shigella's invasive strategies**: Nidhi KAMBOJ (India)<br>**Klebsiella pneumoniae diversity and lifestyle factors in the healthy gut: a role for the food chain?**: Patricia ANTUNES (Portugal)<br>**Post-coital dynamics of the male and female genital microbiome**: Daniel PARK (United States)<br>**Blastocystis sp. relationship with gut microbiota composition in healthy donors from a microbiota transplant centre**: Elisa RUBIO GARC�A (Spain)<br>**Interactions between respiratory viruses, airway microbiome and immune response during pulmonary exacerbations in children with cystic fibrosis**: Joke BASTIAENSSEN (Belgium)<br>**Androgen receptor blockade induces the phagocytosis of wound associated bacteria by monocyte-derived macrophages**: Jessica MCLOUGHLIN (United Kingdom)<br>**Clinical infection patterns and pulmonary tropism of Yarrowia lipolytica in murine models**: Jinhan YU (China)<br>**Interactions between Dolosigranulum pigrum and Corynebacterium species, health-associated bacterial commensals of the human nasopharynx**: Kan YU (Australia)<br>**DPP4 activity and translocation of membrane vesicles of Enterococcus faecium**: Isabell RAMMING (Germany)<br>**Phage-host interaction in Pseudomonas aeruginosa clinical isolates with functional and altered quorum sensing systems**: Dandan LI (China)<br>**Oral microbiome landscape under household quarantine measures during the first wave of COVID-19 pandemic**: Miguel BLANCO FUERTES (Spain)<br>**Interpretation of respiratory virus detection in adults hospitalised with acute respiratory infection: insights from a host response profiling study**: Alex TANNER (United Kingdom)<br>**Mouse model for eradication of Streptococcus pyogenes from the upper respiratory tract**: Fabio FIORINO (Italy)<br>**Live-cell confocal microscopy reveals that intracellular Staphylococcus aureus producing phenol-soluble modulins triggers an autophagic response prior to cytosol access in HeLa cells**: Alicia EYMARON (France) |
| 12/04 | 12:00 - 13:30 | PS067 | 09c. Pre-clinical biofilm studies |  | **Assessment of the cefiderocol anti-biofilm effect against 28 clinical strains of multidrug-resistant Gram-negative bacilli**: Marta D�AZ-NAVARRO (Spain)<br>**VG111 and its impact on Stenotrophomonas sepilia biofilms: unveiling a promising antibiofilm strategy**: Vikas GAUTAM (India)<br>**Efficacy testing of antimicrobial fibrous wound dressings against in vitro polybacterial biofilm**: Kelli RANDM�E (Estonia)<br>**Activity of individual drugs against biofilm in hypervirulent Klebsiella pneumoniae**: Qingqing XU (China)<br>**Beyond resistance ? Exploring biofilm dynamics in carbapenem-resistant Acinetobacter baumannii from urinary tract infections**: Kavitha KUMAR (India)<br>**Biofilm characterisation and antimicrobial susceptibility of Gram-positive bacteria associated with osteoarticular infections**: Paola BOCANEGRA IBARIAS (Mexico)<br>**The role of Cutibacterium acnes in adolescent acne: a study of microbiome diversity and biofilm production**: Alpana MOHTA (India)<br>**Biofilm induction by glucose and/or sodium chloride in S. aureus isolates from the airways of Spanish people with cystic fibrosis**: Paula EGUIZ�BAL (Spain)<br>**Analysis and photodynamic inactivation of biofilm of carbapenemase-resistant isolates of Klebsiella pneumoniae in a regional hospital in Slovakia**: Jaroslava DEKKEROV� (Slovakia)<br>**Reduction of bacterial adhesion on wrinkled surfaces under fluid shear**: Rossella MAURO (Italy)<br>**Effects of small molecules and antimicrobial peptides targeting small RNA00203: pioneering antimicrobial solutions for biofilm-producing, multidrug-resistant Acinetobacter baumannii**: Abebe Mekuria SHENKUTIE (China)<br>**Are biomass and metabolic activity staining biofilm techniques reliable enough to be used in microbiology laboratories?**: Marta D�AZ-NAVARRO (Spain)<br>**Exploring the interaction between antimicrobials and bioactive glass in the Cutibacterium acnes in vitro biofilm formation and in the Galleria mellonella in vivo model**: Mauro Jose COSTA SALLES (Brazil)<br>**Evaluation of biofilm formation and the effectiveness of antimicrobial photodynamic therapy on polydioxanone yarns**: Helv�cio CARDOSO CORR�A P�VOA (Brazil)<br>**Trace/sublethal antimicrobials in hospital wastewaters act as stressors which promote enhanced biofilm-expression in Pseudomonas aeruginosa in clinical and environmental colonisation**: �zge YETIS (United Kingdom)<br>**Differences in pathogenic mechanisms of Gram-positive and Gram-negative strains in medical device-associated infections**: Alba SANCHEZ MORILLO (Spain)<br>**Evaluation of rifampicin's potential for preventing the development and treating Pseudomonas aeruginosa biofilm in respiratory infections**: Est�baliz TORRECILLA-S�DABA (Spain)<br>**Synergistic potential of rifampicin and aztreonam against Pseudomonas aeruginosa biofilm in respiratory infections**: Est�baliz TORRECILLA-S�DABA (Spain)<br>**Genomic characterisation and antibiotic susceptibility of biofilm-forming Borrelia afzelii and Borrelia garinii from patients with erythema migrans**: Giorgia FABRIZIO (Italy)<br>**Impact of penicillin susceptibility and endocarditis source on Enterococcus faecalis biofilm production**: Julian AZZOUZI (United States)<br>**Determination of the MBIC and MBEC of ciprofloxacin and colistin in biofilms produced by Pseudomonas aeruginosa**: Ohiana RODRIGUEZ MEDINA (Spain)<br>**Exploring the biofilm-mediated resistance in polymicrobial infections involving clinically relevant pathogens**: Joana ARA�JO ALVES DE CAMPOS (Portugal) |
| 12/04 | 12:00 - 13:30 | PS068 | 09d.?Experimental and cellular microbiology |  | **Siderophore-PNA conjugates for antisense targeted control of bacterial pathogens**: Mateusz WDOWIAK (Poland)<br>**Extracellular vesicles of minimalistic bacteria as mediators of immune modulation and horizontal gene transfer**: Theresa WAGNER (Switzerland)<br>**3D model of monoculture of lung epithelial cells with/without bacterial infection to evaluate mucosomes interaction and their antibacterial activity**: Emanuela PELUSO (Italy)<br>**Characterisation of a novel H. pylori bacteriophage with therapeutic potential**: Lu�s MELO (Portugal)<br>**Deciphering the redox environment in bacteriophage-infected bacteria by flow cytometry (FCM)**: Jia Hao YEO (Singapore)<br>**Green tea antioxidant epicatechin to inhibit the SOS response and tackle antibiotic resistance dissemination**: Marina MURILLO TORRES (Spain)<br>**Nisin A and cefoxitin combination against staphylococcal biofilms**: Mathieu GREGOIRE (Belgium)<br>**New discovery on the mode of action of letermovir and the resistance mechanism of human cytomegalovirus**: Claire GOURIN (France)<br>**ADAR-mediated RNA editing of influenza A virus RNA is age-dependent and inversely correlates with viral load**: Julia WIDSTR�M (Sweden)<br>**Pangenomic analysis of Haemophilus parainfluenzae reveals distinct metabolic patterns according to colonisation niche**: Sonia P�REZ CASTRO (Spain)<br>**Typing and whole-genome analysis of lysogenic bacteriophages isolated from carbapenem-resistant Acinetobacter baumannii strains**: Gulsen ULUCAM ATAY (T�rkiye)<br>**Monoclonal antibodies for functional studies and therapeutic applications in pneumococcal infections**: Sven HAMMERSCHMIDT (Germany)<br>**Model of activated macrophages infected with Streptococcus pneumoniae for immunomodulatory assays**: Alba SOLER COMAS (Spain) |
| 12/04 | 12:00 - 13:30 | PS069 | 09e. Fundamental science studies using Omics (in vitro and in vivo) |  | **The establishment of a lytic phage library targeting carbapenem-resistant Klebsiella pneumoniae**: Qingqing FANG (China)<br>**Characteristics of outer membrane vesicles from Klebsiella pneumoniae: a proteomic insights**: Qiwen YANG (China)<br>**Pan-genomic analyses of digestive persistent Klebsiella pneumoniae in ICU patient**: Benedicte LANGLOIS (France)<br>**Evolution of human metapneumovirus A2 in vitro and post human challenge: tracking viral polymorphism using next-generation sequencing**: Nicolas NOULIN (United Kingdom)<br>**Multi-OMICS techniques decipher distinct immunotypes and novel diagnostic signatures for EPTB**: Jan RYBNIKER (Germany)<br>**Multi-omics profiling immunosuppressive status in severe pneumonia**: Hongyu WANG (China)<br>**The potential of using photodynamic inactivation to treat microbial infections**: Helena BUJD�KOV� (Slovakia)<br>**Metagenomic analysis reveals enterotype-based prognostic stratification in severe COVID-19 patients**: Etienne RUPPE (France)<br>**Genomic landscape of Achromobacter xylosoxidans**: Luis Angel NU�EZ GARCIA (Mexico)<br>**Penetrating the pilus biogenesis in ESKAPE pathogens through in-silico and in vitro approaches**: Sanket KAUSHIK (India)<br>**in vitro metabolic profiling of Acinetobacter baumannii in artificial urine medium and CAMHB: investigating the synergistic effects of colistin and sulbactam combination therapy**: Xiaolan HUANG (China)<br>**Could archaea belong to Halobacteriales and Methanosarcinales order be biomarkers of schizophrenia? Studies on a rat model**: Dominika SALAMON (Poland)<br>**A PCR-based test for classifying Staphylococcus aureus ST30 strains in phylogenetic groups**: Agnes Marie FIGUEIREDO (Brazil)<br>**Proteomic characterisation of extracellular vesicles from Enterococcus faecalis**: Jean-Christophe GIARD (France)<br>**Response regulator OmpR-regulated metabolite succinate suppresses mucoviscosity of hypervirulence Klebsiella pneumoniae**: Wang LIJUN (China)<br>**Unraveling the regulatory circuits underlying human memory T cell precursor differentiation for developing improved vaccine co-adjuvants**: Samuele NOTARBARTOLO (Italy)<br>**Genomic characteristics of Listeria monocytogenes in clinical listeriosis: implications for pathogenicity and antibiotic resistance**: Muhammad SHAFIQ (China) |
| 12/04 | 12:00 - 13:30 | PS070 | 09f. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers) |  | **Age-stratified analysis of the association between cytokine profiles and clinical outcomes in severe fever with thrombocytopenia syndrome**: Chenxi ZHAO (China)<br>**Therapy modulates the response to T cell epitopes over the spectrum of tuberculosis infection**: Linda PETRONE (Italy)<br>**The PI3K-mTOR-HIF-alpha pathway regulates fibroblast-driven tissue destruction in tuberculosis**: Ramla CUSMAN (United Kingdom)<br>**Engineering Klebsiella pneumoniae's outer membrane proteins as novel antigen for therapeutic purposes**: Virginia BATIGNANI (Italy)<br>**V-delta-2 T-cells response in people with mpox infection: a three-month longitudinal assessment**: Eleonora CIMINI (Italy)<br>**Can the Torque teno virus viral load predict Clostridioides difficile infection and evolution?**: Assaf MIZRAHI (France)<br>**Antigen-specific modulation of inflammation and tissue remodelling in neurocysticercosis**: Luz M. TORIBIO (United Kingdom)<br>**Pre-transplant anti-cytomegalovirus immunoglobulin G titers as predictor of cytomegalovirus infection in seropositive Filipino kidney transplant recipients: a retrospective cohort study**: Vienne PINLAC (Philippines)<br>**Lipopolysaccharide-induced inflammation and cardiomyocyte dysfunction in a cardiac spheroid model**: Simon ATHLIN (Sweden)<br>**Patients with TB disease differ from subjects with TB infection in the ability to in vitro control mycobacterial replication**: Alessandra AIELLO (Italy)<br>**Cytokine modulation of mycobacterial restriction by macrophages**: Auliana Ratri Prabandari HIDAYAT (Indonesia)<br>**Differential miRNA signatures in circulating CD4+ T cells of Indian patients with visceral leishmaniasis and post-kala-azar dermal leishmaniasis**: Ritirupa ROY (Ritirupa ROY)<br>**Single-cell profiling of T-dependent immune response of Borrelia burgdorferi infection in a murine model**: Varpu RINNE (Finland)<br>**Exploring the antimicrobial response of MAIT cells to Staphylococcus aureus and the impact of bacterial immune evasion**: Elisa Justine Melina RAINERI (Sweden)<br>**Alteration of transcriptional immune profile in patients with severe Legionnaires' disease**: Camille ALLAM (France)<br>**Molecular pathways affected by clarithromycin treatment in community-acquired pneumonia: analysis of the ACCESS trial**: Emmanouil STYLIANAKIS (Netherlands)<br>**Reduction in respiratory pathogen exposure and immunity in European children following COVID-19 non-pharmaceutical interventions: a link to the post-pandemic Group A Streptococcus outbreak**: Kitt DOKAL (United Kingdom)<br>**Micro- and nanoplastics  reduce the phagocytosis of E. coli by THP-1 macrophages**: Florian EDBAUER (Germany)<br>**Systemic and mucosal antibody responses to Streptococcus pneumoniae serotype 3 carriage**: Oluwasefunmi AKEJU (United Kingdom)<br>**Differential local immune responses in Group A streptococcal necrotising soft tissue infections**: Laura Marcela PALMA MEDINA (Sweden)<br>**Sepsis-induced immune dysfunction weakens tumour defense and undermines immunotherapy efficacy**: Santiago LETONA (Spain)<br>**Impaired neutrophil respiratory burst response in elderly and infectious states**: Yuhan SUN (China)<br>**Genome-wide DNA methylation profiling in acute Lyme neuroborreliosis and over a one-year follow-up period**: Anna J HENNINGSSON (Sweden)<br>**FTY720-induced cryptococcosis reactivation in persistently infected mice: mechanisms uncovered**: Michiko YOSHIDA (Japan)<br>**Virus and bacteria co-infection breaks the host adaptive immunity against IAV**: Hui QI (China)<br>**Mitigating infectious disease by early neutrophil activation**: Jan CUPPEN (Netherlands)<br>**Arginase-1-mediated T cell suppression by MDSCs in dermatophytic infection: a combined transcriptomic and functional study**: Praveen Kumar SINGH (India)<br>**Co-infection with persistent HPV and Merkel cell polyomavirus enhances IFN-lambdas production in the anal mucosa of MLWH**: Matteo FRACELLA (Italy) |
| 12/04 | 12:00 - 13:30 | PS071 | 10a. Host genetics: Susceptibility to infection & primary immunodeficiency |  | **Metagenomic sequencing reveals differences in lung microenvironment among patients with nontuberculous Mycobacterium pulmonary disease under different immune states**: Le QIN (China) |
| 12/04 | 12:00 - 13:30 | PS072 | 10b. Infections related to solid organ transplantation |  | **Hepatitis B crossover boosters using a different product vs the boosters using the same product for renal transplant patients: a retrospective study with Bayesian inference**: Kentaro IWATA (Japan)<br>**Epidemiological burden of and risk factors for ganciclovir resistant /refractory cytomegalovirus in solid organ transplant patients and haematopoietic stem cell transplant patients: a multicentre cohort study, the ReCySOHT study: preliminary results**: Renato PASCALE (Italy)<br>**Post-surgical infections in liver transplantation performed using robotic surgery: preliminary results of a case-control study**: Elena GHIDONI (Italy)<br>**Infectious complications in heart transplant recipients: a focus on fungal and mycobacterial infections**: Sukru DIRIK (T�rkiye)<br>**Impact of extended criteria donor transplants on infections in kidney and liver transplant recipients and marginal donor definition criteria: a systematic review**: Cecilia BONAZZETTI (Italy)<br>**Is nebulised liposomal amphotericin B universal prophylaxis in lung transplant recipients still useful? A single-centre cohort**: Arnau MONFORTE PALLAR�S (Spain)<br>**Clinical impact of preservation fluid culture in solid organ transplantation: a prospective observational study**: Andrea CONA (Italy)<br>**HHV8-related diseases in solid organ transplantation: a case series**: Cecilia BONAZZETTI (Italy)<br>**Vancomycin-resistant Enterococcus infections after liver transplantation: clinical presentation and factors associated with mortality**: Maristela P. FREIRE (Brazil)<br>**Kidney transplantation in people living with HIV: ten-year experience in Modena**: Adriana CERVO (Italy)<br>**Comparison of risk factors and outcome between high and low cytomegalovirus viremia in living donor R+D+ renal transplant recipients from Pakistan**: Sunil Kumar DODANI (Pakistan)<br>**Single-centre experience with the use of letermovir for prophylaxis of cytomegalovirus in liver transplant recipients**: Regino RODRIGUEZ-ALVAREZ (Spain)<br>**Diagnostic stewardship in early postoperative kidney transplantation: the role of CRP and procalcitonin in infection prediction**: Imran HASANOGLU (T�rkiye)<br>**Experience with isavuconazole in lung transplant recipients with Aspergillus infection**: Jose Tiago SILVA (Spain)<br>**Impact of pre-transplant infection and multi-drug resistant (MDR) bacteria colonisation on in-hospital post-transplant survival in subjects with pre-transplant liver failure**: Alice MUL� (Italy)<br>**Inpatient antimicrobial usage among solid organ transplant recipients in Japan: a ten-year nationwide database study**: Koh OKAMOTO (Japan)<br>**Comprehensive insights into post-liver transplant infections: a study from a Quaternary care hospital in India**: Vaishnavi VELMANI (India)<br>**Invasive aspergillosis after lung transplantation: effectiveness of nebulised amphotericin-B prophylaxis and statins as preventive strategies**: Douwe Frans POSTMA (Netherlands)<br>**Evaluating maribavir use in solid organ transplant recipients: a real-world perspective**: Mark HERRINGTON (United States)<br>**Vancomycin systemic absorption in lung trasplant recipients treated with inhaled vancomycin**: Gonzalo ESCUDERO ARN�S (Spain)<br>**Lifestyle habits to minimise infection risk in kidney transplant recipients: a single-centre survey**: Tamara RUIZ MERLO (Spain)<br>**Safety of adjuvant respiratory syncytial virus vaccine in lung and allogeneic haematopoietic cell transplant recipients**: Adrian Anthony ALEXANDER (Canada)<br>**Impact of prior mycobacterial and Aspergillus infections on post-lung transplant infections: risk factors, clinical features and prognosis**: Miki NAGAO (Japan)<br>**Impact of recipient age on the incidence of infection following kidney transplantation**: Mario FERNANDEZ RUIZ (Spain)<br>**Go the extra mile: a solid organ transplant-specific antibiogram in a tertiary care centre in Japan**: Satoshi KITAURA (Japan)<br>**Evaluating the efficacy of HBIG and antiviral therapy in preventing hepatitis B recurrence in liver transplant patients: a study from data registry of Montaseriyeh hospital**: Rozita KHODASHAHI (Islamic Republic Of)<br>**Epithelial lining fluid (ELF) concentrations of beta-lactam agents in the lung allograft**: Laura N. WALTI (Switzerland)<br>**Pre-transplant lymphocyte count and HCMV-specific T-cell response as predictive markers of severe HCMV reactivations in kidney transplant recipients**: Irene CASSANITI (Italy)<br>**Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients : an interim analysis of a three-year prospective, observational study**: Milo GATTI (Italy)<br>**Burden of first severe infections in kidney transplant recipients: a nationwide French cohort study**: Giovanna MELICA (France) |
| 12/04 | 12:00 - 13:30 | PS073 | 10c. Infections related to haematopoietic stem cell transplantation |  | **Prospective evaluation of short- and long-term immune responses to DTaP-IPV and DTaP vaccination in adult allogeneic HSCT recipients**: Taiichiro KOBAYASHI (Japan)<br>**Ethnic disparities in response to CMV immunotherapy using intravenous CMV hyperimmune globulin in paediatric allo-HSCT recipients**: Chiara RODARO (Italy)<br>**Toxoplasmosis after allogeneic haematopoietic cell transplantation: 17 years of experience with Toxoplasma gondii  PCR**: Juan GEA-BANACLOCHE (United States)<br>**Changing epidemiology of febrile neutropenia in patients undergoing allogeneic haematopoietic stem cell transplantation**: Siwar FRIGUI EP OUESLATI (Tunisia)<br>**Implementing de-escalation of antimicrobial therapy to targeted agents in haematopoietic stem cell transplantation patients with bloodstream infections**: Nicoletta DI LAURIA (Italy)<br>**Oral contezolid treatment for skin and soft tissue infections in paediatric patients with heamatologic disorders: a retrospective analysis of 13 cases**: Yu ZHANG (China)<br>**Letermovir primary cytomegalovirus prophylaxis in allogeneic haematopoietic cell transplant recipients: data from the first multicentre Latin American study**: Fabian Armando HERRERA (Argentina)<br>**Toxoplasma and allogeneic stem cell transplantation**: Cristina Teresa FUENTES MORALES (Spain)<br>**Hospital-acquired and ventilator-associated bacterial pneumonia in neutropaenic cancer patients or haematopoietic stem cell transplant recipients: the CARINA study**: Carlota GUDIOL (Spain)<br>**Tuberculosis among allogeneic bone marrow transplant recipients in India**: Satish SWAIN (India)<br>**Cellular immune response to RSV vaccine and quadrivalent inactivated influenza vaccine in allogeneic stem cell transplant recipients in the early post-transplant period**: Ellen WALSH (Ireland)<br>**SARS-CoV-2 infection prior to hematopoietic stem cell transplantation does not increase mortality or the risk of graft-versus-host disease**: Bruno RANDI (Brazil)<br>**Assessment of T-cell-mediated, SARS-CoV-2-specific immune responses in patients after allogeneic haematopoietic stem cell transplantation: a prospective diagnostic study**: Michaela STEINHILPER (Germany)<br>**Evaluation of invasive pneumococcal diseases and vaccination adherence in patients undergoing hematopoietic stem cell transplantation**: Adriana BAQUEIRO ABAD RIBEIRO (Brazil)<br>**Epidemiology and outcomes of carbapenem resistant Enterobacterales in immunosuppressed population**: Basem ALRADDADI (Saudi Arabia)<br>**Isavuconazole for invasive fungal infections in patients with haematologic malignancies and haematopoietic stem cell transplantation: data from the first multicentre Latin American study**: Fabian Armando HERRERA (Argentina)<br>**Antifungal prophylaxis strategies in patients with allogeneic haematopoietic stem cell transplantation: impact on empirical antifungal treatment**: Fabian Armando HERRERA (Argentina)<br>**Infection in VEXAS patients undergoing haematopoietic stem cell transplantation**: Megan BIGGS (United States)<br>**Incidence of acute kidney injury in patients treated with beta-lactam monotherapy or beta-lactam/amikacin combination therapy after autologous haematopoietic stem cell transplantation**: Sarah DR�GER (Switzerland)<br>**Risk factors and a machine learning model to predict adenovirus infection in allogeneic haematopoietic stem cell transplant recipients**: Isabel Cristina RAM�REZ-S�NCHEZ (Colombia)<br>**Safety and efficacy of contezolid in haematological patients with Gram-positive infections: a retrospective analysis**: Luyang CHANG (China) |
| 12/04 | 12:00 - 13:30 | PS074 | 10d. Infections related to cell-based therapies |  | **Cytomegalovirus infections in patients with relapsed/refractory multiple myeloma on novel therapies**: Jennifer MAKHOUL (United States)<br>**Longitudinal cytokine expression in CAR-T-treated aggressive-lymphoma patients**: Gemma REYNOLDS (Australia)<br>**Predicting risk of infection in CAR-T-treated lymphoma patients: utility of immune-profiling**: Gemma REYNOLDS (Australia) |
| 12/04 | 12:00 - 13:30 | PS075 | 10e. Infections related to cancer treatment (incl neutropaenia) |  | **Infectious risks with blinatumomab exposure in B-cell acute lymphoblastic leukemia**: Seohyeon IM (United States)<br>**Epidemiology, risk factors and outcome of neutropaenic enterocolitis in onco-heamatological patients according to chemotherapy regimen**: Pierre-Yves BOCHUD (Switzerland)<br>**Microbiological background of medical-related osteonecrosis of the jaw bones**: Edit ZSOLDIN� URB�N (Hungary)<br>**Cytomegalovirus (CMV) reactivation after chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies treatment for hematologic malignancies**: Juhui HAN (Republic Of)<br>**Phenotypic and genotypic characterisation of atypical non-lactose-fermenting Escherichia coli in cancer patients: an emerging diagnostic challenge**: Vijeta BAJPAI BATRA (India)<br>**Molecular epidemiology and antimicrobial resistance profiles of Pseudomonas aeruginosa causing bloodstream infections in neutropenic cancer patients**: Irene CADENAS JIM�NEZ (Spain)<br>**Characterisation of bacteraemia caused by Staphylococcus aureus in oncologic patients and mortality-related factors**: Juan Fernando CONTRERAS VALERO (Colombia)<br>**Risk of infection by carbapenemase-producing Enterobacterales, associated factors, and a predictive model for its development in oncological patients**: Juli�n Andres HOYOS PULGARIN (Colombia)<br>**Comparison of virus-specific T-cell therapy and CD45RA+ T-cell-depleted donor lymphocyte infusion against COVID-19 among adult patients with hematologic malignancies**: Balint Gergely SZABO (Hungary)<br>**NGS-based pathogen detection in bronchoalveolar lavage fluid obtained from immunocompromised patients with pulmonary infections**: Anna Marie RUCKDESCHEL (Germany)<br>**Risk of infection in multiple myeloma patients receiving bispecific antibodies**: Eduardo APARICIO-MINGUIJ�N (Spain)<br>**Clinical utility of serum procalcitonin in cancer patients with suspected sepsis episode**: Nitin BANSAL (India)<br>**Enterococcal bacteraemia in children undergoing anticancer therapy or haematopoietic stem cell transplantation: a multicentre nationwide survey in Poland (2014-2021)**: Aleksandra KR�LAK (Poland)<br>**Infectious complications in patients with relapsed and refractory multiple myeloma undergoing novel bispecific antibody therapy**: Silpa JETTY (United States)<br>**Antibiotic de-escalation in neutropenic patients with Enterobacterales bacteraemia: an important antimicrobial stewardship programme strategy in the multi-drug resistant era**: Fabian Armando HERRERA (Argentina)<br>**Characterisation of infections in immunosuppressed patients with lung cancer in Northwest Spain**: Berta PERNAS-SOUTO (Spain)<br>**Guideline adherence for vancomycin prescribing in febrile neutropaenia cases in Jordan**: Aseel ABUSARA (Jordan)<br>**Bacteraemia in neutropaenic patients admitted to the intensive care unit with septic shock: aetiology, clinical characteristics, outcome and impact of multidrug resistance on mortality**: Fabian Armando HERRERA (Argentina)<br>**Clinical impact of OXA-48-producing Enterobacterales rectal colonisation on heamatologic patients with febrile neutropaenia**: Miguel RODR�GUEZ-FERN�NDEZ (Spain)<br>**Bacterial agents and antibiotic resistance in febrile neutropenia in Africa: a systematic review and meta-analysis**: Temitope OBADARE (Nigeria)<br>**Tuberculosis (TB) screening and TB disease in patients on immune checkpoint inhibitors (ICIs)**: Yii Ean TEH (Singapore)<br>**Bloodstream infection in heamatological malignancy patients**: Ebru ORUC (T�rkiye) |
| 12/04 | 12:00 - 13:30 | PS076 | 10f. Infections related to other forms of immunosuppression (e.g. gastrointestinal, rheumatological, dermatological disease, biologicals) |  | **A proposal of the refined diagnostic criteria for invasive pulmonary aspergillosis in autoimmune inflammatory rheumatic diseases treated with immunosuppressive agents**: Takashi KURITA (Japan)<br>**Bloodstream infection and risk for plasma cell neoplasms: a large population-based cohort study**: Adam STEWART (United States)<br>**Temporal timing patterns of herpes zoster events in relation to diagnosis of immunocompromising conditions**: Omid REZAHOSSEINI (Denmark)<br>**Timing of pneumococcal infections in adults with diseases associated with immunocompromised states: temporal patterns and implications for vaccination**: Omid REZAHOSSEINI (Denmark)<br>**IL-5 inhibitors and screening for helminth infection**: Sarah JAWAD (United Kingdom) |
| 12/04 | 12:15 - 13:15 | FIPL1 | Fireplace: Asia: An AMR Hot Zone | Giulia DE ANGELIS (Italy), Robert Leo SKOV (Denmark) | ****: David L. PATERSON (Singapore) |
| 12/04 | 12:15 - 13:15 | IS01 | Advancements in paediatric RSV prevention: navigating the evolving clinical landscape and public health strategies | Monika REDLBERGER-FRITZ (AustriaESCMID-appointed chair) | **Welcome and Introduction**: Monika REDLBERGER-FRITZ (Austria)<br>**Burden of RSV disease in infants**: Joanne WILDENBEEST (Netherlands)<br>**Development of new monoclonal antibody to prevent RSV disease**: Louis BONT (Netherlands)<br>**From theory to practice - public health implementation for RSV**: Federico MARTIN�N-TORRES (Spain)<br>**Panel Discussion and Q&A**: Monika REDLBERGER-FRITZ (Austria) |
| 12/04 | 12:15 - 13:15 | IS02 | Revisiting treatment strategies for MBL-producing Enterobacterales and S. maltophilia: what's new? | Matteo BASSETTI (Italy), David VAN DUIN (United StatesESCMID-appointed chair) | **Welcome and Introduction - MBLs on the rise: current insights on epidemiology and disease burden**: Matteo BASSETTI (Italy)<br>**Navigating the challenges: the importance of surveillance and early diagnosis in the management of MBL-producing bacterial infections?**: Camilla RODRIGUES (India)<br>**Revisiting the unmet need: what's new in the treatment landscape***: Yehuda CARMELI (Yehuda CARMELI)<br>**Panel Discussion and Q&A - When should the contemporary treatment options be used for MBL infections*?**: Matteo BASSETTI (Italy) |
| 12/04 | 12:15 - 13:15 | IS03 | Options for best-in-class influenza and COVID-19 vaccines: methodologies, challenges and opportunities in assessing vaccine performance | Meral AKCAY (France), Tyra Grove KRAUSE (DenmarkESCMID-appointed chair) | **Welcome and Introduction**: Meral AKCAY (France)<br>**A comparative analysis of timing and hospitalisation burden of influenza and COVID-19: US, EU and UK**: Nabila SHAIKH (United Kingdom)<br>**Vaccine options for the control of SARS-CoV-2: why having different vaccine platforms matter for public health?**: Albert OSTERHAUS (Germany)<br>**Vaccine options for control of Influenza: methodologies, challenges and opportunities in assessing vaccine performance**: Salah MAHMUD (Canada)<br>**Panel Discussion and Q&A**: Meral AKCAY (France) |
| 12/04 | 12:15 - 13:15 | IS05 | mRNA innovation in action: a new era for respiratory care | Albert VOLLAARD (NetherlandsESCMID-appointed chair) | **Welcome and Introduction**: Albert VOLLAARD (Netherlands)<br>**Panel Discussion and Q&A**: Albert VOLLAARD (Netherlands) |
| 12/04 | 12:30 - 12:50 | IPT05 | Evolving impact of long COVID |  | **Evolving impact of long COVID**: Roger PAREDES (Spain) |
| 12/04 | 13:00 - 13:20 | IPT06 | Molecular diagnostic tests: how do you QC? Increase compliance for your IQC programs |  | **Molecular diagnostic tests: how do you QC? Increase compliance for your IQC programs**: Chris CONNELLY (United States) |
| 12/04 | 13:30 - 14:30 | EF021 | Infections in hemato-oncological hosts: from bacterial to viral | Genovefa PAPANICOLAOU (United States) | **Vancomycin-resistant Enterococcus faecium bloodstream infection in patients with hematological malignancy and stem cell transplant: a case-control study**: Jollee FUNG (Canada)<br>**Bacteremia secondary to urinary tract infection in oncology patients: risk factors and impact of multidrug-resistant Gram-negative bacilli.**: Ignacio GRAFIA (Spain)<br>**Rectal carriage of multidrug-resistant organisms and subsequent bloodstream infections in hematologic patients undergoing hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy**: Charalampos CHARALAMPIDIS (Greece)<br>**The RUSTIC Study: Respiratory Virus Infection in a Contemporary Longitudinal Cohort of Patients with Haematological Malignancy**: Benjamin TEH (Australia)<br>**Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity**: Patrizia BONO (Italy)<br>**Safety and tolerability of SYN-004 in allogeneic hematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)**: Erik DUBBERKE (United States)<br>**Standardized gastrointestinal cytomegalovirus (CMV) tissue quantitative-nucleic-acid testing (QNAT) compared to immunohistochemistry in allogeneic hematopoietic cell transplant (HCT) recipients**: Sara DE ARAG�N DE LA CRUZ (Switzerland)<br>**Real-life experience with maribavir for the treatment of cytomegalovirus infection in hematological patients.**: Jorge BOAN PEREZ (Spain) |
| 12/04 | 13:30 - 14:30 | EF022 | Syndromic testing is still coming of age | Tommaso GIANI (Italy) | **Bacterial infections of the central nervous system: addressing the diagnostic gap in non- community-acquired meningitis**: Giulia MENCHINELLI (Italy)<br>**Epidemiological surveillance of central nervous system infections through a rapid syndromic testing platform**: Melisa REY (Spain)<br>**Impact of Syndromic Panel Implementation on Meningitis/Encephalitis Diagnosis, Antimicrobial Use, Costs, and Hospital Stay in a Regional Australian Hospital**: Shradha SUBEDI (Australia)<br>**Performance evaluation of the NxTAG� GPP Panel for the detection of gastrointestinal pathogens by comparison with current routine methods in Nantes University Hospital.**: Sophie GIBAUD (France)<br>**Correct discrimination of Monkeypox virus clades by fast syndromic testing**: Sven REISTER (Germany)<br>**Managing a Mycoplasma pneumoniae Outbreak: Impact of Syndromic Panels on Antimicrobial Prescriptions in Pediatric Emergencies**: Luis BRUSCA (Spain)<br>**Performance of BIOFIRE� FILMARRAY� Pneumonia plus in general population, solid organ transplant recipients and patients with hematologic malignancies – Interim analysis**: Riccardo RICCARDI (Italy)<br>**Impact of the molecular rapid diagnostic panel testing in adjustment of antimicrobial therapy in febrile neutropenic patients with bacteremia**: Sorawit CHANTHARASUT (Thailand)<br>**BacteREVEAL: Analytical performance and contribution of BioFire� BCID2 and Vitek� REVEALTM in intensive care patients with Gram-negative bloodstream infections**: Claire ROGER (France) |
| 12/04 | 13:30 - 14:30 | EF023 | Effective microbiology for the management of sepsis | Maurizio SANGUINETTI (Italy) | **Molecular epidemiology of Klebsiella bloodstream infection-causing isolates across England using Nanopore longread-only sequencing: An interim analysis of the NEKSUS study**: Dorottya NAGY (United Kingdom)<br>**Investigating seasonality of antibiotic resistance associated with E. coli and Klebsiella pneumoniae bloodstream infections**: Sam LIPWORTH (United Kingdom)<br>**Sensitivity of a host-protein test for microbiologically confirmed bacterial infections**: Roy NAVON (Israel)<br>**Comparative genomics of Klebsiella pneumoniae from gut colonisation and bloodstream infections reveal novel genetic associations**: Marit HETLAND (Norway)<br>**Conventional microbiology vs. conventional microbiology + nucleic acid-based multiplex real-time polymerase chain reaction (MPCR) test kit in septic shock: results of a matched cohort study**: Gamze SANLIDAG ISBILEN (T�rkiye)<br>**Contribution of Escherichia coli microbiological factors to the presentation as sepsis/septic shock in patients with bacteraemia: a matched case-control study**: Natalia MALDONADO (Spain)<br>**Simplified and rapid bacterial identification with antimicrobial resistance detection in bacteremia by on-chip multiplexed LAMP.**: Capucine TREILLE (France)<br>**Community-onset bloodstream infection among people with opioid use disorders: A twenty-year population-based cohort study in Queensland, Australia.**: Kevin LAUPLAND (Australia)<br>**Microbiological diagnosis tools for primary and secondary abdominal aortic infections requiring surgery**: Sarah SOUEGES (France) |
| 12/04 | 13:30 - 14:30 | EF024 | A never-ending evolution of antimicrobial resistance | Antonio OLIVER (Spain) | **Gfa, a novel integron-born fosfomycin resistance mechanism**: Nicolas KIEFFER (Spain)<br>**Regulons of RamA, RarA and SoxS mediated tigecycline resistance and oxidative stress among in vitro tigecycline resistant evolution trajectory of Klebsiella pneumoniae.**: Xiaojuan WANG (China)<br>**Assessing the impact of altered penicillin binding proteins on susceptibility to novel antimicrobials among clinical isolates of carbapenemase-producing Escherichia col**: Chaitanya TELLAPRAGADA (Sweden)<br>**Enterococcus faecalis penicillin-binding protein-4 sequence differences based on penicillin minimum inhibitory concentration**: Olivia FUNK (United States)<br>**Uncommon genomic rearrangements drive vancomycin resistance in vanB-positive Enterococcus faecium**: Kyriaki XANTHOPOULOU (Germany)<br>**Heteroresistance in Enterococcus faecalis: prevalence and mechanistic insights across clinically relevant antibiotics**: Sheida HEIDARIAN (Sweden)<br>**Side effects of rifampicin resistance: transcriptome modulation by rpoB mutations in Staphylococcus aureus**: M�lanie ROCH (Switzerland)<br>**Novel continuous experimental evolution methodology revealing rapid resistance development and cross-resistance**: Thadd�us ECHELMEYER (Germany) |
| 12/04 | 13:30 - 14:30 | ME054 | How antimicrobial tolerance impacts polymicrobial biofilm-associated infections |  | ****: Hans STEENACKERS (Belgium), Brian CONLON (United States) |
| 12/04 | 13:30 - 14:30 | ME055 | Long acting injectables to treat and prevent infections: an example from HIV field |  | ****: Monica GANDHI (United States), Pedro CAHN (Argentina) |
| 12/04 | 13:30 - 14:30 | MEET64 | Antimicrobial Stewardship Study Group open meeting (ESGAP) | Diane ASHIRU-OREDOPE (United KingdomESCMID official), Lucy CATTEAU (BelgiumESCMID official), Mark G. J. DE BOER (NetherlandsESCMID official), Filippo MEDIOLI (ItalyESCMID official), Rita MURRI (ItalyESCMID official), Nathan PEIFFER-SMADJA (FranceESCMID official) |  |
| 12/04 | 13:30 - 14:30 | MEET65 | Food- and Water-borne Infections Study Group open meeting (EFWISG) | Merica CAREV (CroatiaESCMID official), Ana Raquel FREITAS (PortugalESCMID official), Bruno LOPES (United KingdomESCMID official), Azucena MORA GUTI�RREZ (SpainESCMID official), Stefan ZIMMERMANN (GermanyESCMID official) |  |
| 12/04 | 13:30 - 14:30 | OS017 | Bad bacteria | Maristela P. FREIRE (Brazil), Siegbert RIEG (Germany) | **Vancomycin Dependent Enterococci: An evolutionary dead end or the ultimate evolution of a superbug**: Ruchika GUPTA (BAGGA) (Canada)<br>**Whipple's disease: one of medicine's great imitators**: Saumiya KESAVAN (United Kingdom)<br>**Phage Therapy as a Rescue Treatment for Recurrent Pseudomonas aeruginosa Bentall Infection**: Victor EIFERMAN (France)<br>**A clinical case of Legionella longbeachae pneumonia featuring unique epidemiological features in a major italian hospital**: Silvia GUERRIERO (Italy)<br>**Francisella tularensis – First autochthonous case in the UK**: Gemma VANSTONE (United Kingdom) |
| 12/04 | 13:30 - 14:30 | OS018 | Battling the Spore: C. difficile epidemiology and management | Nicolas BENECH (France), Fidelma FITZPATRICK (Ireland) | **Molecular epidemiology and antimicrobial resistome of Clostridioides difficile from private and public healthcare settings in three provinces in South Africa**: Hlambani SHIRINDA (South Africa)<br>**Screening for Clostridioides difficile colonization at admission and during hospitalization**: Nagham L�a KHANAFER (France)<br>**Revolutionizing CDI treatment: Are shorter antibiotic regimens the future**: Marek DURICEK (Czech Republic)<br>**Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of Clostridioides difficile infection**: Elena RUBIO-MART�N (Spain)<br>**Gut phageome profiling in Clostridioides difficile infection and faecal microbiota transplantation**: Carmen CHEN (Switzerland) |
| 12/04 | 13:30 - 14:30 | OS019 | Microbiome Dynamics and Health: From Pathogenesis to Therapeutic Potential | Mauricio FARFAN (Chile), Eija Inkeri K�N�NEN (Finland) | **Multi-omics integrated analysis revealed the key role of Fusobacterium periodonticum in colorectal tumorigenesis by decanoic acid promoting neutrophil chemotaxis.**: Xiaobing CHU (China)<br>**Exploring the respiratory microbiome in COPD patients: The role of Haemophilus spp. in disease pathogenesis**: Paula CAMPS-MASSA (Spain)<br>**Using the in vitro MiGut system to simulate the ulcerative colitis microbiome and post-antibiotic recovery supported by a pre-defined consortium of microbes**: Ines B. MOURA (United Kingdom)<br>**Functional characterization of the Brazilian Yanomami microbiome along an urbanization gradient: Insights into the impacts of Westernization on human health**: Marie THORP (Belgium)<br>**Colonization resistance of the intestinal microbiota to multidrug-resistant bacteria?**: Khanh VILLAGEOIS-TRAN (France) |
| 12/04 | 13:30 - 14:30 | OS020 | How to evaluate AMS programs | Esther CALBO (Spain), Sabiha ESSACK (South Africa) | **Preference-based instrumental variables for estimating the causal effects of antibiotic prescribing decisions in common infections: Assessing potential validity using CPRD data**: Nam NGUYEN (United Kingdom)<br>**Novel antibiotic spectrum metrics to quantify the impact of antimicrobial stewardship: a multicentre study**: Ben MOSHY (United Kingdom)<br>**Utilizing a weighted-incidence syndromic antibiogram to evaluate antimicrobial therapies and resistance trends in community-acquired infections in a community teaching hospital**: Vanthida HUANG (United States)<br>**Capturing days of therapy per days of service as a stewardship tool to identify outliers in prescribing broad-spectrum antimicrobials in the hospital setting**: Arielle HOPKINS (United States)<br>**Timing of Novel β-Lactams vs. Alternatives in Hospitalized Patients with Gram-Negative Infections: Line of Therapy (LoT) Analysis Preliminary findings**: Emre YUCEL (United States) |
| 12/04 | 13:30 - 14:30 | SY051 | Year in infectious diseases | Nur BENZONANA (T�rkiye), Evelina TACCONELLI (Italy) | ****: Yoav KEYNAN (Canada), Elisa CORDERO MATIA (Spain) |
| 12/04 | 13:30 - 14:30 | SY052 | Exploring children's role in infection spread | Angelika BERGER (), Sanjay PATEL (United Kingdom) | **Are children really super-spreaders of respiratory viruses?**: Emmanuel ANDR� (Belgium)<br>**Should schools be closed at the start of the next pandemic?**: Vittoria COLIZZA (France) |
| 12/04 | 13:30 - 14:30 | SY053 | Developing guidelines with AI tools: are they ready for prime time? | Miranda LANGENDAM (Netherlands), Blin NAGAVCI (Kosovo) | **The PROs and CONs of using AI tools for developing guidelines**: Holger SCHUENEMANN (Italy)<br>**AI in action: validated tools for speeding up your systematic reviews and how to use them**: Sara FERNANDEZ (Norway) |
| 12/04 | 13:30 - 15:30 | IS06 | Enter a new era of MDx for antimicrobial resistance | Te-Din Daniel HUANG (Belgium), Heiman WERTHEIM (NetherlandsESCMID official) | **Welcome and Introduction**: Te-Din Daniel HUANG (Belgium)<br>**More surveillance swabs and more sequencing: the best strategy to reduce and control MDR microorganisms diffusion**: Stefania STEFANI (Italy)<br>**Advantages of molecular methods over culture methods to optimise screening for carriage of CPE, ESBL and VRE**: Theresa CUNNINGHAM (Ireland)<br>**Routine STI-AMR testing: past and future perspectives**: Carsten TIEMANN (Germany)<br>**Pre-treatment STI-AMR testing for better diagnostics and resistance control of Mycoplasma genitalium infection**: Luis PI�EIRO (Spain)<br>**Panel Discussion and Q&A**: Te-Din Daniel HUANG (Belgium) |
| 12/04 | 13:30 - 15:30 | IS07 | Rewriting the plot: understanding invasive mould disease diagnosis and treatment for vulnerable patients | Cornelia LASS-FL�RL (Austria), Stefan SCHWARTZ (GermanyESCMID-appointed chair) | **Welcome and Introduction - The pilot episode: welcome and launch of our exploration into IMD**: Cornelia LASS-FL�RL (Austria)<br>**Better call microbiology: uniting with microbiologists for effective and timely IMD diagnosis**: Arunaloke CHAKRABARTI (Arunaloke CHAKRABARTI)<br>**The crown: exploring the realm of IMD management challenges in paediatric haematology-oncology**: Andreas H. GROLL (Germany)<br>**True detective: solving the puzzle of Mucorales and Aspergillus co-infections**: Malgorzata MIKULSKA (Italy)<br>**Racing against time to diagnose and manage IMD in critical care**: Joost WAUTERS (Belgium)<br>**Panel Discussion and Q&A - Season finale: audience questions and final reflections on IMD**: Cornelia LASS-FL�RL (Austria) |
| 12/04 | 13:30 - 15:30 | IS09 | COVID-19 5 years later: advancing hospital care in the new normal | Roy CHEMALY (United StatesESCMID official), Andrew USTIANOWSKI (United Kingdom) | **Welcome and Introduction - The new normal in COVID-19**: Andrew USTIANOWSKI (United Kingdom)<br>**The different faces of COVID-19: clear cause vs contributing factor**: Robert KRAUSE (Austria)<br>**Advancing hospital care: the interplay between guidelines and clinical judgement**: Cristobal RODR�GUEZ-LEAL (Spain)<br>**Bridging clinical gaps in COVID-19 care**:  TBA (TBA)<br>**Panel Discussion and Q&A**: Andrew USTIANOWSKI (United Kingdom) |
| 12/04 | 13:30 - 15:30 | IS10 | Maximising efficiency in microbiology: navigating resource scarcity with lab automation | Antony CROXATTO (Switzerland), Jacques SCHRENZEL (SwitzerlandESCMID-appointed chair) | **Welcome and Introduction**: Antony CROXATTO (Switzerland)<br>**Modernising microbiology: the multidimensional impact of automation assessed by HTA**: Lucrezia FERRARIO (Italy)<br>**Optimising automation: efficiency gains through continuous LEAN improvement**: Andrew BAMBER (United Kingdom)<br>**Innovative imaging: completing the automation transformation**: Christie VERMEIREN (Canada)<br>**Panel Discussion and Q&A**: Antony CROXATTO (Switzerland) |
| 12/04 | 13:30 - 15:30 | M5 | Malaria differential diagnosis (advanced) | Debbie NOLDER (United Kingdom), Claire ROGER (France) |  |
| 12/04 | 13:30 - 17:00 | TAE2 | TAE Day: afternoon round | Mary HORGAN (Ireland), Jose Ramon PANO-PARDO (Spain), Valentijn SCHWEITZER (Netherlands), Luigia SCUDELLER (Italy), Annelies ZINKERNAGEL (Switzerland), G�lsen �ZKAYA SAHIN (Sweden) |  |
| 12/04 | 14:00 - 14:20 | IPT08 | BACTEROMIC: One system ... Many comprehensive solutions |  | **BACTEROMIC: One system . Many comprehensive solutions**: Lukasz RICHTER (Poland) |
| 12/04 | 14:45 - 15:45 | EF029 | Vaccination uptake-challenges and opportunities | Joanne M. LANGLEY (Canada) | **Electronic nudges to increase influenza vaccination uptake among patients with heart failure: insights from 3 nationwide randomized trials enrolling >2 million patients**: Niklas Dyrby JOHANSEN (Denmark)<br>**Psychological Predictors of Influenza Vaccination Intent Among Healthcare Workers in Bulgaria**: Petar VELIKOV (Bulgaria)<br>**Determinants of COVID-19 vaccine uptake in patients with hematologic malignancies: a nationwide cohort study**: Quincy HOFSINK (Netherlands)<br>**Inequality in vaccine uptake among children in Denmark in the national childhood vaccination programme**: Anne Christine Mariager BRESCHEL (Denmark)<br>**Prevalence and associated factors of parental refusal rates for routine immunisation: A cross-sectional study in Peshawar, Khyber Pakhtunkhwa, Pakistan-2024**: Muhammad HAKIM (Pakistan)<br>**Shingles Prevalence, Vaccine Awareness, and Acceptance in People Living with HIV**: Dilara YAMAN (T�rkiye)<br>**Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden, 2018−2022**: Andreas PALMBORG (Sweden)<br>**Monkeypox (mpox) vaccination willingness and determinants among people living with HIV (PLWH) in turkey**: Cemre BOSNAK (T�rkiye) |
| 12/04 | 14:45 - 15:45 | EF030 | Viruses crossing the blood-brain barrier |  | **Clinical characteristics and outcome of Herpes simplex virus type 1 and varicella zoster virus encephalitis: A prospective population-based cohort study**: Laerke DUERLUND (Denmark)<br>**Arbovirus associated neurological disease in adults and children in Brazil: a multicentre case-control study**: Suzannah LANT (United Kingdom)<br>**Challenges in managing Central nervous system infections: Battling the Unknown Enemy, West Nile virus vs unknown etiology**: Cosmin-Alexandru MARIN (Romania)<br>**Spatial and temporal profiling of the immune responses induced by Japanese encephalitis virus in a mouse model**: Zhihua OU (China)<br>**Intrathecal immunoglobulin synthesis in tick-borne encephalitis**: Sambor S. GRYGORCZUK (Poland)<br>**B and T cell responses to Tick-borne Encephalitis Virus**: Nuria MAYOLA DANES (Sweden)<br>**Enterovirus infections in pediatric central nervous system (CNS) diseases: molecular epidemiology and neuroimaging insights**: Deepanjli SHARMA (India)<br>**Neuroimaging findings and their correlation with autopsy findings: Prospective study on Rabies encephalitis**: Madhav MOHATA (India)<br>**Toxoplasma gondii IgG Screening and Central Nervous System Complications among People with HIV in the Combination Antiretroviral Therapy Era**: Taohung OU (China) |
| 12/04 | 14:45 - 15:45 | EF031 | AMS around the world: know your data! | Eoghan DE BARRA (Ireland) | **Duration of antibiotic treatment for respiratory tract infections in primary care.**: Carl LLOR (Spain)<br>**Antibiotic prescribing for common acute infections in Pakistan - an analysis using IQVIA prescriber healthcare surveys**: Nam NGUYEN (United Kingdom)<br>**Antibiotic prescribing for common acute infections in Egypt - an analysis using IQVIA prescriber healthcare surveys**: Nam NGUYEN (United Kingdom)<br>**Population based analysis of the impact of Japan's AMR national action plan and the COVID-19 pandemic on antimicrobial prescription**: Ryuji KOIZUMI (Japan)<br>**Quality of antibiotic prescribing in Portuguese hospitals: a snapshot of the first National Antimicrobial Prescribing Survey.**: Carlos PALOS (Portugal)<br>**Evaluating the impact on 28-day mortality of different empiric AWaRe antibiotic treatment strategies for hospital-acquired infections across different hospital settings.**: Cherry LIM (United Kingdom)<br>**Update on WHO's Global antibiotic use surveillance system (GLASS-AMU)**: Benedikt HUTTNER (Switzerland)<br>**Harmonisation trajectory of Global-Point Prevalence Survey (Global-PPS) and WHO-PPS**: Ann VERSPORTEN (Belgium)<br>**Implementation of prospective audit and feedback strategy in intensive care units: Analysis of antimicrobial prescription patterns in a Guatemalan tertiary care hospital**: Nancy SANDOVAL (Guatemala) |
| 12/04 | 14:45 - 15:45 | FO063 | Science communication in a noisy world: podcasting and social media in ID/CM | Emily G. MCDONALD (Canada) | **The ID:IOTS guide to creating a successful CM/ID podcast"**: Callum MUTCH (United Kingdom)<br>**Using social media for CM/ID education**: Scott JAKE (United States)<br>**Podcasting and social media for antimicrobial stewardship and pharmacy**: Erin MCCREARY (United States) |
| 12/04 | 14:45 - 15:45 | KN056 | Defending against dengue: global epidemiology and strategies for prevention and control | Anu KANTELE (Finland), Carlos SEAS (Peru) | ****: Fernanda BOULOS (Brazil) |
| 12/04 | 14:45 - 15:45 | ME061 | How to use large language models and machine learning for improving One Health |  | ****: Javier FERN�NDEZ (Spain), Nicolas RADOMSKI (Italy) |
| 12/04 | 14:45 - 15:45 | ME062 | Untangling the web: antimicrobial dose adjustments in renal impairment |  | ****: Claire ROGER (France), Isabel SPRIET (Belgium) |
| 12/04 | 14:45 - 15:45 | MEET66 | Fungal Infection Study Group open meeting (EFISG) | Robina AERTS (BelgiumESCMID official), Dimitrios P. KONTOYIANNIS (United StatesESCMID official), Katrien LAGROU (BelgiumESCMID official), Fanny LANTERNIER (FranceESCMID official), Malcolm RICHARDSON (United KingdomESCMID official), Jon SALMANTON-GARCIA (GermanyESCMID official) |  |
| 12/04 | 14:45 - 15:45 | MEET67 | Infections in the Elderly Study Group open meeting (ESGIE) | Niccol� BUETTI (SwitzerlandESCMID official), Marco FALCONE (ItalyESCMID official), Gaetan GAVAZZI (FranceESCMID official), Jordi RELLO (SpainESCMID official), Dafna YAHAV (IsraelESCMID official) |  |
| 12/04 | 14:45 - 15:45 | OS025 | Bacterial battles: a paediatric perspective on infections and interventions | Angelika BERGER (), Julie TOUBIANA (France) | **Strong Alignment Between National Standard Treatment Guidelines and WHO AWaRe Book Recommendations for Primary Care Pediatric Infections**: Daniele DONA (Italy)<br>**Correlation between antibiotic consumption and digestive colonization with multidrug-resistant Enterobacterales in a paediatric haematology department**: Siwar FRIGUI EP OUESLATI (Tunisia)<br>**Interleukin-6 as a diagnostic biomarker for sepsis in neonates, children and pregnant women – a real-world cohort study**: Sean Olann WHELAN (Ireland)<br>**Impact of rapid diagnostic stewardship interventions to reduce blood culture utilization in a pediatric medical center**: Esther VAUGON (Canada)<br>**Infective endocarditis: A Decade of Experience at a Tertiary Pediatric Care Centre**: Maia DE LUCA (Italy) |
| 12/04 | 14:45 - 15:45 | OS026 | Carbapenem resistance Gram-negatives, what's new in treatment? | Matteo BASSETTI (Italy), Maria Milagro MONTERO (Spain) | **Ceftriaxone sulbactam disodium EDTA combination(CSE) as a treatment option for carbapenem resistant gram negative bacilli - to be or not to be?**: Yogita VERMA (India)<br>**Sulbactam-durlobactam as an effective alternative option against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates in Swizterland**: Christophe LE TERRIER (Switzerland)<br>**Optimising Difficult-to-treat Gram-negative Bacterial Infection Outcomes with Personalised Fosfomycin-Based Combination Therapy Guided by in vitro Antibiotic Combination Testing**: Tze-Peng LIM (Singapore)<br>**Management of infections caused by ST308 New Dehli metallo-ß-lactamase-producing Pseudomonas aeruginosa with in vitro-guided combination antibiotic therapy**: Jocelyn TEO (Singapore)<br>**In vitro activity of cefepime/enmetazobactam against clinical isolates of Enterobacterales in Portugal: A multicentre retrospective study**: Hugo CRUZ (Portugal) |
| 12/04 | 14:45 - 15:45 | OS027 | Staphylococcus aureus: colonisation, virulence, and persistence | Stefano GIULIERI (Australia) | **The nasal microbiome redefines and predicts Staphylococcus aureus nasal colonisation status**: Dinesh AGGARWAL (United Kingdom)<br>**Development of a Staphylococcus aureus human nasal colonisation model**: Abdou HACHANI (Australia)<br>**Selection-free, virulence gene promoter-controlled CRISPR interference system for in vivo pathogenesis study of Staphylococcus aureus - A proof of concept**: Roni MIAH (Norway)<br>**Placebo-controlled study of competitive exclusion using Lactococcus lactis to reduce transmission of LA-MRSA from pigs to humans**: Birgitta DUIM (Netherlands)<br>**Rifampicin-induced Staphylococcus aureus persister formation is driven by CodY and oxidative stress level**: Nicola PORDONE (France) |
| 12/04 | 14:45 - 15:45 | OS028 | Unlocking the potential of the human microbiome for clinical diagnostics | John W. A. ROSSEN (Netherlands), Maria VEHRESCHILD (Germany) | **Deep learning-enhanced wellness scores: Advancing gut microbiome-based health predictions**: Ozkan Ufuk NALBANTOGLU (T�rkiye)<br>**Comparison of Second-Generation and Third-Generation Sequencing technologies for 16S rRNA amplicon-based gut microbiome analysis**: Elisa RUBIO GARC�A (Spain)<br>**Donor for fecal microbiota transplantation: a challenging research.**: Beatrice Silvia ORENA (Italy)<br>**Antibiotic resistance genes diversity and antimicrobial effects in the vaginal microbiome during pregnancy**: Nassim BOUTOUCHENT (France)<br>**Distinct gut microbiota and metabolic profiles in brain tumor patients: Bridging microbial insights to CNS oncology**: Aycan GUNDOGDU (T�rkiye) |
| 12/04 | 14:45 - 15:45 | SY057 | Macrolides in community-acquired pneumonia: therapeutic necessity or path to overuse? | Marc J.M. BONTEN (Netherlands), Karin THURSKY (Australia) | **Pro: maximising outcomes with evidence-based use**: Evangelos GIAMARELLOS-BOURBOULIS (Greece)<br>**Con: the risks of routine (over)use**: Aur�lien DINH (France) |
| 12/04 | 14:45 - 15:45 | SY058 | Top papers in transplant ID | Nicolas MUELLER (Switzerland), Alessandra MULARONI (Italy) | **Top 10 papers in infections in SOT**: Patricia MUNOZ (Spain)<br>**Top 10 paper in infections in HCT and cellular therapy**: Joshua HILL (United States) |
| 12/04 | 14:45 - 15:45 | SY059 | Value-based syndromic diagnostics in medical microbiology: Pro / Con debate | Hege Vangstein AAMOT (Norway), Eric CLAAS (Netherlands) | **Pro: clinical benefit and potential for improved patient outcomes**: Kirstine K. S�GAARD (Denmark)<br>**Con: limitations, costs, and possible overuse of syndromic panels**: Gilbert GREUB (Switzerland) |
| 12/04 | 14:45 - 15:45 | SY060 | We need to talk about toilets. | Stephanie J. DANCER (United Kingdom), Juliette SEVERIN (Netherlands) | **Infection risks from sanitation engineering**: Davey JONES (United Kingdom)<br>**Ventilation in toilets: how can we improve it?**: Michael GORMLEY (United Kingdom) |
| 12/04 | 15:00 - 15:20 | IPT09 | T cell directed mRNA vaccines for infectious diseases |  | **T Cell directed mRNA vaccines for infectious diseases**: Nadine SALISCH (Germany) |
| 12/04 | 15:30 - 15:50 | IPT10 | Data-driven approaches to managing patients at high risk for severe COVID-19 |  | **Data-driven approaches to managing patients at high risk for severe COVID-19**: Carolina GARCIA VIDAL (Spain) |
| 12/04 | 16:00 - 16:20 | IPT11 | Innovation in preventing the unseen threat: central line-associated bloodstream infections |  | **Innovation in preventing the unseen threat: central line-associated bloodstream infections**: Nisha GUPTA (United States) |
| 12/04 | 16:00 - 17:00 | FIPL2 | Fireplace: Defending against dengue: global epidemiology and strategies for prevention and control | Anu KANTELE (Finland), Carlos SEAS (Peru) | ****: Fernanda BOULOS (Brazil) |
| 12/04 | 16:15 - 17:15 | EF033 | Current treatment options for invasive fungal infections | Andreas H. GROLL (Germany) | **The paediatric European Confederation of Clinical Mycology (ECMM) Quality (paed-EQUAL) Score for the management of candidaemia in children and neonates**: Zoi Dorothea PANA (Cyprus)<br>**Prevalence rate, species distribution and antifungal susceptibility of bloodstream infections caused by rare yeasts of the Saccharomycetales order documented in 28 Brazilian medical centers**: Carolina PALAMIN BUONAFINE (Brazil)<br>**Rezafungin showed high in vitro activity and very low resistance rate against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024**: Jesus GUINEA (Spain)<br>**Posaconazole Drug-Drug Interaction Potential is Similar Across Bodyweight**: Rebecca E. WRISHKO (United States)<br>**Phase 2, open-label, non-comparative clinical trial evaluating the safety and efficacy of posaconazole in paediatric patients 2 to <18 years old with invasive aspergillosis**: Hyoung Jin KANG (Republic Of)<br>**Activity of manogepix against a worldwide collection of mould isolates from 2023**: Marisa WINKLER (United States)<br>**Candida auris displays an inoculum effect with multiple antifungal drug classes**: Ronen BEN-AMI (Israel)<br>**In vitro olorofim activity against Aspergillus spp clinical isolates collected as part as two national surveys on azole resistance conducted in Spain (ASPEIN II and III)**: Jesus GUINEA (Spain) |
| 12/04 | 16:15 - 17:15 | EF034 | Surgical site infections: epidemiology, risk factors, and prevention strategies | Trisha PEEL (Australia) | **Incidence of Surgical Site Infections (SSIs) from the automated patient-based surveillance system, SPICMI, France**: Pascal ASTAGNEAU (France)<br>**Beta-lactam versus non-beta-lactam antimicrobial prophylaxis and its association with the surgical site infection rate, a nationwide cohort study with 348 793 patients**: Selina LARGIAD�R (Switzerland)<br>**Cutibacterium species in Neurosurgical Infections: Not Such a "Cute" Pathogen After All**: James DONNELLY (Ireland)<br>**The polymicrobial nature of wound infections in an emergency orthopaedic ward in Northern Nigeria - implications for treatment and patient outcome**: Kate COOK (United Kingdom)<br>**Efficacy of Octenidine Dihydrochloride Versus Chlorhexidine Gluconate Solutions in Reducing Surgical-Site Infections in Total Hip and Knee Arthroplasty: A Comparative Analysis**: Artsiom ABIALEVICH (Israel)<br>**Impact on rates of surgical site infection of requiring pre-authorization of surgical antibiotic prophylaxis choice and post-operative antibiotic doses**: Carmenchu Marie VILLAVICENCIO (Philippines) |
| 12/04 | 16:15 - 17:15 | MEET68 | Mycobacterial Infections Study Group open meeting (ESGMYC) | Daniela CIRILLO (ItalyESCMID official), Lorenzo GUGLIELMETTI (FranceESCMID official), Yousra KHERABI (FranceESCMID official), Catherine ONG (SingaporeESCMID official), Onya OPOTA (SwitzerlandESCMID official), Daria PODLEKAREVA (DenmarkESCMID official) |  |
| 12/04 | 16:15 - 17:15 | MEET69 | Forensic and Postmortem Microbiology Study Group open meeting (ESGFOR) | Domitille CALLON (FranceESCMID official), Marta COHEN (United KingdomESCMID official), Nihan ZIYADE (T�rkiyeESCMID official) |  |
| 12/04 | 16:15 - 17:45 | IS11 | Innovative antibiotics: are we using them in the right patients, at the right time? The example of cefiderocol in CRGNI | Mathias PLETZ (Germany), Pranita TAMMA (United StatesESCMID-appointed chair) | **Welcome and Introduction**: Mathias PLETZ (Germany)<br>**Are we using innovative antibiotics optimally?**: Gennaro DE PASCALE (Italy)<br>**What has real world experience of cefiderocol taught us about its place in therapy?**: Paula RAM�REZ (Spain)<br>**Panel Discussion and Q&A**: Mathias PLETZ (Germany) |
| 12/04 | 16:15 - 17:45 | IS12 | The power of prevention: incorporating adult vaccination into health systems | Maria GANCZAK (PolandESCMID-appointed chair), Marie-Christine TRUCHET (France) | **Welcome and Introduction**: Maria GANCZAK (Poland)<br>**The preventable burden of co-circulating vaccine-preventable respiratory diseases in adults**: Charles FELDMAN (South Africa)<br>**The impact of respiratory infections on non-communicable diseases**: Eva POLVERINO (Spain)<br>**Driving change through global vaccine advocacy to build robust immunisation programmes**: Michael MOORE (Australia)<br>**Panel Discussion and Q&A**: Maria GANCZAK (Poland) |
| 12/04 | 16:15 - 17:45 | IS13 | Embracing the change: success stories of innovation in clinical microbiology | Fusun CAN (T�rkiyeESCMID-appointed chair), Gilbert GREUB (Switzerland) | **Welcome and Introduction**: Gilbert GREUB (Switzerland)<br>**Embracing change to empower people to self-sample for STI testing**: Barbara VAN DER POL (United States)<br>**Driving the changing needs of diagnostics: how should labs prepare for the next unknown?**: Giuseppe TOGNI (Switzerland)<br>**The automation transition journey: ready for the change?**: Chris ALLAN (United Kingdom)<br>**The automation transition journey: shifting mindset, embracing innovation**: Annette SKOVBY (Denmark)<br>**The automation transition journey: impacts and outcomes**: C�cile MEEX (Belgium)<br>**Panel Discussion and Q&A**: Gilbert GREUB (Switzerland) |
| 12/04 | 16:15 - 17:45 | IS14 | Details make the difference. Do you know everything about the new antibiotics? | Matteo BASSETTI (Italy), Tomislav KOSTYANEV (DenmarkESCMID-appointed chair) | **Welcome and Introduction - Are All BL/BLI combinations equal?**: Matteo BASSETTI (Italy)<br>**BL/BLIs combinations. An antimicrobial activity review**: Laurent DORTET (France)<br>**BL/BLIs combinations. Lung ELF PK/PD review**: Markus ZEITLINGER (Austria)<br>**Role of new BL/BLIs combinations for Gram-negative bloodstream infections**: Carolina GARCIA VIDAL (Spain)<br>**F2F debate: BL/BLIs combinations for the treatment of ESBLs and Carbapenem Resistant infections; OXA-48 vs KPC infections - same approach?**: Luke MOORE (United Kingdom)<br>**Panel Discussion and Q&A**: Matteo BASSETTI (Italy) |
| 12/04 | 16:15 - 17:45 | IS15 | Changing microbiology: advanced spectroscopy and molecular biology techniques | Elena DE CAROLIS (ItalyESCMID-appointed chair), Markus KOSTRZEWA (Germany) | **Welcome and Introduction**: Markus KOSTRZEWA (Germany)<br>**Application of Fourier transform infrared spectroscopy (FTIR) in infection control: investigation of fungal and bacterial transmission events**: Arthur PRANADA (Germany)<br>**The rising significance of filamentous fungi as pathogens and the crucial role of modern diagnostics**: Birgit WILLINGER (Austria)<br>**CMV RNA testing: a game changer in the management of personalized therapies**: Carlo Federico PERNO (Italy)<br>**Panel Discussion and Q&A**: Markus KOSTRZEWA (Germany) |
| 12/04 | 16:15 - 18:15 | EW070 | Malaria: when the drugs don't work Management of treatment failure in non-endemic countries | Laura NABARRO (United Kingdom), Caroline R�NNBERG (Sweden) | **Malaria in the non-endemic setting: who to treat as an outpatient and how to detect treatment failure**: Emmanuel BOTTIEAU (Belgium)<br>**Malaria resistance mutations in the non-endemic setting: role of genomic surveillance**: Anna ROSANAS URGELL (Belgium)<br>**How to manage Plasmodium Knowlesi infection**: Giri Shan RAJAHRAM (Malaysia)<br>**Epidemiology and control of Plasmodium Knowlesi**: Kimberly FORNACE (Singapore) |
| 12/04 | 16:15 - 18:15 | EW071 | The rare art of writing scientific articles: from conception to submission | Marlieke DE KRAKER (Switzerland), Mical PAUL (Israel) | **Expressing yourself correctly: writing tips**: Angela HUTTNER (Switzerland)<br>**Constructing your manuscript for an original article**: Jes�s RODR�GUEZ-BA�O (Spain)<br>**The use of artificial intelligence tools for writing articles: what to do and not to do**: Erlangga YUSUF (Netherlands)<br>**Selecting the best journal for my manuscript**: Andre KALIL (United States) |
| 12/04 | 16:15 - 18:15 | LB006 | The Trial Run: recent trials on S. aureus bacteraemia management | Julia Anna BIELICKI (United Kingdom), Vance FOWLER (United States) | **Introduction**: Julia Anna BIELICKI (United Kingdom)<br>**Benzylpenicillin versus (flu)cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia: a randomised controlled trial of the S. aureus network adaptive platform (SNAP)**: Steven TONG (Australia)<br>**Cefazolin versus (flu)cloxacillin for the treatment of penicillin-resistant, methicillin-susceptible Staphylococcus aureus bacteraemia: a randomised controlled trial within the S. aureus network adaptive platform (SNAP)**: Joshua Saul DAVIS (Australia)<br>**Cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a randomised, controlled, non-inferiority trial**: Xavier LESCURE (France)<br>**Trial Discussion**: Julia Anna BIELICKI (United Kingdom), Vance FOWLER (United States) |
| 12/04 | 16:15 - 18:15 | M6 | Morphological diagnosis of faecal protozoa | Debbie NOLDER (United Kingdom), Claire ROGERS (United Kingdom) |  |
| 12/04 | 16:15 - 18:15 | OS032 | Unraveling respiratory viruses, 2025 | Eeva BROBERG (Sweden), Florian KRAMMER (United States) | **Human metapneumovirus infections in hospitalized adults compared to respiratory syncytial virus and influenza infections over ten years in France**: Paul LOUBET (France)<br>**Unveiling animal susceptibility to influenza viruses (H1N1(pdm09) and H5N1 HPAIV) using animal-derived respiratory organoids**: Ferran TARR�S-FREIXAS (Spain)<br>**Exploring the impact of acute lung hypoxia on CD8 T cell phenotypes following severe influenza infection.**: Brydie HUCKESTEIN (United States)<br>**Virological characterisation of RSV after Nirsevimab Breakthrough Infections in a Multicentre Observational Real-world Study in France**: Slim FOURATI (France)<br>**Baseline immunity to highly pathogenic avian influenza viruses in a healthcare worker cohort**: Corine GEURTS VAN KESSEL (Netherlands)<br>**Impact of reinfection on post-acute sequelae of COVID-19 over multi-organ systems**: Janice Yu Jin TAN (Singapore)<br>**Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study**: Stanislava BRATKOVIC (Denmark)<br>**The burden of respiratory syncytial virus in children <3 years old presenting to primary, secondary and tertiary care in England: report from the STOP RSV prospective surveillance study**: Emma CARTER (United Kingdom)<br>**Targeted metagenomic sequencing of influenza, RSV, and symptomatic respiratory infections from UK healthcare workers**: Marissa KNOLL (United Kingdom) |
| 12/04 | 16:15 - 18:15 | SY064 | PK/PD to avoid emergence of resistance? | Joseph MELETIADIS (Greece), Anne-Grete M�RTSON (Netherlands) | **PK/PD and antibacterial therapy**: Dolors SOY-MUNER (Spain)<br>**PK/PD and antifungal therapy**: Roger BR�GGEMANN (Netherlands)<br>**PK/PD and antiviral therapy**: Joe STANDING (United Kingdom)<br>**PK/PD considerations in anthelminthic treatment**: Jennifer KEISER (Switzerland) |
| 12/04 | 16:15 - 18:15 | SY065 | Gram-positives, are they still going? | Diederik BATHOORN (Netherlands), Stefania STEFANI (Italy) | **The vanco chronicles: enterococci's global journey**: Guido WERNER (Germany)<br>**Pitfall in susceptibility testing of Gram-positives**: Helena ZEMLICKOVA (Czech Republic)<br>**Drivers for daptomycin and linezolid resistance in Gram-positives**: Glen CARTER (Australia)<br>**What is new in treatment against MDR Gram-positives?**: Alex SORIANO (Spain) |
| 12/04 | 16:15 - 18:15 | SY066 | Biomarker testing to manage respiratory infections in primary care in low resource settings | Sonia LEWYCKA (Vietnam), Heiman WERTHEIM (Netherlands) | **The Vietnamese experience with CRP testing in the community setting**: Thi Thuy Nga DO (Vietnam)<br>**The Nigerian experience with CRP testing in the community setting**: Augustine ONWUNDUBA (Nigeria)<br>**CRP testing in diagnosing tuberculosis in Zambia and South Africa**: Helen AYLES (Zambia)<br>**The health economics of CRP testing in LMICs**: Yoel LUBELL (Thailand) |
| 12/04 | 16:15 - 18:15 | SY067 | STIs: an ongoing crisis | Dagmar HEUER (Germany), Tomislav MESTROVIC (Croatia) | **STI treatment options are running out due to AMR**: Magnus UNEMO (Sweden)<br>**Genomic surveillance of Neisseria gonorrhoeae strains**: Petra WOLFFS (Netherlands)<br>**Evolutionary insights into syphilis and Treponema pallidum**: Mathew BEALE (United Kingdom)<br>**Challenges in chlamydial STI infections**: Cecile BEBEAR (France) |
| 12/04 | 16:15 - 18:15 | SY068 | Tick-borne encephalitis: contemporary diagnosis and management | Joanna Maria ZAJKOWSKA (Poland), Dace ZAVADSKA (Latvia) | **Tick-borne encephalitis: immune response and clinical experience**: Sara GREDMARK RUSS (Sweden)<br>**TBE immune responses and vaccine effectiveness**: Karin STIASNY (Austria)<br>**NS1 antibodies: diagnostics and screening of seroprevalence of TBE virus infection**: Gerhard DOBLER (Germany)<br>**Treatment for TBE: where do we stand?**: Daniel RUZEK (Czech Republic) |
| 12/04 | 16:15 - 18:15 | SY069 | Controlled human infection models | Frederick HAYDEN (United States), Nikolai SIEMENS (Germany) | **Updates on the dengue human infection model**: Kirsten LYKE (United States)<br>**CHIM in endemic countries**: Melissa KAPULU (Kenya)<br>**Controlled human infection models of parasitic infections**: Meta ROESTENBERG (Netherlands)<br>**Controlled human infection models of non-typhoidal Salmonella**: Malick GIBANI (United Kingdom) |
| 12/04 | 17:15 - 18:15 | EF035 | Genomics in pathogen surveillance | V�tor BORGES (Portugal) | **Genomic Surveillance of Invasive Group A Streptococcus in Argentina's 2023 Epidemic: Unveiling Hypervirulent emm1 Lineages and Pediatric emm12 Burden**: Lucia CIPOLLA (Argentina)<br>**Understanding the population structure of Moraxella catarrhalis using core-genome multilocus sequence typing**: Iman YASSINE (United Kingdom)<br>**Impact of the COVID-19 pandemic on the Streptococcus pyogenes clones causing adult invasive infections**: Mario RAMIREZ (Portugal)<br>**Unveiling the Hidden Complexity of Providencia: Genomic Insights into Species Reclassification and Antibiotic Resistance**: Xu DONG (China)<br>**Genomic description of outbreak of VIM-1 carrying Enterobacter in Switzerland suggests plasmid transmission between sequence types**: Helena SETH-SMITH (Switzerland)<br>**Genomic epidemiology of Klebsiella pneumoniae bloodstream infections in a german tertiary centre: increased virulence in carbapenem-resistant strains**: Leonard KNEGENDORF (Germany)<br>**Phylogenetic mixing and undetected circulation of multiple Candida auris lineages following recognition of imported cases in Italy**: Vincenzo DI PILATO (Italy)<br>**Using Long-Read Sequencing for Core Plasmid Multilocus Sequence Typing to Investigate Plasmid Relationships Among Bacterial Species in German Hospital Wastewater**: Anurag Kumar BARI (Netherlands)<br>**Screening for rectal colonization with multidrug-resistant pathogens: usage of rapid metagenomic long-read technology**: Srinithi PURUSHOTHAMAN (Switzerland) |
| 12/04 | 17:15 - 18:15 | EF036 | Heads up! CNS infections | Jacob BODILSEN (Denmark) | **Central Nervous System Involvement by Mycobacterium avium Complex in Advanced HIV: A Rare and Underdiagnosed Challenge**: Estefania SIENRA IRACHETA (Mexico)<br>**Acute disseminated encephalomyelitis following bacterial meningoencephalitis – Two Case reports & Review of Literature**: Megha PRIYADARSHI (India)<br>**Streptococcus equi Subspecies zooepidemicus Endocarditis and Meningitis in a 62-Year-Old Patient: A Case Report and Literature review**: Davide CHEMELLO (Italy)<br>**Breaking barriers: meropenem-vaborbactam as a game-changer for KPC central nervous system infections**: Francesca PRATAVIERA (Italy)<br>**Multidrug-Resistant Klebsiella pneumoniae Meningitis in the Absence of Intracranial Devices: A Case Report**: Mariana CHUMBITA (Spain)<br>**Triple Threat: Sequential Meningitis Infections in an Immunosuppressed Patient with Morganella morganii, Acinetobacter baumannii, and Vancomycin-resistant Enterococcus faecium**: Yasemin �AKIR KIYMAZ (T�rkiye)<br>**Invasive pulmonary Arthrographis kalrae infection with cerebral abscesses in an immunocompromised child**: Beatrice WINKEL (Netherlands)<br>**Treatment of herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient**: Alexander BIRKMANN (Germany)<br>**A case of influenza A (H1N1) encephalitis: Rare neurological implication in a healthy adult**: Naresh Kumar MIDHA (India) |
| 12/04 | 17:15 - 18:15 | MEET70 | Staphylococci Study Group open meeting (ESGS) | Anna GOODMAN (United KingdomESCMID official), Marjolein HENSGENS (NetherlandsESCMID official), Barbara C. KAHL (GermanyESCMID official), Marc STEGGER (DenmarkESCMID official), Steven TONG (AustraliaESCMID official) |  |
| 12/04 | 17:15 - 18:15 | MEET86 | Compromised Host Infections Study Group open meeting (ESGICH) | Elisa CORDERO MATIA (SpainESCMID official), Maddalena GIANNELLA (ItalyESCMID official), Michael G ISON (United StatesESCMID official), Nicolas MUELLER (SwitzerlandESCMID official), Monica SLAVIN (AustraliaESCMID official) |  |
| 13/04 | 08:30 - 09:30 | EF039 | Novel approaches to antiviral therapy | Pinyo RATTANAUMPAWAN (Thailand) | **Obeldesivir exhibits broad anti-RSV activity and a high barrier to resistance in vitro and is efficacious in a non-human primate challenge model of RSV infection**: Jared PITTS (United States)<br>**EDP-323, a first-in-class, oral, RSV L-protein inhibitor reduces disease severity (respiratory mucus production) and accelerates viral clearance in a human viral challenge study**: John DEVINCENZO (United States)<br>**A Combined In Silico and In Vitro Pipeline for Optimizing Nanobodies Targeting Surface Proteins of Pathogens: Applications to SARS-CoV-2, WNV, and Influenza A Virus**: Ciro Leonardo PIERRI (Italy)<br>**Bemnifosbuvir and Remdesivir exhibit potent antiviral activity against tick-borne encephalitis virus in vitro**: Denis GRANDGIRARD (Switzerland)<br>**Combinations of antiviral drugs demonstrating synergistic inhibition of multiple respiratory RNA viruses**: Samuel ELLIS (United Kingdom)<br>**The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants**: Anuj GAGGAR (United States)<br>**Efficacy of ganciclovir against CMV infection is dependent on treatment initiation time**: Lalitya SUDARSONO (Netherlands)<br>**Efficacy of molnupiravir and baloxavir against influenza A H1N1 infection in vitro and in vivo**: Danlei LIU (China)<br>**Human defensin derived peptide showing broad antiviral activity against human adenoviruses**: Xiankun WANG (China) |
| 13/04 | 08:30 - 09:30 | EF040 | New frontiers in parasitic disease and migrant health research | Miriam Jos� �LVAREZ-MART�NEZ (Spain) | **Targeting metabolic bioenergetics: the ‘Achilles' heel' of Leishmania**: Deblina SARKAR (India)<br>**Leishmaniasis in Southern Alicante (Spain): what is the new patient profile?**: M� Dolores HERN�NDEZ RABAD�N (Spain)<br>**Schistosoma haematobium infection is associated with oncogenic gene expression in cervical mucosa, with enhanced effects following treatment**: Anna MERTELSMANN (Switzerland)<br>**Associations between water and sanitation service, risk of intestinal schistosomiasis, infection intensity, and liver fibrosis in selected households living near Lake Albert: a descriptive cross-sectional study?**: Germain LAM (United Kingdom)<br>**Schistosomiasis detected by Screening of sub-Saharan African Unaccompanied Minor Refugees in Berlin between 2023 and 2024**: Gabriela EQUIHUA MARTINEZ (Germany)<br>**NADPH oxidase of the mosquitoes and the antioxidant genes repertoire of the bacteria coordinate mosquito-bacteria interaction in midgut**: Baolin SONG (China)<br>**Molecular detection and sequencing of the genes encoding the predicted enzymes; Amidase, NADH ubiquinone oxidoreductase, and sodium neurotransmitter symporter in Onchocerca volvulus**: Anabel ACHEAMPONG (Ghana)<br>**Tuberculosis outcomes among international migrants living in Europe compared to the non-migrant population: a systematic review and meta-analysis**: Giacomo GUIDO (Italy) |
| 13/04 | 08:30 - 09:30 | MEET88 | Critically Ill Patients Study Group open meeting (ESGCIP) | Matteo BASSETTI (ItalyESCMID official), Hakan ERDEM (T�rkiyeESCMID official), Stefan HAGEL (GermanyESCMID official), Despoina KOULENTI (United KingdomESCMID official), Jean-Francois TIMSIT (FranceESCMID official) |  |
| 13/04 | 08:30 - 10:00 | IS16 | New horizon of RSV LRTD in infants: reflection on two seasons of prevention options | Markus KNUF (Germany), Federico MARTIN�N-TORRES (SpainESCMID-appointed chair) | **Welcome and Introduction**: Markus KNUF (Germany)<br>**Landscape of RSV LRTD prevention strategies for infants**: Laura CASTELLS VILELLA (Spain)<br>**Local implementation strategies and real-world evidence for the prevention  of RSV LRTD in infants**: Laura CASTELLS VILELLA (Spain)<br>**Real-world experience and the evolution of the immunoprophylaxis against RSV LRTD in a broad infant population**: Laura CASTELLS VILELLA (Spain)<br>**Panel Discussion and Q&A**: Markus KNUF (Germany) |
| 13/04 | 08:30 - 10:00 | IS17 | Unlocking evidence: opening doors to integrate real-world evidence into the treatment of MDR Gram-negative bacterial infections | Christian GISKE (SwedenESCMID-appointed chair), Beatrice GRABEIN (Germany) | **Welcome and Introduction**: Beatrice GRABEIN (Germany)<br>**Rral-world evidence (RWE) and me: what is RWE and why is it important to me in my daily role?**: David VAN DUIN (United States)<br>**Connecting the dots: leveraging RWE to optimise early appropriate therapy for improved patient outcomes**: Paula RAM�REZ (Spain)<br>**A mountain of RWE: robust data that support the value of ceftazimide-avibactam for the treatment of MDR Gram-negative bacterial infections**: David L. PATERSON (Singapore)<br>**Panel Discussion and Q&A**: Beatrice GRABEIN (Germany) |
| 13/04 | 08:30 - 10:00 | IS18 | Addressing diverse clinical needs in respiratory infections: choosing the appropriate test, in the right location, to best serve your patient population | Truls Michael LEEGAARD (NorwayESCMID-appointed chair), Adam THORNBERG () | **Welcome and Introduction**: Adam THORNBERG (Adam THORNBERG)<br>**Respiratory infection control and prevention: insights from daycare settings**: Enni SANMARK (Finland)<br>**Molecular point of care respiratory virus testing: operational experience from an Integrated Healthcare Network in Texas, United States**: Robyn OLNEY (Robyn OLNEY)<br>**Decision making and clinical implementation for syndromic respiratory testing**: Erin MCELVANIA (United States)<br>**Panel Discussion and Q&A**: Adam THORNBERG (Adam THORNBERG) |
| 13/04 | 08:30 - 10:00 | IS19 | Invasive fungal disease: navigating the risks, benefits and challenges of current practice | Roger BR�GGEMANN (NetherlandsESCMID-appointed chair), Patricia MUNOZ (Spain) | **Welcome and Introduction**: Patricia MUNOZ (Spain)<br>**Antifungal stewardship in a time of rising resistance**: Malgorzata MIKULSKA (Italy)<br>**Time is of the essence: the ICU perspective**: Robert KRAUSE (Austria)<br>**Addressing the crisis on our wards**: Tobias LAHMER (Germany)<br>**Interactive case series: recent experience with novel antifungal treatment**: Patricia MUNOZ (Spain)<br>**Panel Discussion and Q&A**: Patricia MUNOZ (Spain) |
| 13/04 | 08:30 - 10:00 | IS20 | Redefining preparedness: monitoring evolving pathogens and the changing epidemiology of STI's and HIV | Cecile BEBEAR (FranceESCMID-appointed chair), Anna Maria GERETTI (United Kingdom) | **Welcome and Introduction**: Anna Maria GERETTI (United Kingdom)<br>**Confidence for today, protection for tomorrow: how a global network of virus hunters is transforming healthcare by staying one step ahead**: Gavin CLOHERTY (United States)<br>**Speeding up diagnosis: community-based rapid testing for HIV, syphilis and viral hepatitis in Europe and Central Asia - challenges and opportunities**: Laura FERN�NDEZ L�PEZ (Spain)<br>**Introduction of Prep and DoxyPEP: what are the implications for HIV/STI testing?**: J�rgen ROCKSTROH (Germany)<br>**Panel Discussion and Q&A**: Anna Maria GERETTI (United Kingdom) |
| 13/04 | 08:30 - 10:30 | EW077 | New tools in acute bacterial infections and sepsis: from machine learning to precision medicine | Benjamin MCFADDEN (Australia), Rita MURRI (Italy) | **Differentiating acute infection, sepsis and sepsis mimics in the ED?**: Lisa MELLHAMMAR (Sweden)<br>**Machine learning for early recognition of sepsis**: Karsten BORGWARDT (Germany)<br>**How to avoid common mistakes in randomised clinical study design**: Yin MO (Singapore)<br>**Improved clinical trials in community-acquired pneumonia using precision medicine**: Lennie DERDE (Netherlands) |
| 13/04 | 08:30 - 10:30 | EW078 | Implementing metagenomics in my lab and mistakes to avoid | Hege Vangstein AAMOT (Norway), Claudio NEIDH�FER (Germany) | **Is metagenomics right for my lab?**: Paula M�LLING (Sweden)<br>**Understanding the experimental and certification aspects of metagenomics**: Mads ALBERTSEN (Denmark)<br>**Navigating tools, techniques, and procurement**: Basil Britto XAVIER (Netherlands)<br>**Setting realistic goals and outcomes for metagenomics integration**: Claire BERTELLI (Switzerland) |
| 13/04 | 08:30 - 10:30 | EW079 | New guidelines for management of brain infections | Jacob BODILSEN (Denmark), Kartika MAHARANI (Indonesia) | **Tuberculous meningitis: what can we learn from the first global guidelines?**: Joseph DONOVAN (Vietnam)<br>**WHO guidelines on bacterial meningitis: change of clinical practice?**: Matthijs BROUWER (Netherlands)<br>**ESCMID encephalitis guidelines 2024: what's new?**: Tom SOLOMON (United Kingdom)<br>**WHO guidelines for cryptococcal meningitis: success stories and barriers to implementation**: Nelesh GOVENDER (South Africa) |
| 13/04 | 08:30 - 10:30 | M7 | Faecal examination (eggs and cysts -advanced) | Debbie NOLDER (United Kingdom), Claire ROGERS (United Kingdom) |  |
| 13/04 | 08:30 - 10:30 | OS037 | Whole genome sequencing: tracking transmission and reservoirs in outbreaks | Eric CLAAS (Netherlands), Paul G. HIGGINS (Germany) | **From outbreaks to outcomes: Harnessing WGS for IPC in a high-risk paediatric setting**: Nathaniel STOREY (United Kingdom)<br>**Why do routine genome-oriented surveillance for Pseudomonas aeruginosa?**: Anca RATH (Germany)<br>**TreeTime estimation depicts transmission dynamics of clinical and environmental Pseudomonas aeruginosa from common reservoirs in healthcare environment through whole genome sequencing (WGS)**: �zge YETIS (United Kingdom)<br>**Understanding Serratia transmission during a neonatal ICU outbreak: A combined genotyping and risk factor analysis**: Kaisa JAAKKOLA (France)<br>**Genomic Insights into the Regional Transmission of KPC-Producing Bacteria: Clonal and Non-Clonal Plasmid Sharing**: Chaitra SHANKAR (United States)<br>**Genome-oriented analysis of the first outbreaks involving the novel Serratia sarumanii at a neonatal unit**: Anca RATH (Germany)<br>**Evaluating the Utility of Whole-Genome Sequencing to Optimise Infection Prevention and Control in a Hospital Setting: Findings from the GENOTIPE Study**: James PRICE (United Kingdom)<br>**Outbreak of Carbapenem-Resistant Acinetobacter seifertii in a Neonatal Intensive Care Unit: Genomic Characterization and Surveillance.**: Dariane PEREIRA (Brazil)<br>**Unveiling the Clonal Dynamics and transmission mechanism of Carbapenem-Resistant Klebsiella pneumoniae in the ICU environment**: Xinhong HAN (China)<br>**Survey of Infection Prevention staff perception of WGS integration into routine IPC practice**: Dorothy LING (Australia) |
| 13/04 | 08:30 - 10:30 | OS038 | Making fast for making better: AMR rapid diagnostics | Giulia DE ANGELIS (Italy), Onur KARATUNA (Sweden) | **Point of care rapid lateral flow antibiotic resistance test to detect carbapenem resistance in lower respiratory tract infections**: Julia ROGERS (United Kingdom)<br>**Evaluation of a new rapid Lateral flow immunoassay for the detection of DHA-producing Gram-negative bacteria**: Christian MOGUET (France)<br>**The NitroSpeed Taniborbactam NP test; easy detection of β-lactamase sensitivity to taniborbactam**: Otavio RARO (Switzerland)<br>**Rapid detection of β-lactamase-mediated resistance to aminopenicillins from urines.**: Patrice NORDMANN (Switzerland)<br>**Rapid detection of antibiotic resistance in direct urine samples**: Marit BOT (Netherlands)<br>**Next-Generation Utilizer Dipsticks for direct-from-sample phenotypic Antibiotic Susceptibility Testing in UTIs**: Emre ISERI (Sweden)<br>**Screening for ceftriaxone-resistant Neisseria gonorrhoeae with the Urogenital and Resistance kit (AusDiagnostic)**: Aymeric BRAILLE (France)<br>**Comparative evaluation of rapid antimicrobial susceptibility testing assays for Gram-negative bacteria from positive blood cultures**: Damiano SQUITIERI (Italy)<br>**Rapid detection of Carbapenemases directly from positive blood culture bottle: A tool for early shifting from empirical to targeted therapy**: Kanika CHAUDHARY (India) |
| 13/04 | 08:30 - 10:30 | SY072 | Tackling the emergence of dengue and other Aedes-borne diseases in Europe | Fernanda BOULOS (Brazil), Martin P. GROBUSCH (Netherlands) | **How dengue, chikungunya and zika virus disease became emerging threats to Europe**: Celine GOSSNER (Sweden)<br>**Surveillance of dengue in urbanised tropical regions**: Vincent Junxiong PANG (Singapore)<br>**Mosquito surveillance and control: opportunities and challenges**: David ROIZ (France)<br>**Tracking autochthonous arboviral infection**: Luisa BARZON (Italy) |
| 13/04 | 08:30 - 10:30 | SY073 | Proxy indicators: bridging the gap between surveillance and antimicrobial stewardship | Bhanu SINHA (Netherlands), Annelies VERBON (Netherlands) | **A broad spectrum of possibilities: spectrum scores as a unifying metric**: C�line PULCINI (France)<br>**Proxy indicators to estimate appropriateness of antibiotic prescriptions**: Diane ASHIRU-OREDOPE (United Kingdom)<br>**How to bridge the gap between surveillance and antimicrobial stewardship**: Mark G. J. DE BOER (Netherlands)<br>**Health economics, surveillance and antimicrobial stewardship**: Zhu NINA JIAYUE (United Kingdom) |
| 13/04 | 08:30 - 10:30 | SY074 | Difficile to treat: advanced management strategies in difficult to treat CDI | Fr�d�ric BARBUT (France), Kerrie DAVIES (United Kingdom) | **Severe CDI: when standard protocols fail**: Hynek BARTOS (Czech Republic)<br>**Therapies for complicated CDI**: Emma BISHOP (Australia)<br>**Recurrent CDI: Breaking the cycle**: Andrea MARINO (Italy)<br>**Live biotherapeutic products for Clostridioides difficile infection**: Simon GOLDENBERG (United Kingdom) |
| 13/04 | 08:30 - 10:30 | SY075 | Diphtheria: from re-emergence to vaccine strategies | Helena SETH-SMITH (Switzerland), Julie TOUBIANA (France) | **Diphtheria: from clinical picture to medical management**: Regina OLADOKUN (Nigeria)<br>**The epidemiology of diphtheria worldwide over the last half-century: more than one comeback**: Andreas HOEFER (Sweden)<br>**There's more than one toxigenic Corynebacterium: the current genomics landscape of diphtheria-associated strains**: Sylvain BRISSE (France)<br>**Diphtheria vaccination: a reappraisal**: Gayatri AMIRTHALINGAM (United Kingdom) |
| 13/04 | 08:30 - 10:30 | SY076 | AMR Surveillance in low resource countries: insights into clinical and policy translation | Kwame Ohene BUABENG (Ghana), H. Rogier VAN DOORN (Vietnam) | **New indicators in national monitoring and evaluation of AMR supported by improved data utilisation**: Direk LIMMATHUROTSAKUL (Thailand)<br>**Interdisciplinary investigation of the drivers and burden of AMR in urinary tract infections**: Stephen MSHANA (United Republic Of)<br>**A clinically-oriented AMR surveillance network: case-based surveillance and implementation**: Paul TURNER (Cambodia)<br>**National prescribing guidelines based on AMR surveillance data**: Vilada CHANSAMOUTH (Lao People's Democratic Republic) |
| 13/04 | 09:30 - 10:30 | EF041 | Contemporary diagnostic approaches for fungal infections | Ilse D. JACOBSEN (Germany) | **Evaluation of persistence of C. auris colonization in a cohort of patients discharged from a C. auris endemic area**: Martina BAVASTRO (Italy)<br>**A pilot study of digital retinal photography (DRP) and tele-ophthalmology of patients with candidemia.**: Cornelius CLANCY (United States)<br>**Epidemiology and diagnosis of Pneumocystis pneumonia : a 11 years-surveillance in France**: Alexandre ALANIO (France)<br>**Chronic pulmonary aspergillosis coexisting with pulmonary cystic echinococcosis: a global systematic review**: Aayush ADHIKARI (Nepal)<br>**Implementation and performance of a universal Mucorales PCR assay for diagnosis of mucormycosis**: Allison HAAS (United States)<br>**Blood cultures (BCs) contain populations of genetically diverse Candida strains that may differ in antifungal resistance and tolerance**: Cornelius CLANCY (United States)<br>**Clinical validation of a urinary antigen test as an aid to diagnose invasive aspergillosis in hematology patients**: Yuri VANBIERVLIET (Belgium)<br>**Genomic epidemiology of Greek Candida auris clinical isolates**: Maria SIOPI (Greece) |
| 13/04 | 09:30 - 10:30 | EF042 | Prosthetic and device-associated infections | Marjan WOUTHUYZEN-BAKKER (Netherlands) | **Case series of gluteal Apophysomycosis post intramuscular injection**: Ramakrishnan SIVASANKARAN (India)<br>**MIGRATING mesh - an unusual cause of pyogenic liver abscess**: Martine CARIS (Netherlands)<br>**Ceftaroline salvage monotherapy: successful treatment of a cerebrospinal fluid drain infection caused by a multidrug-resistant Staphylococcus epidermidis strain**: Maria Daria DI TRAPANI (Italy)<br>**Timeline of early infections post porcine xenothymokidney transplant**: Henry NEUMANN (United States)<br>**Invasive Non-tuberculous mycobacteria Infection in children undergoing Cardiac Surgery at the specialized Cardiology Hospital of Peshawar**: Maria KHAN (Pakistan)<br>**Use of multiplex PCR assay analysis in patients with suspected implant-based breast reconstruction infection: a single center experience**: Alberto PAGOTTO (Italy)<br>**PET CT controls and Dalbavancin therapeutic drug monitoring can help guiding Dalbavancin treatment duration of complicated cardiovascular infections**: Christina KUJAT (Germany)<br>**A complex case of pelvic bone infection caused by carbapenem-resistant Acinetobacter baumanii successfully treated with eravacycline**: Manuel ZAGARRIGO (Italy)<br>**Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?**: Marco BONGIOVANNI (Switzerland) |
| 13/04 | 09:30 - 10:30 | KN080 | Infections after solid organ transplantation: past, present and future | Nina KHANNA (Switzerland), Priscilla RUPALI (India) | ****: Jay FISHMAN (United States) |
| 13/04 | 09:30 - 10:30 | MEET72 | Respiratory Viruses Study Group open meeting (ESGREV) | Roy CHEMALY (United StatesESCMID official), Paraskevi C. FRAGKOU (GreeceESCMID official), Siran KESKE (T�rkiyeESCMID official), Barbara RATH (FranceESCMID official), Chrysanthi SKEVAKI () |  |
| 13/04 | 09:30 - 10:30 | MEET73 | Public Health Microbiology Study Group open meeting (ESGPHM) | Aura AGUIRRE-BELTRAN (DenmarkESCMID official), Titia M. KORTBEEK (), Marc J. STRUELENS (SwedenESCMID official), Olivier VANDENBERG (BelgiumESCMID official), Guido WERNER (GermanyESCMID official) |  |
| 13/04 | 10:00 - 10:20 | IPT12 | Isothermal recombinase polymerase (RPA) reagents for diagnostic assay development and research |  | **Isothermal recombinase polymerase (RPA) reagents for diagnostic assay development and research**: Agne ALMINAITE (Lithuania) |
| 13/04 | 10:30 - 10:50 | IPT13 | Fosmanogepix - a novel clinical phase 3 stage antifungal agent |  | **Fosmanogepix - a novel clinical phase 3 stage antifungal agent**: Marc ENGELHARDT (Switzerland) |
| 13/04 | 10:30 - 11:30 | MEET74 | PK/PD of Anti-Infectives Study Group open meeting (EPASG) | Birgit KOCH (NetherlandsESCMID official), Cornelia LANDERSDORFER (AustraliaESCMID official), Sonia LUQUE (SpainESCMID official), Sebastian WICHA (GermanyESCMID official), Markus ZEITLINGER (AustriaESCMID official) |  |
| 13/04 | 10:45 - 11:45 | FIPL3 | Fireplace: Infections after Solid organ transplantation: past, present and future | Nina KHANNA (Switzerland), Priscilla RUPALI (India) | ****: Jay FISHMAN (United States) |
| 13/04 | 11:00 - 11:20 | IPT14 | Drive for discovery: the long road for new uUTI antibiotic approvals |  | **Drive for discovery: the long road for new uUTI antibiotic approvals**: Judith ABSALON (United States) |
| 13/04 | 11:00 - 12:00 | EF049 | Sometimes it's hard to be a woman | Debora KONOPNICKI (Belgium) | **Interleukins 17 and 18: Key players in Cervical Cancer Progression in Indian Population**: Priyal GUPTA (India)<br>**Risk evaluation of iatrogenic transmission of Human Papillomavirus (HPV) during gynaecological procedures**: Beatrice CASINI (Italy)<br>**Rubella screening in pregnancy – Slovakian one-center retrospective analysis around COVID-19 pandemic**: Zuzana PARALICOV� (Slovakia)<br>**The impact of maternal influenza infection and vaccination during pregnancy on birth outcomes**: Balasubramani GOUNDAPPA (United States)<br>**Use of valaciclovir therapy during pregnancy for the prevention of congenital cytomegalovirus infection: a monocentric experience**: Giulia LORENZETTI (Italy)<br>**Multi-systemic long-term sequelae following SARS-CoV-2 Omicron infection in pregnancy: a population-based cohort study**: Yong Yi TAN (Singapore)<br>**The Impact of OAS1 rs4766664 and OAS3 rs10735079 Polymorphisms on the Clinical Course of COVID-19 in Pregnant Women**: Sema KIRIK YILMAZ (T�rkiye)<br>**Sex-stratified analysis of T cell activation, exhaustion, proliferation and HIV reservoir among PLWH**: Letizia SANTINELLI (Italy) |
| 13/04 | 11:00 - 12:00 | EF050 | Expanding MALDI-TOF applications | Belen RODRIGUEZ-SANCHEZ (Spain) | **Application of MALDI-TOF Mass Spectrometry and Machine Learning for the Detection of Vancomycin-Resistant Enterococcus faecium**: Maria S�NCHEZ CUETO (Spain)<br>**Early detection of ampicillin susceptibility in Enterococcus faecium with MALDI-TOF MS and machine learning**: Thomas PICHL (Germany)<br>**Rapid antifungal resistance prediction based on MALDI TOF mass spectrometry**: Diane DUROUX (Switzerland)<br>**Rapid prediction of fluconazole resistance by machine-learning analysis of Candida parapsilosis MALDI-TOF mass profiles**: Carlotta MAGRI (Italy)<br>**Optimizing pretreatment for MALDI-TOF MS: Evaluating the dispersion method for filamentous fungal identification**: Run HUANG (China)<br>**Rapid detection of colistin resistance in Acinetobacter baumannii by a MALDI-TOF MS-based assay**: Ekin KIRBAS (T�rkiye)<br>**Discrimination of clinical Pseudomonas strains at the species level using a large-scale genomically predicted protein mass database with MALDI-MS**: Kanae TERAMOTO (Japan)<br>**Automatic differentiation of Clostridioides difficile ribotypes using MALDI-TOF MS and web-based classification models**: Mario BLAZQUEZ SANCHEZ (Spain)<br>**Identification of sepsis-causing bacteria using shotgun proteomics**: Lisa MEEKES (Netherlands) |
| 13/04 | 11:00 - 12:00 | EF051 | The enemy of my enemy: From jumbo phages to cocktails for difficult to treat infections | Paul G. HIGGINS (Germany) | **Anti-K2 recombinant phage depolymerases as anti-virulence agents against hypervirulent Klebsiella pneumoniae**: M�lanie ROCH (Switzerland)<br>**Jumbo Klebsiella bacteriophage demonstrates efficient multidrug-resistant Klebsiella pneumoniae killing and significant clinical potential**: Yang LIU (Singapore)<br>**A new phage cocktail targeting at Klebsiella pneumoniae**: Xin YIN (China)<br>**Bacteriophages against pulmonary infection and colonization of the gut by multidrug-resistant Klebsiella pneumoniae in murine models**: Anni-Maria �RM�L�-TIZNADO (Sweden)<br>**A novel broad-spectrum phage cocktail effictive for carbapenem resistant Acinetobacter baumannii of capsular type 104/2/7 in vitro**: Li WEI (China)<br>**Proteomic and Genomic Characterization of a Novel Bacteriophage of a New Genus Infecting Pseudomonas aeruginosa**: Sezin UNLU (T�rkiye)<br>**Phages as innovative adjuvants of antibiotics therapy against S. aureus and P. aeruginosa in the context of Cystic Fibrosis**: Antoine GLORIEUX (Belgium)<br>**Evaluation of bacteriophages against Staphylococcus aureus strains isolated from orthopaedic infections**: Sheetal PATPATIA (Finland)<br>**Anti-Staphylococcus aureus phages: assessing the risk of bacterial resistance emergence through selective pressure**: Matthieu DEGREZE (France) |
| 13/04 | 11:00 - 12:00 | FO090 | European CM/ID exam: going forward | Siri GOEPEL (Germany) | **View from medical microbiology**: Maeve DOYLE (Ireland)<br>**view from infectious diseases**: Eoghan DE BARRA (Ireland)<br>**view from trainees (TAE)**: Christian KRAEF (Denmark)<br>**European exam - how to prepare?**: Annelies VERBON (Netherlands) |
| 13/04 | 11:00 - 12:00 | KN081 | The new frontiers in antimicrobial stewardship | Jose Ramon PANO-PARDO (Spain), Jeroen SCHOUTEN (Netherlands) | ****: Karin THURSKY (Australia) |
| 13/04 | 11:00 - 12:00 | LB002 | Investigation of intriguing outbreaks | Ana Raquel FREITAS (Portugal), Marc J. STRUELENS (Sweden) | **AI-driven live cough rate tracking for public health surveillance**: Mikael K�GEB�CK (Sweden)<br>**Evolving cluster of severe infective endocarditis with non-toxigenic C. diphtheriae amongst people experiencing homelessness and substance misuse in the UK**: Rebecca CORDERY (United Kingdom)<br>**Molecular surveillance of artemisinin and sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Uganda: results of ERASE study**: Mariangela L'EPISCOPIA (Italy)<br>**Investigation of an international pseudo-outbreak involving Paraburkholderia fungorum blood culture contamination**: Jacob MORAN-GILAD (Israel) |
| 13/04 | 11:00 - 12:00 | ME088 | Global AMR Policy after UNGA: what do we do now! |  | ****: Gisela ROBLES AGUILAR (United Kingdom), Mike SHARLAND (United Kingdom) |
| 13/04 | 11:00 - 12:00 | ME089 | How to teach Medical Mycology |  | ****: Katrien LAGROU (Belgium), Mihai MARES (Romania) |
| 13/04 | 11:00 - 12:00 | OS043 | Navigating disinfection challenges: resistance, outbreaks, and efficacy | Hillary A. CRADDOCK (Ireland), Stephanie J. DANCER (United Kingdom) | **Prolonged disinfectant exposure impacts the antimicrobial resistance of healthcare-associated microorganisms: a systematic review**: �ngela Rita FERNANDES (Portugal)<br>**Sink-associated outbreak of verona integron-encoded metallo-??-lactamase-producing carbapenem-resistant Pseudomonas aeruginosa in a Dutch intensive care unit**: Marieke VAN DEN BOS  KROMHOUT (Netherlands)<br>**Carbapenemase-producing Enterobacterales outbreak control by replacement of toilets or long-term disinfection? A real-life experience.**: Anne Line ENGSBRO (Denmark)<br>**Tolerance of Klebsiella pneumoniae biofilms to disinfection with peracetic acid**: Mardjan ARVAND (Germany)<br>**Bringing balance to the formulation: disinfection efficacy and material compatibility**: Jake JENNINGS (United Kingdom) |
| 13/04 | 11:00 - 12:00 | OS044 | Unusual presentations of unusual parasites | Emmanuel BOTTIEAU (Belgium), Marcelo Victor RADISIC (Argentina) | **Atypical neonatal cutaneous myiasis: a diagnostic challenge mimicking pustular rash in a resource-limited setting**: Doris EKWEM AMARACHI (Uganda)<br>**An itchy awakening due to Dermanyssus infestation**: Jacques SEVESTRE (France)<br>**Uterine Myiasis: A Rare Case of External Genitourinary Myiasis**: Robert L. JOHNSON (United States)<br>**Neurognathostomiasis Presenting with Cerebral Venous Sinus Thrombosis: A case report of rare clinical manifestation.**: Chatrawee NORSUNGNERN (Thailand)<br>**If at first, you don't succeed… Treatment-resistant Fascioliasis: case report**: Winifred GARR (United Kingdom) |
| 13/04 | 11:00 - 12:00 | OS045 | Social behavioural dynamics of antibiotic use and AMR | Sonia LEWYCKA (Vietnam), Filippo MEDIOLI (Italy) | **Investigating the Knowledge, Attitudes, and Practices around Antimicrobial Resistance and Stewardship Among Syrian Healthcare Professionals: A Cross-Sectional Survey**: Aula ABBARA (United Kingdom)<br>**Gamified Intervention to Enhance Antimicrobial Stewardship: Improving Knowledge and Practices on the Rational Use of Antimicrobials Among Medicines and Therapeutics Committee Members ???**: Sumana MAHADEVAIAH (India)<br>**Healthcare providers' perspectives on antibiotic use and resistance in pregnancy, childbirth, and children under five years of age across four levels of hospitals in Lao PDR, 2024**: Sonephet VANTAVA (Lao People's Democratic Republic)<br>**High gender gap in female labour force participation and reduced gender inequality linked to high antibiotic consumption: Evidence from a global analysis**: Divija SAMRIA (India)<br>**Gender gaps in knowledge of antibiotics and antimicrobial resistance: Evidence from India**: Deepshikha BATHEJA (India) |
| 13/04 | 11:00 - 12:00 | OS046 | Vaccines and prophylaxis against respiratory viral infections | Ana ATTI (United Kingdom), Sophie SCHNEITLER (Germany) | **Public health impact of universal prophylaxis with nirsevimab for prevention of infant hospitalizations due to respiratory syncytial virus. Full 2023-24 season analysis of the NIRSE-GAL study (www.nirsegal.es/en)**: Federico MARTIN�N-TORRES (Spain)<br>**Relative effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trial**: Katrine FELDBALLE BERNHOLM (Denmark)<br>**Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses**: Spyros CHALKIAS (United States)<br>**Effectiveness of RSV vaccine in lung transplant recipients: neutralizing antibody response against reference and seasonal strains**: Neta SHIRIN (Israel)<br>**Novavax investigational COVID-19 Influenza Combination nanoparticle vaccine phase 2 study safety evaluation**: Chijioke BENNETT (United States) |
| 13/04 | 11:00 - 12:00 | OS047 | Clinical studies in UTI | Iva BUTIC (Croatia), Paul Christoffer LINDEMANN (Norway) | **Short versus long antibiotic treatment for pyelonephritis and complicated UTIs: an updated systematic review and meta-analysis of RCTs**: Itay ZAHAVI (Israel)<br>**Antibiotic treatment duration of complicated urinary tract infection patients in Europe: results from the Ecraid POS-cUTI study**: Chantal J.A.R. KATS (Netherlands)<br>**Prevalence and impact of multidrug resistance in a cohort of patients admitted to emergency department for urinary tract infections: the UTILITY study, a prospective multicentre study**: Lorenzo ONORATO (Italy)<br>**Weekly sequential antibioprophylaxis for UTI in neurogenic bladder**: Ruxandra CALIN (France)<br>**Evidence for the duration of antibiotic therapy for chronic bacterial prostatitis: a systematic review**: Laura CORDES (Switzerland) |
| 13/04 | 11:00 - 12:00 | OS048 | Complexities of infections in solid organ transplantation | Silvia CORCIONE (Italy), Monica SLAVIN (Australia) | **Solid Organ Transplants from donors with positive blood cultures: watch out for carbapenem-resistant Enterobacterales**: Andrea CONA (Italy)<br>**Risk factors for carbapenem-resistant Enterobacteriaceae infection after orthotopic liver transplant in a large cohort of pre-transplant CRE carriers**: Matteo RINALDI (Italy)<br>**Serologic follow up of solid organ transplant recipients who receive organs from syphilis seropositive donors.**: Oscar FERNANDEZ GARCIA (Canada)<br>**Prophylaxis strategies and risk of cytomegalovirus in solid organ transplant recipients**: Anja DAHL (Denmark)<br>**Burden of non-microbiologically confirmed infections in solid organ transplant recipients**: Ming ZOU (Switzerland) |
| 13/04 | 11:00 - 12:00 | SY082 | How to address anti-science in our community? | Tuba DAL (T�rkiye), Tyra Grove KRAUSE (Denmark) | **The rise of anti-science: lessons for the future scientist**: Marion KOOPMANS (Netherlands)<br>**Open science for public trust**: Lisa HANSEN (Canada) |
| 13/04 | 11:00 - 12:00 | SY083 | Lyme neuroborreliosis: challenges in diagnosis and treatment | Alexandra MAILLES (France), Joanna Maria ZAJKOWSKA (Poland) | **Challenges in diagnosis of Lyme neuroborreliosis**: Rick DERSCH (Germany)<br>**Challenges in treatment of Lyme neuroborreliosis**: Anne Marit SOLHEIM (Norway) |
| 13/04 | 11:00 - 12:00 | SY084 | Sleeping sickness and Chagas: a tale of the two trypanosomes | Hanne BREKKE (Norway), Irene LOSADA GALVAN (Spain) | **Human African Trypanosomiasis: recent diagnostic and medical practices**: Jean-Mathieu BART (Guinea)<br>**American Trypanosomiasis: Diagnosis, screening and management**:  TBA (TBA) |
| 13/04 | 11:00 - 12:00 | SY085 | Diagnosing the undiagnosed fraction: the final step towards viral hepatitis elimination | Mojca MATICIC (Slovenia), Snjezana ZIDOVEC LEPEJ (Croatia) | **Role of reflex testing strategies in identifying patients with chronic viral hepatitis**: Oana SANDULESCU (Romania)<br>**Management and elimination of hepatitis in hard-to-reach persons**: Suda TEKIN (T�rkiye) |
| 13/04 | 11:00 - 12:00 | SY086 | Impact on including a measure of viability in molecular diagnostic tests | Fusun CAN (T�rkiye), Denise O'SULLIVAN (United Kingdom) | **Viability markers in support of development of Chlamydia screening recommendations**: Petra WOLFFS (Netherlands)<br>**Measuring viability to improve the correlation of AMR markers and clinical outcomes in Neisseria gonorrhoeae**: Tatum MORTIMER (United States) |
| 13/04 | 11:00 - 12:00 | SY087 | Innovating antimicrobial drug discovery and host-pathogen interaction studies using chemical biology | Laurent POIREL (Switzerland) | **Bacterial PROTACs: Do proteolysis-targeting degraders represent a viable strategy for new antimicrobials?**: Morreale FRANCESCA ESTER (United Kingdom)<br>**Activity-based protein profiling of bacterial pathogens: new enzymes and their functions at the host-microbe interface**: Christian Stephan LENTZ (Norway) |
| 13/04 | 11:30 - 11:50 | IPT15 | From dysbiosis to detection: exploring the impact of vaginal microbiome testing on reproductive success |  | **From dysbiosis to detection: exploring the impact of vaginal microbiome testing on reproductive success**: Arne MATERNA (Denmark),  TBA (TBA) |
| 13/04 | 12:00 - 12:20 | IPT16 | The need for rapid diagnostics in sepsis management using innovative OnePCR point of care |  | **The need for rapid diagnostics in sepsis management using innovative OnePCR point of care**: Priyadarshini PANDE (France) |
| 13/04 | 12:00 - 13:30 | PS011 | 02a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention) |  | **Impact of fluoroquinolone exposure on the diagnosis and prognosis of tuberculosis in immunocompromised patients: a propensity-score matched, competing risk analysis**: Sung-Woon KANG (Republic Of)<br>**Whole-genome sequencing and phenotypic DST of bedaquilin, delamanid, proteomanid and linezolid in drug-resistant Mycobacterium tuberculosis in South Korea**: Hee Joo LEE (Republic Of)<br>**Safety, tolerability and pharmacokinetics of single and multiple ascending doses and food-effect of MRX-5 tablets in healthy adult subjects**: Huahui YANG (China)<br>**Modulation of RISK-3 signature in patients at different tuberculosis (TB) stages enrolled in a low-TB endemic country**: Elisa PETRUCCIOLI (Italy)<br>**Comparison of high-frequency ultrasound and contrast computed tomography for detection of spleen micro-abscesses in disseminated mycobacterial infections**: Francesca CATANIA (Italy)<br>**Non-tuberculous and tuberculous Mycobacteria prevalence and drug resistance in Italian and foreign subjects**: Sara CALDRER (Italy)<br>**Diagnostic utility of blood cultures and myelocultures for non-tuberculous mycobacteria infections: a retrospective study in a Portuguese tertiary hospital**: Sara MAGALH�ES (Portugal)<br>**Crossroads of care: TB trends among Italians and migrants in a tertiary hospital in northern Italy**: Luca ROSSI (Italy)<br>**Clinical significance of nontuberculous mycobacteria isolates in a Chinese general hospital**: Yumeng YAO (China)<br>**Secular trends in clinical features and outcomes of peritoneal tuberculosis**: Sandra P�REZ-RECIO (Spain)<br>**Genetic diversity of Mycobacterium bovis BCG clinical isolates from immunocompromised patients with BCG infections**: Suwatchareeporn ROTCHEEWAPHAN (Thailand)<br>**Evaluating the performance of the BACES model in a Dutch cohort with nontuberculous mycobacterial pulmonary disease**: Arthur LEMSON (Netherlands)<br>**Can the BACES score predict clinical outcomes in a Dutch cohort with nontuberculous mycobacterial pulmonary disease?**: Arthur LEMSON (Netherlands)<br>**Tuberculosis infection progression among pregnant women with HIV at high risk of tuberculosis: a sentinel screening study at three Ugandan health facilities**: Ronald OLUM (Uganda)<br>**Management of mycobacterial infections: experience with amikacin use in OPAT at NHS GGC**: Awilly CHOFLE (United Kingdom)<br>**Evaluation of clinical performances of the PATHFAST TB Lam Ag assay, a new diagnostic test for tuberculosis**: Theo FOUCHET (France)<br>**Early acquisition of long-term memory and decline of cytotoxic CD8+ T-cells subpopulations in blood as biomarkers of tuberculosis treatment efficacy in human**: Olivier BAHUAUD (France)<br>**Extrapulmonary tuberculosis: still a persistent issue!**: Rym ABID (Tunisia)<br>**Efficacy of rifapentine plus moxifloxacin vs standard of care for pulmonary tuberculosis: a systematic review and meta-analysis**: Taniela MARLI BES (United States)<br>**Assessment of demographic characteristics, clinical profiles, laboratory findings, and outcome of CNS tuberculosis among paediatric patients in a tertiary care hospital in Bangladesh**: Sarah ALAM (Bangladesh)<br>**Defining drug resistance beyond rifampicin: evaluation of Xpert MTB/XDR assay directly from cerebrospinal fluid (CSF) samples in patients of tuberculous meningitis (TBM)**: Kusum SHARMA (India)<br>**Inhalable statin-encapsulated gelatin microsphere as a host targeted strategy to inhibit matrix metalloproteinases in tuberculosis pathogenesis**: Agrim JHILTA (India)<br>**In-hospital and 90-day post-discharge outcomes in central nervous system tuberculosis: a prospective observational study**: Samarth BHAT K S (India)<br>**Pulmonary and extrapulmonary tuberculosis at an urban setting in eastern India during 2016 to 2023**: Sidhartha GIRI (India)<br>**Time to positivity correlates with treatment initiation and disease severity in patients with Mycobacterium avium-complex in sputum culture**: Alice AXINDER (Sweden)<br>**Detection of cross-border M. tuberculosis clusters using an online cloud genetics processing platform**: Jeremy WESTHEAD (United Kingdom)<br>**Predictors of multidrug-resistant tuberculosis in rural district of Pakistan: a case-control study, 2024**: Muhammad Asif SYED (Pakistan)<br>**The role of lipid biomarkers in inflammatory and mortality in tuberculosis patients**: Oguzhan ACET (T�rkiye)<br>**Evaluation of Mycobacterium tuberculosis derived cell-free DNA (CF-DNA) based multi-targeted real-time PCR (MRTPCR) from cerebrospinal fluid (CSF) samples for diagnosis of tuberculous meningitis (TBM)**: Ananya SHARMA (India)<br>**Improved prediction of bedaquiline resistance from genetic data using automatically-built catalogues**: Adlard ADLARD (United Kingdom)<br>**Analysis of clinical impact of the coronavirus disease (COVID-19) pandemic on the quality of pulmonary tuberculosis management with national reimbursement data**: Young Ah KIM (Republic Of)<br>**Initiation and completion of latent tuberculosis treatment in healthcare workers across two hospital sites in Ireland**: Daragh MCGEE (Ireland)<br>**Routine investigations for tuberculosis on bronchoalveolar fluid lavage in a low-incidence setting: is it worth it?**: Chiara SEPULCRI (Italy)<br>**Performance of a novel dual marker RT-qPCR-based whole-blood test for improved detection of M. tuberculosis infection**: Franziska Maria KANIS (Germany)<br>**Preliminary results from Europe-wide survey “EURO-SURVERY TB” on adjunctive surgical treatment of pulmonary tuberculosis**: Raja IDRIS (Germany)<br>**Unmasking hidden coinfections: a breakthrough real-time PCR approach for detecting and differentiating tuberculosis and Mycobacterial strains**: Henar ALONSO-EZCURRA (Spain)<br>**Evaluation of trace result from Xpert MTB/RIF ultra in a low-burden tuberculosis area**: Marc GORDO-BAST� (Spain)<br>**Predicting development of tuberculosis disease by stratifying T-SPOT.TB results: a retrospective cohort study of diagnostic accuracy among 8,544 individuals**: Ole SKOUVIG PEDERSEN (Denmark)<br>**Evaluation of Truenat drug chips directly from clinical samples for detection of  XDR, pre-XDR, and MDR in patients of extrapulmonary tuberculosis(EPTB) from north India**: Vijeta PATIAL (India)<br>**CXCL-9 and CXCL-10 as potential biomarkers for tuberculosis severity in children**: Martina DI GIUSEPPE (Italy)<br>**The effect on tuberculosis on lung function: a case-control study**: Emma Elisabeth POULSEN (Denmark)<br>**Assessment of in vitro efficacy of three-antibiotics combinations against Mycobacterium abscessus**: Julie CHARLES (France)<br>**Hepatic adverse reactions in anti-tuberculosis treatment**: Hanen BEN HMIDA (Tunisia)<br>**Safety and efficacy of four-month short course regimen in low risk active tuberculosis-a multicentre randomised controlled trial**: Susan Shin-Jung LEE (China)<br>**Identification of differentially expressed transcriptional profiling from active tuberculosis infection to healthy children**: Fang XU (China)<br>**Risk of tuberculosis among patients with inflammatory bowel disease and inflammatory rheumatic disease treated with biological agents in Denmark: a nationwide population-based cohort study**: Christian KRAEF (Denmark)<br>**Characterising Mycobacterium tuberculosis resistance mechanisms to ganfeborole and monitoring drug resistance during Phase 2a clinical trial**: Ana YEPES GARCIA (Spain)<br>**Decoding isoniazid resistance: a comprehensive study of mutation patterns and diagnostic insights in tuberculosis**: Srishty Sananda HOTA (India)<br>**Delayed TB diagnostics and treatment in Ukraine due to the war and preceding COVID-19 epidemics**: Olha KONSTANTYNOVSKA (Ukraine)<br>**Targeted next-generation sequencing: a promising approach in the diagnosis of Mycobacterium tuberculosis and drug resistance**: Fang You YU (China)<br>**HDAC1 mediated acetylome landscape controls mycobacteria-specific T cell memory responses during tuberculosis**: Ashima BHASKAR (India)<br>**Direct identification of Mycobacterium tuberculosis and eight dominant non-tuberculous mycobacterial using a multiplex molecular point-of-care panel**: Qiaolian YI (China)<br>**Nontuberculous mycobacterial diagnosis codes: a good proxy of NTM disease?**: Pernille Grand MOESTRUP (Denmark)<br>**Treatment outcomes in patients with M. abscessus lung infection: national multicentre study of the IRENE project**: Alberto MATTEELLI (Italy)<br>**From fish fin injury to Mycobacteroides abscessus: precision diagnosis in a complex case using shotgun metagenomics**: Ummu Afeera ZAINULABID (Malaysia)<br>**Tuberculosis infection and tuberculosis disease in household contacts of newly diagnosed multidrug-resistant tuberculosis patients**: Sandeep RAO KORDCAL (India)<br>**Utility of Xpert MTB/XDR in GeneXpert MTB/RIF positive extrapulmonary tuberculosis (EPTB) samples: a step towards precision in EPTB management**: Rohit KUMAR (India)<br>**A new multiplex real-time PCR test for the diagnosis of TB and NTM patients**: Federica SORELLA (Italy)<br>**Assessment of isoniazid preventive therapy and barriers of implementation among contacts of pulmonary tuberculosis patients in Raipur district**: Ashish SINHA (India)<br>**TBSure: survey of paediatric TB management practices in the Europe region**: Onya OPOTA (Switzerland)<br>**Epidemiological profile and clinical presentation of cutaneous tuberculosis: systematic review**: Jaime David ACOSTA ESPA�A (Ecuador)<br>**No evidence of nation-specific ecotypes for Mycobacterium avium in Northern Europe**: Ingrid VAN WEERDENBURG (Netherlands)<br>**Asymptomatic tuberculosis: a new challenge**: Marina TADOLINI (Italy)<br>**Bacillus Calmette-Gu�rin (BCG) infection following intravesical BCG administration for bladder cancer: a decade nationwide French study**: Emmanuel LAFONT (France)<br>**Inpatient versus outpatient pulmonary tuberculosis management in Italy: a nationwide survey**: Marina TADOLINI (Italy)<br>**Rapid detection of isoniazid and fluoroquinolone resistance in Mycobacterium tuberculosis using the Xpert MTB/XDR assay in a low TB and low MDR-TB prevalence setting**: H�ctor MORENO (Switzerland)<br>**Increased isolation of Mycobacterium lentiflavum along the years: is it the new Mycobacterium avium?**: Alejandra ARENAS (Spain)<br>**Empirical anti-tuberculous medications in adults with suspected tuberculous meningitis: a retrospective cohort study in Mashhad, Iran**: Fereshteh SHEIBANI (Islamic Republic Of)<br>**Molecular diagnosis of mycobacteria: identification of tuberculous and non-tuberculous species in 733 clinical samples**: Andre DOI (Brazil)<br>**Mycobacterium tuberculosis DNA detection in formalin-fixed paraffin-embedded tissue using digital PCR: a proof-of-concept study**: Billie VELAPATI�O (Canada)<br>**Adjuvant use of TNF-alpha antagonists for TB meningitis: RNA signalling and clinical experience**: Arjan VAN LAARHOVEN (Netherlands)<br>**Comparative evaluation of Xpert, Xpert Ultra, and Truenat for the diagnosis of tuberculous meningitis in central India**: Anvita GUPTA MALHOTRA (India)<br>**Evaluation of comprehensive drug resistance prediction using nanopore targeted NGS reagent with MDR-TB isolates in Japan**: Akiko TAKAKI (Japan)<br>**Epidemiology of non-tuberculous Mycobacteria in Denmark: seven decades of clinical occurrence**: Xenia Emilie Sinding IVERSEN (Denmark)<br>**Clinical management of trace results in a rapid molecular TB diagnostic assay among presumptive cases in Lebanon, a low-TB burden country**: Marianne ANTAR (Lebanon)<br>**Mapping tuberculosis diversity in Lebanon: a pioneering baseline study using whole genome sequencing**: Marianne ANTAR (Lebanon)<br>**Non-tuberculous mycobacterial disease at a tertiary care centre in high tuberculosis and HIV burden setting: a retrospective study**: Saskia JANSSEN-LE ROUX (Netherlands)<br>**Complicated CNS tuberculosis: a retrospective cohort study**: Abhinav SENGUPTA (India)<br>**EndTB-Q trial for pre-XDR-TB: impact of baseline tuberculosis disease extent on efficacy of a shortened, stratified-medicine treatment strategy**: Lorenzo GUGLIELMETTI (France)<br>**Definition of SNPs limit range for unknown non-tuberculous Mycobacteria genomic investigation**: Giulia GATTI (Italy)<br>**Evaluation of bioline TB Ag MPT64 for detecting Mycobacterium tuberculosis complex in acid-fast bacilli-positive cultures**: Jung-Ah KIM (Republic Of)<br>**Targeted next-generation sequencing: a promising approach for Mycobacterium tuberculosis detection and drug resistance in paucibacillary clinical samples**: Wenting JIN (China)<br>**Comparison of three different protocols for identification of nontuberculous mycobacteria species from liquid media by matrix-assisted laser desorption/ionisation-time-of-flight mass spectrometry**: Nezihat Desen B�Y�KSOY (T�rkiye)<br>**Treatment of latent tuberculosis infection: obstacles to reach the goal: the TIBER study, preliminary results**: Carlo PALLOTTO (Italy)<br>**Development and validation of a novel scoring system to differentiate between tuberculous and non-tuberculous pleural effusion**: Atish MOHAPATRA (India)<br>**Molecular characteristics and drug susceptibility of aminoglycosides in multidrug-resistant tuberculosis**: Yinjuan GUO (China)<br>**How to manage drug-sensitive tuberculosis when rifampicin cannot be used? A survey by the study group on Mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine**: Amina ZAFFAGNINI (Italy)<br>**Phenotypic and genotypic antimicrobial susceptibility testing of Mycobacterium avium complex and Mycobacterium kansasii**: Marina VICENTE CIURANS (Spain)<br>**TBM PR-IRIS: a UK wide retrospective cohort study of paradoxical reaction in central nervous system tuberculosis**: Emma CARTER (United Kingdom)<br>**LeuRS-targeting prodrug, MRX-5, expresses anti-Mycobacterium abscessus activity**: Anqi LI (China)<br>**Evaluation of the clinical performance of an enzyme-linked immunosorbent assay and an immunochromatographic lateral flow assay for the detection of Mycobacterium tuberculosis infection in human plasma samples**: Ulrich EIGNER (Germany)<br>**Study of the antimicrobial and antibiofilm activity of eugenol, gallic acid and ellagic acid in Mycobacterium avium complex clinical isolates**: Sara BATISTA ARNAU (Spain)<br>**Accelerated and refined genomic analysis, coupled with epidemiological interventions, to optimise tuberculosis transmission control**: Sheri M SALEEB (Egypt)<br>**Treatment outcomes in Mycobacterium simiae pulmonary disease: a retrospective multicentre cohort study**: Anat ARBEL (Israel)<br>**Rapidly and reproducibly building a catalogue of resistance-associated variants using 46,800 M. tuberculosis samples with genomes and DST data**: Philip FOWLER (United Kingdom)<br>**Pro-angiogenic growth factors and matrix metalloproteinases are key drivers of dysregulated angiogenesis in tuberculosis with diabetes mellitus**: Yi Hao WONG (Singapore)<br>**The microbiological and clinical complexity of infections in patients with treatment-refractory Mycobacterium avium complex lung disease**: Tim DOYLE (United States)<br>**Accelerating Mycobacterium abscessus drug discovery with novel double-reporter strains**: T�nia SILVA (Portugal)<br>**Longitudinal assessment of health-related quality of life in untreated Mycobacterium abscessus pulmonary disease: interim analysis from the Singapore FORMaT trial observational cohort**: Stephanie SUTJIPTO (Singapore)<br>**Infliximab or inflixi-mad? Disordered approaches to pre-immunosuppressive therapy latent TB infection screening**: Miles EDWARDS (United Kingdom)<br>**Pangenome and CNV analysis of clinical Mycobacterium tuberculosis isolates identifies perturbations in phage immunity genes linked to drug resistance and lineage types**: Nikhil BHALLA (India)<br>**Mortality and causes of death in patients with Mycobacterium avium complex isolates through 28 years**: Victor N�STHOLT DAHL (Denmark)<br>**Platelets at tuberculomas worsen CNS-TB by inducing PAD-driven NETs and PI3K/Akt-driven MMP-1 release: data from human, murine and 3D cellular models**: Hyeyoung LEE (Singapore)<br>**Development of potential and cost-effective isoniazid-phytochemical hybrid drugs using an integrated combinatorial approach against Mycobacterium tuberculosis**: Shasank Sekhar SWAIN (India)<br>**Characterisation of mycobacteriophage BluSpix and Mycobacterium smegmatis phage-resistant strain Nigel**: Edith MACHOWSKI (South Africa)<br>**Early bactericidal activity of contezolid in patients with drug-resistant tuberculosis**: Peize ZHANG (China)<br>**Mycobacterium chelonae infective endocarditis: data from the MYBACH registry**: Frieder PF�FFLIN (Germany)<br>**Evaluation of the Xpert MTB/RIF Ultra assay to detect tuberculosis in concentrated urine from inpatients with advanced HIV in Ghana**: Johanna �HSBERG (Denmark)<br>**Prevalence of tuberculosis in cancer patients: a single centre experience from India**: Pradnya Laxman SAMANT (India)<br>**Evaluating the intracellular activity of a phage combination targeting Mycobacterium tuberculosis**: Marta POZUELO TORRES (Netherlands)<br>**GenoMAB: a genomic pipeline for Mycobacterium abscessus antimicrobial resistance**: Salim AGSOUS (France)<br>**Advantages of fluorescence staining technique in the diagnosis of tuberculosis as an alternative to Ziehl-Neelsen: a comparative study in a tertiary Greek hospital**: Gerasimos Socrates CHRISTODOULATOS (Greece)<br>**In vitro activity of imipenem/relebactam alone and in combination against cystic fibrosis isolates of Mycobacterium abscessus**: Madeline SANDERS (United States)<br>**Clinical Mycobacterium tuberculosis isolates exhibit a molecular clock rate below 1 SNP per genome per year**: Kan YU (Australia)<br>**Barriers and facilitators to paediatric tuberculosis management in India: a systematic review**: Matthew WILLIS (United Kingdom)<br>**Chronic mycobacteria infection triggers macrophage senescence**: Edoardo SCARPA (Italy)<br>**Microbiological and clinical characteristics of extrapulmonary nontuberculous mycobacterial disease in a Chinese general hospital, a ten-year retrospective study**: Yumeng YAO (China)<br>**Increasing non-tuberculous mycobacteria recovery rate and regional difference of mycobacterial species over 11 Years in a Korean tertiary care hospital**: Jae Hyeon PARK (Republic Of)<br>**Leprosy is evading eradication: epidemiology and pathogenesis in 2024**: Aidan BAKER JOHAL (United Kingdom)<br>**Extrapulmonary and disseminated tuberculosis in non-immunocompromised patients: a retrospective cohort study**: Sandra RAJME (Mexico)<br>**Disseminated pneumonia associated with achalasia and a Mycobacterium fortuitum group species: phylogenetic characterisation and ESX-complex analysis**: Laura Anne HUGHES (Netherlands)<br>**Characteristics of tuberculosis in migrants and native population: a retrospective study in an Italian hospital**: Drieda ZACE (Italy)<br>**Non-tuberculous mycobacterial skin and soft tissue infections following cosmetic procedures: a multicentric cohort**: Brenda ACEVES S�NCHEZ (Mexico)<br>**Tuberculous meningitis: a ten-year retrospective study regarding treatment and outcomes**: Joana BATISTA (Portugal)<br>**Contezolid in tuberculosis therapy: a retrospective analysis of real-world practice in China**: Peize ZHANG (China)<br>**Evaluation of rifampicin resistance burden in pulmonary and extrapulmonary tuberculosis at a paediatric tertiary care facility in northern India**: Anushika SONI (India)<br>**Pathogen and host determinants of extrapulmonary tuberculosis among 1035 patients in Frankfurt am Main, Germany, 2008-2023**: Nils WETZSTEIN (Germany)<br>**Seasonality of tuberculosis at a capital city in eastern India during 2016 to 2024**: Sidhartha GIRI (India)<br>**Impact of the new WHO critical concentration for rifampicin for diagnosis of rifampicin resistance of Mycobacterium tuberculosis in a low TB prevalence area**: Bettina SCHULTHESS (Switzerland)<br>**In vitro drug susceptibility of rifampicin-resistant and rifampicin-susceptible Mycobacterium tuberculosis in Shanghai, China**: Tao CHEN (China)<br>**Species identification and antimicrobial susceptibility of Mycobacterium abscessus complex clinical isolates from a general hospital**: Rong BAO (China)<br>**A study to evaluate the efficacy, safety, pharmacokinetics-pharmacodynamics of bedaquiline based regimen in multibacillary leprosy not responding to WHO-multidrug therapy (WHO-MDT)**: Himanshi KHERA (India)<br>**Distribution of contezolid concentrations at lesion sites in bone and joint tuberculosis patients**: Wenjuan NIE (China)<br>**Screening of Mycobacterium tuberculosis in medicolegal  autopsy cases in a tertiary care centre in central India**: Diksha CHHABRA (India)<br>**Characterisation of clinical Mycobacterium kansasii complex isolates in routine diagnostics**: Bettina SCHULTHESS (Switzerland)<br>**Trends in isolation frequency of nontuberculous mycobacteria at the national reference laboratory of Mycobacteria, in Athens, Greece, 2015-2023**: Stavroula ANTONOPOULOU (Greece)<br>**Investigation into comorbidities and mortality in clinically diagnosed tuberculosis patients in Kilifi county, Kenya**: Florah WETENDE (Kenya)<br>**Evaluation of the diagnostic accuracy of the Xpert MTB/RIF ultra assay for detecting Mycobacterium tuberculosis complex in routine samples in Denmark, 2020-2023**: Johanna �HSBERG (Denmark)<br>**Species-specific mortality and causes of death in patients with the most common nontuberculous mycobacterial pulmonary isolates in Denmark, 1991-2018**: Andreas ARNHOLDT PEDERSEN (Denmark)<br>**The evaluation of cross-resistance to rifabutin and accompanying mutations by DNA sequence analysis in rifampicin-resistant Mycobacterium tuberculosis complex strains**: Nalan S�R�C�OGLU (T�rkiye)<br>**Evaluation of four matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry systems for identification of non-tuberculous Mycobacteria**: Mei YANG (China)<br>**In silico analysis of phase-specific antigens for the diagnosis and progression prediction of tuberculosis**: Shima MAHMOUDI (Poland)<br>**Using QSAR models to refine antimicrobial peptides against Mycobacterium abscessus**: Gabriel S. OLIVEIRA (Portugal)<br>**Relative bioavailability of rifapentine and isoniazid when crushed in adults with tuberculosis infection: RPT CRUSH**: Thanakorn VONGJARUDECH (Sweden)<br>**Precision medicine in tuberculosis: utilising photoactivatable bedaquiline for controlled therapy**: Diego RONDELLI (Italy)<br>**Chitosan-particle-based cystatin F RNA silencing as a therapeutic strategy to improve the control of intracellular Mycobacterium tuberculosis**: Manoj MANDAL (Portugal)<br>**Comparative analysis of molecular and culture-based methods for detection and drug resistance assessment of Mycobacterium tuberculosis in extrapulmonary specimens**: Katarzyna KANIA (Poland)<br>**A comparative study of Mycobacteria species identification with immunoblot (subjective method) and liquidArray (automatic identification)**: Vera RIBEIRO (Portugal)<br>**Mechanisms of immune evasion by Mycobacterium abscessus in human primary macrophages**: Giorgia MOSCHETTI (Italy)<br>**Comparison between two different sequencing platform for whole-genome sequencing of Mycobacterium tuberculosis complex**: Alice NAVA (France)<br>**Mycobacterium tuberculosis complex genotipic resistance: targeted next generation sequence vs whole-genome sequence**: Alice NAVA (France)<br>**Preliminary results from Phase 2b multicentre, randomised, open clinical trial in people with drug susceptible pulmonary tuberculosis using optimised dose rifampicin, optimised dose moxifloxacin and linezolid (RML TB trial)**: Adri�n S�NCHEZ-MONTALV� (Spain)<br>**Clofazimine vs rifamycin in treating Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis**: Van-Dong NGUYEN (Vietnam)<br>**Drug resistance and genotypic profiling of Mycobacterium tuberculosis strains in Uganda**: Dennis MUJUNI (Uganda)<br>**Host blood biomarkers for the diagnosis of childhood tuberculosis: a systematic review and meta-analysis**: Michael PRODANUK (Canada) |
| 13/04 | 12:00 - 13:30 | PS012 | 02b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host biomarkers, treatment, and outcome prediction) |  | **Impact of antimicrobial dose adjustment timing in patients with Gram-negative bacilli bacteraemia and reduced glomerular filtration rate**: Gerardo Antonio MU�ETON-L�PEZ (Colombia)<br>**Staphylococcal endocarditis treatment, clinical practice vs guidelines: the experience from Agostino Gemelli university hospital, Rome**: Benedetta ANDRIOLO (Italy)<br>**Myocardial infarction and new-onset heart failure following bacteremia: general and pathogen-specific associated risk in a nationwide Danish nested case-control study**: Emilie Marie Juelstorp PEDERSEN (Denmark)<br>**No gender disparities in surgical treatment of infective endocarditis: a Swiss multicentre study**: Jana EPPRECHT (Switzerland)<br>**Staphylococcus aureus bacteraemia time to positivity for risk of infectious endocarditis and mortality**: Calvin MAN (Netherlands)<br>**Predictors of mortality of Enterococcus faecium bacteraemia: results from a five-year retrospective study at Padua university hospital**: Maria MAZZITELLI (Italy)<br>**The role of CD4+ T cells in the acute course of sepsis**: Yifan ZENG (China)<br>**Streptococcus dysgalactiae subsp. equisimilis bacteraemia, emm types and clinical characteristics: a four-year prospective study**: Miia SAUKKOSAARI (Finland)<br>**Navigating troubled waters: a systematic review of reported cases of prosthetic valve endocarditis treated with suppressive antimicrobial treatment**: Pietro VALSECCHI (Italy)<br>**Ampicillin and ceftobiprole: a potent duo against Enterococcus faecalis infective endocarditis**: Luca MARTINI (Italy)<br>**Performance evaluation of an automated microbial detection system for diagnosing bloodstream infections**: Laura DIONISI (Italy)<br>**Carbapenamase gene detection and synergy testing: role in management of blood stream infections due to carbapenem resistant Enterobacterales**: Ranganathan Natarajan IYER (India)<br>**Carbapenem tolerance in Enterobacter bugandensis in neonatal sepsis**: Marie-Liesse ETIENNE (France)<br>**Splenic embolism and infective endocarditis: on radiology and histopathology**: Cristiane LAMAS (Brazil)<br>**Predictive power of LIAISON MeMed VB for bacteraemia in adult patients seen in emergency deparments due to infections**: Laura SERRANO MART�N (Spain)<br>**Challenges in the diagnosis and management of negative blood culture infective endocarditis: insights from a retrospective cohort study**: Beatrice LIGUORO (Italy)<br>**Long-acting antibiotics as sequential therapy for infective endocarditis caused by Gram-positive bacteria: a propensity score-weighted cohort study**: Layla VAHEDI (Italy)<br>**Clinical outcomes of penicillin-based therapy compared to alternative enterococcal treatment in patients with vancomycin-susceptible enterococcal bacteremia: a retrospective cohort study**: Christina BAHRS (Austria)<br>**Evaluation of a point-of-care sepsis risk prediction test in ICU patients: comparison with standard scores, biomarkers, and physician judgement**: Anna WIJEN (Netherlands)<br>**Antimicrobial lock therapy in the treatment of catheter-related bacteraemia in heamodialysis patients**: Hanife Nur KARAKOC (T�rkiye)<br>**Rapid AST enables treatment optimisation over 32-h earlier than standard of care for BSI patients: interim results of the LIFETIMES study**: Emma RENNEL-DICKENS (Sweden)<br>**Long-term suppressive antimicrobial therapy in infective endocarditis: a ten-year retrospective study on 52 patients with prosthetic valve infections at Tor Vergata university hospital**: Alessandra IMENEO (Italy)<br>**Bacteraemias of unknown origin: description and prognostic analysis**: Elena RUBIO-MART�N (Spain)<br>**Infective endocarditis prediction score for non-pyogenes and non-pneumococcal streptococcal bacteremia**: Christopher LAI (China)<br>**Reporting MIC results within 48 hours reduced antibiotic use and costs for patients with bloodstream infection in the intensive care unit**: Qi ZHAO (China)<br>**Improved immunodeficiency detection in patients with invasive airway pathogens: a prospective cohort study**: Bryan TAN (Australia)<br>**Is the early versus late-onset neonatal sepsis paradigm relevant in middle-income settings? An Algerian hospital experience**: Samar AKBI (Algeria)<br>**Epidemiology and risk factors for mortality of Escherichia coli bloodstream infections in Hong Kong**: Rita NG (China)<br>**Epidemiology of Acinetobacter baumannii from bloodstream infections in China over the past decade**: Ping LU (China)<br>**A multicentre international study on Staphylococcus lugdunensis infective endocarditis**: Cristiane LAMAS (Brazil)<br>**Investigating the role of Streptococcus dysgalactiae bloodstream infections in Scotland, 2014-2023**: Leo HUANG (United Kingdom)<br>**Gianella risk score in the carbapenemase´s jungle: performance in mix-carbapenemase setting ??????**: Patricio FAVIER (Spain)<br>**In quest of determining an effective antimicrobial peptide against uropathogenic Escherichia coli in silico and in vitro validation**: Diksha GAKHAR (India)<br>**Risk of endocarditis strongly relates to Streptococcal species and should influence management: focus on the 'small five'**: Gavin DEAS (United Kingdom)<br>**Type I CRISPR-Cas system in neonatal septicaemic Klebsiella pneumoniae: exploring the association with multidrug-resistant bacteria**: Sulagna BASU (India)<br>**Utility of various clinical scores to predict infective endocarditis in patients with Staphylococcus aureus bacteraemia**: Deepak KUMAR (India)<br>**Genomic population structure and adhesion-related virulence factors of invasive nontypeable Haemophilus influenzae isolates**: Tsai-Wen WAN (China)<br>**Risk of infective endocarditis in oncohaematological patients with Enterococcus faecalis bloodstream infection**: Miguel Angel CONSUEGRA PEREZ (Spain)<br>**Epidemiology, phenotypic and genotypic evaluation of carbapenem-resistant Enterobacterales bacteraemia in Qatar**: Hamad ABDEL HADI (Qatar)<br>**Effects of biological sex on mortality and complications in infective endocarditis patients: preliminary results from the multicentre DERIVE cohort study in Germany**: Katharina LAST (Germany)<br>**Important plasma lipid changes related to sepsis progression**: Alba SANCHEZ MORILLO (Spain)<br>**Infective endocarditis in patients with intracardiac devices**: Maricela VALERIO MINERO (Spain)<br>**Symptom duration and outcomes among patients with  Staphylococcus aureus bloodstream infections**: Felicia RUFFIN (United States)<br>**Correlation of pancreatic stone protein (PSP) with septic shock, SOFA, and APACHE scores: an emerging biomarker for disease severity**: Ummu Afeera ZAINULABID (Malaysia)<br>**Comparative genomics between Staphylococcus aureus isolates from patients with bacteraemia and infective endocarditis from public hospitals in Gauteng**: Theevasha GOVENDER (South Africa)<br>**Adherence to Duke-ISCVID and ESC guidelines for infective endocarditis: insights from a three-year retrospective study**: Kate DRUMMOND (Australia)<br>**Serotype V dominance and emerging resistance in Indian Streptococcus agalactiae: genomic insights and antibiotic profiling**: Shincy METTINGAL RAMAKRISHNAN (India)<br>**Long-term antibiotic therapy in non-surgical prosthetic valve endocarditis: a retrospective international multi-centre study (L-TAPE study)**: Linda BUSSINI (Italy)<br>**Clinical characteristics of endocarditis patients with negative valve culture but positive 16S RNA: a cohort study**: Michael THY (France)<br>**Clinical utility of negative predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swabs in infective endocarditis: is there a step forward to antimicrobial stewardship goals?**: Laura-Georgiana TIRLESCU (Romania)<br>**Role of nuclear imaging techniques in the diagnosis and management of infective endocarditis in critically ill patients**: Michael THY (France)<br>**Alpha-toxin production by Staphylococcus aureus is not associated with thrombocytopenia or clinical outcome in bacteremic patients**: Miguel �ngel VERDEJO G�MEZ (Spain)<br>**Association of individual-level amoxicillin prescribing in primary care on Escherichia coli bacteraemia in older adults in England, 2018-2021**: Amelia ANDREWS (United Kingdom)<br>**Predictive factors of early and late mortality and evaluation of therapeutic efficacy in patients with bacteraemia associated with MDR Acinetobacter baumannii: the ITACA (ITalian Advances on Carbapenem-resistant Acinetobacter) study**: Sara Palma GULL� (Italy)<br>**Risk factors for mortality in Elizabethkingia spp. bloodstream infections**: Tiara Joy FOO (Singapore)<br>**Levofloxacin minimum inhibitory concentration greater than 2 mg/L correlates with adverse outcomes in levofloxacin-treated patients with Stenotrophomonas maltophilia bacteraemia**: Ka Lip CHEW (Singapore)<br>**Pancreatic stone protein levels accurately predict severity in sepsis of various causes earlier than other biomarkers**: Dimitrios KOUROUPIS (Greece)<br>**Infective endocarditis: clinical profile and prognosis of patients admitted to a university hospital in San Paulo, Brazil**: Juliana BECKER (Brazil)<br>**The clinical characteristics and prognosis of Staphylococcus argenteus bacteraemia as analysed by massively parallel sequencing in Japan**: Yusuke WATANABE (Japan)<br>**The impact of rapid microbiology identification report and dual AST cards on the antibiotic therapy and economics of hospitalised bloodstream infection patients**: Lulu GONG (China)<br>**Predictive utility of the lactate-to-albumin ratio in 28-day mortality among septic shock patients in Vietnam**: Dang Hai PHAM (Vietnam)<br>**Antimicrobial resistance genes profile and 28-day mortality in Enterobacterales bacteraemia: a retrospective study from a tertiary care centre in Kerala, India**: Vettakkara Kandy Muhammed NIYAS (India)<br>**Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.**: Sunish SHAH (United States)<br>**Clinical impact and therapeutic management of Enterococcus faecium bloodstream infections: a systematic review and meta-analysis**: Federica MALERBA (Italy)<br>**A retrospective study: Enterobacter spp. bloodstream infection in a tertiary hospital in Balearics Islands, Spain**: Alexandre ZIDOUH (Spain)<br>**Comparative evaluation of the utility of serum amyloid A, C-reactive protein, procalcitonin, and precepsin as diagnostic markers for sepsis**: Myeong Hee KIM (Republic Of)<br>**Towards a Belgian national sepsis action plan: Be-SNAP**: Annelies MONDELAERS (Belgium)<br>**Accurate long-term mortality prediction after BSI Using BLOOMY scores: a validation study in a challenging MDR environment**: Matteo MORRA (Italy)<br>**In vitro study on the efficacy of oral antibiotic combinations for oral outpatient treatment of infective endocarditis caused by Staphylococcus aureus, Staphylococcus epidermidis, and Enterococcus faecalis**: Mar�a Alexandra CA�AS (Spain)<br>**Ceftazidime/avibactam plus aztreonam vs comparators in metallo-beta-lactamase-producing Enterobacterales: a multicentre target trial emulation**: Emilio Felipe HUAIER ARRIAZU (Argentina)<br>**Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia**: Sunish SHAH (United States)<br>**Impact of neurological complications on infective endocarditis outcomes**: Fereshteh SHEIBANI (Islamic Republic Of)<br>**Carbapenems vs non-carbapenems as definitive treatment for hypervirulent Klebsiella pneumoniae bacteraemia in Taiwan**: Yi-Tsung LIN (China)<br>**Diagnostic performance and prognostic assessment of ddPCR in patients with sepsis**: Xinlei XU (China)<br>**Revised VIRSTA score for infective endocarditis focusing on persistent fever**: Tomonori TAKANO (Japan)<br>**Non-device-associated right-sided infective endocarditis: bridging gaps in epidemiology and clinical insights**: Elif Mukime SARICAOGLU (T�rkiye)<br>**A nationwide genomic surveillance study of Gram-negative bacteria causing community and hospital-acquired bloodstream infections in China**: Qiwen YANG (China)<br>**Clinical features and outcomes of patients with infective endocarditis and intracardiac abscess compared to patients without intracardiac complications**: Miguel Angel CONSUEGRA PEREZ (Spain)<br>**Enhanced sepsis management with a novel multiplex real-time PCR system**: Christian FINI (Italy)<br>**Herding cats with WISCAs: using weighted incidence syndromic combined antibiograms to inform community-acquired sepsis guideline development**: Kathryn WILKS (Australia)<br>**When staph won't budge: how the world tackles persistent Staphylococcus aureus bacteraemia**: Annette WESTGEEST (Netherlands)<br>**Novel sepsis guideline adherence and useability: impact of a WISCA-derived local sepsis guideline for Queensland, Australia**: Kathryn WILKS (Australia)<br>**Prevalence and clinical presentation of prosthetic osteoarticular material infections in patients with Staphylococcus aureus bacteraemia**: Dasa STUPICA (Slovenia)<br>**Who is the true bad bug? Post COVID-19 increase in incidence of MSSA bacteraemia associated with high mortality in older adults**: Chiara SEPULCRI (Italy)<br>**The complexity of prescribing for sepsis:  is it in the diagnosis of source of infection?**: Kathryn WILKS (Australia)<br>**Dual beta-lactam synergy in Enterococcus faecalis infective endocarditis and its relationship with penicillin/ceftriaxone treatment outcomes**: Genevieve MCKEW (Australia)<br>**Isolated spikes in temperature and leucocyte count do not predict positive blood cultures in the intensive care setting**: Azmi RAHMAN (United Kingdom)<br>**Evaluation of septic shock patients in a tertiar-care educational university hospital: a series of 2314 cases**: Gamze SANLIDAG ISBILEN (T�rkiye)<br>**Clinical features and antimicrobial susceptibility profiles of Gram-negative bloodstream infections in paediatric ICU patients**: Giulia LORENZETTI (Italy)<br>**High carriage of known sepsis causing ExPEC Escherichia coli are the cause of high rates of bacteraemia in Wyoming**: Jordan Aston Tregurtha MATHIAS (United Kingdom)<br>**Molecular epidemiological study of Escherichia coli bloodstream infection-causing isolates across England using nanopore long read-only sequencing: an interim analysis of the NEKSUS study**: Dorottya NAGY (United Kingdom)<br>**Ceftazidime/avibactam in real-world clinical practice**: Gustavo Adolfo M�NDEZ (Argentina)<br>**Robust, rapid and cost-effective diagnosis of bloodstream infections by FT-IR spectroscopy directly from blood culture bottles**: Angela NOVAIS (Portugal)<br>**Burkholderia sepsis in Bangladesh: clinical impact, diagnostic challenges, and molecular epidemiology**: Keegan John HOOG (United Kingdom)<br>**Risk factors and prognostic influence of carbapenem-resistance in Klebsiella spp. bloodstream infections: experience from a tertiary hospital**: Jorge CALDERON PARRA (Spain)<br>**Campylobacter bacteraemia: ten years of experience in a large teaching hospital**: James HARTLEY (United Kingdom)<br>**Sex-specific performance of SIRS, qSOFA, CURB-65, DS-CRB-65 and PSI in predicting mortality from pneumococcal bacteraemia**: Amelieke Johanna Hendrina CREMERS (Switzerland)<br>**Time efficiency in tailoring antimicrobial treatment: a propensity score-matched comparison of sepsis panel-guided and blood culture-guided therapy**: Imran HASANOGLU (T�rkiye)<br>**Sepsis in Germany: an estimation of incidence using two extrapolation approaches**: Annika MEINEN (Germany)<br>**Validating code-based algorithms to detect invasive Escherichia coli disease in US healthcare records: impact of incorporating microbiology culture data in the case definition**: Mark A SCHMIDT (United States)<br>**Sepsis in children with burn injuries: preliminary findings from a prospective observational study from Malawi**: Sebastian SCH�NHERR (Germany)<br>**Hypolipidemia, a novel potential predictor of mortality in infective endocarditis**: Fabian PATAUNER (Italy)<br>**Community and hospital-acquired invasive bacterial infections in hospitalised patients with advanced-HIV disease: a prospective study in Kinshasa, DRC**: Agnese COMELLI (Italy)<br>**High antimicrobial resistance among invasive non-typhoidal Salmonella in hospitalised patients with advanced-HIV disease: a prospective study in Kinshasa, DRC**: Agnese COMELLI (Italy)<br>**Rising rates of sepsis in England: an ecological study**: Victoria ALLEN (United Kingdom)<br>**Validation of Pro-SOFA and Pro-SAPS models incorporating biomarkers PCT, NLR, and CRP in a new patient cohort**: Anandakrishnan NANDAKUMAR (India)<br>**Predictive factors for sepsis by or associated with Stenotrophomonas maltophilia complex (SMC) in adult critically ill patients in Rio de Janeiro: prospective, nested case-case-control study**: Marisa ZENAIDE RIBEIRO GOMES (Brazil)<br>**Cardiac CT scan in infective endocarditis: correlation with transoesophageal findings and feasibility of coronary artery evaluation**: Pietro VALSECCHI (Italy)<br>**How does infective endocarditis due to non-HACEK Gram-negative bacilli progress?**: Nuran SARI (T�rkiye)<br>**Clinical outcomes of cefepime dosing in patients with Pseudomonas infections undergoing renal replacement therapies**: Islam GHAZI (United States)<br>**Neonatal sepsis in quaternary unit in south of Mozambique: preliminary result/study**: Lena Vania MANHIQUE-COUTINHO (Mozambique)<br>**Hypervirulent Klebsiella pneumoniae (HvKp) causing bacteraemia in a tertiary referral hospital**: Domingo FERNANDEZ VECILLA (Spain)<br>**Exploring the virulence potential of Escherichia coli of ST131 fimH27 subclone causing infantile bacteraemia in Mozambican children**: Inacio MANDOMANDO (Mozambique)<br>**Implementation of bedside consultation for Staphylococcus aureus bacteraemia: a pre-post intervention study**: Carlos TARRAZO TARRAZO (Spain)<br>**Restrictive versus liberal fluid management in adult patients with septic shock: a systematic review and meta-analysis**: Christian Jay DOMINGO (Philippines)<br>**Modified PRIEST score for predicting adverse outcome in emergency room patients with suspected infection**: Oren TURGMAN (Netherlands)<br>**Evaluation of the role of geriatrician in the endocarditis team**: Brice ANDRIAMIRADO (France)<br>**Body temperature and serum levels of C-reactive protein and procalcitonin in hospitalised geriatric patients with bacteriaemia**: Sandra SCH�TZE (Germany)<br>**Double-valve infective endocarditis: real-life experience in a tertiary hospital in Italy**: Gloria SANGALETTI (Italy)<br>**Sepsis code programme: outcomes after two years of implementation in a tertiary hospital**: Miguel SUAREZ ROBLES (Spain)<br>**Infective endocarditis in immunocompromised patients: pathogens, complications, and outcomes**: Nuran SARI (T�rkiye)<br>**A metric to measure mortality due to antibiotic-resistant bacteraemia in the UK using public health data**: James STIMSON (United Kingdom)<br>**Clinical spectrum of Enterococcal endocarditis: key findings from a multicentre study**: Mustafa DENIZ (T�rkiye)<br>**Definition of early prosthetic valve endocarditis**: Jorge CALDERON PARRA (Spain)<br>**Short antibiotic treatment for uncomplicated Gram-negative bacilli bacteraemia: real-world experience in a single centre**: Karen Viviana CABEZAS MARQUEZ (Argentina)<br>**Endocarditis due to Gram-negative bacilli and its comparison with endocarditis due to other microorganisms**: Maricela VALERIO MINERO (Spain)<br>**Pantoea spp bacteraemia in national hospital Abuja**: Philip NWAJIOBI-PRINCEWILL (Nigeria)<br>**Genetic characterisation of Enterobacter cloacae strains causing paediatric sepsis**: Maia DE LUCA (Italy)<br>**Sequencing for pathogen detection in valve tissue in clinical diagnostics of infective endocarditis**: Annam�ria MACH�CKOV� (Czech Republic)<br>**Microbiological profile of infective endocarditis episodes in two high-complexity hospitals in Chile, 2012-2022**: Jos� Miguel ORTEGA FUENZALIDA (Chile)<br>**Artificial intelligence assisted management impact on clinical outcomes of sepsis in a tertiary care setting**: Suhail Hassan JALAL (India)<br>**Emergence, adaptation and genomic insights into human variant of methicillin-resistant Staphylococcus aureus clonal complex 398 in Taiwan**: Tsung-Hua WU (China)<br>**Point-of-care testing of procalcitonin serum level: a rapid approach to diagnose sepsis post mortem**: Arneet ARORA (India)<br>**The resistance phenotype and molecular epidemiology of Klebsiella pneumoniae causing bloodstream infections in Indian population: a multicentric retrospective study**: Harshitha GK (India)<br>**Utilising rapid next generation metagenomic sequencing for pathogen identification and antimicrobial resistance characterisation in bloodstream infections: a preliminary study**: Rhoda Cheuk-Ying LEUNG (China)<br>**Linezolid vs high dose daptomycin for the treatment of vancomycin-susceptible Enterococcus faecium blood stream infections: a retrospective observational study**: Mario KAROLYI (Austria)<br>**A descriptive study of patients treated with monotherapy for Stenotrophomonas maltophilia bloodstream infections**: Roberta MONARDO (Italy)<br>**Combination therapy vsmonotherapy for persistent MRSA bacteraemia: a retrospective cohort study**: Ali ALTHUBYANI (United States)<br>**Aging and infective endocarditis: outcomes and challenges in the elderly population**: Martha KESTLER HERNANDEZ (Martha KESTLER HERNANDEZ)<br>**Should antimicrobial treatment be initiated immediately after blood culture collection among all patients with suspicion of infective endocarditis?**: Elisavet STAVROPOULOU (Switzerland)<br>**Genomic diversity of bloodstream infections caused by typhoidal and non-typhoidal Salmonella enterica serovars in India**: Sowmya PR (India)<br>**Cefazolin vs antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis**: Connor PROSTY (Canada)<br>**Evaluation of the NOVA and DENOVA scores and the different versions of Duke criteria for the diagnosis of infective endocarditis among patients with enterococcal bacteremia**: Virgile ZIMMERMANN (Switzerland)<br>**Repeat PET/CT in the follow up of unoperated patients with prosthetic valve endocarditis**: Cristiane LAMAS (Brazil)<br>**Role of CBC positional parameters in defining sepsis and bacteremia**: Cinzia TAVANO (Italy)<br>**Severe invasive Streptococcus pyogenes infections in children and adults: are they the same?**: Marek STEFAN (Czech Republic)<br>**Injecting drug use related septic thrombophlebitis: a retrospective review**: Sophie FOX (United Kingdom)<br>**The antimicrobial resistance patterns and epidemiology of community onset bloodstream infections among children in Liverpool city region**: Marwa ALLAM (United Kingdom)<br>**Bloodstream infections burden and trend in hospitalised patients over ten years: a national bottom-up initiative for disease burden on public healthcare data, 2013-2022**: Carlos KIFFER (Brazil)<br>**Overuse of blood cultures and its associated factors: a single-centre retrospective study**: Shun KOSAKA (Japan)<br>**Genomic epidemiology and phylodynamics of Acinetobacter baumannii bloodstream isolates in China: population superseding and toxification**: Qixia LUO (China)<br>**In-hospital mortality associated with bacteraemia caused by Escherichia coli and Klebsiella spp. with priority resistances**: Omar Fernando MENDOZA-V�ZQUEZ (Mexico)<br>**In vitro antibiotic combination testing-guided therapy vs standard care for the treatment of difficult-to-treat resistant pseudomonal infections**: Jing Heng TOH (Singapore)<br>**Bacteraemia due to Lactobacillus species: a Mayo Clinic experience from 2012 to 2024**: Sofia MOLINA GARCIA (United States)<br>**The impact of antibiotic resistance on 30-day fatality in BSI: a prospective cohort study**: Lal Sude G�CER (T�rkiye)<br>**Outpatient parenteral antimicrobial therapy (OPAT): a four years review in a tertiary care hospital in Belgium**: Sara KAMEL REY (Belgium)<br>**A prospective cohort study on the performance of chatbot artificial intelligence in infective endocarditis management compared to infectious diseases consultation**: Marta VECCHI (Italy)<br>**Diagnosis and severity prediction of bacterial infections and sepsis using a 29-gene host-response test from whole blood**: Daniel HORNUSS (Germany)<br>**Impact of nuclear imaging in the management of infections in critically ill patients**: Camilla GENOVESE (Italy)<br>**Synergistic killing of methicillin-resistant Staphylococcus aureus with ceftaroline or vancomycin combined with carbapenems**: Erlinda R ULLOA (United States)<br>**An AI-driven learning health system to improve sepsis quality of care**: Sylvain MEYLAN (Switzerland)<br>**Evaluating the impact of delayed concordant empirical antibiotics treatment on 30-day mortality in patients with Enterobacterales bloodstream infection in low- and middle-income country settings**: Myo Maung Maung SWE (United Kingdom)<br>**The genotypic and phenotypic continuum of hypervirulence in Klebsiella pneumoniae invasive infection in an endemic region**: Alfred Lok Hang LEE (China)<br>**Positron emission tomography/computed tomography utilisation in infective endocarditis: a retrospective audit**: Huseyin BILGIN (United Kingdom)<br>**Trends in bloodstream infections in critical care: incidence, antimicrobial resistance and mortality (English national surveillance, 2017-2023)**: Andrea MAZZELLA (United Kingdom)<br>**Bloodstream infection with Aerococcus vs Escherichia and Enterococcus: does species matter?**: Torgny SUNNERHAGEN (Sweden)<br>**Gram-negative sepsis, antimicrobial drug susceptibility, and treatment outcomes at two NICU in Addis Ababa, Ethiopia**: Biniyam Tedla MAMO (Ethiopia)<br>**The clinical and economic effects of rapid antimicrobial susceptibility testing report and the dual susceptibility cards on adult ICU patients with bloodstream infection**: Jingxing XIE (China)<br>**BALANCE+ platform trial for Gram-negative bloodstream infections: vanguard phase**: Sean Wei Xiang ONG (Australia)<br>**Delphi consensus document on treatment and follow-up of vascular graft/endograft infection**: Marta HERN�NDEZ-MENESES (Spain)<br>**Incidence, outcomes and risk factors for mortality of patients with sepsis in Korea: a nationwide cohort study**: Yongseop LEE (Republic Of)<br>**Impact of duration of antibiotic treatment for ESBL-producing Enterobacteriaceae bacteraemia in critically patients on in-ICU mortality: a French multicentric retrospective observational cohort**: Agnes MEYBECK (France) |
| 13/04 | 12:00 - 13:30 | PS013 | 02c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging,� treatment & prevention) |  | **Doxycycline in the treatment of outpatient community-acquired pneumonia: propensity matched control cohort study**: Genady DROZDINSKY (Israel)<br>**Interactions between SARS-CoV-2 and S. pneumoniae in adults: from colonisation to disease**: Sara CALVO-SILVERIA (Spain)<br>**Burden and risk factors of 30-day readmissions and mortality after CAP hospitalisation: a population-based cohort study**: Fabian REICHEL (Germany)<br>**Persistence of Haemophilus influenzae and Pseudomonas aeruginosa strains in bronchiectasis patients: a longitudinal study**: Irene CADENAS JIM�NEZ (Spain)<br>**Post COVID-19 disruption of the respiratory microbiome modulates Mycoplasma pneumoniae infections: a multi-centre retrospective investigation study**: Shiyu HUANG (China)<br>**Immunogenicity insights: comparing pneumococcal antibody levels in healthy and diabetic Indian adults**: Akhila M M (India)<br>**Whooping cough outbreak during 2024 in the fourth healthcare area in Asturias (north of Spain): epidemiological analysis**: Mar�a Soledad ZAPICO GONZ�LEZ (Spain)<br>**Incidence of respiratory tract infections and complications in Sweden 2014-2023; developing a surveillance framework to evaluate antibiotic stewardship interventions**: Katarina HEDIN (Sweden)<br>**Comparison of Streptococcus pneumoniae serotypes between children with paediatric parapneumonic pleural effusions/empyema and other invasive pneumococcal diseases: results from two nationwide surveillance systems, Germany, 2010/11-2023/24**: Andrea STRENG (Germany)<br>**A critical analysis of the trends in low immunisation coverage of under-one-year-old against diphtheria, tetanus, and pertussis in Venezuela, 1995-2023**: Alfonso J. RODRIGUEZ-MORALES (Colombia)<br>**Re-emergence of diphtheria in Algeria**: Sadjia MAHRANE (Algeria)<br>**Epidemiology of Mycoplasma pneumoniae infections in paediatric patients: trends and positivity rates from 2017 to 2024**: Maria Del Carmen PEREYRA BOZA (France)<br>**Mortality in community-acquired pneumonia patients with and without microbial detection: a hospitalised cohort study**: Preudtipong NOOPETCH (Thailand)<br>**Whooping cough: the summer B. pertussis epidemic increase in France driven by young vaccine-targeted populations**: Benoit VISSEAUX (France)<br>**Pneumococcal carriage and capsular serotype prevalence among healthy children attending childcare centres in Klang valley, Malaysia: a pre-vaccination retrospective analysis**: Revathy ARUSHOTHY (Malaysia)<br>**Hospitalisation rates, disease burden, and aetiology for community-acquired pneumonia before, during and after the COVID-19 pandemic: a register-based cohort study among adults in Stockholm county, Sweden**: Ridwanul AMIN (Sweden)<br>**Penicillin V as first-line treatment for pneumonia in outpatient care: a register-based study of treatment failures**: Katarina HEDIN (Sweden)<br>**Non-invasive pneumococcal disease in Portugal: serotype distribution, comparison with invasive pneumococcal disease and potential vaccine coverage, 2023-2024**: Mario RAMIREZ (Portugal)<br>**Neurological manifestations associated with Mycoplasma pneumoniae infection in adult patients**: Patricia NADAL-BARON (Spain)<br>**The atypical return of Mycoplasma pneumoniae in a tertiary hospital**: Luc�a TEJEDOR CANTERO (Spain)<br>**Detection of respiratory pathogens in the nasopharynx of children hospitalised with severe pneumonia in sub-Saharan Africa**: Juan Pablo RODRIGUEZ-RUIZ (Belgium)<br>**Clinical and antibiotic resistance patterns in paediatric pneumococcal infections: a retrospective analysis from a tertiary care centre**: G�ls�m Iclal BAYHAN (T�rkiye)<br>**Mycoplasma pneumoniae infection in the paediatric population at a tertiary care hospital**: Esther DE LA HOZ SERENO (Spain)<br>**Active nationwide surveillance of invasive pneumococcal disease (IPD) to enable choice of extended-spectrum PCV for elderlies in Israel**: Romy RIEGER (Israel)<br>**Epidemiology of whooping cough in a Spanish tertiary hospital beyond COVID-19**: Isabel Cristina L�PEZ MESTANZA (Spain)<br>**Resurgence of pertussis in southern Brazil: a two-year analysis of increasing Bordetella pertussis cases**: Dariane PEREIRA (Brazil)<br>**The gastrointestinal resistome and microbiota of children hospitalised with severe pneumonia in sub-Saharan Africa in the PediCAP trial**: Juan Pablo RODRIGUEZ-RUIZ (Belgium)<br>**Risk factors influencing the carriage of Streptococcus pneumoniae among children**: Tian-Chi ZHOU (China)<br>**Re-emergence of diphtheria in Pakistan: a call for reinforced immunisation efforts to prevent future outbreaks**: Zurva ASHRAF (Pakistan)<br>**Study of S. pneumoniae serotypes and their associations with clinical factors/mortality and antimicrobial resistance in the Comunidad Valenciana**: Laura DIAB CASARES (Spain)<br>**Immunoglobulin M of respiratory viral and atypical pathogens among adults with respiratory tract infections in Shanghai, China**: Yinjuan GUO (China)<br>**Insight into the microbiological diagnosis of Streptococcus pneumoniae in pleural fluid in paediatric population with complicated pneumonia: a decade-long study**: Jos� Luis CARRI�N FR�AS (Spain)<br>**Identification of clinical phenotypes in community-acquired pneumonia**: Sonsoles SALTO-ALEJANDRE (Spain)<br>**Post-pandemic shifts in Streptococcus pneumoniae serotypes causing invasive pneumococcal disease (IPD) among US and Canadian children**: Pullagura GOKUL RAJ (Canada)<br>**The role of viridans Streptococci and anaerobic bacteria of the oral cavity in children with parapneumonic pleural effusions/empyema: nationwide hospital surveillance (Germany, 2010/11-2022/23)**: Johannes FORSTER (Germany)<br>**Characteristics, epidemiology and treatment of adults hospitalised for Mycoplasma pneumoniae pneumonia**: Karl HAGMAN (Sweden)<br>**Comparison of microbial diversity in upper and lower respiratory tracts of children using 16S metagenomics sequencing**: Richa RAO (India)<br>**Pathogen distribution and Pneumococcus disease burden of clinical diagnosed pneumonia among children, a multi-centre case-control study**: Jingwen AI (China)<br>**Pneumonia burden and temporal trend in hospitalised patients over ten years: a national bottom-up initiative for disease burden based on public healthcare system secondary data 2013-2022**: Carlos KIFFER (Brazil)<br>**Pneumonia related antimicrobial resistance burden in hospitalised patients over ten years: a national bottom-up initiative for disease and AMR burden on public healthcare data 2013-2022**: Carlos KIFFER (Brazil)<br>**Whole-genome analysis unveils genetic factors driving the Mycoplasma pneumoniae outbreak among children post-COVID-19 in China**: Weiwei JIAO (China)<br>**Sputum yields higher viral detection than oropharyngeal swabs in non-COVID-19 community-acquired pneumonia**: Pei Min THONG (Singapore)<br>**Automated lateral flow immunoassay based on upconverting nanoparticles for serological point-of-care diagnosis of pertussis**: Teppo SALMINEN (Finland)<br>**Integrated study of respiratory microbiota and host response in children with macrolide-unresponsive Mycoplasma pneumoniae pneumonia**: Lin SUN (China)<br>**Monitoring genomic evolution of Bordetella pertussis patient isolates in Austria before and after the COVID-19 pandemic**: Zs�fia SZOJKA (Austria)<br>**Impact of shortages of amoxicillin and amoxicillin/clavulanate on the outcome of bacterial sinusitis in adults: a French retrospective, single-centre study**: Sandra DEVATINE (France)<br>**Reemergence of Bordetella parapertussis and Bordetella pertussis after COVID-19 pandemic in Korea**: Sang Bong HAN (Republic Of)<br>**Epidemiological features of pertussis in the Zenica-Doboj canton, Bosnia-Herzegovina**: Muhamed SKOMORAC (Bosnia And Herzegovina)<br>**Impact of a multimodal algorithm on antibiotic use for acute community-acquired pneumonia in the emergency department: a quasi-experimental time series study**: Donia BOUZID (France)<br>**Outbreak of pneumococcal pneumonia among vaccinated patients in a mental health facility**: N�ria BORRELL-SOL� (Spain)<br>**Predatory bacteria to combat respiratory infections: friend or foe?**: Zeinab MOHSENIPOUR (Islamic Republic Of)<br>**Revolutionising respiratory pathogen detection: evaluation of a multiplex real-time PCR assay for Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis**: Henar ALONSO-EZCURRA (Spain)<br>**Mycoplasma pneumoniae significantly contributes to the burden of hospitalisations due to respiratory infections in Denmark**: Hanne-Dorthe EMBORG (Denmark)<br>**An estimation of costs associated with lower-tract respiratory infections in older adults in Sweden**: Eleana TSOUMANI (Greece)<br>**The largest epidemic of Mycoplasma pneumoniae in more than ten years in Wales: an epidemiological summary, symptoms and risks**: Panoraia KALAPOTHARAKOU (United Kingdom)<br>**Clinical impact of combined treatment of beta-lactam with azithromycin in hospitalised community-acquired pneumonia**: Ilona ZHYGALOVA ZHYGALOVA (Spain)<br>**Increasing numbers of Legionnaires' disease cases caused by Legionella longbeachae during 2024 in Sweden, Scotland, Denmark and Finland**: Lisa WASSERSTROM (Sweden)<br>**Amoxicillin is non-inferior to other antibiotics as treatment of CAP in adults and children: results of a systematic review and meta-analysis of 44 trials**: Lilia POTTER-SCHWARTZ (United States)<br>**Risk of infection in pregnant women with and without chronic respiratory diseases, and association with adverse pregnancy outcomes**: Katarina MONDRUP FUNCH (Denmark)<br>**Post-pandemic trends and clinical features of severe community-acquired pneumonia (CAP) due to Streptococcus pyogenes: a retrospective study in a tertiary care centre**: Mary Paz ROCHE MATHEUS (Spain)<br>**Pneumococcal colonisation in adult patients with acute respiratory infection**: Catalina MEDINA GOMEZ (Spain)<br>**Diagnostic performance of short-trained emergency department physicians for pneumonia using lung ultrasound**: Julien OPPLIGER (Switzerland)<br>**Current epidemiological profile of pertussis diagnosed in children in Tunis, Tunisia**: Yasmine CHELBI (Tunisia)<br>**Characterisation and analysis of a whooping cough outbreak in Albacete, Castilla-La Mancha, Spain**: Sara SIERRA ALCA�IZ (Spain)<br>**Changes in the prevalence of bacteria detected in respiratory infections and antibiotic resistance before and after the COVID-19 pandemic in Korea**: Chorong HAHM (Republic Of)<br>**Comparative outcomes of severe pneumonia: home vs conventional hospitalisation**: Andres BLANCO-DI MATTEO (Spain) |
| 13/04 | 12:00 - 13:30 | PS014 | 02d. Community-acquired abdominal/gastrointestinal infections (incl epidemiology, clinical, imaging, treatment & prevention) |  | **Enteroaggregative Escherichia coli: from a diarrhoeal pathogen to a superbug uropathogen?**: Harpreet KAUR (India)<br>**Campylobacter bacteraemia outcomes: a systematic review with meta-analysis**: Verena ZERBATO (Italy)<br>**Helicobacter pullorum isolated from stool culture in a tertiary hospital in Madrid**: Alejandra ARENAS (Spain)<br>**Prevalence and drug-resistance patterns of enterotoxigenic Escherichia coli among children with diarrhea in Ouagadougou, Burkina Faso**: Alimatou HEMA (Burkina Faso)<br>**Enteric pathogens in flood-affected populations: insights from the Valencia flood event**: Laura ANDR�S ESLAVA (Spain)<br>**Application of whole-genome sequencing and bioinformatics in the epidemiological surveillance of non-typhoidal Salmonella enterica at the clinical level**: Ram�n VELA FERNANDEZ (Spain)<br>**Management of diarrhea among patients attending public health centre and private clinics in Addis Ababa, Ethiopia**: Tadesse EGUALE (Ethiopia)<br>**The role of H. pylori virulence factors triggering pyroptosis in gastritis and ulcer pathology**: Yaren BUYUKCOLAK CEBECI (T�rkiye)<br>**The application value of mNGS and etiologic features in liver abscess with underlying intra-abdominal risk factors**: Beidi ZHU (China)<br>**A two-year longitudinal study of the epidemiology of Escherichia coli enteritis in a Spanish secondary hospital**: Marcos HERNANDO GOZALO (Spain)<br>**A retrospective study of Salmonella enterica in Lombardy (northern Italy) drew attention back to invasive serotypes**: Priscilla PASUTTO (Italy)<br>**A species-specific PCR approach to enhance probiotic studies exploring Christensenella minuta**: Nayna BABAR (Hungary)<br>**Genomic and epidemiological insights into Campylobacter fetus subsp. testudinum B1200: analysis of two clinical isolates with divergent outcomes**: Mohammad Ridhuan MOHD ALI (Malaysia)<br>**Evaluating the awareness of campylobacteriosis among adults in Sri Lanka**: Aadhil AHAMED (Sri Lanka)<br>**I am here if you want to detect me, i am important too: campylobacteriosis in India**: Neelam TANEJA (India)<br>**Clinical characteristics of campylobacteriosis in immunocompromised patients in comparison with immunocompetent patients**: Koh SHINOHARA (Japan)<br>**Symptom profiles and stool shedding dynamics from a first-in-human Salmonella paratyphi murium-controlled human infection model**: Christopher SMITH (United Kingdom)<br>**Prevalence of campylobacteriosis and antimicrobial resistance in Vall�s Occidental: a three-year descriptive study**: Sofia NARV�EZ MORALES (Spain)<br>**Salmonella typing: from serum agglutination to WGS**: Irene MILETO (Italy)<br>**Salmonella enterica serotypes causing infection in Kuwait during 2018-2021, determined by multi-locus sequence typing and whole-genome sequencing**: Amani ALFADHLI (Kuwait)<br>**Description of the first two human cases of infection with Helicobacter zhangjianzhongii, a new Helicobacter closely related to Helicobacter canis**: Philippe LEHOURS (France)<br>**Audit of enteric fever management in Manchester, UK: opportunities for antimicrobial stewardship due to high rates of ceftriaxone susceptibility**: Joseph THOMPSON (United Kingdom)<br>**Clinical and microbiological differences in Klebsiella pneumoniae liver abscess by metastatic spread**: Hyun Ah KIM (Republic Of)<br>**Global warming can exacerbate the infectious diseases occurrence: an analysis of Brazilian typhoid fever cases over 17 years, 2007-2024**: Wania FREITAS (Brazil)<br>**Short-course vs long-course antibiotic therapy for pyogenic liver abscess: a retrospective cohort study**: Geoffrey ROSSI (France)<br>**Identification of potentially new anti-infectives against Helicobacter pylori by repurposing FDA-approved drugs**: Dietmar PFEIFFER (Germany)<br>**Comparison of the high-dose dual treatment with standard quadruple treatment methods containing bismuth subcitrate as the first line of treatment in eradicating Helicobacter pylori infection**: Mohsen ROKNI (Islamic Republic Of)<br>**Diagnostic stewardship for paediatric diarrhea: a qualitative study of parent and provider perspectives**: Anna JONES (United States) |
| 13/04 | 12:00 - 13:30 | PS015 | 02e. Community-acquired urinary tract & genital tract infections (incl epidemiology, clinical, imaging, treatment & prevention) |  | **Microbiome analysis of cervical cancer identified Stenotrophomonas as a potential pathogen involved in tumor progression**: Shruptha KUMARI (India)<br>**Empirical ESBL vs NON-ESBL therapy in a cohort of patients admitted to the emergency department for urinary tract infections: the UTILY study, a multicentre prospective study**: Ilaria DE LUCA (Italy)<br>**Scoping review of reported outcomes in clinical trials on complicated urinary tract infections**: Sebastiaan MOGGRE (Netherlands)<br>**A brief look at the genome of Treponema pallidum in clinical samples from Slovenian patients**: Tina TRIGLAV (Slovenia)<br>**Varied community burden of Chlamydia trachomatis and Neisseria gonorrhoeae infections by anatomic site in men who have sex with men: a longitudinal study**: Rui ZHANG (China)<br>**Effect of E.coli on plasma NTproBNP levels in patients cardiosclerosis after myocardial infarction**: Sevinc ALIYEVA (Azerbaijan)<br>**TechTrials' Brazilian public health documentation of urinary tract infection during COVID-19 pandemic**: Bruna DA SILVA MIRANDA (Brazil)<br>**Adjunctive treatment with doxycycline for the treatment of Mycoplasma genitalium infection: a systematic review**: Tadhg SULLIVAN (United Kingdom)<br>**In vitro activity of thiamphenicol against drug-susceptible and -resistant strains of Mycoplasma genitalium**: Sofie Skovmand RASMUSSEN (Denmark)<br>**Chronic bacterial prostatitis a neglected disease: reevaluation of  pathogen spectrum and new treatment options**: Markus HELL (Austria)<br>**Investigation of individuals diagnosed with ocular syphilis, with and without HIV**: Murat Hakan KIR (T�rkiye)<br>**"Ex vivo-response" to antibiotic therapy in urinary tract infection: early treatment response detected by monitoring bacterial counts in consecutive urines**: Bastian DIRK (Germany)<br>**Surveillance of STIs in symptomatic male patients attending the STI clinic of the university hospital in Buenos Aires, Argentina: high prevalence of extragenital infections**: Maria Lucia GALLO VAULET (Argentina)<br>**Ocular syphilis frequently presents without known sexual risk factors: the importance of ophthalmology screening**: Wayne LEUNG (Canada)<br>**Urinary tract infection related antimicrobial resistance burden in hospitalised patients over 10 years: a national bottom-up initiative for disease and AMR burden on public healthcare data 2013-2022.**: Carlos KIFFER (Brazil)<br>**Urinary tract infection burden and trend in hospitalised patients over ten years: a national bottom-up initiative for disease burden on public healthcare data, 2013-2022**: Carlos KIFFER (Brazil)<br>**Pelvic inflammatory disease in hospitalised patients: a retrospective single-centre analysis in developing country**: Oguzhan ACET (T�rkiye)<br>**Impact of bacteraemia on clinical outcomes and costs in urinary tract infections: a retrospective study**: Eleni POLYZOU (Greece)<br>**Designing and validating real-time PCR assays for Prevotella bivia, Peptostreptococcus anaerobius, and Dialister micraerophilus, three genital anaerobic bacteria associated with HIV acquisition**: Sydney NELSON (United States)<br>**Is Haemophilus sp. a pathogenic species to consider in the clinical entity of urethritis?**: Alicia BORONAT MU�OZ (Spain)<br>**Utilisation of a simplified and practical algorithm to assess potentially unnecessary antibiotic use for suspected urinary tract infections in nursing homes**: Carl LLOR (Spain)<br>**Chlamydia trachomatis prevalence in patients suspected with keratitis: unravelling insights among diverse eye specimen type**: Arash LETAFATI (Islamic Republic Of)<br>**Screening for sexually transmitted infections in a cohort of people living with HIV: a retrospective analysis of a single centre in 2023**: Neva BRACCIALARGHE (Italy)<br>**Sexually transmitted infections and their impact on bacterial vaginosis: findings from a one-year review**: Patricia GARCIA (Spain)<br>**Individualised autovaccine therapy significantly reduces recurrence and improves quality of life in women with recurrent urinary tract infections (rUTI), regardless of non-modifiable risk factors (nmRF).**: Vicens DIAZ BRITO FERNANDEZ (Spain)<br>**Cumulative antibiograms can support adequate management of urinary tract infections if done properly**: Jan Z�VORA (Czech Republic)<br>**Trends and clinical characteristics of anorectal Chlamydia trachomatis infections: a comparative analysis of lymphogranuloma venereum (LGV) and non-LGV serovars**: Loreto SANGORRIN-LAPIEZA (Spain)<br>**Distribution of human papillomavirus genotypes in endocervical exudates from women, Malaga, Spain, 2021-2024**: Marta LERATE ALBA (Spain)<br>**Heterogeneity in assessing the burden of urinary tract infections: a literature review and recommendations**: Elena ADDIS (Italy)<br>**Feasibility of pooling urogenital and extragenital specimens for sexual transmitted infections (STI) screening in asymptomatic individuals**: Aida RAMIREZ MARINERO (Spain)<br>**Validity of leukocyte esterase and/or nitrite results for the diagnosis of bacteriuria in older individuals: a systematic review and meta-analysis**: Ana MORAGAS MORENO (Spain)<br>**The prevalence of sexually transmitted infection pathogens in a Korean single-commercial laboratory over the last three years**: Dongheui AN (Republic Of)<br>**Impact of age on antibiotic resistance and efficacy of antibiotics for women with uncomplicated urinary tract infection**: Steven ARONIN (United States)<br>**Immunosuppressive macrolides inhibit transcription factors and epithelial-mesenchymal transition (EMT) related parameters induced by Chlamydia trachomatis infection in conjunctival epithelial cells**: Javeria PERVAIZ (Austria)<br>**High prevalence and incidence of bacterial sexually transmitted infections among HIV pre-exposure prophylaxis users in Croatia, 2018-2022**: Loris MOCIBOB (Croatia)<br>**Diagnosis and management with urinary behavioral therapy of recurrent acute bacterial cystitis in women: preliminary results of the URICA study**: Maxime VALL�E (France)<br>**Population structure of CTX-M-producing uropathogenic Escherichia coli recovered from patients with complicated urinary tract infection (cUTI) in a high complexity hospital in Bogota (Colombia)**: Juan Carlos GARC�A-BETANCUR (Colombia)<br>**Epidemiological profile of Neisseria gonorrhoeae in the west of Ireland**: Fiona MURPHY (Ireland)<br>**Multi-anatomic site prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection among male in HIV care**: Ngai Sze WONG (China)<br>**Prevalence of sexually transmitted infections in women infected with human papilloma virus**: Miriam LATORRE-MILL�N (Spain)<br>**Performance evaluation of a boric acid-free device designed for pre-analytics in urine culture testing for UTIs**: Valentina IMPERADORI (Italy)<br>**Aerococcus spp., emerging pathogens isolated from a Spanish tertiary care hospital**: Mar�a DE LA MATA FERN�NDEZ (Spain)<br>**Prospective evaluation of ESBL risk factors and empirical treatment based on culture result suitability of community-acquired pyelonephritis**: G�lsah GELISIG�ZEL (T�rkiye)<br>**Streptococcus dysgalactiae as the cause of peripartum infections: a population-based cohort study with a phylogenetic analysis of hospital clusters**: Erik SENNEBY (Sweden)<br>**Vulnerability of people living whith autism: the urgency of inclusive sexual education**: Jeferson MANOEL TEIXEIRA (Brazil)<br>**Actively looking for cases of lymphogranuloma venereum in the southern Tenerife population**: Julia ALCOBA FL�REZ (Spain)<br>**Evaluating a boric acid-free device designed for UTIs pre-analytics in urine molecular and antigenic testing**: Valentina IMPERADORI (Italy)<br>**Investigation of Streptococcus agalactiae colonisation in pregnancy by culture and molecular methods**: Bilge MAZLUMOGLU (T�rkiye)<br>**Antibiotic class comparisons for acute pyelonephritis: a systematic review of randomised, controlled trials**: Digbijay KUNWAR (Nepal)<br>**Breaking the cycle: barriers to UTI prevention in primary care**: Merel E.P. WILMSEN (Netherlands)<br>**A multi-centre retrospective study on urinary tract infections from patients in Turkey reveals alarming antibiotic resistance levels**: Cansel VATANSEVER (T�rkiye)<br>**Microbiology and risk factors for bacteremic urinary tract infection: insights from the largest urological centre in Pakistan**: Asma NASEEM (Pakistan)<br>**Antimicrobial prophilaxis in endourological procedures: early results and challenges**: Carla MIMOSO SANTOS (Portugal)<br>**Could second and third trimester urine culture increase the detection of Group B Streptococcus (GBS) colonisation in pregnancy?**: Alicia GALAR (Spain)<br>**The controversial significance of Stenotrophomonas maltophilia isolation in urine samples: insights from a 15-year single-centre experience**: Chiara MACI (Italy)<br>**Patient characteristics and clinical outcomes among patients with complicated urinary tract infection caused by extended-spectrum beta-lactamase-producing Enterobacterales: a US cohort study**: Alanna FARRELL-FOSTER (United States)<br>**Exudative sexually transmitted infections among PrEP-users, people living with HIV and general population: a retrospective observational study**: Ayla YARCI CARRION (Spain)<br>**Temporal trends of sexually transmitted infections from 2018 to 2023 in two community hospitals in Liguria**: Rachele PINCINO (Italy)<br>**A multicentre, observational study on efficacy and safety of six-month long-term therapy with Uro-Vaxom in patients with recurrent urinary tract infection**: Jeong Woo LEE (Republic Of)<br>**Infections caused by Mycoplasma genitalium: an emerging pathogen**: Jose BAEZA ROS (Spain)<br>**Does age influence the effectiveness of OPAT programmes?**: Azucena RODRIGUEZ-GUARDADO (Spain)<br>**Improving urine culture appropriateness and reducing unnecessary testing through education and feedback in a hospital setting**: Debby BEN-DAVID (Israel)<br>**Treatment failure in patients with uncomplicated urinary tract infection in the United States: a latent class cluster analysis**: Meghan LUCK (United States)<br>**Understanding polymicrobial UTIs : results from a retrospective study and prospective sample collection indicate significant differences in urinary microbial composition and AMR patterns by sample type**: Ashim Kumar DUBEY (Switzerland)<br>**Establishment and validation of a lower genital tract Neisseria gonorrhoeae infection in ovariectomised mice**: David VALTIERRA (United States)<br>**Exposure to continuous suppressive antibiotic therapy in women with recurrent urinary tract infections and the severity of infectious complications: a population-based cohort study**: Carl LLOR (Spain)<br>**What is the most effective culture-based detection approach for Streptococcus agalactiae colonisation in pregnant women?**: Franziska Dorothee SCHULER (Germany)<br>**The O25b-ST131 pandemic uropathogenic E. coli in India: examining antibiotic resistance, virulence, and phylogenetic distribution in community-acquired UTIs**: Deepak KOCHER (India)<br>**Five-Year Review of Diagnostic Practices and Antibiotic Prescribing Patterns for Acute Cystitis: Insights from a University Hospital in Thailand**: Naruemit SAYABOVORN (Thailand)<br>**Streptococcus agalactiae carriage among women living in Tunis, Tunisia over a period of ten years**: Skander CHAABOUNI (Tunisia)<br>**A single-centre outpatient parenteral antimicrobial therapy (OPAT) management experience for severe pelvic inflammatory disease in Ireland**: Kaitlyn O'BRIEN (Ireland)<br>**Prevalence of Streptococcus agalactiae colonisation in the general female population and description of its phenotypic resistance profile**: Marta ROLO (Spain)<br>**Molecular surveillance of Neisseria gonorrhoeae in north Spain**: Mar�a Del Rosario ALMELA FERRER (Spain)<br>**Optimising diagnostic and antibiotic stewardship with BLADDER score**: Jaya PRASANTHI (India)<br>**LGV are we trying too hard?**: Mikel URRUTIKOETXEA-GUTIERREZ (Spain)<br>**Causative  microorganisms  of sexually  transmitted infections in a STI clinic during the year 2024**: Jorge-Alfredo PEREZ-GARC�A (Spain) |
| 13/04 | 12:00 - 13:30 | PS016 | 02f. Community-acquired skin, soft tissue, bone & joint infections (incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses) |  | **Blood ozonisation as a complementary treatment in infective chronic wound healing: a single centre experience**: Alberto PAGOTTO (Italy)<br>**Comparative analysis of community-acquired and hospital-acquired necrotising soft-tissue infections in critically ill patients: a ten-year retrospective study**: Michael THY (France)<br>**Clinical epidemiology, risk factors, and outcomes of carbapenem-resistant Klebsiella pneumoniae wound infection**: Yan FENG (China)<br>**Clonal persistence of methicillin-susceptible Staphylococcus aureus ST672 in paediatric patients with invasive infections: genomic insights into virulence and resistance**: David Eduardo JU�REZ HINOJOS (Mexico)<br>**Anti-virulence activity of dalbavancin against clinical isolates of Staphylococcus aures: a comparison with "gold standard" antibiotics in paediatric infections**: Alessandra GIARDINA (Italy)<br>**Prevalence and characterisation of PVL-positive MRSA isolates in Moravian region, Czech Republic, 2021-2024**: Ren�ta KARP�SKOV� (Czech Republic)<br>**Comparative efficacies of amoxicillin/clavulanate acid, oxacillin alone or in combination with rifampin against experimental methicillin-susceptible Staphylococcus aureus (MSSA) joint prosthesis infection in rabbit**: Azzam SALEH-MGHIR (France)<br>**Epidemiology and microbiological patterns of fracture related infections among different regions in Brazil: observational and multicentre cohort study**: Rafael BRULL TUMA (Brazil)<br>**Outpatient management of complex bone and joint infections in a virtual hospital setting**: Simran THADANI (United Kingdom), Simran THADANI (United Kingdom)<br>**Clinical characteristics and follow-up of children with primary haematogenous osteomyelitis and septic arthritis: a single-centre experience from Hungary**: Szofia HAJ�SI-KALCAKOSZ (Hungary)<br>**Ceftazidime�ciprofloxacin twice-daily has better outcomes to piperacillin-tazobactam infusion for necrotising otitis externa: a retrospective study**: Sathyavani SUBBARAO (United Kingdom)<br>**Vessels, nerves, and vision: the overlooked trio in diabetic foot infections**: Cansu TOL (T�rkiye)<br>**The role of dalbavancin in managing acute bacterial skin and skin structure infection with treatment noncompliance**: Layan AKKIELAH (Canada)<br>**Use of dalbavancin as an alternative therapy for osteomyelitis, spondylodiscitis and prosthetic joint infections: a retrospective single-centre study**: Filippo BARRECA (Italy)<br>**Skull base osteomyelitis (SBO): an observational study**: Nisarg SHAH (India)<br>**Assessment of topical phage therapy for Pseudomonas aeruginosa burn wound infection**: Sidrah ASGHAR (Pakistan)<br>**Omadacycline for skin and soft tissue infections: a multicentre retrospective analysis of efficacy and safety in real-world clinical practice**: Mohammed AL MUSAWA (United States)<br>**Prevalence of PVL toxin in S. aureus isolated from patients with invasive infections in a tertiary hospital in Navarra**: Ander URIBARRI (Spain)<br>**Streptococcus agalactiae, a frequent but not so well-known cause of bone and joint infections**: Simon JAMARD (France)<br>**Improved peroxidase-like activity and photothermal/photodynamic effect of MAX phase with copper single-atom sites for facilitating diabetic wound repair**: Mei YANG (China), Mei YANG (China)<br>**Emerging insights into Corynebacterium kroppenstedtii associated breast abscesses: a retrospective study**: Sreethish SASI (Qatar)<br>**Risk factors for erysipelas and cellulitis: a national cohort study**: Filip JANS�KER (Sweden)<br>**Diagnostic value of CT-guided percutaneous needle biopsy and/or aspiration in suspected spondylodiscitis cases: five-year audit at Ram�n y Cajal University Hospital**: Marta GONZ�LEZ-SANZ (Spain)<br>**In vitro evaluation of the antibacterial activity of hypochlorite products**: Karolina DYDAK (Poland)<br>**A retrospective review of granulomatous mastitis over four years in a large district general hospital serving a diverse patient population: largest UK dataset**: Nicolas MASSIE (United Kingdom)<br>**Dramatic upsurge of invasive Group A streptococcal infections during 2023-2024 among younger patients without comorbidities in western Sweden**: Ulrika SNYGG-MARTIN (Sweden)<br>**Effectiveness of phage therapy for treatment of acute vs chronic wounds**: Anna NANAVA (Georgia)<br>**Clinical efficacy and safety of omadacycline in the treatment of enterococcal infections**: Sean VAN HELDEN (United States)<br>**Evaluation of the antibiotic treatment against a polymicrobial biofilm made of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus**: Est�baliz TORRECILLA-S�DABA (Spain)<br>**Patients' characteristics, treatment and prognosis of Enterobacter cloacae osteomyelitis: about 146 patients**: L�na SANDJAKIAN (France)<br>**Low-grade infections as a potential cause of arthrofibrosis following total knee arthroplasty**: Ander URIBARRI (Spain)<br>**Optimising regimen of co-amoxiclav (ORCA): the safety and efficacy of intravenous co-amoxiclav at higher dosing frequency in patients with diabetic foot infection**: Jun Jie TAN (Singapore)<br>**Culture-negative native vertebral osteomyelitis: ten-year retrospective analysis at the Mayo clinic**: Rita IGWILO-ALANEME (United States)<br>**High prevalence of pathogenic methicillin-susceptible Staphylococcus aureus ST398-MSSA among atopic dermatitis patients in Portugal**: Diana CAIEIRO (Portugal)<br>**The role of antimicrobial prophylaxis in the treatment of snakebite: a systematic review**: Samuel MOODY (United Kingdom)<br>**External validation of the baseline recurrence risk in cellulitis (BRRISC) score and the additional impact of incorporating acute clinical response**: Martin LLEWELYN (United Kingdom) |
| 13/04 | 12:00 - 13:30 | PS017 | 02g. Community-acquired nervous system and other multi-system or invasive bacterial infections?(incl epidemiology, clinical, imaging, treatment & prevention) |  | **A retrospective study of intracranial abscess and implications of early oral antibiotic switch**: Vishal VARGHESE (United Kingdom)<br>**Changing aetiology and outcomes of brain abscesses in a UK tertiary neurological centre**: Orla HILTON (United Kingdom)<br>**Origins of S. epidermidis strains causing endophthalmitis**: Leandro Andr�s ESCOBAR-HERRERA (Denmark)<br>**In-hospital clinical outcomes of adult tetanus patients admitted at a tertiary government hospital**: Amille Joy TY-LUISTRO (Philippines)<br>**The spectrum of CNS infections at a teaching hospital in Kenya**: Adeel SHAH (Kenya)<br>**Characterisation of paediatric pneumococcal meningitis before and after introduction of 10-valent pneumococcal conjugate vaccine in Tunisia, 2016-2022**: Khaoula MEFTAH (Tunisia)<br>**Neurobrucellosis: a retrospective cohort study in Mashhad, Iran**: Fereshteh SHEIBANI (Islamic Republic Of)<br>**Clinical and microbiological characteristics of invasive pneumococcal diseases in a Hungarian tertiary care institute: 20 years and counting**: B�la K�D�R (Hungary)<br>**Visual impairment in community acquired bacterial meningitis**: Eva Nadine SCHEPERS (Netherlands)<br>**Exploring the relationship between environmental change and meningitis risk in Angola**: James BEVAN (United Kingdom)<br>**Community-acquired bacterial meningitis in adults in the Netherlands: outcome and neurological sequelae**: Evelien Hendrika Gerarda Maria DROST (Netherlands)<br>**Hospital-based surveillance of paediatric pneumococcal meningitis in southern Vietnam: clinical features and antibiotic resistance patterns (2012-2023)**: Cong Hieu TRUONG (Vietnam)<br>**Streptococcus pneumoniae meningitis: clinical review and antimicrobial susceptibility trends over 13 years (2012-2024), a tertiary centre experience in the United States**: Ayesha SAMREEN (United States)<br>**Screening for neuronal auto-antibodies in adults after community-acquired bacterial meningitis**: Steven Lukas STAAL (Netherlands)<br>**Pneumococcal meningitis in adults: a 33-year analysis of serotype distribution and antimicrobial resistance**: Sara CALVO-SILVERIA (Spain)<br>**Trends in primary meningitis: a 14-year retrospective study at hospital universitario Nuestra Senora de la Candelaria, Tenerife**: Maria De Las Huertas GARCIA ATIENZA (Spain)<br>**Comparing the radiological features of infective ring-enhancing brain lesions: a four-year retrospective study in a tertiary referral centre in Singapore**: Edwin SNG (Singapore) |
| 13/04 | 12:00 - 13:30 | PS018 | 02h. Zoonotic bacterial infections (incl vector-borne pathogens, excl AMR) |  | **Q fever in Majorca, Spain**: Mercedes GARCIA (Spain)<br>**Prevalence of Borrelia burgdorferi sensu lato infection in the Czech Republic**: Roman CHLIBEK (Czech Republic)<br>**Comparative evaluation of the infectious potential of zoonotic and human atypical enteropathogenic Escherichia coli (aEPEC) strains using in vivo infection models**: Helv�cio CARDOSO CORR�A P�VOA (Brazil)<br>**Seroprevalence of Bartonella henselae IgG among the healthy population in Korea and associated risk factors**: Anna LEE (Republic Of)<br>**Epidemiological and clinical characteristics of psittacosis using cgMLST by capture sequencing: a multicentre, genome-based study in China**: Jintao HE (China)<br>**Sitafloxacin monotherapy vs standard rifampicin-doxycycline dual therapy for uncomplicated brucellosis: a multicentre, open-label, randomised, non-inferiority trial**: Gang WANG (Belgium)<br>**Functional characterisation of CD57+ OMP-specific CD8+ T cells in acute and chronic brucellosis**: Guanmin YUAN (China)<br>**Tick-borne pathogens in Switzerland: surveillance of Rickettsia, Anaplasma, Coxiella, and Chlamydiae in Ixodes ricinus**: Ehsan GHASEMIAN (Switzerland)<br>**Clinical evaluation of a novel real-time PCR assay for Leptospira DNA detection: advancing leptospirosis diagnosis**: Henar ALONSO-EZCURRA (Spain)<br>**Changing incidence of human granulocytic anaplasmosis in Slovakia, Central Europe**: Klaudia Maria SVIRLOCHOVA (Slovakia)<br>**Quality assessment of the diagnostic testing for Q fever: lessons from five years of external quality control in medical laboratories**: Nathalie WEISS (Germany)<br>**Bacterial genera identified by metagenomics in ticks collected from a Brazilian university**: Debora Stefany FERNANDES GUEDES (Brazil)<br>**TIck-borne lymphadenopathy in northeastern France: human and vector clinical-epidemiological study**: Pierre BOYER (France)<br>**Clinical and epidemiological characteristics of leptospirosis in the Kharkiv region, Ukraine in 2022-2024**: Yaroslava BURMA (Ukraine)<br>**112 year global analysis of human botulinum toxin serotyping**: Tristan LEAROYD (United Kingdom)<br>**Evaluation of human brucellosis patients with and without decreasing serum agglutination test titers**: Ayse Nur CEYLAN (T�rkiye)<br>**A case series of rickettsial infections**: Meriem ABDELJELIL (Tunisia)<br>**Comparison of different treatments and durations for brucellosis: a randomised study**: Petek KONYA (T�rkiye)<br>**Identification of Coxiella species by metagenomics in in ticks collected from a Brazilian university**: Debora Stefany FERNANDES GUEDES (Brazil)<br>**Rickettsiosis by Rickettsia aeschlimannii from  Hyalomma marginatum tick bite in a cattle breeder (southern Italy)**: Maria Grazia CARIGLIA (Italy)<br>**Dengue mortality in southeast Asia region: exploring regional trends and disparities**: Supta Rani SARKER (Bangladesh)<br>**Claims-based algorithm to classify Lyme disease manifestations**: Holly YU (United States)<br>**The burden of Lyme disease (BOLD) study in Europe: PTLD in six European countries and an examination of its criteria**: Holly YU (United States)<br>**Metabolomic profiling of cerebrospinal fluid in Lyme neuroborreliosis: a diagnostic insight**: Ilari KUUKKANEN (Finland)<br>**Background incidence rates of health outcomes for Lyme disease vaccine safety monitoring in hospitalised and outpatient German populations**: Karla Therese L. SY (United States)<br>**Epidemiology of leptospirosis in the United Kingdom**: Ameeka THOMPSON (United Kingdom)<br>**Epidemiology and clinical outcomes of scrub typhus in rural and urban settings: a hospital-based study from south India**: Arvind Krishna DEVARAJ (India)<br>**Foodborne botulism in Brazil: analysis of cases over the last 17 years (2007-2024) and occurrence of an outbreak related to the consumption of chicken mortadella at popular fairs**: Wania FREITAS (Brazil)<br>**Spinal brucellosis: the great mimicker**: Helmi ERNANDES (Tunisia)<br>**Epidemiological and clinical outcomes of human monocytic ehrlichiosis (HME) presenting to a single centre university hospital in the state of Florida, USA**: Liliana FRANCO MOREIRA (United States)<br>**Scrub typhus trend in northeastern Thailand, 2011-2023**: Yupin SUPUTAMONGKOL (Thailand)<br>**Influence of different Leptospira serovars on lung damage in leptospirosis**: Olena ZUBACH (Ukraine)<br>**Development and validation of the microarray for the detection of IgG against Bacillus anthracis, Yersinia pestis and Francisella tularensis**: Olga STUKOLOVA (Russian Federation)<br>**Diagnosis and visualisation of biofilms in Bartonella quintana endocarditis**: Kurosh SARBANDI (Germany)<br>**Comparison of gene detection rates in whole blood, eschar, and erythematous skin samples by polymerase chain reaction in Japanese spotted fever cases**: Shigetoshi SAKABE (Japan)<br>**Challenges in case management of brucellosis: prospective study from an endemic region**: �zlem ALHAN (T�rkiye)<br>**Evaluating the value of serological follow-up in managing Q fever infections**: Pablo PILLADO ALONSO (Spain)<br>**Epidemiological evolution of leptospirosis in French Guiana: a descriptive and comparative analysis of 2016-2022 cases with 2007-2014**: Mathilde ZENOU (France)<br>**Development of monoclonal antibodies and immunoassays targeting VlsE to improve Lyme disease diagnosis**: Victoria DOLANGE (France)<br>**Detection of Leptospira licerasiae, a P2 sub-clade species, in febrile patients, rodents, and livestock in Sri Lanka**: Nipun RATHNAYAKE (Sri Lanka)<br>**Clinical data on symptomatic cutaneous reinfections due to Borrelia burgdorferi sensu lato in Europe: erythema migrans from reinfection differs from primary erythema migrans**: Franc STRLE (Slovenia)<br>**High seroprevalence of Coxiella burnetii among blood donors in Mallorca: implications for diagnostics and surveillance**: Andr�s SU�REZ IBARRA (Spain)<br>**A novel approach for utilising IgG avidity in Lyme serology**: Andr�s Z�KA (Hungary)<br>**The role of serology in the diagnosis of Brucella endocarditis: a literature search**: Reyhan BALKAYA DEMIRTAS (T�rkiye)<br>**Neoehrlichia mikurensis and Borrelia miyamotoi: emerging and neglected pathogens in northern Italy**: Emanuela OLIVIERI (Italy)<br>**Molecular detection of Borrelia burgdorferi in off-season questing ticks: impact of environmental and climatic variables**: Alessandra Mistral DE PASCALI (Italy)<br>**The epidemiology of brucellosis in Oman: a seven-year retrospective analysis, 2017-2023**: Ahad AL BALUSHI (Oman) |
| 13/04 | 12:00 - 13:30 | PS019 | 02i. Other intracellular or rare bacteria |  | **Low counts predict mortality in melioidosis: a retrospective cohort study**: Prithvishree RAVINDRA (India)<br>**Characterisation of an emerging pathogen Pantoea dispersa causing neonatal sepsis in a tertiary healthcare facility in Pakistan**: Julia RZASKA (United Kingdom)<br>**Melioidosis in India: emerging or neglected?**: Ayush GUPTA (India)<br>**Retrospective review of patients with clinically significant Fusobacterium gonidiaformans infection**: Ellen SUGRUE (Ireland)<br>**Enteropathogenic Providencia alcalifaciens: a subgroup of P. alcalifaciens that causes diarrhea**: M. John ALBERT (Kuwait)<br>**Emergence of cases of neurolisteriosis in a single centre: insights into genomic analysis**: Nadim CASSIR (France)<br>**Survival mechanism of pancreatic tumor bacteria and their ability to metabolise chemotherapy drugs**: Zara Ahmad KHAN (Sweden) |
| 13/04 | 12:00 - 13:30 | PS039 | 05a. Drug discovery and new compounds mechanisms of action & spectrum, preclinical data & basic pharmacology�(incl drug design, investigational and non-traditional therapeutics) |  | **Metformin attenuates quorum sensing-regulated virulence factors in Pseudomonas aeruginosa: novel aspects of a multifaceted drug**: Lavanya KHULLAR (India)<br>**Metallo-beta-lactamase inhibitor APC148: impact of choice of Mueller-Hinton broth brand on results from antimicrobial susceptibility testing**: Veronika SMITH (Norway)<br>**Activity of bacteriophages targeting Klebsiella pneumoniae**: Regis TOURNEBIZE (France)<br>**PZ-2645 as a potential agent against biofilm-forming vancomycin-resistant Enterococci (VRE)**: Karolina KLESIEWICZ (Poland)<br>**Eco-friendly resveratrol nano-capsules to combat virulence of methicillin-resistant Staphylococcus aureus**: Michael SHEHAT (Egypt)<br>**A novel class of antibiotics against multidrug-resistant Klebsiella pneumoniae**: Raquel Lobato ALMEIDA (Portugal)<br>**Assessing the therapeutic potential of an apramycin-gallium combination for treating Acinetobacter baumannii lung infections**: Anissa BENKHALED (France)<br>**Effect of zosurabalpin, a pathogen-focused antibiotic, on the gut microbiome of healthy participants**: Andrej TRAUNER (Switzerland)<br>**Phage-antibiotic synergy induces genomic restructuring in multidrug-resistant Pseudomonas aeruginosa to mitigate resistance and virulence**: Yang ZHONG (Singapore)<br>**Enhancing the efficacy of phytic acid as an antimicrobial agent**: Maryam AL SHARQI (United Arab Emirates)<br>**Kill two strains with one phage: broadening the host range of an Italian Acinetobacter baumannii bacteriophage**: Stefano STRACQUADANIO (Italy)<br>**Genomic surveillance as a scalable framework for phage therapy against critically resistant bacterial pathogens**: Balint KINTSES (Hungary)<br>**Effect of GCurNPs on biofilm formation and quorum sensing genes of Pseudomonas aeruginosa**: Jyothi EMBEKKAT KAVIYIL (India)<br>**Potential of phage training to extend the host spectrum of anti-Staphylococcus aureus phages**: Matthieu DEGREZE (France)<br>**Antibacterial susceptibility testing of bacteriophages against Gram-negative pathogens**: Paschalis PARANOS (Greece)<br>**Comparative assessment of interactions between phages and antibacterial agents inhibiting DNA and protein synthesis against Gram-negative clinical isolates**: Paschalis PARANOS (Greece)<br>**Phage heteroresistance in multidrug-resistant Klebsiella pneumoniae clinical isolates**: Paschalis PARANOS (Greece)<br>**Unraveling novel approaches to manage biofilm-associated infection**: Nouha BENTEBBAL (United Arab Emirates)<br>**FNDR-20364: a novel topical antibiotic for skin infections caused by Gram-positive bacteria**: Naveenkumar C N (India)<br>**Novel bacteriophage therapy for multi-drug resistant methicillin-resistant Staphylococcus aureus (MRSA) infectious keratitis**: Thet Tun AUNG (Singapore)<br>**In vitro effectiveness of endodontic triple antibiotic associated with daptomycin**: Natalia IORIO (Brazil)<br>**Wound healing potentials of crude bacteriocins from Lactobacillus rhamnosus and Lactobacillus fermentum  isolated from decaying fruit using albino mice model**: Favour Okwukweka NWAJIOBI (Nigeria)<br>**Evaluation of inhibition of biofilm production after treatment with the combination of phage PSE1720 and meropenem,  in Pseudomonas aeruginosa strains isolated from people with cystic fibrosis**: Giulia TOCCACIELI (Italy)<br>**Go big or go home? Efficacy of two- vs three-phage cocktail targeting DNS-MRSA**: Callan BLEICK (United States)<br>**Beyond the surface: how the transdermal delivery of cannabidiol can unlock new antimicrobial sustained effects**: Tihauan BIANCA MARIA (Romania)<br>**In vitro activity of cefepime/enmetazobactam and comparators against ESBL and plasmid-AmpC-producing Enterobacterales**: Anne SANTERRE HENRIKSEN (Denmark)<br>**In vitro efficacy of cefepime/enmetazobactam against AmpC beta-lactamase-producing Enterobacterales**: Clement MARLAT (France)<br>**Interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp.**: Balaji VEERARAGHAVAN (India)<br>**?????In vitro activity of once-daily, investigational combination, ertapenem/zidebactam (WCK 6777) against cefiderocol non-susceptible E. coli  harbouring NDM and PBP3 insertions**: Balaji VEERARAGHAVAN (India)<br>**Impact of Pseudomonas aeruginosa biofilm composition on bacteriophage activity: overcoming barriers**: Sean VAN HELDEN (United States)<br>**Monitoring of PHAXIAM's phage spectrum of activity on clinical strains (PST CE-IVD)**: Rafael GOMES VON BOROWSKI (France)<br>**Novel 1,3,4-oxadiazole derivatives as promising antibacterial agents**: Theresa HERMANN (Austria)<br>**Italian compassionate phage therapy pipeline: in vitro evaluation of bacteriophages to treat an Acinetobacter baumannii prosthetic joint infection**: Caterina FERRETTI (Italy)<br>**Sustained antimicrobial activities of antibiotic and metal nanoparticles loaded biopolymers**: Sibel DOSLER (T�rkiye)<br>**Phage therapy and antibiotics combination as the best standard treatment for Klebsiella??????: urinary tract infections**: Rizka JARIAH (United Kingdom)<br>**The anti-virulence and immunomodulatory potential of the peptide oreoch-1 against enteroinvasive E. coli infection**: Anna DE FILIPPIS (Italy)<br>**Inhibition of gene expression by multiple mechanisms using locked-nucleic acid gapmers**: Angel MAGA�A (United States)<br>**Phage display-derived neutralising monoclonal antibody as possible vaccine against Staphylococcus aureus collagen adhesin CNA**: Elisa RESTIVO (Italy)<br>**New approach for high eradication of multidrug-resistant bacteria by biosynthesised copper oxide nanoparticle ST@CuONPs using Streptomyces thinghirensis sp. nov**: Souad LOQMAN (Morocco)<br>**Isolation and characterisation of bacteriophages against carbapenemase-resistant strains of Acinetobacter baumannii (CR-Ab)**: Elisa D'ALIESIO (Italy)<br>**Decoding the MIC-permeability relationship in Escherichia coli using advanced statistical machine learning approaches**: Stefan MILENKOVIC (Italy)<br>**Bacteriophages against pulmonary infection and colonisation of the gut by multidrug-resistant Klebsiella pneumoniae in murine models**: Anni-Maria �RM�L�-TIZNADO (Sweden)<br>**Does order of administration matter? Bacteriophage antibiotic combinations against DNS-MRSA isolates**: Callan BLEICK (United States)<br>**Bacteriophage EC10P1 re-sensitises multidrug-resistant Escherichia coli 456 to aztreonam/avibactam**: Andrea GARC�A NAVARRO (Sweden)<br>**Influence of outer membrane permeability and KPC amino acid variation on the activity of cefepime/enmetazobactam against KPC-producing Enterobacterales showing ceftazidime/avibactam resistance**: Roberto RILO-ANTELO (Spain)<br>**In vitro activity of aztreonam/durlobactam against MbetaL-producing Enterobacterales strains**: Ana Carolina RAMOS DA SILVA (United Kingdom)<br>**New potential antibacterial agents using natural product extracts against important foodborne pathogens**: Adriana SILVA (Portugal)<br>**Novel C5-alpha-substituted carbapenems targeting Mycobacterium abscessus: enhanced peptidoglycan protein binding and reduced BlaMab hydrolysis**: Eunjeong SHIN (United States)<br>**Efficacy of solid drug nanoparticles against MRSA: a promising approach to combat AMR**: Samantha DONNELLAN (United Kingdom)<br>**Activity of cefepime/enmetazobactam in highly resistant Gram-negative bacteria in a tertiary care setting in Germany**: Patricia BARTSCH (Germany)<br>**Multiplicity of infection ratios for determining phage activity**: Paschalis PARANOS (Greece)<br>**In vitro activity of a BV500 lead compound against M. abscessus and other NTMs**: Marija MILJKOVIC (Switzerland)<br>**Cefepime/zidebactam: a novel beta-lactam-enhancer mechanism based triple action BCH-DBO antibiotic**: Dilip DUBEY (India)<br>**Probiotics-loaded electrospun matrices: an innovative approach for enhanced wound healing**: Oksana GERULIS (Estonia)<br>**Susceptibility patterns of Pseudomonas aeruginosa isolates exhibiting difficult-to-treat resistance against available and upcoming beta-lactam agents**: Charalampos MYSTAKELIS (United States)<br>**Selection of Pseudomonas aeruginosa phages and improvement of their lytic activity for a therapeutic approach in lung infection**: Sara BOLOGNINI (Italy)<br>**Study of antibacterial activity of aromatic plants extracts on multiresistant bacteria of avian origin**: Naouel KLIBI (Tunisia)<br>**Broad coverage of antibiotic-resistant Klebsiella pneumoniae by multi-specific antibodies against the lipopolysaccharide O-antigen**: Antonio DIGIANDOMENICO (United States)<br>**In vitro activity of a novel synthetic macrocyclic peptide, BRII-693, against carbapenem-resistant A. baumannii and P. aeruginosa isolates from China**: Yun WU (China)<br>**Treating infected wounds with plasma-activated water in vivo in mice**: Katharina RICHTER (Australia)<br>**Bacteriophage-derived endolysin as a therapeutic protein candidate: in vitro activity, stability, and in vivo efficacy in an MRSA-induced skin wound model**: Semra TASDURMAZLI (T�rkiye)<br>**In vitro activity of gepotidacin against baseline uropathogens including drug-resistant phenotypes recovered from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections**: Nicole E. SCANGARELLA-OMAN (United States)<br>**Assessment of zosurabalpin activity in combination with other antibiotics**: Isabelle ERBETTI (Italy)<br>**Antibacterial-bacteriophage interactions: evaluation of E. coli kill kinetics using a combination of meropenem plus an E. coli phage cocktail**: Marie ATTWOOD (United Kingdom)<br>**Synergistic antibacterial activity of SC5005 and DHA against multidrug-resistant Mycobacterium abscessus without detectable resistance**: Hao-Chieh CHIU (China)<br>**Using marine sponge-derived pyrrole-imidazole alkaloids to combat antibiotic resistance**: Victoria KLEIN (United States)<br>**Identification of antibiotic-producing Pseudomonas guguanensis from seawater in Kuwait**: Khadijah DASHTI (Kuwait)<br>**Ready-to-eat food samples as sources of promising bacteriophages for the treatment of multidrug-resistant Klebsiellae including ST147-KL64 and the hypervirulent clone ST23-KL57**: Isidro GARC�A-MENI�O (Germany)<br>**Effect of cefepime/enmetazobactam (FEP-META) versus ceftazidime/avibactam (CAZ-AVI) in combination with aztreonam (ATM) against clinical isolates resistant to different β-lactamase classes**: Alina Karoline NUSSBAUMER-PR�LL (Austria)<br>**The in vitro activity of aztreonam-avibactam against Enterobacterales isolates positive for metallo-beta-lactamases or serine-carbapenemases by commonly used in vitro diagnostic kits**: Mark ESTABROOK (United States)<br>**Phage tail like bacteriocins or tailocins as antimicrobial agents against Pseudomonas aeruginosa clinical strains**: Clara IBARGUREN  QUILES (Spain)<br>**Enhanced antimicrobial activity of the novel polymyxin analogue SPR206 compared to colistin against colistin-susceptible and colistin-resistant Acinetobacter baumannii**: Michelle OUTEDA GARC�A (Spain)<br>**Conjugated oligoelectrolytes: a novel antibiotic platform with activity against nontuberculous mycobacteria**: Kaixi ZHANG (Singapore)<br>**Activity of the novel combination therapies cefepime/nacubactam against 12,613 clinical isolates of Enterobacterales collected worldwide during 2021-2023**: Stephen HAWSER (Switzerland)<br>**Singlet-oxygen producing BODIPYs for topical treatment of wound infections: an in vitro light activated antibacterial study**: Kaja TURZANSKA (Ireland)<br>**Susceptibility of a worldwide collection of 12,613 Enterobacterales isolated during 2021-2023 to the novel combination therapy aztreonam/nacubactam**: Stephen HAWSER (Switzerland)<br>**Cefepime/enmetazobactam as a carbapenem-sparing alternative: activity against extended-spectrum beta-lactamase-producing Enterobacteriaceae, with or without carbapenemases**: Jose GUTIERREZ-FERNANDEZ (Spain)<br>**In vivo and in vitro activity of durlobactam vs Enterobacterales**: Samir MOUSSA (United States)<br>**In vitro susceptibility studies of several novel antimicrobial drugs against carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates**: Jie ZHANG (China)<br>**Chemistry centre for combating antibiotic resistant bacteria (CC4CARB)**: Bruce BLOUGH (United States)<br>**Evaluating phage therapy for multidrug-resistant Klebsiella pneumoniae UTI**: Ruxandra CALIN (France)<br>**Overcoming bacterial defense mechanisms: strategic considerations for effective bacteriophage therapy against Acinetobacter baumannii**: Maria Soledad RAMIREZ (United States)<br>**Enhancing colistin efficacy against multidrug-resistant Klebsiella pneumoniae using farnesol-loaded lipid nanoparticles**: Farras Daffa IMTIYAZ (France)<br>**Efficacy, safety and caecal microbiome analysis of nitroxoline for preventing Salmonella infection in chickens**: Yuqing ZHOU (United Kingdom)<br>**Bacteriophage genome annotation: comparing automatic and manual approaches**: Antoine CULOT (France)<br>**GLP 13-week repeat-dose toxicology studies of MRX-5 in sprague dawley rats and beagle dogs**: Wen WANG (United States)<br>**Benzoxaborole leucyl-tRNA synthetase inhibitor MRX-5: preclinical pharmacokinetics and in vitro drug-drug interaction**: Wen WANG (United States)<br>**N-(4-chlorophenyl)-5-nitro-3-thiophenecarboxamide: a novel, narrow-spectrum antimicrobial agent targeting Helicobacter pylori**: Javier CASADO (Spain)<br>**DDD02049209, a lysyl-tRNA synthetase inhibitor, is active against M. avium in vitro**: Haiqing CHU (China)<br>**The activity of a new bicyclic peptide against colistin-resistant Pseudomonas aeruginosa biofilms**: N�ria MART�N-VILARDELL (Spain)<br>**Bacteriophages-derived endolysins for next tuberculosis stewardship**: Loris RIZZELLO (Italy)<br>**Dynamics of phage sensitivity in multidrug-resistant and non-resistant Pseudomonas aeruginosa: implications for phage therapy**: Viviane C�ssia OLIVEIRA (Spain)<br>**Structural determinants of inhibitor selectivity towards Enoyl ACP Reductase, FabK**: Kristiana AVAD (United States)<br>**Presence of antiphage defense mechanisms in carbapenemase-producing strains isolated from blood cultures in Uruguay**: In�s BADO (Uruguay)<br>**A bispecific monoclonal antibody targeting Psl and PcrV enhances bronchiectasis atient neutrophil-mediated killing of Pseudomonas aeruginosa**: Antonio DIGIANDOMENICO (United States)<br>**Evaluating the efficacy of lytic bacteriophages against multidrug-resistant Enterobacter cloacae strains**: Carl Jay BREGENTE (Philippines)<br>**Investigating probiotic lactobacilli and their bacteriocin-like inhibitory substances (BLISs) as potential therapeutic agents for vaginal infections**: Thuy TRAN THI DIEU (China)<br>**Antibacterial in vitro activity of the novel epimutilins AR-7731, AR-7732, AR-10058, and AR-9842 against MDR and pre-XDR Mycobacterium tuberculosis**: Susanne PAUKNER (Austria)<br>**Jumbo bacteriophages demonstrate indirect anti-bacterial effects against carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates**: Shuhua THONG (Singapore)<br>**In vitro anti-bacterial activity of bacteriophages (phages) to guide treatment against refractory Pseudomonas aeruginosa (PAE) infection**: Shuhua THONG (Singapore)<br>**Olive leaf extract as an antimicrobial agent against Staphylococcus aureus and its resistant strains: in vitro results**: Miriam LATORRE-MILL�N (Spain)<br>**Universal beta-lactamase coverage and potent antimicrobial activity of xeruborbactam plus meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new beta-lactam/beta-lactamase inhibitor combinations**: Luc�a S�NCHEZ-PE�A (Spain)<br>**Impact of bacterial inoculum on the activity of cefepime and cefepime/enmetazobactam against AmpC-hyperproducing Enterobacter spp**: Elisa CIORATA MIHALCEA (Spain)<br>**Optimising combination antibiotic-phage therapies against MRSA: an interdisciplinary approach**: Alastair CLEMENTS (United Kingdom)<br>**Anti-bacterial and anti-inflammatory activity of chitosan nanoparticles as carrier for supernatant of mesenchymal stem cells in a cholera mouse model**: Saeed SHAMS (Islamic Republic Of)<br>**Comprehensive bacteriophage sequencing analysis pipeline empowers insights into host specificity for treating multidrug-resistant Pseudomonas aeruginosa**: Yang ZHONG (Singapore)<br>**Exploring nanomotion technology for phage therapy: a novel diagnostic tool to combat antimicrobial resistance**: Anthony VOCAT (Switzerland)<br>**Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem with the diazabyciclooctane beta-lactamase inhibitor ANT3310**: Jorge ARCA-SU�REZ (Spain)<br>**Impact of engineered Mycoplasma pneumoniae on P. aeruginosa biofilms and respiratory microbiota during experimental ventilator-associated pneumonia**: Laia FERNANDEZ-BARAT (Spain)<br>**Bacteriophage (phage) cocktail resuscitates antibiotics for management of multidrug-resistant Pseudomonas aeruginosa (PAE) infections**: Shuhua THONG (Singapore)<br>**Immune monitoring by flow cytometry (FCM) in patient undergoing phage therapy (PT).**: Jia Hao YEO (Singapore)<br>**Assessment of antibacterial and wound healing potential of bacteriogenic silver nanoparticles (BSNP) synthesised by Klebsiella pneumoniae**: Kunal MADHAV (India)<br>**Enhancement of mupirocin anti-staphylococcal decolonisation therapy by combination with phages**: Alena SIV�KOV� (Czech Republic)<br>**Antimicrobial activity of zosurabalpin against a diverse collection of aerobic and anaerobic bacterial and yeast isolates**: Mariana CASTANHEIRA (United States)<br>**Potent in vitro activity of novel beta-lactam/ beta-lactam enhancer cefepime/zidebactam against K. pneumoniae and P. aeruginosa, enriched with carbapenem resistance collected from four tertiary-care hospitals in India**: Amol SHINDIKAR (India)<br>**Phage therapy induces colonisation resistance for an OXA-48 Salmonella Kentucky ST198 during in vivo Zoophobas morio larvae gut colonisation**: Claudia ALDEIA (Switzerland)<br>**Phage-embedded hydrogel: an emerging personalised therapy for antimicrobial-resistant Staphylococcus aureus skin infections**: Fabrice PIROT (France)<br>**The antimicrobial potential with detailed chemical characterisation of linden honeydew honey from Bosnia and Herzegovina**: Ana BARBARIC (Bosnia And Herzegovina)<br>**Biological role of prolyl hydroxylation in Pseudomonas aeruginosa**: Jabir ALI (United Kingdom) |
| 13/04 | 12:00 - 13:30 | PS040 | 05b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies) |  | **A comparative pharmacodynamic evaluation of epithelial lining fluid exposures of piperacillin/tazobactam achieved by intermittent, extended, and continuous infusion regimens against Pseudomonas aeruginosa clinical isolates in an in vitro hollow-fibre infection model**: Yixuan LI (Australia)<br>**Real-world evidence: cefiderocol therapeutic drug monitoring in critically ill, obese patients in NDM infections**: Giorgia MENEGATTI (Italy)<br>**A beta-lactam antibiotic dose adaptation feasibility randomised controlled trial utilising therapeutic drug monitoring  (ADAPT-TDM study)**: Rekha PAI MANGALORE (Australia)<br>**Population target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO**: Adrian VALADEZ (United States)<br>**Fosfomycin and ceftazidime/avibactam combination as a possible treatment for blaIMP-4 harbouring Escherichia coli: a hollow fibre infection model evaluation**: Mikaela WALKER (Australia)<br>**Piperacillin population pharmacokinetic/pharmacodynamic target attainment with continuous infusion dosing in patients admitted to the ICU with hospital-acquired pneumonia**: Marta ZURAWSKA (United States)<br>**Do current piperacillin-tazobactam dosing regimens achieve optimal epithelial lining fluid (ELF) concentrations in intensive care unit (ICU) patients with pneumonia?**: Helmi SULAIMAN (Malaysia)<br>**Development of a novel complicated urinary tract infection (cUTI) mouse model utilising heamatogenous pyelonephritis in neutropenic thigh-infected mice**: Alexander LEPAK (United States)<br>**Efficacy of ceftazidime/avibactam against ten clinical isolates of Pseudomonas aeruginosa in peritoneal dialysis fluid**: Stephanie SUPPARITSCH (Austria)<br>**A Phase 1, randomised, double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacokinetics (PK) of intravenous ertapenem (ERT) with zidebactam (ZID) in combination (WCK 6777) in healthy adult subjects**: Thomas LODISE (United States)<br>**Phage K exposure generates phage K neutralising activity in a rabbit septic arthritis model**: Sebastian HERREN (United States)<br>**Pharmacokinetics of intrapartum benzylpenicillin: insights into candidate regimens to prevent early onset neonatal Group B Streptococcus disease**: Bonniface OBURA (United Kingdom)<br>**Prediction of vancomycin area-under-the-curve using trough concentrations only: performance evaluation of paediatric population pharmacokinetic models**: Birgit KOCH (Netherlands)<br>**Cefepime/enmetazobactam for Gram-negative PJIs? A porcine study evaluating target tissue concentrations following intermittent short-term infusion and continuous infusion of a novel antibiotic combination**: Maria Bech Damsgaard NIELSEN (Denmark)<br>**Phase 1, randomised, double-blind, placebo-controlled, single-dose study to evaluate the pharmacokinetics of cefepime/zidebactam (WCK 5222) in healthy adult Chinese subjects**: Anouk Edwina MULLER (Netherlands)<br>**Identifying predictors of cefepime pharmacokinetics in bone marrow transplant recipients**: Ronaldo MORALES JUNIOR (United States)<br>**Sub-MIC exposure linked in vivo pharmacokinetic/pharmacodynamic targets (PDTs) of beta-lactam enhancer zidebactam in presence of cefepime against carbapenem-resistant Acinetobacter baumannii (CRAB)**: Anouk Edwina MULLER (Netherlands)<br>**Pharmacokinetics of vancomycin in patients with methicillin-resistant Staphylococcus aureus (MRSA) infections: a comparison between AUC and trough level monitoring for optimising vancomycin dose**: Harivenkatesh NATARAJAN (India)<br>**Determination of the pharmacodynamic targets of BV100 in the neutropaenic murine thigh infection model**: Michel PIEREN (Switzerland)<br>**Determination of the pharmacodynamic targets of BV100 in the neutropaenic murine lung infection model**: Michel PIEREN (Switzerland)<br>**Induction of Meningeal Inflammation via Intraventricular Lipopolysaccharide Inoculation in a Porcine Model**: Theis MARIAGER (Denmark)<br>**Aztreonam/avibactam is more sparing to the gut microbiome than ceftazidime/avibactam with aztreonam in a human in vitro gut model**: Jane FREEMAN (United Kingdom)<br>**Leveraging clinical data to enhance the performance evaluation of ceftriaxone population pharmacokinetic models in children**: Birgit KOCH (Netherlands)<br>**Pharmacokinetics and target attainment of teicoplanin: a systematic review**: Arnaud DE CLERCQ (Belgium)<br>**Unraveling phage pharmacodynamics against KPC-5 Pseudomonas in the hollow fiber infection model**: Thomas NGUYEN (United States)<br>**Pharmacokinetics and intra-individual variability of multidose oritavancin in real-life use**: Giorgia MENEGATTI (Italy)<br>**Dealing with the myth of 40% T>MIC for amoxicillin clavulanate: a hollow-fiber study using clinically relevant concentrations**: Oscar DELLA PASQUA (United Kingdom)<br>**Predicting ciprofloxacin target non-attainment in critically ill patients at treatment initiation: development and external validation of two novel (machine learning) models**: Andre WIERINGA (Netherlands)<br>**PK/PD of colistin in combination with bacteriophages against carbapenemase-producing Klebsiella pneumoniae clinical isolates**: Paschalis PARANOS (Greece)<br>**Understanding meropenem disposition in critically ill children: a population PK analysis**: Thi Van Anh NGUYEN (Belgium)<br>**A murine disease model of Pseudomonas aeruginosa lung infection for drug candidate characterisation**: Lynn MIESEL (China)<br>**Unraveling the bone pharmacokinetics of cefuroxime in periprosthetic joint infection**: Birgit KOCH (Netherlands)<br>**Clavulanate pharmacokinetics in severe paediatric community-acquired pneumonia: findings from PediCAP-A and -B**: Jennie VAN DYK (South Africa)<br>**Efficacy of different piperacillin/tazobactam (TZP) - amikacin (AMK) regimens against ESBL Escherichia coli in a hollow fiber infection model (HFIM) simulating sepsis augmented renal clearance**: Marion GIRY (France)<br>**Effect of augmented renal clearance on in vitro bactericidal activity of cefepime/nemetazobactam against ESBL-producing Escherichia coli evaluated via a mechanism-based modelling**: Marion GIRY (France)<br>**Cefiderocol: stability study in elastomeric device at 32°C**: Clara BERARDI (France)<br>**Population pharmacokinetics and optimised initial dosing of piperacillin in in haematologic patients with febrile neutropenia**: Julia LAPORTE-AMARGOS (Spain)<br>**Focus on enmetazobactam chemical stability in association with cefepime for prolonged infusions, in syringe and elastomeric diffusers**: Akim CHAYEM (France)<br>**Population pharmacokinetic/pharmacodynamic analysis of intravenous temocillin for the treatment of 3rd generation cephalosporin-resistant Escherichia coli bacteraemia (ASTARTE study)**: Fernando DOCOBO P�REZ (Spain)<br>**Evaluation of candidate drugs for repurposing in a Galleria mellonella staphylococcal infection model**: Mariana ANDRADE (Portugal)<br>**Urinary pharmacodynamic profiling of oral amoxicillin-clavulanate in a bladder infection model**: Iain ABBOTT (Australia)<br>**Intense care medicine-optimised dosing nomograms for beta-lactams administered by continuous infusion**: Lisa LEYENBERGER (France)<br>**Pharmacokinetics and safety of BV100 in epithelial lining fluid and plasma**: Valentin AL JALALI (Austria)<br>**External validation of vancomycin population pharmacokinetics models in hospitalised patients with bloodstream infections**: Matteo MORRA (Italy)<br>**Pharmacokinetic/pharmacodynamic target attainment of continuous infusion of ceftazidime and avibactam in plasma and epithelial lining fluid in critically ill patients with nosocomial pneumonia**: Adela BENITEZ-CANO MARTINEZ (Spain)<br>**Distribution of ampicillin and sulbactam into the cerebrospinal fluid of children and adolescents with brain tumors**: Valentin AL JALALI (Austria)<br>**A pooled population pharmacokinetic study of intravenous cefuroxime in neonates and infants: renal function dependent underexposure**: Birgit KOCH (Netherlands)<br>**Clinical trial ProVanc evaluating individualised model selection and dosing tool for vancomycin: safety review**: Hanna Kadri LAAS (Estonia)<br>**Pharmacodynamic target attainment of commercially available fixed-dose daptomycin preparations in hospitalised patients with blood stream infections caused by Staphylococcus aureus**: Emily JAIME (United States)<br>**Sex-dependent variability of isoniazid and rifampicin serum levels in patients with tuberculosis**: Raja IDRIS (Germany)<br>**Characterisation of pharmacokinetics/pharmacodynamics for efficacy of CZ-02-833 against Escherichia coli in a one-compartment in vitro infection model**: Brian VANSCOY (United States)<br>**Antibacterial effect of BV100 plus polymyxin B, at simulated human drug exposures, against Acinetobacter baumannii in an in vitro infection model**: Marie ATTWOOD (United Kingdom)<br>**PKPD modelling of ceftazidime/avibactam and colistin against five KPC-producing Klebsiella pneumoniae**: Romain AUBRY (Sweden)<br>**Early beta-lactam target attainment in critically ill patients: a three-year retrospective cohort study using therapeutic drug monitoring**: Layios NATHALIE (Belgium)<br>**Pharmacokinetics of contezolid in plasma and pulmonary epithelial lining fluid of patients with community-acquired pneumonia**: Hailan WU (China)<br>**Piperacillin in adults 75-year-old and over should be monitored as exposure is two times above the expected levels**: Daniel J.G. THIRION (Canada)<br>**Clinical, microbiological, and pharmacokinetic/pharmacodynamic (PK/PD) target attainment analyses to support EUCAST aztreonam/avibactam minimum inhibitory concentration (MIC) breakpoints against Enterobacterales**: Elena SOTO (United Kingdom)<br>**Development of a murine pneumonia model with methicillin-resistant Staphylococcus aureus (MRSA) to evaluate antibiotic treatments**: Carina MATIAS (Denmark)<br>**Penetration of contezolid into bone tissues and body fluids in patients undergoing artificial hip or knee replacement surgery**: Hailan WU (China)<br>**Lessons from a large multi-national database of children: standard paediatric dosing for vancomycin results in unacceptable exposure variability**: Marc SCHEETZ (United States)<br>**Pharmacokinetics/pharmacodynamics of ANT3310, in combination with meropenem, against carbapenem-resistant Enterobacterales using a neutropaenic murine acute pyelonephritis model**: Brian VANSCOY (United States)<br>**Comparing the impact of renal replacement therapy on clarithromycin pharmacokinetic exposure in critically unwell adults using population pharmacokinetic analysis**: Reya SHAH (United Kingdom)<br>**Amoxicillin blood concentration in high-dose intravenous amoxicillin: look beyond the numbers**: Magali VIDAL (France)<br>**Pharmacokinetic/pharmacodynamic target attainment of cefuroxime in adult patients on general wards with different degrees of renal function: a prospective observational cohort study**: Saskia Eliena ZIECK (Netherlands)<br>**Effect of pH on the bacteriostatic and bactericidal activities of delafloxacin against Escherichia coli isogenic strains harboring diverse chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms**: K�vin ALEXANDRE (France)<br>**Optimisation of cefepime dosing regimen for Pseudomonas aeruginosa infection in Japanese patients using Monte Carlo simulation with pharmacokinetic/pharmacodynamic analysis for efficacy and safety**: Yukihiro HAMADA (Japan)<br>**Pharmacodynamic evaluation of short vs long durations of amikacin combined with meropenem against meropenem-resistant Pseudomonas aeruginosa in hollow fibre infection model**: Yalew WALE (Australia)<br>**Quantification of vancomycin and clindamycin in synovial tissue and bone using ultra-performance liquid chromatography-tandem mass spectrometry**: Soma HERBERS-BAHMANY (Netherlands)<br>**Urinary KIM-1 and vancomycin exposure in children with sepsis-induced MODS**: Justin SHIAU (United States)<br>**Quantification of ceftazidime in vitreous humor using ultra-performance convergence chromatography-tandem mass spectrometry**: Soma HERBERS-BAHMANY (Netherlands)<br>**Ten years of susceptibility testing of linezolid in a tertiary care hospital: model-informed precision dosing as a strategy for rising resistance**: Johannes STARP (Germany)<br>**Effectiveness of meropenem/avibactam combination in suppressing emergence of meropenem-resistant carbapenemase-producing Klebsiella pneumoniae: predictive potential of a pharmacokinetically-based approach to MIC determination**: Kristina SHAPOSHNIKOVA (Russian Federation)<br>**Aztreonam combined with avibactam against Klebsiella pneumoniae: a pharmacokinetically-based approach to MIC determination to improve the prediction of efficacy**: Kristina SHAPOSHNIKOVA (Russian Federation)<br>**Meropenem levels in critically ill patients on continuous veno-venous hemodiafiltration (CVVHDF): exploration of variables and their influence on dose requirements**: Jun Jie TAN (Singapore)<br>**Clinical evaluation of PK/PD target attainment for meropenem therapy: a retrospective observational study**: Simone ZONNENBERG (Netherlands)<br>**The use of vancomycin with drug trough monitoring in methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis: a retrospective cohort study in Gaza**: Mathilde BERGHMANS (Belgium)<br>**Stability of ceftobiprole medocaril in portable elastomeric infusion devices**: Beatriz ESTEBAN-CARTELLE (Spain)<br>**Population pharmacokinetics and Monte Carlo simulations of ceftriaxone to optimise dosage regimen in patients with sepsis**: Nattapat SANGKAKUL (Thailand)<br>**Complementary killing activities of  pbunavirus LS1 and bruynoghevirus LUZ24 phages on planktonic and biofilm of Pseudomonas aeruginosa**: Cindy FEVRE (France)<br>**Inadequate linezolid plasma concentrations in critical ill patients with extracorporeal membrane oxygenation (ECMO): results from 53 patients**: Joerg STEINMANN (Germany)<br>**Population pharmacokinetics (PK) of posaconazole in critically ill patients**: Christina K�NIG (Germany)<br>**Adjunctive antimicrobial effect of ticagrelor at conventional antiplatelet dosages against methicillin-resistant Staphylococcus aureus in vitro and in vivo models**: Taeeun KIM (Republic Of)<br>**Optimised target recommendations against systemic infections in ICU settings caused by Gram-positive cocci: lessons from a hollow-fibre infection model**: Jaap MOUTON (Netherlands)<br>**External evaluation of popPK models for model-informed precision dosing of oral linezolid therapy administered to hospitalised patients**: Antonia LEONHARDT (Germany)<br>**Lateral flow assay innovation for vancomycin: advancing point-of-care therapeutic drug monitoring**: Vasin VASIKASIN (Thailand)<br>**Pharmacodynamic optimisation of temocillin treatment against CTX-M-15-producing K. pneumoniae isolates in a hollow-fiber infection model**: Carlos SA�CO CARBALLO (Spain)<br>**Safety and pharmacokinetics of single ascending doses of APC148, a zinc-chelating MBL-inhibitor, in healthy volunteers**: Bj�rg BOLSTAD (Norway)<br>**Checkerboard coupling PopPK/PD: a rapid optimising solution for drug combination efficacy**: Yan CHEN (Canada)<br>**A draft EUCAST rationale for antimicrobial susceptibility testing and treatment of ESBL infections with cefepime/sulbactam**: Agata SOLTYSINSKA (United Kingdom)<br>**Antibacterial effect of zosurabalpin using simulated human doses against carbapenem resistant Acinetobacter baumannii studied in an in vitro model of infection**: Pippa GRIFFIN (United Kingdom)<br>**Development of a quantitative lateral flow assay for meropenem: a proof-of-concept study for point-of-care therapeutic drug monitoring**: Vasin VASIKASIN (Thailand)<br>**Determining the appropriateness of standard cefepime dosing in septic paediatric cancer patients: a pilot study**: Antonio ARRIETA (United States)<br>**Evaluating the clinical impact of targeting lower versus higher serum vancomycin trough: a retrospective study using a desirability of outcome ranking (DOOR) analysis**: Zong Heng SHI (Canada)<br>**Population pharmacokinetic model averaging for a priori dose optimisation of meropenem and piperacillin in intensive care patients**: Hiie SOEORG (Estonia)<br>**Population pharmacokinetics of vancomycin in critically ill adult patients undergoing continuous renal replacement therapy**: Keely MORRIS (United States)<br>**Predictive score for selecting patients candidate to linezolid therapeutic drug monitoring and need for dosage individualisation**: Sonia LUQUE (Spain)<br>**Pharmacokinetic analysis of ceftazidime/avibactam dosing in patients utilising renal replacement therapy**: Islam GHAZI (United States) |
| 13/04 | 12:00 - 13:30 | PS041 | 05c. New or repurposed antibacterial agents: Clinical studies and randomised trials |  | **Clinical, microbiological and laboratory predictors of on- and off-label dalbavancin treatment failure**: Maria MAZZITELLI (Italy)<br>**Outcomes by MIC values for patients infected with Enterobacterales treated with cefepime/enmetazobactam or piperacillin/tazobactam for complicated urinary tract infections in the phase 3 ALLIUM trial**: Anne SANTERRE HENRIKSEN (Denmark)<br>**Antibacterial compounds against non-growing and intracellular bacteria**: Tanel TENSON (Estonia)<br>**Microbiological outcome of eradication of cefepime/enmetazobactam vs piperacillin/tazobactam against most common Enterobacterales at test of cure; a posthoc analysis from the ALLIUM Phase 3 trial**: Juan Luis QUEVEDO MARIN (United Kingdom)<br>**Systematic review of the efficacy and safety of ceftolozane/tazobactam (C/T) for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI): ZEBRA**: Emre YUCEL (United States)<br>**Systematic literature review of efficacy and safety of ceftolozane/tazobactam (C/T) for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP): INSIGHT**: Emre YUCEL (United States)<br>**Efficacy and Safety of Imipenem/Cilastatin/Relebactam (IMI/REL) in Treating Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections: A Systematic Literature Review of Clinical Trials: RESOLVE**: Emre YUCEL (United States)<br>**Single-centre real-life experience with imipenem/cilastatin/relebactam use at a tertiary care hospital in Italy, June 2022-November 2024**: Michele SPINICCI (Italy)<br>**Ceftazidime/avibactam plus aztreonam vs cefiderocol in the treatment of infections caused by metallo-beta-lactamase-producing microorganisms: real-world data from the Italian cohort SUSANA**: Luca MEZZADRI (Italy)<br>**Bacteriological profile, antimicrobial susceptibility, and treatment outcomes of multidrug-resistant Gram-negative infections using a novel antibiotic combination ceftriaxone/sulbactam+EDTA**: Haritha MADIGUBBA (India)<br>**Ceftaroline for the treatment of Staphylococcus aureus infections: a systematic review with Bayesian meta-analysis**: Eugenia MAGRINI (Italy)<br>**Bacteriophage therapy: an effective approach against multidrug-resistant Acinetobacter baumannii**: Pooja SACHDEVA (India)<br>**Comparison of meropenem/vaborbactam vs ceftazidime/avibactam in the treatment of KPC-producing Klebsiella pneumoniae infections**: Matteo FALTONI (Italy)<br>**Rifabutin exerts potent intracellular and biofilm eradication activity against Acinetobacter baumannii**: Marija MILJKOVIC (Switzerland)<br>**Real-world vs trial populations. a comparison between the clinical characteristics and outcome of the REACT-MDR and five pathogen-focused randomised clinical trials populations**: Gabriele Maria LEANZA (Italy)<br>**Colistin prescribing and outcomes in Kuwait public hospitals**: Sarah ALGHANEM (Kuwait)<br>**Evidence of reinfection and no emergence of resistance following a single oral 3g dose of zoliflodacin demonstrated by whole-genome sequencing (WGS) in a global Phase 3 randomised controlled trial (RCT) for treatment of uncomplicated gonorrhoea**: Magnus UNEMO (Sweden)<br>**Polycationic PEI-based nanoparticles enhance antimicrobial delivery against multidrug-resistant Acinetobacter baumannii**: Krit THIRAPANMETHEE (Thailand)<br>**A Phase 1, randomised, double-blind, first-in-human, dose-escalation study investigating the safety, recovery, and pharmacodynamics of a novel CRISPR-Cas therapeutic (SNIPR001)**: Jonas HINK (Denmark)<br>**Gepotidacin and nitrofurantoin efficacy by baseline uropathogen drug-resistant phenotypes recovered from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections**: Nicole E. SCANGARELLA-OMAN (United States)<br>**Impact of hypoalbuminemia on outcomes of ertapenem**: Lauren FORTIER (United States)<br>**Efficacy and safety of monoclonal antibodies for prevention and treatment of multidrug-resistant organisms' infections: a scoping review**: Emanuele PALOMBA (Italy)<br>**Studies in vitro and in vivo of phage therapy medical products (PTMPs) targeting clinical strains of Klebsiella pneumoniae belonging to the clone ST512**: Ines Maria BLERIOT RIAL (Spain)<br>**Reviving old drugs: targeting FliN of uropathogenic Escherichia coli to treat urinary tract infections**: Harpreet KAUR (India)<br>**Cefiderocol treatment in patients with Gram-negative bacterial infections: European results of the global retrospective observational PROVE study**: Stefano VERARDI (United Kingdom)<br>**Design of a Phase 3b, open-label, single-arm study evaluating clinical symptom improvement with gepotidacin in participants with uncomplicated urinary tract infection (uUTI)**: Jazmin DIAZ-REGA�ON (Spain)<br>**Preliminary zosurabalpin (5�g) disk diffusion quality control ranges using clinical and laboratory standards institute M23 criteria**: Michael HUBAND (United States)<br>**Preliminary findings from a systematic literature review: bactericidal research on multi-drug resistant Pseudomonas aeruginosa (MDR-PsA) infections of Gram-negative using high-level therapeutics (BRIGHT)**: Emre YUCEL (United States)<br>**Off-label use of oritavancin: a case series on clinical efficacy, bed day savings, and cost benefits**: Amani PATEL (United Kingdom)<br>**Clinical application of customised and non-customised bacteriophage therapy in patients with persistent and difficult-to-treat bacterial infections: systematic review and meta-analysis**: Yang LIU (Singapore)<br>**Real-life experience with cefiderocol treatment of multidrug-resistant Gram-negative infections**: Gabriela ABELENDA-ALONSO (Spain)<br>**Efficacy of aztreonam/avibactam, ceftazidime-avibactam, and cefiderocol against multidrug-resistant and putative-hypervirulent Klebsiella pneumoniae isolates**: Bernd NEUMANN (Germany)<br>**Efficacy and safety of oral nafithromycin as a three- and five-day treatment regimen compared with moxifloxacin in adult patients with community-acquired bacterial pneumonia (CABP): a global Phase 2 randomised trial**: Anouk Edwina MULLER (Netherlands)<br>**Ganfeborole in combination with novel antitubercular agent BTZ-043 administered for 14-days to participants with rifampicin-susceptible pulmonary tuberculosis: interim analysis results**: Simon TIBERI (United Kingdom)<br>**Real-world, multicentre experience with ceftazidime/avibactam in the paediatric population**: Taylor MORRISETTE (United States)<br>**Three-year retrospective analysis of the use of cefiderocol in a Spanish tertiary hospital**: Nuria TORMO (Spain) |
| 13/04 | 12:00 - 13:30 | PS042 | 05d. Antimicrobial stewardship and prescribing?(incl interventions, monitoring, impact, decision-support/prediction tools, behavioural aspects) |  | **In vitro susceptibility of NDM-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae to cefepime/zidebactam from a tertiary-care cancer hospital**: Gaurav SALUNKE (India)<br>**Impact of pharmacist-led interventions on antibiotic management in critical care: a prospective observational study of culture-guided therapy**: Ammar MOHAMED MOHIDEEN (India)<br>**Antimicrobial stewardship implementation in a Philippine tertiary hospital: a seven-year surveillance of surgical prophylaxis prescribing practices**: Gina DE GUZMAN BETITO (Philippines)<br>**Where do physicians look for information on antibiotics and antimicrobial resistance? Challenges in keeping up to date, Germany 2024**: Susanne Barbara SCHINK (Germany)<br>**Evaluation of a broad-spectrum antibiotic monitoring tool across a large academic hospital system**: Natalie TUCKER (United States)<br>**Building a foundation of a functioning microbiology diagnostic service in Kilifi county referral hospital**: Jessica GENTRY (United Kingdom)<br>**Reduction of carbapenem prescribing inappropriateness: an antimicrobial stewardship intervention through post-prescription review with feedback**: Alessia FRATER (Italy)<br>**Successful implementation and evaluation of challenges for an antimicrobial stewardship programme at a university hospital emergency department**: Ieva VOITA (Latvia)<br>**The role of early appropriate antibiotic treatment in febrile neutropaenia: identifying targets for antimicrobial stewardship interventions**: Rebecca SCARDELLATO (Italy)<br>**Point prevalence survey of antibiotic use in hospitals in northern Lesotho**: Nikita SASS (Switzerland)<br>**Joint expertise, smarter antibiotics: a collaborative approach to improving orthopaedic surgical antibiotic prophylaxis in a tertiary hospital**: Patricia KILFOYLE (Australia)<br>**2024 assessment of Belgium's national antimicrobial stewardship core elements: progress and areas for improvement**: Lucy CATTEAU (Belgium)<br>**Hospital antimicrobial prescribing in Belgium: linking reimbursement data with clinical context**: Julie DOMEN (Belgium)<br>**Towards tailored perioperative antibiotic prophylaxis: a multicentre pre-intervention analysis in the H2020 REVERSE project**: Elena CARRARA (Italy)<br>**Need for speed: earlier targeted treatment with BCID2 panel, report from an Indian ICU**: Umang AGRAWAL (India)<br>**From overuse to optimised use: reducing fluoroquinolone prescribing through targeted antimicrobial stewardship interventions in tertiary care**: Birgit UNTERKOEFLER (Austria)<br>**Attitudes towards anticipated antibiotic resistance development varies by medical specialty, physician's gender, number of prescriptions, and years in practice, Germany 2024**: Susanne Barbara SCHINK (Germany)<br>**The challenge of preserving reserve antimicrobials in acute surgical wards**: Melwin Kyle SOLIS (Ireland)<br>**Clinical outcomes in gentamicin prescribing and monitoring in United Kingdom hospitals (CO-GENT): national audit, service evaluation and rates of AKI with pre-dose vs nomogram monitoring**: Raqib HUQ (United Kingdom)<br>**Feasibility and cost-saving potential of outpatient antimicrobial therapy using elastomeric pumps in bone marrow transplant patients: a single-centre study in a tertiary care setting in India**: Ritika Kondel BHANDARI (India)<br>**Inappropriate antibiotic prescriptions for cystitis in primary care in the Republic of Korea**: Hey Jin KO (Republic Of)<br>**Changes in antibiotic use in South Korea from 2016 to 2023: using health insurance claim data**: Yujeong KIM (Republic Of)<br>**Implementation of a multi-modal One Health training programme for antimicrobial stewardship in the Asia Pacific region**: Rod JAMES (Australia)<br>**Post-prescription review of carbapenem-based therapies and occurrence of Clostridioides difficile infection**: Francesco PERACCHI (Italy)<br>**Nationwide analysis of antimicrobial prescription in Korean hospitals between 2018 and 2022: the 2024 KONAS report**: Kim YONG CHAN (Republic Of)<br>**Cost savings from outpatient parenteral antimicrobial therapy programme: a systematic review and meta-analysis**: Solomon Ahmed MOHAMMED (Australia)<br>**Antibiotic use in outpatient departments of general hospitals in Vietnam and the opportunities for outreach interventions to improve patient and community knowledge and practices**: Hai Yen NGUYEN (Vietnam)<br>**Antimicrobial photodynamic therapy against a mixed biofilm composed of a cariogenic microbial consortium**: Natalia IORIO (Brazil)<br>**An international multi-centre survey of antimicrobial use in outpatient parenteral antimicrobial therapy (OPAT) or hospital-in-the-home (HITH) programmes**: Zenaw WOLIE (Australia)<br>**The global point prevalence survey (Global-PPS): quality indicators for antimicrobial use for adult patients in the Philippines, 2017-2023**: Jemelyn GARCIA (Philippines)<br>**Antimicrobial stewardship ward rounds: a strategy to reduce ICU antibiotic use**: Pietro VITALE (Italy)<br>**Comparability of outcomes in antimicrobial stewardship research**: Maria NUNEZ-NUNEZ (Spain)<br>**Reinventing the antimicrobial stewardship wheel: specialist-led prospective meropenem prescription review and targeted prescriber's feedback**: Jennifer BRITTON (Ireland)<br>**Investigating the prevalence of statin co-prescription with known interacting antimicrobials and compliance with necessary intra-therapy biochemical monitoring in Beaumont hospital**: Melwin Kyle SOLIS (Ireland)<br>**Impact of a regional antimicrobial stewardship intervention on enhancing antimicrobial appropriateness in E. coli bacteraemia treatment management**: Esther CALBO (Spain)<br>**Comprehensive assessment of antimicrobial use through yearly point prevalence surveys, 2012-2023**: Lina Marcela PARRA (Spain)<br>**Implementation of antimicrobial consumption dashboard: a data-driven approach at university hospitals of Birmingham, United Kingdom**: Nirlep AGRAVEDI (United Kingdom)<br>**Evaluating the impact of a multifaceted antimicrobial stewardship intervention on age and gender inequity in antibiotic utilisation at a tertiary care centre in Karachi, Pakistan**: Nosheen NASIR (Pakistan)<br>**Impact of an antimicrobial stewardship intervention in residential aged care: a multicentre, stepped-wedge cluster randomised trial (START trial)**: Natali JOKANOVIC (Australia)<br>**Appropriateness of antibiotic access and use practices at the community level in eastern Ethiopia**: Dumessa EDESSA (Ethiopia)<br>**Aragon regional bacteraemia surveillance & stewardship (ARBASS) system**: Jose Ramon PANO-PARDO (Spain)<br>**Utilising technology to strengthen and inform antimicrobial stewardship strategies**: Uforma OGRIGRI (United Kingdom)<br>**Enhancing outpatient antimicrobial stewardship: the integral role of infection control nurses**: Antonio C�RDENAS (Spain)<br>**The role of dedicated infectious disease consultant within an antimicrobial stewardship programme: towards a better patients' CARE (deIDcare)**: Cristiana LEANZA (Italy)<br>**Short- versus long-course antibiotic durations for uncomplicated infections in solid tumor patients receiving care in ambulatory oncology clinics**: Christen ARENA (United States)<br>**What are the factors associated with inappropriate antibiotic prescription in UTIs with a high prevalence of MDR pathogens?**: Marco MUSSA (Italy)<br>**Antibiotic consumption patterns of selected narrow- and broadspectrum antibiotics in German acute care hospitals from 2017 to 2023**: Birgitta SCHWEICKERT (Germany)<br>**Three-year experience of antimicrobial stewardship in a tertiary care hospital in Pakistan: successes and challenges**: Quratulain SHAIKH (Pakistan)<br>**Analysis of antibiotic prescription trends in Tunisian tertiary hospitals based on the WHO AWaRe framework**: Ahmed TRIGUI (Tunisia)<br>**What indicators are used to estimate or measure appropriateness of antibiotic prescribing in high-income countries: a rapid systematic review protocol and initial findings**: Rachel BERRY (United Kingdom)<br>**Antimicrobial stewardship in practice: designing interventions to improve surgical prophylaxis practices in a Rwandan university hospital, a mixed methods study using the behaviour change wheel**: Caroline THEUNISSEN (Belgium)<br>**Impact of penicillin allergy label (PAL) on fluoroquinolone prescriptions**: Bee Yean NG (United Kingdom)<br>**Prolonged carbapenem use in the context of a dedicated antimicrobial stewardship programme: a sub-analysis of the CASAS (CArbapenem Sparing Antimicrobial Stewardship) project**: Paola BELLINI (Switzerland)<br>**Dalbavancin in OPAT: a retrospective review of NHS greater Glasgow and Clyde experience**: Awilly CHOFLE (United Kingdom)<br>**Successful implementation of surgical antibiotic prophylaxis (SAP) in ten hospitals of Georgia**: Marika TSERETELI (Georgia)<br>**The impact of β-lactam allergy labels on antibiotics guideline adherence**: Marco BONGIOVANNI (Switzerland)<br>**Remote stewardship, local impact: a case study assessing effectiveness of tele-stewardship on establishing antimicrobial stewardship programmes in Kenya**: Evelyn Nelima WESANGULA (United Republic Of)<br>**Point-of-care detection of carbapenemase-producing Enterobacterales and antimicrobial stewardship interventions**: Maria Leonor SANTOS (Portugal)<br>**The impact of prospective pharmacist-led fluroquinolone review on fluoroquinolone consumption**: Bee Yean NG (United Kingdom)<br>**Impact of the implementation of an antimicrobial stewardship programme (ASP) in a haematologic ward of a tertiary hospital**: Martina BELTRAMI (Italy)<br>**Battling the sepsis clock using BIOFIRE BCID2 Panel: a pre-post intervention audit of time to active antibiotic therapy in an Indian ICU**: Sayli GORE (India)<br>**Comparative clinical care with use of two rapid susceptibility testing techniques: BLT (2021) and MIC-RAST (2023) in Gram-negative bacilli bacteraemia**: M�lanie KERANFLEC'H (France)<br>**Enhancing nursing roles in antimicrobial stewardship: a clinical simulation-based training programme for ICU**: Wanda CORNISTEIN (Argentina)<br>**The impact of antimicrobial stewardship ward rounds on antimicrobial use and predictors of advice, uptake, and outcomes**: Bee Yean NG (United Kingdom)<br>**Strategies adopted for the implementation of clinical decision support systems for antimicrobial stewardship in hospital settings: a systematic review**: Nathan PEIFFER-SMADJA (France)<br>**Pharmacist's perspective of antimicrobial stewardship programmes at primary care setting in San Paulo**: Maura OLIVEIRA (Brazil)<br>**Third-day AMS interventions in a medical ward: implementation and results**: Joana BATISTA (Portugal)<br>**Availability and quality of selected essential antibiotics circulating in Bangladesh: a cross-sectional study**: Matin MD ABDUL (Bangladesh)<br>**Model-based evaluation of an optimised meropenem dosing strategy for critically ill patients with preserved or augmented renal clearance**: Nada DIA (Belgium)<br>**Global antibiotic usage in humans, 2018-2021: an updated spatial modelling study**: Frederick FELL (United Kingdom)<br>**Impact of an Antimicrobial Stewardship Bundle on the outcome of high-risk neutropenic patients with fever; a pre-post study**: Suzanne KUIJPERS (Netherlands)<br>**Training future antimicrobial stewards in the ESCMID AMS certificate training programme: from knowledge to action**: Suzanne KUIJPERS (Netherlands)<br>**Impact of an intervention aimed at nursing staff on antibiotic use for nursing home residents with common infections**: Carl LLOR (Spain)<br>**"Squeezing the balloon": impact of preauthorisation of broad-spectrum antimicrobials on DASC and antimicrobial usage patterns**: Toshibumi TANIGUCHI (Japan)<br>**Impact of hospital relocation and antibiotic consumption on the incidence of multidrug-resistant microorganisms**: Rebecca Rowena PE�A-ZALBIDEA (Spain)<br>**Analysis of antibiotic prescriptions preceding carbapenem-resistant Enterobacterales infections: opportunities for antimicrobial stewardship**: Sock Hoon TAN (Singapore)<br>**Using PEN-FAST score to guide prescription of alternative beta-lactam in penicillin-allergic patients by non-allergists**: Sock Hoon TAN (Singapore)<br>**Pharmacist led cephalosporin drug challenge programme in inpatients with low risk penicillin allergy: an assessment of physician acceptance and outcomes**: Junhao, Ray LIN (Singapore)<br>**Antibiotic prescribing for common acute infections in Indonesia: an analysis using IQVIA prescriber healthcare surveys**: Nam NGUYEN (United Kingdom)<br>**Benchmarking hospital antibiotic use in ten countries: comparing observed versus expected empiric use based on the WHO AWaRe antibiotic book**: Myo Maung Maung SWE (United Kingdom)<br>**Hospital multidisciplinary antimicrobial stewardship on clinical and economic impact of critical blood culture-positive patients**: Minhua CHEN (China)<br>**Antibiotic prescribing patterns by age and sex in English primary care: how it varies and why is it important for AMR?**: Gwen KNIGHT (United Kingdom)<br>**Impact of mobile health applications in the implementation of antimicrobial stewardship programme among healthcare professionals: a systematic review**: Ng RONG XIANG (Malaysia)<br>**Leveraging outpatient antibiotic use data to shape targeted stewardship interventions in Switzerland**: Tamara HABEGGER (Switzerland)<br>**A comparative study of AI-generated vs pharmacist-generated prescription recommendations in south Indian pharmacies: a multicentre cohort study**: Suhail Hassan JALAL (India)<br>**Assessment of physicians' knowledge and attitudes towards antibiotic prescription practices and antimicrobial resistance**: Helmi ERNANDES (Tunisia)<br>**Retrospective analysis of antibiotic consumption patterns in defined daily dose among primary MSF settings in north-west Syria**: Carine NAIM (Lebanon)<br>**Antimicrobial point prevalence survey (PPS) made easy**: Raghu MAMULLAPALLY (United Kingdom)<br>**"They've got other fish to fry": illuminating why surgeons don't prioritise antimicrobial stewardship, and strategies for change**: Hazel PARKER (United Kingdom)<br>**Leveraging a simple tool for sustaining antimicrobial stewardship: a prospective audit and feedback initiative at a tertiary care centre in western India**: Sayli GORE (India)<br>**Watch the piperacillin! Raising awareness and reducing the use of piperacillin/tazobactam in a U.K. district general hospital**: Jean O'DRISCOLL (United Kingdom)<br>**Cost-consequence analysis of diagnostic strategies for community-acquired pneumonia in Spain**: Lopamudra DAS (United States)<br>**The carbapenem sparing antimicrobial stewardship (CASAS) project: an innovative approach to reduce carbapenem consumption in low-users hospital settings**: Marco BONGIOVANNI (Switzerland)<br>**Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: a post hoc emulation trial of the SIMPLIFY randomised trial**: Emanuele RANDO (Italy)<br>**Fluoroquinolones, UK advisories, local guidelines: compliance and consideration of prescribing**: Olivia BARTON-EVANS (United Kingdom)<br>**The impact of a multidisciplinary team featuring a clinical pharmacist on adherence to recommended antimicrobial therapy in neurosurgical units in Thailand**: Kittiya JANTARATHANEEWAT (Thailand)<br>**Unveiling the DOOR for optimising antimicrobial stewardship in Escherichia coli and Klebsiella pneumoniae bloodstream infections in India**: Sriram RADHAKRISHNAN (India)<br>**We removed all urine dipstick tests from our regional hospital in north Denmark**: Shakil A. SHAKAR (Denmark)<br>**Effect of including infectious disease experts in the primary care antibiotic stewardship team on prescribing for upper respiratory tract infections: the IDASP study**: Evelyn SHAW PERUJO (Spain)<br>**The French society for infectious diseases top-five list of recommendations**: Nathan PEIFFER-SMADJA (France)<br>**Large language model-based chatbot to promote prudent antibiotic use among patients: a mixed-methods usability study**: Ermira TARTARI (Malta)<br>**Analysis of antibiotic prescriptions preceding Clostridioides difficile infection: opportunities for antimicrobial stewardship**: Sock Hoon TAN (Singapore)<br>**All you need is... a team! A successful antimicrobial stewardship programme in an ICU in a low middle income country (LMIC)**: Andrea Paola CASSATA (Argentina)<br>**Outpatient point prevalence survey on antimicrobial use at a district hospital in Ghana using the global PPS outpatient protocol**: Obed Kwabena Offe AMPONSAH (Ghana)<br>**Effectiveness of clinical decision support system use for antibiotic stewardship in primary care: a systematic review**: Racha IBRAHIM (France)<br>**Reducing fluoroquinolone prescribing in high-risk patients to minimise toxicities**: Stephen HUGHES (United Kingdom)<br>**Impact of early patient engagement on the outcome of their antimicrobial 48-72 hour review: an interrupted time-series intervention study**: Stephen HUGHES (United Kingdom)<br>**Comparison of surveillance methodologies of respiratory tract infections and antibiotic prescribing in primary care practices in Europe**: Aislinn COOK (United Kingdom)<br>**AWaRe antibiotic prescribing in outpatient clinics at JU hospital: a retrospective study**: Amal AL-BAKRI (Jordan)<br>**Impact of an outpatient parenteral antimicrobial therapy stewardship programme in a hospital at home unit**: Ainhoa VIVERO (Spain)<br>**Software to support antimicrobial stewardship programme: scoping review**: Maria NUNEZ-NUNEZ (Spain)<br>**Quality and reporting of antimicrobial treatment guidelines in Spain**: Maria NUNEZ-NUNEZ (Spain)<br>**Limited evidence of regulatory approval of oral AWaRe antibiotics not included in the WHO Essential Medicines List: the Grey Group**: Shrey MATHUR (United Kingdom)<br>**Monocyte distribution width (MDW): a biomarker to discriminate infectious from central fever in brain injury**: Antonella FRATTARI (Italy)<br>**Antimicrobial use in a tertiary care hospital in a lower middle-income country**: Kushlani JAYATILLEKE (Sri Lanka)<br>**Reducing inappropriate fluoroquinolone prescribing in England in 2024**: Philip HOWARD (United Kingdom)<br>**Impact of a multistep antimicrobial stewardship intervention in cephalosporins prescription for community acquired pneumonia: an interrupted time series analysis**: Raquel DURO (Portugal)<br>**Changes in human antimicrobial consumption in 21 European countries between 2018 and 2021**: Tilleye RUNGHIEN (United Kingdom)<br>**Antibiotic spectrum scores to evaluate antimicrobial stewardship programmes: where are we?**: Beatrice BARDA (Switzerland)<br>**A standardised approach for measuring outpatient antimicrobial use data: development and evaluation of the outpatient global point prevalence survey**: Annelies BOVEN (Netherlands)<br>**Penicillin allergy delabeling in a German university hospital: implementation in inpatient settings (PENGUIN-study)**: Hannah N�RNBERG (Germany)<br>**Out-patient penicillin allergy de-labelling is safe, acceptable, and effective**: Lucy TUNN (United Kingdom)<br>**Outcomes of implementation of a multidimensional antimicrobial stewardship programme in a medical ward of a third-level university hospital in northern Italy**: Maria MAZZITELLI (Italy)<br>**A step towards rational antibiotic use: impact of a multicentre interventional study in ten German non-university hospitals on antimicrobial use, costs and patient outcomes**: Gesche F�RST (Germany)<br>**Antibiotic prescribing practices among Belgian dentists: 2017-2021**: Moira KELLY (Belgium)<br>**Priorities for updating the World Health Organisation AWaRe antibiotic book**: Deborah TONG (Switzerland)<br>**Quality of care, in-hospital mortality and length of hospital stay for community acquired pneumonia in German non-university hospitals before and after an antimicrobial stewardship and infectious diseases specialist intervention**: Roland GIESEN (Germany)<br>**Model-informed precision dosing of vancomycin in critically ill patients infected with Gram-positive organisms: a multi-centre cohort study**: Xi LIN (China)<br>**Antibiotic and diagnostic stewardship programms in low and lower-middle-income countries: a systematic review and meta-analysis**: Emelyne GRES (Italy)<br>**Identifying predictors for antibiotic use: a global point prevalence survey study among 130 hospitals in Belgium, the Philippines and South Africa**: Annelies BOVEN (Netherlands)<br>**Socio-demographic patterns in outpatient antibiotic use in Belgium (2019-2023)**: Elena DAMIAN (Belgium)<br>**Multicentre outpatient monitoring of long-term co-trimoxazole treatment**: Niamh SPENCE (United Kingdom)<br>**Number of emails sent correlated with implementation metrics in a national antimicrobial stewardship programme**: Barbara TRAUTNER (United States)<br>**First-line antibiotic usage used in clinically diagnosed cases of neonatal sepsis in secondary and tertiary healthcare centres in Pakistan, Bangladesh and Nigeria**: Kathryn THOMSON (United Kingdom) |
| 13/04 | 12:00 - 13:30 | PS043 | 05e. Safety, hypersensitivity and adverse effects of treatment |  | **Penicillin allergy de labelling: a whole system approach**: Heather KENNEDY (United Kingdom)<br>**Reduction of vancomycin-associated nephrotoxicity with zileuton**: Cole HUDSON (United States)<br>**Assessing the skin sensitisation potential of common antiseptics using a novel in vitro bioassay developed for medical devices**: Karin RIEDL (Austria)<br>**Adverse effects of long-term use of the oxazolidinones tedizolid and linezolid: a retrospective matched-cohort analysis**: Jordan HAHN (United States)<br>**Detection of early acute kidney injury with urinary metabolomics in a high-dose vancomycin rat model**: Justin SHIAU (United States)<br>**An evaluation of the myelosuppressive effects of co-trimoxazole: a single centre observational review**: Aneeka CHAVDA (United Kingdom)<br>**Ceftibuten/ledaborbactam etzadroxil in participants with varying degrees of renal function**: Paul MCGOVERN (United States)<br>**Promising efficacy of oral nano-silymarin formulation on prevention of vancomycin induced nephrotoxicity: a randomised, triple-blinded, placebo-controlled clinical trial**: Sepideh ELYASI (Islamic Republic Of)<br>**Safety reporting in neonatal antibiotic trials: lessons from NeoSep1**: Louise F HILL (United Kingdom) |
| 13/04 | 12:00 - 13:30 | PS044 | 05f. Pharmacoepidemiology/pharmacoeconomics (incl cost-effectiveness, modelling, data tools) |  | **Counting the pennies: calculating the cost of ancillaries in IV antibiotic administration**: Syed Anas Daud GILANI (United Kingdom)<br>**Cost to families for severe community-acquired childhood pneumonia treatment with oral amoxicillin or co-amoxiclav vs IV-only antibiotic treatment in five sub-Saharan African countries: an economic analysis of the PediCAP randomised controlled trial**: Gillian LEVINE (Switzerland)<br>**Cost-effectiveness analysis of dalbavancin in an acute district hospital in UK**: Alice LIU (United Kingdom)<br>**Using the STEDI AMR value framework to estimate the clinical and economic value of aztreonam/avibactam in treating metallo-beta-lactamase-producing Enterobacterales infections in Spain**: Alfonso DE LOSSADA JUSTE (Spain)<br>**Sweden's partially de-linked reimbursement model for new antibiotics**: Anders TERNHAG (Sweden)<br>**Cefotaxime vs ceftriaxone: current practices in Paris hospitals and new considerations**: Etienne RAPHA�L (France)<br>**What is the cost of antibiotic prescriptions if the costs of antibiotic resistant infections are considered?**: Stephanie EVANS (United Kingdom) |
| 13/04 | 12:00 - 13:30 | PS077 | 11a. General vaccinology (incl in vitro and in vivo studies, safety, regulatory, policy, social aspects) |  | **Correlation of sociodemographic vulnerability versus RSV vaccination rates: preliminary results from a U.S. metropolitan area.**: Fernanda VALDEZ-BLANCO (United States)<br>**The emergence of a hypervirulent Streptococcus pneumoniae serotype 3 after PCV13: a whole-genome sequencing study in Zhejiang, China**: Lin LIU (China)<br>**High hydrostatic pressure technology for low-cost vaccine production: preclinical in vivo testing**: Vittorio SAMBRI (Italy)<br>**A nationwide randomised trial to confirm effectiveness of electronically delivered nudges in increasing influenza vaccination uptake among young and middle-aged adults with chronic disease: NUDGE-FLU-CHRONIC-2**: Niklas Dyrby JOHANSEN (Denmark)<br>**Profiling vaccination patterns in immunosuppressed patients against respiratory infections in community pharmacies**: Daniel J.G. THIRION (Canada)<br>**Immunisation against Chlamydia trachomatis polymorphic membrane protein D tetrapeptide motifs limits early female reproductive tract infection in a mouse model**: Andzoa JAMUS (United States)<br>**The effect of time since first dose of measles-containing vaccine on measles IgG concentration and seronegativity: a retrospective cohort study**: Archchun ARIYARAJAH (Canada)<br>**Investigation of influenza, COVID-19 and pneumococcal vaccination status in adults**: Gamze SANLIDAG ISBILEN (T�rkiye)<br>**Hybrid protection against laboratory-confirmed SARS-CoV-2 infection in a European multi-centre prospective cohort of healthcare workers, 2021–2024**: Madelyn ROJAS CASTRO (France)<br>**Pneumococcal disease and vaccination: descriptive results from a systematic literature review of knowledge, attitudes, and practices surveys and preference elicitation studies**: Heather VANSEGGELEN (Canada)<br>**Pneumococcal vaccination with PCV13 during hospitalisation for acute infection disease: a real-life opportunity for vaccination**: Julie MERINDOL (France)<br>**Investigating the state of vaccine confidence among the general public and parents with young children in Flanders (Belgium)**: Jade PATTYN (Belgium)<br>**Short-term survival following an event of HZ: a register-based matched cohort study in Denmark**: Mads Frederik EIBERG (Denmark)<br>**People living with HIV and vaccination: insights into awareness, recommendations, and attitudes at a tertiary care centre in Turkey**: Derya KAYA (T�rkiye)<br>**Roadmap to improve vaccine effectiveness research and evidence synthesis**: Matt LOIACONO (United States)<br>**Public health impact of herpes zoster vaccination for immunocompromised individuals aged 18-49 years in Germany**: Franziska JAKOBS (Germany)<br>**Strategies for introducing and implementing vaccines for adults into National Immunisation Programmes in Europe: exemplary approaches and key insights of the adult immunisation board meeting**: Marco DEL RICCIO (Italy)<br>**Safety and immunogenicity of co-administration of herpes zoster vaccines with other vaccines in adults: a systematic review and meta-analysis**: Omid REZAHOSSEINI (Denmark)<br>**Development of bipolymer based novel nanoparticles in microsphere system as vaccine adjuvant**: Mani BHARGAVA (India)<br>**Assessing vaccine hesitancy and vaccine literacy in adults in Saudi Arabia, United Arab Emirates, Turkey and South Africa**: Dzhumber UGREKHELIDZE (Switzerland)<br>**Oral combination vaccine against hepatitis B and influenza: development and characterisation**: Himanshu SARAF (India)<br>**Antibody coated liposomes for transmucosal vaccination**: Priyanka GOSAIN (India)<br>**Evaluation of functional antibody responses to sequential PCV13 and PPSV23 vaccination in type 2 diabetes mellitus adults: insights from a first study in the Indian population**: Sravani DHARMAVARAM (India)<br>**The impact of COVID-19 pandemic on poliomyelitis surveillance and immunisation in Armenia**: Goulia OHAN (Armenia)<br>**Current status of seasonal influenza vaccination policy in poultry industry workers in LATAM**: Jose MONTES (Argentina)<br>**Safety and immunogenicity of a novel RH5.1/matrix-M malaria vaccine in UK healthy adults**: Kyra HOLLIDAY (United Kingdom)<br>**Truncated VZV gE induces high-titer neutralising antibodies in micetruncated VZV gE induces high-titer neutralising antibodies in mice**: Song XU (China)<br>**Exploration of the risk-benefit profile of administering dengue vaccines with mixed efficacy estimates in different epidemiological contexts**: Yehuda DAVIS (United Kingdom)<br>**Co-administration of pneumococcal vaccines with common travel vaccines: a systematic review of immunogenicity and safety**: Omid REZAHOSSEINI (Denmark)<br>**Perception of vaccination during mild fever, insights from patients with a recent febrile illness and healthcare professionals: a qualitative study**: Soumaya ESSALIM (France)<br>**Assessing the willingness of future healthcare providers to participate in vaccine trials: a cross-sectional VACCELERATE European study**: Zoi Dorothea PANA (Cyprus)<br>**Current status of HPV gender neutral vaccination (GNV) in Latin America: a call for health equity**: Hebe Noemi VAZQUEZ (United States)<br>**Impact of BCG vaccination on innate immune responses in HIV-exposed uninfected infants in Uganda: a randomised controlled trial**: Rhoda NAMAKULA (Norway)<br>**Immunogenicity and adverse effects of pneumococcal vaccines coadministered with influenza or SARS-CoV-2 vaccines in adults: a systematic review and meta-analysis**: Omid REZAHOSSEINI (Denmark)<br>**Effect of  intravenous immunoglobulins on vaccine response of routine childhood vaccines**: Benno KOHLMAIER (Austria) |
| 13/04 | 12:00 - 13:30 | PS078 | 11b. Antiviral vaccines (excl respiratory and bloodborne viruses) |  | **Paced immune activation by AS04 drives superior cross-protective antibody response in Cervarix**: Valentino D'ONOFRIO (Belgium)<br>**Consolidating evidence on the number needed to vaccinate against herpes zoster in older adults**: Marie NISHIMWE (France)<br>**Kinetics of B and T cell responses to vaccination with chikungunya virus virus-like particle vaccine**: Lauren TINDALE (Canada)<br>**Impact of rotavirus vaccination on the aetiological profile of viral diarrhoea in under-five children in India**: Debasis BISWAS (India)<br>**Identification of immunity gaps and risk groups for future outbreaks of measles, mumps, and rubella: cross-sectional study of seroprevalence in young healthcare professionals in Serbia**: Ana BANKO (Serbia)<br>**Prevalence of HPV and associated risk factors for cervical lesions among women in northern Cameroon: a community-based study**: Fouelifack Nzeko ERIC (Cameroon)<br>**Recombinant zoster vaccine (RZV) does not increase the recurrence of herpes zoster (HZ) in adults ≥50 years of age with HZ history: a randomised clinical trial**: Bisi JEGEDE (United States)<br>**Vaccination uptake among patients on PrEP: patterns and associated factors, 2021-2024**: Albiana CEKREZI (Italy)<br>**Safety of LC16m8 vaccine in HIV-positive and high-risk populations in Bogot�, Colombia: a cohort study**: Carlos Arturo ALVAREZ MORENO (Colombia) |
| 13/04 | 12:00 - 13:30 | PS079 | 11c. Antibacterial vaccines |  | **Immunogenicity and safety of the higher valent pneumococcal conjugated vaccine compared to the 13-Valent pneumococcal conjugated vaccine in older adults: a systematic review and meta-analysis of randomised controlled trials**: Thundon NGAMPRASERTCHAI (Thailand)<br>**Recombinant subunit combined vaccine, a preventable zoonotic One Health approach for enhanced safety and immunogenicity**: Qaiser AKRAM (Pakistan)<br>**Fifteen years of Streptococcus pneumoniae laboratory surveillance: alarming serotype shift and the impact of PCV in Serbia**: Natasa OPAVSKI (Serbia)<br>**Post-pandemic Streptococcus pneumoniae serotype epidemiology and antimicrobial susceptibility among adults =18 years old with invasive and noninvasive pneumococcal disease in the United States, 2022-2023**: Mekki BENSACI (United States)<br>**Silver and gold bimetallic nanoparticles as an innovative bacterial vaccine platform against infections caused by ESKAPE group species**: Nath�lia ANDRADE (Argentina)<br>**Streptococcus pneumoniae carriage in children less than 25 months in North of Algeria (Blida) after introduction of PCV13**: Selma BOUHERAOUA (Algeria)<br>**Serotype distribution of invasive disease-causing Streptococcus pneumoniae after 14 years of systematic vaccination**: Mar�a ALONSO GIR�N (Spain)<br>**Safety, tolerability, and immunogenicity of 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults =50 years: a Phase 1/2, randomised, active-controlled, dose-finding study**: James WASSIL (United States)<br>**Early changes in incidence of paediatric invasive pneumococcal disease after introduction of 15-valent pneumococcal conjugate vaccine in Catalonia, Spain**: Maria CISNEROS (Spain)<br>**Factors influencing uptake of pneumococcal vaccination after invasive pneumococcal disease in two centres in northern Italy**: Giacomo PONTA (Italy)<br>**Pneumococcal vaccination rates among patients hospitalised for Pneumococcal infection at a community teaching hospital**: Shikha MISHRA (United States)<br>**Development of a double-auxotrophic Klebsiella pneumoniae strain as a safe and effective oral vaccine candidate to prevent gastrointestinal colonisation**: Rebeca SANTAMARINA (Spain)<br>**Invasive pneumococcal disease and impact of 7- and 13-valent pneumococcal conjugate vaccines in Singapore children over 24 years**: Jiahui LI (Singapore)<br>**Systematic literature review of the efficacy/effectiveness, immunogenicity and safety of booster vaccinations against pertussis in adults**: Christian RAUSCHERT (Germany)<br>**Torque teno virus load as a predictor of serotype-specific antibody response to the 13-valent conjugated pneumococcal vaccine in adult kidney transplant recipients**: Lykke LARSEN (Denmark)<br>**Estimating the public health impacts of introducing an age-based national Immunisation programme for adult pneumococcal vaccination in Denmark**: Oluwaseun SHAROMI (United States)<br>**Predicting the public health impacts of using different adult pneumococcal vaccines in ≥65-years-old adults in Sweden**: Oluwaseun SHAROMI (United States)<br>**Invasive Streptococcus pneumoniae infections in southern Switzerland: a preventable condition that is not actually prevented**: Niccol� RAMPONI (Switzerland)<br>**Development of live attenuated candidate vaccine by gene knockout method**: Deepak KUMAR (India)<br>**Estimating the health and economic burden of pneumococcal diseases attributable to V116 vs PCV20 serotypes among adults in Austria**: Peter MUELLER (United States)<br>**Estimating the pneumococcal vaccine preventable incidence of childhood pneumonia towards the mitigation of AMR: a vaccine probe study of cross-sectional data from a household survey in rural Vietnam**: Prince Kelechi CHIMA (United Kingdom)<br>**Use of new 21-valent pneumococcal conjugate adult vaccine in the presence of uncertainties around increases in invasive pneumococcal disease clusters caused by serotype 4 in the United States: a model-based threshold analysis**: Zinan YI (United States)<br>**Implications of recently revised pneumococcal vaccination recommendation for adults in Germany**: Mark VAN DER LINDEN (Germany)<br>**Encapsulation of L7/L12 and OMP19 proteins from Brucella melitensis in liposomal adjuvant system as a strategy to develop an effective vaccine against brucellosis**: Mohammadreza ASADIKARAM (Islamic Republic Of) |
| 13/04 | 12:00 - 13:30 | PS080 | 11d. Other preventive modalities (incl new vaccine technologies, antibody-based treatments) |  | **Evaluation of immunoglobulin use as post-exposure prophylaxis during a national measles outbreak in England**: Luke MCGEOCH (United Kingdom)<br>**Design of a smartphone app for recall-based contact tracing**: Caspar GEENEN (Belgium)<br>**Potential public health impacts of gonorrhoea vaccination programmes under declining incidences: a modelling analysis**: Lin GENG (Singapore) |
| 13/04 | 12:00 - 13:30 | PS081 | 11e. Food & water safety, environmental health, vector epidemiology |  | **Insecticide susceptibility of the sand fly leishmaniasis vector Phlebotomus argentipes in Bihar, India**: Ashish SHUKLA (India)<br>**Compatibility study of transport medium with PCR kits for detecting listeria spp. and Staphylococcus aureus from environmental samples**: Ilaria TRIVA (Italy)<br>**Rabbit production system and zoonotic Salmonella serovars: an Italian outbreak associated with Salmonella enteritidis ST11**: Letizia CIRASELLA (Italy)<br>**Antiadherent effect of a polysilazane-based sol-gel coating against Listeria monocytogenes**: John Jairo AGUILERA CORREA (Spain)<br>**Cross-contamination pathways and risk behaviours: insights from food and domestic surfaces in urban slums of bangladesh Enabl**: Syeda NURUNNAHAR (Bangladesh)<br>**Seasonal distribution and diversity of Vibrio spp. in the Baltic Sea of northeastern Germany and associated water systems**: Evgeny A. IDELEVICH (Germany)<br>**Prevalence and genetic characterisation of Listeria monocytogenes isolated from pork production chain in South Korea**: Kun Taek PARK (Republic Of)<br>**Prevalence of multiresistant: Enterobacteriaceae in aquatic ecosystems in Osona, Spain**: Javier D�EZ DE LOS R�OS (Spain)<br>**From sea to clinic: a 13-year study of Vibrio and Shewanella infections in the Atlantic coastal waters in southern Spain and their environmental links**: Sandra TAPIA POZA (Spain)<br>**Prevalence of extended-spectrum beta-lactamase producing-and carbapenemase-resistant Enterobacterales and methicillin-resistant S. aureus isolated from surface water in southern Italy**: Gaia NOBILI (Italy)<br>**Emergence and spreading of blaCTX-M-65 carrying Salmonella infantis in retail poultry meats in Korea**: Yeona KIM (Republic Of)<br>**Monitoring rabbit colibacillosis and antimicrobial resistance: insights for effective interventions and public health impact**: Azucena MORA GUTI�RREZ (Spain)<br>**Detection of extended-spectrum beta-lactamase and carbapenemase-producing Enterobacterales in hospital effluent: a pilot study**: Martin ANDRE (Belgium)<br>**Highest levels of antibiotic resistance seen in exclusively ExPEC Escherichia coli in Wyoming and Wales**: Jordan Aston Tregurtha MATHIAS (United Kingdom)<br>**Re-measuring community ExPEC Escherichia coli carriage in wastewater five years on, 2019-2024**: Jordan Aston Tregurtha MATHIAS (United Kingdom)<br>**Using wastewater to survey community carriage of Staphylococcus aureus at a genomic level in rural Wyoming**: Jordan Aston Tregurtha MATHIAS (United Kingdom)<br>**The role of antibiotics in the management of persistent shedding of shiga toxin-producing Escherichia coli (STEC)**: Gauri GODBOLE (United Kingdom)<br>**Phenotypic heterogeneity and biofilm formation in foodborne neomycin-resistant P. aeruginosa isolates**: Shaista UROOJ (Pakistan)<br>**The role of microbiological criteria for foodstuffs notably GSO 1016/2015 in controlling Escherichia coli O157 in meat in Saudi Arabia and other countries**: Meshari ALHADLAQ (Saudi Arabia)<br>**Emergence and clonal spread of livestock-associated methicillin-resistant Staphylococcus aureus harboring a novel variant staphylococcal chromosome cassette mec in Korean pig farms**: Hyeon Woo CHO (Republic Of)<br>**Co-occurrence of Legionella pneumophila and free-living Amoebae in water conduits in southern Tunisia**: Sameh BELGACEM (Tunisia)<br>**Wastewater-based genomic surveillance key to population-level monitoring of AmpC/ESBL-producing Escherichia coli**: Ahmad Ibrahim AL-MUSTAPHA (Finland)<br>**Detection and molecular characterisation of aflatoxin and ochratoxin produce Aspergillus species in Capsicum spices in Saudi Arabia**: Manal ALMUSA (Saudi Arabia)<br>**Contamination of leafy vegetables and strawberries with Echinococcus granulosus sensu lato and Taenia spp. in Tunisia: implication for food safety**: Ines KAMOUN (Tunisia)<br>**Genomic characterisation of zoonotic bacteria carried by wild birds during the migratory season in Gauteng, South Africa**: Theevasha GOVENDER (South Africa)<br>**Evaluation of water quality through pipe microbiome characterisation using 16S gene metagenomics approach**: Laura CALIGARIS (Italy)<br>**Prevalence and associated risk factors of vancomycin-resistant Enterococcus faecium in well water used for domestic purposes in Ile-Ife, southwestern Nigeria**: Babatunde ODETOYIN (Nigeria)<br>**Large scholar food-borne outbreak caused by Clostridium perfringens type F with plasmid enterotoxin CPE**: Fernando COBO (Spain)<br>**Advancing wastewater-based surveillance of antimicrobial resistance: a novel hybrid approach combining cultivation-based and molecular techniques for the detection of antibiotic resistant bacteria and resistance genes**: Alexandra FOBE (Austria)<br>**Surface hygiene in food environments: challenges with biocide efficacy and bioindicators**: Patricia ANTUNES (Portugal)<br>**Negligible impact of quaternary ammonium compounds on the spread of toxigenic and antibiotic-resistant Clostridium perfringens in rivers used for drinking water production**: Carla NOVAIS (Portugal)<br>**Dominant species and serogroups of Legionella spp. in swimming pool water in the Federation of Bosnia and Herzegovina**: Emilija HRAPOVIC (Bosnia And Herzegovina)<br>**Summer surge of sequence type 283 in Hong Kong: a five-year review of Group B Streptococcus molecular distribution in non-pregnant adults**: Tiffany DIDIK (China)<br>**Environmental surface sampling of respiratory and gastrointestinal pathogens during the 2022-2023 Grand Magal of Touba**: Ihssane OUADDANE (France)<br>**Mapping antimicrobial resistance landscape at a city scale sewage network**: Miquel S�NCHEZ-OSUNA (Spain)<br>**Detection and prevalence of moulds and mycotoxins in food for young children and infants, nuts and grains**: Amir IBRAHIMAGIC (Bosnia And Herzegovina)<br>**Performance comparison of two different sampling strategies in deli food production plant: FLOQSwab and sponges, for the detection of Listeria monocytogenes and Bacillus cereus**: Erica TIRLONI (Italy)<br>**Foodborne Listeria monocytogenes in chicken viscera products: implications for food safety and public health**: Vanessa SILVA (Portugal)<br>**Methicillin resistant Staphylococcus aureus prevalance in abbatoirs and meat shops in the northern border regions between Pakistan and Afghanistan**: Sohail KHAN (Pakistan)<br>**A surveillance study of Cryptosporidium parvum present in organic waste used as fertiliser in Ireland**: Emma HEFFERNAN (Ireland) |
| 13/04 | 12:00 - 13:30 | PS082 | 11f. Veterinary microbiology and One Health (excl AMR) |  | **Genomic analysis of Campylobacter coli strains tolerant to stress conditions associated to food safety suggests possible contamination amongst diverse sources in Brazil**: Carolina Nogueira GOMES (Brazil)<br>**Detection of Leptospira spp. in Marmosets (Callithrix spp.) from the Atlantic Forest (Rio de Janeiro-RJ) of Brazil**: Juliana ARAUJO NOBRE (Brazil)<br>**Multidrug-resistant and ESBL-producing Salmonella Kentucky ST198: a veterinary outbreak with public health implications**: Alessandro BELLATO (Italy)<br>**Potentially azole-resistant and thermal tolerant human and coral pathogen Aspergillus sydowii in wild Spanish Cetaceans: implications for One Health**: Victor GARCIA-BUSTOS (Spain)<br>**Cure of a difficult-to-treat Pseudomonas aeruginosa chronic otitis externa (OE) in a dog with the PYO bacteriophage cocktail followed by antibiotics**: Rapha�l BAUDIN (Switzerland)<br>**Exploring nitroxoline as a solution to antibiotic resistance in poultry production**: Mariia TRUSH (United Kingdom)<br>**Impact of different temperatures on Chlamydia abortus survival and infectivity over time**: Efe ALTUNTAS (Switzerland)<br>**An unconjugated single composite peptide vaccine targeting highly conserved influenza epitopes induced broadly reactive and durable antibodies to multiple influenza viruses in pigs**: Kellie Ann KROSCHER (United States)<br>**Exploring the distribution of virulence factors associated with Escherichia coli through the One Health paradigm**: Sandra A. MART�NEZ-�LVAREZ (Spain)<br>**Active surveillance in an equine intensive care unit identifies clusters of ESKAPEE pathogens in the veterinary hospital environment**: Els BROENS (Netherlands)<br>**Global insights into the accessory genome of Streptococcus equi subspecies equi**: Lingyu HE (China)<br>**Elucidating the endemicity of amphixenotic Ascaris lumbricoides in pigs: the most prospective cross-transmission threat to humans in Haryana, India**: Aman Dev MOUDGIL (India)<br>**Cold atmospheric plasma as an alternative antimicrobial therapy to treat livestock wound infections**: Jessica GHODKE (United Kingdom)<br>**Unveiling tick diversity in cattle in Cameroon: emergence of Rhipicephalus microplus, replacing the original Rhipicephalus spp.**: Muhammad Umair AZIZ (China)<br>**Prevalence of Gram-positive cocci isolated from livestock and livestock farmers in Japan: high prevalence of Mammaliicoccus sciuri**: Ryusei TANIGUCHI (Japan)<br>**Global prevalence and molecular features of high-priority Enterococcus faecium and E. faecalis from guts of food-producing and wild birds**: Idris Nasir ABDULLAHI (Nigeria)<br>**One Health lens on rabies: genomic insights and human-animal interactions in rural Lilongwe, Malawi**: Nathan SINGANO (Zambia)<br>**Toxigenic Corynebacterium ulcerans in raw milk of a cow with acute mastitis and the risk of milk-associated diphtheria in humans**: Anja BERGER (Germany)<br>**Zoonotic gastrointestinal parasites in dogs: an epidemiologic study of agricultural zones in Tunisia**: Lamia ZEMZEMI (Tunisia)<br>**Azole-resistant Aspergillus and Candida isolates in bottlenose dolphins: implications for One Health**: Victor GARCIA-BUSTOS (Spain) |
| 13/04 | 12:00 - 13:30 | PS083 | 11g. Global health & health security (incl policy-making, climate change, biosafety/biosecurity) |  | **The relationship between COVID-19 and final consumption expenditure**: Soichi TAKEISHI (Japan)<br>**Advancing antimicrobial stewardship with the SMART-AMS model: a strategic framework to combat antimicrobial resistance for a healthier future**: Rasha ABDELSALAM ELSHENAWY (United Kingdom)<br>**Korean pandemic response repository through microbial and immunological surveillance and epidemiology (K-PREMISE)**: Shinhee HONG (Republic Of)<br>**Climate-driven antifungal resistance: new challenges in public health**: Daniela DEBONE (Brazil)<br>**Clinical-epidemiologic versus laboratorial exam in the diagnosis on dengue fever in the environmental catastrophe scenario in Rio Grande do Sul, Brazil in 2024**: Manoela LENZI PINTO (Brazil)<br>**Modeling the potential public health and economic impact of timely COVID-19 vaccination with an adapted vaccine in the United Kingdom**: Cale HARRISON (United Kingdom)<br>**A comprehensive analysis of disability-adjusted life years (DALYs) across 85 pathogens: the first-ever pathogen impact atlas on a global, regional and national scale**: Tomislav MESTROVIC (Croatia)<br>**Learning from post-COVID-19 condition for pandemic preparedness: a catalogue of variables for future post-acute infection syndromes**: Lorenzo Maria CANZIANI (Italy)<br>**Heavy rainfall and flooding events and infectious diseases in Denmark**: Nina RISE (Denmark)<br>**Excess mortality during the COVID-19 pandemic compared to previous influenza seasons: estimates from 26 countries in the EuroMOMO network**: Sarah Kristine N�RGAARD (Denmark)<br>**One Health criteria: considerations for One Health interventions and AMR national action plan designs**: Kristina ALUZAITE (United Kingdom)<br>**Time for a multi-generational household respiratory infection vaccination strategy: scoping review**: Ahreej ELTAYEB (United Kingdom)<br>**Effects of climate change on Aedes aegypti abundance and dengue transmission**: Lin GENG (Singapore)<br>**Newest insights into the burden of antimicrobial resistance in Southeast Asia in 2021: a comparative evaluation of predominant resistant pathogens and pathogen-drug combination across countries of the region**: Tomislav MESTROVIC (Croatia)<br>**Trends in prescriber applications to access unregistered antimicrobials in Australia: demonstrating the unmet need in a smaller population**: Andrew BOWSKILL (Australia)<br>**Political, ethical, administrative, regulatory and legal (PEARL) barriers to site activation experienced in a pan-European warm-base clinical trial network**: Priya SHREEDHAR (Germany)<br>**Learning from strengthening national laboratory systems towards global health security: experience of the UK Health Security Agency (UKHSA) international health regulations strengthening project (IHR-SP) laboratory team working across countries in Asia and Africa.**: Olajumoke SULE (United Kingdom)<br>**Sustainability challenges and opportunities of SARS-CoV-2 antigen rapid detection tests in the COVID-19 pandemic: a life cycle assessment**: Isabell WAGENH�USER (Germany)<br>**An investigation of national age–specific fertility rates in the Middle East using cluster analysis**: Soichi TAKEISHI (Japan)<br>**Under-estimated pertussis burden among older adults in Taiwan: a longitudinal seroepidemiological study from 2014 to 2020**: Ming-Han TSAI (China)<br>**Comparative analysis of NS1/IgM rapid diagnostic tests (RDT) with NS-1 and IgM ELISA for dengue cases and its possible correlation with under-reporting of dengue cases in India**: Vishwa Deepak TIWARI (India)<br>**Strategic positioning of the ESGVH-ESCMID for global hepatitis E virus vaccination**: Antonio RIVERO-JUAREZ (Spain)<br>**The impact of armed conflict on the development and global spread of antibiotic resistance: a systematic review**: Guido GRANATA (Italy)<br>**GENTRAIN: genome-based infection chain analysis to increase digitalisation level in the public health sector**: Airin FRANKE (Germany)<br>**A digital tool for the selection of portable screening technologies for detecting substandard and falsified anti-infectives**: C�line CAILLET (United Kingdom)<br>**Omadacycline demonstrated efficacy as both therapeutic treatment and post-exposure prophylaxis against inhalation anthrax and pneumonic plague in cynomolgus macaques**: Jessica PIERCE (United States)<br>**A cross-country comparison of antimalarial drug prices, availability, and affordability: insights from India and Nigeria**: Sriram RADHAKRISHNAN (India)<br>**Developing AWaRe-based antibiotic use quality indicators using sequential consensus methodology**: Jan GOELEN (United Kingdom)<br>**Evaluating the international performance of diagnostics systems for addressing antimicrobial resistance in 174 countries and territories: a systematic global analysis**: Jay PATEL (United Kingdom)<br>**Impact of French public health alerts in a specialty laboratory**: Benoit VISSEAUX (France)<br>**Factors influencing work absenteeism due to acute respiratory infections (ARIs) among healthcare workers**: Helen MUELLER (Germany)<br>**Automating systematic reviews and meta-analyses: a framework for living evidence synthesis in infectious diseases**: Anna GORSKA (Italy)<br>**Differences in causes of death between males and females during periods with and without elevated mortality**: Christel Baag� SCHJ�RRING (Denmark)<br>**When the rain pours, soars the pill: a pharmaco-audit of doxycycline sales in Chennai following Tamil Nadu's flood advisory**: Sarika SARIKA (India)<br>**Epidemiological study of Streptococcus pyogenes in China and data mining based on global isolates**: Shiyu CHEN (China) |
| 13/04 | 12:00 - 13:30 | PS084 | 11h. Infections in low-resource settings (incl disease burden, health infrastructure, health disparities and vulnerable populations) |  | **Outbreak investigation of visceral leishmaniasis in Bihar, India: insights from an endemic region**: Urvashi Geeta RAI (India)<br>**Assessment of HIV-related stigma among healthcare providers**: Merve MERT VAHABI (T�rkiye)<br>**Challenges in preventing pneumococcal disease in Costa Rica: serotypes, vaccination, and risk factors**: Raquel GARCIA-BATAN (Costa Rica)<br>**Acceptance of self-sampling and knowledge about human papilloma virus among women in north India**: Alpana MOHTA (India)<br>**Atypical distribution of cervical HR-HPV in the Congo basin: implication for cervical cancer prevention**: Laurent B�LEC (France)<br>**Socioeconomic factors and treatment limitations of intensive care in hospitalised COVID-19 patients**: Adonis SOTOODEH (Sweden)<br>**Implementation of urine-based HR-HPV testing for cervical cancer prevention in a rural clinic in Eswatini, January 2023-February 2024**: Sante Leandro BALDI (Italy)<br>**Latent tuberculosis infection (LTBI) in an urban homeless population**: David MOYNAN (Ireland)<br>**The mini-lab: the next step towards integrated antimicrobial resistance surveillance in South-Kivu Province, Democratic Republic of Congo**: Chasinga BAHARANYI (The Democratic Republic Of The)<br>**Patient satisfaction with antiretroviral therapy services in selected hospitals of addis ababa, ethiopia using the donabedian model**: Eskedar AZEREFEGNE (Ethiopia)<br>**Antimicrobial resistance of bacterial infections in Mozambique: a systematic review and meta-analysis**: Nafital Joao FRANCISCO (Mozambique)<br>**Awareness, misconceptions and uptake of HPV vaccination among university students in Georgia**: Nita VERULAVA (Georgia)<br>**Development of a WHO list of essential diagnostic tests for bacterial and fungal infections and antimicrobial resistance**: Raghu SRIRAM (Switzerland)<br>**Understanding acute encephalitis syndrome in adults: an etiological perspective from Eastern Uttar Pradesh**: Jaya TAPADAR N�E CHAKRAVARTY (India)<br>**Correlates of acceptability of COVID-19 vaccine among health care workers(HCWs) at Ndola teaching hospital (NTH), Ndola, Zambia**: Hope KALASA (Zambia)<br>**Evaluating the burden of Streptococcus pneumoniae and the pneumococcal vaccine implementation in Mexico**: Marcelo DIAZ-CONDE (Mexico)<br>**Clinical care for adults with chronic Chagas disease in Bolivia: a scoping review**: Miriam M�LLER (Germany)<br>**Antibiotic misuse via OTC medications in south India: results from the BEWARE study**: Harshitha SURESHKUMAR (India)<br>**Development, implementation, and evaluation of a cross-generational strategy to support introduction of the human papillomavirus vaccine and utilisation of cervical cancer screening in Nepal**: Linda KALJEE (United States)<br>**The malaria care cascade and factors associated with receiving a malaria test in children under five and pregnant women with fever : a cross-sectional household survey from Guinea and Sierra Leone**: Gerrit BURGER (Germany)<br>**Improving global access to microbiology diagnostics by means of a comprehensive online open repository**: Liselotte HARDY (Belgium)<br>**Bottom-up approach for an infection burden estimate approach: a Brazilian experience on ICD-10 standardisation process for the use on local secondary database studies**: Carlos KIFFER (Brazil)<br>**A distributional regression approach to socioeconomic inequalities in infectious diseases in the UK**: Murong YANG (United Kingdom)<br>**Results of a randomised feasibility study of an intestinal adsorbent in acute diarrhoea in children in the Gambia**: Paul RAHDEN (Gambia)<br>**Multicentre insights into outpatient parenteral antimicrobial therapy (OPAT): a comprehensive analysis of T�rkiye's unstructured system**: Elif AGULOGLU-BALI (T�rkiye)<br>**Infectious disease control: vaccine access and healthcare disparities in Pakistan**: Fahmeeda IDREES (Finland)<br>**Burden of sexually transmitted diseases (STDs) and impact of the comprehensive health promotion package on screening and prevention among commercial sex workers in northeast India**: Shanthosh Priyan SUNDARAM (India) |
| 13/04 | 12:15 - 13:15 | FIPL4 | Fireplace: The new frontiers in antimicrobial stewardship | Jose Ramon PANO-PARDO (Spain), Jeroen SCHOUTEN (Netherlands) | ****: Karin THURSKY (Australia) |
| 13/04 | 12:15 - 13:15 | IS21 | Reducing the global burden of RSV in infants via maternal immunisation | Debby BOGAERT (United KingdomESCMID-appointed chair) | **Welcome and Introduction**: Debby BOGAERT (United Kingdom)<br>**The global burden of RSV disease in infants**: Paolo MANZONI (Italy)<br>**RSVpreF vaccine clinical overview**: Marta NUNES (France)<br>**Key learnings from the real-world implementation of RSV maternal immunisation**: Irene CETIN (Italy)<br>**Panel Discussion and Q&A**: Debby BOGAERT (United Kingdom) |
| 13/04 | 12:15 - 13:15 | IS23 | Does number of serotypes matter? A new adult-specific pneumococcal conjugate vaccine to expand protection across the lifespan | Zitta Barrella HARBOE (DenmarkESCMID-appointed chair), Robert KRAUSE (Austria) | **Welcome and Introduction**: Robert KRAUSE (Austria)<br>**Overview of PCV21 phase III clinical development programme**: Maria Alejandra ESTEVES JARAMILLO (United States)<br>**Pneumococcal pNeumonia Epidemiology, Urine serotyping, Mental Outcomes (PNEUMO) EU study**: Cristina PRAT AYMERICH (Netherlands)<br>**Adult immunisation as a priority for public health**: Pier Luigi LOPALCO (Italy)<br>**Panel Discussion and Q&A**: Robert KRAUSE (Austria) |
| 13/04 | 12:15 - 13:15 | IS24 | Maximising the impact of syndromic molecular diagnostics: enhancing respiratory infection management and antimicrobial stewardship in the ED and ICU | Maurizio SANGUINETTI (ItalyESCMID-appointed chair), Stefan WINKLER (Austria) | **Welcome and Introduction**: Stefan WINKLER (Austria)<br>**Improving diagnosis and management of patients with acute respiratory infections in emergency departments**: Rangaraj SELVARANGAN (Rangaraj SELVARANGAN)<br>**Evaluating the impact of pneumonia (PN) panel on ICU therapeutic strategies: insights and future directions**: Alessandra BANDERA (Italy)<br>**Syndromic testing: a key tool in the battle against drug-resistant Gram-negative bacilli**: Ali OMRANI (Qatar)<br>**Panel Discussion and Q&A**: Stefan WINKLER (Austria) |
| 13/04 | 12:15 - 13:15 | IS25 | Preventing bacterial infections: a crucial front in the fight against sepsis and antimicrobial resistance | Michele BARTOLETTI (ItalyESCMID-appointed chair), Mariam JASHI (Germany) | **Welcome and Introduction**: Mariam JASHI (Germany)<br>**Sepsis survivor witness**: Wilbert KRUIJSEN (Netherlands)<br>**Sepsis susceptibility and comorbidities**: Antonio ARTIGAS (Spain)<br>**Multidrug-resistant bacteria and sepsis: fact or foe?**: Evelina TACCONELLI (Italy)<br>**From trained immunity to vaccination: room for prevention from multidrug-resistant bacteria?**: Evangelos GIAMARELLOS-BOURBOULIS (Greece)<br>**Panel Discussion and Q&A**: Mariam JASHI (Germany) |
| 13/04 | 12:15 - 13:15 | MEET109 | Sexually Transmitted Infections Study Group open meeting (ESTISG) | Arjan HARXHI (), Justyna KOWALSKA (PolandESCMID official), Jean-Michel MOLINA () |  |
| 13/04 | 12:30 - 12:50 | IPT17 | Physicochemical stability of cefepime/emmetazobactam in medical devices for continuous infusion. Is it possible to use it in OPAT? |  | **Physicochemical stability of cefepime/emmetazobactam in medical devices for continuous infusion. Is it possible to use it in OPAT?**: Dolores SERRANO (Spain) |
| 13/04 | 13:00 - 13:20 | IPT18 | Nontuberculous mycobacteria: an overlooked threat with a growing impact on global public health |  | **Nontuberculous mycobacteria: an overlooked threat with a growing impact on global public health**: Joaquin ORTIZ (Spain) |
| 13/04 | 13:30 - 14:30 | EF054 | Beware the sink! Pathogen reservoirs in drains and waste water | Stephan Juergen HARBARTH (Switzerland) | **Genomic Epidemiology to Investigate Healthcare Environment as Reservoir for Carbapenem-Resistant Organisms in an Academic Hospital in Miami, Florida.**: Adriana JIMENEZ (United States)<br>**Two clusters of carbapenemase-producing Enterobacterales linked to hospital wastewater drainage in utility rooms – an outbreak investigation**: Isabelle VOCK (Switzerland)<br>**Assessing the burden of carbapenemase and colistin antimicrobial resistance genes in hospital wastewater**: Emily AU (Canada)<br>**Hospital wastewater as a reservoir for carbapenemase-producing organisms**: Ahalieyah ANANTHARAJAH (Belgium)<br>**Reversing and controlling microbial proliferation in the water system of a high-risk hospital ward after extended closure and reconstruction**: Dominique L. CHAPUT (United Kingdom)<br>**Whole-genome sequencing as part of the tracking and managing Carbapenemase producing Enterobacterales transmission in an acute hospital setting**: Darragh COFFEY (Ireland)<br>**Is there a solution for hospital acquired infections due to the aquatic reservoir in the near patient environment?**: Hiba ZAYYAD (Israel)<br>**Reducing Antimicrobial Resistance (AMR) across the One Health Landscape: Diverse Perspectives on AMR risks and their mitigation in sinks, drains, and wastewater**: Hillary A. CRADDOCK (Ireland) |
| 13/04 | 13:30 - 14:30 | EF055 | The cutting edge in tuberculosis | Graeme Ayton MEINTJES (South Africa) | **Personalised risk predictions for incident TB and preventive treatment uptake.**: Rubin ROSE-KEY (United Kingdom)<br>**Programmatic migrant screening for tuberculosis identifies a spectrum of clinical phenotypes and outcomes: cohort data from a national migrant screening programme**: Marjan GOHAR (United Kingdom)<br>**An investigation into the relationship between human and animal Mycobacterium bovis isolates using whole genome analysis.**: Mary MANSFIELD (Ireland)<br>**Distinguishing relapse from reinfection in tuberculosis patients from Lithuania**: Laima VASILIAUSKAITE (Lithuania)<br>**Rapid Resistance Profiling of Mycobacterium tuberculosis from Clinical Specimens using Targeted Next-Generation Sequencing: A Pilot Validation Study**: Pratiksha CHHEDA (India)<br>**Inflammation precedes early respiratory worsening in HIV-negative tuberculosis patients during antituberculosis treatment**: Arjan VAN LAARHOVEN (Netherlands)<br>**Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis**: Chaelin KIM (United Kingdom)<br>**A longitudinal study on the evolution of drug resistance during tuberculosis treatment**: Emelia DANSO (Ghana)<br>**Phase 1, randomized, double-blind, parallel-group, dose-escalation safety and tolerability of PLGA encapsulated first line antitubercular drugs nanoparticles in healthy volunteers**: Avaneesh Kumar PANDEY (India) |
| 13/04 | 13:30 - 14:30 | FO097 | Essential diagnostics in Low-Resource Settings: why are we still talking? | Truls Michael LEEGAARD (Norway) | **Training skilled personnel in LMIC and brain drain: is the solution the problem?**: Sipho Kenneth DLAMINI (South Africa)<br>**Leveraging surveillance networks to strengthen basic bacteriology**: Dissou AFFOLABI (Benin)<br>**Clinical bacteriology laboratories in low-resource settings: considerations for sustainability**: Makeda SEMRET (Canada) |
| 13/04 | 13:30 - 14:30 | FO098 | Best of ID Week | Tina TAN (United States) | ****: Seth COHEN (United States) |
| 13/04 | 13:30 - 14:30 | JS1 | Late-breaker research from CMI and CMI Communications |  | **Measuring the impact of hospitalization for infectious diseases on the quality of life of older patients in four European countries: the AEQUI longitudinal matched cohort study (2020-2023)**: Gaetan GAVAZZI (France)<br>**Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial**: Thomas HOLLAND (United States)<br>**The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round: A prospective cohort study**: Elise MITRI (Australia)<br>**Efficacy and safety of mechanical thrombectomy in acute ischemic stroke secondary to infective endocarditis**: Guillermo CUERVO (Spain)<br>**A randomised non-inferiority trial investigating antibiotic adjustments based on blood culture in acute cholangitis**: Sang Hyub LEE (Republic Of) |
| 13/04 | 13:30 - 14:30 | LB003 | New solutions for difficult-to-treat infection | Shampa DAS (United Kingdom) | **Multivalent OMV-based vaccine against Klebsiella pneumoniae**: Beatriz CANO CASTA�O (Spain)<br>**Epidermicin NI01, a first-in-class peptide antibiotic candidate, has potent efficacy in a robust MRSA wound infection model and low allergic reaction liabilities**: Mathew UPTON (United Kingdom)<br>**Minimum inhibitory concentrations of quabodepistat in Mycobacterium tuberculosis clinical isolates from patients with drug-susceptible pulmonary tuberculosis**: Irina KONTSEVAYA (Germany)<br>**Antimicrobial CRISPR-Cas9-based treatment against antibiotic resistant extraintestinal pathogenic E. coli (ExPEC) ST131**: Claudia MORROS-BERNAUS (United Kingdom)<br>**Ultra-narrow spectrum antibiotic against multi-drug resistant gonococci with novel mode of action**: Nhung NGUYEN (Austria) |
| 13/04 | 13:30 - 14:30 | ME095 | Local antimicrobials for deep infections |  | ****: Karolina AKINOSOGLOU (Greece), Pierre TATTEVIN (France) |
| 13/04 | 13:30 - 14:30 | MEET76 | Non-traditional Antibacterial Therapy Study Group open meeting (ESGNTA) | Zuzanna DRULIS-KAWA (PolandESCMID official), Tristan FERRY (FranceESCMID official), Ran NIR-PAZ (IsraelESCMID official), Jean-Paul PIRNAY (), Gina SUH (United StatesESCMID official) |  |
| 13/04 | 13:30 - 14:30 | MEET77 | Mycoplasma and Chlamydia Study Group open meeting (ESGMAC) | Sylvia BRUISTEN (NetherlandsESCMID official), Gilbert GREUB (SwitzerlandESCMID official), Jorgen Skov JENSEN (DenmarkESCMID official), Mirja PUOLAKKAINEN (FinlandESCMID official), Barbara VAN DER POL (United StatesESCMID official) |  |
| 13/04 | 13:30 - 14:30 | OS052 | AI in infectious diseases: the lab and beyond | Miranda LANGENDAM (Netherlands) | **Accurate strain typing of key bacterial pathogens through artificial intelligence analysis of MALDI-TOF mass spectra**: Nenad MACESIC (Australia)<br>**CarbaDetector: An Artificial Intelligence-Driven Prediction Model for Detecting Carbapenemase-Producing Enterobacterales Using Disk-Diffusion**: Linea Katharina MUHSAL (Germany)<br>**AI-Driven Early Infectious Disease Detection in Dutch Primary Care: leveraging Bidirectional Encoder Representations from Transformers (BERT) and Early Recognition using Neural Information Encoding (ERNIE)**: Gijs DANOE (Netherlands)<br>**Predicting potentially infection-related findings in structured radiology reports**: Justin XU (United Kingdom)<br>**Application of Artificial Intelligence in Assisting X-ray Diagnosis of Pediatric Pulmonary Infections**: Haocheng ZHANG (China) |
| 13/04 | 13:30 - 14:30 | OS053 | Immune evasion and intracellular survival strategies | Juliane BUBECK WARDENBURG (United States), Giovanni DELOGU (Italy) | **Capsule-Dependent Modulation of Cell Death Pathways and Immune Evasion in Acinetobacter baumannii**: Hui WANG (China)<br>**Intracellular lifestyle of Acinetobacter baumannii: Role of phospholipase A2 and transcriptional factor EB (TFEB)**: Younes SMANI (Spain)<br>**The role of peg344 of hypervirulent Klebsiella pneumoniae on suppressing autophagy responses of macrophages**: Zeynep Ece KULOGLU (T�rkiye)<br>**c-Myc Inhibits Macrophage Antimycobacterial Response in Mycobacterium tuberculosis Infection**: C�dric DOLL� (Switzerland)<br>**Targeting neutrophil extracellular traps (NETs) prevents tuberculosis immunopathology**: Julia KUTSCHENREUTER (United Kingdom) |
| 13/04 | 13:30 - 14:30 | SY091 | Emerging infectious diseases: staying informed and prepared in a globalised world | Nitin GUPTA (India), Pikka JOKELAINEN (Denmark) | **Lessons learnt from previous outbreaks**:  TBA (TBA)<br>**Disease X: preparedness for the next pandemic**: Yee Sin LEO (Singapore) |
| 13/04 | 13:30 - 14:30 | SY092 | Sex differences in management and outcome of patients with serious bacterial infections | Michele BARTOLETTI (Italy), Merel LAMBREGTS (Netherlands) | **Sex impacts incidence, management, and outcome in bacteraemia**: Annette WESTGEEST (Netherlands)<br>**The complex interplay between gender and sepsis**: Ines LAKBAR (France) |
| 13/04 | 13:30 - 14:30 | SY093 | Immunosenescence and immune response to vaccination | Petar VELIKOV (Bulgaria), Dafna YAHAV (Israel) | **How immunosenescence impacts vaccine response**: Andrea COSSARIZZA (Italy)<br>**Strategies to tackle immunosenescence and improve immune response to vaccination in the elderly**: Inna OVSYANNIKOVA (United States) |
| 13/04 | 13:30 - 14:30 | SY094 | Farm to fork: food-borne antimicrobial resistance | Beatriz GUERRA ROM�N (Spain), Joel MOSSONG (Luxembourg) | **Foodborne risk in meat and fishery products and impact on AMR**: Anders DALSGAARD (Denmark)<br>**Control challenges associated with food-borne multidrug resistance**: Luisa Maria Vieira PEIXE (Portugal) |
| 13/04 | 13:30 - 15:30 | EW096 | Tools for successful development as a medical educator | Giorgia CARUANA (Switzerland), Yoav KEYNAN (Canada) | **Developing your educator professional identity**: Todd CASSESE (United States)<br>**What do IPC doctors need to learn to be prepared**: Simone SCHEITHAUER (Germany)<br>**Communities of practice: successful experience of a transformative collaboration and roadmap**: Erin BONURA (United States)<br>**The critical need for ongoing innovations in medical education**: Cl�mentine SCHILTE (France) |
| 13/04 | 13:30 - 15:30 | IS26 | Expert insights in COVID-19: from vaccination to treatment | Laurent KAISER (SwitzerlandESCMID-appointed chair), Stefania MAGGI (Italy) | **Welcome and Introduction**: Stefania MAGGI (Italy)<br>**The reality of COVID-19 in 2025: is there still a need for vaccination and treatment?**: Colin RUSSELL (Colin RUSSELL)<br>**Keeping pace with viral evolution: updated vaccines to help protect individuals against COVID-19**: Albertus OSTERHAUS (Netherlands)<br>**The role of COVID-19 antivirals today: getting the right treatment to the right patient**: Roger PAREDES (Spain)<br>**From HCPs to patients and carers: why sharing COVID-19 data remains key to improving outcomes**: Sven SCHELLBERG (Germany)<br>**Panel Discussion and Q&A**: Stefania MAGGI (Italy) |
| 13/04 | 13:30 - 15:30 | IS28 | Refining the management of cytomegalovirus and Gram-negative infections: latest updates and therapeutic advances | Dina AVERBUCH (Israel), Maddalena GIANNELLA (ItalyESCMID-appointed chair), Souha S. KANJ (Lebanon) | **Welcome and Introduction**: Dina AVERBUCH (Israel)<br>**Opening Remarks**: Dina AVERBUCH (Israel), Souha S. KANJ (Lebanon)<br>**Part 1: Advancements in CMV management**: Dina AVERBUCH (Israel)<br>**CMV management after HSCT: state of the art update**: Per LJUNGMAN (Per LJUNGMAN)<br>**Navigating the shifting landscape in SOT and evolving RWE**: Nassim KAMAR (France)<br>**Panel discussion and Q&A**: Dina AVERBUCH (Israel)<br>**Part 2: Recent advances in treating pneumonia caused by resistant Gram-negative infections**: Souha S. KANJ (Lebanon)<br>**Novel approaches: clinical evidence and advancements in addressing resistant Gram-negative infections**: Matteo BASSETTI (Italy)<br>**Optimising care for critically ill pneumonia patients: current practices and future directions**: Ignacio MARTIN-LOECHES (Ireland)<br>**Panel Discussion, Q&A and Closing Remarks**: Souha S. KANJ (Lebanon) |
| 13/04 | 13:30 - 15:30 | IS29 | Serious bacterial infections in high-risk populations: a race against time | Diane ASHIRU-OREDOPE (United KingdomESCMID-appointed chair), Tonya VILLAFANA () | **Welcome and Introduction**: Tonya VILLAFANA (Tonya VILLAFANA)<br>**The microbial hurdle: firsthand experience(s) of serious bacterial infections**:  TBA (TBA)<br>**Pit stops in progress: recent developments in bacterial infection research**: Susanna ESPOSITO (Italy)<br>**The bacterial pursuit: a marathon, not a sprint**: Mark H. WILCOX (United Kingdom)<br>**Panel Discussion and Q&A - An ongoing race: perspectives on tackling the bacterial challenge**: James CHALMERS (United Kingdom)<br>**Thank you and Closing Statement**: Tonya VILLAFANA (Tonya VILLAFANA) |
| 13/04 | 13:30 - 15:30 | IS30 | Transforming STI treatment and management with highly-extended molecular point-of-care testing | Jean-Pierre ALLAIN (United Kingdom), Antti HAKANEN (FinlandESCMID-appointed chair) | **Welcome and Introduction**: Jean-Pierre ALLAIN (United Kingdom)<br>**MPox in Africa: myths, facts and the way forward**: Isaac SSEWANYANA (Uganda)<br>**Advancing STI diagnosis**: Sonny Michael ASSENNATO (United Kingdom)<br>**Breaking barriers: impact of point-of-care STI testing**: John WHITE (United Kingdom)<br>**Panel Discussion and Q&A**: Jean-Pierre ALLAIN (United Kingdom) |
| 13/04 | 13:30 - 15:30 | M8 | Malaria differential diagnosis (beginners) | Debbie NOLDER (United Kingdom), Claire ROGERS (United Kingdom) |  |
| 13/04 | 13:30 - 15:30 | SEL | Selective Pressure | Jacob MORAN-GILAD (Israel), Joshua NOSANCHUK (United States), Jose Ramon PANO-PARDO (Spain), Jes�s RODR�GUEZ-BA�O (Spain), Suzanne VAN ASTEN (Netherlands), David VAN DUIN (United States), Anja STERBENC (Slovenia) |  |
| 13/04 | 14:00 - 14:20 | IPT20 | The magic of randomization for understanding the public health value of influenza vaccination |  | **The magic of randomization for understanding the public health value of influenza vaccination**: Mathieu BANGERT (France) |
| 13/04 | 14:30 - 14:50 | IPT21 | Revolutionizing vaginitis diagnosis: the Impact of molecular screening tools |  | **Revolutionizing vaginitis diagnosis: the Impact of molecular screening tools**: Jonas AMZALAG (France) |
| 13/04 | 14:45 - 15:45 | EF059 | Bacterial infections in the post pandemic era | �zlem Kurt AZAP (T�rkiye) | **Genomic epidemiology of invasive meningococcal disease in Scotland: The impact of the COVID-19 pandemic**: Niall AHMAD (United Kingdom)<br>**Targeted probe-capture culture-independent sequencing identifies emergence of Macrolide-Resistant Bordetella pertussis in Australia**: Winkie FONG (Australia)<br>**Invasive pneumococcal disease in Spanish adults. Multicenter analysis of serotypes and lineages in the post-pandemic period.**: Roc�o ESPA�A BONILLA (Spain)<br>**Group A streptococcal infections in Germany from 2017 to 2024: a post-pandemic rebound above expected numbers?**: Anja VON LAER (Germany)<br>**Invasive group A streptococcus infections is often preceeded by seasonal influenza.**: Johan WESTIN (Sweden)<br>**Impact of the COVID-19 Pandemic on Tuberculosis Transmission Rates**: Angela CANNAS (Italy)<br>**Treatment outcomes of bedaquiline-based longer oral regimens in Indian children above 5-years of age**: Dhruv GANDHI (India)<br>**Incidence of Invasive Escherichia coli Disease in the Northwestern United States (2002–2022): Insights from Electronic Health Records**: Maxim BLUM (Belgium)<br>**A prospective controlled cross-sectional study demonstrates significantly higher IgG seroprevalence of leptospirosis among Munich's Eisbach river surfers**: Florian VOIT (Germany) |
| 13/04 | 14:45 - 15:45 | EF060 | AMR in the community | Camilla WIUFF COIA (Denmark) | **Socio-demographic factors associated with community-acquired extended spectrum β-lactamase producing E. coli urinary tract infections at intermunicipal level in France**: Marie PRIME (France)<br>**Prolonged community outbreak of OXA-48-producing Escherichia coli linked to a food premises: Lower Hutt, New Zealand, 2018-2022**: Craig THORNLEY (New Zealand)<br>**Low rates of macrolide resistance found in Mycoplasma pneumoniae cases in Australia**: Rebecca ROCKETT (Australia)<br>**Epidemiology of antibiotic resistance associated with E. coli/Klebsiella pneumoniae bloodstream infections in England 2012-2023**: Sam LIPWORTH (United Kingdom)<br>**The effect of long-term fluoroquinolone prophylaxis on carriage of antimicrobial resistant organisms in children.**: Chante BRAND (South Africa)<br>**Risk factors and prevalence of AntiMicrobial Resistant microbes In the English Community (AMRIC)**: Donna LECKY (United Kingdom)<br>**Risk factors for antimicrobial resistance in community commensal Staphylococcus aureus isolates, a sub-analysis of the AMRIC project.**: Mollie JOYCE (United Kingdom)<br>**Prevalence and risk factors for antimicrobial resistance in invasive pneumococcal disease in southern Ontario in the late post PCV13 era (2014-2023)**: Allison MCGEER (Canada)<br>**Antimicrobial resistance in Streptococcus pneumoniae in the Netherlands: an 11-year trend analysis of surveillance data**: Ilse NAUTA (Netherlands) |
| 13/04 | 14:45 - 15:45 | EF061 | Infections in the immunocompromised: a multifaceted overview | Effrossyni GKRANIA-KLOTSAS (United Kingdom) | **Impact of Donor Colonization or Infection, or preservation fluid  contamination with Multiresistant Bacteria and Fungi in Solid Organ Transplantation. Multicenter registry of Argentina**: Laura Alicia BARCAN (Argentina)<br>**Analysis of viral load kinetics and risk factors for Epstein-Barr virus  DNAemia and Post-transplant lymphoproliferative disorders in pediatric liver transplant recipients - a single centre experience**: Beata KASZTELEWICZ (Poland)<br>**Impact of pre-transplant infection on post-transplant morbidity and graft survival in liver transplant recipients: a prospective cohort study**: Laura MANI-PERREN (Switzerland)<br>**Risks of live-attenuated vaccines in children with primary immunodeficiency**: Siwar FRIGUI EP OUESLATI (Tunisia)<br>**Chagas reactivation/ transmission in kidney transplantation.**: Marcelo Victor RADISIC (Argentina)<br>**Clinical presentation and treatment of tuberculosis in solid organ transplant recipients: a multicentric retrospective analysis**: Julia MOLT� (Spain)<br>**Clinical presentation, risk factors and outcome of non-tuberculous mycobacteria infection in hematopoietic stem-cell transplant recipients: a multinational case-control study**: Mario FERNANDEZ RUIZ (Spain)<br>**Impact of bronchoalveolar lavage results on clinical decision-making among immunocompromised, critically ill patients.**: Chiara FANELLI (Italy)<br>**Campylobacter spp. bloodstream infections: preliminary results from a multicenter differential clinical analysis in immunocompromised and immunocompetent patients.**: Mar�a PANIAGUA-GARC�A (Spain) |
| 13/04 | 14:45 - 15:45 | FO102 | Navigating the future of pandemics across One Health | Xavier LESCURE (France) | **Status of the One Health Joint Plan of Action by the Quadripartite**: Chadia WANNOUS (France)<br>**Evidence review on One Health governance and implementation at the European level**: Tyra Grove KRAUSE (Denmark)<br>**Long-term consequences of emerging viral diseases**: Alfonso J. RODRIGUEZ-MORALES (Colombia) |
| 13/04 | 14:45 - 15:45 | ME101 | How to master conflict management and negotiation in healthcare |  | ****: Esther CALBO (Spain), Jan A.J.W. KLUYTMANS (Netherlands) |
| 13/04 | 14:45 - 15:45 | MEET78 | Clinical Parasitology Study Group open meeting (ESGCP) | Miriam Jos� �LVAREZ-MART�NEZ (SpainESCMID official), Hanne BREKKE (NorwayESCMID official), Beate GR�NER (GermanyESCMID official), Francesca TAMAROZZI (ItalyESCMID official), Jaco J. VERWEIJ (NetherlandsESCMID official) |  |
| 13/04 | 14:45 - 15:45 | MEET79 | Legionella Infections Study Group open meeting (ESGLI) | Anastasia FLOUNTZI (GreeceESCMID official), Sophie JARRAUD (FranceESCMID official), Diane LINDSAY (United KingdomESCMID official), Markus PETZOLD (GermanyESCMID official), Maria SCATURRO (ItalyESCMID official) |  |
| 13/04 | 14:45 - 15:45 | OS056 | Emerging trends in viral hepatitis across Europe | Federico GARCIA (Spain), Neven PAPIC (Croatia) | **One of the largest outbreak of hepatitis A in the 21st century in Europe**: Ivana HOCKICKOVA (Slovakia)<br>**Higher prevalence of Cytomegalovirus and Epstein–Barr virus in acute-on-chronic liver failure – cause or consequence?**: Jannik SONNENBERG (Germany)<br>**Delta in Denmark: current prevalence of hepatitis delta virus infection**: Hugh WATSON (France)<br>**RatHEV as an aetiological agent of acute hepatitis in Europe: results from the ESGHV-RHEV Study**: Antonio RIVERO-JUAREZ (Spain)<br>**Understanding the incidence and risk factors of low-level viremia in chronic hepatitis B: A propensity-matched comparison of tenofovir and entecavir**: Imran HASANOGLU (T�rkiye) |
| 13/04 | 14:45 - 15:45 | OS057 | Precision Medecine: from models to patient care | Anouk Edwina MULLER (Netherlands), Sebastian WICHA (Germany) | **Pharmacokinetics and pharmacodynamics of BPaLM, BPaLC and BPaL regimens for treatment of RR-TB**: Frank KLOPROGGE (United Kingdom)<br>**Physiologically Based Pharmacokinetic Modeling for Nemonoxacin in Predicting the Respiratory System Pharmacokinetic Profile: Based on Comprehensive Preclinical and Clinical Data**: Yinru CHEN (China)<br>**Context-specific genome-scale metabolic modelling reveals metabolic alterations in multidrug-resistant Klebsiella pneumoniae in response to polymyxin B/zidovudine combination**: Jinxin ZHAO (Australia)<br>**Agent-based model predictions of polymyxin B activity on Acinetobacter baumannii**: Hiie SOEORG (Estonia)<br>**Monthly dalbavancin dosing for suppressive therapy: a case series and pharmacokinetic estimation analysis**: Cecilia VOLK (United States) |
| 13/04 | 14:45 - 15:45 | OS058 | In the field with fungi | Beatriz L. GOMEZ (Colombia), Leonardo NIMRICHTER (Brazil) | **Fosmanogepix expanded access in patients with Fusarium infections**: Sanjeet DADWAL (United States)<br>**Voriconazole's hidden toll: unveiling periostitis in a heart transplant recipient and a hematologic patient.**: Gabriel MOTOA (United States)<br>**Unveiling the Uncommon: Managing Geotrichum candidum in Pancreatic Necrosis**: Lisa Marie KRIEGL (Austria)<br>**Detection of siderophores as a superior non-invasive diagnostic tool in unravelling mixed fungal infections**: Vladimir HAVLICEK (Czech Republic)<br>**Efficacy of novel antifungal therapies in refractory Candida and Aspergillus infections: insights from compassionate use and clinical trials**: Sarah SEDIK (Austria) |
| 13/04 | 14:45 - 15:45 | SY099 | How innovations of AMR and HAI surveillance systems help the clinical practice | Pascal ASTAGNEAU (France), Mandy WOOTTON (United Kingdom) | **The EUCAST system in surveillance of AMR**: S�ren G. GATERMANN (Germany)<br>**Insights into developments in the surveillance of HAIs**: Diamantis PLACHOURAS (Sweden) |
| 13/04 | 14:45 - 15:45 | SY100 | The challenge of a healthy microbiota in neonates | Maria VEHRESCHILD (Germany), Walter ZINGG (Switzerland) | **Infant gut microbiome development**: Debby BOGAERT (United Kingdom)<br>**Metagenomic signatures and antibiotic disruption of the gut microbiome in neonates**: Gautam DANTAS (United States) |
| 13/04 | 15:00 - 15:20 | IPT22 | Microbiological diagnosis of sepsis: an emerging molecular approach in a clinical microbiology laboratory setting |  | **Microbiological diagnosis of sepsis: an emerging molecular approach in a clinical microbiology laboratory setting**: Nicasio MANCINI (Italy) |
| 13/04 | 15:00 - 18:30 | Movie Session | Behind the scenes: Contagion | William HANAGE (United States), Luigia SCUDELLER (Italy) |  |
| 13/04 | 15:30 - 15:50 | IPT23 | Molecular testing for intestinal protozoa: how a laboratory developed test compares to one that is FDA-cleared |  | **Molecular testing for intestinal protozoa: how a laboratory developed test compares to one that is FDA-cleared**: Susan MADISON-ANTENUCCI (United States) |
| 13/04 | 16:00 - 16:20 | IPT24 | Implementation of pan-enteric PCR screening at a UK general district hospital - benefits, pitfalls and lessons learnt |  | **Implementation of pan-enteric PCR screening at a UK general district hospital - benefits, pitfalls and lessons learnt**: Elisabetta SAVANCO (United Kingdom) |
| 13/04 | 16:15 - 17:15 | EF065 | The Antibiotic bakery: Novel compounds in the pipeline | Susanne HAEUSSLER (Germany) | **In vitro activity and in vivo proof-of-efficacy of epimutilin derivatives AR-7732, AR-7731, AR-9842 and AR-10058 against AMR bacterial pathogens**: Susanne PAUKNER (Austria)<br>**SC5005 and DHA: A Novel, Rapid-Acting Combination Therapy for Biofilm Eradication in Catheter-Associated Infections**: Yeo HUI HUI (China)<br>**In vitro potency of ceftibuten with xeruborbactam against β-lactamase-producing isolates of Enterobacterales (ENT) from the SENTRY global surveillance programme**: Olga LOMOVSKAYA (United States)<br>**Effect of novel antimicrobial peptides SET-M33L and SET-M33L-PEG on Pseudomonas aeruginosa biofilm formation.**: Alessio FONTANOT (Austria)<br>**Broad spectrum coverage of serine β-lactamase and high in vitro potency against KPC- and OXA-48-like-producing Enterobacterales of meropenem in combination with the novel diazabyciccloctane β-lactamase inhibitor ANT3310**: Luc�a S�NCHEZ-PE�A (Spain)<br>**Antibacterial potential of D-limonene and diallyl disulfide and their interaction with gentamicin against multidrug-resistant Pseudomonas aeruginosa in rat pneumonia model**: Yasir ALMUHANNA (Saudi Arabia)<br>**In vivo pharmacokinetic/pharmacodynamic targets of a novel macrolide antibiotic nafithromycin, determined in neutropenic murine lung infection model of Streptococcus pneumoniae**: Anouk Edwina MULLER (Netherlands)<br>**NiPharmins: novel low resistance-inducing antimicrobials with antibiofilm activity against Staphylococcus aureus**: Alexandra Isabel NUNES (Portugal) |
| 13/04 | 16:15 - 17:15 | EF066 | Modelling infectious disease burden and impact of vaccination | David FISMAN (Canada) | **Evaluating the Impact of Re-vaccination on Pneumococcal Disease in Individuals Previously Vaccinated with PPSV23 in Germany: Comparative Approach**: Oluwaseun SHAROMI (United States)<br>**Modeling the public health impact of a 21-valent PCV in the Canadian adult population**: Oluwaseun SHAROMI (United States)<br>**Estimating the health and economic burden of pneumococcal diseases attributable to PCV21 (V116) vs. PCV20 or PPSV23 serotypes among adults in Norway**: Zinan YI (United States)<br>**Shifting from risk-based to age-based approach for pneumococcal vaccination in adults in France: a comprehensive evaluation**: Oluwaseun SHAROMI (United States)<br>**The socio-economic value of adult respiratory immunisation programmes in the United Kingdom – Are we measuring what matters to society?**: Cale HARRISON (United Kingdom)<br>**Improving Danish all-cause mortality monitoring by nowcasting weekly deaths**: Albert KALN�S (Denmark)<br>**Modelling to identify an optimal ring vaccination strategy to mitigate a smallpox outbreak**: Valentina COSTANTINO (Australia)<br>**The impact of introducing meningococcal C/ACWY booster vaccination among adolescents in Germany: a dynamic transmission modelling study**: Felix G�NTHER (Germany)<br>**Potential public health impacts of gonorrhoea vaccination programmes under declining incidences: a modelling analysis**: Lin GENG (Singapore) |
| 13/04 | 16:15 - 17:15 | EF067 | Blood parasitology at its best | Miriam Jos� �LVAREZ-MART�NEZ (Spain) | **Unexepected P.malariae diagnosis in Italian woman with no history of travel to endemic areas**: Andrea BUSNI (Italy)<br>**A blue-hued mystery: Primaquine-induced methemoglobinemia in mixed infection with Plasmodium vivax and Plasmodium falciparum**: Ummu Afeera ZAINULABID (Malaysia)<br>**Trick or Treat? An unrelenting malaria case**: Catherine UHOMOIBHI (Ireland)<br>**"64% Parasitaemia in Falciparum Malaria: Challenges in Managing Severe Infection and Delayed Haemolysis"**: Fiona MURPHY (Ireland)<br>**Benznidazole treatment in Chagas Disease: a case series in Luigi Sacco Hospital, Milan (Italy)**: Federico SABAINI (Italy)<br>**The Challenge of Managing Visceral Leishmaniasis in Immunocompromised Patients**: Serena VITA (Italy)<br>**Diagnosis and management of visceral leishmaniasis in children in France : a national retrospective study**: Justine DE LARMINAT (France)<br>**Chronic cutaneous leishmaniasis following visceral leishmaniasis in a pediatric patient: a rare report of extensive facial involvement**: Alpana MOHTA (India)<br>**Therapeutic challenges in the management of Disseminated leishmaniasis in a patient with HIV co-infection**: Neetha T R (India) |
| 13/04 | 16:15 - 17:15 | EF068 | A global perspective on antimicrobial resistance surveillance | Mirfin MPUNDU (Zambia) | **Global, regional and country-level prevalence of antimicrobial resistance in human bacterial infections under surveillance in WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS)**: Esther VAN KLEEF (Netherlands)<br>**Comparative analysis of antimicrobial resistance (AMR) burden across european countries**: Achim D�RRE (Germany)<br>**Setting up a regional AMR surveillance network in the Netherlands: challenges and opportunities**: Carsten VAN ROSSUM (Netherlands)<br>**Bridging gaps in antimicrobial resistance surveillance: the CAESAR network's first decade**: Robin JANSSEN (Netherlands)<br>**Global, regional, and national temporal trends in mortality for carbapenem-resistant bacteria from 1990 to 2021: An age-period-cohort analysis**: Chen ZHIHUI (China)<br>**Global Trends and Impact of Antimicrobial Resistance in Paediatric Populations: An Analysis Using WHO AWaRe Classification and Priority Pathogens**: Joseph HARWELL (Australia)<br>**Antibiotic resistance profile and comparative evaluation of WHO AWaRe Guidelines at the Emergency's Children's Surgical Hospital in Uganda**: Lucia BARCELLINI (Italy)<br>**Initiatives in antimicrobial resistance surveillance: Using automated bacteraemia surveillance for hospital-wide multidrug resistance monitoring**: Ferenc Darius RUETHER (Germany)<br>**Global and regional prevalence of antimicrobial resistance in GLASS target bacterial pathogens for bloodstream, urinary tract and gastrointestinal infections: a systematic review of the global literature (2019-2024)**: Benjamin CADDEY (Canada) |
| 13/04 | 16:15 - 17:15 | KN103 | Tuberculosis: where are we now and where should we be | Jon S. FRIEDLAND (United Kingdom), Delia GOLETTI (Italy) | ****: Guy THWAITES (Vietnam) |
| 13/04 | 16:15 - 17:15 | ME108 | Navigating travel medicine: expert tips for safe international travel |  | ****: Sophie SCHNEITLER (Germany), Andreas NEUMAYR (Switzerland) |
| 13/04 | 16:15 - 17:15 | MEET80 | Antimicrobial Resistance Surveillance Study Group open meeting (ESGARS) | Ini ADEBIYI (NigeriaESCMID official), Yesim BESLI (T�rkiyeESCMID official), Iva BUTIC (CroatiaESCMID official), Antonio OLIVER (SpainESCMID official), Spyros POURNARAS (GreeceESCMID official) |  |
| 13/04 | 16:15 - 17:15 | MEET81 | Nosocomial Infections Study Group open meeting (ESGNI) | Cansu CIMEN (GermanyESCMID official), Stephanie J. DANCER (United KingdomESCMID official), Elisabeth PRESTERL (AustriaESCMID official), Margreet C. VOS (NetherlandsESCMID official), Walter ZINGG (SwitzerlandESCMID official) |  |
| 13/04 | 16:15 - 17:15 | OS063 | Improving blood culture diagnostics: rethinking the basics | Direk LIMMATHUROTSAKUL (Thailand), Pilar RETAMAR GENTIL (Spain) | **Blood culture volume, guideline adherence and pathogen yield of 35,433 paediatric blood cultures in Germany**: Johannes FORSTER (Germany)<br>**Changing the paradigm: are two sets of blood cultures always needed?**: Rossana ROSA (Canada)<br>**Evaluating clinical and economic empact of reducing blood culture incubation timings: Time to shift the paradigm?**: Ruchika GUPTA (BAGGA) (Canada)<br>**Revolutionizing hospital workflows with blood culture-free ultra-rapid antimicrobial susceptibility testing: A clinical pilot study**: Sunghoon KWON (Republic Of)<br>**Human in vivo footprints from blood plasma for improved diagnostics in sepsis**: Mirko SONNTAG (Germany) |
| 13/04 | 16:15 - 17:15 | OS064 | Viral immune response - nature or nurture? Exploring the limits of immune response | Malin FLODSTR�M-TULLBERG (Sweden), Florian KRAMMER (United States) | **Orthopoxvirus-specific antibody dynamics up to two years after monkeypoxvirus infection or vaccination**: Christophe VAN DIJCK (Belgium)<br>**DENG-VAC study: preliminary data on immunogenity and reactogenity of Qdenga vaccine versus natural infection**: Alessandra D'ABRAMO (Italy)<br>**Long-Lasting Immunity Followed by Natural CCHFV Infection**: Hanife Nur KARAKOC (T�rkiye)<br>**Why does rabies virus not induce an anti-viral immune response : insights from experimental models and a human cohort**: Corine GEURTS VAN KESSEL (Netherlands)<br>**Establishing a human challenge model for human metapneumovirus: disease characteristics and immune responses**: Nicolas NOULIN (United Kingdom) |
| 13/04 | 16:15 - 17:15 | SY104 | Targeted vs. standard perioperative prophylaxis in Solid Organ Transplant with MDR Gram-negative colonisation | Elda RIGHI (United Kingdom), David VAN DUIN (United States) | **Standard prophylaxis**: Maddalena GIANNELLA (Italy)<br>**Targeted approaches**: Maristela P. FREIRE (Brazil) |
| 13/04 | 16:15 - 17:15 | SY105 | Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and therapeutic approach | Robert A. BONOMO (United States), Arjana TAMBIC ANDRASEVIC (Croatia) | **Novel beta-lactams and beta-lactamase inhibitors: challenges for laboratory diagnostics**: Anna SRAMKOVA (Czech Republic)<br>**Clinical perspectives of novel beta-lactams and beta-lactamase inhibitors**: Parikshit PRAYAG (India) |
| 13/04 | 16:15 - 17:15 | SY106 | Strain dynamics in determining gut microbial colonisation resistance | Silvio Daniel BRUGGER (Switzerland), Li Yang HSU (Singapore) | **Strain dynamics in serious bacterial infections in infants**: Drew SCHWARTZ (United States)<br>**Long-term colonisation dynamics of carbapenemase-producing Enterobacterales**: Niranjan NAGARAJAN (Singapore) |
| 13/04 | 16:15 - 17:15 | SY107 | Communicating (your) ID science for policy and societal impact | Leonard LEIBOVICI (Israel), Ines STEFFENS (Sweden) | **Communicating to policy makers and for societal impact**: Bal�zs BABARCZY (Hungary)<br>**Influencing behaviour through the media and a multichannel communications strategy**: Charlotte HUTCHINSON (United Kingdom) |
| 13/04 | 16:15 - 17:45 | IS31 | The challenges of keeping patients on antifungals. Can new thinking help us? | Cornelia LASS-FL�RL (Austria), Malgorzata MIKULSKA (ItalyESCMID-appointed chair) | **Welcome and Introduction**: Cornelia LASS-FL�RL (Austria)<br>**Challenges and future goals in selecting the right antifungal treatment**: Ali OMRANI (Qatar)<br>**Data-driven insights for antifungal treatment selection**: Dennis NEOFYTOS (Switzerland)<br>**Time to rethink? New ways in which current antifungal treatments can be applied**: Thomas HARRISON (United Kingdom)<br>**Panel Discussion and Q&A**: Cornelia LASS-FL�RL (Austria)<br>**Meetign Close**: Cornelia LASS-FL�RL (Austria) |
| 13/04 | 16:15 - 17:45 | IS32 | Real life challenges in Gram-positive infections: what's the real deal? | Marlene AMARA (FranceESCMID-appointed chair), Alex SORIANO (Spain) | **Welcome and Introduction**: Alex SORIANO (Spain)<br>**Daily microbiological challenges to optimise treatment for serious G+ (and polymicrobial) infections**: Stefania STEFANI (Italy)<br>**Real life scenarios clinicians face when managing complicated G+ infections**: Marco BONGIOVANNI (Switzerland)<br>**Untangling the universe of complicated G+ and polymicrobial skin and skin structure infections**: Matteo BASSETTI (Italy)<br>**Panel Discussion and Q&A**: Alex SORIANO (Spain)<br>**Closing Remarks**: Alex SORIANO (Spain) |
| 13/04 | 16:15 - 17:45 | IS33 | Improving patient management in respiratory infections with innovative and automated diagnostic solutions | Daniela CIRILLO (Italy), Eric CLAAS (NetherlandsESCMID-appointed chair) | **Welcome and Introduction**: Daniela CIRILLO (Italy)<br>**Importance of multiplex molecular tools in the surveillance, diagnostic and management of viral respiratory infections**: Ivan SANZ-MU�OZ (Spain)<br>**New advanced automated urinary antigen testing for determining pneumonia aetiology**: Pablo BECKERS (Belgium)<br>**Sharing of experiences from a maximum care hospital implementing fully automated urinary antigen testing**: Alexander MENZER (Germany)<br>**Impact of a routine automated IGRA testing on latent tuberculosis diagnosis: the experience of an Italian TB reference laboratory**: Paola DAL MONTE (Italy)<br>**Panel Discussion and Q&A**: Daniela CIRILLO (Italy) |
| 13/04 | 16:15 - 17:45 | IS34 | Next-generation molecular diagnostics for multiplex testing of infectious diseases: a performance-driven approach | Neven PAPIC (CroatiaESCMID-appointed chair),  TBA () | **TBA**:  TBA (TBA),  TBA (TBA),  TBA (TBA),  TBA (TBA)<br>**Panel Discussion and Q&A**: Neven PAPIC (Croatia)<br>**Welcome and Introduction**: Neven PAPIC (Croatia) |
| 13/04 | 16:15 - 18:15 | EW109 | Infections in cancer patients: tips for daily practice | Jos� MOLINA GIL-BERMEJO (Spain), Stefan SCHWARTZ (Germany) | **Tailoring pharmacologic prophylaxis in patients with non-haematologic cancer: from viruses to fungi**: Janne VEHRESCHILD (Germany)<br>**Pneumonitis or pneumonia? A practical approach to lung infiltrates in patients with solid tumours**:  TBA (TBA)<br>**The diagnostic dilemmas and treatment challenges of mycobacteria in cancer patients**: Siran KESKE (T�rkiye)<br>**HTLV-1 and T-cell lymphoma - predict & prevent**: Lucy COOK (United Kingdom) |
| 13/04 | 16:15 - 18:15 | LB004 | Trials in severe infections | Lennie DERDE (Netherlands), Steven TONG (Australia) | **Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTART�): a randomised, pragmatic trial**: Francesco COGLIATI DEZZA (Italy)<br>**HRS-8427 versus imipenem-cilastatin for complicated urinary tract infections: a randomised, double-blind phase 2 study**: Mohan JU (China)<br>**Efficacy and safety in a Phase 2 study of intravenous BV100 combined with polymyxin B versus best available therapy in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to carbapenem resistant Acinetobacter baumannii**: Glenn E. DALE (Switzerland)<br>**Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trial**: Michal CANETTI (Israel)<br>**Randomised placebo controlled trial of faecal microbiota transplantation to tackle antimicrobial resistance: inducing bacteriophage network remodelling and enteric pathogen reduction**: Lindsey Ann EDWARDS (United Kingdom)<br>**Double-dose dolutegravir and lamivudine versus efavirenz-based antiretroviral therapy for patients coinfected with HIV and tuberculosis: a multicentre, open-label, randomised trial**: Yinzhong SHEN (China)<br>**Initial vancomycin taper for the prevention of recurrent Clostridioides difficile infection: the TAPER-V randomised controlled trial**: Emily G. MCDONALD (Canada)<br>**Beneficial effects of a clinical metagenomics intervention on clinical outcomes, healthcare economics, and quality of life in patients with sepsis/septic shock: results of the DigiSep-trial**: Thorsten BRENNER (Germany)<br>**Shortened antibiotic treatment for 5 days in patients hospitalised with community-acquired pneumonia (CAP5): a multicentre randomised controlled noninferiority trial**: Simone BASTRUP ISRAELSEN (Denmark)<br>**High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trial**: Reinout VAN CREVEL (Netherlands) |
| 13/04 | 16:15 - 18:15 | M9 | Malaria differential diagnosis (advanced) | Debbie NOLDER (United Kingdom), Claire ROGERS (United Kingdom) |  |
| 13/04 | 16:15 - 18:15 | OS062 | Heterogeneity and complexity of sepsis | Despoina KOULENTI (United Kingdom), Sylvain MEYLAN (Switzerland) | **A consensus immune dysregulation framework for sepsis: results of the SUBSPACE consortium**: Andrew MOORE (United States)<br>**BLOODICU: Bloodstream infections and their outcomes in ICU patients - Insights from the PROSAFE Study**: Camilla GENOVESE (Italy)<br>**Deciphering the Dynamics of Klebsiella pneumoniae Colonization and Infection: Genomic Insights and Microbiome Interactions in ICU Patients**: Wei YU (China)<br>**Antibiotics with anti-anaerobe activity promote enteric pathobionts in ICU patients**: Steven TAYLOR (Australia)<br>**Association between blood culture time to positivity and 30-day bacteremia mortality differs for bacterial groups**: Melissa Hornb�k �VRE (Denmark)<br>**Treatment patterns of patients with sepsis/SIRS/septic shock treated with ceftolozane/tazobactam – results from SPECTRA**: Emre YUCEL (United States)<br>**Risk of myocardial infarction and stroke following bloodstream infection: a population-based self-controlled case series**: Jonathan UNDERWOOD (United Kingdom)<br>**Is transthoracic echocardiography required in all patients with Staphylococcus aureus bacteremia? Validating the VIRSTA and VIRSTA+ scores to define the population at low risk of endocarditis**: Miguel �ngel VERDEJO G�MEZ (Spain)<br>**DNA methylation changes in Sepsis: Potential use as biomarkers**: Ian L�PEZ-CRUZ (Spain)<br>**Host response plasma biomarkers and transcriptomic alterations in critically ill patients with suspected aspiration pneumonia**: Susanne DOELEMAN (Netherlands) |
| 13/04 | 17:30 - 18:30 | EF074 | New methods for rapid pathogen detection and typing | Sylvain BRISSE (France) | **Rapid detection of Shiga toxin-producing Escherichia coli (stx2a and stx2d) in korean diarrheal stool samples: a performance evaluation**: Lee HYEONJI (Republic Of)<br>**Global prevalence of O-serotypes and antibiotic resistance among extraintestinal pathogenic Escherichia coli isolated from older adult patients with bacteraemia (2011–2021)**: Jeroen GEURTSEN (Netherlands)<br>**Strategy for the rapid typing of Salmonella spp using infrared spectroscopy: a one health perspective**: Javiera JIM�NEZ (Chile)<br>**WGS-based surveillance as a paradigm shift in outbreak detection, AMR monitoring and source attribution in Campylobacter**: Alexandra Isabel NUNES (Portugal)<br>**Prevalence of Staphylococcus aureus clonal complex 97 amongst BORSA isolates in a large UK hospital**: Hughes GARETH (United Kingdom)<br>**The effectiveness of clinical laboratory tools in the surveillance of nontuberculous mycobacterium isolations within different counties in Taiwan**: Hsueh-Wei CHU (China)<br>**Rapid detection of oxazolidinone-resistance-related mutations in Enterococcus spp. by using High Resolution Melting-qPCR-typing analysis**: Rosario MUSUMECI (Italy)<br>**An automated pipeline to genotype bacteriophages using third generation sequencing**: Zsolt HAL�SZ (Hungary)<br>**Novel approach for fast, automated strain typing and source tracking by Fourier-transform infrared spectroscopy**: Norman MAUDER (Germany) |
| 13/04 | 17:30 - 18:30 | EF075 | Healthcare (workers') safety revisited | Daniel DIEKEMA (United States) | **Preparedness and cooperation throughout the chain of care during regional-level outbreaks with multidrug resistant organisms: a network analysis and interview study**: Berend BEISHUIZEN (Netherlands)<br>**Preparing First-Line health care workers for 'Virus X' through targeted training (FiLi-Vi-X)**: Annelies MONDELAERS (Belgium)<br>**Analysis of the current situation of hospital inspection practices by German health authorities**: Anna SCHWABE (Germany)<br>**A nationwide survey on the status and implementation of infection prevention and control practice on behalf of INSIEME Project (Italian National project for contrast antibiotic resistance a cooperation between Simit (Italian society of infectious diseases) E (&) Ministry of hEalth)**: Marianna MESCHIARI (Italy)<br>**High level of measles immunity among Dutch healthcare workers with self-reported “unknown” measles immunity status.**: Corianne MEIJER (Netherlands)<br>**Factors associated with positive latent TB screening results in healthcare workers at two tertiary referral hospitals in Ireland**: Ciara ANDERSON (Ireland)<br>**Systematic review of determinants of vaccine hesitancy among healthcare workers**: Valeria GABELLONE (Italy)<br>**Post-pandemic questions on vaccine usage: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines**: Parichehr SHAMSRIZI (Germany)<br>**Do healthcare professionals working in acute healthcare settings identify infection prevention and control related knowledge deficits?**: Aoife KEARNEY (Ireland) |
| 13/04 | 17:30 - 18:30 | EF076 | Knowing me, knowing you: behaviour influencing AMS | Elena CARRARA (Italy) | **Exploring determinants in deciding the optimal antimicrobial dose in patients recieving CRRT: a mixed method study**: Tugba YANIK YAL�IN (T�rkiye)<br>**Behaviour change vs policy change: Key drivers of inappropriate antibiotic use among health care professionals in LMICs – insights from Indian community setting**: Ninu P MATHEW (India)<br>**Contextual determinants to antimicrobial stewardship implementation in 16 hospitals: a four-country analysis in Asia**: Huong VU THI LAN (Vietnam)<br>**SpeakAB, a pilot study to encourage nurses to speak up about antibiotic care**: Maria BOS (Netherlands)<br>**Understanding what matters to patients in antimicrobial stewardship in hospitals. PERSPEcT study update**: Benson JACOB (Ireland)<br>**Determinants of antibiotic prescribing in hospitals from low, middle and high-income countries in Asia**: Srishti CHHABRA (Singapore)<br>**Riding "the antimicrobial rollercoaster": The behavioural and phenomenological science of antimicrobial use in haemato-oncology.**: Chris EADES (United Kingdom)<br>**Addressing Antimicrobial Resistance: Expert Insights and Policy Recommendations for Effective Interventions**: Bahar MADRAN (T�rkiye)<br>**Implementation of hospital antimicrobial stewardship in Europe using a data-driven behaviour change approach: insights from the drive-AMS EU project**: Ines PAUWELS (Belgium) |
| 13/04 | 17:30 - 18:30 | EF077 | Viral aphrodites | R�mi CHARREL (France) | **Potential for international spread of Oropouche virus via commercial air travel**: Mariana TORRES PORTILLO (Canada)<br>**Estimating mpox Clade Ib outbreak size in the Democratic Republic of the Congo to attenuate surveillance gaps during the early stages of the 2024 outbreak**: Mariana TORRES PORTILLO (Canada)<br>**Disparate epitope recognition between MPXV-infected and Smallpox-vaccinated individuals**: Ashley OTTER (United Kingdom)<br>**Diverse residual and late-onset symptoms of severe fever with thrombocytopenia syndrome: insights from a multicenter questionnaire study in Western Japan**: Ryuichi Minoda SADA (Japan)<br>**Post-Acute Sequelae and Excess Healthcare Utilization Following Dengue Infection: A Population-Based Cohort Study**: Jue Tao LIM (Singapore)<br>**Challenges of dengue in haematological malignancy patients: Analysis from the DANGO registry during the 2023-2024 outbreak in Argentina**: Gustavo Adolfo M�NDEZ (Argentina)<br>**Key predictors of critical illness and mortality in Crimean-Congo haemorrhagic fever**: Defne YIGCI (T�rkiye)<br>**Kyasanur Forest Disease in 2024: A Retrospective Cohort Study from a tertiary care centre in South India**: Pothumarthy VENKATA SWATHI KIRAN (India)<br>**Unravelling the aetiology of summer flu-like illness in Czechia**: Michal Frantisek KR�HA (Czech Republic) |
| 13/04 | 17:30 - 18:30 | FIPL5 | Fireplace: Tuberculosis: where are we now and where should we be | Jon S. FRIEDLAND (United Kingdom), Delia GOLETTI (Italy) | ****: Guy THWAITES (Vietnam) |
| 13/04 | 17:30 - 18:30 | MEET82 | Bloodstream Infections Study Group open meeting (ESGBIES) | Michele BARTOLETTI (ItalyESCMID official), Laura ESCOL�-VERG� (SpainESCMID official), Burcu ISLER (AustraliaESCMID official), Brigitte LAMY (FranceESCMID official), Siegbert RIEG (GermanyESCMID official) |  |
| 13/04 | 17:30 - 18:30 | MEET83 | Lyme Borreliosis Study Group open meeting (ESGBOR) | Randi EIKELAND (NorwayESCMID official), Randi EIKELAND (NorwayESCMID official), Volker FINGERLE (GermanyESCMID official), Anna J HENNINGSSON (SwedenESCMID official), Mateusz MARKOWICZ (AustriaESCMID official) |  |
| 13/04 | 17:30 - 18:30 | OS069 | Determining new and revising old breakpoints | Jaroslav HRABAK (Czech Republic), Erika MATUSCHEK (Sweden) | **EUCAST disk diffusion testing of ten additional species of anaerobic bacteria**: Jenny AHMAN (Sweden)<br>**Standardised antimicrobial susceptibility testing protocol for Legionella pneumophila validated across ten European reference laboratories.**: Max SEWELL (United Kingdom)<br>**Antimicrobial susceptibility testing of the combination of aztreonam and avibactam in carbapenem-resistant Enterobacterales: a practical evaluation using the CLSI and EUCAST methods**: Linda CHAN (China)<br>**Determination of optimal disk diffusion mass for zosurabalpin**: Mariana CASTANHEIRA (United States)<br>**The clinical significance of aminoglycoside susceptibility breakpoints modification**: Oryan HENIG (Israel) |
| 13/04 | 17:30 - 18:30 | OS070 | What's new in antifungal guidelines and management | Sharon CHEN (Australia), Helmut SALZER (Austria) | **Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM**: Rosanne SPRUTE (Germany)<br>**Impact of achieving early mycological eradication with rezafungin on all-cause mortality and ICU length of stay**: Matteo BASSETTI (Italy)<br>**An open-label study of ibrexafungerp in patients with refractory fungal infections (FURI)**: Oliver A. CORNELY (Germany)<br>**Novel immunotherapy approach using pan-Candida monoclonal antibodies to treat life-threatening invasive candidiasis and tackle global AMR**: Yixin ZHAO (United Kingdom)<br>**Relative contribution of pharmacokinetics and immune signatures to clinical outcomes in patients with HIV-associated cryptococcal meningitis.**: Katharine STOTT (United Kingdom) |
| 13/04 | 17:30 - 18:30 | OS071 | Intestinal parasitic uncovered: epidemiology and treatment success | Kurt HANEVIK (Norway), Pavla TUMOV� (Czech Republic) | **Giardia- Does the treatment work? The experience from a national tertiary referral centre**: Anna BOT� CASAMITJANA (United Kingdom)<br>**Giardiasis: Who gets it? Experience from a Central London Teaching Hospital.**: Anna BOT� CASAMITJANA (United Kingdom)<br>**Assessing the Effect of Antimicrobial Treatment on the Accuracy of Serial Serum and Urine Testing for Detecting E. histolytica cfDNA**: Priya DATTA (India)<br>**Longitudinal observation of  Blastocystis sp. and Dientamoeba fragilis in children: a very rare occurrence in chronic diseases with gut dysbiosis**: Jakub HURYCH (Czech Republic)<br>**High prevalence of the zoonotic Angiostrongylus cantonensis in rats in Spain**: Javier CABALLERO G�MEZ (Spain) |
| 13/04 | 17:30 - 18:30 | OS072 | Training models - a new model for training | Erin BONURA (United States), Casandra BULESCU (Romania) | **Can ChatGPT4o help build Objective Structured Clinical Examination (OSCE) stations in infectious diseases ?**: S�bastien VILLARD (France)<br>**Large language model in real-world clinical infectious diseases: are we there yet?**: Giorgia CARRA (Switzerland)<br>**Artificial Intelligence-Powered Transformation: Enhancing Public Health Education at Tampere University Towards Sustainable Development Goal 3**: Saeed AHMAD (Finland)<br>**A Survey on Perceived Priorities for the Implementation of Artificial Intelligence in Developing ESCMID Guidelines**: Jos� MOLINA GIL-BERMEJO (Spain)<br>**Expect the unexpected: Longitudinally extensive transverse myelitis in a healthy young adult -  a rare  manifestation of tuberculosis**: Shekhar ANGIREKULA (India) |
| 13/04 | 17:30 - 18:30 | OS073 | Still going viral | Ursula HOFER (United Kingdom), Yee Sin LEO (Singapore) | **Clinical outcomes of adoptive cell therapy for EBV reactivation and EBV-PTLD in primary immunodeficiencies: prophylactic and therapeutic applications of post-allo-HSCT memory T cell infusions.**: Antimo TESSITORE (Italy)<br>**Histopathological proof of herpes simplex pneumonitis in a patient with severe COVID-19 pneumonia**: Jannes HEYLEN (Belgium)<br>**Transmission of dengue virus from donors to recipient after solid organ transplantation. Case series in Argentina.**: Laura Alicia BARCAN (Argentina)<br>**Rash without borders: waning immunity in a travelling physician**: Rodrigo VILLE BENAVIDES (Mexico)<br>**A handful of Orf: a case of successful management with cidofovir in a renal transplant recipient**: Arda KAYA (T�rkiye) |
| 13/04 | 17:30 - 18:30 | SY110 | Immune reconstitution syndrome in infectious diseases: Who. Are. You? | Elisa BORGHI (Italy), Justyna KOWALSKA (Poland) | **IRIS in HIV immunocompromised hosts: a failure of success**: Paola Maria CINQUE (Italy)<br>**Dysregulated host responses to infection**: Michal HOLUB (Czech Republic) |
| 13/04 | 17:30 - 18:30 | SY111 | PK/PD in drug development: what's in it for me? | Sandrine MARCHAND (France), Sebastian WICHA (Germany) | **PK/PD from the EUCAST/regulatory perspective: what tools do we need?**: Joseph MELETIADIS (Greece)<br>**PK/PD for new anti-TB drugs**: Elin SVENSSON (Sweden) |
| 13/04 | 17:30 - 18:30 | SY112 | Year in public health | Ziad A. MEMISH (Saudi Arabia), Catherine MOORE (United Kingdom) | ****: Li Yang HSU (Singapore), Rita OLADELE (Nigeria) |
| 14/04 | 08:30 - 09:30 | EF079 | AMS around the world: what we can learn from each other | Benedikt HUTTNER (Switzerland) | **Battlefield Stewardship: Implementing Antimicrobial Management in the Ukrainian Trauma Pathway**: Hailie UREN (Ukraine)<br>**Evaluating a Tailored Antimicrobial Stewardship Strategy to Optimise IV to Oral Conversion: A Pre and Post-intervention Study**: Mai A H ALYAZJI (United Arab Emirates)<br>**Antimicrobial stewardship program for antibiotic use in the community: impact of multidisciplinary local guidelines during the 2023-2024 influenza a H1N1 season in northern Italy**: Romina CORSINI (Italy)<br>**Effectiveness of Clinical Algorithms combined with Point-of-Care testing to improve Antibiotic Prescribing practices of physicians in outpatient setting of low middle-income country**: Sonia QURESHI (Pakistan)<br>**Antibiotic prescribing behaviour in a public Bangladeshi hospital: a snapshot from BALANCE study**: Md Shafiul KABIR (Bangladesh)<br>**Tailored response to antimicrobial resistance emergence: remote-created stewardship program in a low/middle-income country pediatric hospital**: Patricio FAVIER (Spain)<br>**Weekly interdisciplinary antimicrobial stewardship rounds at two surgical wards show notable potential in optimising antimicrobial treatment**: Gerda BRUNHOFER-BOLZER (Austria)<br>**Antimicrobial stewardship programmes may improve patients' outcome and hospitalization: a sub-analysis of the CASAS (CArbapenem Sparing Antimicrobial Stewardship) Project**: Marco BONGIOVANNI (Switzerland)<br>**“Prescribing antibiotics is a gamble…”: A mixed-methods approach to current practices and implementation challenges of antimicrobial stewardship in a Ugandan tertiary care hospital**: Laura JUNG (Germany) |
| 14/04 | 08:30 - 09:30 | EF080 | Acinetobacter baumannii, still a strong knight to be knocked | Parikshit PRAYAG (India) | **Evaluation of the Antibacterial Activity of New Dermaseptin Derivatives against Acinetobacter baumannii**: Houda HADDAD (Tunisia)<br>**Clonal dissemination of highly resistant Acinetobacter baumannii ST2: Insights from the BALANCE study**: Chaima ABDELLAOUI (United Kingdom)<br>**Prevalence and genomic characterization of Sulbactam-Durlobactam-resistant and Carbapenem-resistant Acinetobacter baumannii in ICU Patients in a tertiary hospital in Hanoi, Northern Vietnam**: Dennis NURJADI (Germany)<br>**In vitro activity of nitroxoline among Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates**: Esther WOHLFARTH (Germany)<br>**Assessing biocide resistance genes and susceptibility to biocides in carbapenem-resistant Acinetobacter baumannii isolates from Thai hospitals**: Made Rai Dwitya WIRADIPUTRA (Thailand)<br>**Epidemiological and Genomic Characteristics of Acinetobacter baumannii in a Hospital in Zhejiang, China: A Study from 2015 to 2020**: Yisha ZHANG (China)<br>**Evaluation of the susceptibility  of Carbapenem-resistant Acinetobacter baumannii to sulbactam-durlobactam**: Juliana CAIER�O (Brazil)<br>**Clonal dissemination of Acinetobacter baumannii International Clone 2 Carrying ArmA and emergence of OXA-23-NDM1 co-producers in India**: Geetha NAGARAJ (India)<br>**Insight into Acinetobacter baumannii's phenotypic and genotypic traits in oncological patients**: Francesca SIVORI (Italy) |
| 14/04 | 08:30 - 10:00 | IS35 | TBE and Lyme borreliosis: a pan European challenge | Andreas PILZ (Austria), Anne Marit SOLHEIM (NorwayESCMID-appointed chair) | **Welcome and Introduction**: Andreas PILZ (Austria)<br>**Tick-borne diseases: from risk to diagnosis of infection**: Katerina KYBICOV� (Katerina KYBICOV�)<br>**Lyme borreliosis in Switzerland:  from seroprevalence to burden**: Reto LIENHARD (Switzerland)<br>**TBE in Latvia: how research data led to new recommendations**: Dace ZAVADSKA (Latvia)<br>**Panel Discussion and Q&A**: Andreas PILZ (Austria) |
| 14/04 | 08:30 - 10:00 | IS36 | Individualised antibiotic strategies: from monotherapy to antibiotic combinations with new perspectives through IV fosfomycin | Shampa DAS (United KingdomESCMID-appointed chair), Selma TOBUDIC (Austria) | **Welcome and Introduction**: Selma TOBUDIC (Austria)<br>**Antibiotic combination therapy from a PK/PD perspective**: Sebastian WICHA (Germany)<br>**Antimicrobial monotherapy vs. combination therapy: weighing microbiological and clinical factors for successful therapy**: Marco FALCONE (Italy)<br>**Rationale for antibiotic combination therapy including IV fosfomycin in the treatment of infections caused by Gram-positive and Gram-negative pathogens**: Alessandra OLIVA (Italy)<br>**Real-world data on IV fosfomycin: the FORTRESS study**: Stefan HAGEL (Germany)<br>**Panel Discussion and Q&A**: Selma TOBUDIC (Austria) |
| 14/04 | 08:30 - 10:00 | IS37 | The RSV landscape in adults: disease burden, public health impact, and the latest clinical and real-world data on vaccination with RSVpreF | Pier Luigi LOPALCO (Italy), Nicolas MUELLER (SwitzerlandESCMID-appointed chair) | **Welcome and Introduction**: Pier Luigi LOPALCO (Italy)<br>**The underrecognised burden of severe RSV in vulnerable adults**: Peter OPENSHAW (United Kingdom)<br>**Bivalent RSV vaccination: RSV protection in adults at increased risk**: Iona MIUNJAL (Iona MIUNJAL)<br>**Helping to protect against RSV with RSVpreF in real world practice**: Joseph LEWNARD (United States)<br>**Panel Discussion and Q&A**: Pier Luigi LOPALCO (Italy) |
| 14/04 | 08:30 - 10:00 | IS38 | Fast-track immunity: rapid immune protection through advanced vaccination strategies | Martin P. GROBUSCH (NetherlandsESCMID-appointed chair), Esther KUENZLI (Switzerland) | **Welcome and Introduction**: Esther KUENZLI (Switzerland)<br>**Abridged preventive regimens against rabies**: Patrick SOENTJENS (Belgium)<br>**Maximising opportunities to help protect last-minute travellers: immunisation against chikungunya**: George KASSIANOS (United Kingdom)<br>**Rapid protection strategies for tick-borne encephalitis vaccination**: Kyra ZENS (Switzerland)<br>**Panel Discussion and Q&A**: Esther KUENZLI (Switzerland) |
| 14/04 | 08:30 - 10:30 | EW118 | How can we infer and track plasmid outbreaks? | Alessandra CARATTOLI (Italy), Jacob MORAN-GILAD (Israel) | **Evolutionary modelling of plasmids**: Manuel ARES ARROYO (France)<br>**How plasmids shape the emergence of nosocomial pathogens**: Jukka CORANDER (Norway)<br>**Understanding the complexity of plasmid outbreaks using bioinformatics**: Torsten SEEMANN (Australia)<br>**Plasmid transmission at the One Health interface**: Nicole STOESSER (United Kingdom) |
| 14/04 | 08:30 - 10:30 | EW119 | This bacterium might harbour AmpC, what should I do?! | S�ren G. GATERMANN (Germany), Pranita TAMMA (United States) | **Laboratory identification of AmpC and its impact on /i>in vitro resistance**: Ana GALES (Brazil)<br>**Divergent levels of AmpC expression in Gram-negative pathogens**: Antonio OLIVER (Spain)<br>**Rational choice of antimicrobial therapy against AmpC-producing pathogens**: Patrick HARRIS (Australia)<br>**Novel antimicrobials active against AmpC: what RCTs tell us in support of their use?**: Amy MATHERS (United States) |
| 14/04 | 08:30 - 10:30 | M10 | Diagnosis of malaria by thick film | Debbie NOLDER (United Kingdom), Claire ROGERS (United Kingdom) |  |
| 14/04 | 08:30 - 10:30 | OS078 | Trending topics in tuberculosis | Delia GOLETTI (Italy), Sean WASSERMAN (United Kingdom) | **Lineage-specific immune responses to Mycobacterium tuberculosis: insights into L4 and L6 pathogenesis**: Marta SILVA (Portugal)<br>**Deciphering the functional role of distinctive Mycobacterium tuberculosis peptidoglycan modifications in modulating antibiotic resistance and the immune response**: C�tia SILVEIRO (Portugal)<br>**Increased innate immune and neutrophil blood transcriptomic signatures associate with poor outcome in HIV-1 tuberculous meningitis**: James BARNACLE (United Kingdom)<br>**Subpopulations in clinical samples of Mycobacterium tuberculosis can give rise to rifampicin resistance and shed light on how resistance is acquired**: Viktoria BRUNNER (United Kingdom)<br>**A systematic comparison of automated Mycobacterium tuberculosis complex whole genome sequencing analysis pipelines**: Ruan SPIES (Vietnam)<br>**Lung ultrasound for the detection of pulmonary tuberculosis using expert and AI-guided interpretation**: Veronique SUTTELS (Switzerland)<br>**Nanomotion Technology for Rapid Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis: Evaluating Novel Benzothiazinone Derivatives.**: Anthony VOCAT (Switzerland)<br>**Rapid drug susceptibility testing of Mycobacterium tuberculosis directly from clinical samples using targeted next-generation sequencing**: Ebba ROSENDAL (Portugal)<br>**Enhancing cerebral tuberculosis therapy with an innovative particulate nose-to-Brain drug delivery system: Insights from pharmacokinetic and pharmacodynamic studies**: Krishna Sudhakar JADHAV (India)<br>**Multi-drug resistant tuberculosis among migrants in Europe**: Sally HAYWARD (United Kingdom) |
| 14/04 | 08:30 - 10:30 | PM1 | Progress and challenges in drug discovery and development | Douglas HUSEBY (Sweden), Jean-Francois TIMSIT (France) | **Antibacterial therapies in clinical development**: Valeria GIGANTE (Switzerland)<br>**Challenges of finding new anti-infectives against bacterial pathogens**: Martin EMPTING (Germany)<br>**Antifungal drugs in clinical development**: Oliver A. CORNELY (Germany)<br>**The pros and cons of pathogen-specific or individualised treatment in acute bacterial infections**: Paul A. TAMBYAH (Singapore) |
| 14/04 | 08:30 - 10:30 | SY113 | Haemorrhagic viral infections | �nder ERG�N�L (T�rkiye), Catherine HOULIHAN (United Kingdom) | **Filovirus disease: evolving therapeutic strategies**: Ian CROZIER (United States)<br>**Jack in the box: Re-emergence of Kyasanur Forest Disease in India**: Kavitha SARAVU (India)<br>**Crimean Congo Haemorrhagic Fever: Newer insights into pathogenesis leading to new vaccines and therapeutics**: Ali MIRAZIMI (Sweden)<br>**Venezuelan Equine Encephalitis: Impact of newer strategies for vector control**: Carlos SEAS (Peru) |
| 14/04 | 08:30 - 10:30 | SY114 | Sepsis Global 2025 | Brigitte LAMY (France), Willem Joost WIERSINGA (Netherlands) | **The ESCMID-ISF Sepsis Award Lecture**: Andrew MOORE (United States)<br>**The WHO Global Maternal Sepsis Study**: Carolina CARVALHO RIBEIRO DO VALLE (Brazil)<br>**Sepsis: year in review**: Sylvain MEYLAN (Switzerland)<br>**How to design and implement a Sepsis National Action Plan (SNAP)**: Erika VLIEGHE (Belgium) |
| 14/04 | 08:30 - 10:30 | SY115 | Challenges in infection management, prevention and antimicrobial stewardship in long-term care facilities | Gaetan GAVAZZI (France), Giusy TISEO (Italy) | **The burden of nosocomial infections in long-term facilities**: Virginie PRENDKI (Switzerland)<br>**Pneumonia in the elderly: management and prevention**: Marcos RESTREPO (United States)<br>**Challenges in the clinical diagnosis of infection in the elderly**: Maheen ABIDI (United States)<br>**Challenges in implementing antimicrobial stewardship in long-term care facilities**: Elena CARRARA (Italy) |
| 14/04 | 08:30 - 10:30 | SY116 | Climate Change: changing risks and adaptation strategies for a world on the move | Rachel LOWE (Spain), Giacomo STROFFOLINI (Switzerland) | **Vector-borne diseases in Europe and clinical consequences**: Tuba DAL (T�rkiye)<br>**Rising temperatures and risks of fungal disease**: Anuradha CHOWDHARY (India)<br>**Strategies for climate prevention and adaptation in a moving world**: Kristie EBI (United States)<br>**AMR in climate change-affected countries**: Esmita CHARANI (South Africa) |
| 14/04 | 08:30 - 10:30 | SY117 | Survival of the parasites: is treatment failure due to antimicrobial resistance? | Hanne BREKKE (Norway), Jaco J. VERWEIJ (Netherlands) | **Nitroimidazole refractory Giardia intestinalis infection**: Pavla TUMOV� (Czech Republic)<br>**Treatment failure in scabies**: Francisco BRAVO (Peru)<br>**Recurrent Enterobius infections**: Sarah EISEN (United Kingdom)<br>**Recent advances in the treatment of Visceral Leishmaniasis and PKDL**: Shyam SUNDAR (India) |
| 14/04 | 09:30 - 10:30 | EF081 | Clinical features and outcome of invasive fungal infections | Marcus DE MELO TEIXEIRA (Brazil) | **Management, outcomes and predictors of mortality of Cryptococcus infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New Zealand**: Julien COUSSEMENT (Guadeloupe)<br>**Incidence of invasive fungal infections in hospitalised paediatric patients in England**: Adilia WARRIS (United Kingdom)<br>**Invasive fungal disease in critically ill patients with cirrhosis: an autopsy study**: Lenn MAESSEN (Belgium)<br>**Non-Aspergillus mould infections in Australia and New Zealand: a multi-centre study on epidemiology and clinical outcomes**: Chin Fen NEOH (Australia)<br>**Leveraging natural language processing (NLP) for early detection of aspergillosis: A retrospective study**: Lisa NWANKWO (United Kingdom)<br>**How often does Mucormycosis (MCM) contribute to mortality in Hematologic Malignancy (HM) patients? Analysis of 103 patients over 20 years**: Sebastian WURSTER (United States)<br>**Emergence of Wickerhamomyces anomalus invasive infections in injecting drug users**: Maxime LEFRANC (France)<br>**Prevalence and risk-factors for secondary localizations during candidemia in intensive care unit patients: the French CandidICU multicenter study**: Jean-Pierre GANGNEUX (France)<br>**Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance**: Adam STEWART (United States) |
| 14/04 | 09:30 - 10:30 | MEET84 | Host and Microbiota Interaction Study Group open meeting (ESGHAMI) | Nicolas BENECH (FranceESCMID official), Silvia CORCIONE (ItalyESCMID official), Ed J. KUIJPER (NetherlandsESCMID official) |  |
| 14/04 | 09:30 - 10:30 | MEET85 | Biofilms Study Group open meeting (ESGB) | Joana AZEREDO (), Elisa BORGHI (ItalyESCMID official), Maria Dolores MACIA ROMERO (SpainESCMID official), Claus MOSER (DenmarkESCMID official), Gordon RAMAGE (United KingdomESCMID official) |  |
| 14/04 | 09:30 - 10:30 | PM6 | Fungal Infections | Alexandra CAMERON (France) | **Introduction on WHOs: reference to the landscape & pipeline analysis of fungal diagnostics therapeutics**: Alexandra CAMERON (France)<br>**Panel Discussion**: Marc ENGELHARDT (Switzerland) |
| 14/04 | 09:30 - 10:30 | SY120 | Year in clinical microbiology | Fidelma FITZPATRICK (Ireland), Maurizio SANGUINETTI (Italy) | ****: Mario RAMIREZ (Portugal), Anna PAPA-KONIDARI (Greece) |
| 14/04 | 11:00 - 11:20 | IPT25 | Genomic data. Insights. Action (I): (Re)Shaping the future of infectious disease management with EIT Pathogena |  | **Genomic data. Insights. Action: (Re)Shaping the future of infectious diseases management with EIT Pathogena**: Emma STANTON (United Kingdom) |
| 14/04 | 11:00 - 12:00 | EF089 | Emerging Infectious Diseases, Zoonoses and Outbreaks |  | **Seasonality of Influenza and Respiratory Syncytial Virus related hospital contacts in Denmark (1999-2021)**: Omid REZAHOSSEINI (Denmark)<br>**Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us?**: Ivan SANZ-MU�OZ (Spain)<br>**The UK Imported Fever Service (IFS): National VHF testing 2023-2024**: Amy BELFIELD (United Kingdom)<br>**Reemergence of Poliovirus in Pakistan: Challenges and Implications for Global Health Security**: Saeed AHMAD (Finland)<br>**Preparing an emerging infectious diseases unit for high-consequence infectious diseases**: Andr� SILVA-PINTO (Portugal)<br>**Correlation between clinical and wastewater measles positivity rate in three towns of karachi, pakistan**: Farah NAZ QAMAR (Pakistan)<br>**Salmonella serovars in wild European hedgehogs (Erinaceus europaeus): an over 12-year monitoring in the Ferrara Province, Italy**: Elisa MASSELLA (Italy)<br>**Clinico-epidemiological and Microbiological Investigation of Diphtheria Outbreak in Odisha, India, 2024**: Ira PRAHARAJ (India)<br>**Seroprevalence of nine causes of acute febrile illness in rural Cambodia and Thailand using a multiplex assay**: Meiwen ZHANG (Thailand) |
| 14/04 | 11:00 - 12:00 | EF090 | Addressing the need for speed: advances in point-of-care testing | Jennifer DIEN BARD (United States) | **Rapid respiratory microbiological POCTs and antibiotic use in primary care: the RAPID-TEST RCT**: Emily BROWN (United Kingdom)<br>**Evaluation of the prototype BIOFIRE� nasal HR panel (nHRP) in children with acute respiratory illness, a nasal swab-based rapid hoSt gene expression test**: Gregory STORCH (United States)<br>**Evaluation of the analytical performance of the Biosynex AMPLIQUICK Fecal Bacteriology kit in the diagnossis of bacterial intestinal infections**: Philippe LEHOURS (France)<br>**Development and Validation of a Novel Rapid Antigen Test for Norovirus Detection: A Comparative Performance Analysis**: Nadin YOUNES (Qatar)<br>**A Rapid Molecular POCT System for Detection of Carbapenem-Resistant Enterobacterales (CRE)**: Seong Yeol CHOI (Republic Of)<br>**Validation of an ultra-rapid, point-of-care, antibiotic susceptibility testing device**: Ardjan VAN DER LINDEN (Netherlands)<br>**Development of a frugal multiplexed paper sensor for rapid detection of sepsis-causing pathogens**: Chaitali SINGHAL (India)<br>**Multianalyte POCT device for a sample-to-result detection of nucleic acid and protein**: Lilas POMMI�S (France)<br>**A smartphone app for point-of-care quantification of lateral flow assays**: Ryan ARMIGER (United Kingdom) |
| 14/04 | 11:00 - 12:00 | FO129 | Predatory journals in CM/ID: from symptoms to cure | Emily G. MCDONALD (Canada) | **The genesis of predatory journals: symptoms and root problems**: Leonard LEIBOVICI (Israel)<br>**The role of editors and publishers of 'reputable journals': what can they do to stop predatory journals?**: Till B�RNIGHAUSEN (Germany)<br>**The roles of authors and academic institutions: towards governance and regulation**: Luigia SCUDELLER (Italy)<br>**Bibliometric literacy in scientific publication**: Lauren MAGGIO (United States) |
| 14/04 | 11:00 - 12:00 | KN121 | HIV: from needle parks to injectables | Mary HORGAN (Ireland), G�lsen �ZKAYA SAHIN (Sweden) | ****: Huldrych G�NTHARD (Switzerland) |
| 14/04 | 11:00 - 12:00 | ME127 | EUCAST: What's new in susceptibility testing |  | ****: Erika MATUSCHEK (Sweden), Rafael CANTON (Spain) |
| 14/04 | 11:00 - 12:00 | ME128 | How to apply organoid models to study infectious disease |  | ****: Jennifer ROHN (United Kingdom), Nathalie SAUVONNET (France) |
| 14/04 | 11:00 - 12:00 | MEET87 | Vaccine Study Group open meeting (EVASG) | Olivier EPAULARD (FranceESCMID official), Zitta Barrella HARBOE (DenmarkESCMID official), Justyna KOWALSKA (PolandESCMID official), Manuel KRONE (GermanyESCMID official), Petar VELIKOV (BulgariaESCMID official) |  |
| 14/04 | 11:00 - 12:00 | OS082 | New insights in bloodstream infections and  endocarditis | Barbara HASSE (Switzerland), Jos� M. MIRO (Spain) | **Different from the start – Sex differences in Staphylococcus aureus bacteremia mortality**: Annette WESTGEEST (Netherlands)<br>**Tracking evolution in action during invasive Staphylococcus aureus infections: the BARISTA study**: Stefano GIULIERI (Australia)<br>**Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection – an exploratory post-hoc analysis of the BALANCE randomized clinical trial**: Sean Wei Xiang ONG (Australia)<br>**Bloodstream infection pathogen diversity and clinical impact revealed through unbiased whole genome sequencing: a prospective genomic epidemiology study**: Nenad MACESIC (Australia)<br>**Risk of infection of intracardiac devices in patients with valvular infective endocarditis who carry cardiovascular implanted electronic devices. Analysis on a national cohort**: Alejandro BLANCO AR�VALO (Spain) |
| 14/04 | 11:00 - 12:00 | OS083 | Don't 'rash' it | Heli HARVALA (Finland), Catherine MOORE (United Kingdom) | **Current Prevalence of Parvovirus B 19 Infections: Ankara Bilkent City Hospital Experience 2019-2024**: Bedia DINC (T�rkiye)<br>**Managing an outbreak of parvovirus B19 infection in pregnancy: clinical outcomes from a single-centre study**: Monica MELCHIO (Italy)<br>**The dark side of the „fifth disease” endemic: human parvovirus B19 infections transmitted through blood transfusions in adults with malignant hematological diseases**: Balint Gergely SZABO (Hungary)<br>**Key learnings from a measles outbreak with multiple hospital exposures in Ireland, May-July 2024**: Ann Marie MURRAY (Ireland)<br>**Measles virus in the context of subacute sclerosing panencephalitis (SSPE)**: Julia DINA (France) |
| 14/04 | 11:00 - 12:00 | OS084 | Weird and unusual infections | Murat AKOVA (T�rkiye), Muge CEVIK (United Kingdom) | **Vertical Transmission of Clade Ib monkeypoxvirus during Pregnancy: Clinical and Histopathological description of 3 cases**: Emmanuel HASIVIRWE VAKANIAKI (The Democratic Republic Of The)<br>**First case of Oropouche fever in the South of Spain**: Isabel Ascensi�n P�REZ HERN�NDEZ (Spain)<br>**Wild hippopotamus bite and Aeromonas spp. infection: a treatment challenge. First case report.**: Jhongert ALZA ARCILA (Colombia)<br>**From the sea to the land: an emerging species**: Katherine Pamela RODR�GUEZ MART�NEZ (Dominican Republic)<br>**The first findings of Wohlfahrtiimonas chitiniclastica and Ignatzschineria species bacteremia in two cases with maggot infested wounds in Scandinavia**: Anne Line ENGSBRO (Denmark) |
| 14/04 | 11:00 - 12:00 | OS085 | Planes, Pains, and Pathogens: The Perils of Travel Medicine | Anu KANTELE (Finland), Carlos SEAS (Peru) | **Fever in returning travelers from tropical regions: what not to miss in an evolving epidemiology**: Stefania CARONNI (Italy)<br>**Tracing the itch: A spatiotemporal analysis of scabies rates and its risk factors using the Global Burden of Disease data**: Saptorshi GUPTA (New Zealand)<br>**Molecular epidemiological characterization of enterotoxigenic and enteroaggregative Escherichia coli causing traveller's diarrhoea and their relationship with clinical features**: Pol OLIVERAS JULIA (Spain)<br>**Bites and bytes – can digital surveillance of travellers' illness predict outbreaks?**: Nadja HEDRICH (Switzerland)<br>**Travel-associated infections and diseases: a retrospective cross-sectional study**: Milan TROJANEK (Czech Republic) |
| 14/04 | 11:00 - 12:00 | OS086 | Marker based diagnostics: forget the pathogen | Virginie PRENDKI (Switzerland), Suzanne VAN ASTEN (Netherlands) | **A 29-mRNA molecular host response test demonstrates enhanced accuracy compared to a protein-based host response test for the diagnosis of bacterial and viral infections**: Natalie WHITFIELD (United States)<br>**Diagnostic accuracy of a bacterial versus viral host-protein test for pediatric inpatients with acute infection**: Tanya GOTTLIEB (Israel)<br>**Diagnostic accuracy of combined urine lipocalin 2 and copper test in acute pyelonephritis or cystitis**: Vladimir HAVLICEK (Czech Republic)<br>**Diagnostic Performance of Whole-Blood RNA Signatures for Tuberculosis Diagnosis in a Cohort of Patients with Non-Tuberculous Mycobacterial Lung Disease**: Patricio ESCALANTE (United States)<br>**Diagnostic utility of MxA and MxA/CRP ratio in differentiating viral and bacterial infections: a prospective cohort study**: Ondrej BER�NEK (Czech Republic) |
| 14/04 | 11:00 - 12:00 | OS087 | Antimicrobial resistance around birth | Julia Anna BIELICKI (United Kingdom), Surbhi MALHOTRA-KUMAR (Belgium) | **Prevalence and risk factors of antibiotic resistance genes in breastmilk and neonatal oral cavity of preterm mother-infant pairs**: Ambika SHARMA (India)<br>**Effect of maternal peripartum antibiotic exposure on the microbial diversity, relative abundance of taxa, and resistome in breastmilk**: Anwesha CHAKRABORTY (India)<br>**Dynamics of gastrointestinal colonisation by antibiotic-resistant bacteria in high-risk infants in Swiss and Greek neonatal intensive care units**: Anouk BRASPENNING (Belgium)<br>**Harnessing functional omics to decipher how probiotics reduce antibiotic resistance gene carriage in infants' gut**: Veronika PETTERSEN (Norway)<br>**Dynamics of gut resistome and mobilome in early life: A meta-analysis**: Veronika PETTERSEN (Norway) |
| 14/04 | 11:00 - 12:00 | OS088 | Advancing diagnostics and preventive measures in hemato-oncological patients | Dina AVERBUCH (Israel), Malgorzata MIKULSKA (Italy) | **Prediction of bacterial and fungal bloodstream infections using machine learning in patients undergoing chemotherapy**: Maristela P. FREIRE (Brazil)<br>**Viral metagenomics in patients with persistent unexplained neutropenic fever- some clues to the cause of fever?**: Abby Patricia DOUGLAS (Australia)<br>**Results of Optifil study: 18F-FDG-PET/CT guided antifungal stewardship in invasive pulmonary aspergillosis**: Fanny LANTERNIER (France)<br>**Long-term immunogenicity and boostability of the 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation: a prospective cohort study**: Sabine HAGGENBURG (Netherlands)<br>**Humoral and cellular immune response to adjuvanted respiratory syncytial virus vaccine RSVPreF3 in adults after allogeneic hematopoietic cell transplantation**: Jonas L�TSCHER (Switzerland) |
| 14/04 | 11:00 - 12:00 | PC1 | Diagnostics | Till T. BACHMAN (United Kingdom) | **Presymptom Health**: Iain MILLER (United Kingdom)<br>**Readily**: Liza L�F (Sweden)<br>**SoundCell**: Aleksandre JAPARIDZE (Netherlands) |
| 14/04 | 11:00 - 12:00 | PM2 | AMR and vaccines | Charlotte VERNHES (Belgium), Ghada ZOUBIANE (United Kingdom) | **Overview of the current evidence of the impact of vaccines on AMR**: Adam CUNNINGHAM (United Kingdom)<br>**Panel discussion: gaps, needs, and opportunities to leverage vaccines against AMR**: Adam CUNNINGHAM (United Kingdom) |
| 14/04 | 11:00 - 12:00 | SY122 | Chronic infections in the era of CFTR modulators: what is going on in cystic fibrosis lungs these days? | Pavel DREVINEK (Czech Republic), Helle Krogh JOHANSEN (Denmark) | **The lung microbiome of people with cystic fibrosis receiving modulator therapy**: Sebastien BOUTIN (Germany)<br>**Tackling chronic infections in people with cystic fibrosis receiving modulator therapy: is it still necessary?**: Alessandra BRAGONZI (Italy) |
| 14/04 | 11:00 - 12:00 | SY123 | Infection prevention and control and intensive care: challenges and solutions | Antonios KATSOUNAS (Germany), Claire ROGER (France) | **Intensive care unit (ICU) and infection: two sides of a coin**: Reto SCHUEPBACH (Switzerland)<br>**Ventilator- associated pneumonia (VAP) and ICU enviroment: how can we improve practices?**: Despoina KOULENTI (United Kingdom) |
| 14/04 | 11:00 - 12:00 | SY124 | Antimicrobial prescribing: myths or pearls? | Massimo FANTONI (Italy), Spyros POURNARAS (Greece) | **Why treat IV when PO is possible?**: Bradley SPELLBERG (United States)<br>**De-escalation of antibiotic therapy to narrow-spectrum IV drugs**: Flaminia OLEARO (Germany) |
| 14/04 | 11:00 - 12:00 | SY125 | Cutting edge methods in mycology | Katrien LAGROU (Belgium), Antonio VENA (Italy) | **Imaging for diagnosing mycoses: focus on 18F-FDG PET/CT**: Ana FERN�NDEZ-CRUZ (Spain)<br>**Exploring the intersection of fungal metagenomics and medical mycology**: Marcus DE MELO TEIXEIRA (Brazil) |
| 14/04 | 11:00 - 12:00 | SY126 | Why is the concept of complicated UTI so complicated? | Gernot BONKAT (Switzerland), Maeve DOYLE (Ireland) | **The concept of complicated UTI: underlying conditions matter**: Suzanne GEERLINGS (Netherlands)<br>**The concept of complicated UTI: the site of infection matters most**: Jes�s RODR�GUEZ-BA�O (Spain) |
| 14/04 | 11:30 - 11:50 | IPT25A | Genomic data. Insights. Action (II): Rapid mNGS for emergency response (RANGER) for HERA's next-generation cross-border threat capability |  | **Rapid mNGS for emergency response (RANGER): building the next-generation cross-border pandemic threat capability for HERA**: Andrew ENGELI (United Kingdom) |
| 14/04 | 12:00 - 12:20 | IPT26 | AMR: are new antibiotics the only solution? |  | **AMR: are new antibiotics the only solution?**: Seamus O'BRIEN (United Kingdom) |
| 14/04 | 12:00 - 13:30 | PS020 | 03a. Resistance surveillance & epidemiology: Community-acquired bacteria |  | **Genomic surveillance identifies C. jejuni lineages carrying a multi resistance gene cassette of Gram-positive origin**: Sangeeta BANERJI (Germany)<br>**Ten-year study of Shigella sonnei: antimicrobial susceptibility trends and risk factors in a Croatian tertiary care clinic**: Silvija SOPREK STRUGAR (Croatia)<br>**Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterised fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2023)**: Rodrigo E. MENDES (United States)<br>**Ten-year trends in methicillin resistance rates of Staphylococcus lugdunensis: a multi-centre surveillance study in Kagawa prefecture, Japan (2013-2023)**: Taichi ITO (Japan)<br>**Emergence of fluoroquinolone resistance in Salmonella paratyphi A isolates from sub-Saharan Africa**: Alexandra SERRIS (France)<br>**Genotype and phenotype of clinical isolates of Aeromonas species and epidemiology of carbapenem-resistant strains in Japan**: Daisuke KITAGAWA (Japan)<br>**Increasing eight-year trend in fusidic acid resistance among MRSA isolates in the Netherlands**: Feline VELTHUIS (Netherlands)<br>**Global phylogeography and genomic surveillance of a recent epidemic Bordetella pertussis ST2 high-risk international clone: a multicentre study in China**: Xi LI (China)<br>**Trends of azithromycin resistance in Neisseria gonorrhoeae from across the Indian subcontinent: time to reflect**: Devanshi SHARMA (India)<br>**Activity of gepotidacin against molecularly characterised beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2023)**: Rodrigo E. MENDES (United States)<br>**Mycoplasma genitalium: what is going on in Argentina? First report**: Maria Bel�n MANCINO (Argentina)<br>**In vitro activity of ceftaroline against bacterial pathogens from paediatric patients collected during the ATLAS global surveillance programme in 2019-2023**: Meredith HACKEL (United States)<br>**In vitro activity of ceftaroline and comparator agents against bacterial pathogens from adult patients collected during the ATLAS global surveillance programme in 2019-2023**: Meredith HACKEL (United States)<br>**Antibiotic susceptibility profiles of Gram-negative bacteria isolated from paediatric and adult UTI patients**: Stefan-Vasile CRISTEA (Romania)<br>**Improving geospatial coverage and granularity of global AMR prevalence estimates: comprehensive systematic literature reviews to complement WHO's global AMR surveillance system (2018-2022)**: Raph L. HAMERS (Indonesia)<br>**Comparison of antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae from blood and non-blood cultures: analysis from the survey of antibiotic resistance (SOAR) study, 2018-2021**: Anand MANOHARAN (India)<br>**Gepotidacin activity against and analysis of susceptibility to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Klebsiella pneumoniae collected in Europe in 2023**: S. J. Ryan ARENDS (United States)<br>**Trends in clindamycin and metronidazole susceptibility of anaerobic clinical isolates: a ten year surveillance**: Ander URIBARRI (Spain)<br>**Virulence and fitness of  CTX-M producing Escherichia coli O25 ST131 in community acquired urinary tract infections in Croatia**: Tajana BALABAN (Croatia)<br>**Six-year trend in decreasing (benzyl)penicillin diameter distribution in Streptococcus pyogenes in the Netherlands**: Rony Elisabeth ZOETIGHEID (Netherlands)<br>**Phenotypic and genotypic distribution of ESBL uropathogens in the community setting of India: a multicentric cross-sectional study**: Swati PUNDIR (India)<br>**Multidrug-resistant invasive non-typhoidal Salmonella in children: asymptomatic shedding as an important source of community infection spread in Kenya**: Samuel KARIUKI (Samuel KARIUKI)<br>**Multidrug-resistant and distribution of �-lactamase genes among diarrheagenic Escherichia coli isolated from under-five children in central Ethiopia**: Tizazu ZELELIE (Ethiopia)<br>**Antimicrobial resistance and genomic diversity of Neisseria gonorrhoeae in Maseru, Lesotho**: Liteboho MADUNA (Lesotho)<br>**Assessment of the European antibiotic resistance epidemiology in community care across drug-bacterium pairs: a spatial-temporal analysis using national surveillance data**: Pauline SORLIN (France)<br>**Molecular epidemiology of mupirocin-resistant Staphylococcus aureus isolated from skin and soft-tissue infections in children**: Mormeneo Bayo SARAY (Spain)<br>**Prevalence and risk factors for ESBL-producing Enterobacterales rectal carriage in a public hospital from Argentina**: Maximiliano Gabriel CASTRO (Argentina)<br>**Mycoplasma genitalium: two years prevalence of azithromycin and moxifloxacin resistance**: Alice NAVA (France)<br>**Molecular genetic analysis of extended-spectrum beta-lactamase-producing Escherichia coli isolated from outpatients at a tertiary care emergency centre: emergence of CTX-M-132-producing Escherichia coli in Japan**: Yasumitsu NOMURA (Japan)<br>**Risk factors associated with community-acquired multidrug-resistant infections**: Diamantina LYMPERATOU (Greece)<br>**Genomic epidemiology and distribution of carbapenemases and extended-spectrum beta-lactamases in Escherichia coliand Klebsiella pneumoniae at a Spanish hospital during 2019-2024**: Sandra A. MART�NEZ-�LVAREZ (Spain)<br>**Improving understanding of Staphylococcus aureus carriage and resistance patterns in high-risk UK armed forces populations: prevalence of MRSA,  PVL-SA carriage and emergence of a MSSA ST398 clone**: William NEVIN (United Kingdom)<br>**Distribution of macrolide resistance among Streptococcus pneumoniae clinical isolates collected from global populations, 2018-2019 and 2022-2023**: Meredith HACKEL (United States)<br>**Analysis of studies about antibiotic resistance of Enterobacter spp. between 2015 and 2022 through One Health approach**: Angie Katherine CASTILLO PE�A (Peru)<br>**Antimicrobial resistance trends of Campylobacter species from a tertiary hospital, 2010-2024**: Shaikha AL-SHOKRI (United States)<br>**Impact of national guidelines for the treatment of community acquitted urinary tract infection on antibiotic resistance in Enterobacterales**: Olivier LEMENAND (France)<br>**Evidence for antimicrobial stewardship and reduced antimicrobial resistance in the mid-west of Ireland, 2012 - 2023: findings from a One Health study**: James POWELL (Ireland)<br>**High prevalence of extended-spectrum beta-lactamase-producing Enterobacterales in patients admitted to a rural hospital in Tanzania**: Iren H�yland L�HR (Norway)<br>**Molecular characterisation of Staphylococcus aureus from persistent respiratory infections: high detection of CC398 isolates**: Paula EGUIZ�BAL (Spain)<br>**Comparing the activity of oral cefditoren with other cephalosporins in Streptococcus pneumoniae clinical isolates non-susceptible to penicillin, 2019-2020**: Julio SEMPERE (Spain)<br>**A five-year antimicrobial resistance trends in Gram-negative bacteraemia isolates**: Lynette PHEE (United Kingdom)<br>**Epidemiology and prevalence of antimicrobial-resistant bacteria in wildlife in Africa**: Jemimmah MWANGI (Kenya)<br>**Higher prevalence of blaOXA-244 in ESBL producing Escherichia coli isolates in the Netherlands: a prospective cohort study**: Julinha THELEN (Netherlands)<br>**Distribution of Mycoplasma pneumoniae macrolide-resistant strains in two regional hospitals in Japan**: Michinori SHIRANO (Japan)<br>**/em>Neisseria gonorrhoeae resistance rates in Cardiff Wales compared to those at a national level according to gonococcal resistance to antimicrobial susceptibility programme (GRASP)**: Leanne DAVIES (United Kingdom)<br>**Increase in azithromycin resistance rate of Neisseria gonorrhoeae during the period 2020-2023 in Greece**: Eirini SIATRAVANI (Greece)<br>**Associations of CRISPR-Cas systems with antibiotic resistance and virulence genes of clinical Enterococcus faecalis isolates in Gauteng, South Africa**: Zander NIEHAUS (South Africa)<br>**Antimicrobial agents in dentifrices and mouthwashes: induction of antiseptic and antibiotic tolerance**: S�lvia OLIVEIRA (Brazil)<br>**High prevalence of macrolide resistance in Streptococcus pneumoniae isolated from nasopharyngeal samples among na�ve six-week-old children in Sierra Leone: a resistome approach**: Mercedes MONTERO-VALE (Spain)<br>**Circulation of blaOXA-244, an emerging resistance gene, in polyclonal E. coli strains in Jerusalem, Israel**: Janko SATTLER (Germany)<br>**Investigation of Escherichia coli ST131 characteristics, an emerging pathogen in Rio de Janeiro**: Isadora BARCELLOS (Brazil)<br>**Antimicrobial susceptibility of Legionella pneumophila to azithromycin and levofloxacin**: Antonio CASABELLA PERNAS (Spain)<br>**The aetiologic agents and resistance rates in community-acquired complicated intra-abdominal infections: where are we locally?**: Eren OZTURK (T�rkiye)<br>**A systematic review of resistance patterns of Corynebacterium diphtheriae.**: Amy PRICE (United Kingdom)<br>**Colistin resistance as an emergent threat among Uropathogenic Escherichia coli and Klebsiella pneumoniae from a rural community health centre, India**: Shipra TOMAR (India)<br>**The impact of ceragenins on Streptococcus mitis clinical isolates**: Cemre �ZKANCA (T�rkiye)<br>**Prevalence and characteristics of methicillin-resistant Staphylococci colonisation in the nasal vestibule of healthy individuals in Japan**: Sayaka ANDO (Japan)<br>**Multidrug-resistant Streptococcus pneumoniae in Vietnamese children: results from a household prevalence survey**: Thu-Trang VU (Vietnam)<br>**Conflict-associated wounds and burns infected with GLASS pathogens in the eastern Mediterranean region: a systematic review**: Aula ABBARA (United Kingdom)<br>**E. coli antimicrobial susceptibility patterns and social determinants of health: an ecological study in Ontario, Canada from 2017-2022**: Rada RUSU (Canada)<br>**High household co-carriage of extended-spectrum beta-lactamases in Hong Kong**: Kwok KIN ON (China)<br>**Prevalence and antimicrobial susceptibility of community-acquired urinary isolates of ESBL-producing Enterobacterales: a three-year retrospective study**: Hugo CRUZ (Portugal)<br>**Molecular characterisation of livestock-associated methicillin-resistant Staphylococcus aureus causing bacteraemia**: Mormeneo Bayo SARAY (Spain)<br>**Carbapenemase-producing Enterobacterales on the rise in community-onset infections**: Yoleidys MARTINEZ-YSASIS (Spain)<br>**A multicentre study: emm typing, PFGE analysis, antimicrobial resistance and biofilm production in Streptococcus pyogenes**: �zgen K�SEOGLU ESER (T�rkiye)<br>**Knowledge of medical residents towards antibiotic resistance and appropriate prescribing**: Asma AMMAR (Tunisia)<br>**Prevalence of multidrug-resistant CS31A-producing E. coli in neonatal calf diarrhea outbreaks in central France**: Eduarda SILVEIRA (Portugal)<br>**Antimicrobial susceptibility testing of Gardnerella spp. vaginal isolates from a tertiary care centre in Slovenia**: Kitty ZNIDAR (Slovenia)<br>**Piperacillin/tazobactam susceptibility in AmpC beta-lactamase producing Enterobacterales**: Kitty ZNIDAR (Slovenia)<br>**Antimicrobial resistance surveillance in Belgian ambulatory care: SARPRIC-UTI study focussing on uncomplicated urinary tract infections in 2024**: Matijs HOUBEN (Belgium)<br>**Whole-genome sequencing analysis of an ESBL producer Shigella sonnei causing an outbreak in Tunisia**: Lamia KANZARI (Tunisia)<br>**Genomic characterisation of community-level transmission dynamics of extended-spectrum E. coli in rural Burkina Faso**: Iana AMKE (United Kingdom)<br>**Study of antimicrobial susceptibility in Brucella spp. strains isolated at CHU Rabta, Tunisia**: Salma ABBES (Tunisia)<br>**Genomic insights of carbapenemase-producing Enterobacter spp. in Argentina**: Fernando PASTERAN (Argentina) |
| 14/04 | 12:00 - 13:30 | PS021 | 03b. Resistance surveillance & epidemiology: Healthcare-associated bacteria |  | **Prevalence of carbapenem-resistant Enterobacteriaceae and extensively drug-resistant Acinetobacter baumannii ????colonisation among hospitalised immunocompromised and critically ill paediatric patients**: Sophida BOONSATHORN (Thailand)<br>**Admission incidence rate and diffusion dynamics of ESBL-producing Klebsiella pneumoniae in adult intensive care units: a five-year genomic monocentre study**: Coraline BERNACHOT (France)<br>**In vitro susceptibility of cefiderocol against carbapenem-resistant Gram-negative bacilli (CRGNB) from Singapore**: Jocelyn TEO (Singapore)<br>**Synergistic and additive effects of fosfomycin in MBL-producing Klebsiella pneumoniae and Pseudomonas aeruginosa isolates**: Esther WOHLFARTH (Germany)<br>**The integrated genomic surveillance reveals extensive clustering among increasing rates of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in Germany**: J�rg B. HANS (Germany)<br>**Molecular characterisation of OXA-48-like-producing Enterobacterales in Germany: insights from the DIOGENES study**: Janko SATTLER (Germany)<br>**Antimicrobial resistance and genetic insights into clinical pathogens from a Kyiv polyclinic**: Tim ERLER (Germany)<br>**Global epidemiology, trends, and clinical severity of hypervirulent Klebsiella pneumoniae infections**: Nagendra Babu DANAVATH (India)<br>**Assessment of in vitro synergy of colistin combined with meropenem, minocycline and Tigecycline in clinical isolates of carbapenem-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli**: Nida FATIMA (India)<br>**Diversity of the vanB cassette within ST117 vancomycin-resistant Enterococcus faecium isolates from Germany**: Kyriaki XANTHOPOULOU (Germany)<br>**Emergence and outbreak of ST80 vancomycin-resistant Enterococcus faecium in Guangdong province, China from 2021 to 2023**: Cong SHEN (China)<br>**Medical tourism in western Germany: review of Arab and Russian patients and their MRSA- and MRGN-status at a tertiary care facility in north Rhine-Westphalia**: Annette EYKING-SINGER (Germany)<br>**Prevalence of healthcare-associated infections and antimicrobial use in ICU wards in Georgia: results of the first ECDC point prevalence survey in 25 hospitals**: Otar CHOKOSHVILI (Georgia)<br>**Intra- and inter-patient evolution of cgMLST in ST-512 KPC-producing Klebsiella pneumoniae**: Mar�a Alejandra MATEO VARGAS (Spain)<br>**Unveiling hidden reservoirs of carbapenemases in Pseudomonas spp. beyond P. aeruginosa**: Guillem PUIGSECH BOIXEDA (Spain)<br>**Greater multidrug resistance in Enterococcus faecium but greater pathogenicity in Enterococcus faecalis isolated from Welsh ICU patients**: Caitlin FARLEY (United Kingdom)<br>**Silent dissemination of identical VanA-carrying linear plasmids in vancomycin-variable Enterococcus faecium: a growing diagnostic concern**: Ana ALMEIDA SANTOS (Portugal)<br>**Enterobacterales involved in plasmid-mediated carbapenem resistance outbreaks in Portuguese hospitals**: Rani Rashmani DE LA RIVI�RE (Portugal)<br>**Retrospective evaluation of culture-proven carbapenem-resistant Gram-negative infections a tertiary care educational university hospital: analysis of 888 cases**: Merve MERT VAHABI (T�rkiye)<br>**Emergence and spread of OXA-48-like carbapenemase-producing Escherichia coliin Baranya County, Hungary**: Agnes Maria SONNEVEND (Hungary)<br>**Genomic epidemiology of carbapenemase-producing Klebsiella pneumoniae in Taiwan, 2014-2020**: Tzu-Wen HUANG (China)<br>**Characterisation of carbapenem-resistant Klebsiella pneumoniae lineages in bloodstream infections in Barcelona (2021-2024)**: Aida CASTANY CARRASCO (Spain)<br>**First identification of Enterobacterales co-producing mcr-10 and broad-spectrum β-lactamase genes in Brazil**: Rafael SILVA ROSA (Brazil)<br>**Risk factors for development of hospital-acquired pneumonia in colonised patients by carbapenem-resistant Acinetobacter baumannii and the role of multisite colonisation: a multicentre clinical experience**: Rocco MORENA (Italy)<br>**Retrospective analysis of 22 years of surveillance of carbapenem-resistant Acinetobacter baumannii clinical isolates in a tertiary hospital in northern Spain**: Maitane ARANZAMENDI ZALDUMBIDE (Spain)<br>**Comparative effectiveness of cefiderocol and ceftazidime/avibactam plus aztreonam against metallo-beta-lactamase-producing Gram-negative isolates**: Fernando DEL NOGAL (Spain)<br>**Prevalence and genetic context of the blaOXA-1 gene in bloodstream isolates of Escherichia coli**: Carlos SA�CO CARBALLO (Spain)<br>**Is the glass half empty? High resistance rates amongst carbapenem-resistant bacteria in a cefiderocol-naive setting**: Christina LOUKA (Greece)<br>**High genetic relatedness between historical and contemporary multidrug resistant bacteria associated with Ukraine**: Zhayne HACKETT (United States)<br>**Emergence and spread of transferable linezolid resistance among Enterococcus faecium in a tertiary hospital in Spain**: Maria S�NCHEZ CUETO (Spain)<br>**Molecular epidemiology and clinical characteristics of carbapenem-resistant Klebsiella pneumoniae bloodstream and pneumonia isolates**: Phillip COX (United States)<br>**Prevalence and mechanism of colistin heteroresistance in Klebsiella pneumoniae in China**: Ying ZHU (China)<br>**VanA Enterococcus faecalis isolated from blood in Poland between 2022-2024**: Malgorzata GRZEGORCZYK (Poland)<br>**Evolution of incidence, risk factors and management of carbapenemase-producing Enterobacterales in a tertiary hospital over the last ten years**: Alicia GALAR (Spain)<br>**Geographic variations in distributions of carbapenemase-encoding genes, susceptibilities, and minimum inhibitory concentrations of inpatient meropenem-resistant Enterobacterales to ceftazidime/avibactam, meropenem/vaborbactam, and aztreonam/avibactam across four global regions: 2020-2022 data from the antimicrobial testing leadership and surveillance**: Po-Ren HSUEH (China)<br>**Prevalence and risk factors of fluoroquinolone resistance in Gram-negative bacterial infections: a systematic review and meta-analysis**: I Made Bayu ANGGRIAWAN (United Kingdom)<br>**Transmission dynamics of multidrug-resistant Klebsiella pneumoniae ST792 and novel ST7120 strains in the paediatric intensive care unit**: Tu-Hsuan CHANG (China)<br>**Phylogenomic analysis of IMP-producing Acinetobacter colistiniresistens revealed a predominant lineage in the regional spread**: Satoshi NISHIDA (Japan)<br>**Emergence of a novel sequence type carbapenem-resistant Klebsiella pneumoniae ST7462 in a healthcare-associated outbreak in Estonia**: Regina RUSSANOVA (Estonia)<br>**Genomic insights into Enterococcus faecium: resistance, virulence, and phylogenetic analysis**: Kuenyoul PARK (Republic Of)<br>**Cephalosporin use and the rise of multidrug-resistant infections: evidence from Guatemala**: Diego ERDMENGER (Guatemala)<br>**Cefiderocol-resistant Acinetobacter baumannii:  before cefiderocol introduction**: Alina GONCHAROVA (Russian Federation)<br>**Antimicrobial resistance patterns among patients admitted with sepsis at a tertiary hospital in Uganda**: Elias NDIBAREMA (Uganda)<br>**Retrospective detection of mcr-9-carrying Enterobacter cloacae cpx. clinical isolates in a tertiary hospital in Tenerife**: Eduardo P�REZ ROTH (Spain)<br>**The activity of cefiderocol against Achromobacter xylosoxidans clinical isolates**: Annarita MAZZARIOL (Italy)<br>**Characterisation of coagulase-negative Staphylococci neonatal sepsis isolates from low-to-middle-income countries for resistance, virulence and phylogeny**: Jawaria AZIZ (United Kingdom)<br>**Fifteen-year trends in resistance patterns of urinary pathogens at a Lebanese tertiary care centre**: Serge TOMASSIAN (Lebanon)<br>**Prevalence of rectal carriage and genomic characterisation of plasmid-mediated AmpC beta-lactamases in Escherichia coli and Klebsiella pneumoniae: results of annual point prevalence studies in a Dutch hospital, 2013-2023**: Veronica WETERINGS (Netherlands)<br>**CTX-M-15-producing high-risk Escherichia coli CC131 and first report of ST1193 causing urinary tract infections in Algeria**: Azucena MORA GUTI�RREZ (Spain)<br>**Carbapenamese resistance in European hospitals: two consecutive point prevalence surveys of Acinetobacter baumannii and Klebsiella pneumoniae**: Eline VERHAGEN (Netherlands)<br>**Arising from the shadows: clonal analysis of multi-drug resistant Enterococcus faecium**: Iv�n BLOISE (Spain)<br>**Insight into the evolution of a carbapenemase-producing Klebsiella pneumoniae ST395 strain in Hungary**: Akos TOTH (Hungary)<br>**Understanding antimicrobial resistance mortality in intensive care units in Paraguay (2022-2023): pilot study**: Ada Evangelina BRIZUELA (Paraguay)<br>**Molecular characterisation of carbapenem-resistant Pseudomonas aeruginosa strains in Portugal**: Maria MENESES (Portugal)<br>**Trends in fatal burden of antibiotic-resistant infections across EU countries from 1990 to 2021**: Gisela ROBLES AGUILAR (United Kingdom)<br>**Multicentre spread of vancomycin- and linezolid-resistant Enterococcus faecium ST2023 in Polish hospitals**: Ewa Nina WARDAL (Poland)<br>**Concerning rise in antibiotic resistance: insights from clinical bacterial isolates at an Albanian university hospital (TWIW 2020 Study)**: Silva TAFAJ (Albania)<br>**MDR bacteraemia in critically ill patients during the COVID-19 pandemic: the MARTINI study**: Georgios SCHINAS (Greece)<br>**A five year trend analysis of prevalence and antimicrobial susceptibility pattern of coagulase-negative Staphylococci (CoNS) in a tertiary care centre, south India**: Jaya PRASANTHI (India)<br>**Surveillance of temporal trends and antimicrobial resistance in nosocomial respiratory pathogens, Switzerland, 2007 to 2022**: Rami SOMMERSTEIN (Switzerland)<br>**Genetic characterisation of carbapenem-resistant Acinetobacter baumannii isolates recovered in intensive care units in Paraguay**: Sandra SANCHEZ-URTAZA (Spain)<br>**Evaluation of the efficacy of novel beta-lactam/beta-lactamase inhibitors against carbapenem-resistant Enterobacterales**: Sae Am SONG (Republic Of)<br>**Synergistic effect of ceftazidime/avibactam with aztreonam on carbapenemase-producing Enterobacteriaceae: the ray of hope against NDM**: Dip MUKHERJEE (India)<br>**The changing epidemiology of carbapenemase producing Enterobacterales in a Spanish tertiary hospital**: Est�baliz UGALDE (Spain)<br>**In vitro activity of delafloxacin against quinolone-resistant Staphylococcus aureus should always be tested**: Celia SANCHEZ (Spain)<br>**Prevalence and Antimicrobial Susceptibility of blaOXA-51 negative Acinetobacter spp. as a Cause of Human Infection in Per�.**: Rosario OPORTO LLERENA (Peru)<br>**Description of susceptibility profile of metallo-beta-lactamases-producing and non-carbapenemase-producing P. aeruginosa**: Ana Bel�n BORREGO ALCAIDE (Spain)<br>**A Klebsiella pneumoniae ST147 NDM-1/OXA-48 unique clone circulating in diverse hospitals in southern Italy**: Emanuele NICITRA (Italy)<br>**Activity of novel broad-spectrum antimicrobials against multi-carbapenemase producers Enterobacterales from southern Spain, 2018-2023**: Mercedes DELGADO VALVERDE (Spain)<br>**Antibiotic resistance patterns in Pseudomonas spp.: an eight year surveillance study in an Algerian hospital**: Asma BENMOHAMMED (Algeria)<br>**Coproduction of carbapenemases in Enterobacterales: emergence of a new phenomenon in a Spanish tertiary hospital**: Est�baliz UGALDE (Spain)<br>**Recent emergence of carbapenem-resistant Salmonella paratyphi in India: resistance profile and phylogenetic analysis**: Tharani Priya THIRUMOORTHY (India)<br>**Genotype and phenotype of carbapenemase-producing Escherichia coli in England, 2023-24**: Valentina PENNETTA (United Kingdom)<br>**Impact of the cessation and reopening of international travel during the COVID-19 pandemic on the incidence of MRSA and CPO in Norway, 2016-2024**: Anders SKYRUD DANIELSEN (Norway)<br>**Molecular epidemiology of carbapenemase-producing Enterobacterales, extended-spectrum beta-lactamase-producing Enterobacterales, and carbapenem-producing Pseudomonas aeruginosa in hospitalised patients in Suriname**: Carlotte ROZEMOND (Netherlands)<br>**Molecular epidemiology of carbapenemase-producing Enterobacter spp. in Hungary**: Adrienn HANCZVIKKEL (Hungary)<br>**Comprehensive study on healthcare-associated urinary tract infections in Serbia**: Ina GAJIC (Serbia)<br>**WHO's global antimicrobial resistance and use surveillance system (GLASS): is national surveillance coverage improving?**: Esther VAN KLEEF (Netherlands)<br>**One-year epidemiological surveillance of Klebsiella pneumoniae producing both NDM and OXA-48 Carbapenemases in an acute-care healthcare setting**: Sofia ZERVA (Greece)<br>**In vitro susceptibility to sulbactam/durlobactam of carbapenem-resistant Acinetobacter baumannii isolated from bloodstream infections: a multicentre study in Brazil**: Laura CZEKSTER ANTOCHEVIS (Brazil)<br>**Antimicrobial susceptibility and clonal structure of Acinetobacter spp. isolated from hospitalised patients in Poland in 2023**: Dorota ZABICKA (Poland)<br>**Trends in antimicrobial resistance: a three-year cumulative AST analysis of blood culture isolates in a tertiary hospital in Istanbul**: Yunus Emre TOK (T�rkiye)<br>**Enhanced surveillance and outbreak investigation through the use of whole-genome sequencing (WGS) in Greece**: Michalis POLEMIS (Greece)<br>**Emergence of carbapenemase-producing Enterobacter hormaechei in Marseille hospitals, France: a success-story analysis**: Linda HADJADJ (France)<br>**Tracking resistance in anaerobic bacteria (2016-2024) from an Irish hospital's perspective**: Damien KELLY (Ireland)<br>**Colistin and carbapenem-resistant Klebsiella pneumoniae isolates from Tunisia: a decade of rising resistance, 2012-2023**: Wejdene MANSOUR (Tunisia)<br>**Increase in blaNDM-1 among carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex clinical isolates collected in 2023 from US and European medical centres**: Mariana CASTANHEIRA (United States)<br>**Molecular epidemiology of methicillin-resistant Staphylococcus aureus in central, eastern, and south-eastern Europe: systematic review**: Jan TKADLEC (Czech Republic)<br>**Emergence and persistent spread of NDM-carrying Klebsiella pneumoniae high-risk clones in a tertiary hospital in Tenerife**: Maria De Las Huertas GARCIA ATIENZA (Spain)<br>**Resistance to antimicrobial agents in Escherichia coli and Klebsiella pneumoniae from hospitalised patients: results of the PEG surveillance study, 1984-2022/23**: Esther WOHLFARTH (Germany)<br>**Multidrug-resistant Pseudomonas aeruginosa: Mayo Clinic ten-year experience**: Kemar BARRETT (Jamaica)<br>**Fosfomycin resistance in Enterobacterales: a one-year surveillance in northern Italy**: Katerina CHUDEJOVA (Czech Republic)<br>**Prevalence and mechanisms of drug-resistant Acinetobacter baumannii isolated from hospitals in Japan: emergence of colistin resistance**: Sayaka YAMAGUCHI (Japan)<br>**Colistin resistance among multidrug-resistant Enterobacterales in an Algerian hospital: preliminary findings**: Samar AKBI (Algeria)<br>**Real world in vitro synergy to doxycycline, ceftriaxone/sulbactam/edetate, and chloramphenicol in ceftazidime/avibactam-resistant, aztreonam synergy-negative isolates from a tertiary referral centre in southern India**: Nimitha K MOHAN (India)<br>**Molecular epidemiology of methicillin susceptible Staphylococcus aureus in the Czech Republic: prospective multicentre study**: Jan TKADLEC (Czech Republic)<br>**Cefepime/taniborbactam exhibits limited cross-resistance with ceftazidime/avibactam and ceftolozane/tazobactam against carbapenem-nonsusceptible Enterobacterales and multidrug-resistant Pseudomonas aeruginosa from Europe 2018-2023**: Meredith HACKEL (United States)<br>**In vitro activity of aztreonam/avibactam and comparator agents against metallo-beta-lactamase (MBL)-positive carbapenem-resistant E. coli and Klebsiella  spp.collected from patients with bloodstream infections (BSI) as part of the ATLAS surveillance programme (2020-2022), India**: Akshata Sushant MANE (India)<br>**Antimicrobial resistance in bacterial isolates from nine Ukrainian war casualties: a retrospective bicentric observational study**: Diana Isabela STRACHINARU (Belgium)<br>**Multidrug-resistant organisms amidst ongoing conflict in Ukraine: surveillance and resistance patterns**: Magda METREVELI (Georgia)<br>**Cefiderocol activity against resistant bacteria from patients with ventilator associated pneumonia from European and US hospitals**: Sean NGUYEN (United States)<br>**Analysis of multidrug-resistant organisms from Poland and Estonia**: Nino TRAPAIDZE (Georgia)<br>**Activity of cefiderocol against clinical isolates of Acinetobacter baumannii complex collected from five European countries as part of SENTRY antimicrobial surveillance programme, 2020-2023**: Christopher LONGSHAW (United Kingdom)<br>**Activity of cefiderocol against clinical isolates of Stenotrophomonas maltophilia collected from five European countries as part of the SENTRY antimicrobial surveillance programme 2020-2023**: Christopher LONGSHAW (United Kingdom)<br>**Activity of omadacycline against multidrug-resistant and molecularly characterised Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals, 2020-2023**: Rodrigo E. MENDES (United States)<br>**In vitro activity of cefepime/taniborbactam and comparators against Enterobacterales and P. aeruginosa collected in Europe (2018-2023) stratified by beta-lactamase carriage**: Mark WISE (United States)<br>**The landscape of carbapenemases in Canada 2019-2023, data from the Canadian nosocomial infection surveillance programme (CNISP)**: Laura MATASEJE (Canada)<br>**In vitro activity of mecillinam against multi-drug resistant Enterobacterales**: Mariano Paulo ECHEGORRY (Argentina)<br>**Carbapenem resistance enterobacteriaceae (CRE) at university college hospital, Ibadan, Nigeria**: Paul TURNER (Cambodia)<br>**In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against clinical isolates of KPC-producing Klebsiella pneumoniae from a Greek hospital**: Anastasios VOGIATZAKIS (Greece)<br>**Evaluating chlorhexidine antimicrobial susceptibility of S. aureus and methicillin-resistant S. aureus blood culture isolates following implementation of CHG-bathing**: Peiyi Vicki CHOW (Singapore)<br>**Molecular characterisation and epidemiology of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa (CRE/CRPA) among hospitalised patients in five public hospitals from South Africa**: Renata DA COSTA (Switzerland)<br>**Microbiological and epidemiological characteristics of carbapenemase-producing Enterobacteriaceae in urine cultures during the year 2024 at a tertiary hospital**: Laura LOPEZ GONZALEZ (Spain)<br>**Outbreak investigation of extensively drug-resistant Acinetobacter baumannii of ST2 in the intensive care unit of a Lebanese hospital**: Tsolaire SOURENIAN (Czech Republic)<br>**Molecular characterisation and epidemiology of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa (CRE/CRPA) among hospitalised patients in five public/private hospitals from India**: Balaji VEERARAGHAVAN (India)<br>**RpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis**: Mia AARRIS (Denmark)<br>**Linking carbapenem-resistant E. coli in hospital-admitted patients and the environment in Bangladesh: An emerging public health threat.**: Amrita PONDIT (United Kingdom)<br>**In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa isolates from geriatric patients with respiratory tract infections in the Asia/Pacific region: SMART, 2019-2023**: Mark WISE (United States)<br>**Activity of the novel beta-lactam/beta-lactamase inhibitor combination cefepime/enmetazobactam against Acinetobacter spp.**: Gabriela Alejandra BAEZ BARROSO (Spain)<br>**Activity of ceftolozane/tazobactam, imipenem/relebactam and comparators against clinical isolates of Pseudomonas aeruginosa from hospitalised patients in Kuwait, Oman, Qatar, and United Arab Emirates: SMART 2018-2023**: Mark WISE (United States)<br>**Activity of ceftolozane/tazobactam and comparators against phenotypic ESBL-producing, carbapenemase-negative clinical Enterobacterales isolates from South Africa: SMART 2018-2023**: Mark WISE (United States)<br>**Activity of ceftolozane/tazobactam, imipenem/relebactam and comparators against clinical isolates of Pseudomonas aeruginosa from hospitalised patients in Southeastern Europe: SMART 2018-2023**: Mark WISE (United States)<br>**A systematic review of prevalence and epidemiological characteristics of carbapanemease-producing Enterobacterales (CPE) in the United Kingdom**: Uzair Akbar ALI (United Kingdom)<br>**Activity of imipenem/relebactam and comparators against clinical Gram-negative isolates collected in the Latin American region: SMART 2021-2023**: Mark WISE (United States)<br>**Precision analysis of the carbapenemase- and/or ESBL-producing Acinetobacter baumannii clinical isolates by national microbiology reference laboratory in Latvia**: Inara KAMPENUSA (Latvia)<br>**Emergence of Klebsiella pneumoniae ST-11 expressing KPC-2 and NDM-5 carbapenemases in an Algerian university hospital**: Nadjat AGGOUNE KHINACHE (Algeria)<br>**The clonal diversity of extensively resistant Acinetobacter baumannii isolated in Egyptian clinical settings**: Salma SALEM (Egypt)<br>**Epidemiology of multi-drug resistant bacteria among foreign combatants wounded in Ukraine**: Aubrey POWELL (United States)<br>**In vitro activity of aztreonam/avibactam against ceftazidime/avibactam-resistant Enterobacterales isolates collected as a part of the ATLAS global surveillance Sstudy, 2019-2023**: Mark ESTABROOK (United States)<br>**The highly resistant NDM-14-producing K. pneumoniae ST147 clone reaching the Canary Islands, Spain, 2023**: Tania BLANCO MART�N (Spain)<br>**Temporal changes in carbapenem resistance genes in Klebsiella pneumoniae: a 12-year study from a university hospital in Turkey**: Murat TELLI (T�rkiye)<br>**In vitro antimicrobial susceptibility testing of cefiderocol against Gram-negative bacteria isolated from cystic fibrosis patients**: Marjan MOTAMEDI (Austria)<br>**Surveillance of Acinetobacter baumannii by clustering analysis with sequence type characterisation**: Valentina DIMARTINO (Italy)<br>**Trends in incidence rates of microorganisms among patients with bloodstream infections at intensive care units in South Korea from 2011 to 2022: data from the Korean national healthcare-associated infections surveillance system (KONIS)**: Yu-Mi LEE (Republic Of)<br>**Evaluating cefiderocol susceptibility in carbapenem-resistant Klebsiella pneumoniae: a comparative analysis of CLSI and EUCAST guidelines**: Y�sra AGAOGLU (T�rkiye)<br>**Characterisation of colistin resistant Enterobacterales isolated from clinical specimens from public hospitals in Gauteng, South Africa**: Mohamed SAID (South Africa)<br>**Antimicrobial susceptibility and virulence profiles of invasive and non-invasive vancomycin-resistant Enterococci at the university hospital centre Zagreb: preliminary results**: Ivana MAREKOVIC (Croatia)<br>**The prevalence and prognostic value of antimicrobial resistance within nosocomial settings: a global systematic review and meta-analysis of over 20,000 patients**: Daniel PAN (United Kingdom)<br>**Activity of cefiderocol against metallo-beta-lactamase-carrying Enterobacterales, stratified by allele, collected as part of the SENTRY antimicrobial surveillance programme**: Boudewijn DEJONGE (United States)<br>**ACORN2: prospective clinically oriented antimicrobial resistance surveillance data from 19 hospitals across Africa and Asia**: Jill HOPKINS (Thailand)<br>**In vitro activities of the essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin, and other comparators against carbapenem-resistant organisms with different carbapenemase genes: a multicentre study in China, 2021**: Yun WU (China)<br>**Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterised clinical isolates, causing infections in hospitals in European and adjacent regions, 2020-2023**: Rodrigo E. MENDES (United States)<br>**The activity of cefiderocol against Enterobacterale carrying multiple carbapenemases, collected as part of the SENTRY antimicrobial surveillance programme**: Jason J. BRYOWSKY (United States)<br>**Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterised clinical isolates, causing infections in hospitals in European and adjacent regions, 2020-2023**: Rodrigo E. MENDES (United States)<br>**Tracking of trimethoprim resistance determinants in MRSA: a genetic analysis of hospital isolates in Kuwait**: Samar BOSWIHI (Kuwait)<br>**Association of integron diversity with reduced biocide susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates from public hospitals in Gauteng, South Africa**: Egan MULONDO (South Africa)<br>**Frequency and antimicrobial resistance pattern of microorganisms isolated from cerebrospinal fluid samples in Brazilian public hospitals**: Jussimara MONTEIRO NURMBERGER (Brazil)<br>**Automated surveillance of bloodstream infections in Germany: a proof-of-concept study and first results**: Imke WIETERS (Germany)<br>**Exploring the role of KPC variants in cross-resistance to last-line antibiotics**: Fernando PASTERAN (Argentina)<br>**Genomic insights into methicillin resistant Staphylococcus aureus population structure, dissemination and diversity in the United Arab Emirates using whole-genome sequencing**: Syrine Nouara BOUCHERABINE (United Arab Emirates)<br>**Trends in the in vitro activity of aztreonam/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global urveillance study in Latin America, 2019-2023**: Mark ESTABROOK (United States)<br>**Trends in the in vitro activity of ceftazidime/4avibactam and beta-lactamase carriage among Pseudomonas aeruginosa isolates collected as a part of the ATLAS global surveillance study in 2019-2023**: Mark ESTABROOK (United States)<br>**Prevalence and risk factors for multi-drug resistant Enterobacterales in long-term care facilities**: Erika ASPERGES (Italy)<br>**Trends in the in vitro activity of aztreonam/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global surveillance study in Middle East/Africa, 2019-2023**: Mark ESTABROOK (United States)<br>**Trends in the in vitro activity of aztreonam/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global surveillance study in Asia/Pacific, 2019-2023**: Mark ESTABROOK (United States)<br>**Trends in the in vitro activity of aztreonam/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global surveillance study in Europe, 2019-2023**: Mark ESTABROOK (United States)<br>**In vitro activity of aztreonam/avibactam against Enterobacterales isolates collected from patients in intensive care units and other wards, by global region ATLAS surveillance study, 2019-20**: Mark ESTABROOK (United States)<br>**Susceptibility of Enterobacterales collected globally to aztreonam/avibactam and comparator agents stratified by infection source: ATLAS surveillance programme 2019-2023**: Mark WISE (United States)<br>**High prevalence of NDM-production and its adverse impact on in-vitro susceptibility of newer antibiotics against Indian Pseudomonas aeruginosa isolates**: Umang AGRAWAL (India)<br>**In vitro activity of aztreon/amavibactam against carbapenem-resistant Enterobacterales isolates by region collected as a part of the ATLAS global surveillance study, 2019-2023**: Mark ESTABROOK (United States)<br>**In vitro activity of ceftazidime/avibactam (CAZ-AVI) and comparators against Pseudomonas aeruginosa collected worldwide stratified by ICU vs non-ICU, ATLAS global surveillance programme, 2019-2023**: Meredith HACKEL (United States)<br>**Antimicrobial activity of aztreonam-avibactam against carbapenemase-producing Pseudomonas aeruginosa from German hospitals**: Sophie Louise M�LLER (Germany)<br>**Emergence of resistance and consumption of cefazolin vs anti-Staphylococcal penicillins: an exploratory cross-sectional study in French healthcare facilities**: Laure-Line JOUBERT (France)<br>**Trends in the in vitro activity of ceftazidime/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global surveillance study in Europe, by subregion 2019-2023**: Mark ESTABROOK (United States)<br>**In vitro activity of ceftazidime/avibactam against Enterobacterales stratified by global region and year of collection, ATLAS global surveillance programme, 2018-2023**: Meredith HACKEL (United States)<br>**Phylogenetic and population structure analyses reveal intra-clonal diversification and emergence of successful clades of carbapenemase-producing Klebsiella pneumoniae ST258 from Argentina**: Fabrizzio Nicol�s MORANDINI (Argentina)<br>**Proportion of Staphylococcus aureus with a vancomycin MIC of 1 mg/L increases from 12% in 2013 to 70% in 2020, during COVID-19 restrictions in Singapore**: Timothy BARKHAM (Singapore)<br>**In vitro activity of sulbactam/durlobactam against clinical Acinetobacter baumannii isolates in China**: Qingye XU (China)<br>**In vitro evaluation of the efficacy of aztreonam/avibactam and aztreonam plus ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa: revisiting the role of ceftazidime**: Juliana CAIER�O (Brazil)<br>**Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolated in intensive care unit**: Xiao TINGTING (China)<br>**Contact precautions vs horizontal strategies to limit the spread of third-generation cephalosporin resistant Gram-negative bacteria on intensive care units: results of a country-wide, multicentred, non-randomised, before-after studies on intensive care units**: Beate SCHLOSSER (Germany) |
| 14/04 | 12:00 - 13:30 | PS022 | 03c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB) |  | **Evaluation of FDA-cleared rapid antimicrobial susceptibility testing (AST) methods for bloodstream infections: impact on clinical decision-making in a tertiary care setting**: Manohar MUTNAL (United States)<br>**Rifabutin MIC test strip development for susceptibility testing against Acinetobacter baumannii**: Birgit SCHELLHORN (Switzerland)<br>**Evaluation of a two-hour antimicrobial susceptibility assay for bacteraemia using flow cytometry**: Maria Adelina GIMENO (Spain)<br>**Evaluation of a wide panel of antibiotic discs and Mueller-Hinton agar plates with laboratory automation**: Matteo LUCCHINI (Italy)<br>**In vitro synergistic activity of amoxicillin and cephalosporin on non-faecalis and non-faecium Enterococcaceae**: Romain MILLOT (France)<br>**Performance evaluation of a novel rapid AST system on Gram-negative blood culture isolates at a tertiary university hospital in northern Greece**: Paraskevi MANTZANA (Greece)<br>**A novel ultra-rapid phenotypic susceptibility method for ceftazidime/avibactam**: Cid�lia PINA-VAZ (Portugal)<br>**Direct antimicrobial susceptibility testing on clinical urine samples by laboratory automation**: Jamie WORSWICK (United Kingdom)<br>**Evaluation of VITEK REVEAL fast antimicrobial susceptibility testing compared to disk diffusion for Gram-negative bloodstream infections**: Rebekah DUMM (United States)<br>**Rapid direct antibiotic susceptibility testing of positive blood cultures using cell pellet**: Paraskevi MANTZANA (Greece)<br>**Cefiderocol is a promising treatment alternative agent against highly virulent and antimicrobial-resistant Stenotrophomonas maltophilia, an emerging pathogen**: �zgen K�SEOGLU ESER (T�rkiye)<br>**Antimicrobial susceptibility and resistance mechanisms in clinical Bacteroides fragilis group isolates**: Eleni KALOGEROPOULOU (Greece)<br>**Performance for detecting carbapenemase classes with an automated antimicrobial susceptibility testing system**: Laurence PAGES MONTEIRO (France)<br>**Antimicrobial susceptibility testing assay using scanning electron microscopy for aminoglycosides: a pilot investigation**: Omar ZMERLI (France)<br>**Penicillin-resistant, ampicillin-susceptible Enterococcus faecalis (PRASEF) strains and their extended beta-lactam resistance**: Bernardo Alfonso MARTINEZ-GUERRA (Mexico)<br>**Antimicrobial susceptibility testing and clinical outcomes of non-cystic fibrosis Burkholderia cepacia complex infections**: Ka Lip CHEW (Singapore)<br>**Towards antibiotic susceptibility testing (AST) direct from urine: interim results from the analytical validation of microcapillary AST**: Julie HART (United Kingdom)<br>**In vitro synergistic effect of mecillinam with avibactam against Klebsiella pneumoniae clinical isolates producing various carbapenemases**: Eleni VOUDANTA (Greece)<br>**Detection and differentiation of carbapenemases among Enterobacterales isolates using advanced system expert and new expertise rules of the VITEK 2**: Laurent DORTET (France)<br>**Synergistic potential of colistin combinations against carbapenem- and colistin-resistant enterobacteriaceae: in-vitro and in-vivo insights**: Archana ANGRUP (India)<br>**Two years with RAST in Enterobacteria: clinical impact and concordance**: Elena ALVARADO (Spain)<br>**Evaluation of the card VITEK AST-N442 among a collection of clinical Enterobacteriaceae isolates**: Fran�ois GRAVEY (France)<br>**Comparison of various methods for identifying Nocardia isolates and determining antibiotic susceptibilities**: Ekin KIRBAS (T�rkiye)<br>**A prospective, observational, cross-sectional, single-arm study using nanomotion-based technology (Resistell AST) for rapid Gram-negative antibiotic susceptibility testing (NANO-RAST)**: Giorgia CARUANA (Switzerland)<br>**Rapid antimicrobial resistance diagnosis in sepsis: a comparative study of a microfluidic rapid AST system and broth microdilution on Gram-negative pathogens**: Sarah DI SOPRA (Italy)<br>**Performance of antibiotic susceptibility testing methods for novel beta-lactam/beta-lactamase inhibitors and temocillin in carbapenemase-producing Enterobacterales: a comparative study**: Cansu CIMEN (Germany)<br>**Extraction of viable Gram-positive bacteria from blood for rapid antimicrobial susceptibility testing**: Daniel SPENCER (United Kingdom)<br>**Development of a novel antibiotic susceptibility test using Raman spectroscopy**: Giang NGUYEN (United Kingdom)<br>**Synergy between orally bioavailable antibiotics and dalbavancin against MRSA**: Brian WERTH (United States)<br>**In vitro activity of delafloxacin against Escherichia coli isolates producing bacteraemia with different susceptibility profiles to ciprofloxacin and levofloxacin**: Cristina EL�AS L�PEZ (Spain)<br>**Rapid susceptibility testing of cefiderocol directly from positive blood cultures using a microfluidic agar-diffusion assay**: Amanda �MAN (Sweden)<br>**Synergistic effect of ceftazidime/avibactam with meropenem and aztreonam against carbapenem-resistant Klebsiella pneumoniae**: Yun WU (China)<br>**Optimisation and improvement of in vitro drug susceptibility method for mucoid Pseudomonas aeruginosa**: Yun WU (China)<br>**In-vitro activity of cefiderocol and eravacycline in multidrug-resistant strains of Achromobacter xylosoxidans and Achromobacter denitrificans: implementation of a rapid testing protocol**: Angela CHARLES (United States)<br>**Colistin, meropenem/vaborbactam, imipenem/relebactam, and eravacycline testing in carbapenem-resistant Gram-negative rods: a comparative evaluation of broth microdilution, gradient test, and VITEK 2**: Patrick FORSTNER (Austria)<br>**Evaluation of the VITEK REVEAL  AST system vs Accelerate Pheno for antimicrobial susceptibility testing of Gram-negative bacteria directly from positive blood cultures**: Suzane SILBERT (United States)<br>**Evaluating in vitro antibiotic synergy for paediatric multidrug-resistant Gram-negative bloodstream isolates at a tertiary public hospital in South Africa**: Prenika JAGLAL (South Africa)<br>**In vitro activity of cefiderocol against Burkholderia cepacia complex from patients with cystic fibrosis assessed by two methods**: Hedda Luise VERHASSELT (Germany)<br>**Cefiderocol susceptibility against carbapenem-resistant Gram-negative bacilli: a study on Indian clinical strains**: Sarita MOHAPATRA (India)<br>**Comparison of three methods for detecting metronidazole resistance determinants (nim) in Bacteroides fragilis group organisms**: Hanshu FANG (China)<br>**Evaluation of an automated antimicrobial susceptibility testing system performance for colistin susceptibility in Klebsiella pneumoniae and Escherichia coli isolates**: Arzu ILKI (T�rkiye)<br>**Resistance levels to beta-lactams based on oxacillin disk difusion test in Sreptococcus pneumoniae**: Eleni KALOGEROPOULOU (Greece)<br>**Comparative evaluation of an automated antimicrobial testing system for carbapenemase detection in K. pneumoniae and E. coli isolates using CIM and genotypic methods**: �zlem Gizem NIGDELIOGLU SEZER (T�rkiye)<br>**Are disk diffusion and agar gradient diffusion reliable for mecillinam susceptibility?**: Vasiliki KOUMAKI (Greece)<br>**The effect of beta-lactamase genes and chromosomal gene mutations on the cefiderocol susceptibility of New Delhi metallo-beta-lactamase (NDM) producing Enterobacterales isolates from Merseyside hospitals, comparing cefiderocol antibiotic susceptibility testing methods**: Caitlin DUGGAN (United Kingdom)<br>**The PIM test: rapid phenotypic detection of penicillinase-producing Staphylococcus aureus without zone edge reading**: Dhouha KARRAY (Tunisia)<br>**Identification of Corynebacterium clinical isolates at the species level using phenotypic, molecular methods and assessment of the rapid emergence of high-level resistance to daptomycin and vancomycin**: �zgen K�SEOGLU ESER (T�rkiye)<br>**In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Pseudomonas aeruginosa**: Jacqueline FINDLAY (Switzerland)<br>**Evaluation of rapid phenotypic antimicrobial susceptibility testing from positive blood cultures at a quaternary care academic medical centre**: Andrew E. CLARK (United States)<br>**Metallo-beta-lactamase producing Pseudomonas aeruginosa: the fractional inhibitory concentration index as a tool to evaluate antibiotic synergy**: Guido GRANATA (Italy)<br>**Evaluation of a ready-to-use metronidazole agar dilution panel for antimicrobial susceptibility testing of anaerobic bacteria**: Ulrik Stenz JUSTESEN (Denmark)<br>**Comparative analysis using linear regression models to identify predictors of AMR in Africa**: Oluwasegun DARAMOLA (Nigeria)<br>**Influence of pH on antibiotic efficacy against uropathogenic Escherichia coli**: Anne-Christine AUST (Germany)<br>**Evaluation of aztreonam/avibactam alone and in combination with colistin against ESBL- and carbapenemase-producing Klebsiella pneumoniae**: Elin FERM�R (Sweden)<br>**Evaluation of direct blood culture antimicrobial susceptibility testing in routine diagnostic settings**: Al Hawaj HASSAN (Saudi Arabia)<br>**Resistance detection to fluoroquinolones by an automated AST system in Escherichia coli**: Gilles ZAMBARDI (France)<br>**Evaluation of cefepime/enmetazobactam efficacy against BLEE + OXA 48 resistant strains**: Luis GAGO MANTILLA (Spain)<br>**Rapid AST for patients with suspected urosepsis: optimised sample management to reduce time to guide antibiotic therapy**: Maria ROLF (Sweden)<br>**Evaluation of CLSI, EUCAST and a lab developed rapid antimicrobial susceptibility test directly from positive blood culture**: Yan CHEN (Canada)<br>**Laboratory performance in antimicrobial susceptibility testing of anaerobic bacteria (EUCAST disc diffusion methodology): results of an external quality assessment study, 2024**: Michael BUHL (Germany)<br>**Evolution of rapid colistin resistance detection methods in Klebsiella pneumoniae and  Acinetobacter baumannii strains**: Fatma ERDEM (T�rkiye)<br>**In vitro activity of cefepime/zidebactam (FPZ) against extended-spectrum beta-lactamase (ESBL) producers and carbapenem-resistant Enterobacterales (CRE) isolates**: Lucia MACCARI (Argentina)<br>**Area of technical uncertainty: a paradigm for clinical microbiology**: Jose Carlos DE GRACIA D�AZ (Spain)<br>**Evaluation of direct-from-blood-culture disc diffusion testing for Gram-negative bacteraemia at a regional microbiology laboratory**: Austin YAN (Canada)<br>**Comparison of broth microdilution and antimicrobial gradient strip test in determining in vitro activity of aztreonam/avibactam in metallo-beta-lactamase-producing Enterobacterales**: Anna DUDAKOVA (Germany)<br>**Performance assessment of a cefepime-taniborbactam gradient diffusion strip for antimicrobial susceptibility testing of Enterobacterales and Pseudomonas aeruginosa**: Greg MOECK (United States)<br>**Evaluation of a novel rapid phenotypic antimicrobial susceptibility testing system**: Ping REN (United States)<br>**Cefepime/taniborbactam (FTB) epidemiological cutoff values (ECOFFs) against key Enterobacterales species and Pseudomonas aeruginosa**: Greg MOECK (United States)<br>**Biofilms and beta-lactamases affect cefiderocol activity in multidrug-resistant Acinetobacter baumannii**: Ilaria CAVALLO (Italy)<br>**Do we still have treatment options for infections caused by carbapenemase-producing Enterobacterales?**: Anezka GRYNDLEROVA (Czech Republic)<br>**Evaluation of meropenem, ertapenem and temocillin screening breakpoints in the EUCAST rapid antimicrobial susceptibility testing (RAST) for rapid detection of OXA-48-producing Klebsiella pneumoniae directly from positive blood cultures**: Yeliz TANRIVERDI CAYCI (T�rkiye)<br>**Meropenem/vaborbactam against planktonic and biofilm forms of carbapenem-resistant Klebsiella pneumoniae**: Francesca SIVORI (Italy)<br>**Colistin resistance in Klebsiella pneumoniae: phenotypic assays shed light on genomic mechanisms**: Kavitha KUMAR (India)<br>**Novel antibiotic susceptibility testing (AST) of Coxiella burnetii towards doxycycline using tabletop scanning electron microscopy (SEM)**: Rita ABOU ABDALLAH (Lebanon)<br>**A sepsis solution in a large clinical laboratory: evaluation of three fast phenotypic antimicrobial susceptibility testing approaches from positive blood cultures**: Eric RANSOM (United States)<br>**In vitro activity of aztreonam and aztreonam/avibactam against carbapenemase-producing Enterobacterales in Peru**: Liliana CAYTUIRO (Peru)<br>**Standardising aztreonam/relebactam disk diffusion susceptibility testing in Enterobacterales: a step towards reliable clinical application**: Mariano Paulo ECHEGORRY (Argentina)<br>**Combining oxacillin and benzylpenicillin disk diffusion to categorise benzylpenicillin susceptibility in Streptococcus pneumoniae without MIC testing**: Erika MATUSCHEK (Sweden)<br>**Evaluation of imipenem/relebactam for MicroScan dried Gram-negative MIC panels from a multicentre assessment of Enterobacterales and Pseudomonas aeruginosa**: Christine HASTEY (United States)<br>**ETEST imipenem/relebactam (IRPA) for antimicrobial susceptibility testing of Pseudomonas aeruginosa: performance results from a multicentre study**: Aur�lie COLLANGE (France)<br>**Personalised antimicrobial susceptibility clinical breakpoint interpretation using clinical prediction modelling: a microsimulation study**: Alex HOWARD (United Kingdom)<br>**Performance of the LifeScale rapid AST vsclinical standards of care**: Masaw AKBARI (United States)<br>**Colistin susceptibility in Klebsiella pneumoniae isolates: comparison of broth microdilution and automated systems with qPCR-based investigation of mcr gene presence**: Irmak OZKUBAT KORKMAZ (T�rkiye)<br>**Emerging evidence of antimicrobial resistance in Capnocytophaga canimorsus may have significant implications for empiric treatment choices**: Zoja GERMUSKOVA (Switzerland)<br>**In vitro activities of aztreonam/nacubactam and cefepime/nacubactam against carbapenemase-producing Enterobacterales collected as part of a global surveillance study in 2021-2022**: Mark ESTABROOK (United States)<br>**Increased antibiotic susceptibility of Gram-positive bacteria in cerebrospinal fluid compared to broth**: Jennifer Stella WIRTH (Germany)<br>**Delafloxacin as the only anionic flouroquinolone with excellent activity against multi-drug resistant bacteria especially in acidic environments: an in vitro study**: Markus HELL (Austria)<br>**Controlled inoculum functionality of an automated rapid AST system leads to consistent MIC determination**: Jenny G�RANSSON (Sweden)<br>**Study on the susceptibility of the fifth-generation cephalosporin ceftaroline to Gram-positive bacteria**: Li ZHIDONG (China)<br>**Comparative evaluation of cefepime/taniborbactam MIC testing with gradient strip and CLSI broth microdilution methods**: Marion POMPILO (France)<br>**Early evaluation of rapid antimicrobial susceptibility testing by volatile organic compounds detection: a comparative study**: Min Kyung SO (Republic Of)<br>**A systematic review and individual bacterial species-level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria**: Getnet ASSEFA (Australia)<br>**A 2-plate method for the detection of ESBL and carbapenemase-producing Enterobacterales.**: Julie CREIGHTON (New Zealand)<br>**Antibiotic susceptibility of Gram-negative bacteria in cerebrospinal fluid compared to Mueller-Hinton broth and artificial cerebrospinal fluid**: Roland NAU (Germany)<br>**Evaluation of the Sysmex PA-100 system for rapid antibiotic susceptibility testing in urinary samples from borate tubes**: Chlo� BELOT (France)<br>**Evaluation of the broth disk elution method for determining the synergistic activity of the aztreonam and ceftazidime-avibactam combination**: Banu BAYRAKTAR (T�rkiye)<br>**A prospective comparison of five methods for rapid antimicrobial susceptibility testing (RAST) for Gram-negative bacteraemia**: Christine UITZ (Austria)<br>**Phenotypic detection of transferable linezolid resistance in Enterococcus faecalis: implications for monitoring gene dissemination**: Clara MORET�-CASTELLSAGU� (Spain)<br>**Inducible clindamycin resistance in Streptococcus harboring erm genes: evaluation of a new screening test**: Jennifer GIESEN (United States)<br>**Comparative study of nalidixic acid and pefloxacin for quinolone resistance screening in Enterobacterales**: Lorena L�PEZ CERERO (Spain)<br>**Challenges of cefiderocol susceptibility testing: agreement between a commercial method and disk-diffusion in metallobetalactamase-producing Klebsiella spp.**: Ines Maria PORTILLO CALDERON (Spain)<br>**Cefiderocol's dark side: the challenge of accurate in vitro testing**: Sara CARLONI (Italy)<br>**Antimicrobial susceptibility of anaerobic bacteria from bloodstream infections in Germany: a multicentre study**: Denise STARK (Germany)<br>**Gepotidacin MIC determination: comparative evaluation of a new gradient strip to the CLSI 2024 reference method on 290 clinical isolates**: Veronique SAUVONNET (France)<br>**In vitro antibacterial activity of a fosfomycin/trimethoprim/sulfamethoxazole combination plus anti-mycobacterial agents against reference strains of non-tubercular Mycobacterium spp.**: Dalon ARRINGTON (United States)<br>**Performance evaluation of three routine methods for testing the susceptibility of 450 outpatient Escherichia coli isolates to mecillinam**: Esther WOHLFARTH (Germany)<br>**Exploring microtubule targeting agents as novel antimicrobial therapeutics**: Amira Zhor Rim ZINAI (France)<br>**In vitro activity of cefiderocol against carbapenem-resistant Escherichia coli (CREC): a multicentre study in China**: Ye LU (China)<br>**Comparative study on the effectiveness of two gradient strips with imipenem/relebactam on Enterobacterales and P. aeruginosa strain collections**: Marion POMPILO (France)<br>**Performance of ceftazidime/avibactam and ceftolozane/tazobactam automated susceptibility testing results for carbapenem-resistant Pseudomonas aeruginosa**: Emily JACOBS (United States)<br>**Evaluation of MIC determination with dalbavancin gradient test in Enterococcus faecalis, Enterococcus faecium and Staphylococcus epidermidis**: Frida MALM (Sweden)<br>**Evaluation of a semi-automated system for antibiotic susceptibility testing: a comparison with manual method**: Merav STRAUSS (Israel)<br>**Performance of a new system for rapid antimicrobial susceptibility testing of Gram-negative bacteraemia: results from a prospective mono centric study in South Africa**: Yohann BALA (France)<br>**Rapid phenotypic susceptibility testing from patient blood cultures with growth of Streptococci or other Gram-positive bacteria**: Jenny G�RANSSON (Sweden)<br>**Ultra-rapid antibiotic susceptibility testing workflow for neonatal sepsis: from blood sample to AST result in nine hours**: Alexander STURM (Switzerland)<br>**Phenotypic and molecular analysis of the in vitro activity of fluoroquinolones against clinical isolates of Corynebacterium spp.**: Montserrat MU�OZ ROSA (Spain)<br>**Unlocking rapid phenotypic AST direct-from-blood with automated microbial detection and quantitative growth monitoring**: Elinor MCSORLEY (United Kingdom) |
| 14/04 | 12:00 - 13:30 | PS023 | 03d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB) |  | **Emergence of Klebsiella pneumoniae ST15 isolates harbouring blaSFO-1 on a conjugative plasmid: a silent and persistent threat in community-acquired infections**: Giovanni LORENZIN (Italy)<br>**Aztreonam/avibactam resistance rates and resistance mechanisms of NDM-carbapenemase-producing-Enterobacterales (CPE) and NDM/OXA48-like-dual-CPE in Singapore**: Ka Lip CHEW (Singapore)<br>**Persistence, dissemination and evolution of IMP-15 carbapenemase-producing isolates of Pseudomonas aeruginosa in Gran Canaria**: Gabriel TALTAVULL PONS (Spain)<br>**DNA methyltransferases in Escherichia coli affects fitness and genome stability**: Jee Hong KIM (Republic Of)<br>**Presence of the hypervirulent Clone ST23 of Klebsiella pneumoniae producing VIM-1 in the Canary Islands**: Pi�a Delgado CARMEN (Spain)<br>**Molecular and microbiological characteristics of E. coli harboring mutant CTX-M-15 (A80V)**: Bongyoung KIM (Republic Of)<br>**Energy metabolism deficiencies enhance the susceptibility of Staphylococcus aureus and its small colony variants (SCVs) to lugdunin**: Mei-Hui LIN (China)<br>**Characterisation of a novel KPC-2 variant, KPC-228, conferring resistance to ceftazidime-avibactam in an ST11-KL64 hypervirulent Klebsiella pneumoniae**: Bingjie WANG (China)<br>**Description of the first cases of GES-type Class A carbapenemase-producing Pseudomonas aeruginosa in the Canary Islands**: Pi�a Delgado CARMEN (Spain)<br>**Optimising ceftolozane/tazobactam therapy against OXA-type beta-lactamase producing XDR Pseudomonas aeruginosa: insights from clinical case and hollow-fiber model correlations**: Sandra DOMENE (Spain)<br>**Preventing OXA-type beta-lactamase producing XDR Pseudomonas aeruginosa infections: correlating clinical outcomes with hollow-fiber model results for ceftazidime/avibactam therapy**: Maria Milagro MONTERO (Spain)<br>**Investigating the prevalence and mechanisms of antibiotic resistance in Enterobacteriaceae: insights into carbapenemase and colistin resistance genes**: Zahra SADEGHI (Islamic Republic Of)<br>**High level of clindamycin resistance in clinically relevant anaerobes and emergence of cfiA gene mediated carbapenem-resistance in Bacteroides spp., a phenotypic and molecular perspective from Croatia**: Anita NOVAK (Croatia)<br>**Complex evolution of KPC variants conferring ceftazidime-avibactam resistance from a single patient during ceftazidime-avibactam therapy**: Shen SIQUAN (China)<br>**Colistin and octenidineiInduced in-vitro selective pressure on Pseudomonas aeruginosa clinical isolates: antimicrobial activity and mechanisms of cross-resistance**: Laurent POIREL (Switzerland)<br>**Description and characterisation of blaIMP-106: a new blaIMP variant from Pseudomonas aeruginosa isolated in a bacteriemia from a paediatric haematological patient in Canary Islands**: Gabriel TALTAVULL PONS (Spain)<br>**Tigecycline resistance in Staphylococcus aureus resulting from the combined action of tetracycline resistance determinants tetM and tetL**: Mollie HURST (United Kingdom)<br>**Plasmid-mediated antimicrobial resistance in Enterobacter cloacae blood isolates: a bioinformatic approach**: Stefano Adri�n ENDARA REGALADO (Ecuador)<br>**Prevalence of vancomycin variable enterococci in the Netherlands and the mechanism of resistance induction**: Christian VON WINTERSDORFF (Netherlands)<br>**In vivo emergence of cefiderocol resistance in both Klebsiella pneumoniae and Acinetobacter baumannii during prolonged treatment in a single patient**: Valerio CAPITANI (Italy)<br>**Integrated genomic and transcriptomic analysis of multi-drug resistant colistin tolerant Pseudomonas aeruginosa to identify tolerance related genes**: Cansel VATANSEVER (T�rkiye)<br>**Role of S155, D159 and R214 amino-acid residues in the active site of OXA-48 variants**: Thierry NAAS (France)<br>**Engineered conjugative vectors as vehicles to study resistance and virulence in Klebsiella pneumoniae**: Riccardo POLANI (Italy)<br>**Staphylococcus aureus bacteraemia: detection and characterisation of blaZ**: Dhouha KARRAY (Tunisia)<br>**Pseudomonas aeruginosa mechanisms involved in decreased susceptibility to a quaternary ammonium compound**: Camille COTET (France)<br>**Mechanisms of antimicrobial peptide and antibiotic interactions on membrane permeabilisation and deactivation of Escherichia coli**: Terri CAMESANO (United States)<br>**Antimicrobial resistance and virulence in Pseudomonas aeruginosa strains from hospitalised COVID-19 patients in an international hospital**: Yolanda SAENZ (Spain)<br>**Understanding bacterial resistance mechanisms: insights from porin mutations in Klebsiella pneumoniae**: Matteo CECCARELLI (Italy)<br>**Emergence of polymyxin B-resistant Klebsiella pneumoniae in experiment tigecycline resistance evolution without exposure to polymyxin B**: Xiaojuan WANG (China)<br>**Temocillin efficacy and emergence of resistance in Enterobacter cloacae complex in a murine peritonitis model**: Nelly ALANBARI (France)<br>**Whole-genome sequencing characterisation of a new KPC variant-carrying Klebsiella pneumoniae strain isolated from a transplanted patient and resistant to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam**: Claudia VAIANA (Italy)<br>**Prevalence and genetic characterisation of carbapenem-resistance mechanisms and integrons in Pseudomonas aeruginosa isolates from poultry in Tunisia**: Sirine MEJRI (Tunisia)<br>**Heteroresistance to cefiderocol in clinical isolates of Stenotrophomonas maltophilia**: Cristina EL�AS L�PEZ (Spain)<br>**Genetic correlates of synergy mechanisms of daptomycin plus fosfomycin in daptomycin-susceptible and -resistant methicillin-resistant Staphylococcus aureus**: Warren ROSE (United States)<br>**Emergence and spread of ST5 methicillin-resistant Staphylococcus aureus with accessory gene regulator dysfunction: genomic insights and therapeutic challenges**: Shengnan JIANG (China)<br>**NagX, a periplasmic b-N-acetylglucosaminidase, contributes to NagZ-independent beta-lactamase expression in Stenotrophomonas maltophilia**: Tsuey-Ching YANG (China)<br>**Phage-plasmid borne methionine tRNA ligase mediates epidemiologically relevant antimicrobial persistence**: Kate BAKER (United Kingdom)<br>**Impact of pBMB9393 plasmid in biofilm formation and autolysis in MRSA ST239**: Raquel NUNES (Brazil)<br>**Resistance mechanisms in multidrug-resistant Klebsiella pneumoniae ST792 and ST7120 strains causing invasive disease in the paediatric intensive care unit**: Tu-Hsuan CHANG (China)<br>**Phenotypic and genomic characterisation of ST11-K1 CR-hvKP with highly homologous blaKPC-2-bearing plasmids in China**: Han YU-LING (China)<br>**Dated evolutionary analysis of ST-78 A. baumannii pinpoints acquisition of antimicrobial resistance genes prior to clonal expansion and global spread**: Ting LUO (United States)<br>**Characterisation of DHFR mutation conferring resistance to trimethoprim in Burkholderia thailandensis**: Sophie GUILLIER (France)<br>**First report of OXA-204-producing Pseudomonas guariconensis: expanding the horizon of carbapenemase dissemination**: Nadia JAIDANE (Tunisia)<br>**Emergence of resistance to beta-lactam/beta-lactamase inhibitor combinations through horizontally acquired carbapenem-hydrolysing class D beta-lactamase OXA-1054 in Pseudomonas aeruginosa sequence type 303**: Luc�a GONZ�LEZ PINTO (Spain)<br>**Ribosomal mutations mediated reduced omadacycline susceptibility in Acinetobacter baumannii**: Yue YAO (China)<br>**KHM-2, a novel metallo-carbapenemase identified in Pseudomonas mosselii**: Katie HOPKINS (United Kingdom)<br>**Resistance, transfer and evolution mechanism research of ceftazidime/avibactam-resistant Klebsiella pneumoniae causing nosocomial cloning spread**: Weiwei YANG (China)<br>**Dual AmpC and AmpD mutations in Pseudomonas aeruginosa: unraveling the mechanisms of resistance to ceftazidime and avibactam**: Albane ROZEHOLC (France)<br>**Molecular mechanism of eravacycline resistance in tigecycline-nonsusceptible Acinetobacter baumannii**: Zitong PAN (China)<br>**In vivo acquired-resistance to ceftazidime/avibactam, cefiderocol and meropenem/vaborbactam in KPC-producing Klebsiella pneumoniae**: Lydia GALVEZ BENITEZ (Spain)<br>**Ceftazidime/avibactam resistance characteristics emerged diversely in carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa from an intensive care unit**: Junxin ZHOU (China)<br>**Characterising cas gene variability and its impact on antibiotic resistance in carbapenem-resistant Acinetobacter baumannii**: Mullika CHOMNAWANG (Thailand)<br>**Investigation of carbapenem-resistant Klebsiella pneumoniae harboring double resistance mechanisms**: Olga KOUTSOPETRA (Greece)<br>**Experimental evolution of mutational pathways to aminoglycoside resistance in Escherichia coli**: Peechanika PINWEHA (United Kingdom)<br>**Decreased porin transcription promotes resistance to taniborbactam when combined with meropenem**: Zhuoren ZHUOREN (United Kingdom)<br>**LiaF is required for LiaX-mediated protection against cell membrane acting antibiotics like daptomycin and bacitracin but not vancomycin**: Diana PANESSO (United States)<br>**The GelE metalloprotease is a key modulator of the LiaFSR response against daptomycin and antimicrobial peptides through LiaX cleavage in Enterococcus faecalis**: Kavindra SINGH (United States)<br>**Molecular mechanisms and distribution of cefiderocol-non-susceptible NDM-producing Escherichia coli in China**: Chengkang TANG (China)<br>**Genetic and phenotypic characterization of a novel ST45-K43 Carbapenem-resistant Klebsiella pneumoniae strain causing bloodstream infection: a potential clinical threat**: Xiaobing CHU (China)<br>**A strain of Serratia marcescens exhibiting high-level tolerance to meropenem**: Xiaobing CHU (China)<br>**Scarless excision of an insertion sequence in the OmpK36 promoter restores meropenem susceptibility in a non-carbapenemase-producing Klebsiella pneumoniae**: Yingying DU (China)<br>**The role of Pseudomonas aeruginosa extracellular vesicles in antimicrobial resistance and virulence**: Laura LEAL-V�LEZ (Spain)<br>**Tigecycline drives the adaptive evolution of TetX-positive Klebsiella pneumoniae into hyper-resistant mutants of different mucoid types**: Nadira RAKHI (United Kingdom)<br>**Macrolide resistance determinants and their associations in streptococci from selected livestock and wildlife species**: Guillem L�PEZ DE EGEA VEGAS (Spain)<br>**Phenotypic and kinetic characterisation of in vivo selected KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam**: Cristina EL�AS L�PEZ (Spain)<br>**Sub-inhibitory concentration of imipenem exposure influences the transcriptional response of auto-inducer II quorum-sensing system in Escherichia coli harbouring blaNDM**: Chandrayee DESHAMUKHYA (India)<br>**First national survey of antibiotic susceptibility in E. coli isolated from urine cultures in Uruguay and the emergence of blaCTX-M-27 in human clinical isolates in South America**: Rafael VIGNOLI (Uruguay)<br>**A dominant antimicrobial resistance plasmid in multidrug-resistant Escherichia coli isolates of a tertiary care hospital**: Vera SCHWIERZECK (Germany)<br>**Emergence of blaCTX-M-65 producing non-typhoidal Salmonella isolates in Korea**: Jeong Hwan SHIN (Republic Of)<br>**Comparative molecular study of virulence factors and antibiotic resistance between exoU and exoS Pseudomonas aeruginosa from microbial keratitis**: Tanzina AKTER (Australia)<br>**First detection of plasmid-mediated PAC-2 beta-lactamase conferring resistance to ceftazidime/avibactam in Klebsiella quasipneumoniae ST526**: Sandra Y. SAAVEDRA (Colombia)<br>**Multiple dissemination mechanisms of blaNDM-1 in a single institution revealed by whole-genome sequencing**: Romina PAPA-EZDRA (Uruguay)<br>**Linezolid-resistance in the Finegoldia genus: a yet undescribed resistance emergent in bone infections**: Vincent JEAN-PIERRE (France)<br>**Jumping to conclusions: the role of tetM in Group B Streptococcus (GBS) evolution**: Rachael DELLAR (United Kingdom)<br>**Do CRISPR-Cas control the levels of plasmid-associated antimicrobial resistance genes in coagulase-negative staphylococci?**: Idris Nasir ABDULLAHI (Nigeria)<br>**Genomic characterisation of acquired colistin resistance determinants in Pseudomonas aeruginosa isolated from people with cystic fibrosis in Gauteng, South Africa**: Thabo HAMIWE (South Africa)<br>**Molecular basis of amoxicillin-clavulanate resistance in clinical isolates of Escherichia coli**: Sofia ASENSIO GALLEGO (Spain)<br>**Hypervirulance profiling of Klebsiella pneumoniae in abscess samples**: Selin BELGE (T�rkiye)<br>**Description of lysogenic phages present in carbapenem-resistant Pseudomonas aeruginosa isolates from Peru**: Luciano Augusto PALOMINO KOBAYASHI (Peru)<br>**Comparative in silico characterisation of plasmids carrying the high-level mupirocin resistance ileS2 gene**: Eduardo P�REZ ROTH (Spain)<br>**Influence of iron acquisition systems on the in vitro activity of cefiderocol on Escherichia coli**: Laurence ARMAND-LEFEVRE (France)<br>**Mercury exposure stimulates colistin resistance and virulence in Acinetobacter baumannii**: Ghazal SHAHROKHI (T�rkiye)<br>**Natural rare alleles in NucS increased mutation rates to clarithromycin and amikacin in Mycobacterium abscessus**: Bing LI (China)<br>**In238 mediated dissemination of blaVIM-4 gene into various species of Enterobacterales at a university hospital in Hungary**: R�ka MESZ�NA (Hungary)<br>**Longitudinal antimicrobial resistance development in uropathogenic Escherichia coli in kidney transplant recipients**: Kaan KOCER (Germany)<br>**In vivo efficacy of cefiderocol in a murine sepsis model against Pseudomonas aeruginosa: impact of resistance development to ceftolozane/tazobactam and ceftazidime/avibactam**: Arianna RODR�GUEZ COELLO (Spain)<br>**Molecular mechanism of Sed-1 beta-lactamase expression and high-level resistance in Citrobacter sedlakii**: Ryuichi NAKANO (Japan)<br>**Chromosomal integration of vanA operon conferring vancomycin resistance in Enterococcus faecium: a genomic investigation**: Tram VO (France)<br>**Emergence of novel genetic combination in blaIMP-6 encoding plasmids harboured by Enterobacterales: diverse genetic backgrounds**: Koichi YAMAGUCHI (Japan)<br>**Characterisation of major OXA-48-carrying plasmids within a tertiary healthcare institution**: Jocelyn TEO (Singapore)<br>**Investigation of OXA-48 variants in Enterobacterales isolates in an OXA-48 endemic area**: Sevval ARDUC (T�rkiye)<br>**The emerging concern of IMP variants being resistant to the only IMP-type metallo-beta-lactamase inhibitor, xeruborbactam**: Christophe LE TERRIER (Switzerland)<br>**Drugging the epigenome: G4s as a new therapeutical target in bacteria**: �ngela ALCARAZ MART�NEZ (Spain)<br>**Evolving characteristics of multidrug-resistant Gram-negative conflict-associated wound infections in Ukraine, 2024**: Scott PALLETT (United Kingdom)<br>**Production of multiple carbapenemases linked to heteroresistance in Enterobacterales**: Roberto SIERRA (Switzerland)<br>**IncHI2 plasmids drive dissemination of carbapenemase gene blaIMP among healthcare-associated Enterobacterales in the UK, 2014-2022**: Frank WILLIAMS (United Kingdom)<br>**Distribution of carbapenemase genes in A. baumannii isolates in a region with high carbapenem resistance**: Hanife TUTAN (T�rkiye)<br>**Molecular detection of gyr A and par C mutations in clinical isolates of Pseudomonas aeruginosa obtained from Farwaniya hospital in Kuwait**: Wadha ALFOUZAN (Kuwait)<br>**Are we overdosing with vancomcyin? Eagle effect of vancomycin against Clostridioides difficile observed in vitro**: Jane FREEMAN (United Kingdom)<br>**Correlating phenotypic and genotypic determinants of biocide tolerance and adaptation in Proteus mirabilis**: Vicky BENNETT (United Kingdom)<br>**A high-resolution genomic and phenotypic analysis of resistance evolution of an Escherichia coli strain from a critically unwell patient treated with piperacillin/tazobactam**: Alice FRASER (United Kingdom)<br>**Detection of OXA-48-like in carbapenem-resistant Klebsiella pneumonia: a challenge for diagnostic microbiological laboratories**: Arwa AL RUJAIBI (Oman)<br>**Clonal analysis of multidrug-resistant Pseudomonas aeruginosa: differences between carbapenemase-producing and non-carbapenemase-producing isolates**: Iv�n BLOISE (Spain)<br>**Carbapenem resistance mechanisms in Bacteroides spp.**: Maria AZNAR FERNANDEZ (Spain)<br>**Characterisation of plasmids harboured by drug-resistant Acinetobacter baumannii isolates and their role in antibiotic resistance**: Thabo HAMIWE (South Africa)<br>**In vivo development of high-level cefiderocol and ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae associated with mutations in KPC and the sensor histidine kinase, EnvZ**: Jacqueline FINDLAY (Switzerland)<br>**Activity of zidovudine against carbapenemase-producing Enterobacterales, including cefiderocol and aztreonam/avibactam resistant isolates, and characterisation of in vitro selected resistant isolates**: Roberta Maria ANTONELLO (Italy)<br>**Influence of ligand gated ion channel on cefiderocol susceptibility in clincal E. hormaechei isolates**: Pia TUROWSKI (Germany)<br>**Characterisation of the novel carbapenemase OXA-1207**: Julian SOMMER (Germany)<br>**Plasmid network analysis reveals key drivers of third generation cephalosporin resistance in urinary Escherichia coli isolates**: B�lint TIMMER (Hungary)<br>**First characterisation of newly discovered extended spectrum betalactamase SED-2**: Lisa-Marie H�FKEN (Germany)<br>**First report of CTX-M-15-producing Salmonella enterica ser. Typhimurium (S. Typhimurium) in South America**: In�s BADO (Uruguay)<br>**Improvement of hydrolytic activity against meropenem in NDM-1Q123Y variant: first identification in a P. aeruginosa clinical strain**: Alessandra PICCIRILLI (Italy)<br>**An elevated expression of mrcB is an indicative potential biomarker for AMR detection**: Nikita KARMAKAR (India)<br>**Exploring the whole-genome of XDR A. baumannii strains isolated from patients treated with cefiderocol**: Alessandra PICCIRILLI (Italy)<br>**Genomic islands as drivers of carbapenem resistance and virulence in Pseudomonas aeruginosa ST235**: Yolanda SAENZ (Spain)<br>**Comparative genomic analysis identifies specific genes associated with a high-risk diffusion Klebsiella pneumoniae ST405 intensive care unit clone**: Coraline BERNACHOT (France)<br>**Diversity and characterisation of intrinsic Ambler class B metallo-beta-lactamases in Sphingobacterium spp.**: Laurent DORTET (France)<br>**Development of Colistin Resistance is associated with loss Of Hypermucoviscocity phenotype In CR-HVKP**: Reham SOBHY (Egypt)<br>**Phenotypic and kinetic characterisation of PER-14: a novel beta-lactamase variant resistant to avibactam and relebactam**: Melina RUGGIERO (Argentina)<br>**The role of the AcrAB-TolC efflux pump in glyphosate tolerance and its antagonistic effect with ciprofloxacin in Escherichia coli**: Sophie Alexandra BARON (France)<br>**Identification of the RamR regulon of Enterobacter cloacae complex by omic approaches**: Blandine HAREL (France)<br>**Heteroresistance to polymyxin B in Acinetobacter baumannii**: Aimee DAUM (United Kingdom) |
| 14/04 | 12:00 - 13:30 | PS024 | 03e. Resistance detection/prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods) |  | **Optimising an accurate amplification-free CRISPR/Cas12a-based assay for GES beta-lactamases detection**: Daniel PABLO MARCOS (Spain)<br>**Molecular characterisation of carbapenemase-producing Serratia marcescens in Germany**: Lukas Markus SCHAFFARCZYK (Germany)<br>**Reinvigorating AMR resilience leveraging CRISPR-Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security : a systematic review**: Olalekan John OKESANYA (Nigeria)<br>**AMRrules: expert-curated interpretive standards for AMR genotypes**: Kathryn HOLT (United Kingdom)<br>**Detection of major high-risk clones of Pseudomonas aeruginosa using MALDI-TOF mass spectrometry and machine learning algorithms**: Xavier MULET (Spain)<br>**Whole-genome sequencing of carbapenemase-producing Klebsiella pneumoniae isolated from a medical laboratory in Yaounde: first report of a blaNDM-1 positive- high-risk clone  ST 147 in Cameroon**: Rom�o TSAYEM FOU�M�N� (Cameroon)<br>**New accurate point-of-care device for detection of Klebsiella pneumoniae carbapenemase**: Maria Leonor SANTOS (Portugal)<br>**Genomic traits associated with phenotypic antimicrobial resistance to trimethoprim-sulfamethoxazole in Staphylococcus epidermidis**: Ella SVEGRUP (Sweden)<br>**Evaluation of the NG-TEST blood culture PREP kit for ESBL detection directly from positive blood cultures using the NG-TEST CTX-M MULTI lateral flow immunoassay**: Arnaud CHALIN (France)<br>**Lethal pan-drug-resistant hypervirulent strains of Klebsiella pneumoniae with diverse genotypes**: Leila VALI (United Kingdom)<br>**Detection of carbapenemases in extensively-drug resistant Klebsiella pneumoniae**: Amal BERRIRI (Tunisia)<br>**Rapid detection of carbapenemase-producing Enterobacterales from positive blood cultures using the NG-TEST blood culture PREP and the NG-TEST CARBA 5 assays**: Arnaud CHALIN (France)<br>**Expediting carbapenemase-producing Enterobacterales detection in positive blood cultures**: Callebaut CALLEBAUT (Belgium)<br>**Evaluation of a rapid automatised system for MDR bacteria carriers detection on ICU patients**: Guillermo Carlos MART�NEZ CARRI�N (Spain)<br>**Molecular mechanisms of CAZ-AVI resistance in K. pneumoniae from a tertiary care hospital in Turkey**: Ozlem KOYUNCU OZYURT (T�rkiye)<br>**CefiderocolFinder: a pipeline to detect genetic adaptations implicated in cefiderocol resistance in multidrug-resistant microorganisms of Ukrainian patients in the Netherlands**: Bryan VAN DEN BRAND (Netherlands)<br>**Molecular characterisation of Klebsiella pneumoniae clinical isolates through whole-genome sequencing: a comprehensive analysis of serotypes, sequence types, and antimicrobial and virulence genes**: Tarun Kumar SUVVARI (India)<br>**Extended susceptibility testing for refractory Helicobacter pylori infection: an argument for regional testing to guide antimicrobial decision making**: Harin NAVALAN (United Kingdom)<br>**Iridium oxide-based biosensors towards the quantification of ESBL production**: Jennifer LAWRENCE (United Kingdom)<br>**Using random mutagenesis to predict mutations within the KPC-2 gene that confer resistance to beta-lactam/beta-lactamase inhibitor combinations**: Hawa AHMED (United Kingdom)<br>**Genomic characterisation of zoonotic multidrug-resistant Salmonella isolated from slaughtered chickens in northwest Nigeria**: Abdurrahman Hassan JIBRIL (Nigeria)<br>**Predicting carbapenem-resistant Klebsiella pneumoniae from flagged blood cultures with MALDI-TOF mass spectrometry and machine learning**: Jiaxin YU (China)<br>**Rapid and cost-effective detection of blaOXA-23-like carbapenemase genes in Acinetobacter baumannii using the LAMP technique**: Nanphanita CHOMNAWANG (Thailand)<br>**A DNA nanopore sensor for the rapid detection of antibiotic resistance**: Ivan BARISIC (Austria)<br>**Transcriptomic analysis of ceftriaxone tolerant- phenotypes of Neisseria gonorrhoeae reveals downregulation of ribosomal gene expression**: Sheeba Santhini BASIL (Belgium)<br>**Antibiotic resistance and genetic determinants in Helicobacter pylori: insights from Omani clinical isolates**: Zaaima AL-JABRI (Oman)<br>**Comparative analysis of rapid phenotypic tests for carbapenem-resistance in Aeromonas**: Bin SUN (China)<br>**Genomic characterisation of extended-spectrum beta-lactamase-producing and third-generation cephalosporin-resistant Escherichia coli isolates from Ethiopia**: Deneke WOLDE (Ethiopia)<br>**Comparative performance of two PCR-based platforms for the detection of Staphylococcus aureus small colony variants**: Camille HAMULA (Canada)<br>**Advancing monitoring and prediction of antimicrobial resistance trajectories using flexible spatiotemporal modelling: a roadmap for early warning systems**: Kasim ALLEL (United Kingdom)<br>**Integrative metagenomics and an ensemble learning model reveals novel microbial biomarkers and pathogenic elements in colorectal cancer patients**: Abdulaziz ASCANDARI (Morocco)<br>**Increasing prevalenc and molecular epidemiology of carbapenemase-producing carbapenem resistant Enterobacterales in Taiwan**: Hsi-Hsun LIN (China)<br>**Detection of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales in wildlife**: Babatunde BEYIOKU (Israel)<br>**Rapid detection of cfia-positive Bacteorides fragilis from blood culture using matrix-assisted laser desorption ionisation time of flight mass spectrometry in a tertiary hospital in Spain**: Isabel Cristina L�PEZ MESTANZA (Spain)<br>**Widespread diversity of fosfomycin resistance gene in Staphylococci: a silent threat**: Yiyi CHEN (China)<br>**whole-genome sequencing of linezolid-resistant Enterococcus faecium: unravelling resistance mechanisms and outbreaks**: Ema HOLUBOV� (Czech Republic)<br>**Pilot study on development of a fast clinical diagnostic test to detect synergy between two antibiotics using growth curve kinetics**: Sanne VAN DEN BERG (Netherlands)<br>**Genomic analysis of invasive Streptococcus pneumoniae isolates in the Canary Islands: role of penicillin-binding protein transpeptidase domains in predicting beta-lactam susceptibility**: Noelia HERNANDO PARRE�O (Spain)<br>**Genomic analysis of vancomycin-resistant Staphylococcus aureus**: Geehan SULEYMAN (United States)<br>**Rapid detection of temocillin resistance in third-generation cephalosporin resistant Enterobacteriaceae**: Lorena L�PEZ CERERO (Spain)<br>**Antibiotic resistance in metagenomes on global and population scales**: Mahkameh SALEHI (Finland)<br>**Rapid NP detection of cefepime/taniborbactam susceptibility/resistance in Enterobacterales**: Christophe LE TERRIER (Switzerland)<br>**Diagnostic algorithm for the detection of carbapenemases and extended spectrum beta-lactamases in carbapenem-resistant Pseudomonas aeruginosa**: Stefano MANCINI (Switzerland)<br>**Importance of rapid species identification vs rapid AST in processing positive blood cultures**: Kaisu Hellevi RANTAKOKKO-JALAVA (Finland)<br>**Whole-genome analysis of extensively drug-resistant Enterobacter hormaechei isolated from two US hospitalised patients**: Christen ARENA (United States)<br>**Genomic insights into CRISPR-Cas systems vsvirulence platforms and drug resistance among Escherichia coli isolates**: Sandra A. MART�NEZ-�LVAREZ (Spain)<br>**Evaluation of Bacteroides fragilis cfiA subtyping by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry and comparison of EUCAST and CLSI based susceptibility testing**: Tin Long LUI (China)<br>**Optimising long-read sequencing for AMR gene detection: a comparative study**: Tim T. SEVERS (Netherlands)<br>**Use of melting curve assays for the characterisation of macrolides and fluoroquinolones resistance in Mycoplasma genitalium**: Maria De Las Huertas GARCIA ATIENZA (Spain)<br>**Tracking the emergence of cephalosporinase cepA and carbapenemase cfiA Bacteroides hominis (former Bacteroides fragilis division II) strain**: Fernando COBO (Spain)<br>**Clinical performance evaluation of a vancomycin resistance real time PCR assay in the context of a vanB-carrying Enterococci outbreak in a tertiary hospital in Spain**: Henar ALONSO-EZCURRA (Spain)<br>**Rethinking AMR sampling: can non-sterile samples predict resistance in blood/sterile samples at a country level?**: Quentin J LECLERC (France)<br>**Klebsiella pneumoniae ST22: a novel menace?**: Vittoria MATTIONI MARCHETTI (Italy)<br>**Analysis of available Phytobacter spp. genomes indicates the emergence of a potential new multidrug-resistant opportunistic pathogen within the Enterobacterales**: Marcelo PILLONETTO (Brazil)<br>**A long-awaited tool for reliable detection of staphylococcal penicillinase using an innovative fluorogenic probe**: Frederic LAURENT (France)<br>**Suboptimal performance of three screening methods in rectal swab for the detection of carbapenemase-producing Gram-negative bacilli**: Diego JOSA (Colombia)<br>**Simple models can be used to assess impact of antibiotic consumption on resistance in critical priority bacteria and the role of interventions in its reduction**: Stefanus Petrus RAUTENBACH (United Kingdom)<br>**Evaluation of a diagnostic algorithm for rapid detection of extended-spectrum β-lactamase and carbapenemase directly from blood cultures**: Efthymia PROTONOTARIOU (Greece)<br>**Methyltransferases in candidate phyla radiation: a weapon or a simple shield?**: Riyad RAZZOUK (France)<br>**Investigation of a modified carbapenem inactivation method for rapid detection and characterisation of carbapenemase production in Klebsiella pneumoniae isolates from blood culture**: Yunus Emre TOK (T�rkiye)<br>**Novel chromosomal target of cefiderocol resistance in Acinetobacter baumannii: a genomic and functional analysis to identify and validate in vivo acquired chemoresistance**: Sara CARLONI (Italy)<br>**Are cycle threshold (Ct) values useful for predicting culture results of molecular positive carbapenemase producing Enterobacterales (CPE) screening samples?**: Mairead SKALLY (Ireland)<br>**Cefiderocol resistance in clinical isolates of KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: molecular insights**: Cristina RIAZZO (Spain)<br>**Development and comparative evaluation of antimicrobial resistance quality control materials through absolute quantification using ddPCR and dPCR systems**: Liang-Chun LIU (United States)<br>**Mutational analysis of hypermutable Pseudomonas aeruginosa from people with cystic fibrosis in South Africa**: Shristi MAHABIR (South Africa)<br>**Comparative genomic analysis of extended spectrum beta-lactamase (ESBL) producing Salmonella enteritidis showed ESBL dissemination pattern mediated by transposon Tn21**: Junbum LEE (Republic Of)<br>**Rectal resistome analysis of patients colonised and non-colonised by carbapenemases by PCR and hybridisation**: Diego JOSA (Colombia)<br>**Development of a clinical scoring system to predict carbapenem-resistant Enterobacterales in patients with pneumonia**: Bernardo Alfonso MARTINEZ-GUERRA (Mexico)<br>**Development of loop-mediated isothermal amplification (LAMP)-based assay for rapid detection of fosfomycin resistance gene**: Scaccia NAZARENO (Brazil)<br>**Shared resistome and mobilome in global human and poultry gut metagenomes**: Shivang BHANUSHALI (Finland)<br>**Clinical performance of the RIDA GENE MRSA real-time PCR assay in human nasal/throat swabs, wound swabs, and culture under IVDR**: Eva NAUMANN (Germany) |
| 14/04 | 12:00 - 13:30 | PS025 | 03f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs, excl case series) |  | **Early vs late combination daptomycin and ceftaroline therapy in patients with persistent MRSA (methicillin-resistant Staphylococcus aureus) bacteraemia**: Bibek KOIRALA (United States)<br>**Comparison of clinical characteristics and outcomes in non multidrug-resistant and multidrug-resistant Pseudomonas aeruginosa bacteraemia: preliminary results of a Spanish multicentre prospective cohort study (IRVIPA study)**: Elena SENDRA �LVAREZ DE CIENFUEGOS (Spain)<br>**Ceftolozane/tazobactam vs carbapenems for treatment of ESBL bloodstream infections**: Dimitrios BASOULIS (Greece)<br>**Clinical, microbiological and costs dynamics of Streptococcus pneumoniae infections related to COVID-19 pandemic: could macrolide resistance tell a story?**: Raluca-Mihaela MATORU (Romania)<br>**Comparison of novel β-lactam/β-lactamase inhibitors in a prospective single-institution study**: Amalia ANASTASOPOULOU (Greece)<br>**Preliminary analysis of a retrospective cohort of patients with invasive infections caused by difficult-to-treat-resistance Pseudomonas aeruginosa (DTR-PA)**: Antonella GALLICCHIO (Italy)<br>**Universal need for appropriate treatment: risk factors for mortality in patients with infections due to carbapenem-resistant Gram-negative bacteria**: Bernardo Alfonso MARTINEZ-GUERRA (Mexico)<br>**Effectiveness and safety of ceftazidime/avibactam in the paediatric population: an interim analysis of prospective observational study**: Lorenzo CHIUSAROLI (Italy)<br>**Determinants of the change of empiric antibiotic therapy upon reception of laboratory data: results from a nationwide antibiotic surveillance system in Madagascar, the TSARA project**: Christelle ELIAS (France)<br>**Comparative efficacy and renal safety of ceftazidime/avibactam vscolistin-based regimens in XDR Gram-negative infections: a propensity score matched cohort study**: Imran HASANOGLU (T�rkiye)<br>**Evaluating the efficacy of tobramycin and gentamicin spacers in managing prosthetic joint infections caused by Pseudomonas aeruginosa, implications of changing minimal inhibitory concentration breakpoints**: Pansachee DAMRONGLERD (Thailand)<br>**Real-life use of cefiderocol in the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections: comparison between cefiderocol regimens and monotherapy**: Sara COVINO (Italy)<br>**Mortality risk associated with healthcare-associated infections caused by multidrug-resistant Pseudomonas aeruginosa in southern China: a competing risk model analysis using a propensity-score-matching longitudinal cohort**: Jiancong WANG (Germany)<br>**Management and outcomes of haematological patients colonised by MBL-producing Enterobacterales: a single-centre retrospective analysis**: Flavia BADALUCCO CIOTTA (Italy)<br>**Analysis of 30-day mortality in patients with carbapenem-resistant Enterobacterales (CRE) bacteraemia: non-carbapenemase CRE and antimicrobial stewardship**: Yoon Soo PARK (Republic Of)<br>**The impact of carbapenem-resistant infections in intensive care units: focus on non-fermenting Gram-negative bacilli and survival analysis**: Juliette DESSEMON (France)<br>**High prevalence of multi-drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae isolates amongst mechanically ventilated acute respiratory distress syndrome patients as an independent predictor of mortality**: Thejesh SRINIVAS (India)<br>**Ceftaroline as a therapeutic option: an in vitro study on methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates from Alexandria, Egypt**: Mohammed A. EL-KHOLY (Egypt)<br>**Trends, management and outcome of infections caused by MBL-producing organisms in paediatric ICUs: a five-year experience at an Italian tertiary care hospital**: Sarah BARNI (Italy)<br>**Ceftolozane/tazobactam for the treatment of pulmonary exacerbations in adult cystic fibrosis patients: clinical experience from a tertiary care centre**: Tommaso MANCIULLI (Italy)<br>**Clinical characteristics of patients with hospital-acquired P. aeruginosa ST773 NDM-1 clonal spread**: Laura MORATA (Spain)<br>**Impact of antimicrobial resistance on mortality in Spanish hospitals (2022–2024)**: Lina Marcela PARRA (Spain)<br>**Comparison of the clinical outcomes of patients with carbapenem-resistant and susceptible Enterobacterales in Japan**: Sho SAITO (Japan)<br>**Impact of macrolide resistance on clinical outcomes in Mycoplasma pneumoniae infections: a retrospective observational review**: Yen Tsen SAW (United Kingdom)<br>**Extensively drug-resistant Acinetobacter baumannii complex (XDR-AB) colonisation and clinical outcomes in neonates: a retrospective case-control study**: Gugulethu PHAMBANE (South Africa)<br>**Adherence to EUCAST-2024 guidelines in the management of urinary tract infections caused by inducible AmpC beta-lactamase-producing Enterobacterales in a tertiary hospital**: Luis FUERTES (Spain)<br>**Has survival from difficult-to-treat antibiotic resistant (DTR) Gram-negative infections improved in the era of next-generation antibiotics? Retrospective cohort study, 262 US hospitals, 2016-2023**: Morgan WALKER (United States)<br>**Exploring antibiotic options for different carbapenemase-producing CRE strains**: Bin SUN (China)<br>**Comparison of ceftazidime/avibactam with best available therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections: a multi-centre retrospective matched-cohort study**: Abdullah Tarik ASLAN (Australia)<br>**Socio-economic status is linked to disparities in 30-day mortality among patients with antibiotic non-susceptible Enterobacterales**: Heather HENDERSON (United States)<br>**Evolution of carbapenemase-producing Enterobacteriaceae during 2023 and 2024 in urine cultures at a tertiary hospital**: Luis GAGO MANTILLA (Spain)<br>**Monomicrobial infections by carbapenemase-resistant A. baumannii, difficult-to-treat resistant Pseudomonas aeruginosa and metallo-beta-lactamase-producing Enterobacterales: preliminary data from an emulation trial**: Flavio SANGIORGI (Italy)<br>**Increasing antimicrobial resistance in chronic endometritis: a 2020-2024 cross-sectional study**: Luisa FRALLONARDO (Italy)<br>**The burden of antimicrobial resistant bacteraemia in Ontario: a population-wide cohort study of attributable mortality from 110 pathogen-antibiotic combinations**: Kevin BROWN (Canada)<br>**Reassess the breakpoint of polymyxin B: comparing polymyxin B and ceftazidime/avibactam in CRE infection**: Dayu CHEN (China)<br>**Molecular and clinical characteristics of community-acquired, community-onset healthcare-associated, and hospital-acquired extended-spectrum beta-lactamases-producing Escherichia coli bacteraemia**: Wei Ting LIN (China)<br>**Risk factors for mortality in patients treated with ceftazidime/avibactam for carbapenem-resistant Klebsiella pneumoniae bacteraemia**: Yi-Tsung LIN (China)<br>**Treatment failure rates do not differ according to temocillin MIC in the treatment of Enterobacterales blood stream infection: an observational study**: Mohamed TOORANI (United Kingdom)<br>**Clinical outcomes of Stenotrophomonas maltophilia bloodstream infection: role of comorbidities and antimicrobial susceptibility profile**: Sergio ALVAREZ MULETT (United States)<br>**Cefepime vs carbapenems for AmpC-producing Enterobacterales in bacteraemia from deep-seated sources: phenotypic and genotypic focus**: Nicole SLAIN (United States)<br>**Effectiveness of ceftazidime/avibatam in carbapenem-resistant Enterobacterales bacteraemia**: Yongseop LEE (Republic Of)<br>**A two-year prospective study on hospital-acquired bacteraemias caused by multidrug-resistant organisms in a high-prevalence country**: Sotiria GRIGOROPOULOU (Greece)<br>**Impact of extended-spectrum beta-lactamase (ESBL) production on mortality in patients with bloodstream infection due to Escherichia coli: analysis of the PROBAC cohort**: Paula OLIVARES NAVARRO (Spain)<br>**Clinical profile and outcomes of patients infected with carbapenemase-producing carbapenem-resistant Enterobacterales: a cross sectional study from two hospitals in Ethiopia**: Kibrewossen AKILILU (Ethiopia)<br>**Piperacillin/tazobactam vs cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis**: Ilaria DE LUCA (Italy)<br>**Comparative evaluation of definitive therapy for deep-seated Stenotrophomonas maltophilia infections**: Hunter CURRY (United States)<br>**Epidemiology and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae infections in cancer patients: a prospective cohort study**: Akshay Arjun SHELKE (India)<br>**Effect of Escherichia coli and Staphylococcus aureus antimicrobial resistance on bloodstream infection outcomes in low- and middle-income countries: results from the ACORN2 study**: Jill HOPKINS (Thailand)<br>**Comparative analysis of 30-day and one-year mortality in carbapenem-resistant vs non-carbapenem resistant Enterobacterales bacteraemia**: Mabel Zhi Qi FOO (Singapore) |
| 14/04 | 12:00 - 13:30 | PS026 | 03g. Spread of resistance (incl carriage, reservoirs, ecology, One Health models, excl nosocomial transmission) |  | **Diversity of SCCmec elements in bovine methicillin-resistant Staphylococcus haemolyticus: uncovering shared and novel multidrug-resistance cassettes**: Chahrazed BELHOUT (Switzerland)<br>**MDRO Colonisation in HIV patients: effects of probiotic and synbiotic treatments**: Maria PIQUET FERRET (Spain)<br>**Faecal colonisation with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in rural Burkina Faso**: Daniel VALIA (Burkina Faso)<br>**Wildlife or human health in danger? Wild boar (Sus scrofa) as environmental sentinels of antimicrobial resistance (AMR) and food safety risks**: Vanesa GARC�A MEN�NDEZ (Spain)<br>**High prevalence of mecC-carrying S. aureus isolates in nasal microbiota of European-wild-rabbits in the Iberian-Peninsula**: Carmen GONZ�LEZ-AZCONA (Spain)<br>**Wastewater based epidemiology (WBE) as a tool for tracking pathogens and antimicrobial resistance within care homes**: Deirdre GILPIN (United Kingdom)<br>**Prevalence of extended spectrum beta-lactamase (ESBL)-producing Enterobacterales among wildlife in Israel**: Babatunde BEYIOKU (Israel)<br>**The global emergence of tmexCD-toprJ and blakpc/ndm co-carrying superbugs**: Kaiwen SONG (China)<br>**Monitoring pathogens and AMR in wastewater using nanopore sequencing**: Peter DELPUTTE (Belgium)<br>**Carbapenem resistance in ESPAKEE pathogens isolated from filth-flies collected from hospital wards**: Teresa IANNETELLI (United Kingdom)<br>**Emergence and spread of ceftriaxone resistant Salmonella Kentucky in India: One Health approach**: Praveen THILAGAN (India)<br>**Diffusion of OXA-48-producing Enterobacterales strains in Normandy: a five years prospective study**: Camille COTET (France)<br>**Critical antibiotic resistance detected in pig and rabbit farms threatens public health: high-risk clones on the rise**: Adriana SILVA (Portugal)<br>**Novel strains of Escherichia coli among paediatric population of rural communities in India: genomic insights**: Geetha NAGARAJ (India)<br>**Quantifying the bystander effect of antimicrobials on microbiome composition and resistome to optimise antimicrobial stewardship**: Joseph LEWIS (United Kingdom)<br>**Critically important antimicrobials consumption and resistance in the One Health context in Pakistan**: Mashkoor MOHIN (Pakistan)<br>**Intra and interhost evolution analysis revealed the circulation of two closely related plasmids carrying blaNDM-1 gene**: Valentine BERTI (France)<br>**Negative correlation between bloodstream iron acquisition virulence factors and non-classical terminal class 1 integrons in ESBL-producing Escherichia coli suggests potential fitness trade-offs between virulence and resistance**: Yang ZHONG (Singapore)<br>**Investigating ESBL-producing E. coli circulating among domestic dogs and wild hooded crows in Hungary's largest cities using whole-genome sequencing**: Isma BENMAZOUZ (Hungary)<br>**One Health approach to antimicrobial resistance: insights from a Portuguese open air laboratory**: Pedro TEIXEIRA (Portugal)<br>**Carbapenemase-producing Kluyvera: epidemiology of an evolving species**: Gabrielle LEVI (Israel)<br>**Core genome analysis of 1302 IncI1 plasmids from a multi-species international collection reveals geographic- and/or species-specific plasmid evolution**: Javier Eduardo FERNANDEZ (Switzerland)<br>**Carriage of antibiotic-resistant Escherichia coli in Swedish children: a nationwide study**: Ellinor BERGGREN (Sweden)<br>**Focus on the neglected class A carbapenemases (IMI, NmcA and FRI) using a One Health approach**: Chlo� DUPONT (France)<br>**Wastewater environment as reservoir of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae: a molecular characterisation study**: Mario Sergio PINO HURTADO (Spain)<br>**Development and deployment of robotic antimicrobial susceptibility platform (RASP) for high resolution One Health AMR surveillance**: Sam ABRAHAM (Australia)<br>**Drivers of community-level transmission dynamics of antimicrobial resistance in rural Burkina Faso**: Raneem AIZOUK (United Kingdom)<br>**Characterisation of antibiotic-resistant Klebsiella spp. isolated from wastewater and drinking water treatment plants in the metropolitan area of Barcelona, Spain**: Victoria Del Pilar BALL�N TORRES (Spain)<br>**The emerging resistance index: ranking resistance to newly-approved antibiotics in the 2024 WHO critical- and high-priority bacterial pathogens**: Jacopo GARLASCO (Italy)<br>**Resistome and phylogenomic of Escherichia coli strains obtained from diverse sources in Jimma, Ethiopia**: Mulatu GASHAW (Ethiopia)<br>**LuxS/AI-2 system facilitate the dissemination of antibiotic-resistant plasmids in Klebsiella pneumoniae**: Fang You YU (China)<br>**Identification of antibiotic resistance genes in bacterial pathogens from street food sold at urban parks in Quito, Ecuador**: Jaime David ACOSTA ESPA�A (Ecuador)<br>**Prevalence and antimicrobial resistance of Salmonella strains isolated from chicken samples in southern Italy**: Fiorenza PETRUZZI (Italy)<br>**Multi-layered ecological interactions determine growth of clinical antibiotic-resistant strains within human microbiomes**: Ricardo LEON-SAMPEDRO (Switzerland)<br>**Phenotypic and genomic characterization of cephalosporinase-producing Proteus mirabilis isolates from gulls in southern France**: Nicolas MARTEL (France)<br>**Global landscape of community carriage of antimicrobial resistant bacterial pathogens: a systematic review and meta-analysis**: Chaokun HONG (United Kingdom)<br>**Antimicrobial resistance through a One Health perspective: insights from a survey on the commensal microbiota of heavy breeder hens from Bolivian farms**: Maria MICIELI (Italy)<br>**Where global warming stands on plasmids-encoded resistance transfer?**: Otavio RARO (Switzerland)<br>**Microbial biodiversity as a barrier to the spread of antimicrobial resistance in soil**: Sonia GALAZKA (Austria)<br>**Molecular epidemiology of NDM-producing Escherichia coli isolates in Croatia**: Josip UJEVIC (Croatia)<br>**Prevalence, antibiotic resistance, and molecular characterisation of methicillin-resistant Staphylococcus aureus: a study from peri-urban dairy farms in Pakistan????**: Aitezaz AHSAN (Pakistan)<br>**Antibiotic resistance of Escherichia coli isolated from European hedgehogs (Erinaceus europaeus) in a wildlife rehabilitation centre**: Ilaria PRANDI (Italy)<br>**Phylogroups, resistance, and risk: a study of STEC in Brazilian dairy sheep**: Nat�lia CARRILLO GAETA (Brazil)<br>**Staphylococcus aureus carriage in hedgehogs (Erinaceus europaeus) admitted to a wildlife rescue centre in north-western Italy**: Alessandro BELLATO (Italy)<br>**Nation-wide spread of an outbreak-associated IncFIB-multidrug-resistance plasmid, the Netherlands, 2016-2022**: Gijs TEUNIS (Netherlands)<br>**Large-scale genomic survey of non-typhoidal Salmonella enterica Serovar Minnesota strains in chicken products reveals the emergence of multidrug-resistant clones**: Khaloud ALZAHRANI (Saudi Arabia)<br>**Identification of IncF plasmids conferring both glyphosate and paraquat tolerance in Klebsiella spp. clinical strains isolated from farmers in Thailand: a new One Health threat?**: Sophie Alexandra BARON (France)<br>**Prevalence of resistance to critically important antibiotics for human health in different intensive livestock production systems in Uruguay**: Rafael VIGNOLI (Uruguay)<br>**Pre-treatment microbiome predicts ESBL-producing Enterobacteriaceae colonisation in ceftriaxone-exposed patients**: Quentin LE BASTARD (France)<br>**Detection of cefotaxime resistance Escherichia coli isolates collected from livestock waste**: Amir IBRAHIMAGIC (Bosnia And Herzegovina)<br>**Prevalence and role of contact-dependent growth inhibition (CDI) system, cdiTYTH-1, in carbapenem-resistant Acinetobacter baumannii**: Chen CHYI-LIANG (China)<br>**Epidemiology and genomic features of blaNDM-carrying carbapenem-resistant Salmonella enterica**: Hui LIU (China)<br>**Identification of cefiderocol resistance genes in environmental samples**: R�mi GSCHWIND (France)<br>**Surveillance of wastewater in San Paulo, Brazil, identifies geographic and socio-economic factors linked to antimicrobial resistance and virulence in Escherichia coli strains**: Yanfang ZHANG (United Kingdom)<br>**Molecular and genetic characteristics of drug resistant Enterobacterales isolated from hospital sewage in Japan**: Yuki SUZUKI (Japan)<br>**Carbapenemase producing Enterobacterales monitoring in dogs and cats in the Netherlands**: Els BROENS (Netherlands)<br>**Spread of multiple E. coli clones from pigs carrying blaCTX-M-32 on the chromosome in Cuba**: Rosa Elena HERN�NDEZ (Cuba)<br>**EARS-Vet: a network for surveillance of antimicrobial resistance in clinical isolates from animals in the EU/EEA**: Lucie COLLINEAU (France)<br>**Travelling increases the diversity of extended-spectrum beta-lactamases carrying Enterobacterales and plasmids in the Czech Republic**: Suhanya Veronica PRASAD (Czech Republic)<br>**Sources of methicillin-resistant Staphylococcus aureus isolates in Swedish dogs**: Ulrika WINDAHL (Sweden)<br>**Detection of blaKPC-2-carrying IncP-6 plasmids in Aeromonas isolates from different wastewaters settings in Spain**: Laura MONGE-OLIVARES (Spain)<br>**Relationship between the molecular diversity of plasmids and antibiotic resistance of Staphylococcus aureus isolates from private hospitals in Gauteng, South Africa**: Thabo HAMIWE (South Africa)<br>**Identifying antibiotic resistance genes against novel beta-lactamase inhibitor-antibiotic combinations in environmental and clinical resistomes**: Erika NAGRAND (Hungary)<br>**Nasal carriage and multiple antibiotic resistance indices of Staphylococcus aureus among healthcare students at the Ahmadu Bello university, Nigeria**: Idris Nasir ABDULLAHI (Nigeria)<br>**Guts of healthy humans and animals habor critical priority and pandemic Escherichia coli clones**: Idris Nasir ABDULLAHI (Nigeria)<br>**One Health circulation of carbapenemase-producing Enterobacterales in Lome, Togo**: Signara GUEYE (France)<br>**Unveiling the sex-specific impact on antimicrobial resistance (AMR): a Bayesian hierarchical model approach using vivli data**: Simon PROCTER (United Kingdom)<br>**Mechanistic exploration of the factors contributing to differing patterns of antibiotic resistance in Staphylococcus aureus bloodstream infection by demography in the UK**: Gwen KNIGHT (United Kingdom)<br>**Predicting the future burden of antimicrobial resistance depends on population demographics, and the age and sex-specific rates of incidence and resistance**: Gwen KNIGHT (United Kingdom)<br>**Carbapenemase-positive Enterobacterales from residual waters: prevalence of high-risk clones producing KPC-2**: Jo�o Pedro RUEDA FURLAN (Brazil)<br>**Imported herbs represent a source of clinically-relevant lineages of Klebsiella spp. in the food chain**: Isidro GARC�A-MENI�O (Germany)<br>**Critical emergence and spread of multidrug-resistant CTX-M-15-producing Enterobacteriaceae in a veterinary teaching hospital settings: implications for infection control and One Health**: Nat�lia CARRILLO GAETA (Brazil)<br>**Isolation of hospital-associated vancomycin resistant Enterococcus faecium clones from German rivers**: Paul G. HIGGINS (Germany)<br>**WGS analysis of ESBL-producing Enterobacterales and aeromonas from Singapore surface water reveals aquatic drug-resistant isolates as hidden reservoirs of mobile resistance elements**: Yang ZHONG (Singapore)<br>**High-risk clones and plasmids associated with extended spectrum beta-lactamase producing Klebsiella pneumoniae isolates from environmental water, broiler poultry and humans in South Africa**: Theevasha GOVENDER (South Africa)<br>**First identification of carbapenemase genes in Delftia tsuruhatensis isolated from hospital sewage in Japan**: Hiroyuki FUJIKURA (Japan)<br>**Evaluation of humans, dogs, and household dust as reservoirs of methicillin-resistant Staphylococcus spp. in the community and analysis of an intervention to reduce air-bound dissemination**: Ilana CAMARGO (Brazil)<br>**Emergence of IMP-producing Pseudomonas aeruginosa ST1047 with pandemic potential from Ukraine**: Brendan JONES (United States)<br>**Evaluating the effect of feeding calves waste milk on the distribution of bacterial taxa and resistance genes distribution in faecal samples in dairy farms in New Zealand**: Natalia GONZALEZ (New Zealand)<br>**Acceptable' concentrations of enrofloxacin in food lead to reduced enrofloxacin susceptibility in a mouse model of gastrointestinal Klebsiella pneumoniae**: Chris KENYON (Belgium)<br>**Prevalence and genetic characteristics of drug-resistant Escherichia coli isolated from wild deer inhabiting tourist spots in Japan**: Akiyo NAKANO (Japan)<br>**Comparing aminoglycoside and β-lactam resistance gene prevalence in neonatal gut microbiome according to mode of delivery**: Rida TOUFIQ (United Kingdom)<br>**Circulation of emerging MCR-1-producing Salmonella infantis from retail food in Egypt**: Hazem RAMADAN (Egypt)<br>**Third-generation cephalosporins-resistant Enterobacterales in community-dwelling individuals, their pet dogs, and household dust**: Ilana CAMARGO (Brazil)<br>**High-frequency detection of vancomycin- and linezolid-resistant Enterococci in poultry caecum samples from slaughterhouses in Tunisia**: Islem TRABELSI (Tunisia)<br>**Clinical threat of blaNDM-positive Providencia spp. harboured by flies collected in hospitals across Nigeria**: Shonnette PREMCHAND-BRANKER (United Kingdom)<br>**Occurrence of carbapenemase resistance genes and proteins in Klebsiella pneumoniae extracellular membrane vesicles**: Marina MURILLO TORRES (Spain)<br>**Population dynamics of multidrug-resistant Klebsiella pneumoniae infections in Portuguese companion animals**: Vanessa SILVA (Portugal)<br>**Prevalence and characterisation of extended-spectrum beta-lactamase-producing Escherichia coli from hospital patients and poultry farmers in Ibadan, Oyo state**: Ini ADEBIYI (Nigeria)<br>**Multidrug-resistant Salmonella in slaughtered food animals: a growing public health concern in Pakistan**: Aitezaz AHSAN (Pakistan)<br>**Clonal spread of topical treatment-resistant Staphylococcus aureus causing childhood impetigo in Navarra**: I�aki BEGUIRISTAIN CALVO (Spain)<br>**Escherichia coli carrying extended spectrum of beta-lactamase in pets and pregnant women in San Paulo, Brazil: an One Health view, preliminary data**: Guillermo Mois�s PORRAS COTRINA (Brazil)<br>**A first step towards One Health: genomic comparison of Klebsiella pneumonia from different ecological niches in Vietnam**: Trang NGUYEN (Vietnam)<br>**Antibiotic resistance profiles and genetic characterisation of Gram-negative bacteria isolated from lake Nokou� and surrounding environments in Benin**: Victorien DOUGNON (Benin)<br>**ESBL-/AmpC- and carbapenemase-producing Escherichia coli detection in urine samples of companion animals in Italy**: Gabriele RATTI (Italy)<br>**The ARISE project: evaluating wastewater-based antimicrobial resistance surveillance strategies in alignment with EU regulatory changes**: Theresa HOHL (Austria)<br>**Wildlife and aquatic reservoirs of mecC-MRSA: a study on prevalence, genetic diversity, and resistance**: Vanessa SILVA (Portugal)<br>**Presence of carbapenem-resistant Enterobacteriaceae and antibiotics residues in urban surface water**: Silvia Figueiredo COSTA (Brazil)<br>**Genomic analysis of tetX(4) carrying colistin-resistant E. coli from pigs in Thailand**: Nwai Oo KHINE (China) |
| 14/04 | 12:00 - 13:30 | PS027 | 03h. Policy aspects of AMR (incl societal impact, economics, mitigation) |  | **A cross-sectional study on the prevalence and patterns of over-the-counter purchase of antibiotics in Liberia; an urgent call for rational use**: Bode Ireti SHOBAYO (Sweden)<br>**Antibiotic dispensing in community pharmacies: a critical area for multifaceted antimicrobial stewardship on the supply and demand sides**: Abdullah Al MASUD (Australia)<br>**Vaccines and AMR: an analysis of the funding landscape for human bacterial vaccines in low-and middle-income countries**: Catherine FLECK-VIDAL (Sweden)<br>**Economic burden of antibiotic resistance on the human health sector: a cost of illness study in tertiary hospitals in Uganda**: Elly NUWAMANYA (Uganda)<br>**Current framing of antimicrobial resistance to the public, subject experts, and policy makers: a scoping review of national action plans and key policy documents**: Samkele MKUMBUZI (South Africa)<br>**It is not the lack of access but the lack of money that affects patients' ability to treat uncomplicated UTIs in the community in Uganda**: Miriam NANTAMU (United Kingdom)<br>**Understanding the contextual factors in the management of antimicrobial resistance in Uganda**: Deborah EKUSAI SEBATTA (Uganda)<br>**Operationalising One Health to combat antimicrobial resistance in Brazil: challenges, governance, and pathways to integration**: Juliana CORR�A (Brazil)<br>**Understanding power dynamics and financial interest among stakeholders: antibiotic transaction in commercial poultry farming in Bangladesh**: S M Murshid HASAN (Bangladesh)<br>**Strengthening antimicrobial stewardship: the role of national surveillance and reporting in reducing antimicrobial resistance**: Diego ORTIZ (Germany)<br>**Women with higher household bargaining power have greater knowledge of antibiotics and antimicrobial resistance: evidence from rural Vietnam**: Deepshikha BATHEJA (India)<br>**Length of hospital stay and associated treatment costs for patients with susceptible and antibiotic-resistant Salmonella infections: systematic review and meta-analysis**: Chaelin KIM (United Kingdom)<br>**Fair share of AWaRe using benchmarking to derive "expected" levels of access/watch/reserve antibiotic use for 177 countries based on population health needs**: Aislinn COOK (United Kingdom)<br>**Prevalence of antibiotic self-medication and knowledge of antimicrobial resistance among community members in Neno district rural Malawi: a cross-sectional study**: George Dalitso LIMWADO (Malawi)<br>**Insights from STAR 2 on understanding changing attitudes and perceptions towards antibiotic use for respiratory tract infections in Europe**: Adrian SHEPHARD (United Kingdom)<br>**AMROrbit Scorecard: a dynamic phase space model for strategic monitoring and actionable insights on global AMR trajectories**: Jasmine KAUR (India)<br>**Health economic impact of antimicrobial resistance in bloodstream infections in low- and middle-income countries: results from the ACORN2 study**: Jill HOPKINS (Thailand)<br>**Bacterial culture practices and views on antimicrobial resistance among hospital physicians in Africa and Asia: ACORN2 KAP survey**: Jill HOPKINS (Thailand)<br>**Social determinants of antibiotic use in Vietnam: a mediation analysis**: Ha LE THANH (Vietnam)<br>**Strengthening antimicrobial resistance surveillance through external quality assessment**: Menuk JAYAWARDENA (Australia)<br>**Expansion of antimicrobial stewardship and infection control programme of ICMR in secondary care hospitals**: Arya KUMAR (India)<br>**Impact of disparities in access to antibiotics on inferring burdens of difficult-to-treat antibiotic resistance: a real-world data analysis and simulation study**: Sarah WARNER (United States)<br>**Global pricing of key AWaRe (access, watch, reserve) antibiotics: ensuring affordability and equity in optimising antimicrobial use**: Kasim ALLEL (United Kingdom)<br>**From people to leaders: bridging communities and policy for global AMR mitigation**: Anna Karin SJOBLOM (Sweden)<br>**Wider health system strengthening would be required to optimise the impact of new AWaRe antibiotics in low- and middle-income countries across sub-Saharan Africa**: Emily GAURUHN (Netherlands) |
| 14/04 | 12:00 - 13:30 | PS028 | 04a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods) |  | **Evaluation of shorter incubation time for automated blood culture systems in critically ill patients**: Ayan MANDAL (India)<br>**Reaffirming the role of the reverse algorithm diagnostic strategy in syphilis screening through the performance of a treponemal point-of-care test**: Maitrayee NARAYAN (India)<br>**Synergy of electric field-mediated sample preparation and light-scattering based pathogen growth detection for accelerated time to positivity**: Sandra REISCHL (Austria)<br>**Contamination of CSF culture: serious risk to patient safety**: Rahul GARG (India)<br>**Evaluating semi-automatic homogenisation of tissue samples for improved diagnostics of tissue infections**: Callebaut CALLEBAUT (Belgium)<br>**Evaluation of an immunofluorescence point-of-care device for to detect cell wall polysaccharides of Streptococcus pneumoniae in urine samples**: Manuel Antonio RODRIGUEZ IGLESIAS (Spain)<br>**"Beat it!": tissue homogenisation by vibratory mill provides high bacteriological culture yield in routine tissue samples**: Farah FIECHTER (Switzerland)<br>**Where do we stand with the Gram stain? Evaluation of the reproducibility of Gram stain preparation and reading of bronchoalveolar lavage and endotracheal aspirate specimens**: Melanie YARBROUGH (United States)<br>**Comparative performance evaluation of routine swab systems in microbiology and molecular diagnostics**: Peter Michael KELLER (Switzerland)<br>**Validation of a new microbiological control protocol for corneal grafts stored in tissue-C**: Martin FAYOLLE (France)<br>**Evaluation of the impact of a rapid test for Group A streptococcal antigen in a community pharmacy**: Mariana CARVALHO (Portugal)<br>**Towards improved diagnostics: a tunable sputum model for streamline sample preparation and diagnosis**: Zahra AZIZI (Austria)<br>**Sputum collection in children 6 -14 years: sequence randomised crossover trial of a low-cost positive expiratory pressure device for tuberculosis testing**: Ellen MITCHELL (Belgium)<br>**I-dOne: a diagnostic tool in the field of identification of clinically relevant microbial strains**: Giulio CAMARLINGHI (Italy)<br>**Early diagnosis of urinary tract infection requires direct testing of bacterial counts in urine**: Bastian DIRK (Germany)<br>**Investigating chlamydia specific antibody titres and avidity in trachoma infection and disease progression**: Hannah JEAL (United Kingdom)<br>**Performance of a rapid test for Group A Streptococcus in paediatric pleural empyema**: Helene FAURY (France)<br>**Evaluation of the suitability of MDR enterobacteria chromogenic media for Fourier-transform infrared spectroscopy**: Miriam CORDOVANA (Germany)<br>**A single centre prospective comparative study: roll-plate vs sonication technique of microbiological diagnosis of tunneled long-term catheters**: Christian Johann LERCHE (Denmark)<br>**Impact of delayed incubation on blood culture diagnostics**: Andreas JACOBS �STERHEGN JENSEN (Denmark)<br>**Evaluation of a sponge-based transport device for urine culture in a nephrology outpatient clinic**: Lamiss MEJDOUBI (Austria)<br>**Diagnostic pitfalls of auramine O smear microscopy: a retrospective study of adult nontuberculous mycobacteria infections misdiagnosed with and treated for tuberculosis**: Leong Tung ONG (Malaysia)<br>**Reducing the blood culture contamination rate in the emergency department: a good start**: Ellen BROWNE (Ireland)<br>**Early detection of Aerococcus species from automated incubation of chromogenic media**: Delphine JACOB (France)<br>**Capability of automated individual blood volume measurement system for monitoring paediatric blood culture volumes**: Joshua HERR (United States)<br>**Not all positive blood cultures are significant, so why process them as such?**: Colin HUDSON (United Kingdom)<br>**Improved time-to-detection with the new formulation of commercially available aerobic blood culture vials: a real-world evidence study**: Kayla VAN BENTEN (United States)<br>**The ongoing relevance of conventional culture method in the recovery of Salmonella spp. from faecal samples tested with real-time PCR**: A.M.B. Nilmini WIJESOORIYA (United Kingdom)<br>**Comparison of multiple blood cultures and unique blood cultures in testing performance for suspected bloodstream infections**: Hui YANG (China)<br>**Evaluation of performance of antimicrobial-neutralising effect of novel resin blood culture vials**: Eun Jeong WON (Republic Of)<br>**Comparison of commercially available liquid amies collection and transport systems for the viability preservation of aerobes, anaerobes and fastidious bacteria**: Francesco BONOMETTI (Italy)<br>**A service evaluation of peritoneal dialysis fluid culture methods: universal and blood culture bottles**: Jessica LEWIS (United Kingdom)<br>**Retrospective study of an urinary antigen detection test performance for the diagnosis of Legionella pneumophila pneumonia in a Spanish tertiary hospital**: Garc�a Garc�a SAMUEL (Spain)<br>**Discrimination of foodborne bacteria using an electronic nose based on MOS sensors**: Silvia Figueiredo COSTA (Brazil)<br>**A new formulation of CHROM-ID OXA48 chromogenic media: a before/after impact study for carbapenemase-producing Enterobacterales detection**: Olivier DAUWALDER (France)<br>**Comparison of the performance of a new chemiluminescent immunoassay for Helicobacter pylori faecal antigen detection**: Marco Antonio SEMPERE ALCOCER (Spain)<br>**No culture left behind and no sepsis left unchecked: use the latest technologies at their full potentials**: Xuan QIN (United States)<br>**A novel ultrasensitive single-molecule counting C. difficile toxin A/B assay for reduced testing complexity and more accurate diagnosis of disease**: Johanna SANDLUND (United States) |
| 14/04 | 12:00 - 13:30 | PS029 | 04b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects) |  | **Does lab automation reduce incubation time in diagnosis of orthopaedic infections? Laboratory automation combined with NGS for the diagnosis of infections: first results from a reference centre**: Sara Giordana RIMOLDI (Italy)<br>**Barriers to quality management system implementation and accreditation in Teso sub-region, Uganda: a study on laboratory non-conformances**: Charline KATUROLE (Uganda)<br>**Pre-analytical features of the first routine blood culture from 55,558 patients at a tertiary hospital in San Paulo, Brazil**: Evangelina ARAUJO (Brazil)<br>**Optimising blood culture turnaround times: analysis of a regional microbiology hub and spoke laboratory network**: Conor MULROONEY (Ireland)<br>**Automated culture systems in a microbiology laboratory specialising in gastroenteric samples**: Stanca-Luci PANDREA (Romania)<br>**Consequences of method change on plastic waste consumption in clinical microbiology**: Volkan �ZENCI (Sweden)<br>**Automatising the identification of invasive Group A Streptococcus through laboratory data available in the Norwegian surveillance system for communicable diseases laboratory database**: Jo�o PIRES (Norway)<br>**Encoding culture media tests using LOINC terminology**: B�atrice CELLI�RE (France)<br>**Automated inoculation of respiratory samples for enhanced bacteriological analysis**: Demi ELSHOUT (Netherlands)<br>**Early MDRO screening on chromogenic media with automated culture systems**: Delphine JACOB (France)<br>**Automation of blood cultures using microbiology laboratory automation: enhancing efficiency in microbiological diagnostics**: Colin MANS (Netherlands)<br>**How to implement a 24/7 lab with full automation to improve patient management and antimicrobial stewardship: a preliminary single-centre experience**: Riccardo CAPUANO (Italy)<br>**Setting automatic review rules to improve the accuracy of rapid antimicrobial susceptibility testing results**: Zhonghao WANG (China)<br>**Round-the-clock microbiology: a game changer for early bacteraemia detection and treatment**: Alberto VAZQUEZ BLANQUI�O (Spain)<br>**5Ws analysis of blood culture contamination rates in an Australian medical laboratory**: Zahraa AL-SULTANI (Australia)<br>**Improving diagnostic stewardship: an example from Coxiella serology**: Ameeka THOMPSON (United Kingdom)<br>**Pre-analytical resource development supporting clinical integration of microbiology services in LMICs**: Maxencia NABIRYO (Uganda)<br>**Laboratory automation in microbiology: a positive impact on turnaround time (TAT) of paediatric microbiological samples**: Paola BERNASCHI (Italy) |
| 14/04 | 12:00 - 13:30 | PS030 | 04c. MALDI-TOF and other proteomic methods |  | **DOT-MGA for rapid determination of susceptibility to ceftazidime/avibactam and aztreonam combination among Enterobacterales**: Juliana CAIER�O (Brazil)<br>**Toward sustainable and reproducible MALDI-TOF MS: impact of target selection and hardware maintenance on mass spectral quality**: Yukino G�TLIN (Switzerland)<br>**Evaluation of FT-IR spectroscopy for E. coli ST-131 differentiation**: Miriam CORDOVANA (Germany)<br>**Evaluation of the performance of a bacterial identification system by mass spectrometry by matrix-assisted laser desorption/ionisation and time of flight (MALDI-TOF MS)**: Kamelia Zahra YALA (Algeria)<br>**Streamlining pathogen identification: advanced rapid blood culture enrichment technology for MALDI-TOF MS diagnostics**: Run HUANG (China)<br>**Performance of a rapid MALDI-TOF MS assay for antimicrobial susceptibility testing**: Evgeny A. IDELEVICH (Germany)<br>**Comparison of mass spectrometry (MALDI-TOF MS) and genomic analysis (rMLST, hsp60 and chromosomal AmpC) for the identification of Enterobacter cloacae complex species**: Esther RECACHA (Spain)<br>**A novel approach for Klebsiella pneumoniae typing by Fourier-transform infrared spectroscopy**: Donatella LOMBARDO (Italy)<br>**Evaluation of a new device using MALDI-TOF systems for fast identification of Gram-negative pathogens from positive blood cultures**: Kaley REEDY (United States)<br>**Infra-red spectroscopy (FTIR) for the rapid identification of Gram-negative bacteria involved in urosepsis**: Craig WILLIAMS (United Kingdom)<br>**Application evaluation of MALDI-TOF MS in rapid identification of filamentous fungi**: Guangyu FU (China)<br>**Application of MALDI-TOF MS in the detection of drug-resistant phenotype of Staphylococcus aureus**: Dehao ZHOU (China)<br>**Fast and user-friendly discrimination of highly virulent Streptococcus agalactiae clonal complexes by MALDI-TOF MS**: Miriam CORDOVANA (Germany)<br>**Comparison of the filamentous fungi library database of the matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) with the MSI-2 database for identification of medically important molds**: Peter LASCARIDES (United States)<br>**Mycobacterium avium complex (MAC): a group of emerging pathogenic species, in patients with diseases associated to the respiratory tract**: Alicia BORONAT MU�OZ (Spain)<br>**Discrimination of cronobacter sakazakii from other Cronobacter strains using lipid analysis with MALDI-ToF MS in negative ion mode**: Miriam STERNEL (Germany)<br>**Prediction of linezolid-resistant Enterococcus faecium using MALDI-TOF MS and machine learning**: Andre INGEBRETSEN (Norway) |
| 14/04 | 12:00 - 13:30 | PS031 | 04d. Molecular diagnostics (incl POCT and syndromic testing) |  | **Distribution of microorganisms in patients followed up with a diagnosis of central nervous system infection and evaluation of clinical usefulness of cerebrospinal fluid multiplex PCR panel**: Elif Ozge DAMAR MIDIK (T�rkiye)<br>**Performance of two multiplex-real-time PCR kits detecting sexually transmitted pathogens**: Florence DOUCET POPULAIRE (France)<br>**Evidence of phage as the source of unconfirmed positive Neisseria gonorrhoeae results in throat swabs**: Owen SPILLER (United Kingdom)<br>**Optimisation of microbiological diagnosis of suspected meningitis using an off-label syndromic molecular panel in paediatric cerebrospinal fluid samples**: Venere CORTAZZO (Italy)<br>**Sepsis on critical patients: performance and evaluation of a new molecular test from direct whole blood**: Antonina Tindara FERRARA (Italy)<br>**Impact of molecular biology on the diagnosis of sexually transmitted infections at a public hospital in Montevideo, Uruguay**: Matilde OUTEDA (Uruguay)<br>**False positive pathogen detection in central nervous system infections by syndromic testing**: Friederike VON LOEWENICH (Germany)<br>**Rapid molecular detection of antibiotic resistance markers using PathCRISP test**: Bhargava C N (India)<br>**Comparison of molecular testing methods for diagnosing non-tuberculous mycobacterial infections**: Leilei WANG (China)<br>**Long-term preservation of bacterial DNA using a transport medium: evaluation across different storing temperatures and molecular assays**: Ilaria TRIVA (Italy)<br>**Development and evaluation of a rapid and sensitive RPA-assisted CRISPR/Cas12a assay for detecting Salmonella paratyphi and Salmonella paratyphi A**: Jobin JACOB JOHN (India)<br>**Analytical performance evaluation of automated multiplex real-time PCR for detection of pathogens related with acute undifferentiated febrile illnesses: severe fever with thrombocytopenia syndrome virus, Orientia tsutsugamushi, Leptospira, and hantavirus**: Hyun-Seung LEE (Republic Of)<br>**Evaluation of the BD COR automated random access system for the high-throughput testing of genital and non-genital samples for Chlamydia trachomatis and Neisseria gonorrhoeae with the BD CTGCTV2 assay**: Shoshanna MAY (United Kingdom)<br>**Seasonal patterns of gastrointestinal pathogens in a tertiary-care hospital in northern Greece: a multi-pathogen surveillance study**: Zafeirios TSINARIS (Greece)<br>**Evaluation of the co-morbidity of HPV, STIs and bacterial vaginosis**: Melanie POLKE (Germany)<br>**Determination of bacteria and fungi by sequencing in clinical practise**: Lenka KRAMNA (Czech Republic)<br>**Performance evaluation of the QIAstat-Dx meningitis/encephalitis panel: results from five studies**: Flora Marzia LIOTTI (Italy)<br>**Accelerating molecular diagnostics: development of a novel rapid, integrated PCR system for acute respiratory infections detection**: Run HUANG (China)<br>**Colorimetric-loop mediated isothermal amplification assay for Helicobacter pylori detection**: Yosita LEEPROMMA (Thailand)<br>**Enhancing STI and UTI detection with a novel, versatile, fast and reliable tool for nucleic acid extraction**: Laura PASTOR-BERNAD (Spain)<br>**Transforming Salmonella detection via One-Pot CRISPR-Cas12-based assay**: Mandar NAIK (India)<br>**Etiologies and ophthalmological characteristics of infectious uveitis: insights from multiplex real-time PCR**: Selin Gamze KILIC SINCI (T�rkiye)<br>**BioFire joint infection panel for samples other than synovial fluid**: Nicola BENVENUTO (Italy)<br>**Synergising PlexPlus chemistry, instrumentation and software: advancing multiplex PCR solutions**: Sabrina ALBET (France)<br>**Performance of a direct-from-sample next generation sequencing based pan-bacterial, pan-fungal assay on tissue samples**: Simone JETHA (India)<br>**Fabrication of a sensitive surface plasmon resonance-based nanorods-shaped gold nanobiosensor for the specific detection of Vibrio cholerae**: Saeed SHAMS (Islamic Republic Of)<br>**Evaluation of a laboratory-developed RT-PCR assay for the detection of Pneumocystis jirovecii using a high throughput system**: Jae Hyeon PARK (Republic Of)<br>**Oropharyngeal swabs as a non-invasive alternative for diagnosis of lower respiratory tract infections in children**: Wen-Tyng KANG (China)<br>**Performance of interspace profiling (ISpro) for diagnosis of bacterial pericarditis**: Martine BOS (Netherlands)<br>**Development of a multiplex real-time PCR assay for the simultaneous detection of three fungal pathogens in respiratory samples**: Zeqi ZHOU (China)<br>**Interventional study to evaluate the impact of a rapid screening strategy in improving control of carbapenemase-producing organisms (CPOs) and vancomycin-resistant Enterococci (VREs)**: Sandrine BOISSET (France)<br>**Replacing stool culture with multiplex PCR in a primary care setting: a six months experience**: Marie BL�MEL (Austria)<br>**Identification of Staphylococcus aureus by polymerase chain reaction using novel primers from heat shock protein**: Tomiwa ADESOJI (Nigeria)<br>**Introduction and initial validation of a novel real time-PCR system for rapid identification of bacteria and resistance genes from positive blood cultures**: Nadine THEISSEN (Germany)<br>**Bringing the heat: a new generation of thermophilic Bst polymerases mitigate non-specific LAMP**: Rita SIM�ES (Portugal)<br>**Fast, thermostable and inhibitor-resistant: the future of reverse transcription in molecular diagnostics**: In�s FONSECA COSTA (Portugal)<br>**Evaluation of the EasySeq full-length 16S sequencing kit for bacterial identification in clinical samples: a multicentre study**: Tim T. SEVERS (Netherlands)<br>**Culture-independent identification of microbial pathogens and antimicrobial resistance genes in intensive care units**: Zihan XIA (China)<br>**Utility of stool Xpert assay in the diagnosis of paediatric pulmonary and intestinal tuberculosis: a study from western India**: Dhruv GANDHI (India)<br>**New microfluidic device with magnetic attraction for resistance genes**: Maria Leonor SANTOS (Portugal)<br>**Diagnostic yield of bacterial PCRs for identifying the infectious etiology for paediatric pleural effusion**: Amy LEBER (United States)<br>**Evaluation of the BioFire FilmArray RP2.1 panel for detection and quantification of viral and bacterial respiratory pathogens**: Onya OPOTA (Switzerland)<br>**Evaluating the efficacy of a multiplex PCR sepsis panel for pathogen detection in non-blood neurosurgical samples**: Luis BRUSCA (Spain)<br>**Application and performance of 16S/18S amplicon sequencing in diagnostic management of culture-negative infections**: Vincenzo DI PILATO (Italy)<br>**Influence of rapid molecular testing in optimising clinical and therapeutic management of pneumonia**: Alicia GALAR (Spain)<br>**Optimisation of diagnostic specificity in bacterial infections by duplex 16S rDNA PCR**: Coralie BOUCHIAT (France)<br>**Very rapid and accurate detection of acute bacterial meningitis in clinical samples**: Stefan ZIMMERMANN (Germany)<br>**Impact of multiplex PCR for rapid microbiological diagnosis of patients with severe pneumonia in emergency department: a pragmatic controlled trial**: Chien-Chang LEE (China)<br>**New NAAT kits for rapid and accurate detection and differentiation of pathogenic E. coli**: Heike ABICHT (Germany)<br>**Comparison of GP and central laboratory BioFire FilmArray point-of-care test performance as part of the RAPID-TEST RCT**: Emily BROWN (United Kingdom)<br>**Rapid molecular diagnostics for respiratory infections: cycle thresholds and co-infections**: Maria Antonella ZINGAROPOLI (Italy)<br>**Automated high-throughput molecular diagnostic system for the simultaneous detection of four sexually transmitted infection pathogens in human urine and vaginal swab specimen**: Jeonghee KIM (Republic Of)<br>**Molecular diagnostics for paediatric bone and joint infection**: Zain CHAUDHRY (United Kingdom)<br>**Evaluation of multiplex PCR panel dynamics during antibiotic treatment to predict clinical success in ICU patients with severe hospital-acquired pneumonia: a multicentre prospective study**: Julien DESSAJAN (France)<br>**No time, no problem: transitioning to extraction-free workflow for stool testing using PCR**: Susanne WOLFENSTETTER (Germany)<br>**Analytical feasibility of the cobas eplex gastrointestinal panel: a multiplex PCR syndromic test currently in development**: Pedro L. RODRIGUEZ (United States)<br>**Performance of a novel molecular test in culture-negative periprosthetic hip and knee periprosthetic joint infections**: Susana GARDETE-HARTMANN (Austria)<br>**Clinical performance of a fully automated real-time PCR assay for the detection of Clostridium difficile in human stool samples under IVDR**: Jasmin K�FFER (Germany)<br>**Clinical performance of a fully automated real-time PCR assay for the detection of Chlamydophila pneumonia, Legionella pneumophila and Mycoplasma pneumoniae in human bronchoalveolar lavage under IVDR**: Jasmin K�FFER (Germany)<br>**Ct values in fast syndromic testing: putative applications in CNS infection diagnosis**: Camenforte NESTOR (Spain)<br>**Selective application of FilmArray for effective antibiotic management in meningitis patients**: Nathan NICOLAU-GUILLAUMET (France)<br>**Enhanced pathogen detection and antimicrobial optimisation in ARDS: multiplex PCR vs standard diagnostics**: Martina GASSNER (Germany)<br>**Improved accuracy in Group B Streptococcus detection: a validation study across two medical centres**: Pninit SHAKED MISHAN (Israel)<br>**A comparative evaluation of multiplex PCR panels for gastrointestinal pathogen detection in clinical stool samples**: Laura SEIJAS PEREDA (Spain)<br>**Comparative evaluation of the standard M10 and Xpert C. difficile assays for the detection of toxigenic Clostridioides difficile in stools**: Fr�d�ric BARBUT (France)<br>**Evaluation of the hologic aptima vaginitis assays for microbiological diagnosis of vaginitis in women with abnormal vaginal discharge attending primary care**: Peter MUIR (United Kingdom)<br>**Evaluation of the effect of gastrointestinal system multiplex PCR panel positivity on the relapse of ulcerative colitis patients**: Merve BUYUKKORUK (T�rkiye)<br>**Validation of a real time PCR assay using cerebrospinal fluid samples with clinical suspicion of bacterial meningitis from a tertiary hospital in Spain**: Henar ALONSO-EZCURRA (Spain)<br>**Updated coverage of circulating and emerging toxigenic Clostridioides difficile strains by a commercial PCR test**: Isabella ELLENA TICKLER (Italy)<br>**Rapid detection of ESKAPE pathogens from whole blood in patients with spondylodiscitis and infective endocarditis combining PCR and MRI**: Lucie C�CHOV� (Czech Republic)<br>**Transforming reagents for revolutionary point-of-care molecular diagnostics: lyophilised PCR master mix beads for cold-chain-free and rapid testing**: Golara GOLBAGHI (Canada)<br>**Lyophilisation as a successful technique to produce easy-to-use, robust, and room-temperature-stable magnetic particles for molecular diagnostic applications**: Golara GOLBAGHI (Canada)<br>**Can syndromic molecular tests be used for the diagnosis of urinary tract infections?**: Tug�e �ZYOL ATKAYA (T�rkiye)<br>**Performance of an automated, multiplex RT-PCR panel with external quality assessment programmes for respiratory pathogens**: Elizabeth PAZ GOMERO (Sweden)<br>**Mucorales PCR testing in bronchoalveolar lavage samples of immunocompromised patients with and without fungal infections**: Sarah SEDIK (Austria)<br>**Utilisation of the BioFire FilmArray blood culture identification 2 panel for rapid and accurate identification of bacteraemia pathogens**: Jeonghyun CHANG (Republic Of)<br>**Rapid random-access molecular diagnostic assay for STI pathogens**: Dana SAGAS (Israel)<br>**Outcomes of a meningitis/encephalitis syndromic PCR algorithm at a regional UK hospital**: James Roderick GRIFFITHS (United Kingdom)<br>**Failure to detect Streptococcus pneumoniae due to false negative PCR results caused by a large insertion in the Spn9802 fragment**: Myrthe Margriet Anne TOOROP (Netherlands)<br>**Highly multiplexed broad pathogen detection assay for diagnosis of intraocular infections**: Paulo Jose MARTINS BISPO (United States)<br>**Validation of targeted next-generation nanopore sequencing for routine diagnosis of gastroenteritis**: Nicolas VERGAUWE (Belgium)<br>**Comparison of three commercial nucleic amplification tests for CT and GC testing in urine and vaginal swabs**: Salma KODSI (United States)<br>**Diagnosis of sexually transmitted infections with multiplex RT-PCR and analysis of symptoms**: F�sun KIRCA (T�rkiye)<br>**Evaluation of an innovative RT-PCR assay allowing detection of all respiratory viruses in a single classic PCR well**: Benoit VISSEAUX (France)<br>**Comparison of RHAM isothermal nucleic acid amplification technology and culture method: advancing screening for Streptococcus agalactiae**: Colosimo CLAUDIA (Italy)<br>**Clinical diagnostic performance of droplet digital PCR for pathogen detection in patients with Staphylococcus aureus bloodstream infections**: Hiroki KITAGAWA (Japan)<br>**Diagnostic value of PCR whipple: a retrospective multicentre study**: Elo�se LE BANNER (France)<br>**Comparative analysis of workflow efficiency and safety in enteric bacterial pathogen detection methods**: Lauren COOPER (United States)<br>**Urgent care (UC) clinician perceptions and identification of target populations for a novel point-of-care test (POCT) for pharyngitis**: Alexander LEPAK (United States)<br>**Evaluation of PCR in saliva and stool for Whipple's disease diagnosis: a retrospective study from 2019 to 2024**: Guillermo Carlos MART�NEZ CARRI�N (Spain)<br>**Molecular assay of atypical community-acquired pneumonia from different matrices**: Colosimo CLAUDIA (Italy)<br>**Laboratory evaluation of the Biofire FilmArray pneumonia panel compared to standard-of-care testing in patients admitted to an ICU in Swansea, UK**: Rhys EVANS (United Kingdom)<br>**Development of a simple tool for the detection of pneumonia-causing bacteria in children**: Arturo MART�NEZ TREJO (Spain)<br>**Rapid and accurate pathogen detection in joint infections: assessing the performance of the BioFire joint infection panel in Korean tertiary hospitals**: Hae-Seong JEONG (Republic Of)<br>**Evaluation of a real-time polimerase chain reaction assay for the direct diagnosis and genital colonisation of Streptococcus agalactiae in pregnant women**: Aida RAMIREZ MARINERO (Spain)<br>**Impact of multiplex polymerase chain reaction testing in patients with bacteraemia in Japan**: Daisuke KITAGAWA (Japan)<br>**In silico evaluation of pilV-I PCR for identifying the hyperepidemic Klebsiella pneumoniae ST258 clone in contemporary isolates**: Fernando PASTERAN (Argentina)<br>**Evaluation of clinical usefulness of a commercial multiplex PCR for diagnosing mycobacterial infections: a multicentre study**: Llanos SALAR-VIDAL (Spain)<br>**Promising novel molecular approaches compared to culture for detecting periprosthetic joint infections**: Elizabeth MORREEL (Belgium)<br>**Assessment of a qPCR syndromic device's C. difficile tcdA/tcdB assay with clinical relevance**: Rebecca SMITH AGUASCA (Spain)<br>**The impact of targeted molecular ciprofloxacin resistance testing on positive gonorrhoea samples in NHS Grampian**: Ijeoma OKOLIEGBE (United Kingdom)<br>**Filmarray GI system for the diagnosis of gastrointestinal tract infections**: Konstantina KONTOPOULOU (Greece)<br>**Epidemiology and antibiotic resistance genotypes of respiratory pathogens in critical care units and non-critical care units in private chain hospitals**: Anis Farhanah ROSLEE (Malaysia)<br>**Neuro-meningeal infections caused by enterovirus: epidemiological and microbiological profiles**: Doria BENSERSA-NEDJAR (Algeria)<br>**Microbial cell-free DNA NextGen sequencing diagnostics in solid organ transplant recipients**: Edison CANO CEVALLOS (United States)<br>**Application of a film array meningitis/encephalitis panel for the diagnostic investigation of adult patients with syndromic symptomatology: a five-year retrospective epidemiological study**: Maria TERZAKI (Greece) |
| 14/04 | 12:00 - 13:30 | PS032 | 04e. Strain typing and surveillance (incl molecular, genomic and other advanced methods) |  | **Optimising IR-FTIR spectroscopy for epidemiological tracking Klebsiella pneumoniae ST512 strains**: Maria RIESGO (Spain)<br>**Invasive Streptococcus pyogenes population in the Russian Federation**: Irina TSVETKOVA (Russian Federation)<br>**Whole-genome analysis to establish genetic thresholds for excluding recent transmission of livestock-associated MRSA**: Thera HABBEN JANSEN (Netherlands)<br>**Comparative genomic analysis of sequence type 72 (ST72), a successful community clone of Staphylococcus aureus strains**: Jae-Seok KIM (Republic Of)<br>**Sequencing for Listeria monocytogenes outbreak detection and source attribution: latest advances**: Michael BIGGEL (Switzerland)<br>**Unveiling the molecular epidemiology of invasive Group A Streptococcus in Bologna and Imola (2022–2024)**: Eva MANNINO (Italy)<br>**Impact of different whole-genome sequences production procedures and sequence analysis pipelines on genotyping and clustering of Campylobacter strains**: Philippe LEHOURS (France)<br>**A 12-year molecular surveillance and virulence determination of Listeria monocytogenes in Slovenia**: Tom KORITNIK (Slovenia)<br>**Long-read sequencing: a standalone tool for Listeria monocytogenes outbreak investigations?**: Asta LILI LAUGESEN (Denmark)<br>**Molecular epidemiology of invasive Streptococcus pyogenes in Hungary, January 2023-May 2024**: T�th KINGA (Hungary)<br>**Multi locus sequence typing of Pseudomonas aeruginosa strains isolated from people with cystic fibrosis in elexacaftor/tezacaftor/ivacaftor treatment**: Maria Francesca LIPORACE (Italy)<br>**Is Group A Streptococcus emm1/ST28 a new threat in Brazil?**: Andr� RIO TINTO (Brazil)<br>**Xpert Carba-R screening of digestive carriers of carbapenemase-producing GNB vs conventional techniques**: Mohamed Azzedine BACHTARZI (Algeria)<br>**Long term Staphylococcus aureus carriage dynamics in people who inject drugs**: Jimmy J�RGENSEN (Sweden)<br>**Developing a robust approach to determining plasmid transmission in the hospital setting**: Jane HAWKEY (Australia)<br>**Genotypic methods directly from epidemiological samples to detect resistance markers of Gram-negative bacilli: a reality?**: Leticia FONT�N GARC�A-RODRIGO (Spain)<br>**Comprehensive comparative and pan-genome analysis of Staphylococcus lugdunensis isolates from the UK and globally**: Lucy LAMB (United Kingdom)<br>**Discrimination of Salmonella serogroups and differentiation between typhoidal and non-typhoidal strains using ATR-FTIR spectroscopy**: Maira NAPOLEONI (Italy)<br>**Fourier-transform infrared spectroscopy as a new tool to investigate Clostridioides difficile outbreaks**: Kerstin LOCHER (Canada)<br>**Typing of food- and water-borne pathogens by Fourier transform infrared-spectroscopy (FT-IR)**: Stefan ZIMMERMANN (Germany)<br>**A longitudinal surveillance on molecular evolution of methicillin-resistant Staphylococcus aureus from children in Shanghai, China, 2013-2022**: Bingjie WANG (China)<br>**Discrimination of genus Legionella and serogroup of Legionella pneumophila strains using ATR-FTIR spectroscopy**: Ignazio ARRIGO (Italy)<br>**Local genomic surveillance of laboratory-confirmed human Salmonella isolates in Vigo-Galicia, Spain**: Carlos DAVI�A NU�EZ (Spain)<br>**The clinical spectrum of cutaneous nocardiosis using gene sequencing at tertiary care centre, India: an observational study**: Sudeshna DAS (India)<br>**Implementation of Fourier-transform infrared (FTIR) spectroscopy into clinical microbiology lab**: Ola SALACH (Israel)<br>**Bioinformatic updates addressing methylation-related basecalling issues of long-read sequencing data resolve typing issues in a multicentre performance study**: Johanna DABERNIG-HEINZ (Austria)<br>**Validation by whole-genome sequencing of the use of Fourier-transform infrared spectroscopy (FTIR) to rapidly assess Pseudomonas aeruginosa clonality in the microbiological management of patients with cystic fibrosis**: Serena RAIMONDI (Holy See (vatican City State))<br>**Molecular typing to discriminate between typhoid and nontyphoid Salmonella species**: Sylvia BRUISTEN (Netherlands)<br>**Evaluation of FT-IR for the differentiation of Campylobacter jejuni strains regarding their potential to induce Guillain-Barr� syndrome**: Miriam CORDOVANA (Germany)<br>**Evaluation of Fourier-transform infrared spectroscopy as a method for rapid Streptococcus pneumoniae serotyping**: Pere-Joan CARDONA (Spain)<br>**Application of Fourier-transform infrared spectroscopy to differentiate the Bacillus cereus group**: Miriam CORDOVANA (Germany)<br>**Differentiation of Shigella spp. serotypes by FT-IR spectroscopy**: Miriam CORDOVANA (Germany)<br>**Characterisation of an outbreak caused by vancomycin-resistant Enterococcus faecium and linezolid-resistant E. faecium using Fourier-transform infrared (FTIR) spectroscopy**: Maria S�NCHEZ CUETO (Spain)<br>**Tackling invasive listeriosis outbreaks in northern Italy: the role of genomic surveillance**: Maria GORI (Italy)<br>**Optimisation of long-read whole-genome sequencing for surveillance of antibiotic resistance detection and typing in low-and-middle-income countries**: Natasia THORNVAL (Denmark)<br>**Evaluation of Fourier-transform infrared spectroscopy for typing of Klebsiella pneumoniae strains involved in hospital outbreaks**: Federica MARINO (Italy)<br>**Rapid outbreak detection of Raoultella bacteraemia in haemodialysis patients: evaluating the use of FTIR spectroscopy and whole-genome sequencing**: Marco Antonio ROLD�N RUIZ (Spain)<br>**Evaluation of Fourier-transform infrared spectroscopy as an alternative technique for typing Salmonella enterica**: Nathaly LADINES REYES (Spain)<br>**Study of the epidemiology of emm types of Group A Streptococcus strains**: Konstantina KONTOPOULOU (Greece)<br>**Evaluation of IR BIOTYPER performance for identification of Streptococcus pneumoniae serotypes**: Juliana CAIER�O (Brazil)<br>**Application of  IR technology for rapid typing and resistance prediction in carbapenem-resistant Klebsiella oxytoca complex**: Wei Yu HSU (China)<br>**Emergence of emm3.93 Streptococcus pyogenes clone in iGAS infections: epidemiological insights from Belgium, May 2023-September 2024**: Stefanie VAN KLEEF VAN KOEVERINGE (Belgium)<br>**Phage-inspired rapid Klebsiella K-typing**: Zuzanna DRULIS-KAWA (Poland)<br>**Clonality of Acinetobacter baumannii blaOXA-24/40-like isolated from hospitals in southern Brazil using Fourier-transform infrared spectroscopy (FT-IR) methodology**: Marcelo PILLONETTO (Brazil)<br>**Evaluation of FT-IR spectroscopy for vancomycin-resistant Enterococcus faecium outbreak delimitation**: Antoni ESCALAS BORDOY (Spain)<br>**Enhancing infectious disease diagnostics: hierarchical strain typing from high to low resolution and genomic context-based language model for antibiotic resistance prediction**: Sein PARK (Republic Of)<br>**Fourier transform infrared (FT-IR) spectroscopy for discrimination between global Escherichia coli ST131 subclades**: Astrid RASMUSSEN (Denmark)<br>**Evaluation of FT-IR spectroscopy and machine learning for the serotyping of Streptococcus pneumoniae**: Miriam CORDOVANA (Germany)<br>**Enhanced genomic relatedness determination of Group A Streptococcus isolates using whole-genome sequencing compared to emm typing in England**: Kathrin LOOSLI (United Kingdom)<br>**Rapid differentiation of global multidrug-resistant and hypervirulent Klebsiella pneumoniae sublineages using FT-IR spectroscopy**: Rita MARTINS (Portugal)<br>**An emm typing study performed in Turkey utilising the quadriplex real-time PCR assay**: Bedia DINC (T�rkiye)<br>**Fourier-transform infrared spectroscopy as a tool for clonal clustering in hospital-associated Serratia marcescens outbreaks**: Sam VAN GOETHEM (Belgium)<br>**Two Group B Streptococci ST283 invasive infections in Portugal raise the possibility of the emergence of this unusual lineage in Europe**: Mario RAMIREZ (Portugal) |
| 14/04 | 12:00 - 13:30 | PS033 | 04f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing) |  | **Species clustering of the viridans group streptococci with whole-genome sequencing (WGS)**: Wa Ode Dwi DANINGRAT (United Kingdom)<br>**Plasmidome analysis of the Klebsiella pneumoniae diversity panel collection**: William STRIBLING (United States)<br>**Emergence of Vibrio paracholerae with co-occurrence of Vibrio cholerae and its diagnostic-public health implications**: Mohammad Ridhuan MOHD ALI (Malaysia)<br>**Developing pipeline partnerships: the use of GenomeKey's genomic analysis pipeline to understand the epidemiology of Staphylococcus aureus (SA) isolates from a UK Teaching hospital with a high incidence of both blood stream infection (SABSI) and people who inject drugs (PWID)**: Phillipa BURNS (United Kingdom)<br>**Tiny patient, big challenge: decoding MDR Salmonella enterica Typhimurium ST29 with whole-genome sequencing**: Salamah Faisal UMMU (Malaysia)<br>**The explorative analysis of multiple copies of tigecycline resistance genes on bacterial genome assemblies**: Aditya Kumar LANKAPALLI (United Kingdom)<br>**Can be antimicrobial resistance predicted from metagenomic data of culture-negative 16S rDNA-positive synovial fluid samples?**: Jakub KANTOR (Czech Republic)<br>**Identification of Listeria monocytogenes persister types in the Austrian food chain**: Julia STEGER (Austria)<br>**In vivo detection, isolation and genomic characterisation of predatory bacteria in human faecal samples**: Mario ROMERO RIVERA (Spain)<br>**From environmental to epidemic: how genomic surveillance allowed identification and characterisation of a new epidemic clone of Pseudomonas aeruginosa in our cystic fibrosis centre**: Martina ROSSITTO (Italy)<br>**Evaluation of three commercial kits for Pseudomonas aeruginosa genomic DNA extraction: optimising yield and quality for long read sequencing**: Anurag Kumar BARI (Netherlands)<br>**Phenotypic and genotypic characterisation of Klebsiella pneumoniae isolates from ten Colombian hospitals using the EPISEQ CS**: Nelly Carolina MENA (Colombia)<br>**Genomic insights into Streptococcus pneumoniae in Indian paediatric carriage: serotype, virulence, and antimicrobial resistance profiles**: Vaishnavi Vishram NAIK (India)<br>**Optimised methods for bacterial whole-genome sequencing from positive blood culture broths**: Patricia SIMNER (United States)<br>**Double-zone-haemolysis in coagulase-positive staphylococci and in silico analysis of haemolysin (hlb) gene polymorphisms**: Javier LATORRE (Spain)<br>**Haemophilus influenzae genomes harbour novel prophages**: Saskia PROUD (United Kingdom)<br>**Molecular insights into Group B Streptococci from antenatal women attending a tertiary care centre in South India**: Sheela Devi CHANDRAKESAN (India)<br>**Application of whole-genome sequencing to investigate a collection of Elizabethkingia spp. isolates in a surgical and transplantation ICU**: Georgia CHASIOTI (Greece)<br>**Is there a difference between invasive and non-invasive Streptococcus pyogenes isolates?**: Marek STEFAN (Czech Republic)<br>**Whole-genome characterisation of Escherichia coli isolates from older women with urinary tract infection or asymptomatic bacteriuria: a pilot study**: Caroline SCHNEEBERGER-VAN DER LINDEN (Netherlands)<br>**Culture vs next-generation sequencing for infective endocarditis: performance of the 16S/ITS NGS in cardiac valve samples as a rapid and direct diagnostic tool**: Jose ALEXANDER (United States)<br>**Genome-based identification of Desulfovibrio strains from bacteraemia in Spain**: Francisco FRANCO �LVAREZ DE LUNA (Spain)<br>**Analysing uropathogenic Escherichia coli isolates with mutations conferring low-level resistance to quinolones and low-level resistance to fosfomycin**: Soraya HERRERA-ESPEJO (Spain)<br>**Antimicrobial resistance and molecular typing of Streptococcus suis causing systemic clinical cases in pig production in Spain**: Anna VILAR� VIVES (Spain) |
| 14/04 | 12:00 - 13:30 | PS034 | 04g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects, excl fundamental science) |  | **Skin microbiome in intensive care unit patients: temporal shifts in bacterial and fungal communities**: Teresa NASCIMENTO (Portugal)<br>**Dietary habits and vaginal environment: can a beneficial impact be expected?**: Marielle Ezekielle DJUSSE (Italy)<br>**Microbial signatures of sexual contact: forensic and clinical implications**: Jasmin BAUMGARTNER (Switzerland)<br>**Comparison of two 16S metagenomic protocols for high-throughput microbiome sequencing: library preparation and bioinformatics performance**: Anna FAGERSTR�M (Sweden)<br>**Evaluation of a shotgun metagenomic NGS workflow for microbial pathogen detection from complex clinical samples using a host DNA depletion**: Jakub KANTOR (Czech Republic)<br>**Assessing potential bias introduced by sequential vaginal swab collection on microbiome profiling**: Anna FRANZONI (Italy)<br>**Gut microbiota and hypothalamic inflammation as determinants of binge eating behavior prior to obesity**: Sedreh NASSIRNIA (Switzerland)<br>**Exploration of urinary microbiome in patients at various stages of bladder cancer, India: association of Campylobacterales with muscle-invasive carcinoma**: Inderjit SINGH (India)<br>**Effect of antibiotic use on the gut microbiome of neonates: a northern Nigeria cohort study**: Chinenye AKPULU (United Kingdom)<br>**The bile microbiota composition in pathological conditions: a pilot study**: Giulia GATTI (Italy)<br>**Culturomics insights into phenotypic antimicrobial resistance evolution in the gut microbiota of allogenic stem cell transplant patients**: Elisa SOSA (Switzerland)<br>**Tips and tricks for microbiota investigation using SEM: sample preparation, imaging and landscape analysis correlated to multi-omics approach**: Sara BELLALI (France)<br>**Comparative analysis of two comercial sequencing platforms for 16S rRNA profiling of respiratory microbial communities**: Guillem MACIP SANCHO (Spain)<br>**Gut microbiota differences linked to weight gain and antiretroviral therapy in people living with HIV are enterotype specific but minor compared to those linked to sexual orientation**: Jan KEHRMANN (Germany)<br>**Towards optimal endometrial microbiota sampling: a comparison of flush and biopsy using nanopore sequencing**: Sebastien BONTEMS (Belgium)<br>**Rapid determination of the vaginal microbiome using nanopore sequencing at lowlands science**: Eefje SCHRAUWEN (Netherlands)<br>**Microbiota and resistome nanopore-based metagenomic analysis of Swiss expatriates living in Africa**: Edgar Igor CAMPOS-MADUENO (Switzerland)<br>**Characterisation of the skin and oral microbiome in younger and older adults**: Duncan NEWMAN (United Kingdom)<br>**Analyses of hospital microbiomes revealed critical pathogens associated with HAIs**: Julio Cesar ORTEGA CAMBARA (United Kingdom) |
| 14/04 | 12:00 - 13:30 | PS035 | 04h. Clinical metagenomics |  | **Benchmarking bacterial DNA extraction protocols to recover high molecular weight DNA from faecal reference material for long-read metagenomic sequencing**: Molly HALES (United Kingdom)<br>**Implementation of a rapid next-generation sequencing (NGS) based agnostic diagnostic for enhanced intensive care unit (ICU) care at a tertiary hospital in Dhaka, Bangladesh**: Jannat Ara KHANOM (Bangladesh)<br>**Correlation between nanopore respiratory metagenomics and quantitative respiratory culture**: Virve Irene ENNE (United Kingdom)<br>**Detection of pathogenic microorganisms usingmetagenomic next-generation sequencing in the emergency department**: Torsten SCHROEDER (Germany)<br>**Using metagenomics for pathogen screening in pregnancy complications**: Leysa FORREST (United Kingdom)<br>**The use of metagenomics to evaluate different ESBL stool screening methods**: Laura DI MURRO (United Kingdom)<br>**Accurate and cost-effective metagenomic next-generation sequencing for meningitis and encephalitis on a novel sequencing platform**: Ryan SHEAN (United States)<br>**Proof-of-concept of a clinical metagenomics method for bacterial bloodstream infection detection using selective cell lysis and adaptive sampling**: Claudia NGUYEN (Switzerland)<br>**Impact of saponin treatment on human mycoplasmas and implications for clinical metagenomics sequencing**: Charlotte DIXON (United Kingdom)<br>**Diagnostic utility of nanopore full-length 16S rRNA gene sequencing for direct bacterial identification in chronic endometritis**: Geetha NAGARAJ (India)<br>**Enhancing pathogen detection: shotgun metagenomics for tropical parasitic and fungal diagnostics**: C�cile ANGEBAULT (France)<br>**Optimisation of routine workflow for 16SrRNA and ITS-2 targeted-NGS in a clinical laboratory**: Richard CHALVIGNAC (France)<br>**When should targeted 16S-metagenomics be performed? A 15-months feedback**: Aubin SOUCHE (France)<br>**Improvement of pathogen detection using metagenomic shotgun sequencing in cystic fibrosis**: Eline CAUWENBERGHS (Belgium)<br>**25 vs 35 cycles of amplification of 16S rRNA gene for targeted NGS in PJI diagnosis: which does it better?**: Ander URIBARRI (Spain)<br>**Refining 16S rRNA targeted NGS diagnostic criteria and thresholds for PJI diagnosis**: Ander URIBARRI (Spain)<br>**Exploring DNA and RNA plant viruses as internal controls for clinical metagenomic sequencing**: Kira WAAGNER BIRKELAND (Norway)<br>**Pathogen detection and anti-microbial resistance prediction performance of mNGS and tNGS in HIV+ pulmonary infections**: Wei FEILI (China)<br>**Impact of next generation sequencing (NGS) in culture negative infections coupled with infectious diseases consultation**: Edwin VARGAS (United States)<br>**Defining criteria for the distinction between infective versus non-infective in metagenomic analysis of CSF samples**: Amos ADLER (Israel)<br>**Semi-quantitative targeted next-generation sequencing in pathogen diagnosis and drug resistance prediction in severe lower respiratory tract infection**: Sun WENKUI (China)<br>**Partial V6-V8 or full 16SrRNA PCR + targeted-NGS for clinical diagnosis?**: Aubin SOUCHE (France)<br>**A 16s turnkey pipeline at last! Routine evaluation of a commercial software**: Tiphaine ROUSSEL-GAILLARD (France)<br>**Metagenomics in the diagnosis of pneumonia: a systematic review**: Samuel QUARTON (United Kingdom)<br>**Diagnostic utility of metagenomics next generation sequencing (mNGS) based on 16S rRNA sequencing in sterile samples**: Pugazhvanan CHIDAMBARAM RAJENDRAN (India) |
| 14/04 | 12:00 - 13:30 | PS036 | 04i. Bioinformatics tools & pipelines |  | **A validation and evaluation study of successive phylogenetic analysis by timely antimicrobial resistant organisms tracking (TAROT) for STEC**: Kotaro AOKI (Japan)<br>**MethylomeMiner: a simple tool for processing and analysing DNA methylation data from sequencing**: Katerina SABATOVA (Czech Republic)<br>**Comparative analysis of a commercial platform and an in-house pipeline for processing whole genome sequencing data**: Garc�a Garc�a SAMUEL (Spain)<br>**Phylogenetic, serologic and sequence type analysis of 28,000 human and animal Escherichia coli genomes: on the lookout for the colibactin pks-island**: Charbel AL BAYSSARI (Lebanon)<br>**Automated detection of antimicrobial resistance markers in next-generation sequencing data**: Sam DIERICKX (Belgium)<br>**Visualising reference laboratory test results using dashboards: an aid to public health reporting and action**: Janie OLVER (United Kingdom)<br>**AMRProfiler: a comprehensive tool for identifying antimicrobial resistance genes and mutations across species**: Anargyros SKOULAKIS (Greece)<br>**The PHAPRO toolbox: from phage characterisation to product quality assessment for phage therapy**: Alessia CARRARA (Switzerland)<br>**zAMPExplorer: a versatile shiny app for microbiota profiling in clinical microbiology**: Sedreh NASSIRNIA (Switzerland)<br>**Computational methylome analysis pipeline for uncovering DNA methylation sites in Klebsiella pneumoniae core genome**: Marketa JAKUBICKOVA (Czech Republic)<br>**Kraken visualisation tool for clinical mNGS infectious disease diagnostics**: Jennifer LU (United States)<br>**Automated offline container with graphic user interface for genome assembly of both short-read and long-read**: H. Rogier VAN DOORN (Vietnam)<br>**A comprehensive tool for analysing Klebsiella pneumoniae genomes: the BGA pipeline**: Juan Carlos GARC�A-BETANCUR (Colombia)<br>**A rapidly adaptable platform for processing and analysing sequences of tiled amplicon-sequenced viruses to inform responses to future epidemics**: Junko TAKATA (United Kingdom)<br>**Comparative analysis of new bioinformatic pipelines for enhanced surveillance and outbreak investigation of Klebsiella pneumoniae**: Hege Vangstein AAMOT (Norway)<br>**Comparing bacterial plasmid recovery in Hybracter vs Trycycler for long-read assemblies data**: Messiah ODEYALE (United States)<br>**Bioinformatics analysis for low-frequency drug resistance mutations in HIV-1**: Fredrik DYRKELL (Sweden)<br>**Enhancing AMR research and surveillance: introducing the AMRgen R package for gene and phenotypic resistance interpretation**: Natacha COUTO (United Kingdom) |
| 14/04 | 12:00 - 13:30 | PS037 | 04j. Artificial intelligence based tools and digital health |  | **When ESCMID meets OpenAI over cups of coffee: brewing collaborative insights to streamline utility and interpretation of clinical guidelines with ChatGPT-4**: Raksha KOCHI (India)<br>**How can large language models be used for clinical microbiology and infectious diseases: a tale of two applications**: Benjamin MCFADDEN (Australia)<br>**AIM-GNB: an artificial intelligence-assisted monitor for early prediction of Gram-negative bacteraemia using machine learning and heamatological data in the emergency department**: Po-Ren HSUEH (China)<br>**Prediction of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae from raman spectra by artificial intelligent raman detection and identification system (AIRDIS) with machine learning**: Po-Ren HSUEH (China)<br>**Developing a mobile application for the delivery of personalised test-guided antibiotic combinations for difficult-to-treat bacterial infections: a user-centered design study**: Tze-Peng LIM (Singapore)<br>**Identification of unmet needs for design and procuring digital services to address antimicrobial resistance (AMR) in hospital settings**: Maddalena ILLARIO (Italy)<br>**Integrating AI into microbiology laboratory automation (MLA) for screening of urine cultures**: Lee TAI FEN (China)<br>**Applying human-centred design (HCD) to develop an assisted microbiological order set: an innovative prototype from Aragon, Spain**: Galadriel PELLEJERO-SAGASTIZ�BAL (Spain)<br>**Using artificial intelligence to integrate dynamic antibiograms and research into electronic medical record systems for enhanced antibiotic decision support**: Fredrick MUTISYA (Kenya)<br>**AI-powered innovations: enhancing accuracy in antibiotic susceptibility testing**: Mariska OKKEMA-VAN DER LEI (Netherlands)<br>**BakRep: a searchable large-scale web repository for bacterial genomes, characterisations and metadata**: Oliver SCHWENGERS (Oliver SCHWENGERS)<br>**Machine learning for genomic AST prediction in metagenomic data from respiratory clinical samples**: Jason D WITTENBACH (United States)<br>**Revolutionising sepsis diagnosis: AI-powered pathogen identification from blood smears**: Monika BRZYCHCZY-WLOCH (Poland)<br>**Evaluation of six large language models answering pre-analytical questions in medical microbiology**: Michelle BRESSAN (Switzerland)<br>**Performance of Orienter-FA280 automated faeces analyser: preliminary evaluation**: Orcun ZORBOZAN (T�rkiye)<br>**Machine learning as a diagnostic tool for intestinal methanogen overgrowth and small intestinal bacterial overgrowth: a new frontier diagnosing**: Haseeb TARIQ (United Kingdom)<br>**Streamlining MRSA screens and urine cultures with AI-driven automatic release**: Gemma STAITE (United Kingdom)<br>**Machine learning models incorporating virulence genes and serotype for identifying hypervirulent Klebsiella pneumoniae: a proof of concept study with 569 strains**: Han YU-LING (China)<br>**Evaluation of the comercial urine culture application for automated urine culture analysis**: Petrus VAN DER WALT (Canada)<br>**MicroBIS A novel AI/ML based platform for bacterial and antimicrobial resistance identification and prediction**: Harry AKLIGOH (United States)<br>**Predicted pathogens from blood culture with advanced pre-trained vision transformer models**: Mei-Hui LEE (China)<br>**Application of machine learning models for prediction of AMR in Africa**: Tochukwu AGBOEZE (Nigeria)<br>**Assessing the quality and appropriateness of artificial intelligence-generated outputs for sepsis management: a comparative study**: Sriram RADHAKRISHNAN (India)<br>**Can artificial intelligence (AI) models be trusted? Determining the variables for building accurate prediction models for antimicrobial resistance**: Neha NITYADARSHINI (India)<br>**Enhancing antimicrobial prescription accuracy: an integrated evaluation of a clinical decision support system in a private hospital setting**: Lucas OLIVEIRA DE MORAIS (Brazil)<br>**Using machine learning to identify factors associated with blood culture contamination in an Australian medical laboratory**: Zahraa AL-SULTANI (Australia)<br>**Artificial intelligence modelling prediction for rapid serotype prediction of Shiga-toxin Escherichia coli by lipid profiling mass spectrometry**: Tania BLANCO MART�N (Spain)<br>**Machine learning-guided clustering: a new approach for KPC detection**: Val�ncio Siqueira ANDR� (United States)<br>**Fourier-transform infrared spectroscopy (FTIR) as a tool for predicting Group A Streptococcus (GAS) emm-type using a machine learning model**: Valeria FOX (Italy)<br>**Digital holographic microscopy: use of AI to enable rapid slide digitisation and interpretation**: Kenneth SMITH (United States)<br>**Artificial intelligence vs clinical scores: evaluating mortality prediction in sepsis patients in a tertiary care hospital South India**: Roshni MURALI (India)<br>**Automated species identification of clinically common Aspergillus using artificial intelligence based on colony morphology**: Jinhan YU (China)<br>**ShigaMS: an artificial intelligence prediction tool for Shigella spp identification and serotyping from MALDI-TOF MS lipid profiles**: Albert MORENO-MINGORANCE (Spain)<br>**Integrating artificial intelligence to optimise STI PCR testing decisions: a data-driven approach to enhancing diagnostic microbiology**: Thunyapon PIPATTAWEEPON (Thailand) |
| 14/04 | 12:00 - 13:30 | PS038 | 04k. Other novel diagnostic technologies |  | **Sequencing of bacterial rpoB and 16S rRNA gene amplicons for infectious disease diagnostics**: Joanna Malgorzata BIVAND (Norway)<br>**Ultrafast antibiotic susceptibility testing of 8 multidrug resistant Gramnegative rods with Raman single beam trapping using the Biospex platform**: J�rgen HELD (Germany)<br>**Agnostic sample preparation for bacteria, yeasts and viruses from blood, sputum and saliva**: Julia DOLEZEL (Austria)<br>**Catalase-based sputum liquefaction for diagnosing respiratory infections caused by Pseudomonas aeruginosa at the point-of-care**: Roberto DE LA RICA (Spain)<br>**Rapid, repeatable cell counting of bacteria using cytometric methods and FiSH**: Robbie HAINES (Australia)<br>**Sampling washing machine water to detect scabies (Sarcoptes scabiei)**: Gregorius Johannes SIPS (Netherlands)<br>**Ultra-fast pathogen identification in sepsis diagnosis using an optomechanical sensor assisted by artificial intelligence**: Blanca CABALLERO (Spain)<br>**Quartz crystal microbalance as a diagnostic tool for Lyme borreliosis: a proof-of-concept study**: Sofia SOMAJO (Sweden)<br>**Neural network prediction of bacterial pneumonia by host transcriptomic analysis of metagenomic data**: Kelvin TO (China)<br>**Viability assessment of Neisseria gonorrhoeae in male urine samples by a novel nucleic acid amplification test (NAAT)**: Sabrina ALBET (France)<br>**Multicentre evaluation of the pattern single-cell microbiology platform for microorganism identification and antimicrobial susceptibility testing directly from lower respiratory tract specimens**: Carey-Ann BURNHAM (United States)<br>**Improving blood culture interpretation: the role of IR biotyper for S. hominis**: Marco Antonio ROLD�N RUIZ (Spain)<br>**Rapid detection of carbapenem-resistant Klebsiella pneumoniae using CRISPR/Cas13a technology**: Jing HUANG (China)<br>**PEDOT:PSS OECTs as versatile devices for real-time monitoring of monkeypox virus antiviral assays**: Alessandra SCAGLIARINI (Italy)<br>**Harnessing synthetic nanobodies for characterisation and diagnosis of Staphylococcus aureus infections**: Arpita SAHOO (Switzerland)<br>**Rapid detection of antimicrobial susceptibility based on holographic imaging system**: Li ZHIDONG (China)<br>**Loop mediated isothermal amplification assay: a reliable tool to detect SNPs in chloroquine resistance genes of Plasmodium falciparum in field settings**: Davinder KAUR (India)<br>**Feasibility of microbiology interventions for surveillance of antimicrobial resistance in district level hospitals in Vietnam**: Huong VU THI LAN (Vietnam)<br>**Metabolic profiling of Pseudomonas aeruginosa infection in cystic fibrosis**: Rutuja H. PATIL (Czech Republic)<br>**A newly developed method for rapidly and accurately detecting the hypervirulent genotype of Klebsiella pneumoniae**: Claudia ROTONDO (Italy)<br>**Rapid nanopore sequencing as a key diagnostic tool in adrenal histoplasmosis after a year of uncertainty**: Ummu Afeera ZAINULABID (Malaysia)<br>**[13C]CO2 breath testing for detecting and monitoring bacterial infection**: Marina LOPEZ-ALVAREZ (United States)<br>**A novel phage-derived receptor binding protein for rapid and specific detection of Escherichia coli O157:H7 and related Shiga toxin-producing strains**: S�lvio SANTOS (Portugal) |
| 14/04 | 12:15 - 13:15 | FIPL6 | Fireplace: HIV: from needle parks to injectables | Mary HORGAN (Ireland), G�lsen �ZKAYA SAHIN (Sweden) | ****: Huldrych G�NTHARD (Switzerland) |
| 14/04 | 12:15 - 13:15 | IS39 | Fighting foes, old and new: maintaining and expanding direct protection against persistent and emerging serotypes in adults with pneumococcal vaccination | Carmen ARDANUY (Spain), Mario RAMIREZ (PortugalESCMID-appointed chair) | **Welcome and Introduction - Opening remarks on the importance of pneumococcal vaccination**: Mario RAMIREZ (Portugal)<br>**Addressing persistent and emerging serotypes in a dynamic epidemiological landscape**: Gili REGEV-YOCHAY (Israel)<br>**Improving vaccine uptake among adults with PCV20**: Jana SHAW (United States)<br>**Panel Discussion and Q&A**: Mario RAMIREZ (Portugal) |
| 14/04 | 12:15 - 13:15 | IS40 | RSV and hMPV disease burden in adults: a dual dilemma | Siran KESKE (T�rkiyeESCMID-appointed chair) | **Welcome and Introduction**: Siran KESKE (T�rkiye)<br>**RSV and hMPV disease burden in adults**: Harish NAIR (France)<br>**Panel Discussion and Q&A**: Siran KESKE (T�rkiye) |
| 14/04 | 12:15 - 13:15 | IS41 | Bridging the gap: innovative partnerships to expand global antimicrobial access | Marc MENDELSON (South AfricaESCMID-appointed chair), Paul SCHAPER (United States) | **Welcome and Introduction**: Paul SCHAPER (United States)<br>**Moderator-led discussion with panellists on access barriers to antibiotics in low- and middle-income countries (LMICs)**: Paul SCHAPER (United States)<br>**Moderator-led discussion with panellists on new approaches to support antibiotic access in LMICs**: Paul SCHAPER (United States)<br>**Opne Q&A with Audience**: Paul SCHAPER (United States)<br>**Closing Remarks**: Paul SCHAPER (United States) |
| 14/04 | 12:15 - 13:15 | IS42 | Bloodstream infections: management, clinical algorithms and rapid diagnostic solution | Elda RIGHI (United KingdomESCMID-appointed chair), Birgit WILLINGER (Austria) | **Welcome and Introduction**: Birgit WILLINGER (Austria)<br>**Blood culture management, stewardship and best practices to support BSI management**: Robin PATEL (United States)<br>**Sepsis management among BSI, clinical algorithms, decision support systems**: Timothy RAWSON (United Kingdom)<br>**AMS in BSI associated sepsis, full potential of rapid diagnostic solution**: Maurizio SANGUINETTI (Italy)<br>**Panel Discussion and Q&A**: Birgit WILLINGER (Austria) |
| 14/04 | 12:15 - 13:15 | IS43 | Decentralised point-of-care molecular diagnostics for accessible STI testing | Kwame Ohene BUABENG (GhanaESCMID-appointed chair), Harald KESSLER (Austria) | **Welcome and Introduction**: Kwame Ohene BUABENG (Ghana)<br>**Evaluation of new cartridge-based test for STI detection**: Vittorio SAMBRI (Italy)<br>**Usability of the HPV POC PCR platform and an overview of the STI situation in Zimbabwe**: Stanford MUPANDASEKWA (Zimbabwe)<br>**Empowering community health: performance of point-of-care molecular diagnostics for HPV in urban Indonesia**: Endah INDRIASTUTI (Indonesia)<br>**Panel Discussion and Q&A**: Kwame Ohene BUABENG (Ghana) |
| 14/04 | 12:15 - 13:15 | MEET110 | AI and Digitalisation Study Group open meeting (ESGAID) | Bram LESTRADE (NetherlandsESCMID official), Paula M�LLING (SwedenESCMID official) |  |
| 14/04 | 13:30 - 14:30 | EF093 | Real world experience with modern HIV treatment: the art of ART |  | **Use of long-acting cabotegravir/rilpivirine in HIV-viraemic individuals: a metanalysis**: Marco BONGIOVANNI (Switzerland)<br>**Assessment of HIV-DNA, immune activation and senescence biomarkers during injectable cabotegravir/rilpivirine treatment**: Maria MAZZITELLI (Italy)<br>**Impact of Cabotegravir plus Rilpivirine Long-Acting on Body Composition: Results from a Prospective Study**: Andrea DE VITO (Italy)<br>**Real-World Efficacy and Tolerability of Long-Acting Cabotegravir/Rilpivirine in Older Woman with Polypharmacy and Comorbidities**: Marta ROSAS CANCIO-SU�REZ (Spain)<br>**Two-year comparative analysis of lipid profile changes between INSTI-based single tablet regimens in treatment-naïve people living with HIV: real-world evidence from South Korea**: So Yun LIM (Republic Of)<br>**Long-acting antiretroviral therapy in PLWH with prior HBV exposure**: Jose Ignacio MATEO GONZALEZ (Spain)<br>**Protease inhibitors in today's antiretroviral landscape: are we tracking resistance?**: Jorge CISCAR SORIANO (Spain)<br>**Effect after Switching from Efavirenz to Rilpivirine on Liver Steatosis Among People Living with HIV with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial**: Laddarat SRIKHAM (Thailand)<br>**Impact of maternal dolutegravir on growth outcomes of HIV-exposed uninfected children: A prospective study**: Ezekielluoga YORAM (United Republic Of) |
| 14/04 | 13:30 - 14:30 | EF094 | Speed, convenience and performance of virus diagnostic methods | Hans H. HIRSCH (Switzerland) | **Prospective evaluation of a rapid diagnostic test in a tertiary hospital and prospects for reinforced dengue surveillance in Catalonia (Northeastern Spain)**: Laura HORVATH (Spain)<br>**Sequence-Independent Single-Primer Amplification (SISPA) followed by Next-Generation Sequencing for Diagnosing Viral Respiratory Tract Infections**: Priscila TRINDADE (Brazil)<br>**Seasonal trends and co-infection dynamics of respiratory pathogens: insights from a yearlong study**: Zafeirios TSINARIS (Greece)<br>**Speed meets reliability in respiratory infections diagnosis with a new nucleic acid extraction workflow**: Laura PASTOR-BERNAD (Spain)<br>**Pathobiome characterization and role in disease severity in children under 5-years with respiratory infection symptoms**: Leonardo TERRANOVA (Italy)<br>**Viral viability markers of SARS-CoV-2: A Comparison of cell culture genomic RNA RT-PCR and subgenomic RNA RT-PCR**: Cuesta-Chasco CUESTA CHASCO (Spain)<br>**Diagnostic performance of Hepatitis B virus surface antigens in the Netherlands using type-specific external quality assessment**: Emiel VANHULLE (Netherlands)<br>**Low utility of parallel testing by multiplex and individual real-time PCR assays for the diagnosis of viral meningitis and encephalitis at a large public hospital in the United States.**: Alicia CUBER (United States)<br>**Plasma Separation Card as an alternative sampling method for quantitative HCV RNA testing with high comparability to EDTA plasma**: Federico GARCIA (Spain) |
| 14/04 | 13:30 - 14:30 | FO136 | Diversity in CM and ID: gender gaps and policy traps | Andre FUCHS (Germany) | **How to avoid parity traps in ID/CM research?**: Muge CEVIK (United Kingdom)<br>**Gender gaps in visibility at scientific conferences**: Sarah DELLIERE (France)<br>**Psychological determinants of empowerment at individual and societal level**:  TBA (TBA) |
| 14/04 | 13:30 - 14:30 | KN130 | Infectious disease challenges in an ever-changing environment | Jacob MORAN-GILAD (Israel), Annelies ZINKERNAGEL (Switzerland) | ****: Pamela RENDI WAGNER (Sweden) |
| 14/04 | 13:30 - 14:30 | ME134 | The older solid organ transplant recipient: between frailty, immunosenescence and infection |  | ****: Maheen ABIDI (United States), Alaa ATAMNA (Israel) |
| 14/04 | 13:30 - 14:30 | MEET75 | Travel and Migration Infection Study Group open meeting (ESGITM) | Peter CHIODINI (United KingdomESCMID official), Ferenc Bal�zs FARKAS (HungaryESCMID official), Irene LOSADA GALVAN (SpainESCMID official), Corneliu Petru POPESCU (RomaniaESCMID official), Caroline R�NNBERG (SwedenESCMID official), Christian WEJSE (DenmarkESCMID official) |  |
| 14/04 | 13:30 - 14:30 | OS091 | Genomic and molecular drivers of bacterial virulence and resistance | Ecaterina NOROC (Republic Of), Guido WERNER (Germany) | **Characterization of the virulence shaping and adaptability in the methicillin-resistant Staphylococcus aureus ST9 lineage.**: Yiyi CHEN (China)<br>**Elucidating molecular mechanisms of bacterial conjugation: towards an improved understanding of plasmid evolution and epidemiology**: Sophia DAVID (United Kingdom)<br>**Clinical carbapenem-resistant Klebsiella pneumoniae (CRKP) strains carrying a mutH mutation are hypermutators that have heightened virulence and readily develop β-lactam/β-lactamase resistance**: Shaoji CHENG (United States)<br>**Genomic insights into the new prophages of MDR Pseudomonas aeruginosa: an example of phage-host-phage interaction**: Aylin USKUDAR GUCLU (T�rkiye)<br>**Genome-wide association study (GWAS) reveals importance of vaginal epithelium associated genes in case of recurrent vaginitis**: Reet M�NDAR (Estonia) |
| 14/04 | 13:30 - 14:30 | OS092 | Mycobacterial mayhem | Seif AL-ABRI (Oman), Linda AULIN (Netherlands) | **Limitations of the Xpert� MTB/RIF assay: A series of four clinical cases**: Allison HAAS (United States)<br>**Pharmacokinetic analysis of blood and cerebrospinal fluid contezolid concentrations in a patient with tuberculous meningoencephalitis**: Wenjuan NIE (China)<br>**Is this the first case of Mycobacterium stephanolepidis infection in humans?**: Sandra P�REZ-RECIO (Spain)<br>**Diagnostic Aspects of a Bacillus Calmette-Gu�rin Infection Following Intravesical Treatment for Bladder Cancer**: Keun Ju KIM (Republic Of)<br>**Mycobacterium abscessus: Is Shorter Antibiotic Therapy Combined with Surgery Sufficient?**: Maria Jo�o LOPES (Portugal) |
| 14/04 | 13:30 - 14:30 | PC2 | Bioinformatics | Tim-Christoph ROLOFF (Switzerland) | **BugSeq**: Elizabeth OGUNDARE (Canada)<br>**Solu Healthcare**: Timo SARATTO (Finland)<br>**Clover Bioanalytical Software**: Luis MANCERA PASCUAL (Spain)<br>**SmartGene**: Stefan EMLER (Switzerland)<br>**Abrinca**: Thomas RODER (Switzerland) |
| 14/04 | 13:30 - 14:30 | PM3 | Future prospects of electronic clinical decision support systems in stewardship programs |  | **Opportunities for clinical decision support systems in infectious disease management**: Nathan PEIFFER-SMADJA (France)<br>**CDSS and AMS programs: the Lumed example**: Valiquette LOUIS (Canada) |
| 14/04 | 13:30 - 14:30 | SY131 | Vaccines and antimicrobial resistance | Iva BUTIC (Croatia), Zitta Barrella HARBOE (Denmark) | **The impact of current and future vaccines on AMR: from pneumococcal to COVID-19**: Mateusz HASSO-AGOPSOWICZ (Switzerland)<br>**Can vaccines against AMR be translated into policy?**: William HAUSDORFF (United States) |
| 14/04 | 13:30 - 14:30 | SY132 | Predicting antibiotic susceptibility profiles from whole genome sequences: state-of-the-art | Werner RUPPITSCH (Austria), Balaji VEERARAGHAVAN (India) | **Impact of the WHO's developed catalogue of mutations on rapid TB diagnosis and treatment**: Thomas SCH�N (Sweden)<br>**Antimicrobial resistance prediction using whole genome sequencing**: Patricia SIMNER (United States) |
| 14/04 | 13:30 - 14:30 | SY133 | Probiotics in infectious diseases: current state-of-play | Nicolas BENECH (France), Silvia CORCIONE (Italy) | **Probiotics in infectious diseases: the perfect complement to antimicrobial therapies?**: Lena BIEHL (Germany)<br>**The horizon of next generation probiotics for infectious diseases**: Cormac GAHAN (Ireland) |
| 14/04 | 13:30 - 15:30 | EW135 | Transforming your research idea into an appropriate study design | Casandra BULESCU (Romania), Mary HORGAN (Ireland) | **Designing high-quality research studies: methodological skills and knowledge**: Mical PAUL (Israel)<br>**How to design and run scientific studies using AI agents as research assistants**: Alyssa BILINSKI (United States)<br>**Designing your first study: how to construct a workable project when your work environment may not help**: Thomas T�NGD�N (Sweden)<br>**Bridging early-career professionals with partners and seniors**: Giorgia CARUANA (Switzerland) |
| 14/04 | 13:30 - 15:30 | IS44 | Expert insights on diagnostics and antimicrobial resistance | Laurent DORTET (FranceESCMID-appointed chair), Devasena GNANASHANMUGAM (United States) | **Welcome and Introduction**: Devasena GNANASHANMUGAM (United States)<br>**Protecting patient pathways and healthcare delivery though the intelligent use of diagnostics**: Alison Helen HOLMES (United Kingdom)<br>**Rapid respiratory testing: experience of POC and laboratory molecular testing in a large teaching hospital Trust**: Nicholas MACHIN (United Kingdom)<br>**The Kentucky Viral Hepatitis Treatment (KeY Treat) Trial: a model of care in a rural appalachian county, US**: Jennifer HAVENS (United States)<br>**Antimicrobial resistance, an update from the Middle East**: Mohammad ALZUNITA (Saudi Arabia)<br>**Impact of carbapenemase-PCR in outbreak management: cost vs. benefit**: Thomas BOLLINGER (Germany)<br>**Panel Discussion and Q&A**: Devasena GNANASHANMUGAM (United States) |
| 14/04 | 13:30 - 15:30 | IS45 | Influenza connect: challenging conversations in respiratory vaccination | David FISMAN (CanadaESCMID-appointed chair), Ines ZOLLNER-SCHWETZ (Austria) | **Welcome and Introduction**: David FISMAN (Canada)<br>**Roundtable: why are respiratory vaccination rates suboptimal?**: David FISMAN (Canada)<br>**Debate: which should we be more concerned about, COVID-19 or influenza?**: David FISMAN (Canada)<br>**Interactive discussion: how do we optimise protection against influenza and COVID-19?**: David FISMAN (Canada)<br>**Q&A and Closing Remarks**: David FISMAN (Canada) |
| 14/04 | 13:30 - 15:30 | IS46 | From guidelines to clinical practice: towards better care for patients with Clostridioides difficile infection | Simon GOLDENBERG (United KingdomESCMID-appointed chair), Beno�t GUERY (Switzerland) | **Welcome and Introduction - CDI patient journey**: Beno�t GUERY (Switzerland)<br>**Clinical care pathway and associated challenges in CDI treatment**: Vanessa STADLBAUER-K�LLNER (Austria)<br>**Gut microbiota and CDI: what do we know?**: Fr�d�ric BARBUT (France)<br>**Microbiome-related approaches in CDI management of patients at risk for severe and recurrent CDI**: Beno�t GUERY (Switzerland)<br>**Identification of patients at risk of recurrence and current treatment of CDI**: Andrea MARINO (Italy)<br>**CDI patients with chronic kidney disease (CKD)**: Uta KUNTER (Germany)<br>**Microbiota driven new treatment approaches of CDI**: Elena REIGADAS RAMIREZ (Elena REIGADAS RAMIREZ)<br>**Panel Discussion and Q&A**: Beno�t GUERY (Switzerland)<br>**Summary and Close**: Beno�t GUERY (Switzerland) |
| 14/04 | 13:30 - 15:30 | IS47 | The double burden: clinical perspectives on RSV and hMPV | Simona RUTA (RomaniaESCMID-appointed chair), Daiana STOLZ (Switzerland) | **Welcome and Introduction**: Daiana STOLZ (Switzerland)<br>**25 years of hMPV research: where are we now and where are we heading?**: Bernadette VAN DEN HOOGEN (Netherlands)<br>**A comprehensive look at disease burden of RSV and hMPV**: Thushan DE SILVA (United Kingdom)<br>**Clinical insights on hMPV and RSV: learnings from real-life cases**: Paul LOUBET (France)<br>**Q&A and Closing Statement**: Daiana STOLZ (Switzerland) |
| 14/04 | 13:30 - 15:30 | M11 | Morphological diagnosis of faecal protozoa | Debbie NOLDER (United Kingdom), Claire ROGERS (United Kingdom) |  |
| 14/04 | 14:00 - 14:20 | IPT27 | Beyfortus� (nirsevimab) and its outcomes against RSV LRTD in real-world analyses from Galicia (Spain) |  | **Beyfortus� (nirsevimab) and its outcomes against RSV LRTD in real-world analyses from Galicia (Spain)**: Lucia LOPEZ GRANADOS (France) |
| 14/04 | 14:30 - 14:50 | IPT28 | Lateral flow assays: optimizing fiber pads in test development and manufacture |  | **Optimizing fiber pads in test development and manufacture**: Klaus HOCHLEITNER (United Kingdom) |
| 14/04 | 14:45 - 15:45 | EF099 | Infection Prevention in Action: Innovations, Insights, and Global Intervention | Allison MCGEER (Canada) | **A Candida auris cgMLST Scheme for Enhanced Outbreak Surveillance and Global Epidemiological Tracking**: Casey HARLESS (United States)<br>**Machine Learning-Augmented Clinical Scoring System for Predicting KPC Infections in Healthcare Crisis Scenarios**: Andres REARTE (Argentina)<br>**Incident infections with respiratory syncytial virus in a hospital-based healthcare worker cohort, 2023-2024 winter season**: Camelia SAVULESCU (France)<br>**Evaluation of the efficiency of reusable terminal filters for showers for nosocomial legionellosis prevention in a French university hospital**: Nagham L�a KHANAFER (France)<br>**Emerging uncommon non-fermenters and their decreasing antibiotic susceptibility in patients with prolonged hospital stay**: Vikas KHILLAN (India)<br>**Air and surface sampling around mpox Clade 1b in hospitals in the UK**: Susan GOULD (United Kingdom)<br>**Utilization of a healthcare facilities rapid assessment tool to define infection prevention and control and Water, Sanitation and Hygiene baseline criterion met during Democratic Republic of Congo mpox outbreak from August to November 2024**: April BALLER (Switzerland)<br>**The REACT study: Exploring the BSI Potential of KPC, NDM, VRE, and CRAB rectal colonization**: Marta COLANERI (Italy) |
| 14/04 | 14:45 - 15:45 | EF100 | Cefiderocol: an efficient Trojan horse? | Anna SRAMKOVA (Czech Republic) | **Acceleration of Emergence of Cefiderocol Resistance in Microfluidic Evolution System**: Bowen LI (China)<br>**The hidden link between cefiderocol resistance and increased virulence in Klebsiella pneumoniae: Insights from a TraDIS-based investigation**: Elias EGER (Germany)<br>**Resistance profiles of Carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?**: Ioannis BALTAS (United Kingdom)<br>**Impact of cefiderocol therapy on patient survival across different multi-drug resistant Gram-negative bacilli infections: insights from the SUSANA cohort.**: Nicol� CORTI (Italy)<br>**Decoding resistance: investigating cefiderocol's battle against carbapenem-resistant Acinetobacter baumannii**: Yi-Tzu LEE (China)<br>**Long-read sequencing reveals novel genetic factors in cefiderocol resistance in Pseudomonas aeruginosa ATCC 27853: A stepwise adaptive evolution study**: Maria Joao CARDOSO (Netherlands)<br>**Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales clinical isolates causing infection in hospitals in Europe and adjacent regions**: Rodrigo E. MENDES (United States)<br>**Cefiderocol activity against planktonic and biofilm forms of β-lactamase-producing Pseudomonas aeruginosa from people with cystic fibrosis**: Giorgia FABRIZIO (Italy)<br>**Activity of cefiderocol against clinical isolates of Pseudomonas aeruginosa collected from five European countries as part of SENTRY antimicrobial surveillance program 2020-2023**: Christopher LONGSHAW (United Kingdom) |
| 14/04 | 14:45 - 15:45 | EF101 | Immunology of bacterial pathogens |  | **Serotype 38 Streptococcus pneumoniae emerges as one of the dominant serotypes causing invasive pneumococcal disease in Germany and Poland, but not in the Netherlands**: Karim HAJJI (Netherlands)<br>**Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116: a secondary analysis of five phase 3 studies**: Maria Alejandra ESTEVES JARAMILLO (United States)<br>**Baseline serotype-specific IgG responses to pneumococcal vaccines in type 2 diabetes: implications for vaccine strategy in vulnerable populations**: Shincy METTINGAL RAMAKRISHNAN (India)<br>**Protection against invasive meningococcal disease and gonorrhoea, 5 years post introduction of a 4CMenB immunisation program in infants and adolescents in South Australia**: Helen MARSHALL (United States)<br>**Molecular epidemiology and correlates of protection among group B Streptococcus from carriage and disease: assessing vaccine coverage in Brazil**: Tatiana PINTO (Brazil)<br>**Impact of BCG vaccination on adaptive immune responses to mycobacterial and non-mycobacterial antigens in HIV-exposed, uninfected infants.**: Rhoda NAMAKULA (Norway)<br>**Immune signature against Klebsiella pneumoniae proteins in a mother-baby cohort from Blantyre, Malawi**: Eva HEINZ (United Kingdom)<br>**A comprehensive computational mapping of B-cell epitopes in the Klebsiella pneumoniae porinome**: Sonia PRIETO MARTIN GIL (Spain)<br>**Chronic infection induces a broadly neutralizing antibody response to Elastase B of Pseudomonas aeruginosa**: Alexandra ALBUS (Germany) |
| 14/04 | 14:45 - 15:45 | KN137 | Staphylococcus aureus host-microbe interaction: ecology, disease, and vaccine development | Werner RUPPITSCH (Austria), Annelies ZINKERNAGEL (Switzerland) | ****: Juliane BUBECK WARDENBURG (United States) |
| 14/04 | 14:45 - 15:45 | ME140 | Bioinformatic tools from start to finish |  | ****: V�tor BORGES (Portugal), Clare SLOGGETT (Australia) |
| 14/04 | 14:45 - 15:45 | ME141 | AI use in antimicrobial stewardship |  | ****: Shruti GOHIL (United States), Jose Ramon PANO-PARDO (Spain) |
| 14/04 | 14:45 - 15:45 | MEET89 | Epidemiological Markers Study Group open meeting (ESGEM) | Sylvain BRISSE (FranceESCMID official), Natacha COUTO (United KingdomESCMID official), Benjamin Peter HOWDEN (AustraliaESCMID official), Angela NOVAIS (PortugalESCMID official), Sandra REUTER (GermanyESCMID official) |  |
| 14/04 | 14:45 - 15:45 | OS095 | Community respiratory tract infections: latest trends and approaches | Catia CILLONIZ (Spain), Aur�lien DINH (France) | **Mycoplasma pneumoniae increase in 2023/24 causes disease in adults in Europe**: Bianca Margaretha Maria STRENG (Netherlands)<br>**Serotype distribution of pneumococcal community-acquired pneumonia in hospitalized adults in Germany**: Dian KARSSEN (Netherlands)<br>**Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: a Bayesian latent class analysis**: Jia WEI (United Kingdom)<br>**Causes of death and risk factors for 90-day mortality and readmission in community-acquired pneumonia.**: Fatimah AL-ZERGANI (Denmark)<br>**Oropharyngeal carriage of gut-derived Enterobacterales increases RTI risk in long-term aged care residents**: Sophie MILLER (Australia) |
| 14/04 | 14:45 - 15:45 | OS096 | Trends in antifungal resistance | Alexandre ALANIO (France), Ana ALASTRUEY-IZQUIERDO (Spain) | **Turning resistance into vulnerability: leveraging genetic insights to predict collateral sensitivity and synergism for effective multidrug therapies**: Kara SCHMIDLIN (United States)<br>**Role of the C2585G substitution in the MRR1 gene in the development of azole resistance in Candida parapsilosis sensu strictu.**: Iacopo FRANCONI (Italy)<br>**Fungaemia in a tertiary Madrid hospital from 2007 to 2024: changes in species epidemiology, increase in echinocandin resistance and low patient-to-patient transmission in recent years**: Jesus GUINEA (Spain)<br>**A multicentre study for determination of epidemiological cutoff values for rezafungin and four comparators against Candida auris with EUCAST broth microdilution reference methodology**: Joseph MELETIADIS (Greece)<br>**Decoding Candida auris Resistance in Latin America: Candida.app vs. Pathogenwatch**: Jaime David ACOSTA ESPA�A (Ecuador) |
| 14/04 | 14:45 - 15:45 | OS097 | Update on zoonotic and enteric infections | Steen ETHELBERG (), Kavitha SARAVU (India) | **A large-scale epidemiological study of Campylobacter employing whole genome analysis reveals the evolution of highly virulent and multidrug-resistant clones in the UK.**: Bruno LOPES (United Kingdom)<br>**Population dynamics and evolution of multidrug resistant clones of Shigella sonnei in Metropolitan France**: Carolina SILVA NODARI (France)<br>**Shiga toxin-producing Escherichia coli O26 as an increasingly common cause of haemolytic uraemic syndrome in England: A fifteen-year analysis of national enhanced surveillance data**: Luke MCGEOCH (United Kingdom)<br>**Incidence, clinical presentation, and outcomes of Pasteurella infections: a population-based Danish study**: Laura �BO LARSEN (Denmark)<br>**Natural history of latent brucellosis and efficacy evaluation of B-spot in active and latent cases: A 12-month prospective cohort study**: Hongyu WANG (China) |
| 14/04 | 14:45 - 15:45 | OS098 | Opportunistic infections in the Immunocompromised | Aleksandra BARAC (Serbia), Olivier LORTHOLARY (France) | **Dog scratch disease? A case of Vibrio vulnificus in a liver transplant patient**: Emily KIM (United States)<br>**Mpox infection among solid organ transplant recipients: a single center experience at a U.S. Tertiary Care Facility.**: Julia BINI VIOTTI (United States)<br>**Histoplasmosis in Hansen's Disease: Thalidomide for TNF-alpha Inhibition in ENL with a Risk of Opportunistic Infections**: Karthick Kumar VAITHEESWARAN (India)<br>**Nocardiosis in a kidney transplant recipient: pros & cons of tedizolid**: Mariachiara PELLEGRINO (Italy)<br>**Mycobacterium genavense-Associated IRIS with Macrophage Activation Syndrome: A Case Report Highlighting Diagnostic Challenges**: Marco MEROI (Italy) |
| 14/04 | 14:45 - 15:45 | PC3 | Vaccines | Charlotte VERNHES (Belgium) | **Immunethep**: Pedro MADUREIRA (Portugal)<br>**Vaxdyn**: Jos� INFANTE (Spain)<br>**Baxerna**: Lyudmila KOVALCHUKE (Belgium)<br>**LimmaTech Biologics**: Hanna BOBROVSKY (Switzerland) |
| 14/04 | 14:45 - 15:45 | PM4 | Do we need new antibiotics? | Ursula THEURETZBACHER (Austria) | **Yes: antibacterial resistance threatens medical outcomes**: Evelina TACCONELLI (Italy)<br>**No: the bang for buck lies elsewhere'**: Marc MENDELSON (South Africa) |
| 14/04 | 14:45 - 15:45 | SY138 | Global clones and evolving resistance mechanisms towards newer beta-lactams: Where are we heading? | Yesim BESLI (T�rkiye), Spyros POURNARAS (Greece) | **Carbapenemase-producing Enterobacterales: the not so good, the bad and the ugly.**: Arjana TAMBIC ANDRASEVIC (Croatia)<br>**The P. aeruginosa frightening cocktail: high-risk clones, horizontally-acquired resistance and evolving mutational resistome**: Katy JEANNOT (France) |
| 14/04 | 14:45 - 15:45 | SY139 | How to manage bacterial meningitis in low resource settings | Joseph DONOVAN (Vietnam), Christina OBIERO (Kenya) | **Bacterial meningitis diagnosis and surveillance**: Divya DEODHAR (Oman)<br>**Clinical presentation and management of CNS infections**: Kartika MAHARANI (Indonesia) |
| 14/04 | 16:00 - 17:00 | FIPL7 | Fireplace: Staphylococcus aureus host-microbe interaction: ecology, disease, and vaccine development | Werner RUPPITSCH (Austria), Annelies ZINKERNAGEL (Switzerland) | ****: Juliane BUBECK WARDENBURG (United States) |
| 14/04 | 16:15 - 17:15 | EF104 | Cutting-edge technologies to improve viral diagnostics | Patricia ALVAREZ (Brazil) | **How straightforward is the switch from qPCR to dPCR in a routine lab setting for quantification of Varicella-zoster virus in CSF samples**: Ariane BAUMH�GGER (Germany)<br>**A novel biosensor for the detection of RSV infection**: Carla ZANNELLA (Italy)<br>**Insufficient sexual health bloods don't always need throwing away!**: Stephanie HUTCHINGS (United Kingdom)<br>**A comparison of 4 HAV serology assays: the value of consensus results as a reference standard**: Taeyang CHIN (Belgium)<br>**Advancing herpesvirus diagnostics: clinical evaluation of a high-performance real-time PCR assay**: Henar ALONSO-EZCURRA (Spain)<br>**Evaluation of microbiological techniques for the diagnosis of West Nile Virus in the Virgen del Rocío hospital area (Sevilla, Spain).**: Maria AZNAR FERNANDEZ (Spain)<br>**Development of Non-Cross-Reactive Monoclonal Antibodies Against West Nile Virus and Usutu Virus Non-Structural Protein 1 to Improve Early Diagnosis**: Martina CECONI (Belgium)<br>**Enhancing Diagnostics and Global Standards through the QCMD Viral Metagenomics EQA**: Greg SUTTON (United Kingdom)<br>**Analysis of HIV-1 drug-resistence in newly diagnosed subjects using Next Generation Sequencing**: Valeria MICHELI (Italy) |
| 14/04 | 16:15 - 17:15 | EF105 | New data in non-tuberculous mycobacterial disease | Lorenzo GUGLIELMETTI (France) | **Deciphering genotypic resistance to amikacin in Mycobacterium abscessus using whole genome sequencing and a specific pipeline (GenoMAB)**: Camille ALLAM (France)<br>**Pseudomonas aeruginosa rapidly kills Mycobacterium abscessus in dual-species biofilms in vitro**: Melissa MCDANIEL (Netherlands)<br>**Distribution of contezolid in different tissues of mice and human patients infected with Mycobacterium abscessus**: Wenjuan NIE (China)<br>**Exploration of clofazimine and bedaquiline activity against clinical strains of Mycobacterium abscessus to advance innovative therapeutic strategies**: Cano Fern�ndez MARIA (Spain)<br>**Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria**: Sohinee SARKAR (Australia)<br>**Recovery of Non-Tuberculous Mycobacteria and Detection of Dominant Circulating Clones in Indoor Water Samples from Germany**: Nils WETZSTEIN (Germany)<br>**Deciphering the Epidemiology of Mycobacterium chimaera: Genetic Lineages, Environmental Sources, and Infection Prevention Insights**: Giovanni LORENZIN (Italy)<br>**Evaluation of a novel media for susceptibility testing of Mycobacterium avium-intracellulare complex isolates**: Tristan GRAMS (United States)<br>**Emerging cases of Mycobacterium chelonae endocarditis associated with BioIntegral bioprostheses**: Judith KIKHNEY (Germany) |
| 14/04 | 16:15 - 17:15 | EF106 | The ABC (allergy, bloodstream infections and clinical decision support) in AMS | C�line PULCINI (France) | **Evaluation of the allergy fact checker, a clinical decision support system to promote non-invasive delabeling of incorrect penicillin allergy labels: a mixed-methods study**: Dries WETS (Belgium)<br>**Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trial.**: Jonathan SANDOE (United Kingdom)<br>**Stewardship interventions reduced blood culture utilization by 40% during BD BACTEC™ Blood Culture media shortage**: Xena LI (Canada)<br>**Prescriptive Impact of Rapid Microbiological Diagnostics in Bloodstream Infections Caused by Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus (PRIMEKA): A Retrospective Single-Center Cohort Study.**: Federica SALVATI (Italy)<br>**The inappropriate use of antibiotics for blood culture contamination and colonisation by multidrug-resistante microorganisms: the role of counselling on antibiotic prescription**: Rebecca Rowena PE�A-ZALBIDEA (Spain)<br>**Factors influencing meropenem prescription following the 2020 EUCAST � I � definition update : a multicentric observational study in Belgian hospitals**: Lucy CATTEAU (Belgium)<br>**Impact of an Antimicrobial Stewardship Mobile Application on Antimicrobial Prescribing, Length of Hospital Stay, and Cost Savings**: Zahir Osman Eltahir BABIKER (United Arab Emirates)<br>**Evaluation of a model-based clinical decision support system for empirical antimicrobial therapy**: Mads Lause MOGENSEN (Denmark)<br>**A rapid systematic review of criteria to facilitate prompt intravenous-to-oral antimicrobial switch in children and young people in England.**: Rebecca OETTLE (United Kingdom) |
| 14/04 | 16:15 - 17:15 | JS2 | Late-breaker research from the Lancet group: new interventions for familiar and new infectious diseases | Syeda Saleha HASSAN (United Kingdom), Ursula HOFER (United Kingdom) | **Phase 3 randomised trial of oral gepotidacin for the treatment of uncomplicated gonorrhoea (EAGLE-1)**: Janet WILSON (United Kingdom)<br>**The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America**: Jan Felix DREXLER (Germany)<br>**The WHO Bacterial Priority Pathogens List: guiding research and development, and informing innovative public health strategies to address antimicrobial resistance**: Hatim SATI (Switzerland)<br>**Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three RSV seasons: a randomized trial**: Alberto PAPI (Italy) |
| 14/04 | 16:15 - 17:15 | LB005 | Emerging pathogens in humans, animals and vectors | Anna J HENNINGSSON (Sweden) | **Genome-wide association study identifies ABCG1 as a susceptibility locus for tick-borne encephalitis**: Piyush GAMPAWAR (Austria)<br>**First detection of tick-borne encephalitis virus in Belgian ticks, May 2024**: Elena PORTELL-BUJ (Belgium)<br>**H5N1 human infection in the United Kingdom: a One-Health approach**: Richard PULESTON (United Kingdom)<br>**Spread of a fusidic acid and methicillin-resistant Staphylococcus aureus clone causing impetigo in Europe**: Anders Rhod LARSEN (Denmark)<br>**Increase of PVL-positive livestock-associated MRSA in the Netherlands: a growing concern beyond livestock settings**: Karuna VENDRIK (Netherlands) |
| 14/04 | 16:15 - 17:15 | ME145 | Fungal meningitis: recognition and current status of management |  | ****: Olivier LORTHOLARY (France), Janis BLAIR (United States) |
| 14/04 | 16:15 - 17:15 | MEET71 | ESCMID Study Group for Urinary Tracy Infections (ESGUTI) | Angela HUTTNER (SwitzerlandESCMID official), Matthieu LAFAURIE (FranceESCMID official), Merel LAMBREGTS (NetherlandsESCMID official) |  |
| 14/04 | 16:15 - 17:15 | MEET90 | Veterinary Microbiology Study Group open meeting (ESGVM) | Els BROENS (NetherlandsESCMID official), Patrick BUTAYE (BelgiumESCMID official), Lina CAVACO (DenmarkESCMID official), Sally Jane CUTLER (United KingdomESCMID official), Ana VALE (IrelandESCMID official) |  |
| 14/04 | 16:15 - 17:15 | MEET91 | Brain Infections Study Group open meeting (ESGIB) | Jacob BODILSEN (DenmarkESCMID official), Marion LE MARECHAL (FranceESCMID official), Marco Rinaldo OGGIONI (ItalyESCMID official), Reinout VAN CREVEL (NetherlandsESCMID official), Emma Cecilia WALL (United KingdomESCMID official) |  |
| 14/04 | 16:15 - 17:15 | OS102 | AI tools empowering AMR prediction in WGS and MALDI-TOF | Oliver NOLTE (Switzerland), Patricia SIMNER (United States) | **A scalable machine learning approach to predict antimicrobial susceptibility from whole genome sequencing data**: Yinzheng ZHONG (United Kingdom)<br>**Machine Learning-Based Antimicrobial Resistance Prediction of 11 antibiotics for Klebsiella pneumoniae from Clinical NGS Data**: Qiwen YANG (China)<br>**AI-Powered Real-Time Plasmid Prediction Using Nanopore Sequencing**: Ela Djamila SAUERBORN (Germany)<br>**MALDI-TOF Prediction model based on machine learning algorithm for the detection of ST23 high-virulence K. pneumoniae**: Laurent DORTET (France)<br>**Predicting rifampicin resistance in Mycobacterium tuberculosis complex with a machine learning based MALDI-TOF MS approche**: Yun-Wen SUN (China) |
| 14/04 | 16:15 - 17:15 | OS103 | Polymicrobial interactions and competition | Alessandra BRAGONZI (Italy), Kimberly KLINE (Switzerland) | **The Klebsiella pneumoniae type VI secretion system effector Tle4 facilitates adaptation survival by damaging the cell membrane of competing bacteria**: Wanzhen LI (China)<br>**Candida albicans promotes TSST-1 production in Staphylococcus aureus by depleting glucose and lifting carbon catabolite repression**: Mathias CARRIOU (France)<br>**Understanding polymicrobial biofilm dynamics: focus on Pseudomonas aeruginosa and its molecular interactions**: Shubhangi KANSAL (India)<br>**Intra- and interspecific antagonism inhibits growth of Staphyloccous aureus in human nasal microbial communities**: Laura BR�LISAUER (Switzerland)<br>**Combination therapy against drug resistance biomimetic dual-species biofilm model of Pseudomonas aeruginosa and Staphylococcus aureus**: Paria MOJARRAD (Finland) |
| 14/04 | 16:15 - 17:15 | PC4 | Therapeutics | Ursula THEURETZBACHER (Austria) | **Fundaci�n MEDINA**: Olga GENILLOUD (Spain)<br>**Antabio**: Marc LEMONNIER (France)<br>**Infex Therapeutics**: Peter JACKSON (United Kingdom)<br>**MetalloBio**: Jim A. THOMAS (United Kingdom)<br>**Kinvard Bio**: Lloyd PAYNE (United States)<br>**Deutsches Zentrum f�r Infektionsforschung**: Silke ALT (Germany) |
| 14/04 | 16:15 - 17:15 | SY143 | ESCMID guidelines for the vaccination of immunocompromised individuals: solid organ transplant recipients | Elisa CORDERO MATIA (Spain), Zitta Barrella HARBOE (Denmark) | **Vaccination against respiratory pathogens**: Albert VOLLAARD (Netherlands)<br>**Other vaccines**: Olivier EPAULARD (France) |
| 14/04 | 16:15 - 17:15 | SY144 | What's the role of infant and maternal immunisation for paediatric RSV prevention? | Joanne M. LANGLEY (Canada), Peter OPENSHAW (United Kingdom) | **Pros and cons of passive infant immunisation with mAb before their first RSV season**: Federico MARTIN�N-TORRES (Spain)<br>**Pros and cons of maternal vaccination in preventing severe RSV infections in infants.**: Anne VERGISON (Luxembourg) |
| 14/04 | 16:15 - 17:30 | EA | Excellence Award Lectures | Jon S. FRIEDLAND (United Kingdom), Robert Leo SKOV (Denmark) | **Towards pandemic prevention, moonshot or utopia?**: Marion KOOPMANS (Netherlands)<br>**Can global warming bring new infectious diseases?**: Arturo CASADEVALL (United States) |
| 14/04 | 16:15 - 17:45 | IS48 | Unlocking rapid, comprehensive pathogen genomics with real-time nanopore sequencing | Hege Vangstein AAMOT (NorwayESCMID-appointed chair), Justin O'GRADY (United Kingdom) | **Welcome and Introduction**: Justin O'GRADY (United Kingdom)<br>**Implementing next generation sequencing for rapid diagnostics and public health investigations**: Kimberlee MUSSER (United States)<br>**Reliable whole-genome genotyping for bacterial surveillance using nanopore sequencing data**: Gabriel WAGNER-LICHTENEGGER (Austria)<br>**Implementing portable, real-time 16S rRNA sequencing in the healthcare sector enhances antimicrobial stewardship**: Anna SMIELEWSKA (United Kingdom)<br>**Utilising nanopore metagenomic sequencing for rapid identification of infections**: Judith BREUER (Judith BREUER)<br>**Panel Discussion and Q&A**: Justin O'GRADY (United Kingdom) |
| 14/04 | 16:15 - 17:45 | IS49 | Antimicrobial resistance and immunocompromised patients in the era of personalised medicine: are we doing our best? | Rafael CANTON (SpainESCMID-appointed chair), Christian ECKMANN (Germany) | **Welcome and Introduction**: Christian ECKMANN (Germany)<br>**The toll of AMR on cancer patients: from quality of life to death**: Antonella CARDONE (Italy)<br>**Is AMR in haematology-oncology patients compromising innovative cancer care?**: Oliver A. CORNELY (Germany)<br>**AMR in the ICU: a never-ending menace**: Ignacio MARTIN-LOECHES (Ireland)<br>**Access to rapid diagnostic tools to optimise tailored treatment**: Louise SWEENEY (United Kingdom)<br>**Impact of AMR on vulnerable patients: a call to action**: Marco FALCONE (Italy)<br>**Panel Discussion and Q&A**: Christian ECKMANN (Germany)<br>**Closing Remarks**: Christian ECKMANN (Germany) |
| 14/04 | 16:15 - 17:45 | IS50 | Conquering the superbug crisis: new hope for treating carbapenem-resistant Acinetobacter baumannii | Ana GALES (BrazilESCMID-appointed chair), Sumathi NAMBIAR (United States) | **Welcome and Introduction**: Sumathi NAMBIAR (United States)<br>**The impact of carbapenem-resistant A. baumannii on global healthcare**: David L. PATERSON (Singapore)<br>**Optimising polymyxin B: clinical strategies, personal insights, and case-based approaches to effective and safe use**: Helmi SULAIMAN (Malaysia)<br>**Optimising drug pharmacokinetics and pharmacodynamics for enhanced therapeutic outcomes for CRAB infections**: Markus ZEITLINGER (Austria)<br>**Advancing treatment for CRAB with rifabutin for injection: a comprehensive review of Phase 2 clinical trial data**: Frantzeska FRANTZESKAKI (Greece)<br>**Panel Discussion and Q&A**: Sumathi NAMBIAR (United States) |
| 14/04 | 16:15 - 17:45 | IS51 | The present and future of cytomegalovirus viral load monitoring in transplant patients: from quantification harmonisation to new therapeutic strategies | Scott HAUENSTEIN (United States), Andre KALIL (United StatesESCMID-appointed chair) | **Welcome and Introduction**: Scott HAUENSTEIN (United States)<br>**The importance of CMV viral load measurement accuracy in guiding clinical decisions in the era of new therapeutic options**: Giovanna TRAVI (Italy)<br>**Are CMV viral load reported in international units adequate to compare results across laboratories? A question of commutability**: Vincent THIBAULT (France)<br>**Would a redesigned WHO International Standard for human cytomegalovirus resolve the commutability issue among nucleic acid amplification tests?**: Jacqueline FRYER (United Kingdom)<br>**Panel Discussion and Q&A**: Scott HAUENSTEIN (United States) |
| 14/04 | 16:15 - 18:15 | EW146 | How to detect, manage and communicate hospital outbreaks | Margaret IP (China), Rossitza VATCHEVA-DOBREVSKA (Bulgaria) | **How to detect hospital outbreaks**: David FISMAN (Canada)<br>**How to confirm hospital outbreaks using genomics**: John W. A. ROSSEN (Netherlands)<br>**How to rapidly respond to an ongoing hospital outbreak**: Ermira TARTARI (Malta)<br>**How to communicate hospital outbreaks via scientific publication**: Ines STEFFENS (Sweden) |
| 14/04 | 16:15 - 18:15 | M12 | Faecal examination (eggs and cysts -advanced) | Debbie NOLDER (United Kingdom), Claire ROGERS (United Kingdom) |  |
| 14/04 | 16:15 - 18:15 | PM5 | Innovation in direct from blood detection of BSIs | Till T. BACHMAN (United Kingdom), Robin PATEL (United States) | **Ultra-rapid pathogen ID and AST directly from whole blood**: Tae Hyun KIM (Republic Of)<br>**Swedish Foundation for Strategic Research Project Ultrafast bacterial species identification and antibiotic susceptibility testing**: Johan ELF (Sweden)<br>**Direct from blood pathogen and antibiotic-resistant marker identification in about one hour**: Kimberle CHAPIN (Spain)<br>**Critical review**: Anna Maria PERI (Australia) |
| 14/04 | 16:15 - 18:15 | SY142 | Precision genomics to improve infectious diseases management | Jacob MORAN-GILAD (Israel), Nicole STOESSER (United Kingdom) | **Human genomics approaches to infection immunity**: Fergus HAMILTON (United Kingdom)<br>**Applying bacterial GWAS to uncover new mechanisms of antibiotic resistance**: Marco GALARDINI (Germany)<br>**Evolution in action: large-scale within-host evolution analyses of persistent bacterial infections**: Stefano GIULIERI (Australia)<br>**Machine learning in bacterial genomics and metagenomics**: Francesco ASNICAR (Italy) |
| 14/04 | 17:30 - 18:30 | EF110 | Advancing diagnostics and treatment of endocarditis | Beno�t GUERY (Switzerland) | **18F-FDG-PET/CT improves source control of extra-cardiac complications in infective endocarditis**: Jan M. PRINS (Netherlands)<br>**Comparing Duke criteria updates: Advancing IE diagnosis in patients with prosthetic intracardiac materials**: Matthaios PAPADIMITRIOU OLIVGERIS (Switzerland)<br>**In vivo Dalbavancin efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and high-level aminoglycoside resistant (HLAR) Enterococcus faecalis (EFAE) experimental endocarditis model.**: Cristina GARCIA DE LA MARIA (Spain)<br>**Identification and validation of clinical phenotypes in Staphylococcus aureus blood stream infection and their association with mortality (FEN-AUREUS study)**: Jes�s RODR�GUEZ-BA�O (Spain)<br>**Enterococcal Infective Endocarditis: demographics, comorbidities, diagnostic evaluation and mortality outcomes**: Mita SINGH (United Kingdom)<br>**Health related quality of life of patients with infective endocarditis – preliminary data of the DERIVE cohort**: Charlotte MEYER-SCHWICKERATH (Germany)<br>**The optimal management of Enterococcus faecium catheter-related bloodstream infections: a gap to bridge**: Ilaria RANCAN (Italy)<br>**Ceftobiprole alone versus in combination with ampicillin against borderline penicillin-resistant, vancomycin-resistant Enterococcus faecalis**: Olivia FUNK (United States)<br>**Risk factors for in- hospital mortality in 500 cases of infective endocarditis**: Cristiane LAMAS (Brazil) |
| 14/04 | 17:30 - 18:30 | EF111 | Don't blink: STIs are everywhere | Mathew BEALE (United Kingdom) | **Neurosyphillis and Mpox co-infection mimic HIV encephalitis**: Lamiss MEJDOUBI (Austria)<br>**An unusal cause of transverse myelitis**: Junais KOLERI (Qatar)<br>**Ocular Syphilis, an uncommon presentation form of syphilis: two cases**: Romina KARDASHI (Germany)<br>**Case report of a severe skin infection in a young man on PrEP and DoxyPEP**: Milan ZL�MAL (Czech Republic)<br>**Serowaffling in PrEP Users: The Difficulty of HIV Diagnosis – A Case Report.**: Pablo PILLADO ALONSO (Spain)<br>**Severe disseminated mpox in a patient with advanced HIV: A case report**: Maria Ana QUADROS FLORES (Portugal)<br>**Sensorimotor polyneuropathy in a patient affected by HIV-1: an atypical presentation of neurosyphilis associated to anti-SOX-1 antibodies**: Arianna LIPPI (Italy) |
| 14/04 | 17:30 - 18:30 | EF112 | Clinical considerations in resistant organisms | Divya DEODHAR (Oman) | **Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicenter clinical experience**: Francesca SERAPIDE (Italy)<br>**Clinical outcomes of MSSA bacteremia exhibiting the cefazolin inoculum effect and development of a novel diagnostic method**: Sadako YOSHIZAWA (Japan)<br>**Third- and fourth-generation cephalosporins for the treatment of infections due to OXA48 carbapenemase-producing Enterobacterales**: Alejandro BLANCO AR�VALO (Spain)<br>**Are meropenem or imipenem-cilastatin effective therapies for patients with invasive ertapenem-resistant infections?**: Anne Sophie PETERS (Chile)<br>**Oral Fosfomycin after Carbapenems as de-escalating therapy in Complicated Urinary Tract Infection: A randomized controlled trial**: Kirun ANGKANAVISAN (Thailand)<br>**Oral switch vs. intravenous antibiotics treatment for serious carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa infections on hospital discharge: the next frontier for oral switch?**: Christen ARENA (United States)<br>**Metallo-β-lactamase colonization and subsequent risk of infection: a retrospective study.**: Carol LEE LUNA FERNANDES (Brazil)<br>**Polymyxin including therapy versus colistin including therapy in the therapy of carbapenem-resistant Gram-negative infections: A retrospective matched cohort study**: Merve MERT VAHABI (T�rkiye)<br>**Prognostic factors and role of clinical management in carbapenem-resistant Acinetobacter baumannii bacteraemia: results from a prospective, international, multicentre cohort (EURECA)**: Francesco COGLIATI DEZZA (Italy) |
| 14/04 | 17:30 - 18:30 | ME149 | How to perform molecular surveillance of multidrug resistant bacteria |  | ****: Martina LENGEROVA (Czech Republic), Henrik HASMAN (Denmark) |
| 14/04 | 17:30 - 18:30 | MEET92 | Implant-associated Infections Study Group open meeting (ESGIAI) | Craig ABOLTINS (AustraliaESCMID official), Jaime ESTEBAN (SpainESCMID official), Efthymia GIANNITSIOTI (GreeceESCMID official), Barbara HASSE (SwitzerlandESCMID official), Marjan WOUTHUYZEN-BAKKER (NetherlandsESCMID official) |  |
| 14/04 | 17:30 - 18:30 | OS107 | Novel vaccines in clinical development | Mateusz HASSO-AGOPSOWICZ (Switzerland), Hanna M. NOHYNEK (Finland) | **Safety and immunogenicity of a seasonal booster dose of the 6-valent, OspA-based Lyme borreliosis vaccine candidate VLA15 in a healthy population aged 5-65 years**: Messier MESSIER (France)<br>**Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial**: Hiwot HIRUY (United States)<br>**Development of a Rapid-Acting Oral Cholera Vaccine: Phase I Clinical Trial**: Alisse HANNAFORD (United States)<br>**Safety and immunogenicity of a Group B Streptococcus vaccine in participants aged 55-75 years**: Lidia OOSTVOGELS (Denmark)<br>**Aggregated summary of immunogenicity and safety for the chikungunya virus virus-like particle (VLP) vaccine development programme**: Lauren TINDALE (Canada) |
| 14/04 | 17:30 - 18:30 | OS108 | Novel approaches to preventing device-related infections | Natividad BENITO (Spain), Preeti MALANI (United States) | **Clinical and microbiological impact of antibiotic-impregnated catheters in ventriculoperitoneal shunt infections in adults.**: Manuela SANZ DE MENA (Spain)<br>**Reducing drainage-associated meningitis by using an antiseptic dressing: A randomized controlled trial AntiRedMen**: Simone SCHEITHAUER (Germany)<br>**Efficacy of antimicrobial envelopes in preventing cardiac implantable electronic device infections – systematic review and meta-analysis**: Akanksha MAHAJAN (Australia)<br>**A bundled approach to reducing central line associated blood stream infections (CLABSI) in hemodialysis (HD) patients**: Jayvee GUERRERO (Canada)<br>**Increased long-term mortality in patients with prosthetic joint infection after primary total hip arthroplasty – a cohort study with 89'709 patients**: Nadine IMHASLY (Switzerland) |
| 14/04 | 17:30 - 18:30 | OS109 | Training CM/ID - a global view | Mihai MARES (Romania), Priya NORI (United States) | **Specialist training in infectious diseases in Europe**: Jon SALMANTON-GARCIA (Germany)<br>**Infectious Diseases Residency Training over the World**: Pelin IRK�REN (T�rkiye)<br>**Five years of experience with the virtual International Postgraduate Diploma in Infection Prevention and Control from the Infection Control Africa Network.**: Alma TOSTMANN (Netherlands)<br>**Combatting challenges in laboratory capacity through an innovative, longitudinal Gram stain training programme for blood culture specimens in Zimbabwe.**: Tinashe Cynthia MWATURURA (Zimbabwe)<br>**Benefit of the implementation of Entrustable Professional Activities (EPA) as an assessment tool in the Laboratory of clinical bacteriology: a study focused on the improvement of residents' skills and feelings.**: H�l�ne PAILHORI�S (France) |
| 14/04 | 17:30 - 18:30 | PM7 | Health technology assessment of innovations in infectious diseases: hurdles and facilitators | Claudia WILD (Austria) | **Using health economics to decide which interventions to prioritise to reduce the burden of AMR**: Koen POUWELS (United Kingdom)<br>**Innovative approaches and techniques in Vaccination strategies**: Cornelis BOERSMA (Netherlands)<br>**Using anti-microbial testing to reduce (unnecessary) antibiotic prescriptions**: Maarten POSTMA (Netherlands) |
| 14/04 | 17:30 - 18:30 | SY147 | Avian influenza in mammals: jumps under the radar | Patricia ANTUNES (Portugal), Ana VALE (Ireland) | **Threat of highly pathogenic avian influenza to non-traditional hosts, including humans**: Thijs KUIKEN (Netherlands)<br>**Recent changes in the epidemiology of avian influenza in relation to human health risks**: Ron FOUCHIER (Netherlands) |
| 14/04 | 17:30 - 18:30 | SY148 | Echinococcosis: neglected but expanding | Daniel GRUPEL (Israel), Francesca TAMAROZZI (Italy) | **Expansion and diversity of cystic echinococcosis**: Pedro LEGUA (Peru)<br>**Management of echinococcosis: evidence, eminence and new developments**: Beate GR�NER (Germany) |
